Cover Page for Protocol 
 
Sponsor name:  [CONTACT_3454] A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN7415-4310 
Official title of study: A Multi-Centre, Randomised, Open-Label, Controlled Trial 
Evaluating the Efficacy and Safety of Prophylactic 
Administration of Concizumab in Haemophilia A and B 
Patients with Inhibitors 
Document date: 24 June 2020 
 
/LQN
/LQN/LQN
/LQN
/LQN
/LQN
/LQN/LQN
/LQN/LQN/LVWRIFRQWHQWV
3URWRFROYHUVLRQ  
3URWRFROYHUVLRQ  
3URWRFROYHUVLRQ  
3URWRFROYHUVLRQ  
3URWRFRODPHQGPHQW  
3URWRFRODPHQGPHQW  
3URWRFRODPHQGPHQW  
,76XEVWDQWLDO DPHQGPHQW&0&  
6XEVWDQWLDODPHQGPHQW,% FRQFL]XPDEHG $WWDFKPHQW,DQG,,  &21),'(17,$/'DWH 1RYR1RUGLVN
9HUVLRQ
6WDWXV&RQFL]XPDE
7ULDO,'11&OLQLFDO7ULDO5HSRUW
$SSHQGL[-XQH

)LQDO
3URWRFRODQGSURWRFRODPHQGPHQWVCONFIDENTIAL
 
 
 
 
 
Redacted protocol 
Includes redaction of personal identifiable information only. 
 
 
 
. 
 
 
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 1 of 137
Protocol
NN7415-4310
A Multi-Centre, Randomised, Open-Label, Controlled Trial 
Evaluating the Efficacy and Safety of Prophylactic 
Administration of Concizumab in Haemophilia A and B 
Patients with Inhibitors
Trial phase: [ADDRESS_931809] be restricted to relevant 
parties.
3URWRFROY
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931810] of abbreviations.......................................................................................................... ...............................9
1 Summary....................................................................................................................... ...........................15
2 Flow chart .................................................................................................................... ............................18
2.1 Visits and assessments...................................................................................................... ...........18
2.2 Explanatory descriptions.................................................................................................... ..........21
3 Background information and rationale for the trial............................................................................ 23
3.1 Background information...................................................................................................... ........23
3.1.1 Haemophilia............................................................................................................... 23
3.1.2 Concizumab ...............................................................................................................2 4
3.2 Rationale for the trial ..................................................................................................... ..............27
4 Objective(s) and endpoint(s) .................................................................................................. ................28
4.1 Objective(s)................................................................................................................ ..................28
4.1.1 Primary objective.......................................................................................................28
4.1.2 Secondary objectives .................................................................................................28
4.2 Endpoint(s)................................................................................................................. ..................28
4.2.1 Primary endpoint........................................................................................................28
4.2.2 Secondary endpoints..................................................................................................28
[IP_ADDRESS] Supportive seconda ry endpoints..........................................................28
4.2.3 Exploratory endpoints................................................................................................29
[IP_ADDRESS] Exploratory saf ety endpoints...............................................................29
[IP_ADDRESS] Exploratory patient reported outcome endpoints ................................29
5 Trial design .................................................................................................................. ............................31
5.1 Type of trial ............................................................................................................... ..................31
5.1.1 Surgery................................................................................................................... ....32
5.2 Rationale for trial design.................................................................................................. ............32
5.3 Treatment of patients ....................................................................................................... ............35
5.3.1 Concizumab arm........................................................................................................36
[IP_ADDRESS] Concizumab prophylactic treatment (main and extension part)..........36
5.3.2 Comparator arm (eptacog alfa (rFVIIa))....................................................................37
[IP_ADDRESS] On-demand treatment (main part) .......................................................37
[IP_ADDRESS] Concizumab prophylactic treatment (extension part)..........................37
5.3.3 Dose escalation ..........................................................................................................3 7
5.3.4 Co-administration of ep tacog alfa (rFVIIa) ...............................................................[ADDRESS_931811] ..........................................................................41
5.5 Rationale for treatment ..................................................................................................... ...........41
6 Trial population.............................................................................................................. .........................42
6.1 Number of patients.......................................................................................................... .............423URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931812] ................................................................50
8.1.5 Withdrawal from trial ................................................................................................50
8.1.6 Review/ evaluation of clinical ou tcome.....................................................................50
8.1.7 Visit 1 (Screening part)..............................................................................................51
8.1.8 Training of patients at visit 1, visit 2 and visit 9........................................................51
8.1.9 Treatment period at home ..........................................................................................52
8.1.10 Staggered recruitment................................................................................................52
8.1.11 Treatment period – Main part ....................................................................................52
[IP_ADDRESS] Visit 2 (Randomisation) ......................................................................52
[IP_ADDRESS] Visit 3 (Phone call for eptacog alfa (rFVIIa) on-demand arm and 
PK visit for conciz umab arm) .............................................................54
[IP_ADDRESS] Visit 4, 5, 6, 7 and 8 ............................................................................55
[IP_ADDRESS] Visit 9..................................................................................................56
8.1.12 Treatment period – Extension part.............................................................................57
[IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog 
alfa (rFVIIa) on-demand arm).............................................................57
[IP_ADDRESS] Visit 9.2 (ONLY patients previously on the eptacog alfa (rFVIIa) 
on-demand arm) ..................................................................................58
[IP_ADDRESS] Visit 10................................................................................................59
[IP_ADDRESS] Visit 10.1 (ONLY patients previously on the eptacog alfa 
(rFVIIa) on-demand arm)....................................................................60
[IP_ADDRESS] Visit 11................................................................................................61
[IP_ADDRESS] Visit 11.1 (ONLY patients previously on the rFVIIa on-demand 
arm) .....................................................................................................61
[IP_ADDRESS] Visit 12, 13, 14 and 15 ........................................................................62
[IP_ADDRESS] Visit 16................................................................................................63
8.1.13 Visit 17 (End of trial) - Follow-up part......................................................................648.1.14 Unscheduled Visit......................................................................................................64
8.2 Patient related infor mation/assessments ..................................................................................... .65
8.2.1 Demography...............................................................................................................6 5
8.2.2 Concomitant illness and medical hi story other than haemophilia .............................65
8.2.3 Concomitant medication............................................................................................65
8.2.4 Details of Haemophilia, Haemophilia treatment and bleed history...........................66
8.3 Efficacy assessments........................................................................................................ ............67
8.3.1 Bleeding epi[INVESTIGATOR_1841] ......................................................................................................67
8.4 Safety assessments.......................................................................................................... .............703URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 4 of 137
8.4.1 Physical examination .................................................................................................70
8.4.2 Body measurements...................................................................................................71
8.4.3 Vital Signs............................................................................................................... ...71
8.4.4 Electrocardiogram......................................................................................................72
8.4.5 Adverse events...........................................................................................................7 2
[IP_ADDRESS] Medication error..................................................................................72
[IP_ADDRESS] Adverse events requiring additional data collection ...........................72
8.5 Laboratory assessments ...................................................................................................... .........74
8.5.1 Laboratory assessmen ts for efficacy..........................................................................75
[IP_ADDRESS] Thrombin generation...........................................................................75
[IP_ADDRESS] Free TFPI.............................................................................................76
8.5.2 Laboratory assessments for safety .............................................................................76
[IP_ADDRESS] Urinalysis ............................................................................................76
[IP_ADDRESS] Haematology .......................................................................................76
[IP_ADDRESS] Biochemistry .......................................................................................77
[IP_ADDRESS] FVIII/FIX activity ...............................................................................77
[IP_ADDRESS] Coagulation parameters.......................................................................[IP_ADDRESS] FVIII/FIX inhibitors............................................................................78
[IP_ADDRESS] Anti-concizumab antibodies................................................................78
[IP_ADDRESS] Concizumab  ELISA ............................................................................80
[IP_ADDRESS] FVII ELISA.........................................................................................81
[IP_ADDRESS] Total TFPI ...........................................................................................81
8.5.3 Human Biosamples....................................................................................................81
8.6 Other assessments........................................................................................................... .............82
8.6.1 Patient reported outcomes..........................................................................................82
8.6.2 Training.................................................................................................................. ....83
[IP_ADDRESS] Concizumab and NovoPen
®4 ..............................................................83
[IP_ADDRESS] eptacog alfa (rFVIIa)...........................................................................83
[IP_ADDRESS] eDiary..................................................................................................84
8.6.3 Surgery................................................................................................................... ....84
8.7 Patient compliance.......................................................................................................... .............84
8.8 Treatment compliance........................................................................................................ ..........85
9 Trial supplies ................................................................................................................ ...........................86
9.1 Trial products.............................................................................................................. .................86
9.2 Labelling ................................................................................................................... ...................86
9.3 Storage ..................................................................................................................... ....................87
9.4 Drug accountability and destruction ......................................................................................... ...87
9.5 Auxiliary supplies.......................................................................................................... ..............88
10 Interactive voice/web response system ........................................................................................ ..........89
11 Randomisation procedure and b reaking of blinded codes ..................................................................89
11.1 Randomisation .............................................................................................................. ...............89
11.2 Breaking of blinded codes .................................................................................................. .........89
12 Adverse events, and t echnical complaints..................................................................................... ........90
12.1 Definitions ................................................................................................................ ...................90
12.1.1 Adverse event ............................................................................................................ 90
12.1.2 Serious adverse event.................................................................................................91
12.1.3 Non-serious adverse event .........................................................................................923URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931813] .............................................................................94
12.1.7 Technical complaints .................................................................................................98
12.2 Reporting of adverse events................................................................................................ .........98
12.3 Follow-up of adverse events ................................................................................................ ......101
12.4 Technical complaints and tec hnical complaint samples ............................................................102
12.4.1 Reporting of technical complaints ...........................................................................102
12.4.2 Collection, storage and shipment of technical complaint samples ..........................103
12.5 Pregnancies ................................................................................................................ ................103
12.5.1 Pregnancies in female pa rtners of male patients......................................................103
12.6 Precautions and/or overdose ................................................................................................ ......104
12.7 Rules for putting enrolment on hold ........................................................................................ ..105
12.8 Committees related to safety............................................................................................... .......105
12.8.1 Novo Nordisk sa fety committee ..............................................................................105
12.8.2 Data monit oring committee .....................................................................................105
13 Case report forms............................................................................................................ ......................106
13.1 Corrections to cas e report forms........................................................................................... .....107
13.2 Case report form flow...................................................................................................... ..........107
13.3 Electronic diary........................................................................................................... ...............107
14 Monitoring procedures ........................................................................................................ .................109
15 Data management.............................................................................................................. ....................110
16 Computerised systems......................................................................................................... ..................111
17 Statistical considerations ................................................................................................... ...................112
17.1 Sample size calculation.................................................................................................... ..........113
17.2 Definition of analysis sets................................................................................................ ..........114
17.3 Primary endpoint........................................................................................................... .............114
17.3.1 Estimand and primary statistical analysis................................................................114
17.3.2 Sensitivity analysis ..................................................................................................115
17.3.3 Additional analysis ..................................................................................................115
17.4 Supportive secondary endpoints ............................................................................................. ...116
17.4.1 Supportive secondary efficacy endpoints ................................................................116
17.4.2 Supportive secondary safety endpoints....................................................................116
17.4.3 Supportive secondary phar macokinetic endpoints...................................................117
17.4.4 Supportive secondary pha rmacodynamic endpoints................................................117
17.4.5 Exploratory endpoints..............................................................................................118
[IP_ADDRESS] Exploratory saf ety endpoints.............................................................118
[IP_ADDRESS] Exploratory patient reported-outcome endpoints ..............................118
17.5 Interim analysis........................................................................................................... ...............118
18 Ethics ....................................................................................................................... ...............................120
18.1 Benefit-risk assessment of the trial....................................................................................... .....120
18.2 Informed consent ........................................................................................................... ............122
18.3 Data handling.............................................................................................................. ...............122
18.4 Information to patien ts during trial....................................................................................... .....123
18.5 Premature termination of the trial and/or trial site.....................................................................12 33URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 6 of 137
19 Protocol compliance.......................................................................................................... ....................124
19.1 Protocol deviations ........................................................................................................ ............124
19.2 Prevention of missing data................................................................................................. ........124
20 Audits and inspections ....................................................................................................... ...................125
21 Critical documents ........................................................................................................... .....................125
22 Responsibilities ............................................................................................................. .........................127
23 Reports and publications..................................................................................................... .................128
23.1 Communication of results................................................................................................... .......128
23.1.1 Authorship ............................................................................................................... 129
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) .........................................................129
23.2 Investigator access to data and review of results .......................................................................129
24 Retention of clinical trial docume ntation and human  biosamples....................................................130
24.1 Retention of clinical trial documentation.................................................................................. .130
24.2 Retention of human biosamples.............................................................................................. ...130
24.2.1 Antibody samples ....................................................................................................131
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities............[ADDRESS_931814] of key staff and relevant departments, if applicable for the individual . 
Appendix 1 Patient Reported Outcomes3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 7 of 137
Table of Figures
Page
Figure 3–1 Individual predicted PK profiles based on data merged with recorded spontaneous (circles) 
and traumatic (triangles) bleeding epi[INVESTIGATOR_535038]-up period. All data originates from explorer™3 (N=24 patients). PK of concizumab is subdivided into 
three exposure levels of !20 ng/mL, 20-100 ng/mL, and > 100 ng/mL together with the 
number of contributing patients. LL OQ: lower limit of quantification. ......................................26
Figure 5–1 Schematic diagram of the trial design................................................................................ ..........31
Figure 5–2 Individual predicted concizumab concentration profiles for all concizumab-treated patients 
in explorer™2 (n=4 patients) and explorer™3 (n=18 patients). The horizontal lines 
indicate 100 ng/mL, and the shaded areas represent the full range (min-max) of the 
individual predicted profiles. ................................................................................................. ......34
Figure 5–3 Dose escalation for one individu al patient in the c oncizumab arm .............................................38
Figure 5–4 Dose escalation for one indivi dual patient in the comparator arm...............................................39
Figure 8–1 Visit schedule – concizumab arm. ...................................................................................... .........46
Figure 8–2 Visit schedule – eptacog alfa (rFVIIa ) arm later switching to  concizumab.................................46
Figure 12–1 Reporting of AEs .................................................................................................... ...................100
Figure 17–1 Definition of main and exten sion part ............................................................................... ........1193URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 8 of 137
Table of Tables
Page
Table 5–[ADDRESS_931815] of products provided by N ovo Nordisk ............................................................................. ...35
Table 8–[ADDRESS_931816] op of bleeding epi[INVESTIGATOR_1865]................................................................................ .........68
Table 8–2 Definitions of bleeding epi[INVESTIGATOR_1841] (cause of bleed) ..................................................................... ..68
Table 8–3 Definition of bleeding epi[INVESTIGATOR_535021] t recommendation.....................................69
Table 9–1 Trial products........................................................................................................ .......................86
Table 9–2 Storage conditions.................................................................................................... ....................87
Table 17–1 Power in superiority comparison between concizumab prophylaxis and on-demand 
treatment under different assumptions of ABR for concizumab and over-dispersion 
(assuming on-dem and ABR=24). ..............................................................................................1143URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931817] aspartate aminotransferaseAT antithrombinAUC area under curveBP blood pressureBU Bethesda UnitCCDS company core data sheet CLAE clinical laboratory adverse eventC
max maximum plasma concentration
CNS central nervous system
concizumab Bthe name [CONTACT_687671] B. B is the formulation 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931818] correction DUN dispensing unit numberDVT deep vein thrombosisECG electrocardiogrameCRF electronic case report formeDiary electronic diaryeITMF electronic investigator trial master fileELISA enzyme-linked immunosorbent assay3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 11 of 137
EMA european medicines agency
EOT end of trialePRO electronic patient reported outcome
eptacog alfa the name ‘eptacog alfa (rFVIIa)’ will be used throughout 
the protocol and the product is identical to 
rFVIIa,‘NovoSeven
®, and ‘NiaStaseRT®’
ETP endogenous thrombin potential FAS full analysis setFDA U.S. Food and Drug AdministrationFDAAA U.S. Food and Drug Administration Amendment ActFIX coagulation factor IXFPFV first patient first visitFVIIa activated coagulation factor VIIFVIII coagulation factor VIIIFVIII:C plasma activity of factor VIIIFX coagulation factor XFX
a activated coagulation factor X
GCP Good Clinical PracticeGGT gamma glutamyl transferaseGHN global haemophilia network3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931819] cell protein
IB investigator’s brochureIC informed consent ICH International Conference on Harmonisation ICMJE International Committee of Medical Journal EditorsID identificationIEC independent ethics committeeIgG4 immunoglobulin G4IMP investigational medicinal product
INNInternational Non-Proprietary Names for Pharmaceutical 
Substances 
IRB institutional review boardISTH International Society on Thrombosis and HaemostasisIT information technologyi.v. intravenous(-ly)IWRS interactive web response systemLBBB left bundle branch blockLPFV last patient first visitLPLV last patient last visit3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931820] level 
NIMP non investigational medicinal productPCD primary completion date PD pharmacodynamicsPEF peak expi[INVESTIGATOR_687507]4D every 4
thday3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 14 of 137
eptacog alfa (rFVIIa)the name ‘eptacog alfa (rFVIIa)’ will be used throughout 
the protocol and the product is identical to ‘NovoSeven®’
sABR spontaneous annualised bleeding rate
SAE serious adverse eventSAS safety analysis setsBE spontaneous bleeding epi[INVESTIGATOR_687508].c. subcutaneous(-ly)SI international system of unitsSmPC summary of product characteristicsS[LOCATION_003]R suspected unexpected serious adverse reactionTAT thrombin-antithrombin complexTEAE treatment emergent adverse eventsTIA transient ischemic attackTF tissue factorTFPI [INVESTIGATOR_687509]3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 15 of 137
1 Summary
The main objective for the phase 2 trial NN7415-4310, explorer™4, is to assess the efficacy of 
concizumab administered s.c. once daily to prevent bleeding epi[INVESTIGATOR_56178] A and B
patients with inhibitors. Furthermore, this trial aims to assess the longer-term efficacy and safety of 
concizumab in haemophilia A and B patients with inhibitors and to establish the safety of treating 
breakthrough bleeding epi[INVESTIGATOR_687510] (rFVIIa) in these patients.
Objective(s) and endpoint(s)
Primary objective
∀To assess the efficacy of concizumab administered s.c. once daily in preventing bleeding 
epi[INVESTIGATOR_56178] A and B patients with inhibitors.
Secondary objectives
∀To assess the longer-term efficacy of concizumab in haemophilia patients with inhibitors
∀To assess the safety of concizumab in haemophilia patients with inhibitors
∀To assess the safety of administering recombinant factor VIIa (rFVIIa) to haemophilia 
patients with inhibitors that are exposed to concizumab 
∀To assess the immunogenicity of concizumab in haemophilia patients with inhibitors
Primary endpoint
∀The number of bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
Key secondary endpoints
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
∀Number of treatment emergent adverse events (TEAEs) during at least 24 weeks from
treatment onset
Time frames for evaluation of Objectives/Endpoints
All endpoints referring to the time frame of at least [ADDRESS_931821] (or has withdrawn). In addition, number of bleeding epi[INVESTIGATOR_51953] 76 
weeks of treatment with prophylactic concizumab will be analysed. The extension part of the trial 
will provide additional safety and long-term efficacy data.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 16 of 137
Trial design
The trial is a multi-centre, randomised (2:1), open-label, controlled trial, aiming to evaluate the 
efficacy and safety of concizumab 0.15 mg/kg (with potential dose escalation) administered daily 
s.c. in haemophilia patients with inhibitors. We expect 16 patients to complete treatment in 
concizumab arm (concizumab prophylaxis) and 8 patients in comparator arm (rFVIIa on demand). 
The dose regimen is selected based on relevant PK and TFPI [INVESTIGATOR_535039]/PD modelling of 
the results from the preceding explorer™ trials. Both on-demand and prophylaxis patients will be 
eligible for the trial. 
For all patients treated with concizumab (concizumab arm and comparator arm extention part) a 
loading dose of 0,5 mg/kg concizumab will be given as the first dose, followed by [CONTACT_687617] 0,15 mg/kg. All patients in treatment with concizumab will in a non-bleeding 
state receive a single dose of 90 μg/kg eptacog alfa (rFVIIa) one week after dosing with 
concizumab. Hereafter, patients will be closely clinically observed at the site for potential safety 
issues for at least 12h and evaluated again at the site after 24h. 
The total trial duration for the individual patient will be approximately 86-88 weeks, consisting of a 
2-4 week screening period, a subsequent 76-week treatment period and an 8-week follow-up period.
eptacog alfa (rFVIIa) for treatment of bleeding epi[INVESTIGATOR_687511]. The patient will not be provided with trial product or eptacog alfa (rFVIIa) after end of 
trial.
The trial is split into a main part which lasts [ADDRESS_931822] completed a minimum of 24 weeks of eptacog alfa (rFVIIa) on-demand or have 
withdrawn. The analysis of the main part of the trial aims to substantiate the clinical proof of 
concept (CPoC) that concizumab has the potential to prevent bleeding epi[INVESTIGATOR_687512]. The extension part of the trial will provide additional safety and long-
term efficacy data. 
Trial population
Number of patients planned to be screened: [ADDRESS_931823]: 26
Number of patients expected to complete the trial: 243URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 17 of 137
Key inclusion criteria
∀Informed consent obtained before any trial related activities. Trial related activities are any 
procedures that are carried out as part of the trial, including activities to determine the 
suitability for the trial
∀Male haemophilia A or B patients with inhibitors aged ≥ 18 years at the time of signing 
informed consent
∀Patients currently in need of treatment with by[CONTACT_687618]
∀Known or suspected hypersensitivity to trial product(s) or related products
∀Known inherited or acquired bleeding disorder other than haemophilia
∀Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX
Key Efficacy assessment
∀Number of bleeding epi[INVESTIGATOR_535025] 24 weeks of treatment onset
Key Safety assessment
∀Number of treatment emergent adverse events during at least 24 weeks of treatment onset
Trial products
The following products will be used in the trial:
∀Investigational Medicinal Products:
oconcizumab B, 100mg/mL to be administered s.c. with NovoPen®4 and needles
oeptacog alfa (rFVIIa), 5mg /vial and histidine (solvent). Reconstituted eptacog alfa 
(rFVIIa) is for intravenous administration and used in the trial at visit 3 and 9.1 for all patients with the purpose of investigating the safety of administering eptacog alfa 
(rFVIIa) to haemophilia patients
∀Non Investigational Medicinal Product :
oeptacog alfa (rFVIIa) 5 mg /vial and histidine (solvent). Reconstituted eptacog alfa is for 
intravenous administration and used in this trial for treatment of bleeding epi[INVESTIGATOR_1841]3URWRFROY
CONFIDENTIAL
Protocol UTN: U1111-1179-2925 Date: 15 March 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_931824] no.: 2016-000510-30 Version: 1.0 Page: 18 of 137
2 Flow chart
2.1 Visits and assessments
explorerTM4 trial periods Screening Treatment main a,bTreatment extension b Follow-
up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16Un-
scheduled e 17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169 176 197 225 253 281 309 337 393 449 505 533When 
applicable589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1w 4w 8w 12w 16w 20w 24w 25w 28w 32w 36w 40w 44w 48w 56w 64w 72w 76w - 84w
PATIENT RELATED INFO/ASSESSMENTS
Informed consent/ Genotypi[INVESTIGATOR_535029]-term 
storage consent●
In/exclusion criteria ● ●g
Demography ●
Concomitant illness/Medical history ●
Concomitant medication ● ●●●●●●●●●●●●●●●●●●● ● ●
Details of Haemophilia/Haemophilia treatment and 
bleed history●
Withdrawal criteria/ Criteria for premature 
discontinuation of trial product●●●●●●●●●●●●●●●●●●● ● ●
Randomisation (IWRS) ●
EFFICACY
Bleeding epi[INVESTIGATOR_1841] h, i●●●●●●●●●●●●●●●●●●● ● ●
Thrombin generation (central lab) ● ●●j, k●●●●●●l●j●●●●●●●●●●l● ●
Free TFPI (central lab)  ● ●●k●●●●●●l●●●●●●●●●●●l● ●
SAFETY
Physical examination ● ●●k●● ● ● ● ●
Body measurements ● ●m●k, m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m
Vital signs ● ●n●k, n●●●●●●n●n●●●●●●●●●● ● ●
ECG ●
Adverse events ● ●●●●●●●●●●●●●●●●●●● ● ●3URWRFROY_
Protocol UTN: U1111-1179-2925 Date: 15 March 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_931825] no.: 2016-000510-30 Version: 1.0 Page: 19 of 137
explorerTM4 trial periods Screening Treatment main a,bTreatment extension b Follow-
up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16Un-
scheduled e 17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169 176 197 225 253 281 309 337 393 449 505 533When 
applicable589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1w 4w 8w 12w 16w 20w 24w 25w 28w 32w 36w 40w 44w 48w 56w 64w 72w 76w - 84w
Injection site reaction  ●●k●●●●●●●●●●●●●●●●● ●
Urinalysis (local lab) ●
Haematology (local lab) ● ●●j, k●●●●●●l●j●●●●●●●●●●l● ●
Biochemistry (central lab) ● ●●k●●●●●●l●●●●●●●●●●●l● ●
FVIII/ FIX activity (central lab) ● ●l●l
Coagulation parameters (central lab) ● ● ●●●●●●l●●●●●●●●●●l● ●
Coagulation parameters (PT, APTT and Fibrinogen 
(local lab))●j, k●j
FVIII/FIX  inhibitors (central lab) ● ●l●l
Anti-concizumab antibodies (ADA) (special lab) o● ●●k, p●p●p●p●p●p●l, p●●●●●●●●●●●l● ●
Concizumab  ELISA (special lab) ●●k, p●p●p●p●p●p●l, p●●●●●●●●●●●l● ●
FVII ELISA (special lab) ●j,k●j
Total TFPI (special lab) ● ●●k●●●●●●l●●●●●●●●●●●l● ●
TRIAL MATERIAL
IWRS call ● ●●k●●●●●●●●●●●●●●●●● ● ●
Dispensing visit (concizumab)r●k●k●k●k●k●k●k●●●●●●●●●●● ●
Dispensing visit (eptacog alfa, histidine)q● ●k● ●● ● ● ●●●●● ●
Administration of trial product (concizumab)r●k, s●k●d, s ● ●
Administration of trial product (eptacog alfa) ●k, t●t
Drug accountability (concizumab) ●k●k●k●k●k●k●k●●●●●●●●●●● ●
Drug accountability (eptacog alfa) ●●k●●●●●●●●●●●●●●●●● ● ●
New dose of trial product e, u●●●●●● ●●●●●●●●● ●
PRO questionnaires ● ●●k●●●●●● ● ●
REMINDERS
Human biological specimen for storage (central lab) ● ●3URWRFROY
Protocol UTN: U1111-1179-2925 Date: 15 March 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_931826] no.: 2016-000510-30 Version: 1.0 Page: 20 of 137
explorerTM4 trial periods Screening Treatment main a,bTreatment extension b Follow-
up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16Un-
scheduled e 17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169 176 197 225 253 281 309 337 393 449 505 533When 
applicable589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) [ADDRESS_931827] ●
Training v● ● ●● ●
Compliance: eDiary ●●●●●●●●●●●●●●●●●● ● ●
End of treatment ●
End of trial ●
The cells marked in ‘red’ are only for the patients randomised to eptacog alfa (rFVIIa) arm.3URWRFROY
Protocol UTN: U1111-1179-2925 Date: 15 March 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_931828] no.: 2016-000510-30 Version: 1.0 Page: [ADDRESS_931829] according to patient’s individual training need on concizumab administration, NovoPen®4, eDiary training etc. Visit [ADDRESS_931830] be registered in the eCRF.
i Eptacog alfa will be given to treat breakthrough bleeding epi[INVESTIGATOR_1841]. 
jSampling time schedule for thrombin generation, haematology,  coagulation parameters and FVII ELISA: pre-dose (-1 hour), post-d ose: 10 min (±2 min), 1h 
(± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points, except pre-dose, occ ur after eptacog alfa 
administration.
k ONLY for patients randomised to concizumab arm.
l At visit [ADDRESS_931831] not treat themselves with concizumab until sampling  has been performed.
m Only body weight should be measured. 
nVital signs should be evaluated before and after trial drug administration at visit 2 and visit 3 for concizumab arm and at visi t 9 and visit 9.1 for patients in 
eptacog alfa arm switching to concizumab treatment.
oIn case clinical signs of e.g. hypersensitivity reactions or immune related events are seen, additional samples for ADAs may be  taken. All antibody samples 
from the affected patient will be analysed on an ongoing basis. If antibodies are detected, additional blood samples will be tak en and stored for characterisation 
of the antibodies.
p Blood sampling for anti-concizumab antibodies and concizumab ELISA testing should only be collected for patients on concizumab.
q If needed dispensing of eptacog alfa, histidine, trial injection kits and Direction For Use (DFU). 
r First treatment dose of concizumab is a loading dose and will be administered at visit [ADDRESS_931832] received any  by[CONTACT_687619],(e.g., 
eptacog alfa, FEIBA®) for prophylaxis or treatment of a bleeding epi[INVESTIGATOR_5319] a period of 24h (for eptacog alfa) or 48h (for FEIBA®) prior to first 
concizumab. Only eptacog alfa is allowed after visit 2.3URWRFROY
Protocol UTN: U1111-1179-2925 Date: 15 March 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_931833] no.: 2016-000510-30 Version: 1.0 Page: 22 of 137
t Eptacog alfa administered in a non-bleeding state at site at visit 3 for the concizumab arm and at visit 9.1 for the eptacog al fa arm.
uPatient treated with concizumab should be dose escalated at next scheduled visit if he experiences ≥[ADDRESS_931834] and whenever needed afterwards. Patients randomised to eptacog  alfa will be re-trained in 
NovoPen®4 and s.c. administration at visit 9 and 9.1. If necessary training can be performed as needed at other visits. The eDiary will  be provided to the 
patients at visit 2 if the patient feels capable in s.c. administration and using the eDiary. Further the patients will be trai ned in recognition of signs/symptoms of 
thrombosis.3URWRFROY
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931835] of 
the clinical trial at a trial site.
The INN name [CONTACT_687672] (synonyms used  during early 
development are NNC0172-2021, anti-TFPI, NN7415 or mab2021). Throughout this document 
“concizumab” is used as the name [CONTACT_535317].
3.1 Background information
3.1.1 Haemophilia
Haemophilia is an inherited bleeding disorder characterised by [CONTACT_535209], 
typi[INVESTIGATOR_535031]. Haemophilia A is caused by a partial or complete deficiency of 
blood coagulation factor VIII (FVIII). In haemophilia B, it is factor IX (FIX) that is deficient. 
Inheritance is chromosome X-linked; therefore the disease mainly affects males. The incidence of 
haemophilia A and B on average is estimated to be about 1 in 5000 live male births 4. According to 
the World Federation of Haemophilia global survey of [ZIP_CODE], about 178,500 persons are diagnosed 
with haemophilia worldwide. Of these, about 80% have haemophilia A. 
Haemophilia is classified as “severe”, “moderate” or “mild” according to the plasma activity of the 
affected coagulation factor6. With a deficiency of FVIII or FIX, the degree of activation of 
coagulation FX becomes insufficient. Consequently, the thrombin burst is delayed and insufficient 
for normal haemostasis7. The haemostatic plug, if formed, in these patients is fragile and easily 
dissolved by [CONTACT_56264]. This leads to impaired haemostasis and spontaneous 
prolonged bleeding epi[INVESTIGATOR_1841]. In severe haemophilia, bleeding in joints occurs spontaneously and is
the most frequent symptoms of the disease. Recurrent bleeding epi[INVESTIGATOR_56175] - most 
commonly a weight bearing joint - lead to chronic arthropathy, muscular atrophy and deformities. 
Treatment of bleeding epi[INVESTIGATOR_535032] (on-demand treatment) may delay arthropathy, but 
does not prevent it. The majority of children with severe haemophilia experience their first bleeding
epi[INVESTIGATOR_687513] a joint prior to age [ADDRESS_931836] developed inhibitors towards FVIII or FIX, replacement therapy is rendered 
ineffective. Though prevalence studies and registry data indicate that the prevalence of inhibitors in 
the haemophiliac population overall has been reported to be between 5% and 7%9, the prevalence 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931837] patients with severe haemophilia (FVIII:C < 1%) is higher and has been reported to be up 
to 30%9, 10. These patients may be treated with by[CONTACT_71363], activated FVII (NovoSeven®) and 
activated prothrombin complex concentrate (FEIBA®) given as i.v. injections. 
Current treatment options in haemophilia, replacement therapy or by[CONTACT_687620], are hampered 
by [CONTACT_535211] i.v. injections. Furthermore, by[CONTACT_687621]-lives, therefore prophylactic treatment is burdensome. It is
also generally acknowledged that the efficacy profile of by[CONTACT_687622]. Consequently, delayed or sub-optimal treatment occurs in a significant number of patients
with inhibitors. A new therapeutic agent that can be administered subcutaneously will represent a 
major improvement in the treatment of these patients in a prophylaxis setting.
3.1.[ADDRESS_931838], concizumab, is a humanised recombinant monoclonal antibody (mAb) of the 
immunoglobulin G4 (IgG4) isotype with a molecular weight of 149 kilo Dalton’s.  Like other 
antibodies, concizumab is composed of two light chains and two heavy chains linked together by 
[CONTACT_95999]. To prevent formation of half-antibodies, the serine at position 241 in the heavy 
chain has been replaced with a proline (S241P (Kabat annotation))10. The mechanism of action of 
concizumab is based on the concept of inhibiting the activity of a natural coagulation inhibitor, 
tissue factor pathway inhibitor (TFPI). TFPI [CONTACT_832] a potent inhibitor of the initiation phase of the 
coagulation process, i.e. the activation of (FX) to FXa by [CONTACT_535213] (TF)/factor VIIa (FVIIa) 
complex. TFPI [INVESTIGATOR_535033]/FVIIa complex, forming a TF/FVIIa/FXa/TFPI [INVESTIGATOR_535034]. Thus, concizumab prevents both inhibition of FXa and inhibition of FVIIa/TF by [CONTACT_535214]. In this manner, sufficient amounts of FXa to 
ensure effective haemostasis in the absence of a functional activated factor IX/activated factor VIII 
(FIXa/ FVIIIa) complex may be generated. This is a new concept that remains to be documented 
safe and efficacious in patients with haemophilia. More information about the physiological role of 
TFPI [INVESTIGATOR_535035]’s Brochure. 
Key differentiators of this new mode of action (MoA) and the key benefit of concizumab in patients 
with severe haemophilia A and B with inhibitors is reduced treatment burden due to subcutaneous 
administration potentially leading to better adherence, more patients on prophylactic treatment and 
ultimately better outcome. 
Four clinical trials with concizumab have been completed thus far: the first human-dose trial 
(NN7415-3813, explorer
TM1)11, a single dose trial in Japanese healthy subjects (NN7415-3981), 
two multiple dose trials (NN7415-3986, explorerTM2) and (NN7415-4159, explorer™3). When the 
first cohort with 4 (four) healthy subjects in explorer™2 was completed, prior to the initiation of the 
2ndcohort, the trial was halted, due to findings related to thrombosis in an ongoing 26-week toxicity 
study in primates. In this trial animal had concizumab plasma concentrations several hundred fold 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 25 of 137
above clinically relevant concentrations. Follow up investigations confirmed that the animal’s 
condition was related to thrombosis in the lungs caused by [CONTACT_687623]. Before the initiation of the fourth phase 1 trial (NN7415-4159), explorer™3,
a new 52 week non-clinical toxicology study was conducted in primates to investigate the findings 
in the previous study. The conclusion from this new non-clinical study was that the results from 
non-clinical studies support further clinical development of concizumab. Explorer™3 was a 
multiple dose clinical trial which aimed to investigate the safety, pharmacokinetics and 
pharmacodynamics of concizumab at five different dose levels in adult severe haemophilia A 
patients without inhibitors. In this trial multiple doses of concizumab were administered s.c. over a 
period of six weeks.
The explorer™3 trial was finalised following the completion of cohort 3 (0.8 mg/kg s.c. every 4 
days for 6 weeks). Blinded preliminary safety and PK/PD data from the cohort was reviewed by [CONTACT_535216]. Marked changes in coagulation parameters were observed including 
a decrease from baseline in fibrinogen and a pronounced increase in D-dimer and F1+[ADDRESS_931839] variation in pro-coagulant response to the drug 
was observed. Based on this, the Novo Nordisk safety committee (see Section 12.8.1 ) decided not 
to proceed to cohort 4 (1.1 mg/kg s.c. every 4 days for 6 weeks). No clinical consequences or 
serious adverse events were seen in the completed cohorts in explorer™3.
The PK results from explorer™3 showed exposure-response in terms of fewer bleeding epi[INVESTIGATOR_535036] 100 ng/mL. 
Individual predicted PK profiles merged with recorded spontaneous and traumatic bleeding epi[INVESTIGATOR_535037] 3–1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 26 of 137
Figure 3–1 Individual predicted PK profiles based on data merged with recorded spontaneous 
(circles) and traumatic (triangles) bleeding epi[INVESTIGATOR_535020]-up period. All data originates from explorer™3 (N=24 patients). PK of 
concizumab is subdivided into three exposure levels of !!20 ng/mL, 20-100 ng/mL, 
and > 100 ng/mL together with the number of contributing patients. LLOQ: lower limit of quantification.
a‘Time in trial’ refers to the time that the patients spent on each concizumab exposure level, and the !20 ng/mL level 
therefore also includes the screening period (not shown on this figure).
A large difference between the peak and trough plasma concentrations of concizumab were 
observed as well, especially in the highest dose group (0.80 mg/kg) of explorer™3. In patients who 
received 0.25, 0.5 and 0.8 mg/kg doses a significant overlap in plasma concentrations of
concizumab was seen due to high between-patient variability in concizumab.
Single doses of concizumab up to 9 mg/kg have been administered to haemophilia patients in the 
first human dose trial with concizumab, explorer™1. These doses resulted in plasma concentrations 
of concizumab that were significantly higher than the ones that are modelled to be reached in the 
highest escalated daily dose (0.25 mg/kg) of explorer™4. 
In a drug–drug interaction study in monkeys (NN215431), three doses of up to 1 mg/kg of
NovoSeven®were administered at 2h intervals, alone or in the presence of a steady state 
concentration of concizumab. No notable clinical observations were made, no treatment-related 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 27 of 137
adverse findings were seen, i.e. no thrombi or other signs of excessive coagulation. Increased 
concentrations of thrombin–anti-thrombin (TAT) and D-dimer were seen, which tended to be 
additive when both concizumab and eptacog alfa (rFVIIa) were present in circulation.
For an assessment of benefits and risks of the trial, see Section 18.1.
For further information, please refer to the Investigator’s Brochure.
3.[ADDRESS_931840] been finalised. Key safety and preliminary 
efficacy results from these phase 1 studies support further development of concizumab in 
haemophilia patients. Therefore, the main objective in the phase 2 of concizumab development is to 
assess efficacy and safety and provide data that will guide for the confirmatory phase 3 concizumab 
trials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 28 of 137
4 Objective(s) and endpoint(s)
4.1 Objective(s)
4.1.1 Primary objective
To assess the eff icacy of concizumab administered  s.c. once daily in preventing bleeding epi[INVESTIGATOR_687514] A and B patients with inhibitors
4.1.2 Secondary objectives
∀To assess the longer-term efficacy of concizumab in haemophilia patients with inhibitors
∀To assess the safety of concizumab in haemophilia patients with inhibitors
∀To assess the safety of administering recombinant factor VIIa (rFVIIa) to haemophilia 
patients with inhibitors that are exposed to concizumab 
∀To assess the immunogenicity of concizumab in haemophilia patients with inhibitors
4.2 Endpoint(s)
4.2.1 Primary endpoint
∀The number of bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
4.2.2 Secondary endpoints
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
∀The number of bleeding epi[INVESTIGATOR_51953] 76 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_51953] 76 weeks from treatment onset
Supportive secondary safety endpoints
∀Number of treatment-emergent adverse events (TEAEs) during at least 24 weeks from
treatment onset
∀Number of TEAEs during 76 weeks from treatment onset
∀Number of TEAEs within 24 hours of rFVIIa administration
∀Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset
∀Occurrence of anti-concizumab antibodies during 76 weeks from treatment onset
∀Change from baseline of fibrinogen during 24 weeks from treatment onset
∀Change from baseline of fibrinogen during 76 weeks from treatment onset
∀Change from baseline of D-dimer during 24 weeks from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 29 of 137
∀Change from baseline of D-dimer during 76 weeks from treatment onset
∀Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
∀Change from baseline of F1 + 2 during 76 weeks from treatment onset
∀Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
∀Change from baseline of PT during 76 weeks from treatment onset
∀Change from baseline of activated partial thromboplastin time (APTT) during 24 weeks 
from treatment onset
∀Change from baseline of APTT during 76 weeks from treatment onset
∀Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
∀Change from baseline of AT 76 weeks from treatment onset
Supportive secondary pharmacokinetic endpoints
∀Concentration of concizumab prior to the last dose administration at 24 weeks 
∀Concentration of concizumab prior to the last dose administration at 76 weeks 
Supportive secondary pharmacodynamic endpoints
∀Free TFPI [INVESTIGATOR_687515] [ADDRESS_931841] dose administration at 76 weeks 
∀Thrombin generation
oPeak thrombin generation (nM) prior to the last dose administration at 24 weeks 
oPeak thrombin generation (nM) prior to the last dose administration at 76 weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 24 
weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 76 
weeks
oVelocity index (nM/min) prior to the last dose administration at 24 weeks 
oVelocity index (nM/min) prior to the last dose administration at 76 weeks 
4.2.3 Exploratory endpoints
[IP_ADDRESS] Exploratory safety endpoints
∀Number of adverse events related to technical complaints during at least 24 weeks from 
treatment onset 
∀Number of adverse events related to technical complaints during at least 76 weeks from 
treatment onset 
[IP_ADDRESS] Exploratory patient reported outcome endpoints
∀Change in Hemo-TEM after 24 weeks from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 30 of 137
∀Change in Hemo-TEM after 76 weeks from treatment onset
∀Change in VERITAS-Pro®or VERITAS-PRN®after 24 weeks from treatment onset
∀Change in VERITAS-Pro®or VERITAS-PRN®after 76 weeks from treatment onset
∀Change in SF-36v2 after 24 weeks from treatment onset
∀Change in SF-36v2 after 76 weeks from treatment onset
∀Change in SDS after 24 weeks from treatment onset
∀Change in SDS after 76 weeks from treatment onset
∀Change in TSQM after 24 weeks from treatment onset
∀Change in TSQM after 76 weeks from treatment onset
∀Change in SIAQ-ISRQ after 24 weeks from treatment onset
∀Change in SIAQ-ISRQ after 76 weeks from treatment onset
∀Change in PGI-C after 24 weeks from treatment onset
∀Change in PGI-C after [ADDRESS_931842] will be evaluated in the main 
part of the trial. All endpoints referring to a time frame of 76 weeks will be evaluated in the 
extension part of the trial. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 31 of 137
5 Trial design
5.1 Type of trial
The trial is a multi-centre, randomised (2:1), open-label, controlled trial, aiming to evaluate the 
efficacy and safety of concizumab 0.15 mg/kg (with potential dose escalation) administered daily 
s.c. in haemophilia patients with inhibitors. The selected dose regimen is based on relevant PK and 
TFPI [INVESTIGATOR_535039]/PD modelling of the results from the preceding explorer™ trials. Both on-
demand and prophylaxis patients will be eligible for the trial. 
Figure 5–1 Schematic diagram of the trial design
The total trial duration for the individual patient will be approximately 86-88 weeks, including a 2-4 
week screening period, a 76 week treatment period, and a follow-up period of 8 weeks, see Figure 
5–[ADDRESS_931843] completed a minimum of 24 weeks of eptacog alfa (rFVIIa) on-demand or have 
withdrawn.
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 32 of 137
In the concizumab arm bleeding epi[INVESTIGATOR_687516] 
(rFVIIa). In all patients treated with concizumab a single 90 μg/kg dose of eptacog alfa (rFVIIa)
will be administered in a non-bleeding state one week after dosing with concizumab has been 
initiated. The investigator will evaluate if there are any safety concerns [ADDRESS_931844] eptacog alfa 
(rFVIIa) administration. Furthermore, the scheduled administration of eptacog alfa (rFVIIa) for the 
first 4 patients entering the trial with concizumab will be staggered.
In the comparator arm, in the main part, patients will receive eptacog alfa (rFVIIa) on-demand 
treatment. After completion of the main part, the patients will continue the trial in the extension part 
being treated with prophylactic concizumab 0.15 mg/kg (with potential dose escalation) s.c. daily 
administration.
Human biosamples (plasma, serum, and/or DNA for genotypi[INVESTIGATOR_007]) will be collected in this trial  for 
future exploratory analysis to pursue a deeper insight into the biology of TFPI, coagulation, and 
effect of concizumab on joint health.  That may include coagulation parameters and markers of joint 
status and damage. Acceptance of storage of human biosamples is voluntary and will not affect the 
patients’ participation in the trial. Therefore, patients will have the possibility to sign the informed 
consent for the trial and participate, while refusing permission for human biosamples to be stored 
for future exploratory analysis, see Section 8.1.1 .
An independent data monitoring committee (DMC) will be established for this trial. The DMC will 
review all safety data from the ongoing trial with concizumab exposure, see Section 12.8.2 .
5.1.1 Surgery
Minor surgery is allowed in this trial. Major surgery conducted earlier than one month (30 days) 
prior to trial start is allowed, see exclusion criteria no 6.
Minor surgery is defined as an invasive operative procedure where only the skin, the mucous 
membranes or superficial connective tissue is manipulated. Examples of minor surgery include 
implanting of central venous access devices (ports, CVC, pumps and other CVADs) in 
subcutaneous tissue, skin biopsies or simple dental procedures.
5.2 Rationale for trial design
Explorer™4 is a phase 2, clinical proof of concept (CPoC), and safety trial. The trial aims to 
substantiate CPoC that concizumab has the potential to prevent bleeding epi[INVESTIGATOR_687517]. A dose escalation design will allow cautious dose escalation in order to 
identify an efficacious and safe concizumab dose for the individual patient. A comparator arm is 
included to assess if concizumab is superior to on-demand treatment. Furthermore, the trial will 
give a possibility to assess safety of co-administration of eptacog alfa (rFVIIa) to the patients 
exposed to the concizumab treatment. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 33 of 137
The duration of 24 weeks for the main part of the trial is deemed necessary in order to obtain 
information on the annualised bleeding rate on concizumab prophylaxis. The duration of the 
extension part of the trial will be 52 weeks and provide further information on efficacy, i.e.
annualised bleeding rate, and also provide additional safety data upon 76 weeks treatment with 
concizumab.
A total of 26 patients previously on prophylaxis (PPX) or on-demand (OD) treatment will be 
randomised into one of the two arms, with 16 patients in the concizumab arm and 8 patients in the 
comparator arm see Figure 5–1 . Concizumab will be administered s.c. daily for patients randomised 
to the concizumab arm in the main and the extension part of the trial. For patients in the comparator 
arm in the extension part treatment will be changed from on-demand with rFVIIa to prophylaxis 
with concizumab. 
The concizumab dose regimens will be starting with 0.15 mg/kg with the possibility to escalate to
0.20 mg/kg and 0.25 mg/kg based on bleeding frequency, see Section 5.3.3 .
Daily dosing with concizumab 0.15 mg/kg aims to ensure steady-state levels of concizumab plasma 
concentrations above 100 ng/mL for the majority of the patients starting on this dose. The PK 
results from explorer™3 showed exposure response in terms of fewer bleeding epi[INVESTIGATOR_535042] 100 ng/mL, see Figure 3–[ADDRESS_931845] the opportunity 
to be dose escalated to the dose of 0.2 mg/kg. A further dose escalation to 0.25 mg/kg per day is 
permitted, again based on the bleeding rate, see Section 5.3.33URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 34 of 137
Figure 5–2 Individual predicted concizumab concentration profiles for all concizumab-treated 
patients in explorer™2 (n=4 patients) and explorer™3 (n=18 patients). The 
horizontal lines indicate 100 ng/mL, and the shaded areas represent the full range 
(min-max) of the individual predicted profiles.1
Due to the high between patient variability in concizumab concentration observed in explorer™3, a significant overlap in plasma concentrations of concizumab in patients who received 0.25, 0.5 and 
0.8 mg/kg doses was seen, see Figure 5–[ADDRESS_931846] mean plasma concentrations of concizumab, and thus different efficacy at each 
                                                
1Plasma concentrations in the same range as those in explorer™3 are expected to be reached in this trial with daily dose adminis tration. The starting 
dose for all patients will be 0.15 mg/kg daily. The plasma steady-state exposure for a typi[INVESTIGATOR_687518] a typi[INVESTIGATOR_535044] 0.8 mg/kg Q4D (cohort 3 of explorer3) in terms of both Cmax and AUC 0-24h. For 0.20 mg/kg dail y and 0.25 
mg/kg, the plasma steady-state exposure levels for a typi[INVESTIGATOR_687519] 40% and 70% respectively, comp ared to the typi[INVESTIGATOR_687520] 3rd cohort of explorer™3 (AUC and Cmax). The maximum predicted plasma exposure levels (Cmax and AUC 0-24 h) for the 
0.15 mg/kg daily dose level is predicted to be more than 8 fold lower than for 0.80 mg/kg Q4D. For 0.20 mg/kg daily both Cmax an d AUC 0-24h are 
predicted to be more than 3 times lower than for 0.80 mg/kg Q4D. For 0.25 mg/kg daily, the maximum Cmax and AUC 0-24h are predi cted to be 
35% lower than for 0.80 mg/kg Q4D .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931847], the titration trial design allows patients to start on a low 
dose, which is expected to ensure prophylaxis but not marked changes in coagulation parameters, 
for the majority of patients. Escalation to the next dose level will only occur in the case of lack of 
efficacy ( ≥ 3 spontaneous bleeding epi[INVESTIGATOR_535047] 12 weeks). In addition, the PK of 
concizumab is heavily influenced by [CONTACT_535219], which means that small 
differences in concizumab dose ultimately leads to large differences in plasma concentrations. 
Therefore, daily dosing is proposed for the phase 2 trial, explorer™4. Daily dosing will allow for 
the increase in trough levels and thus better efficacy may be expected with a lower dose.
A loading dose of 0.5 mg/kg concizumab will be given as the first dose, followed by [CONTACT_687617] 0.15 mg/kg in order to ensure steady-state levels at the time of eptacog alfa 
(rFVIIa) administration. eptacog alfa (rFVIIa) will be administered one week after initiation of 
dosing with concizumab in a non-bleeding state to assess safety of treatment with eptacog alfa 
(rFVIIa) in patients exposed to concizumab treatment.
Embryonic exposure in pregnant female partners of men treated with concizumab is highly unlikely 
and there is no need for protocol requirements for use of contraception in phase 2 and 3 trials.
5.3 Treatment of patients
The following products will be administered in the trial.
Table 5–[ADDRESS_931848] of products provided by [CONTACT_687624] B a100 mg/mL solution for s.c. 
injection in a 3 mL 
cartridgebSubcutaneous 
administration using
NovoPen®4For prophylactic 
treatment in 76 weeks 
(for concizumab arm in 
the main part and 
extension part).
For prophylactic 
treatment in 52 weeks 
(for comparator arm in 
the extension part).
eptacog alfa (rFVIIa)a, c5 mg/vial Powder for solution 
for i.v. injectionIntravenous 
administrationFor treatment of 
breakthrough bleeding 
epi[INVESTIGATOR_687521] (screening, 
main, extension and 
follow up part). c
Administration of 
doses higher than histidine solvent (5 mL) Prefilled syringes for 
solution for i.v. 
injection 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 36 of 137
90μg/kg to patients 
exposed to concizumab is not allowed.
For on-demand 
treatment at the discretion of the 
investigator in 24 
weeks for comparator 
arm in the main part. 
In the concizumab arm 
and comparator arm 
after switching to 
concizumab in the 
extension part of the 
study a single 90 μg/kg 
dose for initial safety assessments in a non-
bleeding state.
a
Will be provided for as 
long as patients 
participate in the trial 
(screening, main, extension and follow 
up part)
aInvestigational medicinal product (IMP)
b Not to be confused with the daily injected volume (~150 μL, depending on dose strength and body weight)
cNon-investigational medicinal product (NIMP)
The NovoPen®4 injector will be supplied by [CONTACT_535242] s.c. administration of 
concizumab. It will be labelled in accordance with national legislation and a copy of the label can 
be found in the Trial Materials Manual, see Section 9.
5.3.1 Concizumab arm
[IP_ADDRESS] Concizumab prophylactic treatment (main and extension part)
Concizumab will be given s.c. once daily 0.15 mg/kg (with potential dose escalation to 0.20 and 
0.25 mg/kg). The dose escalation criteria are described, see Section 5.3.[ADDRESS_931849] dose of 
concizumab will be given at the trial site under medical supervision. 
A loading dose of 0.5 mg/kg will be given as the first concizumab dose at visit 2 in order to ensure 
steady state levels at the time of the administration of eptacog alfa (rFVIIa) in a non-bleeding state 
at visit 3, see Section 5.3.4 . 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 37 of 137
The patients will be trained in s.c. administration of concizumab with NovoPen®[ADDRESS_931850] scheduled treatment visit. 
5.3.2 Comparator arm (eptacog alfa (rFVIIa))
[IP_ADDRESS] On-demand treatment (main part)
During the main part of the trial, patients will receive eptacog alfa (rFVIIa) for treatment of 
bleeding epi[INVESTIGATOR_1841], with a dose regimen at the discretion of the investigator.
[IP_ADDRESS] Concizumab prophylactic treatment (extension part)
After completion of the main part, the patients will continue the trial in the extension part and will 
switch to prophylactic treatment with s.c. daily administration of concizumab 0.15 mg/kg (with 
potential dose escalation to 0.20 and 0.25 mg/kg) s.c. daily administration. 
The same dose escalation criteria as described below (for the initial concizumab arm) will apply.
A loading dose of 0.5 mg/kg will be given as the first concizumab dose at visit [ADDRESS_931851] 2 weeks of the treatment with concizumab 0.15 mg/kg is considered as a run-in period. 
Hence, bleeding epi[INVESTIGATOR_687522] 2 weeks should not influence a dose escalation 
decision. 
All spontaneous bleeding epi[INVESTIGATOR_1841] (sBEs) are counted from 2 weeks after visit 2 (or visit 9 when
switching from eptacog alfa (rFVIIa) to concizumab) (first treatment visit) until visit 16 (end oftreatment visit), i.e. a total of [ADDRESS_931852] take into account the 
full clinical pi[INVESTIGATOR_535049], including 
coagulation parameters. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 38 of 137
Dose 0.15 mg/kg: 
When sBE occurs, the investigator will determine if ≥[ADDRESS_931853] occurred within the preceding 12
weeks (including the current sBE). If yes, and if investigator deems it safe, the patient will be dose 
escalated from 0.15 to 0.20 mg/kg at the next scheduled visit. If the investigator judges that this 
visit is scheduled too late, he/she should contact [CONTACT_687625].
Dose 0.20 mg/kg: 
When sBE occurs, the investigator will determine if ≥[ADDRESS_931854] occurred within the preceding 12
weeks (including the current sBE), counting only new sBEs from the beginning of the 0.20 mg/kg 
treatment period. If yes, and if investigator deems it safe, the patient will be dose escalated from 
0.20 to 0.25 mg/kg at the next scheduled visit. If the investigator judges that this visit is scheduled 
too late, he/she should contact [CONTACT_687625].
Dose 0.25 mg/kg: 
Patients are not dose escalated further regardless of the number of sBEs.The possibility of dose escalation at unscheduled visits is necessary in order to avoid  bleeding
epi[INVESTIGATOR_687523]: e.g. if the dose escalation eliciting bleeding epi[INVESTIGATOR_687524] a scheduled visit, the patient will avoid to wait8 weeks for the next scheduled visit (in the 
extension part).
Figure 5–3 Dose escalation for one individual patient in the concizumab arm
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 39 of 137
Figure 5–4 Dose escalation for one individual patient in the comparator arm
5.3.4 Co-administration of eptacog alfa (rFVIIa)
eptacog alfa (rFVIIa) will be used for treating breakthrough bleeding epi[INVESTIGATOR_687525]; one 
week after initiation of dosing with concizumab, a single 90 μg/kg dose of eptacog alfa (rFVIIa)
will be administered in a non-bleeding state at the trial site under medical supervision to assess 
safety of treatment with eptacog alfa (rFVIIa) in patients exposed to concizumab treatment. 
Hereafter, patients will be closely clinically observed at the site for potential safety issues for at 
least 12h and evaluated again at site after 24h. Between 12h and 24h, the patient must either stay at 
the site or at a hotel or at home if he lives nearby [CONTACT_687626] 3 or 9.1 the day after.
Dosing of eptacog alfa (rFVIIa) in the first 4 patients randomised to concizumab arm will be 
staggered so that the period between eptacog alfa (rFVIIa) administrations from one patient to 
another is at least 48 hours. If no safety concerns are observed (for example signs and symptoms of 
thromboembolism, such as swelling, pain and redness of the leg, shortness of breath, and chest 
pain) by [CONTACT_687627] (rFVIIa) and when 
the next daily concizumab dose is to be given, the investigator allows the individual patient to 
administer concizumab prophylactically at home and if needed, treat breakthrough bleeding 
epi[INVESTIGATOR_687526] (rFVIIa). The patients will receive prophylactic doses of 
concizumab 0.15 mg/kg daily throughout the main part (24 weeks) and the extension part (52 
weeks), unless dose escalation criteria are fulfilled, see Section 5.3.3 . 
In case safety concerns are raised by [CONTACT_687628] (rFVIIa) administration and 
these concerns meet the described criteria for putting enrolment of additional patients on hold, 
dosing in the individual patients will be halted and further recruitment in the trial will be halted, see 
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 40 of 137
Section 12.7.  In case safety concerns that do not meet the criteria for putting enrolment of 
additional patients on hold are observed by [CONTACT_093], dosing in that individual patient will be 
halted until further evaluation. In such cases, all available data will be assessed by [CONTACT_169645] (DMC), see Section 12.8.2 .
5.3.5 Treatment of bleeding epi[INVESTIGATOR_687527] 1 and visit 2 can be treated with any by[CONTACT_71360] 
(e.g., eptacog alfa (rFVIIa), FEIBA®) up to a period of 24 hours (for eptacog alfa (rFVIIa)) or 48 
hours (for FEIBA®) prior to first concizumab administration at visit 2. Novo Nordisk will provide 
eptacog alfa (rFVIIa) throughout the trial. The patient can treat himself and then he must call the 
site. The bleeding epi[INVESTIGATOR_687528]. 
Breakthrough bleeding epi[INVESTIGATOR_687529] 2-[ADDRESS_931855] be treated with eptacog alfa (rFVIIa). Upon breakthrough bleeding epi[INVESTIGATOR_687530]. The investigator should instruct the patient about 
whether he should go to the site to receive treatment or if he can administer a single dose of eptacog 
alfa (rFVIIa) which is not higher than 90 μg/kg without delay to treat the breakthrough bleeding
epi[INVESTIGATOR_1865]. If the patient is instructed to administer the eptacog alfa (rFVIIa) dose at home, following 
the administration, the patient should immediately go to the site for further clinical evaluation. The 
bleeding epi[INVESTIGATOR_687531] (eDiary).
Breakthrough bleeding epi[INVESTIGATOR_687529] [ADDRESS_931856] be treated 
with eptacog alfa (rFVIIa). The patient can treat himself without delay but must inform the site that 
a bleeding epi[INVESTIGATOR_71274]. Doses of eptacog alfa (rFVIIa) that are lower than 90 μg/kg may be 
used to treat breakthrough bleeding epi[INVESTIGATOR_687532]. Administration of 
doses higher than 90 μg/kg to patients exposed to concizumab is not allowed. If a single dose of 
eptacog alfa (rFVIIa) is not sufficient to stop a bleeding epi[INVESTIGATOR_1865], the patient should inform the site 
and in agreement with the investigator may administer a second dose of eptacog alfa (rFVIIa) not 
higher than 90 μg/kg 2-3h after the first dose has been administered. The same procedure should be 
repeated in case the second dose of eptacog alfa (rFVIIa) is not sufficient to stop the bleeding 
epi[INVESTIGATOR_1865]. If more than three 90 μg/kg doses of eptacog alfa (rFVIIa) are needed to stop a bleeding 
epi[INVESTIGATOR_1865], the patient should go to the site without delay. The definition and diagnostic criteria of 
DIC, acute myocardial infraction, stroke, deep vein thrombosis, pulmonary embolism and 
peripheral artery occlusion is provided in section 12.1.[ADDRESS_931857] be recorded in 
the eDiary.
Breakthrough bleeding epi[INVESTIGATOR_687529] 16 and visit 17 (follow-up part) may be treated with 
eptacog alfa (rFVIIa) or other products at the discretion of the investigator. The patient can treat 
himself with eptacog alfa (rFVIIa) at home without delay. Only eptacog alfa (rFVIIa) will be 
provided by [CONTACT_3454]. The bleeding epi[INVESTIGATOR_535167].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 41 of 137
See Table 5–1 and Table 8–3 .
5.3.6 Prohibited medication 
∀Treatment with anti-fibrinolytics (e.g. tranexamic acid, aminocaproic acid)
∀Heparin, except for sealing of central venous access ports according to local practice
∀Vitamin-K antagonists
∀Direct oral anticoagulants (DOACs)
∀Home treatment (between visit 2 and visit 16) with activated prothrombin complex 
concentrates (FEIBA®)
5.[ADDRESS_931858]
When discontinuing trial products (visit 16 or earlier), the patient should be switched to a suitable 
marketed product at the discretion of the investigator. Only eptacog alfa (rFVIIa) will be provided by [CONTACT_3454]. The patient will not be provided with concizumab or eptacog alfa (rFVIIa) after 
end of trial (EOT) (visit 17) by [CONTACT_3454].
5.[ADDRESS_931859] 24 weeks (the main part of the trial) is considered necessary for 
providing robust data that allow demonstration of clinical proof of concept and to support decision 
making regarding a phase 3 confirmatory trial. Dosing for additional 52 weeks will provide 
valuable long term efficacy and safety data.
Breakthrough bleeding epi[INVESTIGATOR_687533]. Therefore, it is expected that breakthrough bleeding epi[INVESTIGATOR_687534]. 
Consequently, eptacog alfa (rFVIIa) will be provided by [CONTACT_687629][INVESTIGATOR_1841]. In order to minimize the likelihood of any unforeseen adverse 
events associated with administration of eptacog alfa (rFVIIa) in these circumstances,
administration of eptacog alfa (rFVIIa) in a controlled setting will be performed at visit 3 or 9.1. 
Please refer to the Investigator’s Brochure for further information.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 42 of 137
6 Trial population
6.1 Number of patients
Number of patients planned to be screened: [ADDRESS_931860]: 26
Number of patients expected to complete the trial: 24
∀Preferably 21 haemophilia A patients
∀Preferably [ADDRESS_931861] be answered “yes”. 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine the suitability 
for the trial
2. Male haemophilia A or B patients with inhibitors aged ≥ 18 years at the time of signing 
informed consent
3. For patients treated on-demand, a minimum of six bleeding epi[INVESTIGATOR_8728] 24 weeks (or 
twelve bleeds during 52 weeks) prior to screening
4. Documented history of high-titer inhibitors towards FVIII or FIX, defined as ≥[ADDRESS_931862] be answered “no”. 
1. Known or suspected hypersensitivity to trial product(s) or related products
2. Previous participation in this trial. Participation is defined as signed informed consent
3. Participation in any clinical trial of an approved or non-approved investigational medicinal 
product within the last 30 days or 5 half-lives (whichever is longer) from the last drug 
administration before screening
4. Any disorder which in the investigator’s opi[INVESTIGATOR_1649], might jeopardise patient’s safety or 
compliance with the protocol
5. Known inherited or acquired bleeding disorder other than haemophilia
6. Major surgery conducted within one month prior to the initiation of trial activities or major 
surgery planned to occur during the trial3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931863] a significant infection or known systemic inflammatory 
condition which requires systemic treatment according to the investigator’s judgement
10. Hepatic dysfunction defined as elevated liver transaminases (ALT) >3 times the upper limit of 
normal laboratory reference ranges at screening
11. Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) ≤ 60 ml/min/1.73 
m2for serum creatinine measured at screening for patients without evidence of renal damage
12. Platelet count ≤ 100x109/L at screening
13. Fibrinogen level < the lower limit of normal
14. Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX
15. Antithrombin levels below the normal reference range at screening
6.[ADDRESS_931864] if the following applies:
1. Included in the trial in violation of the inclusion and/or exclusion criteria and/or randomised in 
violation of the randomisation criteria
2. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
3. Incapacity or unwillingness to follow the trial procedures
4. Anaphylactic reaction 
5. Thromboembolic event
6. Event of Disseminated Intravascular Coagulation
7. Loss of efficacy due to neutralizing antibodies
See Section 8.1.[ADDRESS_931865] 
prematurely.
6.5 Withdrawal from trial
The patient may withdraw consent at will at any time. 
See section 8.1.5 for procedures to be performed for patients withdrawing consent.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931866] been treated and therefore familiar 
with eptacog alfa (rFVIIa) on-demand treatment, this trial population is considered the most suitable 
for assessing the safety of administering eptacog alfa (rFVIIa) to patients in whom plasma TFPI 
[INVESTIGATOR_687535]. Finally, the trial population reflects the patient population that will be selected 
in a potential subsequent phase 3 trial in which the efficacy and safety of concizumab are to be 
confirmed.  3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 45 of 137
7 Milestones
Planned duration of recruitment period (FPFV-LPFV): 28 weeks
Planned FPFV: 16-Aug-2017
Planned FPFT: 30-Aug-2017
Planned LPFV: 28-Feb-2018
Planned LPLV: 23-Oct-2019
The total duration of concizumab treatment in this trial is 76 weeks for an individual patient
randomised to concizumab prophylaxis treatment at visit 2.
The total duration of concizumab treatment in the trial is 52 weeks for an individual patient 
randomised to eptacog alfa (rFVIIa) on-demand treatment at visit 2.
EOT is defined as last patient last visit (LPLV).
Recruitment
The screening and randomisation rate will be followed closely via the interactive web response 
system (IWRS) in order to estimate when to stop screening. All investigators will be notified 
immediately when the recruitment period ends, after which no further patients may be screened and 
the IWRS will be closed for further screening. All patients screened during the recruitment period 
and found eligible for randomisation can be randomised in a 2:1 allocation to either the concizumab 
or the comparator arm within the timelines specified in the flow chart (see Section 2).
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov, novonordisk-trials.com and 
clinicaltrials.jp. According to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure,
how-we-disclose-trial-information, it will also be disclosed according to other applicable 
requirements such as those of the International Committee of Medical Journal Editors (ICMJE),[ADDRESS_931867] (FDAAA),13European Commission 
Requirements,[ADDRESS_931868] at these web sites, Novo Nordisk may 
disclose the investigator’s contact [CONTACT_49707]. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.
Primary Completion Date (PCD) is the last assessment of the primary endpoint, and is for this 
protocol LPFT (visit 2) + [ADDRESS_931869] completed visit 9. The PCD determines the 
deadline for results disclosure at ClinicalTrials.gov according to FDAAA.133URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 46 of 137
8 Methods and assessments
Assessments to be performed at the scheduled and at the unscheduled visits in the trial are described 
in this section, Figure 8–1 , Figure 8–2 and in Section 2.  
Figure 8–1 Visit schedule – concizumab arm.
Figure 8–2 Visit schedule – eptacog alfa (rFVIIa) arm later switching to concizumab.
8.[ADDRESS_931870] of the following scheduled parts and visits depending upon
which arm the patient is randomised to:
Screening Part:
∀Visit 1 (screening visit)
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 47 of 137
Main Part:
∀Visit 2 (Randomisation and 1sttreatment visit with concizumab at site for patients 
randomised to the concizumab-arm)
∀Home treatment with concizumab daily
∀Visit 3 (treatment and PK-visit with concizumab and eptacog alfa (rFVIIa) at site only for 
patients randomised to the concizumab-arm - phone visit for patients randomised to the 
eptacog alfa (rFVIIa) on-demand arm)
∀Visit 4 (Assessment visit, patients treat themselves at home)
∀Visit 5 (Assessment visit, patients treat themselves at home)
∀Visit 6 (Assessment visit, patients treat themselves at home)
∀Visit 7 (Assessment visit, patients treat themselves at home)
∀Visit 8 (Assessment visit, patients treat themselves at home)
∀Visit 9 (Assessment visit, after the visit patients treat themselves at home – 1sttreatment 
visit with concizumab at site for patients randomised to the eptacog alfa (rFVIIa) arm)
Extension Part:
∀Visit 9.1 (treatment and PK-visit with concizumab and eptacog alfa (rFVIIa) at site ONLY
for patients randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 9.2 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 10 (Assessment visit, patients treat themselves at home)
∀Visit 10.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 11 (Assessment visit, patients treat themselves at home)
∀Visit 11.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on demand-arm)
∀Visit 12 (Assessment visit, patients treat themselves at home)
∀Visit 13 (Assessment visit, patients treat themselves at home)
∀Visit 14 (Assessment visit, patients treat themselves at home)
∀Visit 15 (Assessment visit, patients treat themselves at home)
∀Visit 16 (Assessment visit, no treatment at home before the visit and End of Treatment)
Follow-up Part:
∀Visit 17 (Assessment visit and End of Trial)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 48 of 137
Unscheduled Part: 
∀Unscheduled visits can occur e.g. for dispensing of trial product, dose escalation or when an 
assessment of bleeding epi[INVESTIGATOR_535056].
The duration of the visits (V1-V17) will depend on the assessments and the patient’s individual 
training and/or discussion need on concizumab and eptacog alfa (rFVIIa) administration, 
NovoPen®4, usage of eDiary, completion of the PRO etc.
8.1.[ADDRESS_931871] be obtained before any trial related activity at visit 1, see Section 18.2.
The trial includes a separate informed consent for long-term storage of human biosamples, see 
Section 24.2.
Storage of human biosamples and/or genotypi[INVESTIGATOR_687536]’ 
participation in the trial. Therefore, patients will have the possibility to sign the informed consent 
for the trial and participate, while refusing permission for biological specimens and/or genotypi[INVESTIGATOR_535057].
8.1.[ADDRESS_931872] address(es) and telephone number(s) of relevant trial clinic staff. Patients should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
Each patient will be assigned a unique 6-digit patient number which will remain the same 
throughout the trial.
8.1.3 Screening failures and re-screening
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reason for not continuing in the trial.
Serious and non-serious adverse events from screening failures must be transcribed by [CONTACT_687630]. Follow-up on serious adverse events (SAEs) must be carried out 
according to Section 12. A screening failure session must be made in the IWRS. The case book 
must be signed in the eCRF. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 49 of 137
Re-screening is NOT allowed if the patient has failed one of the inclusion or exclusion criteria; this 
includes re-sampling if the patient has failed one of the inclusion or exclusion criteria related to 
laboratory parameters. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931873] undertake procedures 
similar to those for visit 9 (the last treatment in the main part) or visit 16 (the last treatment visit in 
the extension part) as soon as possible. The follow up visit (visit 17) must be performed 8 weeks 
(window minus 7 days) after last dose of trial drug. 
The primary reason for premature discontinuation of trial product must be specified in the end of 
treatment form in the eCRF, and final drug accountability must be performed. A treatment 
discontinuation session must be made in the IWRS.
Permanent premature discontinuation of treatment with trial product will lead to patient withdrawal 
from the trial.
8.1.[ADDRESS_931874] aim to undertake procedures similar to those 
for visit 9 (the last visit in the main part) or visit 16 (the last visit in the extension part) as soon as 
possible depending on where the patient is in the trial schedule.
The end-of-trial form must be completed, and final drug accountability must be performed even if 
the patient is not able to come to the trial site. A treatment discontinuation session must be made in 
the IWRS and the case book must be signed in the eCRF.
Although a patient is not obliged to give his reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the patient’s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in 
the end-of-trial form in the eCRF.
8.1.6 Review/ evaluation of clinical outcome
Novo Nordisk has constituted an internal concizumab safety committee and established an external 
DMC to perform ongoing safety surveillance of safety data relevant to concizumab, see Section 
12.8.
Review of eDiary data and laboratory reports etc. must be documented either on the documents or 
in the patient’s medical record.
If unclear entries or discrepancies in the eDiary or ePRO are identified and a clarification is needed, 
the patient must be asked for clarification and a conclusion made in the patient’s medical record. 
Care must be taken not to bias the patient.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 51 of 137
8.1.7 Visit 1 (Screening part)
Informed consent must be obtained before any trial related activity, see Section 18.2
All assessments to be performed at screening are listed in Section 2.
After informed consent is given, patients will be asked to complete the ePRO questionnaires before 
any other trial related activities are performed according to Section 8.6.1 :
∀Hemo-TEM,
∀VERITAS-Pro®or VERITAS-PRN®
Assessment results from physical examination and body measurements, as well as measurements of 
vital signs, urinalysis and ECG and details of any contemporary adverse events, must be entered 
into the eCRF.
A screening confirmation call must be performed in the IWRS, at the day of the visit.
The investigator must review all information obtained from the screening procedures. If a patient 
does not meet all inclusion criteria or meets one or more of the exclusion criteria for the trial the 
patient does not qualify to be enrolled.
For bleeding epi[INVESTIGATOR_535058] (Visit1) to randomisation visit 
(Visit 2), information about the bleeding epi[INVESTIGATOR_535059] 2. 
Patients will be provided with eptacog alfa (rFVIIa), trial injection kits and direction for use (DFU) 
to cover the potential eptacog alfa (rFVIIa) treatment after the screening part of the trial and 
investigator will ensure that the patients are capable of treating themselves with eptacog alfa 
(rFVIIa).
Dispensing of eptacog alfa (rFVIIa) should be performed in IWRS.
The patient must be instructed to call the site if any bleeding epi[INVESTIGATOR_1841], questions or issues arise after 
he has left the site.
8.1.8 Training of patients at visit 1, visit 2 and visit 9
During visit 1 and visit 2 and visit 9 (comparator arm) patients must be trained in self-
administration of concizumab in the home setting using NovoPen®4. The dose of concizumab to be 
administered must be communicated to the patient at visit 2 (if they are randomised to concizumab) 
or at visit 9 (if they are randomised to eptacog alfa (rFVIIa) and switching to concizumab at visit 9). 
Furthermore, patients must be instructed and trained in the importance of reporting all the home 
treatments with concizumab, details of the bleeding epi[INVESTIGATOR_687537] (rFVIIa) 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931875], performed independently by [CONTACT_4677], preferably in the morning. Home treatment starts after visit 2 (concizumab arm) or when the 
patient is comfortable self-administrating trial product subcutaneously (concizumab) and 
intravenously (eptacog alfa (rFVIIa)).
8.1.10 Staggered recruitment
Dosing of eptacog alfa (rFVIIa) in the first 4 patients randomised to the concizumab arm will be 
staggered until the 4thpatient randomised to the concizumab arm has completed visit 3 without any 
safety concerns raised by [CONTACT_093]. Until this time point, enrolled patients will not be 
randomised until the previous patient randomised to concizumab has completed visit 3 without any 
safety concerns raised by [CONTACT_093]. Novo Nordisk will as sponsor control and communicate 
the staggered recruitment process. 
8.1.11 Treatment period – Main part
[IP_ADDRESS] Visit 2 (Randomisation)
Visit 2 should be scheduled 14 to 28 days after visit 1. The date of visit 2 will be considered as trial 
day 1.
It is important to verify the in/exclusion criteria again and review central laboratory tests from 
screening. 
The patients must be in a non-bleeding state and should not have received any by[CONTACT_71360] 
(e.g., eptacog alfa (rFVIIa), FEIBA®) for treatment of bleeding epi[INVESTIGATOR_42988] a period of 24 hours 
(for eptacog alfa (rFVIIa)) or 48 hours (for FEIBA®) prior to the potential first concizumab 
administration (depending on the treatment arm). After visit 2 only treatment with eptacog alfa 
(rFVIIa) for bleeding epi[INVESTIGATOR_71249].
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 53 of 137
∀Hemo-TEM
∀SF-36v2 
∀SDS
∀TSQM 
∀SIAQ-ISRQ
All assessments listed in 2, must be performed before potential administration of concizumab
(depending on the treatment arm). Vital signs must be assessed both before (within 1 hour) and after 
concizumab administration. Pre-dose blood sampling must take place no more than 1 hour before 
concizumab administration. 
Assessment results from concomitant medication, vital signs, body measurement (weight only) and 
details of adverse events must be entered into the eCRF.
A randomisation and dispensing call must be performed in the IWRS. 
In order to determine the correct amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the Trial Materials Manual (TMM) on 
basis of the patient’s current body weight. Investigator will communicate the daily dose of 
concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
For patients randomised to the concizumab arm, the first treatment with the loading dose of 
concizumab will be given. 
The time point at which the completion of the first dose takes place corresponds to ‘Time on 
treatment’ = [ADDRESS_931876] concizumab and/or eptacog alfa (rFVIIa)
and trial injection kits and an eDiary device to be able to conduct and report home treatment and 
bleeding epi[INVESTIGATOR_687538].
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa) during the 
trial as instructed by [CONTACT_093]. Drug accountability must be performed for eptacog alfa 
(rFVIIa), if applicable according to section 9.4.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site. If the patient on concizumab needs to treat a 
bleeding epi[INVESTIGATOR_687540] (rFVIIa) at home, then he must visit the site immediately after. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 54 of 137
[IP_ADDRESS] Visit 3 (Phone call for eptacog alfa (rFVIIa) on-demand arm and PK visit for 
concizumab arm)
eptacog alfa (rFVIIa) on-demand arm:
Visit 3 for eptacog alfa (rFVIIa) on-demand arm is a phone call scheduled 7 days after visit 2 (with 
a visit window of +1 day).
All relevant assessments listed in Section 2, must be discussed.
Assessment results from concomitant medication and details of adverse events must be entered into 
the eCRF.
concizumab arm:
Visit 3 is to be scheduled 7 days after visit 2 (with a visit window of +1 day) and the visit takes two 
days. 
All assessments are listed in Section 2, and must be performed accordingly and recorded in the 
eCRF.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to Section 8.6.1 :
∀PGI-C
∀Hemo-TEM
Pre-dose blood sampling must take place no more than 1 hour before eptacog alfa (rFVIIa)
administration. Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa) dosing.
eptacog alfa (rFVIIa) should be administered to the trial patients at the site under the surveillance of 
medically trained trial site staff. Patient should continue his daily concizumab injections regardless 
of eptacog alfa (rFVIIa) administration. 
Samples for thrombin generation, haematology, coagulation parameters and FVII ELISA are taken 
pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h 
(± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (±20 min) and 24h (±20 min). 
The investigator must ensure all assessments are performed as described in Section 2, Investigator 
is requested to conclude after [ADDRESS_931877] four patients will be staggered according to section 8.1.9 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931878] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visits the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until the next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site. 
[IP_ADDRESS] Visit 4, 5, 6, 7 and 8
Patients should treat themselves at home according to their individual dosing schedule regardless of 
when visits 4, 5, 6, 7 and 8 are scheduled. 
Visits 4, 5, 6, 7 and 8 are to be scheduled on trial day 29 (4 weeks), day 57 (8 weeks), day 85 (12 
weeks), day 113 (16 weeks) and day 141 (20 weeks) respectively with a visit window of ±7days.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀PGI-C
∀Hemo-TEM
All assessments are to be performed according to Section 2, and the assessment results from 
concomitant medication, vital signs, body measurement (weight only) and details of adverse events 
must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687541] e-Diary. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients randomised to concizumab arm at visit 2, 
evaluate if an escalation of the concizumab doses is needed according to the escalation rules 
described in section 5.3.[ADDRESS_931879] be performed in the IWRS.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931880] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visits the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until the next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
At visit 8 patients should be reminded that treatment with concizumab (concizumab arm) must take 
place after the blood sampling at visit 9.
[IP_ADDRESS] Visit 9
Visit 9 is to be scheduled on trial day 169 (24 weeks) with a visit window of ±7days.
Patients randomised to eptacog alfa (rFVIIa) on-demand treatment at visit [ADDRESS_931881] treatment (loading dose) with concizumab will take 
place. 
Treatment with concizumab must take place after the blood sampling for both the patients on the 
concizumab arm as well as patients on the eptacog alfa (rFVIIa on-demand) arm.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀PGI-C
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments are to be performed according to Section 2, and the assessment results from 
physical examination, concomitant medication, vital signs, body measurement (weight only) and 
details of adverse events must be entered into the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931882] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab and eptacog alfa 
(rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be performed 
for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
8.1.12 Treatment period – Extension part
[IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog alfa (rFVIIa)
on-demand arm)
Visit 9.1 is to be scheduled on trial day 176 (25 weeks) with a visit window of +[ADDRESS_931883] no more than 1 hour before eptacog alfa (rFVIIa)
administration. Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa) dosing.
eptacog alfa (rFVIIa) should be administered at the site under the surveillance of medically trained 
trial site staff. Patient should continue his daily concizumab injections regardless of eptacog alfa 
(rFVIIa) administration. 
A dispensing call must be performed in the IWRS.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931884] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
Samples for thrombin generation, haematology, coagulation parameters and FVII ELISA are taken 
pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h 
(± 10 min), 3h (± 10 min), 6h (± 10 min), 9 h (± 10 min) and 12h (±20 min) and 24h (±20 min). 
Investigator is requested to conclude after [ADDRESS_931885] the conclusion in the eCRF before the next dose of concizumab is given the day after. 
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 9.2 (ONLY patients previously on the eptacog alfa (rFVIIa) on-demand 
arm)
Visit 9.2 is to be scheduled on trial day 197 (28 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, 
evaluate if an escalation of the concizumab doses is needed according to the escalation rules 
described in section 5.3.[ADDRESS_931886] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931887] the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 10
Visits 10 is to be scheduled on trial day 225 (32 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight only) and details of adverse events must be entered into the 
eCRF.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 .
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687543] 5.3.[ADDRESS_931888] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 60 of 137
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 10.1 (ONLY patients previously on the eptacog alfa (rFVIIa) on-demand 
arm)
Visit 10.1 is to be scheduled on trial day 253 (36 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, 
evaluate if an escalation of the concizumab doses is needed according to the escalation rules 
described in section 5.3.[ADDRESS_931889] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 61 of 137
[IP_ADDRESS] Visit 11
Visit 11 is to be scheduled on trial day 281 (40 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687543] 5.3.[ADDRESS_931890] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site. 
[IP_ADDRESS] Visit 11.1 (ONLY patients previously on the rFVIIa on-demand arm) 
Visit 11.1 is to be scheduled on trial day 309 (44 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, 
evaluate if an escalation of the concizumab doses is needed according to the escalation rules 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931891] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 12, 13, 14 and 15
Visits 12, 13, 14 and 15 are to be scheduled on trial day 337 (48 weeks), 393(56 weeks), day 449 
(64 weeks) and day 505 (72 weeks) respectively with a visit window of ±7 days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687543] 5.3.[ADDRESS_931892] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 63 of 137
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site. 
At visit [ADDRESS_931893] after the 
blood sampling at visit 16.
[IP_ADDRESS] Visit 16
Visit 16 is to be scheduled on trial day 533 (76 weeks) with a visit window of ±7days. Further visit 
[ADDRESS_931894] day of treatment with concizumab.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs and details of adverse events must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. 
In the period from visit 16 to visit 17 patients can be treated with eptacog alfa (rFVIIa) or other 
products at the discretion of the investigator to treat eventual bleeding epi[INVESTIGATOR_1841]. Only eptacog alfa 
(rFVIIa) will be provided by [CONTACT_687631].  
If necessary, a dispensing call must be performed in the IWRS. At the visit the patient will be 
provided with eptacog alfa (rFVIIa) and trial injection kits to be able to conduct home treatment 
until next scheduled visit. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 64 of 137
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. NovoPen®[ADDRESS_931895] be performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_1841]) arise 
after he has left the site. 
8.1.13 Visit 17 (End of trial) - Follow-up part
Visit 17 is to be scheduled on trial day 589 (84 weeks) with a visit window of minus 7 days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
physical examination, body measurements (weight only), vital signs and details of adverse events 
must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687544]. Patients should be asked if their female partner has become 
pregnant, see Section 12.5.1 .
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa), eDiary 
device and Trial card. Drug accountability must be performed for eptacog alfa (rFVIIa).
End-of-Trial information must be entered in the End-of-Trial form in the eCRF.
Completion or treatment discontinuation (if the trial is not completed) session should be performed 
in IWRS, see Section 10.
8.1.[ADDRESS_931896] be 
performed via IWRS.
The following forms can be found in the unscheduled visit in the eCRF:
∀Bleeding epi[INVESTIGATOR_1841]
∀Dosing with eptacog alfa (rFVIIa), concizumab including dose escalation, see Section 5.3.3 .
∀Surgery3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 65 of 137
∀Local, special and central laboratory (re-)sampling/results
∀Body measurements
8.2 Patient related information/assessments 
8.2.1 Demography
Demography will be recorded at screening and consists of:
∀Date of birth (according to local regulation)
∀Sex 
∀Ethnicity (according to local regulation)
∀Race (according to local regulation)
8.2.2 Concomitant illness and medical history other than haemophilia
A concomitant illness is any illness, other than haemophilia, that is present at the start of the trial 
(i.e. at the first visit) or found as a result of a screening procedure or other trial procedures 
performed before first exposure to trial product. All concomitant illnesses should be reported in the 
concomitant illness forms in the eCRF except information on haemophilia with inhibitors which is 
to be reported in the haemophilia medical history section of the eCRF.
Medical history is a medical event, other than haemophilia, which the patient has experienced in 
the past. Only relevant medical history should be reported. 
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable. 
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE. 
It must be possible to verify the patient’s medical history in source documents such as patient’s 
medical record, see Section 6.2and 6.3.
If a patient is not from the investigators own practice; the investigator must make a reasonable 
effort to obtain a copy of the patient’s medical record from relevant party e.g. primary physician.  
The investigator must document any attempt to obtain external medical information by [CONTACT_135540](s) when information was requested and who has been contact[INVESTIGATOR_530].  
8.2.3 Concomitant medication
A concomitant medication is any medication, other than the concizumab and eptacog alfa 
(rFVIIa), which is taken during the trial, including the screening and follow-up period .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931897] be reported according to Section 12. If the change 
influences the patient’s eligibility to continue in the trial, the monitor must be informed.
8.2.4 Details of Haemophilia, Haemophilia treatment and bleed history
All available information on haemophilia, prior to screening should be recorded in the eCRF. 
∀Diagnosis of haemophilia (date)
oClassification of haemophilia type (haemophilia A/B) 
oSeverity of haemophilia (severe, moderate or mild)
oAetiology of haemophilia (congenital or acquired)
∀Family history of
oHaemophilia (Y/N)
oInhibitors (Y/N)
oProthrombotic disorders (Y/N)
oThromboembolism (Y/N)
∀Inhibitor tests taken (Y/N)
oDate (dd-mmm-yyyy) 
oResult (BU)
∀Cut-off for positive inhibitor result
∀Deficiency factor level
The following information on bleeding epi[INVESTIGATOR_535068]:
∀Type of treatment 
oProphylaxis or on-demand
oStart date 
oStop date 
∀Number of bleeding epi[INVESTIGATOR_535069]
∀Coagulation factor product(s)
oBrand name, or if the brand is not known, the type of product, (plasma derived or 
recombinant)
∀Dosage used for prophylaxis
∀Dosing frequency during prophylaxis 
∀Approximate dose to treat a bleeding epi[INVESTIGATOR_1865] 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 67 of 137
∀Approximate number of doses to treat a bleeding epi[INVESTIGATOR_1865]
∀Target joint listing (definition: a target joint is a joint in which [ADDRESS_931898] occurred within a consecutive 6-month period)
oLocation
oPosition (left/right)
oNumber of bleeding epi[INVESTIGATOR_1841]
8.3 Efficacy assessments
8.3.1 Bleeding epi[INVESTIGATOR_687545] (rFVIIa) and symptoms related to the underlying 
disease must be captured in the eDiary by [CONTACT_535227]. The trial 
site should be informed of the details of all bleeding epi[INVESTIGATOR_1841], including those that are treated 
outside of the trial site. 
All information captured during visits to the trial site will be collected in the eCRF. 
When home treatment is initiated at visit 2 all bleeding epi[INVESTIGATOR_687546] (rFVIIa) injection occurring outside the trial site should be entered in the eDiary by 
[CONTACT_102], Section 13.3.
The completed eDiary is considered source data.
For reporting of bleeding epi[INVESTIGATOR_687547]/SAEs, please refer to Section 12. In case of life-
threatening bleeding epi[INVESTIGATOR_1865], it should always be reported as an SAE, see Section 12.1.[ADDRESS_931899] be recorded for any bleeding epi[INVESTIGATOR_1865], including bleeding epi[INVESTIGATOR_687548] (rFVIIa):
∀Start date and time
∀Stop date and time (see Table 8–1 )
∀Anatomical location
oPosition (left/right)
∀Cause (see Table 8–2 )
ospontaneous
otraumatic
opost-surgical
∀Severity (see Table 8–3 )
omild/moderate, severe
oclassification and recording of severe bleeding epi[INVESTIGATOR_687549]
∀Treatment, if any 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 68 of 137
oeptacog alfa (rFVIIa) administration or other product administration 
odose, date, stop time 
oother medicinal treatments related to the bleeding epi[INVESTIGATOR_1865] (pain relieving 
medication, non-medical therapy etc.)
orecord as concomitant medication  (section 8.2.3 )
∀Symptoms during bleeding epi[INVESTIGATOR_1865](s)
oPain 
oBlood in urine
oTingling sensation
oSwelling
oMouth/Gum bleed
oWarmth
oLoss of movement
oBruises
oNose bleed
Only report the bleeding epi[INVESTIGATOR_535074]/SAE if fatal, life threatening or evaluated as related to 
trial product, see Section 12.1.1 and12.1.2 .
Table 8–1 Definition of stop of bleeding epi[INVESTIGATOR_535075]: When the patient experiences/observes signs of cessation of the active bleeding 
epi[INVESTIGATOR_535076]; pain relief, no increase in swelling/limitation of motion and 
improvement in other objective signs of the bleeding epi[INVESTIGATOR_535077]: When pain and objective signs of the bleeding epi[INVESTIGATOR_687550] 8–2 Definitions of bleeding epi[INVESTIGATOR_1841] (cause of bleed)
Category Definition
Spontaneous Not linked to a specific, known action or event
Traumatic Caused by a specific, known action or event (e.g. injury or exercise)
Post-surgical Bleeding epi[INVESTIGATOR_535079]. Bleeding epi[INVESTIGATOR_687551]3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 69 of 137
Table 8–3 Definition of bleeding epi[INVESTIGATOR_535081]/Moderate Examples: uncomplicated musculoskeletal 
bleeding epi[INVESTIGATOR_1841] (joint, muscular bleeding 
epi[INVESTIGATOR_434840]), 
mucosal- or subcutaneous bleeding epi[INVESTIGATOR_434838]/moderate bleeding epi[INVESTIGATOR_687552]/moderate bleeding epi[INVESTIGATOR_1841]: 
∀patient must call the site between 
visit 1-2 and visit 3-16 (see 2-3 
and 9-9.1 below)
∀patient must call the site between 
visit 2-3 or visit 9-9.1 (eptacog 
alfa arm) and if treated at home, 
go to the site immediately after
∀patient can treat themselves at 
home between visit 16 and visit 17
Severe Examples: intracranial, retroperitoneal, 
iliopsoas and internal neck bleeding epi[INVESTIGATOR_1841]; 
muscle bleeding epi[INVESTIGATOR_535145]; bleeding epi[INVESTIGATOR_80799] 
a significant decrease in the haemoglobin 
level (>3g/dl)
Severe bleeding epi[INVESTIGATOR_535085]-threatening bleeding epi[INVESTIGATOR_687553] a bleeding epi[INVESTIGATOR_687554], i.e. the original dosing schedule should be maintained unless investigator judges 
otherwise. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 70 of 137
Dosing for bleeding epi[INVESTIGATOR_687555] (rFVIIa) should be documented in the eCRF (visit 1 
to visit 2) and eDiary (visit 2 to visit 17). After visit [ADDRESS_931900] be recorded either in 
the eDiary (if treated at home) or in the eCRF (if treated at the trial site), see section 13.3.
Investigator must instruct the patient not to perform preventive treatment with eptacog alfa (rFVIIa)
after bleeding stop as defined in Table 8–[ADDRESS_931901] the patient to use eptacog alfa (rFVIIa) as rescue medication to treat 
bleeding epi[INVESTIGATOR_488840] [ADDRESS_931902] review the bleeding and treatment data collected by [CONTACT_687632] 13.3.
For in-between visit administrations of trial drug, patients will self-administer concizumab (and 
eptacog alfa (rFVIIa) as rescue medication) and will record treatment in the eDiary, which will be 
reviewed during periodic calls to/contact [CONTACT_687633].
8.[ADDRESS_931903] physical examination and include the following.
∀General appearance
∀Head, ears, eyes, nose, throat, neck
∀Respi[INVESTIGATOR_2133]
∀Cardiovascular system
∀Gastrointestinal system including mouth
∀Genito-urinary system, breast(s)
∀Musculoskeletal system
∀Central and peripheral nervous system
∀Skin
∀Lymph node palpation
The investigator must evaluate the results of the examination and classify them as either:
∀Normal or abnormal
∀If abnormal the investigator must: 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931904] if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as Medical History (Section 8.2.2 )
oIf observed after screening: report an AE/SAE (Section 12)
Measurements will be reported in the eCRF.
8.4.2 Body measurements
∀Height (cm), at screening
∀Body weight (kg), (with one decimal)
The body weight assessed at each visit will be used for calculation of the concizumab dose to be 
administered until next visit.
Measurements will be reported in the eCRF.
8.4.[ADDRESS_931905] administration unless otherwise 
specified.
∀Body temperature (°C)
∀Systolic and diastolic blood pressure, sitting (BP) (mmHg)
∀Pulse, sitting (beats/min)
∀Respi[INVESTIGATOR_535095]: At visits 2 and visit 3 (for patients randomised to concizumab) and at visit 9 and visit 9.1
(for patients initiating concizumab treatment at visit 9), the measurements are also performed after 
concizumab administration.
The investigator must evaluate the vital signs and classify the outcome as either: 
∀Normal or abnormal
∀If abnormal the investigator must: 
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness, section 8.2.2
oIf observed after screening: report an AE/SAE, section 123URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931906] evaluate the ECG [standard 12 lead] at screening and classify the outcome as
either:
∀Normal or abnormal. 
∀If abnormal the investigator must: 
oSpecify the abnormality
oRecord if the result is clinically significant? (Yes/No)
oIf observed before or at Screening: record as Medical History, section 8.2.2
oIf observed after screening: report an AE/SAE, section [ADDRESS_931907] been 
reviewed. Outcome will be reported in the eCRF.
8.4.5 Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12. 
[IP_ADDRESS] Medication error
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form: 
∀Trial product involved 
∀Classification of medication error
∀Whether the patient experienced any adverse event(s) as a result of the medication error 
∀Suspected primary reason for the medication error 
For definition of medication errors, see Section 12.1.4 .
[IP_ADDRESS] Adverse events requiring additional data collection
For some AEs additional data collection is required and specific event forms must be completed in 
the eCRF in addition to the AE form . 
In case any of these events fulfil the criteria for a serious adverse event, please report accordingly, 
see Section 12.
For the following AEs additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 73 of 137
Injection site reaction 
Investigation of injection site reactions will be performed locally at all visits after visit 2 until visit 
16 based on patient feedback and by [CONTACT_687634]:
Symptoms e.g.
∀Pain 
∀Numbness
∀Itching
∀Burning
Signs e.g.
∀Redness (mm x mm)
∀Induration (mm x mm)
∀Swelling
∀Dimpling
∀Macula
∀Haematoma
∀Bleeding
∀Other (visual reactions)
Any injection site reaction symptom (evaluated at visit 2-16) should be recorded in the AE form and 
the injection site reaction form, see Section 12.1.5 .
A separate AE should be recorded for each injection site reaction symptom. The affected area 
should also be evaluated for redness and induration in mm using a ruler. To ensure all local 
injection site assessments are performed at the injection site, the area around the site will be marked 
with a pen prior to injection. 
In the event of a local reaction, additional visual assessments (as described above) will be 
performed until resolution as judged necessary by [CONTACT_093].
Assessment of injection site reactions can be performed at any time, if deemed necessary by [CONTACT_1275].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931908] be 
obtained if available on the hypersensitivity reaction form: 
∀Signs and symptoms associated with the event
∀Time of appearance after administration of trial drug
∀Relevant immunological tests performed, see Section [IP_ADDRESS]
∀Treatment given for the reaction
∀Previous history of similar reactions
∀Association with the trial product(s)
∀Relevant risk factors associated with the event
∀Storage condition of the trial product
∀Total number of doses, from first day on trial product, up to the time of this event
8.5 Laboratory assessments
An approximate total blood volume of 725 mL will be taken from each patient on the concizumab 
arm and 625 mL from each patient on the eptacog alfa (rFVIIa) arm.
A laboratory manual will be provided for detailed description of obtaining and processing blood 
samples.
All laboratory blood samples collected for this trial except for haematology samples at all visits and 
coagulation parameters at visits 3 and 9.1 are to be shipped for analysis at central laboratories or 
further distribution to special laboratories. Haematology samples (all visits) and coagulation 
parameters (visit 3 and 9.1) are to be analysed locally. Ports cannot be used for blood sampling.
The laboratory provides results to the trial sites in the units preferred by [CONTACT_135545].
Laboratory reports listing results from centrally analysed samples will be made available for the 
investigator. Investigator must review and evaluate the results and report AEs for results which are 
clinically significant. Laboratory reports will where possible indicate normal ranges.
Categorisation of clinical significance for out of range results may not be required for the following 
laboratory parameters and the investigator is therefore not required to perform a categorisation even though these parameters are listed in the laboratory report: FVIII/FIX activity, FVIII/FIX inhibitor 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931909], Thrombin generation, Free TFPI (TFPI [INVESTIGATOR_535096]), concizumab concentration 
in plasma, anti-concizumab antibodies, Total TFPI [INVESTIGATOR_687556].
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. The investigator must review all laboratory results for 
concomitant illnesses and AEs and report these according to Section 8.2.[ADDRESS_931910] be sent to the central laboratory for analysis; 
if additional laboratory sampling is needed, e.g. to follow up on AEs, this must be done at a local 
laboratory except for biomarkers and anti-drug antibodies (anti-concizumab IgE antibodies and 
anti-concizumab antibodies).
Laboratory samples will be destroyed no later than at finalisation of the clinical trial report (CTR).
Antibody samples and human biosamples, if applicable, will be stored as described in Section 24.2.
The investigator may not be able to review the results of antibody measurements in relation to AEs 
as these are often analysed after LPLV.
8.5.1 Laboratory assessments for efficacy
[IP_ADDRESS] Thrombin generation
The Thrombin Generation Assay (TGA) will be collected at all visits. 
Further at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9 h (± 10 min), 12h (± 20 min) and 24h (± 20 min).
The TGA is included as an exploratory PD assessment.
The generation of thrombin is a fundamental part of the haemostatic system, and is a key 
measurable parameter of the formation of a clot under bleeding or thrombotic conditions. The 
thrombin burst is crucial for the formation of a stable fibrin clot. 
The Calibrated Automated Thrombogram (CAT) method (used by [CONTACT_535235]) will be 
used to measure thrombin generation (TG). This method uses a slow acting fluorogenic substrate 
that allows continuous measurement of thrombin generation in double centrifuged citrated plasma. 
In this assay set-up thrombin generation is initiated by [CONTACT_687635]. The result is obtained by [CONTACT_49719] a constant known thrombin activity in a 
parallel non tissue factor initiated sample. The assay has been validated fit-for-purpose.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 76 of 137
The thrombin generation endpoints are defined but not limited to:
∀The Endogenous Thrombin Potential (ETP) – the area under the curve 
∀Peak thrombin generation
∀Velocity Index 
[IP_ADDRESS] Free TFPI
[INVESTIGATOR_687557] (TFPI [INVESTIGATOR_535096]) will be collected at all visits, pre-dose at visit 2 and 3 
(concizumab arm) and visit 9 and 9.1 (eptacog alfa (rFVIIa) arm). 
The free TFPI [INVESTIGATOR_687558]  
 (named and referred to  TOTAL TFPI) and will be used for PD assessments. 
8.5.2 Laboratory assessments for safety
[IP_ADDRESS] Urinalysis
∀pH
∀Protein
∀Glucose
∀Bilirubin
This is a semi qualitative measurement which will be performed (locally) at the screening visit by 
[CONTACT_535236]. The results will be recorded in the 
eCRF.
The investigator must evaluate the results and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must: 
oRecord if the result is clinically significant? (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
[IP_ADDRESS] Haematology
Haematology samples are to be sampled and analysed locally at all visits. 
Further at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa), 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9 h (± 
10 min), 12h (± 20 min) and 24h (± 20 min).
∀Haemoglobin 
∀Erythrocytes (cell count)
∀Thrombocytes (platelet count)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 77 of 137
∀Leucocytes (cell count) 
∀Differential leucocytes cell count 
oLymphocytes
oMonocytes
oNeutrophils
oEosinophils 
oBasophils
The investigator must evaluate the results and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must: 
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
Haematology results are to be entered into the eCRF.
[IP_ADDRESS] Biochemistry
Biochemistry samples are to be sampled and analysed centrally at all visits.
∀Creatinine 
∀Albumin 
∀Bilirubin; total, direct, indirect
∀Aspartate aminotransferase (AST) 
∀Alanine aminotransferase (ALT)
∀Gamma glutamyltransferase (GGT) 
∀Alkaline phosphatase
∀C-reactive protein (CRP)
The investigator must evaluate the results of the examination and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must: 
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
[IP_ADDRESS] FVIII/FIX activity
FVIII/FIX activity is to be sampled and analysed centrally at visit 1, visit 9 and visit 16. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 78 of 137
∀FVIII activity level (IU/mL) or
∀FIX activity level (IU/mL)
[IP_ADDRESS] Coagulation parameters
Coagulation parameters will be performed centrally at all visits with the exception of visit 3 and 
visit 9.1 where the PT, APTT, and Fibrinogen will be performed locally.
Further at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa) at 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9h (±10 min) and 12h (±20 min) and 24h (± 20 min) locally.
∀Fibrinogen – centrally and locally
∀Prothrombin time (incl. INR) (PT) centrally and locally
∀D-dimer – only centrally
∀Prothrombin fragment 1+2 – only centrally
∀Activated partial thromboplastin time (APTT) – centrally and locally
∀Antithrombin (AT) activity – only centrally
The investigator must evaluate the results of the examination and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must: 
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
Coagulation parameters analysed locally are to be entered into the eCRF.
[IP_ADDRESS] FVIII/FIX inhibitors
FVIII/FIX inhibitor level will be measured by [CONTACT_535237] 1, visit 9 and visit 16. 
∀FVIII inhibitors (BU) or
∀FIX inhibitors (BU)
[IP_ADDRESS] Anti-concizumab antibodies
Samples for the determination of anti-drug antibodies collected during the treatment period must be 
drawn at all visits and prior to administering concizumab at visit 2 and 3 (concizumab arm) and 
visit 9 and 9.1 (eptacog alfa (rFVIIa) arm) and visit 16 for both arms.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931911] concizumab (anti-drug antibodies [ADA]) will be 
performed at specialised laboratories whereas assessment of neutralising antibodies will be 
performed at Novo Nordisk.
Analysis for ADA will be done with a bridging ECL assay (binding ADA assay), using labelled 
concizumab for antibody capture and detection. Confirmed positive samples will be characterised 
for binding to IgG backbone, CDR region or the S241P mutation. Furthermore, positive samples 
will be characterised for neutralising activity using a modified TFPI [INVESTIGATOR_535100] 
(neutralising ADA assay). All antibody assays are validated according to international guidelines 
and recommendations.
The following analyses will be available:
∀Anti-concizumab antibodies assay
∀Specificity assay (Anti-concizumab antibodies cross reacting with IgG4 backbone, CDR 
region or S241P mutation) 
∀Anti-concizumab neutralising antibodies assay
The samples will be analysed in batches during the trial and results will be available to the data 
monitoring committee approximately every third month after the first patient has been dosed. 
Neutralising antibodies will be analysed and reported at the EOT. A detailed description of the 
assay methods will be included in the antibody analysis report at the end of the trial.
In the event that a trial patient develops binding ADAs towards concizumab during the course of the 
trial and has measurable binding ADAs at his End-of-Trial visit, the patient may attend an ADA 
follow-up visit. The ADA positive patients will be called for additional visits, e.g. every 4 to 6 
weeks, for safety assessment and blood sampling for ADA and PD markers (free TFPI [INVESTIGATOR_535203]). The ADA positive patients will be followed no longer than one year after 
End-of-Trial. 
Hypersensitivity
If suspi[INVESTIGATOR_1884] a hypersensitivity reaction occurs, patients should be instructed to contact [CONTACT_535238], see Section 12.1.5 .
In the event of a severe local and/or systemic hypersensitivity reaction possibly or probably related 
to trial product, blood sampling for assessment of anti-concizumab IgE antibodies as well as anti-
concizumab antibodies should be conducted in relation to the reaction and no later than 1-2 weeks 
after the event. Additional testing may be performed if deemed relevant (e.g. anti-Host Cell Proteins 
(HCP) antibodies). 
In the event of a severe systemic hypersensitivity reaction to trial product it is recommended also to 
test for tryptase (total and/or mature tryptase) within 3 hours of the reaction. Moreover, a baseline 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931912] the hypersensitivity reaction for assessing the 
persistence of the IgE response. Tryptase measurements are not required at the follow up visits.
Additionally, basophil activation testing may be performed if deemed relevant. This can be 
performed using existing samples and/or by [CONTACT_535239]’s basophil cells from an additional 
blood sample taken 3-4 weeks and no later than 2 months after the event. Similarly, prick tests 
and/or intra-dermal tests may be performed if relevant using trial product or components of trial 
product. Complement may be measured in case of suspi[INVESTIGATOR_535101].
Results from the following additional tests will be reported to Novo Nordisk Safety Operations for 
inclusion in the ARGUS database and included in the narratives, if measured.
Test to be performed in case of severe hypersensitivity
∀Anti-concizumab IgE antibodies
∀Anti-concizumab antibodies (additional to scheduled time points)
Additional testing may be performed if deemed relevant e.g.
∀Anti-Host Cell Proteins (HCP) antibodies
∀Anti-HCP IgE antibodies
∀Basophil activation results
∀Prick test/intra-dermal test
∀Complement test results
Furthermore, it is recommended locally to test for
∀Tryptase (total and/or mature tryptase)
[IP_ADDRESS] Concizumab ELISA
Concizumab ELISA will be collected at all visits except at screening only for the concizumab arm. 
Samples will be collected pre-dose at visit 2 and 3 for concizumab arm and visit 9 and 9.1 for 
eptacog alfa (rFVIIa) arm) and visit 16 for both arms. 
Concizumab will be quantified using a validated ELISA assay. 
Recombinant human TFPI [INVESTIGATOR_687559]. A colorimetric detection signal is 
obtained by [CONTACT_687636]-human IgG4 specific 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 81 of 137
antibodies with the chromogenic substrate TMB (3,3´,5,5´-tetramethylbenzidine). The amount of 
anti-TFPI [INVESTIGATOR_535103], quality control and test samples correlates with the obtained 
signal strength. 
Validation of the assay follows current guidelines for bioanalytical method validation. Bioanalytical 
data will be reported in a bioanalytical report.
[IP_ADDRESS] FVII ELISA
FVII ELISA will be collected at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) pre-
dose eptacog alfa (rFVIIa) and post-dose at 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 
min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points, except pre-dose, occur 
after eptacog alfa (rFVIIa) administration.
FVII in plasma will be quantified using a validated enzyme-linked immunosorbent assay (ELISA).
The FVII ELISA will detect the total sum of FVII in a sample, including endogenous FVII, eptacog 
alfa (rFVIIa) and FVII in complex with other molecules e.g. antithrombin. The ELISA has been 
validated for measuring FVII in human citrated plasma samples. Validation follows current 
guidelines for bioanalytical method validation. Bioanalytical data will be reported in a bioanalytical 
report.
[IP_ADDRESS] Total TFPI
[INVESTIGATOR_687560]. Samples will be collected pre-dose at visit 2 and 3 
(concizumab arm) and visit 9 and 9.1 (eptacog alfa (rFVIIa) arm) and visit 16 for both arms.
The total TFPI [INVESTIGATOR_67147] (free and concizumab bound) will be included as an exploratory biomarker 
assessment. 
The assay is an ELISA, where TFPI [INVESTIGATOR_687561] a polyclonal anti-TFPI [CONTACT_30936], distanced from 
the binding site of concizumab; meaning that both free TFPI [INVESTIGATOR_687562]. Detection will be obtained with a monoclonal antibody against TFPI, which does not bind 
to the concizumab epi[INVESTIGATOR_9230]. 
Data will be reported in ng/mL TFPI.
8.5.3 Human Biosamples
If patient permission is obtained plasma, serum and/or DNA for genotypi[INVESTIGATOR_535109], see Section 2. The blood samples can be stored up to 15 years, for future 
potential exploratory purposes please refer to section 24.2.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 82 of 137
Antibody samples storage and retention, see Section 24.2.1 . The investigator is not able to review 
the results of antibody measurements in relation to AEs as these are analysed after LPLV. Plasma 
and serum is taken at visit 1 and 17. DNA for genotypi[INVESTIGATOR_687563] 1.
8.6 Other assessments
8.6.1 Patient reported outcomes 
A newly developed disease-specific electronic PRO (ePRO) the Hemophilia Treatment Experience 
Measure (Hemo-TEM) - is being validated in this trial. In order to assess the psychometric 
properties of Hemo-TEM, other questionnaires will be provided; see further appendix 1 .
The following ePRO questionnaires will be used in the trial:
∀Hemophilia Treatment Experience Measure (Hemo-TEM)
∀Validated Hemophilia Regimen Treatment Adherence Scale - Prophylaxis (VERITAS-Pro®)
or Validated Hemophilia Regimen Treatment Adherence Scale (VERITAS-PRN®) 16
∀36-Item Short Form Health Survey (SF-36v2) (4 week recall)17
∀Patient’s Global Impression of Change (PGI-C)
∀Sheehan Disability Scale (SDS)18
∀Treatment Satisfaction Questionnaire for Medication (TSQM, version II)19 20 21
∀Injection Site Reaction Questionnaire (ISRQ) domain of SIAQ (SIAQ-ISRQ)22
The ePROs should be assessed at the scheduled visits following the order listed below:
∀visit 1 (Hemo-TEM, VERITAS-Pro®or VERITAS-PRN®)
∀visit 2 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 3 (PGI-C, Hemo-TEM)
∀visit 4 (PGI-C, Hemo-TEM)
∀visit 5 (PGI-C, Hemo-TEM)
∀visit 6 (PGI-C, Hemo-TEM)
∀visit 7 (PGI-C, Hemo-TEM)
∀visit 8 (PGI-C, Hemo-TEM) 
∀visit 9 (PGI-C, Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 10 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ) 
∀visit 16 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
At visit 1: before any visit-related activities all patients should complete Hemo-TEM and 
VERITAS-Pro® (if the patient at baseline receives prophylactic treatment) or VERITAS-PRN® (if 
the patient at baseline receives on-demand treatment).
At visit 2: before any visit-related activities all patients should complete Hemo-TEM, SF-36v2, 
SDS, TSQM and SIAQ-ISRQ.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 83 of 137
At visit 3-8: before any visit-related activities the patient should complete the PGI-C before the 
Hemo-Tem. These are the rules that apply:. 
∀If the patient responds “1” to question 1 in the PGI-C, the patient should also complete the 
Hemo-TEM. In this case the patient should not fill in the PGI-C any more in the trial and the 
Hemo-TEM only again at visits 9, 10 and 16. 
∀If the patient responds “0” or “2” to question 1 in the PGI-C, the patient should not complete 
any other questionnaires at this visit, but should repeat the procedure at next visit. 
Exception: Patients randomised to eptacog alfa (rFVIIa) on-demand should not complete the 
ePRO at visit 3 as this is a phone visit.
At visit 9 if the patient has responded “0” or “2” in the PGI-C at all previous visits, the patient 
should complete PGI-C. All patients should complete Hemo-TEM, SF-36v2, SDS, TSQM and 
SIAQ-ISRQ.  
At visit [ADDRESS_931913].
[IP_ADDRESS] Concizumab and NovoPen
®4
Direction for use (DFUs) will be available as a hand out for patients at visit 2. Training in 
NovoPen®4 can start at screening (visit 1) and s.c administration of concizumab using the 
NovoPen®[ADDRESS_931914] dose at the trial site (visit 2). Patients must be instructed that 
injections are to be performed subcutaneously, not intravenously. Concizumab and NovoPen®[ADDRESS_931915] be documented in the 
medical records.
Detailed instructions can be found in the DFUs .
[IP_ADDRESS] eptacog alfa (rFVIIa)
A direction for use (DFU) will be available as hand out for patients at visit 1. Training must be 
performed at site until patients feel comfortable performing the treatment. The training must be 
documented in the medical records. 
The following should be emphasised for eptacog alfa (rFVIIa):3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 84 of 137
∀eptacog alfa (rFVIIa) should be slowly injected intravenously over 2 to 5 minutes
Detailed instructions can be found in the DFU
[IP_ADDRESS] eDiary
Training on the use of the eDiary can start at visit 1. The eDiary will be provided to the patients at 
visit 2.
Training must be repeated at the site until patients feel comfortable using the device. The training 
must be documented in the medical records.
During the home treatment period the patient must ensure that all home treatments of concizumab, 
details of bleeding epi[INVESTIGATOR_687537] (rFVIIa) treatments associated with these bleeding 
epi[INVESTIGATOR_535111].
It will be the responsibility of the investigator or delegated staff to assess the eDiary data 
throughout the conduct of the trial and to ensure data entry compliance (timely entry, no duplicate 
data, no missing data etc.) and retraining if necessary.
For patients completing the trial or in case of withdrawal, the eDiary will be collected at the EOT.
8.6.3 Surgery
Minor surgery can be performed within this trial at the investigator’s discretion according to local 
guidelines. Definition of minor surgery, see Section 5.1.1. Major surgery is not allowed, see 
exclusion criteria no 6.
For minor surgery the following should be recorded in the eCRF:
∀Date, stop time and dose of preventive treatment with eptacog alfa (rFVIIa) before surgery, 
if this was deemed necessary by [CONTACT_093]
∀Indication for surgery
∀Location of surgery
∀Date of surgery
∀Start and stop time of surgery
8.7 Patient compliance
Throughout the trial, the investigator will remind the patients to follow the trial procedures and 
requirements to ensure patient compliance. If a patient is found to be non-compliant, the investigator will remind the patient of the importance of following the instructions given including 
taking the trial products as prescribed.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 85 of 137
8.8 Treatment compliance 
Treatment compliance will be monitored and documented through timely review of eDiary data and 
drug accountability. 
Concizumab will be administered at the trial site at visit 2 for the concizumab arm supervised by 
[CONTACT_687637] 2 if the patient 
feels comfortable with the s.c. administration. Administration of eptacog alfa (rFVIIa) for bleeding 
epi[INVESTIGATOR_535179] a medically trained trial staff or at home by [CONTACT_4677], see Section 8.3.1 . 
Drug accountability will be performed and will be used to assess patient compliance together with 
the patients’ adherence to trial procedures. 
Compliance check includes a cross check between records in EDC/eDiary (number of 
administrations and bleeding epi[INVESTIGATOR_1841]) and the used/returned cartridges/vials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931916] not be used if it contains visible particles or discoloration.
The reconstituted eptacog alfa (rFVIIa) solution appears clear and colourless. Do not use the 
reconstituted solution if it contains visible particles or if it is discoloured.
Trial products must not be dispensed to any person not included in the trial.
9.1 Trial products
The following trial products will be provided by [CONTACT_3454], Denmark:
Table 9–[ADDRESS_931917] Strength Dosage form Route of 
administrationContainer/
delivery device
concizumab B 
(IMP)100 mg/mL Solution for injection s.c. injection 3 mL cartridge
eptacog alfa
(IMPaand NIMPb)5 mg/vial Powder for solution
for injectioni.v. injection Vial
histidine 5 mL N/A Solvent for solution 
for injectioni.v. injection prefilled syringe
aInvestigational Medicinal Product (IMP) given as IMP for a single dose at visit [ADDRESS_931918] (NIMP) given as NIMP for bleeding epi[INVESTIGATOR_535113]®[ADDRESS_931919] will be distributed to the trial sites according to enrolment 
and randomisation. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931920] 
dispensing visit (see Section 2). 
9.3 Storage 
Table 9–[ADDRESS_931921] Storage conditions
(not-in-use)In-use conditions In-use timea
concizumab B 100 mg/mL Store in refrigerator (2oC-8oC)
Do not freeze
Protect from lightStore at room temperature 
(below 30°C)
Do not refrigerate
Protect from lightUse within 4 weeks 
(28 days)
eptacog alfa
5mgStore between 2oC-25oC  
Do not freeze
Protect from lightFor single use
Do not freeze
Protect from light
To be used immediately 
after reconstitutionIf not used 
immediately, store in 
refrigerator (2oC-8oC)
for up to [ADDRESS_931922] from lightFor single use N/A
aIn-use time for concizumab starts when first dose is administered from an individual cartridge and for eptacog alfa
(rFVIIa) when the product is reconstituted
The investigator must ensure that trial product is kept under proper storage conditions and record 
and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any patient before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take 
appropriate action to ensure correct storage.
Investigator must instruct the patient to use and store trial product according to the label.
9.4 Drug accountability and destruction
Drug accountability of all trial products (concizumab and eptacog alfa (rFVIIa) received at site is 
the responsibility of the investigator. The patient will be asked to return all used, partly used and 
unused trial product during the trial as instructed by [CONTACT_093], except for histidine which 
should be discarded at home and not accounted for.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 88 of 137
All cartridges (concizumab) and vials (eptacog alfa (rFVIIa)) must be accounted for as used, partly 
used or unused. 
The investigator will perform drug accountability using the IWRS Drug Accountability module.
Returned trial product (used/partly used and/or unused), expi[INVESTIGATOR_135522]-allocated trial product.
Non-allocated trial product including expi[INVESTIGATOR_215519].
Destruction of concizumab and eptacog alfa (rFVIIa) can be performed on an on-going basis and 
will be done according to local procedures after accountability is finalised and reconciled by [CONTACT_36102]. Destruction of products must be documented in the IWRS.
For Japan only : Responsibility for storage and drug accountability of the trial drug product at the 
trial site rests with the head of the trial site. The head of the trial site could assign some or all of the 
responsibilities for accountability of the trial drug product at the trial sites to a trial product storage 
manager (a pharmacist in principle). The trial product storage manager should control and take 
accountability of the trial drug product in accordance with procedures specified by [CONTACT_3454]. 
The head of the trial site or the trial product storage manager must ensure the availability of proper 
storage conditions, and record and evaluate the temperature.
9.5 Auxiliary supplies
Novo Nordisk will provide the auxiliaries for this trial:
∀For concizumab administration: NovoPen®4, needles and DFUs
∀For eptacog alfa (rFVIIa) reconstitution and administration: Trial Injection Kit and DFU
Only needles and trial injection kit provided by [CONTACT_535244].
For further guidance please see the TMM.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 89 of 137
10 Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone.  
Access to the IWRS must be restricted to and controlled by [CONTACT_36301]. 
IWRS is used for: 
∀Screening
∀Screening failure
∀Randomisation
∀Medication arrival
∀Dispensing
∀Dispensing verification
∀Treatment discontinuation 
∀Completion
∀Drug accountability
∀Data change
IWRS user manuals will be provided to each trial site.
11 Randomisation procedure and breaking of blinded codes
11.1 Randomisation 
Randomisation will be handed by [CONTACT_8784]. 
All patients included in the screening period and eligible for the trial will enter the trial and be 
randomised at visit 2 in a 2:1 allocation to either concizumab prophylaxis arm or eptacog alfa 
(rFVIIa) on-demand arm.
11.2 Breaking of blinded codes
Not applicable for this trial.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 90 of 137
12 Adverse events, and technical complaints
12.1 Definitions
12.1.1 Adverse event 
An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal 
product, and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
∀A clinically significant worsening of a concomitant illness
∀A clinical laboratory adverse event (CLAE): a clinical laboratory abnormality which is 
clinically significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is of a severity that requires active management. Active management includes active treatment 
or further investigations, for example change of medicine dose or more frequent follow-up 
due to the abnormality.
The following should not be reported as AEs:
∀Pre-existing conditions, including those found as a result of screening or other trial 
procedures performed before exposure to trial product (pre-existing conditions should be 
reported as medical history or concomitant illness)
∀Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the patient has signed the informed consent
∀Bleeding epi[INVESTIGATOR_56238] (e.g. pain, swelling, synovitis, arthralgia, injection 
site haematoma) in connection with bleeding epi[INVESTIGATOR_49622]/SAEs unless the event is fatal, life-threatening or evaluated by [CONTACT_535245]. All bleeding epi[INVESTIGATOR_687564]/eDiary.
The following three definitions are used when assessing an AE:
∀Severity 
∀Mild – no or transient symptoms, no interference with the patient’s daily activities
∀Moderate – marked symptoms, moderate interference with the patient’s daily activities
∀Severe – considerable interference with the patient’s daily activities; unacceptable
∀Causality 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931923](s): 
∀Probable - Good reason and sufficient documentation to assume a causal relationship
∀Possible - A causal relationship is conceivable and cannot be dismissed
∀Unlikely - The event is most likely related to aetiology other than the trial product
∀Final outcome 
∀Recovered/resolved - The patient has fully recovered or by [CONTACT_135548]-related activity after the patient signed the informed consent
∀Recovering/resolving - The condition is improving and the patient is expected to 
recover from the event. This term is only applicable if the patient has completed the trial 
or has died from another AE
∀Recovered/resolved with sequelae - The patient has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE
∀Not recovered/not resolved - The condition of the patient has not improved and the 
symptoms are unchanged or the outcome is not known
∀Fatal - This term is only applicable if the patient died from a condition related to the 
reported AE. Outcomes of other reported AEs in a patient before he died should be assessed as “recovered/resolved”, “recovering/resolving”, “recovered/resolved with 
sequelae” or “not recovered/not resolved”. An AE with fatal outcome must be reported 
as an SAE
∀Unknown - This term is only applicable if the patient is lost to follow-up
12.1.2 Serious adverse event
A serious adverse event (SAE) is an experience that at any dose results in any of the following:
∀Death
∀A life-threatening
aexperience
∀In-patient hospi[INVESTIGATOR_36220]
∀A persistent or significant disability or incapacityc
∀A congenital anomaly or birth defect
∀Important medical events that may not result in death, be life threateningaor require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement 
- they may jeopardise the patient and may require medical or surgical intervention to prevent 
one of the outcomes listed in the definition of SAEd
a.The term “life threatening” in the definition of SAE refers to an event in which the patient was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 92 of 137
b.The term “hospi[INVESTIGATOR_11956]” is used when a patient: 
∀Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay or 
∀Stays at the hospi[INVESTIGATOR_36223] [ADDRESS_931924] should be 
regarded as a hospi[INVESTIGATOR_11956]. Hospi[INVESTIGATOR_17957], trial related and social purposes do 
not constitute AEs and should therefore not be reported as AEs or SAEs. Hospi[INVESTIGATOR_49627], planned before trial inclusion, are not considered AEs or SAEs.
c.A substantial disruption of a patient’s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the patient has significant, persistent or permanent change, 
impairment, damage or disruption in his body function or structure, physical activity and/or quality 
of life).
d.For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not result in hospi[INVESTIGATOR_36224].
The following adverse events must always be reported as an SAE using the important medical event 
criterion if no other seriousness criteria are applicable:
∀Suspi[INVESTIGATOR_36225] 
∀Risk of liver injury defined as ALT or aspartate aminotransferase (AST) >3 x UNL and total 
bilirubin >2 x UNL, where no alternative aetiology exists (Hy's law).
12.1.3 Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.
12.1.4 Medication errors
A medication error concerning trial products is defined as:
∀Administration of wrong drug
Note: Use of wrong DUN is not considered a medication error unless it results in administration
of wrong drug.
∀Wrong route of administration
∀Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product
∀Accidental administration of a lower or higher dose than intended. However, the 
administered dose must deviate from the intended dose to an extent where clinical 
consequences for the trial patient were likely to happen as judged by [CONTACT_093], 
although they did not necessarily occur3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931925] be reported on an AE form and a specific event form, see Section [IP_ADDRESS]
12.1.[ADDRESS_931926].
In this trial the following AEs require the completion of specific event forms in the eCRF:
∀Injection site reaction, see Section [IP_ADDRESS]
∀Hypersensitivity type reactions, incl. anaphylactic reactions, see Section [IP_ADDRESS]
Injection site reactions: 
Any injection site reaction symptom must be recorded on the AE form and the injection site 
reaction form.
Hypersensitivity type reactions:
In cases where clinical signs of a severe and immediate hypersensitivity reaction resembling a type
I hypersensitivity reaction are present, blood should be sampled for central laboratory assessment of 
anti-drug IgE antibodies and anti-drug binding antibodies. In the event of an immediate systemic 
hypersensitivity reaction to the trial product, it is recommended to also test for tryptase (total and/or 
mature tryptase) within 3 hours of the reaction. Moreover, a baseline tryptase measurement is 
necessary ~1 week after the immediate severe hypersensitivity reaction due to individual to 
individual variation in tryptase baseline concentration. Tryptase concentrations (if measured) must 
be interpreted and considered in the context of a complete workup of each patient.
Special attention should be given to clinical signs and symptoms of hypersensitivity reactions of 
type II and III. Common clinical signs and symptoms characteristic for these type of reactions may 
include, but are not limited to: fever/malaise, cutaneous eruptions, arthralgia, lymphadenopathy, 
itching, headaches and myalgia. Related laboratory findings may include, but are not limited to: 
mild proteinuria or haematuria, leukopenia or leucocytosis, decreased complement levels or 
increased complement split products and transient elevations of serum creatinine levels. In cases 
where there is a suspi[INVESTIGATOR_535115], additional 
sampling for the purpose of measuring ADA will be performed. 
Definition of anaphylaxis (25)
Anaphylaxis is highly likely when any one of the following 3 criteria is fulfilled:
∀Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal
tissue or both (e.g. generalised hives, pruritus or flushing, swollen lips-tongue-uvula) and at
least one of the following:
a) Respi[INVESTIGATOR_7798] (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced peak
expi[INVESTIGATOR_10229] [PEF], hypoxemia)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 94 of 137
b) Reduced blood pressure (BP) or associated symptoms of end-organ dysfunction (e.g.
hypotonia [collapse], syncope, incontinence)
∀Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for that
patient (minutes to several hours):
a) Involvement of the skin-mucosal tissue (e.g. generalised hives, itch-flush, swollen 
lips-tongue-uvula)
b) Respi[INVESTIGATOR_7798] (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced PEF,
hypoxemia)
c) Reduced BP or associated symptoms (e.g. hypotonia [collapse], syncope, 
incontinence)
d) Persistent gastrointestinal symptoms (e.g. crampy abdominal pain, vomiting)
∀Reduced BP after exposure to known allergen for that patient (minutes to several hours):
Systolic BP of less than 90 mm Hg or greater than 30% decrease from that person’s baseline
BP.
If a patient fulfils any of the three criteria of anaphylaxis outlined above, the patient should receive 
epi[INVESTIGATOR_238]/adrenalin immediately. Dose regimen should be according to hospi[INVESTIGATOR_535116], and the patient should be transferred to an emergency department or intensive care unit, 
if clinically warranted.
Events not fulfilling the criteria for an anaphylactic reaction and other allergic reactions must be 
treated at the discretion of the treating physician. If according to the investigators judgement, 
hypersensitivity type reactions that require systemic treatment are suspected, dosing with 
concizumab should be stopped immediately and treatment at the discretion of the treating physician 
initiated.
12.1.[ADDRESS_931927] (AESI) is an event, which in the evaluation of safety, has a 
special focus. In this trial, the following AEs fulfil the AESI criteria:
∀Thromboembolic events including but not limited to, 
odisseminated intravascular coagulation (DIC) (A),
oclinical signs or laboratory indications of arterial and venous thrombosis including 
myocardial infarction (B), 
opulmonary embolism (C), 
ostroke (D), 
odeep vein thrombosis (E), 
oother clinically significant thromboembolic events (F) and peripheral artery 
occlusion (see below G), see definitions below
The AESIs must be reported on an AE form and a safety information form.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 95 of 137
A) Definition of disseminated intravascular coagulation (DIC), as defined below:
The definition of DIC in this trial should be made according to the International Society on
Thrombosis and Haemostasis (ISTH) criteria. Thus , a DIC diagnosis may be based on clinical signs 
and symptoms of a bleeding tendency or thrombotic tendency, organ dysfunction and the laboratory 
parameters criteria as listed below:
∀Platelet count (>100 × 109/L = 0, <100 × 109/L = 1, <50 × 109/L = 2)
∀Elevated D-dimer (no increase = 0, moderate increase = 2, strong increase = 3)
∀Prolonged PT (<3 s = 0, >3 but <6 s = 1, >6 s = 2)
∀Fibrinogen level (>1 g/L = 0, <1 g/L = 1)
∀Calculate score: ≥5 compatible with overt DIC
B) Myocardial infarction is defined according to the “Third Universal Definition of
Myocardical Infarction” (26)
Criteria for acute myocardial infarction - The term acute myocardial infarction (MI) should be used 
when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial 
ischemia. Under these conditions any one of the following criteria meets the diagnosis for MI:
∀Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin
(cTn)] with at least one value above the 99th percentile upper reference limit (URL) andwith at least one of the following:
∀Symptoms of ischemia
∀New or presumed new significant ST-segment–T wave (ST–T) changes or new left
bundle branch block (LBBB)
∀Development of pathological Q waves in the ECG
∀Imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality
∀Identification of an intracoronary thrombus by [CONTACT_687638] - Any one of the following criteria meets the diagnosis for
prior MI:
∀Pathological Q waves with or without symptoms in the absence of non-ischemic causes.
Imaging evidence of a region of loss of viable myocardium that is thinned and fails tocontract, in the absence of a non-ischemic cause.
∀Pathological findings of a prior MI.
Recurrent myocardial infarction -Incident MI is defined as the individual’s first MI. When features 
of MI occur in the first 28 days after an incident event, this is not counted as a new event for 
epi[INVESTIGATOR_535117]. If characteristics of MI occur after 28 days following an incident MI, it is
considered to be a recurrent MI.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 96 of 137
C) Definition of pulmonary embolism:
The “Clinical Practice Guideline from the American Academy of Family Physicians and the
American College of Physicians” on diagnosis of venous thromboembolism recommends diagnostic
imaging studies for patients with intermediate or high pre-test probability of pulmonary embolism
(27).
Accordingly, the definition of pulmonary embolism is the following: obstruction of a pulmonary 
artery or one of its branches, most frequently by [CONTACT_535246] a leg or 
pelvic vein, diagnosed by [CONTACT_37408]:
∀Positive findings in ventilation/perfusion scan
∀Positive findings in a spi[INVESTIGATOR_23585] (helical) computerised tomography (CT) or angiography
∀Positive findings in a magnetic resonance imaging (MRI)
∀Positive findings in a pulmonary angiography
D) Definition of stroke:
The definition of central nervous infarction is according to the American Heart
Association/American Stroke Association Expert Consensus Document:  “An Updated Definition of 
Stroke for the 21st Century” (28).
Accordingly, the term “stroke” should be broadly used to include all of the following:
Definition of central nervous system (CNS) infarction: CNS infarction is brain, spi[INVESTIGATOR_687565], based on:
o1. pathological, imaging or other objective evidence of cerebral, spi[INVESTIGATOR_687566] a defined vascular distribution or
o2. clinical evidence of cerebral, spi[INVESTIGATOR_687567] 24 hours or until death, and other etiologies excluded
Note: CNS infarction includes haemorrhagic infarctions, types I and II; see “Haemorrhagic 
Infarction”.
Definition of ischemic stroke: An epi[INVESTIGATOR_535119],
spi[INVESTIGATOR_687568]. Note: Evidence of CNS infarction is defined above.
Definition of silent CNS infarction: Imaging or neuropathological evidence of CNS infarction,
without a history of acute neurological dysfunction attributable to the lesion.
Definition of intracerebral haemorrhage: A focal collection of blood within the brain parenchyma or
ventricular system that is not caused by [CONTACT_278066]. Note: Intracerebral haemorrhage includes
parenchymal haemorrhages after CNS infarction, types I and II - see “Haemorrhagic Infarction”).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 97 of 137
Definition of stroke caused by [CONTACT_535247]: Rapi[INVESTIGATOR_535120] a focal collection of blood within the brain parenchyma or
ventricular system that is not caused by [CONTACT_278066].
Definition of silent cerebral haemorrhage: A focal collection of chronic blood products within the
brain parenchyma, subarachnoid space or ventricular system on neuroimaging or neuropathological
examination that is not caused by [CONTACT_535248] a history of acute neurological dysfunction
attributable to the lesion.
Definition of subarachnoid haemorrhage: Bleeding into the subarachnoid space (the space between
the arachnoid membrane and the pia mater of the brain or spi[INVESTIGATOR_1831]).
Definition of stroke caused by [CONTACT_535249]: Rapi[INVESTIGATOR_535121]/or headache because of bleeding into the subarachnoid space (the
space between the arachnoid membrane and the pia mater of the brain or spi[INVESTIGATOR_1831]), which is not
caused by [CONTACT_278066].
Definition of stroke caused by [CONTACT_535250]: Infarction or haemorrhage in the brain,
spi[INVESTIGATOR_687569] a cerebral venous structure. Symptoms or signs
caused by [CONTACT_535251].
Definition of stroke, not otherwise specified: An epi[INVESTIGATOR_535122], persisting ≥24 hours or until death, but 
without sufficient evidence to be classified as one of the above.
Definition of a Transient Ischemic Attack: The definition of Transient Ischemic Attack is according
to the American Heart Association/American Stroke Association. A Transient ischemic attack (TIA) is a transient epi[INVESTIGATOR_535123], spi[INVESTIGATOR_687570], without acute infarction 
(29).
E) Definition of deep vein thrombosis:
The “Clinical Practice Guideline from the American Academy of Family Physicians and the
American College of Physicians” on diagnosis of venous thromboembolism recommends
ultrasound scanning for patients with intermediate or high pre-test probability of DVT in the lower
extremities27. Accordingly, venous thrombosis should be demonstrated by [CONTACT_49734],
duplex ultrasound, colour Doppler imaging or venography (phlebography).
F) Definition of other clinically significant thromboembolic events:
Signs or suspi[INVESTIGATOR_1884] a clinically significant thromboembolic event (e.g. visceral arterial 
embolus/thrombus, extremity arterial embolus/thrombus or portal venous thrombosis). Superficial 
thrombophlebitis is not considered a clinically significant thromboembolic event unless evaluated 
as such by [CONTACT_093].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 98 of 137
G) Definition of peripheral artery occlusion:
Clinical signs of acute arterial occlusion verified by [CONTACT_535252]-brachial index (ABI) test, Doppler and
ultrasound (Duplex) imaging, computerised tomographic angiography, MRA or conventional
angiography. The 2011 American College of Cardiology Foundation/American Heart Association
Focused Update of the Guideline for the Management of Patients with Peripheral Artery Disease
could serve as a reference for the diagnosis of lower extremity peripheral artery disease (30).
12.1.[ADDRESS_931928] 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of technical complaints:
∀The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
∀All packaging material including labelling
∀Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)
12.[ADDRESS_931929]-treatment follow-up period (visit 17). The events must be recorded in the applicable eCRF 
forms in a timely manner, see timelines below and Figure 12–[ADDRESS_931930] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: “Have you experienced any problems since the last contact?”
All AEs, either observed by [CONTACT_31698], must be reported by [CONTACT_36306]. All AEs must be recorded by [CONTACT_49738]. The investigator should 
report the diagnosis, if available. If no diagnosis is available, the investigator should record each 
sign and symptom as individual AEs using separate AE forms.  
For SAEs, a safety information form must be completed in addition to the AE form. If several 
symptoms or diagnoses occur as part of the same clinical pi[INVESTIGATOR_1103], one safety information form can 
be used to describe all the SAEs. 
AESIs regardless of the seriousness must be reported using the AE form and safety information 
form.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931931].
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the CRF/eCRF within the specified 
timelines:
∀SAEs: The AE form within 24 hours and the safety information form within 5 calendar
days of the investigator’s first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered in the 
eCRF. 
For SAEs requiring reporting on a specific event form : In addition to the above the specific 
event form within 14 calendar days from the investigator’s first knowledge of the AE.
∀Non-serious AEs fulfilling the AESI criteria: The AE form and safety information form
within 14 calendar days of the investigator’s first knowledge of the event.
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by [CONTACT_6791], e-mail or courier within the same timelines as stated above. When the 
eCRF becomes available again, the investigator must enter the information on the form into the 
eCRF. 
Contact [CONTACT_8972] (fax, telephone, e-mail and address) are provided in the investigator trial master file. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 100 of 137
Figure 12–1 Reporting of AEs
Novo Nordisk assessment of AE expectedness: 
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents: Investigator’s Brochure; current version and any updates thereto.
When eptacog alfa (rFVIIa), NovoSeven®is used as IMP, expectedness should be performed 
according to the Company Core Data Sheet (CCDS).
Reporting of trial product-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and ICH GCP1. In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial 
procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including EMA, of trial product-related S[LOCATION_003]Rs. In addition, Novo Nordisk will inform the
IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local requirement and ICH GCP1, 
unless locally this is an obligation of the investigator.
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931932]:
If an AE is considered to have a causal relationship with a Novo Nordisk marketed product used as 
non-investigational medicinal product (eptacog alfa (rFVIIa)) or concomitant medication in the 
trial, it is important that the suspected relationship is reported to Novo Nordisk, e.g. in the 
alternative aetiology section on the safety information form. Novo Nordisk may need to report this 
adverse event to relevant regulatory authorities.
12.[ADDRESS_931933] be reported to Novo Nordisk according to the following:
∀SAEs: All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. 
Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to 
another AE) may be closed with the outcome “recovering/resolving” or “not recovered/not 
resolved”. Cases can be closed with the outcome of “recovering/resolving” when the patient
has completed the follow-up period and is expected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator’s first knowledge of the 
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs. 
∀Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until 
the end of the follow-up period stated in the protocol, whichever comes first, and until all 
queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs 
ongoing at time of death (where death is due to another AE) may be closed with the 
outcome “recovering/resolving” or “not recovered/not resolved”. Cases can be closed with 
the outcome of “recovering/resolving” when the patient has completed the follow-up period 
and is expected by [CONTACT_36308].
∀Non-serious AEs fulfilling the AESI criteria: Non-serious AE fulfilling the AESI criteria 
must be followed as specified for non-serious AEs. Follow-up information on AESIs should 
only include new (e.g. corrections or additional) information and must be reported within 14 
calendar days of the investigator’s first knowledge of the information. This is also the case 
for previously reported non-serious AEs which subsequently fulfil the AESI criteria.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931934] be reported as follow up 
with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_931935].
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the investigational medicinal product occurring to a patient after the patient has 
ended the trial, the investigator should report this SAE within the same timelines as for SAEs 
during the trial. 
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of technical complaints 
All technical complaints on any of the following products: 
∀Concizumab B 100 mg/mL, solution for injection in a 3 mL cartridge
∀NovoPen®4
∀Novo Nordisk needles
∀Eptacog alfa (rFVIIa) 5 mg/vial, powder for solution for injection in a vial 
∀Histidine 5 mL, solvent for solution for injection in a prefilled syringe
∀Novo Nordisk trial injection kit
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Centre, Novo Nordisk.
Contact [CONTACT_8972] (fax, e-mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any AEs, AESI and/or 
SAEs.
Technical complaints must be reported on a separate technical complaint form: 
∀One technical complaint form must be completed for each affected DUN 
∀If DUN is not available, a technical complaint form for each batch, code or lot number must 
be completed 
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
∀Technical complaint assessed as related to an SAE within 24 hours
∀All other technical complaints within 5 calendar days3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931936] coordinate the shipment to 
Customer Complaint Centre, Novo Nordisk (the address is provided in Attachment I ) and ensure 
that the sample is sent as soon as possible. A copy of the technical complaint form must be included 
in the shipment of the sample. If several samples are returned in one shipment, the individual 
sample and the corresponding technical complaint form must be clearly separated.
The investigator must ensure that the technical complaint sample contains the batch, code or lot 
number and, if available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical
complaint form why it is unobtainable. 
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product.
12.[ADDRESS_931937] be instructed to notify the investigator if their female partner becomes pregnant 
during the trial, except in the screening period (from visit 1 to dosing with concizumab at visit 2 or 
visit 9 depending on the arm). At the last scheduled visit (visit 17), male patients must be asked if 
their female partner has become pregnant.
If a female partner has become pregnant during the trial, the investigator must follow-up on the 
pregnancy outcome and until the newborn infant is one month of age, irrespective of whether the 
trial is completed or not. The investigator must ask the male patient and assess if the pregnancy 
outcome is normal or abnormal. 
When the pregnancy outcome is normal this information is recorded in the patient’s medical record 
only, no further information is collected and reported to Novo Nordisk. When the pregnancy 
outcome is abnormal (i.e. congenital anomalies, foetal death including spontaneous abortion and/or 
any anomalies of the foetus observed at gross examination or during autopsy), the following must 
be reported by [CONTACT_136760] (e.g. in PDF format) or by [CONTACT_6791].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 104 of 137
1. Reporting of pregnancy information
Information from the male patient has to be reported on the Paternal Form. Furthermore, 
information from the female partner (including information about the pregnancy outcome and 
health status of the infant until the age of one month) has to be reported on the Maternal Forms 
1A, 1B and 2, after an informed consent has been obtained from the female partner. 
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator’s first knowledge of initial or follow-up information. 
2. Reporting of AE information
The following AEs in the foetus and newborn infant have to be reported:
oNon-serious AEs evaluated as possible/probably related to the father’s treatment 
with the trial product(s)
oSAEs in the foetus and newborn infant - whether or not related to the father’s 
treatment with the trial product(s). This includes an abnormal outcome - such as 
foetal death (including spontaneous abortion) and congenital anomalies (including 
those observed at gross examination or during autopsy of the foetus)
Forms and timelines for reporting AEs:
Non-serious AEs: 
∀Paper AE formawithin 14 calendar days of the investigator’s first knowledge of the initial 
or follow-up information to the non-serious AE
SAEs: 
∀Paper AE formawithin 24 hours of the investigator’s first knowledge of the SAE
∀Paper safety information form within 5 calendar days of the investigator’s first knowledge 
of the SAE
∀SAE follow-up information to the AE form and/or safety information form within 24 
hours of the investigator’s first knowledge of the follow-up information
aIt must be clearly stated in the AE diagnosis field on the AE form if the event occurred in the 
patient, foetus or newborn infant. 
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_931938].
12.6 Precautions and/or overdose
Dose limiting toxicities of concizumab have not been investigated in clinical trials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931939] been no reports about overdosing of concizumab and therefore no experience with 
overdose and overdose reactions exists. In case of a concizumab overdose, symptomatic medical 
treatment according to the clinical condition should be applied. No antidote exists in case of 
concizumab overdose.
Any overdose should be reported as an AE, with or without clinical manifestations. Overdoses are 
considered medication errors.
Treatment should be as appropriate and in accordance with hospi[INVESTIGATOR_49631].
12.7 Rules for putting enrolment on hold
If one of below mentioned criteria is fulfilled, enrolment of additional patients in the clinical trial 
programme will be placed on hold. An urgent safety committee meeting will be scheduled to decide 
further actions. Dosing of patients on treatment may continue while further evaluation is made by 
[CONTACT_56317]. 
∀Significant thromboembolic event*
∀Event of DIC 
∀Anaphylactic reaction related to trial drug administration
∀Death of trial patient which may be related to the trial product
* Superficial thrombophlebitis or venous thrombosis associated with indwelling catheters is not considered a significant 
thromboembolic event unless evaluated as such by [CONTACT_535253]/or detected 
by [CONTACT_66969], or if trends in AEs, clinical observations or laboratory parameters 
raise concerns about the safety of continued treatment, the safety committee (see Section 12.8.1 )
will decide if further dosing of any patients in the clinical trial programme should be continued, 
paused or discontinued.
12.[ADDRESS_931940] the safety 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931941] interaction with those in trial 
management. The DMC recommendations should be addressed directly to the Novo Nordisk Global 
Safety department and the internal Novo Nordisk safety committee for concizumab. It is the 
responsibility of the Novo Nordisk internal safety committee for concizumab to take action(s) for
patient safety based on the DMC recommendations.
Information regarding responsibilities, procedures and workflow to be used by [CONTACT_215575].
13 Case report forms 
For this trial a combination of electronic case report forms (eCRFs) and paper CRFs will be used.
Novo Nordisk will provide a system for the electronic case report forms (eCRF). This system and 
support services to the system will be provided by [CONTACT_215576].
Ensure that all relevant questions are answered, and that no empty data field exists. If a test or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper CRFs:
∀Pregnancy forms
∀Technical complaint forms  
∀AE forms 
∀Safety information forms
The paper version of the technical complaint form, AE form, and safety information form must only 
be used to ensure timely reporting when/if the electronic CRF is unavailable.
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered, 
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. 
If a test/assessment has not been done and will not be available, indicate this by [CONTACT_565] “ND” (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 107 of 137
indicate this by [CONTACT_565] “NA” (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
[CONTACT_36321], the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1 Corrections to case report forms 
Corrections to the eCRF data may be made by [CONTACT_36322]’s delegated staff. 
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]’s delegated staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].
13.[ADDRESS_931942] ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
13.3 Electronic diary
Novo Nordisk will provide the patient with an eDiary for electronic recording of details of their 
home treatment, bleeding epi[INVESTIGATOR_535124] (i.e. use of eptacog alfa 
(rFVIIa)). 
The eDiary and related support services will be supplied by a vendor working under the direction 
and supervision of Novo Nordisk. 
Patients will be instructed in the use of the eDiary by [CONTACT_535254]. The eDiary will be dispensed to the patient at visit 2. After visit 2 and 
onwards, data will be entered by [CONTACT_535255].
The eDiary will be returned by [CONTACT_687639].
All data entered will be transferred from the device to an electronic database, where it is kept as a 
certified copy of the source data. Data entered in the device will upon confirmation of a successful 
back-up be deleted from the device.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931943] the number of vials/cartridge accounted for as used by [CONTACT_102]. 
Upon review the Investigator must document that the review has taken place and any actions 
required e.g. retraining of the patient or decision to amend or correct the data reported by [CONTACT_4677]. 
If the Investigator finds it necessary to amend or correct eDiary data, the patient must be consulted 
prior to requesting the actual data change. A Data Request Correction (DRC) must be submitted to the eDiary vendor. An audit trail will be maintained.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931944] 6 patients 
recruited in the trial. The monitoring visit intervals will depend on the outcome of the centralised 
monitoring of the eCRFs (remote assessment of data by [CONTACT_3454]), the trial site's recruitment 
rate and the compliance of the trial site to the protocol and GCP, but will not exceed 12 weeks until 
LPLV at the trial site. This only applies to sites with scheduled, ongoing and/or discontinued 
patients.
The monitor must be given direct access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by [CONTACT_535258]).
All data must be verifiable in source documentation other than the eCRF. eDiary data is entered by 
[CONTACT_535259]. 
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any time for any data element.
For historical data such as medical history, details of haemophilia and haemophilia treatment 
history, a reasonable effort must be made by [CONTACT_093], considering local requirements, to 
obtain this information from external sources, if not known by [CONTACT_102]. It is accepted that the 
earliest practically retainable record should be considered as the location of the source data and 
therefore the source document. This means that for laboratory results (e.g. biochemistry and 
haematology) a signed printout of the electronic results must be available.
Source data generated by [CONTACT_36323]; any correction must be explained, signed and dated 
by [CONTACT_36324].
The monitor will ensure that the eCRFs are completed and paper CRFs (if any) collected, that 
ePROs and eDiaries are completed and reviewed by [CONTACT_687640], if any.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 110 of 137
The following data will be source data verified for screening failures:
∀Date for obtaining informed consent
∀Inclusion and exclusion criteria
∀Screen failure reason if possible
∀Date patient left the trial
∀Data relating to AEs if applicable
∀Demography, see section 8.2.1
∀Date of visit
Monitors will review the patient’s medical records and other source data (e.g. the eDiaries and 
ePROs) to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are 
found, the investigator must be questioned about these.
A follow-up letter (paper or electronic) will be sent to the investigator following each monitoring 
visit. This should address any action to be taken.
[ADDRESS_931945] the identity of patients in all presentations and publications as required by 
[CONTACT_5737], regional and national requirements.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931946] Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.
Novo Nordisk will use the Global Haemophilia Network Investigator Portal to distribute and share
trial-related documents and information with the participating sites. After trial completion, Novo 
Nordisk will supply each trial site with long-life CDs or other relevant archiving containing the 
electronic Investigator Trial Master File (eITMF) for each trial site. These CDs or other relevant 
archiving will contain site-specific trial documentation as well as trial specific news and other 
relevant trial information, including audit trail on documents and site staff users. The GHN Portal 
software and hardware implementation are compliant with the requirements of FDA 21 CFR Part 11 
and ICH E6 (EU directive for personal data protection).13 1
Novo Nordisk will provide electronic tablets for reporting of all PROs questionnaires described in section 8.6.1 and in Appendix 1 . In case the electronic tablet is revoked the questionnaires will be 
available in paper.
The eDiary and ePRO software and hardware implementation are compliant with the requirements 
of FDA 21
CFR Part 11 and ICH E6 (EU directive for personal data protection).13 1After trial completion, each
trial site will be supplied with long-life CDs. These CDs will contain site-specific patient records
including the patient’s eDiaries and audit trail including any data additions and corrections made on
each form. The eDiary vendor will furthermore retain and securely store copi[INVESTIGATOR_687571] 15 years or as required by [CONTACT_56325].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931947] patient has completed a minimum of 24 weeks of treatment or 
at LPFT (visit 2) + [ADDRESS_931948] patient has withdrawn before visit 9. Please refer to Figure 
17–1 for further information. 
Data from when the on-demand treated patients are transferred to concizumab s.c. prophylaxis will 
not be included in this evaluation. Observations from the extension part in the on-demand arm will 
be summarised separately as well as combined with observations from the main part when reporting 
the extension part data.
Endpoints comprising number of bleeding epi[INVESTIGATOR_535125]. Multiple bleeding locations occurring from the same event (e.g., due to a bicycle 
accident) or at the same time point will be counted as one bleeding epi[INVESTIGATOR_1865]. Further, the endpoints 
will not include re-bleed. A re-bleed is defined as a bleeding epi[INVESTIGATOR_1865] (worsening of bleeding site 
conditions e.g. swelling, pain) within 72 hours after stoppi[INVESTIGATOR_31081] a previous bleeding epi[INVESTIGATOR_687572] (or subset of the same) anatomical location. If a bleeding epi[INVESTIGATOR_535127] 
[ADDRESS_931949] of the 24 patients has completed 24 weeks of dosing (or has withdrawn 
before that).
Two criteria will be evaluated in a hierarchical fashion in support of CPoC comprising a 
comparison of the ABR of all patients in the concizumab group, irrespective of individual dose 
titration, with the ABR of the patients in the on-demand arm using different sets of observations. 
The primary CPoC criterion aims at evaluating the effect of concizumab when given at the last dose 
level reached for the patient. Hence, for this evaluation, only observations from the period where 
patients are on their end dose at time of analysis will contribute to the analysis. Furthermore, 
observations from the [ADDRESS_931950] one succeeds.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 113 of 137
The referred comparisons will be made using a negative binomial model with log of exposure time 
in main part as offset and regimen as factor (concizumab vs. on-demand). For each criterion, 
evidence of effect will be concluded if the 95% confidence interval of the treatment ratio is below 1.
Clinical arguments for the hierarchical test approach
Concizumab exhibits non-linear PK due to target mediated drug disposition and it is expected that 
the dose response curve of the ABR is rather steep. This implies that patients that are on a dose 
which is not efficacious are likely to bleed as patients that are not treated at all. Subset of data 
collected from the last dose clinically deemed as efficacious would reflect the efficacy of 
concizumab in the given patient.
17.1 Sample size calculation
The estimand will be defined as the “if all patients had adhered” estimand.
The treatment ratio between prophylactic s.c. concizumab and on-demand i.v. eptacog alfa (rFVIIa)
during at least 24 weeks for all randomised patients if all patients adhered to trial drug and did not 
initiate alternative treatment options.
This estimand is a de jure estimand assessing the expected added benefit a patient can achieve if 
continuing treatment with prophylactic s.c. concizumab as compared to on-demand i.v. eptacog alfa 
(rFVIIa) under similar conditions as observed in this trial.
The sample size calculation has been determined based on this estimand and the CPoC criteria 
taking the small patient population into account, while also aiming for an acceptably narrow 95% 
confidence interval for the rate ratio. 
Sufficient inference on bleeding epi[INVESTIGATOR_687573] 16 patients in the concizumab arm and 8 in the comparator arm. It is expected 
that the treatment duration of the main part allowing for escalation time for some patients is on
average 6 months in the below calculations.
When evaluating the power of the negative binomial analysis referred above, annual bleeding rates 
of 24 and 6 are assumed for the on-demand patients and the end dose concizumab regimen, 
respectively. Assuming further over-dispersion of 7, the power for concluding superiority of the 
concizumab regimen becomes approximately 80%. The power under varying values of true ABR 
and over-dispersion for the primary CPoC criterion are shown below in Table 17–1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 114 of 137
Table 17–1Power in superiority comparison between concizumab prophylaxis and on-demand 
treatment under different assumptions of ABR for concizumab and over-
dispersion (assuming on-demand ABR=24).
Power Over-dispersion (over 6 months)
ABR (concizumab) 6 7 8
6 89% 82% 75%
7 84% 75% 70%
8 77% 69% 66%
For the secondary CPoC criterion that includes data prior to potential dose escalation, it is expected 
that the treatment duration of the main part is on average 8 months with an average ABR of 7.6 for 
the concizumab regimen. This yields a marginal power of approximately 70% for the secondary 
CPoC criterion.
In prior Novo Nordisk trials conducted in haemophilia patients, the typi[INVESTIGATOR_2855] 1-year over-dispersion 
for non-inhibitor patients on prophylaxis with FVIII or FIX has been in the range 4-8, implying 24 
weeks over-dispersion of 3-5 (e.g. in NN7008-3543, NN7088-3859 and NN7999-3747). In the 
NN7128-1907 trial in inhibitor patients, larger 1-year over-dispersion values of approximately 21 
and 18, respectively, were observed during an initial 3-month on-demand period and a subsequent 
3-month prophylaxis period. It is expected that the variation in the current trial will be smaller, 
partly due to the longer duration of the trial and partly due to an expected more homogenous patient 
population. Another published trial including inhibitor patients, comparing prophylaxis using 
FEIBA®with on-demand treatment, showed 6-month over-dispersion of 4-532. On that background, 
an over-dispersion of 7 over the 24 weeks in main part of the current trial is deemed realistic.
17.2 Definition of analysis sets
All dosed patients will be included in the Full Analysis Set (FAS) as well as in Safety Analysis Set 
(SAS).
17.[ADDRESS_931951] 24 weeks from treatment 
onset. 
The endpoint will be analysed when the main part of trial has been completed.
17.3.1 Estimand and primary statistical analysis
The estimand for the primary endpoint is the “if all patients had adhered” estimand.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 115 of 137
The treatment ratio between prophylaxis s.c. concizumab and on-demand i.v. eptacog alfa (rFVIIa)
during at least 24 weeks for all randomised patients if all patients adhered to trial drug and did not 
initiate alternative treatment options.
This estimand is a de jure estimand assessing the expected added benefit a patient can achieve if 
continuing treatment with prophylactic s.c. concizumab as compared to on-demand  i.v. eptacog 
alfa (rFVIIa) under similar conditions as observed in this trial.
The estimand for the primary endpoint will be estimated using negative binomial regression with 
log of exposure time in main part as offset and regimen as factor, providing an estimate of the ABR 
ratio between regimens (concizumab prophylactic and on-demand eptacog alfa (rFVIIa)) with 
corresponding 95% confidence interval and also actual estimate of the ABR with corresponding 
95% confidence interval for each regimen. This analysis has the underlying assumption that the 
missing data mechanism is “missing at random”, i.e. MAR.  Under this assumption, the statistical 
behaviour of the missing data (given the observed responses and the mean value structure) is 
assumed to be the same as for the observed data. The estimand will be estimated based on the FAS
and only data collected prior to discontinuation of trial product or initiation of alternative treatment 
options will be used to draw inference. 
17.3.[ADDRESS_931952] a worse outcome compared to what was observed during the 
main part of the trial. This will be done by [CONTACT_1583] a value Δto the observed bleeding epi[INVESTIGATOR_687574]. The offset is maintained as being the exposure 
during the main part since it is not possible to identify the amount of missing observation time.The 
degree of worsening, Δi,will gradually be increased to evaluate at which point concizumab 
prophylaxis no longer is superior to on-demand eptacog alfa (rFVIIa). The results of the primary 
analysis will be considered robust if the tippi[INVESTIGATOR_687575].
17.3.3 Additional analysis
An additional evaluation of the primary endpoint will be made, including actual concizumab dose 
level as additional factor in the primary analysis model specified above. Point estimates and 95% 
confidence interval will be provided for the ABR at the different dose levels of concizumab (0.15, 
0.20 and 0.25 mg/kg). Furthermore, an analysis with individual steady state PK/PD assessments 
included as covariates in the negative binomial regression model as specified for the primary 
analysis of number of bleeding epi[INVESTIGATOR_687576]/PD and ABR that potentially could guide dose-selection. The referred steady-state 
PK/PD assessments comprise the concizumab trough level, TFPI [INVESTIGATOR_535160] s.c. dose 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 116 of 137
administration, peak thrombin generation (nM) , Endogenous thrombin potential  (nMxmin)  and 
velocity index (nM/min).
17.4 Supportive secondary endpoints
17.4.1 Supportive secondary efficacy endpoints
∀The number of bleeding epi[INVESTIGATOR_51953] 76 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_51953] [ADDRESS_931953] 24 weeks from treatment onset will be 
addressed in terms of the same estimand as for the primary endpoint. The estimand will be 
estimated using the same negative binomial regression model as for the primary endpoint.   
Furthermore, an additional evaluation will be made, where actual concizumab dose is included as 
factors in the model.
The remaining supportive secondary efficacy endpoints will be summarised descriptively by 
[CONTACT_71397]. In addition, number of bleeding epi[INVESTIGATOR_51953] 76 weeks of treatment with 
prophylactic concizumab will be analysed using a negative binomial model with log of trial 
duration as offset, providing estimates of the ABR with confidence interval for that particular 
regimen.
17.4.2 Supportive secondary safety endpoints
∀Number of TEAEs during at least 24 weeks from treatment onset
∀Number of TEAEs during 76 weeks from treatment onset
∀Number of TEAEs within 24 hours of rFVIIa administration 
∀Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset
∀Occurrence rate of  anti-concizumab antibodies during 76 weeks from treatment onset
∀Change from baseline of fibrinogen during 24 weeks from treatment onset
∀Change from baseline of fibrinogen during 76 weeks from treatment onset
∀Change from baseline of D-dimer during 24 weeks from treatment onset
∀Change from baseline of D-dimer during 76 weeks from treatment onset
∀Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
∀Change from baseline of F1 + 2 during 76 weeks from treatment onset
∀Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
∀Change from baseline of PT during 76 weeks from treatment onset
∀Change from baseline of activated partial thromboplastin time (APTT) during 24 weeks 
from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 117 of 137
∀Change from baseline of APTT during 76 weeks from treatment onset
∀Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
∀Change from baseline of AT [ADDRESS_931954] recent version of Medical Dictionary for Regulatory 
Activities (MedDRA) coding.
TEAE is defined as an event that has onset from the first exposure to treatment until the last visit in 
the trial. Treatment-emergent adverse event endpoints will be summarised by [CONTACT_9313], 
preferred term, seriousness, severity and relation to trial product. All adverse events will further be 
listed.
Frequency of binding anti-concizumab antibodies will by [CONTACT_535262].
All laboratory safety endpoints will be plotted by [CONTACT_5586], both as absolute values and change from 
baseline. Laboratory safety endpoints will further be summarised and listed.
17.4.3 Supportive secondary pharmacokinetic endpoints
∀Concentration of concizumab prior to the last dose administration at 24 weeks  
∀Concentration of concizumab prior to the last dose administration at 76 weeks  
The pharmacokinetic endpoints will be summarised and listed.
17.4.4 Supportive secondary pharmacodynamic endpoints
∀Free TFPI [INVESTIGATOR_687515] [ADDRESS_931955] dose administration at 76 weeks 
∀Thrombin generation
oPeak thrombin generation (nM) prior to the last dose administration at 24 weeks 
oPeak thrombin generation (nM) prior to the last dose administration at 76 weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 24 
weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 76 
oVelocity index (nM/min) prior to the last dose administration at 24 weeks 
oVelocity index (nM/min) prior to the last dose administration at 76 weeks 
The PD endpoints will be summarized and listed.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 118 of 137
17.4.5 Exploratory endpoints
[IP_ADDRESS] Exploratory safety endpoints
∀Number of adverse events related to technical complaints during at least 24 weeks from 
treatment onset 
∀Number of adverse events related to technical complaints during at least 76 weeks from 
treatment onset 
Adverse events related to technical complaints will be listed and summarised
[IP_ADDRESS] Exploratory patient reported-outcome endpoints
∀Change in Hemo-TEM after 24 weeks from treatment onset
∀Change in Hemo-TEM after 76 weeks from treatment onset
∀Change in VERITAS-Pro®or VERITAS-PRN®after 24 weeks from treatment onset
∀Change in VERITAS-Pro®or VERITAS-PRN®after 76 weeks from treatment onset
∀Change in SF-36v2 after 24 weeks from treatment onset
∀Change in SF-36v2 after 76 weeks from treatment onset
∀Change in SDS after 24 weeks from treatment onset
∀Change in SDS after 76 weeks from treatment onset
∀Change in TSQM after 24 weeks from treatment onset
∀Change in TSQM after 76 weeks from treatment onset
∀Change in SIAQ-ISRQ after 24 weeks from treatment onset
∀Change in SIAQ-ISRQ after 76 weeks from treatment onset
∀Change in PGI-C after 24 weeks from treatment onset
∀Change in PGI-C after 76 weeks from treatment onset
VERITAS-Pro®or VERITAS-PRN®, SF-36v2, SDS and TSQM will be scored according to their 
respective scoring algorithms. Change from visit 2 to visit 9 will be analysed with an ANCOVA 
model including regimen as a factor and baseline score as covariate.
The PRO endpoints will be summarised using descriptive statistics and the remaining 
questionnaires (Hemo-TEM, PGI-C, SIAQ-ISRQ) will be summarised and listed using descriptive 
statistics.
17.[ADDRESS_931956] patient has completed a minimum of 24 weeks of treatment or at LPFT 
(visit 2) + [ADDRESS_931957] patient has withdrawn before visit 9. Other reporting of the trial
might be done during the extension part once the data collection and review of the main part data 
has been finalised and individual CTRs might in such case be issued. A CTR describing results 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931958] patient has either completed or 
withdrawn from the trial. All main conclusions regarding clinical proof of concept and dose 
guidance for phase 3 will be based on the reporting after the main part, see Figure 17–1 .
Figure 17–1 Definition of main and extension part
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 120 of 137
18 Ethics
18.1 Benefit-risk assessment of the trial
Benefits
Results from a multiple dose phase 1 trial where concizumab was dosed for approximately 6 weeks 
showed a trend towards efficacy in a limited number of patients who reached concizumab plasma 
concentrations above 100 ng/mL, see Section 3.1.2 . Based on these results, it is expected that the 
majority of the patients randomised to the concizumab treatment with 0.15 mg/kg daily dose will be 
protected from bleeding epi[INVESTIGATOR_1841].  Patients who experience excessive bleeding epi[INVESTIGATOR_687577] a possibility to be escalated to a higher dose where bleeding preventive
efficacy of concizumab treatment is expected to improve. For haemophilia patients with inhibitors 
and who are treated on-demand, expected improved efficacy is considered to be a major benefit in 
participating in this trial. Also, concizumab is administered s.c. and might reduce the burden of 
frequent i.v. injections associated with current treatment options in haemophilia patients with 
inhibitors.
Information gained from this trial will contribute to gaining regulatory approval for a product that is 
anticipated to offer clinical advantages over currently available products. 
Risks
No risks have been recognised as identified risks by [CONTACT_535263]. However, the nonclinical toxicity studies have identified 
thromboembolic events as a potential risk when treating non-human primates with concizumab at 
high exposures.
As observed for other pro-coagulant compounds, there is a potential safety risk of thrombosis and 
vascular ischemia with reaching very high concizumab plasma concentrations. In non-clinical 
toxicity studies with concizumab, thrombi were observed at high doses. However, a no observed 
adverse effect level ( NOAEL) for concizumab has been identified in non-haemophilic animals at 
plasma concentrations several folds higher than the currently anticipated effective plasma 
concentration (mean area under curve [AUC] and C max) based on PK modelling.
In a drug–drug interaction study in monkeys, three doses of up to 1 mg/kg of NovoSeven®were 
administered at 2-h intervals, alone or in the presence of a steady state concentration of 
concizumab. Increased concentrations of thrombin–anti-thrombin (TAT) and D-dimer were seen, 
which tended to be additive when both concizumab and eptacog alfa (rFVIIa) were present in 
circulation. No notable clinical observations were made. 
In clinical trials, except for one case of superficial thrombophlebitis in a healthy volunteer who 
received a single dose of 1mg/kg, no other thromboembolic events were observed.  A phase 13URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 121 of 137
multiple dose trial was finalised in haemophilia A patients (0.8 mg/kg s.c. every 4 days for 6 
weeks). In this clinical trial, marked changes in coagulation parameters were observed including a 
decrease from baseline in fibrinogen and a pronounced increase in D-dimer and F1+2 outside of 
normal range in patients with high plasma concentrations of concizumab. These changes were not 
judged as clinically significant by [CONTACT_535264][INVESTIGATOR_535134]™[ADDRESS_931959] not been observed so far in clinical trials. Furthermore, even if antibodies 
towards concizumab occur, the risk for the rate of immune complex formation exceeding the 
clearance capacity is considered low. Please refer to the Investigator’s Brochure for further 
information.
If antibodies against concizumab develop, they might also inhibit the function of the administered 
drug. The consequence of this could be that the patient may not be able to benefit from the drug in 
the future. Antibody development against concizumab is not expected to reduce the effect of other 
treatment options.
Theoretical risks include bleeding due to consumption of coagulation factors and adverse reactions 
due to potentiation of inflammatory reactions or tissue damage due to impairment of tissue repair 
mechanisms33 34. TFPI [INVESTIGATOR_535135], in addition to its role in 
haemostasis, is implicated in tissue repair processes and in a variety of physiological and 
pathophysiological states where repair mechanisms are activated. These include sepsis, DIC, 
inflammation, atherosclerosis, cancer and crush injuries35 36, 37.
There may be a risk of allergic reactions, including severe (anaphylactic) reactions, in connection 
with concizumab administration. Severe allergic reactions may potentially be life-threatening and 
thus, the trial products will be administered to the trial patients at the site under the surveillance of 
medically trained trial site staff in the beginning of the trial.
Overall the anticipated benefits from participating in the trial outweigh the potential risks.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931960] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki2.
Before any trial-related activity, the investigator must give the patient verbal and written 
information about the trial and the procedures involved in a form that the patient can read and 
understand. 
The patients must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.
The investigator must ensure the patient ample time to come to a decision whether or not to 
participate in the trial. 
A voluntary, signed and personally dated informed consent must be obtained from the patient 
before any trial-related activity.  
The responsibility for seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualified person, in accordance with local 
requirements. The written informed consent must be signed and personally dated by [CONTACT_135562]-related activity.
If information becomes available that may be relevant to the patient’s willingness to continue 
participating in the trial, the investigator must inform the patient in a timely manner, and a revised
written patient information must be provided and a new informed consent must be obtained.
Only applicable for Japan: As a minor is unable to provide legally binding consent, informed 
consent must be sought from the parent(s)/LAR(s) on the child’s behalf prior to enrolling a child in 
the trial, according to local requirements.
18.[ADDRESS_931961] to follow up, then the patient’s data will be handled 
as follows:
∀Data already collected and any data collected at the end-of-trial visit will be retained by 
[CONTACT_3454], entered into the database and used for the CTR. 
∀Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used it will always be in accordance with local regulations and IRBs/IECs.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931962] be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely terminated, the investigator must inform the patients 
promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. 
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of patients who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the patients
should be described.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931963] be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database. 
Documentation on protocol deviations must be kept in the investigator trial master file and sponsor 
trial master file.
19.[ADDRESS_931964] or withdrawal of consent to secure 
early mitigations in collaboration with the trial sites. 
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, 
see Section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by [CONTACT_36340] (e.g. re-training of site staff).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931965] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.
21 Critical documents
An Investigator Portal (Global Haemophilia Network [GHN]) will be used as primary media for 
exchange and handling of investigator trial master file documents between Novo Nordisk and the 
site and for electronic storage of these documents during trial conduct. 
Before a trial site is allowed to start screening patients, written notification from Novo Nordisk 
must be received and the following documents must be available to Novo Nordisk:
∀Regulatory approval and/or acknowledgement of notification as required 
∀Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, patient information/informed consent form, 
any other written information to be provided to the patient and patient recruitment materials
∀List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
∀Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
∀Signed receipt of Investigator’s Brochure
∀SmPC or similar labelling of eptacog alfa (rFVIIa)
∀Signed and dated Agreement on Protocol
∀Signed and dated Agreement on Protocol Amendment, if applicable
∀Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigator’s 
site and Novo Nordisk
∀Source document agreement
∀Central laboratory certification and normal ranges
∀Insurance statement, if applicable
∀Financial disclosure form from investigator and sub-investigator(s)
∀Description of research facility obtained (applicable for sites outside the US)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 126 of 137
Only applicable for US trial sites: 
∀For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
∀For US trial sites: FDA form [ADDRESS_931966] be completed and signed by [CONTACT_237205] 1572:
For US sites:
∀Intended for US sites
∀Conducted under the IND
∀All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
∀Intended for participating sites outside of the US
∀Not conducted under the IND
∀All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
For local laboratory parameters the following will be collected:
∀Laboratory normal ranges
∀Laboratory certification, QA scheme or similar documentation
∀Laboratory assay methods (only non-standard assays) and/or analytical methods 
By [CONTACT_36343], each investigator agrees to comply fully with ICH GCP1
applicable regulatory requirements and the Declaration of Helsinki2. 
By [CONTACT_36343], each investigator also agrees to allow Novo Nordisk to make 
investigator’s name [CONTACT_36374] [CONTACT_36344].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931967] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the patients.
At least investigator must be trained in the current protocol version at a Novo Nordisk Investigator 
meeting or by [CONTACT_687641]. It is recommended that all site staff 
completes the web protocol training.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents including the patient identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
patients to a specific qualified physician who will be readily available to patients during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931968], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial.
One investigator will be appointed by [CONTACT_18036] (signatory 
investigator) on behalf of all participating investigators. The signatory investigator will be 
appointed based upon the criteria defined by [CONTACT_36346]38. 
23.[ADDRESS_931969] for 
Clinical Trial Disclosure how-we-disclose-trial-information.
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, 
for example when the CTR is available. This includes the right not to release the results of interim 
analyses, because the release of such information may influence the results of the entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_931970] intellectual property.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 129 of 137
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators’ and Novo Nordisk opi[INVESTIGATOR_36255].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038]. 
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors38(sometimes referred to as the Vancouver 
Criteria).
23.1.2 Site-specific publication(s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
patients, and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should always reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication policy, submission of a primary publication will take place no later than [ADDRESS_931971] access 
to the database. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 130 of 137
24 Retention of clinical trial documentation and human biosamples
24.1 Retention of clinical trial documentation
Patients’ medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other patient data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These data must be retained by [CONTACT_21655]. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least [ADDRESS_931972].
Only applicable for Spain: 25 years retention according to the Spanish Royal Decree 1090/2015.
The files from the trial site/institution must be retained for 15 years after EOT as defined in Section 
7, or longer if required by [CONTACT_36348]. In any case trial files cannot be 
destroyed until the trial site/institution is notified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.  
24.2 Retention of human biosamples
This trial will involve collection of human biosamples at visit 1 (screening visit) and at visit 17
(EOT) and these samples are to be stored maximum [ADDRESS_931973] the patients’ participation in the trial. 
Therefore, patients will have the possibility to sign the informed consent for the trial and 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 131 of 137
participate, while refusing permission for biological specimens to be stored for future exploratory 
analysis.
∀Human biosamples will be stored at the central laboratory 
∀1.0 mL citrated plasma, 1.2 mL serum and/or 2.0 mL whole blood (DNA for genotypi[INVESTIGATOR_007])
will be obtained
∀The intended use of the stored human biosamples e.g.: As new biomarkers related to the 
disease and/or safety, efficacy or mechanism of action of concizumab may evolve during the 
conduct of the trial, the analyses of the stored human biosamples may also include 
biomarkers that are unknown at present or have not been included in the scientific 
hypotheses at initiation of the trial
∀Human biosamples may be transferred to third parties e.g. research consortia
∀The human biosamples will be transferred and stored after the EOT at a designated central 
laboratory
∀Confidentiality and personal data protection will be ensured during storage after the EOT
∀The human biosamples may be transferred to other countries (not applicable if local 
regulations prohibit export of human biosamples)
∀The human biosamples will be destroyed at the latest 15 years from EOT
∀The patient may request the stored human biosamples to be destroyed by [CONTACT_535265]. The results obtained from any already performed analyses of the samples will still 
be used
∀Novo Nordisk and laboratory will have access to the stored human biosamples 
∀Potential consequences for the patient and their relatives: In the event that the collected
human biosamples (plasma, serum and/or DNA for genotypi[INVESTIGATOR_007]) will be used in the future, 
the investigator will become directly informed by [CONTACT_535266]. In such case, 
a written summary of the findings, including listings of patient specific values, will be 
provided once a firm conclusion from the results has been drawn by [CONTACT_3454]. 
Potentially, observations of neoplastic diseases, serious hereditary diseases, other un-
treatable diseases, or any other abnormal findings could be part of the observations. Patients
can contact [CONTACT_687642], see Section 5.1.
24.2.1 Antibody samples
Antibody samples will be retained until drug approval by U.S. Food and Drug Administration 
(FDA) and/or European Medicines Agency (EMA). 
The retained antibody samples may be used for later analysis for further characterisation of 
antibody responses towards drug if required by [CONTACT_49769]. Remaining 
blood from the samples already collected may be used for further development of Anti-Drug 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931974] 
terminates, but no longer than 15 years from EOT after which they will be destroyed. 
The patients’ identity will remain confidential and the antibody samples will be identified only by 
[CONTACT_56324], visit number and trial identification number. No direct identification of the patient
will be stored together with the samples.
Only Novo Nordisk staff and bio-repository personnel will have access to the stored antibody 
samples. 
Patients can contact [CONTACT_215591].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 133 of 137
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to Investigator’s 
Brochure, unexpected SAEs where a causal relationship cannot be ruled out, protocol amendments 
according to local requirements, deviations to the protocol implemented to eliminate immediate 
hazards to the patients, new information that may affect adversely the safety of the patients or the 
conduct of the trial (including new benefit-risk analysis in case it will have an impact on the 
planned follow-up of the patients), annually written summaries of the trial status, and other 
documents as required by [CONTACT_1036]/IEC.
The investigator must ensure submission of the CTR synopsis to the IRB/IEC (not applicable for 
Japan).
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the patients.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_36258].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the CTR according to national requirements.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931975] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_18033].
Novo Nordisk accepts liability in accordance with:
Only applicable for Austria: Arzneimittelgesetz (BGBI. Nr. 185/1983) last amended with  BGBl. 
II Nr. 105/2015
Only applicable for [LOCATION_009]: The French Public Health Code article L 1121-10 (law no 2004-[ADDRESS_931976] 2004. “The sponsor is responsible for 
identification of the harmful consequences of the biomedical research for the person lending 
himself thereto and for indemnification of his beneficiaries, except in case of proof, incumbent on 
it, that the prejudice is not attributable to his fault or the fault of any intervening party, without the 
sponsor’s being entitled to call on acts by a third party or the voluntary withdrawal of the person 
who had initially consented to cooperating in the research”
Only applicable for Poland: Novo Nordisk carries liability for the Trial exclusively in the scope 
defined by [CONTACT_687643] 6 September 2001 (uniform version Journal pf Laws of 2008 No. 45 item 271 with 
amendments). In order to support potential claims for liability attributable to the Trial, Novo 
Nordisk and Investigators are covered by [CONTACT_687644].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 135 of 137
27 References
1. International Conference on Harmonisation. ICH Harmonised Tripatite Guideline. Guideline 
for Good Clinical Practise E6(R2), Step 4. [ADDRESS_931977] amended by [CONTACT_941] 64th WMA General Assembly, Fortaleza, Brazil. October 2013.
3. International Organization for Standardization. ISO [ZIP_CODE]:2011, Clinical investigation of 
medical devices for human subjects - Good clinical practice. [ADDRESS_931978] Investigators. Am J Hematol. 1998;59(4):288-94.
5. World Federation of Hemophilia. Report on Annual Global Survey 2014.6. White GC, 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. 
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
7. Hoffman M, Monroe III. A cell-based model of hemostasis. Thrombosis and haemostasis. 
2001;85(6):958-65.
8. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-9.9. Wight J, Paisley S. The epi[INVESTIGATOR_687578] A: a systematic review. 
Haemophilia. 2003;9(4):418-35.
10. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino 
acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993;30(1):105-8.
11. Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, et al. Safety and 
pharmacokinetics of anti-TFPI [CONTACT_30936] (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743-54.
12. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351(12):1250-1.
13. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007.
14. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_931979] of clinical trials on medicinal products for human use, article 11. Official Journal of the European Communities. 01 May 2001.
15. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March laying down 
Community procedures for the authorisation and supervision of medicinal products for 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 136 of 137
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. April 2001.
16. Duncan NA, Kronenberger WG, Roberson CP, Shapi[INVESTIGATOR_71324]. VERITAS-PRN: a new 
measure of adherence to epi[INVESTIGATOR_535136]. Haemophilia. 2010;16(1):47-53.
17. Maruish ME. User's manual for the SF-36v2 Health Survey (3rd ed.). Lincoln, RI: 
QualityMetric Incorporated2013.
18. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin 
Psychopharmacol. 1996;[ADDRESS_931980] 3:89-95.
19. Atkinson MJ, et al. Validation of a general measure of treatment satisfaction, the Treatment 
Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
20. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the 
treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;[ADDRESS_931981] 1:S9-S24.
21. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of 
an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.
22. Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid 
arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9:2.
23. Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. Official Journal 
L 1692 12/07/1993.
24. European Commission. The Rules Governing Medicinal Products in the European Union, 
Volume 4, Annex 13, Investigational Medicinal Products (ENTR/F/2/AM/an D[2010] 3374). 03 Feb 2010.
25. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et 
al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-7.
26. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third 
universal definition of myocardial infarction. Circulation. 2012;126(16):2020-35.
27. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. Current diagnosis 
of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med. 2007;5(1):57-62.
28. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated 
definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064-89.
29. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition 
and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 March 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 137 of 137
Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the 
value of this statement as an educational tool for neurologists. Stroke. 2009;40(6):2276-93.
30. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 
ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(19):2020-45.
31. U.S. Food and Drug Administration. Code of Federal Regulations, 21 CFR Part 11, 
Electronic Records, Electronic Signatures. 2009 2009.
32. Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-
inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365(18):1684-92.
33. Levi M, Keller TT, van GE, ten CH. Infection and inflammation and the coagulation system. 
Cardiovasc Res. 2003;60(1):26-39.
34. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, Hall CL. Tissue factor 
pathway inhibitor binds to platelet thrombospondin-1. J Biol Chem. 2000;275(41):[ZIP_CODE]-21.
35. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. 
Arterioscler Thromb Vasc Biol. 2004;24(6):1015-22.
36. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in 
angiogenesis and cancer. Arterioscler Thromb Vasc Biol. 2005;25(8):1545-50.
37. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol. 
2005;25(1):47-56.
38. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly Work in Medical Journals. December 
update 2016.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 1 of 136
Protocol
NN7415-4310
A Multi-Centre, Randomised, Open-Label, Controlled Trial 
Evaluating the Efficacy and Safety of Prophylactic 
Administration of Concizumab in Haemophilia A and B 
Patients with Inhibitors
Trial phase: 2
Includes: Protocol Version 1 (15 March 2017); Protocol Amendment no 1 (05 May 2017) for all 
participating countries.
Protocol originator
, Senior International Trial Manager 
Biopharm Trial Ops [ADDRESS_931982] be restricted to relevant 
parties.
3URWRFROY
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931983] of abbreviations .......................................................................................................... .........................9
1 Summary ............................................................................................................................... .............15
2 Flow chart .................................................................................................................... ......................18
2.1 Visits and assessments ...................................................................................................... ......18
2.2 Explanatory descriptions .........................................................................................................21
3 Background information and rationale for the trial .........................................................................23
3.1 Background information ..........................................................................................................23
3.1.1 Haemophilia ..........................................................................................................23
3.1.2 Con cizumab ...........................................................................................................24
3.2 Rationale for the trial ...............................................................................................................27
4 Objective(s) and endpoint(s) ..............................................................................................................28
4.1 Objective(s) ............................................................................................................................28
4.1.1 Primary objective ...................................................................................................28
4.1.2 Sec ondary objectives .............................................................................................28
4.2 Endpoint(s) .............................................................................................................................28
4.2.1 Prima ry endpoint ...................................................................................................28
4.2.2 Sec ondary endpoints ..............................................................................................28
[IP_ADDRESS] Supportive secondary endpoints .......................................................[ADDRESS_931984] oratory endpoints ............................................................................................29
[IP_ADDRESS] Exploratory sa fety endpoints ............................................................29
[IP_ADDRESS] Exploratory patient re ported outcome endpoints ...............................29
5 Trial design .................................................................................................................. ......................31
5.1 Type of trial ............................................................................................................... .............31
5.1.1 S urgery ..................................................................................................................32
5.2 Rationale for trial design .........................................................................................................32
5.3 Treatment of patients ...............................................................................................................35
5.3.1 Concizumab arm ....................................................................................................36
[IP_ADDRESS] Concizumab prophylactic treatment (main and extension part) ..........36
5.3.2 Comparator arm (eptacog alfa (rFVIIa)).................................................................37
[IP_ADDRESS] On-demand treatment (main part) .....................................................37
[IP_ADDRESS] Concizumab prophylactic treatment (extension part) .........................37
5.3.3 Dose escalation ......................................................................................................37
5.3.4 Co-administration of ep tacog alfa (rFVIIa).............................................................[ADDRESS_931985] .......................................................................41
5.5 Rationale for treatment ............................................................................................................41
6 Trial population .............................................................................................................. ...................42
6.1 Number of patients ..................................................................................................................423URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931986] ..............................................................49
8.1.5 Withdra wal from trial .............................................................................................49
8.1.6 Review / evaluation of clinical outcome ..................................................................49
8.1.7 Visit 1 (Screen ing part)..........................................................................................50
8.1.8 Traini ng of patients at visit 1, visit 2 and visit 9 ......................................................50
8.1.9 Treatment peri od at home ......................................................................................51
8.1.10 Sta ggered recruitment ............................................................................................51
8.1.11 Treatment period – Main part.................................................................................51
[IP_ADDRESS] Visit 2 (R andomisation) ...................................................................51
[IP_ADDRESS] Visit 3 (Phone call for eptacog alfa (rFVIIa) on-demand arm and 
PK visit for concizumab arm) ...........................................................53
[IP_ADDRESS] Visit 4, 5, 6, 7 and 8 .........................................................................54
[IP_ADDRESS] Visit 9 ..............................................................................................55
8.1.12 Treatment period – E xtension part..........................................................................56
[IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog 
alfa (rFVIIa) on-demand arm) ..........................................................56
[IP_ADDRESS] Visit 9.2 (ONLY patients previously on the eptacog alfa (rFVIIa) 
on-demand arm) ...............................................................................57
[IP_ADDRESS] Visit 10 ............................................................................................58
[IP_ADDRESS] Visit 10.1 (ONLY patients previously on the eptacog alfa 
(rFVIIa) on-demand arm) .................................................................59
[IP_ADDRESS] Visit 11 ............................................................................................60
[IP_ADDRESS] Visit 11.1 (ONL Y patients previously on the rFVIIa on-demand 
arm) .................................................................................................60
[IP_ADDRESS] Visit 12, 13, 14 and 15 .....................................................................61
[IP_ADDRESS] Visit 16 ............................................................................................62
8.1.13 Visit 17 (End of trial) - Follow-up part ...................................................................63
8.1.14 Unscheduled Visit..................................................................................................63
8.2 Patient related information/assessments ...................................................................................64
8.2.1 Dem ography ..........................................................................................................64
8.2.2 Concom itant illness and medical history other than haemophilia ............................64
8.2.3 Conco mitant medication ........................................................................................65
8.2.4 Details  of Haemophilia, Haemophilia treatment and bleed history ..........................65
8.3 Efficacy assessments ...............................................................................................................66
8.3.1 Bleeding epis odes ..................................................................................................66
8.4 Safety assessments .......................................................................................................... ........693URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 4 of 136
8.4.1 Phys ical examination .............................................................................................69
8.4.2 Body measurements ...............................................................................................70
8.4.3 V ital Signs .............................................................................................................70
8.4.4 Electrocardiogram ..................................................................................................71
8.4.5 Adverse ev ents.......................................................................................................71
[IP_ADDRESS] Medicati on error ...............................................................................71
[IP_ADDRESS] Adverse events requiri ng additional data collection ..........................71
8.5 Laboratory assessments ...........................................................................................................73
8.5.1 Labora tory assessments for efficacy .......................................................................74
[IP_ADDRESS] Thrombin generation ........................................................................74
[IP_ADDRESS] Free TFPI .........................................................................................75
8.5.2 Labor atory assessments for safety ..........................................................................75
[IP_ADDRESS] Urinalys is.........................................................................................75
[IP_ADDRESS] Haematology ....................................................................................75
[IP_ADDRESS] Biochemistry ....................................................................................76
[IP_ADDRESS] FVIII/FIX activity ............................................................................76
[IP_ADDRESS] Coagulati on parameters ....................................................................77
[IP_ADDRESS] FVIII/FIX inhibitors .........................................................................77
[IP_ADDRESS] Anti-concizumab antibodies .............................................................77
[IP_ADDRESS] Concizumab ELISA .........................................................................79
[IP_ADDRESS] FVII ELI SA .....................................................................................80
[IP_ADDRESS] Total TFPI ........................................................................................80
8.5.3 Human Bios amples ................................................................................................80
8.6 Other assessments ........................................................................................................... ........81
8.6.1 P atient reported outcomes ......................................................................................81
8.6.2 Training .................................................................................................................8 2
[IP_ADDRESS] Concizumab and NovoPen®4............................................................82
[IP_ADDRESS] eptacog alfa (rFVIIa) ........................................................................82
[IP_ADDRESS] eDiary ..............................................................................................83
8.6.3 S urgery ..................................................................................................................83
8.7 Patient compliance ..................................................................................................................83
8.8 Treatment compliance .............................................................................................................84
9 Trial supplies ............................................................................................................................... .......85
9.1 Trial products ..........................................................................................................................85
9.2 Labelling ............................................................................................................................... ..85
9.3 Storage..................................................................................................................... ...............86
9.4 Drug accountability and destruction ........................................................................................86
9.5 Auxiliary supplies ...................................................................................................................87
10 Interactive voice/web response system ..............................................................................................88
11 Randomisation procedure and breaking of blinded codes................................................................88
11.1 Randomisation ........................................................................................................................88
11.2 Breaking of bli nded codes .................................................................................................. .....88
12 Adverse events, and technical complaints ..................................................................................... ....89
12.1 Defi nitions ..............................................................................................................................8 9
12.1.1 Adverse ev ent ........................................................................................................89
12.1.2 Serious advers e event.............................................................................................90
12.1.3 Non-serious adve rse event......................................................................................913URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931987] ..........................................................................93
12.1.7 Technical complaints .............................................................................................97
12.2 Reporting of a dverse events .....................................................................................................97
12.3 Follow-up of adve rse events................................................................................................ ..100
12.4 Technical complaints a nd technical complaint samples ..........................................................101
12.4.1 Reporti ng of technical complaints ........................................................................101
12.4.2 Co llection, storage and shipment of technical complaint samples .........................102
12.5 Pre gnancies ...........................................................................................................................102
12.5.1 Pregnancies in female pa rtners of male patients....................................................102
12.6 Precautions and/or overdose ..................................................................................................103
12.7 Rules for putting enrolment on hold ......................................................................................104
12.8 Committees related to safety .................................................................................................104
12.8.1 Novo N ordisk safety committee ...........................................................................104
12.8.2 Data m onitoring committee ..................................................................................105
13 Case report forms ............................................................................................................ ................105
13.1 Corrections to case report forms ............................................................................................106
13.2 Case report form flow ...........................................................................................................106
13.3 Electronic diary .....................................................................................................................106
14 Monitoring procedures ........................................................................................................ ............108
15 Data management ............................................................................................................................109
16 Computerised systems ......................................................................................................... ............110
17 Statistical considerations .................................................................................................................111
17.1 Sample size calculation .........................................................................................................112
17.2 Definition of analysis sets ......................................................................................................113
17.3 Primary endpoint ...................................................................................................................113
17.3.1 Estima nd and primary statistical analysis .............................................................113
17.3.2 Sens itivity analysis ..............................................................................................114
17.3.3 Add itional analysis ..............................................................................................114
17.4 Supportive sec ondary endpoints ............................................................................................115
17.4.1 Suppor tive secondary efficacy endpoints ..............................................................115
17.4.2 Suppor tive secondary safety endpoints .................................................................115
17.4.3 Suppor tive secondary pharmacokinetic endpoints .................................................116
17.4.4 Suppor tive secondary pharmacodynamic endpoints ..............................................116
17.4.5 Explor atory endpoints ..........................................................................................117
[IP_ADDRESS] Exploratory sa fety endpoints ..........................................................117
[IP_ADDRESS] Exploratory patient re ported-outcome endpoints .............................117
17.5 Interim analy sis........................................................................................................... ..........117
18 Ethics....................................................................................................................... .........................119
18.1 Benefit-risk asse ssment of the trial ....................................................................................... .119
18.2 Informed consent ..................................................................................................................121
18.3 Data handling ........................................................................................................................121
18.4 Information to patients during trial ........................................................................................122
18.5 Premature termination of the trial and/or trial site ..................................................................1223URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 6 of 136
19 Protocol compliance .........................................................................................................................123
19.1 Protocol  deviations ................................................................................................................123
19.2 Prevention of missing data ................................................................................................. ...123
20 Audits and inspections ....................................................................................................... ..............124
21 Critical documents........................................................................................................... ................124
22 Responsibilities ............................................................................................................................... ..126
23 Reports and publications ..................................................................................................... ............127
23.1 Communicati on of results ......................................................................................................127
23.1.1 Aut horship ...........................................................................................................128
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) .......................................................128
23.2 Investigator access to data and review of results ....................................................................128
24 Retention of clinical trial documentation and human biosamples ..................................................129
24.1 Retention of clinical trial documentation ...............................................................................129
24.2 Retention of human  biosamples.............................................................................................1 29
24.2.1 Anti body samples ................................................................................................130
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities ...........[ADDRESS_931988] of key staff and relev ant departments, if applicable for the individual . 
Appendix 1 Patient Reported Outcomes3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 7 of 136
Table of Figures
Page
Figure 3–1 Individual predicted PK profiles based on data merged with recorded spontaneous (circles) 
and traumatic (triangles) bleeding epi[INVESTIGATOR_535038]-up period. All data originates from explorer™3 (N=24 patients). PK of concizumab is subdivided into 
three exposure levels of !20 ng/mL, 20-100 ng/mL, and > 100 ng/mL together with the 
number of contributing patients. LLOQ: lower limit of quantification. .....................................26
Figure 5–1 Schematic diagram of the trial design ................................................................................ ......31
Figure 5–2 Individual predicted concizumab concentration profiles for all concizumab-treated patients 
in explorer™2 (n=4 patients) and explorer™3 (n=18 patients). The horizontal lines 
indicate 100 ng/mL, and the shaded areas represent the full range (min-max) of the 
individual predicted profiles. ...................................................................................................34
Figure 5– 3 Dose escalation for one individual patient in the concizumab arm ............................................38
Figure 5–4 Dose escalation for one indivi dual patient in the comparator arm .............................................39
Figure 8–1 Visit schedule – concizumab arm. ...........................................................................................46
Figure 8–2 Visit schedule – eptacog alfa (rFVIIa) arm later switching to concizumab. ...............................46
Figure 12–1 Reporting of AEs .................................................................................................... ................99
Figure 17–1 Definition of main and extension part ....................................................................................1183URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 8 of 136
Table of Tables
Page
Table 5–[ADDRESS_931989] of products provided by [CONTACT_3454] .............................................................................35
Table 8–1 Definition of stop of bleeding epi[INVESTIGATOR_1865] .....................................................................................67
Table 8–2 Definitions of bleeding epi[INVESTIGATOR_1841] (cause of bleed) ....................................................................67
Table 8–3 Definition of bleeding epi[INVESTIGATOR_535138] ...................................68
Table 9–1 Trial products ..........................................................................................................................85
Table 9–2 Storage conditions.................................................................................................... ...............86
Table 17–1 Power in superiority comparison between concizumab prophylaxis and on-demand 
treatment under different assumptions of ABR for concizumab and over-dispersion 
(assuming on-demand ABR=24). ..........................................................................................1133URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931990] aspartate aminotransferaseAT antithrombinAUC area under curveBP blood pressureBU Bethesda UnitCCDS company core data sheet CLAE clinical laboratory adverse eventC
max maximum plasma concentration
CNS central nervous system
concizumab Bthe name [CONTACT_687671] B. B is the formulation 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931991] correction DUN dispensing unit numberDVT deep vein thrombosisECG electrocardiogrameCRF electronic case report formeDiary electronic diaryeITMF electronic investigator trial master fileELISA enzyme-linked immunosorbent assay3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 11 of 136
EMA european medicines agency
EOT end of trialePRO electronic patien t reported outcome
eptacog alfa the name ‘eptacog alfa (rFVIIa)’ will be used throughout 
the protocol and the product is identical to rFVIIa,‘NovoSeven
®, and ‘NiaStaseRT®’
ETP endogenous thrombin potential FAS full analysis setFDA U.S. Food and Drug AdministrationFDAAA U.S. Food and Drug Administration Amendment ActFIX coagulation factor IXFPFV first patient first visitFVIIa activated coagulation factor VIIFVIII coagulation factor VIIIFVIII:C plasma activity of factor VIIIFX coagulation factor XFX
a activated coagulation factor X
GCP Good Clin ical Practice
GGT gamma glutamyl transferaseGHN global haemophilia network3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931992] cell protein
IB investigator’s brochureIC informed consent ICH International Conference on Harmonisation ICMJE International Committee of Medical Journal EditorsID identificationIEC independent ethics committeeIgG4 immunoglobulin G4IMP investigational medicinal product
INNInternational Non-Proprietary Names for Pharmaceuti cal 
Substances 
IRB institutional review boardISTH International Society on Thrombosis and HaemostasisIT information technologyi.v. intravenous(-ly)IWRS interactive web response systemLBBB left bundle branch blockLPFV last patient first visitLPLV last patient last visit3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_931993] level 
NIMP non investigational medicinal productPCD primary completion date PD pharmacodynamicsPEF peak expi[INVESTIGATOR_687507]4D every 4
thday3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 14 of 136
eptacog alfa (rFVIIa)the name ‘eptacog alfa (rFVIIa)’ will be used throughout 
the protocol and the product is identical to ‘NovoSeven®’
sABR spontaneous annualised bleeding rate
SAE serious adverse eventSAS safety analysis setsBE spontaneous bleeding epi[INVESTIGATOR_687508].c. subcutaneous(-ly)SI international system of unitsSmPC summary of product characteristicsS[LOCATION_003]R suspected unexpected serious adverse reactionTAT thrombin-antithrombin complexTEAE treatment emergent adverse eventsTIA transient ischemic attackTF tissue factorTFPI [INVESTIGATOR_687509]3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 15 of 136
1 Summary
The main objective for the phase 2 trial NN7415-4310, explorer™4, is to assess the efficacy of 
concizumab administered s.c. once daily to pre vent bleeding epi[INVESTIGATOR_56178] A and B 
patients with inhibitors. Furthermore , this trial aims to assess the l onger-term efficacy and safety of 
concizumab in haemophilia A and B patients with i nhibitors and to establish the safety of treating 
breakthrough bleeding epi[INVESTIGATOR_687510] (rFVIIa) in these patients.
Objective(s) and endpoint(s)
Primary objective
∀To assess the efficacy of concizumab administered s.c. once daily in preventing bleeding 
epi[INVESTIGATOR_56178] A and B patients with inhibitors.
Secondary objectives
∀To assess the longer-term efficacy of concizumab in haemophilia patients with inhibitors
∀To assess the safety of concizumab in haemophilia patients with inhibitors
∀To assess the safety of administering recombinant factor VIIa (rFVIIa) to haemophilia 
patients with inhibitors that are exposed to concizumab
∀To assess the immunogenicity of concizumab in haemophilia patients with inhibitors
Primary endpoint
∀The number of bleeding epi[INVESTIGATOR_687579] 24 weeks from treatment onset
Key secondary endpoints
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from tr eatment onset
∀Number of treatment emergent adverse events (TEAEs) during at least 24 weeks from
treatment onset
Time frames for evaluation of Objectives/Endpoints
All endpoints referring to the time frame of at least [ADDRESS_931994] (or has withdrawn). In addition, number of bleeding epi[INVESTIGATOR_51953] 76 
weeks of treatment with prophylactic concizumab will be analysed. The extension part of the trial will provide additional safety and long-term efficacy data.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 16 of 136
Trial design
The trial is a multi-centre, randomised (2:1),  open-label, controlled trial, aiming to evaluate the 
efficacy and safety of concizumab 0.15 mg/kg (with potential dose escalation) administered daily s.c. in haemophilia patients with inhibitors. We expect 16 patients to complete treatment in 
concizumab arm (concizumab prophylaxis) and 8 pati ents in comparator arm (rFVIIa on demand). 
The dose regimen is selected based on relevant PK and TFPI [INVESTIGATOR_535039]/PD modelling of the results from the preceding explorer™ trials. Only on-demand patients will be eligible for the trial.
For all patients treated with concizumab (concizumab arm and comparator arm extention part) a 
loading dose of 0,5 mg/kg concizumab will be gi ven as the first dose, followed by [CONTACT_687617] 0,15 mg/kg. All patients in treatment with concizumab will in a non-bleeding 
state receive a single dose of 90 μg/kg eptacog alfa (rFVIIa) one week after dosing with 
concizumab. Hereafter, patients will be closely clinically observed at the site for potential safety 
issues for at least 12h and evaluated again at the site after 24h.
The total trial duration for the individual patient w ill be approximately 86-88 weeks, consisting of a 
2-4 week screening period, a subsequent 76-week treatment period and an 8-week follow-up period.
eptacog alfa (rFVIIa) for treatment of bleeding epi[INVESTIGATOR_687511]. The patient will not be provided with trial product or ep tacog alfa (rFVIIa) after end of 
trial.
The trial is split into a main part which lasts [ADDRESS_931995] completed a minimum of 24 weeks of eptacog alfa (rFVIIa) on-demand or have withdrawn. The analysis of the main part of the trial aims to substantiate the clinical proof of 
concept (CPoC) that concizumab has the potential to prevent bleeding epi[INVESTIGATOR_687512]. The extension part of the trial will provide additional safety and long-term efficacy data.
Trial population
Number of patients planned to be screened: [ADDRESS_931996]: 26Number of patients expected to complete the trial: 243URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR 1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 17 of 136
Key inclusion criteria
∀Informed consent obtained before any trial r elated activities. Trial related activities are any 
procedures that are carried out as part of the trial, including activities to determine the 
suitability for the trial
∀Male haemophilia A or B patients with inhibitors aged ≥ 18 years at the time of signing 
informed consent
∀Patients currently in need of treatment with by[CONTACT_687618]
∀Known or suspected hypersensitivity to trial product(s) or related products
∀Known inherited or acquired bleeding disorder other than haemophilia
∀Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX
Key Efficacy assessment
∀Number of bleeding epi[INVESTIGATOR_535025] 24 weeks of treatment onset
Key Safety assessment
∀Number of treatment emergent adverse events during at least 24 weeks of treatment onset
Trial products
The following products will be used in the trial:
∀Investigational Medicinal Products:
oconcizumab B, 100mg/mL to be administered s.c. with NovoPen®4 and needles
oeptacog alfa (rFVIIa), 5mg /vial and histidine (solvent). Reconstituted eptacog alfa 
(rFVIIa) is for intravenous administration and used in the trial at visit 3 and 9.1 for all patients with the purpose of investigating the safety of administering eptacog alfa (rFVIIa) to haemophilia patients
∀Non Investigational Medicinal Product :
oeptacog alfa (rFVIIa) 5 mg /vial and histidine (solvent). Reconstituted eptacog alfa is for 
intravenous administration and used in this trial for treatment of bleeding epi[INVESTIGATOR_1841]3URWRFROY
CONFIDENTIAL
Protocol UTN: U1111-1179-2925 Date: 05 May 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_931997] no.: 2016-000510-30 Version: 2 Page: 18 of 136
2 Flow chart
2.1 Visits and assessments
explorerTM4 trial periods Screening Treatment main a,bTreatment extension b Follow-
up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16Un-
scheduled e 17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169 176 197 225 253 281 309 337 393 449 505 533When 
applicable589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1w 4w 8w 12w 16w 20w 24w 25w 28w 32w 36w 40w 44w 48w 56w 64w 72w 76w - 84w
PATIENT RELATED INFO/ASSESSMENTS
Informed consent/ Genotypi[INVESTIGATOR_535029]-term 
storage consent●
In/exclusion criteria ● ●g
Demography ●
Concomitant illness/Medical history ●
Concomitant medication ● ●●●●●●●●●●●●●●●●●●● ● ●
Details of Haemophilia/Haemophilia treatment and 
bleed history●
Withdrawal criteria/ Criteria for premature 
discontinuation of trial product●●●●●●●●●●●●●●●●●●● ● ●
Randomisation (IWRS) ●
EFFICACY
Bleeding epi[INVESTIGATOR_1841] h, i●●●●●●●●●●●●●●●●●●● ● ●
Thrombin generation (central lab) ● ●●j, k●●●●●●l●j●●●●●●●●●●l● ●
Free TFPI (central lab)  ● ●●k●●●●●●l●●●●●●●●●●●l● ●
SAFETY
Physical examination ● ●●k●● ● ● ● ●
Body measurements ● ●m●k, m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m
Vital signs ● ●n●k, n●●●●●●n●n●●●●●●●●●● ● ●
ECG ●
Adverse events ● ●●●●●●●●●●●●●●●●●●● ● ●3URWRFROY
Protocol UTN: U1111-1179-2925 Date: 05 May 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_931998] no.: 2016-000510-30 Version: 2 Page: 19 of 136
explorerTM4 trial periods Screening Treatment main a,bTreatment extension b Follow-
up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16Un-
scheduled e 17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169 176 197 225 253 281 309 337 393 449 505 533When 
applicable589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1w 4w 8w 12w 16w 20w 24w 25w 28w 32w 36w 40w 44w 48w 56w 64w 72w 76w - 84w
Injection site reaction  ●●k●●●●●●●●●●●●●●●●● ●
Urinalysis (local lab) ●
Haematology (local lab) ● ●●j, k●●●●●●l●j●●●●●●●●●●l● ●
Biochemistry (central lab) ● ●●k●●●●●●l●●●●●●●●●●●l● ●
FVIII/ FIX activity (central lab) ● ●l●l
Coagulation parameters (central lab) ● ● ●●●●●●l●●●●●●●●●●l● ●
Coagulation parameters (PT, APTT and Fibrinogen 
(local lab))●j, k●j
FVIII/FIX  inhibitors (central lab) ● ●l●l
Anti-concizumab antibodies (ADA) (special lab) o● ●●k, p●p●p●p●p●p●l, p●●●●●●●●●●●l● ●
Concizumab  ELISA (special lab) ●●k, p●p●p●p●p●p●l, p●●●●●●●●●●●l● ●
FVII ELISA (special lab) ●j,k●j
Total TFPI (special lab) ● ●●k●●●●●●l●●●●●●●●●●●l● ●
TRIAL MATERIAL
IWRS call ● ●●k●●●●●●●●●●●●●●●●● ● ●
Dispensing visit (concizumab)r●k●k●k●k●k●k●k●●●●●●●●●●● ●
Dispensing visit (eptacog alfa, histidine)q● ●w●k● ●● ● ● ●●●●● ●
Administration of trial product (concizumab)r●k, s●k●d, s ● ●
Administration of trial product (eptacog alfa) ●k, t●t
Drug accountability (concizumab) ●k●k●k●k●k●k●k●●●●●●●●●●● ●
Drug accountability (eptacog alfa) ●●k●●●●●●●●●●●●●●●●● ● ●
New dose of trial product e, u●●●●●● ●●●●●●●●● ●
PRO questionnaires ● ●●k●●●●●● ● ●
REMINDERS
Human biological specimen for storage (central lab) ● ●3URWRFROY
Protocol UTN: U1111-1179-2925 Date: 05 May 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_931999] no.: 2016-000510-30 Version: 2 Page: 20 of 136
explorerTM4 trial periods Screening Treatment main a,bTreatment extension b Follow-
up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16Un-
scheduled e 17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169 176 197 225 253 281 309 337 393 449 505 533When 
applicable589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) [ADDRESS_932000] ●
Training v● ● ●● ●
Compliance: eDiary ●●●●●●●●●●●●●●●●●● ● ●
End of treatment ●
End of trial ●
The cells marked in ‘red’ are only for the patients randomised to eptacog alfa (rFVIIa) arm.3URWRFROY
Protocol UTN: U1111-1179-2925 Date: 05 May 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932001] no.: 2016-000510-30 Version: 2 Page: [ADDRESS_932002] according to patient’s individual training need on concizumab administration, NovoPen®4, eDiary training etc. Visit [ADDRESS_932003] be registered in the eCRF.
i Eptacog alfa will be given to treat breakthrough bleeding epi[INVESTIGATOR_1841]. 
jSampling time schedule for thrombin generation, haematology,  coagulation parameters and FVII ELISA: pre-dose (-1 hour), post-d ose: 10 min (±2 min), 1h 
(± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points, except pre-dose, occ ur after eptacog alfa 
administration.
k ONLY for patients randomised to concizumab arm.
l At visit [ADDRESS_932004] not treat themselves with concizumab until sampling  has been performed.
m Only body weight should be measured. 
nVital signs should be evaluated before and after trial drug administration at visit 2 and visit 3 for concizumab arm and at visi t 9 and visit 9.1 for patients in 
eptacog alfa arm switching to concizumab treatment.
oIn case clinical signs of e.g. hypersensitivity reactions or immune related events are seen, additional samples for ADAs may be  taken. All antibody samples 
from the affected patient will be analysed on an ongoing basis. If antibodies are detected, additional blood samples will be tak en and stored for characterisation 
of the antibodies.
p Blood sampling for anti-concizumab antibodies and concizumab ELI SA testing should only be co llected for patients on concizumab.
q If needed dispensing of eptacog alfa, histidine, trial injection kits and Direction For Use (DFU). 
r First treatment dose of concizumab is a loading dose and will be administered at visit [ADDRESS_932005] received any  by[CONTACT_687619],(e.g., 
eptacog alfa, FEIBA®) for treatment of a bleeding epi[INVESTIGATOR_5319] a period of 24h (for eptacog alfa) or 48h (for FEIBA®) prior to first concizumab. Only 
eptacog alfa is allowed after visit 2.3URWRFROY
Protocol UTN: U1111-1179-2925 Date: 05 May 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932006] no.: 2016-000510-30 Version: 2 Page: 22 of 136
t Eptacog alfa administered in a non-bleeding state at site at visit 3 for the concizumab arm and at visit 9.1 for the eptacog alf a arm.
uPatient treated with concizumab should be dose escalated at next scheduled visit if he experiences ≥[ADDRESS_932007] and whenever needed afterwards. Patients randomised to eptacog  alfa will be re-trained in 
NovoPen®4 and s.c. administration at visit 9 and 9.1. If necessary training can be performed as needed at other visits. The eDiary will  be provided to the 
patients at visit 2 if the patient feels capable in s.c. administration and using the eDiary. Further the patients will be train ed in recognition of signs/symptoms of 
thrombosis.
w Only for patients randomised to on-demand arm.3URWRFROY
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932008] of 
the clinical trial at a trial site.
The INN name [CONTACT_687673] i ngredient is concizumab (synonyms used during early 
development are NNC0172-2021, anti-TFPI, NN7415 or mab2021). Throughout this document “concizumab” is used as the name [CONTACT_535317].
3.1 Background information
3.1.1 Hae mophilia
Haemophilia is an inherited bleeding disorder characterised by [CONTACT_535209], 
typi[INVESTIGATOR_535031]. Haemophilia A is  caused by a partial or complete deficiency of 
blood coagulation factor VIII (FVIII). In haemophilia B, it is factor IX (FIX) that is deficient. 
Inheritance is chromosome X-linked; therefore the disease mainly affects males. The incidence of haemophilia A and B on average is estimated to be about 1 in 5000 live male births 
4. According to 
the World Federation of H aemophilia global survey of [ZIP_CODE], about 178,500 persons are diagnosed 
with haemophilia worldwide. Of th ese, about 80% have haemophilia A.
Haemophilia is classified as “severe”, “moderate” or “mild” according to the plasma activity of the 
affected coagulation factor6. With a deficiency of FVIII or FIX, the degree of activation of 
coagulation FX becomes insufficient. Consequently, the thrombin burst is delayed and insufficient 
for normal haemostasis7. The haemos tatic plug, if formed, in these patients is fragile and easily 
dissolved by [CONTACT_56264]. This leads to impaired haemostasis and spontaneous prolonge d bleeding epi[INVESTIGATOR_1841]. In severe haemophilia, bleeding in joints occurs spontaneously and is
the most frequent symptoms of the disease. Recurrent bleeding epi[INVESTIGATOR_56175] - most 
commonly a weight bearing joint - lead to chronic arthropathy, muscular atrophy and deformities. 
Treatment of bleeding epi[INVESTIGATOR_535032] (on -demand treatment) may delay arthropathy, but 
does not prevent it. The majority of children with severe haemophilia experience their first bleedingepi[INVESTIGATOR_687513] a joint prior to age [ADDRESS_932009] developed inhibitors towards FVIII or FIX, replacement therapy is rendered 
ineffective. Though prevalence studies and registry data indicate that the prevalence of inhibitors in 
the haemophiliac population overall has been reported to be between 5% and 7%9, the prevalence 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932010] p atients with se vere haemophilia (FVIII:C < 1%) is higher and has been reported to be up 
to 30%9, 10. These patients may be treated with by[CONTACT_71363], activated FVII (NovoSeven®) and 
activated prothrombin complex concentrate (FEIBA®) given as i.v. injections.
Current treatment options in haemophilia, replacement therapy or by[CONTACT_687620], are hampered 
by [CONTACT_535211] i.v. injections. Furthermore, by[CONTACT_687621]-lives, the refore prophylactic treatment is burdensome. It is 
also generally acknowledged that the efficacy profile of by[CONTACT_687645]. Consequently, delayed or sub-optimal treatme nt occurs in a significant number of patients
with inhibitors. A new therapeutic agent that can be administered subcutaneously will represent a 
major improvement in the treatment of these patients in a prophylaxis setting.
3.1.[ADDRESS_932011], concizumab, is a humanised recombinant monoclonal antibody (mAb) of the 
immunoglobulin G4 (IgG4) isotype with a molecu lar weight of 149 kilo Dalton’s.  Like other 
antibodies, concizumab is composed of two light chains and two heavy chains linked together by [CONTACT_95999]. To prevent formation of half-antibodies, the serine at position 241 in the heavy chain has been replaced with a proline (S241P (Kabat annotation))
10. The mechanism of action of 
concizumab is based on the concept of inhibiting the activity of a natural coagulation inhibitor, 
tissue factor pathway inhibitor (TFPI). TFPI [CONTACT_832] a potent inhibitor of the initiation phase of the coagulation process, i.e. the activation of (FX) to FXa by [CONTACT_535213] (TF)/factor VIIa (FVIIa) 
complex. TFPI [INVESTIGATOR_687580]/FVIIa complex, forming a TF/FVIIa/FXa/TFPI [INVESTIGATOR_535034]. Thus, concizumab prevents both 
inhibition of FXa and inhibition of FVIIa/TF by  [CONTACT_535214]. In this manner, sufficient amounts of FXa to 
ensure effective haemostasis in the absence of a functional activated factor IX/activated factor VIII (FIXa/ FVIIIa) complex may be generated. This is a new concept that remains to be documented safe and efficacious in patients with haemophilia. More information about the physiological role of TFPI [INVESTIGATOR_535035]’s Brochure.
Key differentiators of this new mode of action (MoA) and the key benefit of concizumab in patients 
with severe haemophilia A and B with inhibitors is reduced treatment burden due to subcutaneous administration potentially leading to better adherence, more patients on prophylactic treatment and 
ultimately better outcome. 
Four clinical trials with concizumab have been co mpleted thus far: the first human-dose trial 
(NN7415-3813, explorer
TM1)11, a single dose trial in Japanese healthy subjects (NN7415-3981), 
two multiple dose trials (NN7415-3986, explorerTM2) and (NN7415-4159, explorer™3). When the 
first cohort with  4 (four) healthy sub jects in explorer™2 was completed, pri or to the initiation of the 
2ndcohort, the trial was halted, due to findings re lated to thrombosis in an ongoing 26-week toxicity 
study in primates. In this trial animal had concizumab plasma concentrations several hundred fold 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 25 of 136
above clinically relevant concentrations. Follow up investigations confirmed that the animal’s 
condition was related to thrombosis in the lungs caused by [CONTACT_535268]. Before the initiation of the fourth phase 1 trial (NN7415-4159), explorer™3,a new 52 week non-clinical toxicology study was conducted in primates to investigate the findings 
in the previous study. The conclusion from this new non-clinical study was that the results from 
non-clinical studies support further clinical development of concizumab. Explorer™3 was a multiple dose clinical trial which aimed to inve stigate the safety, pharmacokinetics and 
pharmacodynamics of concizumab at five different dose levels in adult severe haemophilia A 
patients without inhibitors. In this trial multiple doses of concizumab were administered s.c. over a 
period of six weeks.
The explorer™3 trial was finalised following th e completion of cohort 3 (0.8 mg/kg s.c. every 4 
days for 6 weeks). Blinded preliminary safety and PK/PD data from the cohort was reviewed by [CONTACT_535216]. Marked changes in coagulation parameters were observed including 
a decrease from baseline in fibrinogen and a pronounced increase in D-dimer and F1+[ADDRESS_932012] variation in pro-coagulant response to the drug 
was observed. Based on this, the Novo Nordisk safety committee (see Section 12.8.1 ) decided not 
to proceed to cohort 4 (1.1 mg/kg s.c. every 4 days for 6 weeks). No clinical consequences or 
serious adverse events were seen in the completed cohorts in explorer™3.
The PK results from explorer™3 showed exposure-response in terms of fewer bleeding epi[INVESTIGATOR_535036] 100 ng/mL. Individual predicted PK profiles merged with recorded spontaneous and traumatic bleeding 
epi[INVESTIGATOR_535037] 3–1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 26 of 136
Figure 3–1 Individual predicted PK profiles based on data merged with recorded spontaneous 
(circles) and traumatic (triangles) bleeding epi[INVESTIGATOR_535020]-up period. All data originates from explorer™3 (N=24 patients). PK of 
concizumab is subdivided into three exposure levels of !!20 ng/mL, 20-100 ng/mL, 
and > 100 ng/mL together with the number of contributing patients. LLOQ: lower 
limit of quantification.
a‘Time in trial’ refers to the time that the patients spent on each concizumab exposure level, and the !20 ng/mL level 
therefore also includes the screening period (not shown on this figure).
A large difference between the peak and trough plasma concentrations of concizumab were 
observed as well, especially in the highest dose group (0.80 mg/kg) of explorer™3. In patients who 
received 0.25, 0.5 and 0.8 mg/kg doses a significant overlap in plasma concentrations of
concizumab was seen due to high betw een-patient variability in concizumab.
Single doses of concizumab up to 9 mg/kg have been administered to haemophilia patients in the 
first human dose trial with concizumab, explorer™1. These doses resulted in plasma concentrations 
of concizumab that were significantly higher than the ones that are modelled to be reached in the 
highest escalated daily dose (0.25 mg/kg) of explorer™4.
In a drug–drug interaction study in monkeys  (NN215431), three doses of up to 1 mg/kg of 
NovoSeven®were administered at 2h intervals, alone or in the presence of a steady state 
concentration of concizumab. No notable clinical obse rvations were made, no treatment-related 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 27 of 136
adverse findings were seen, i.e. no thrombi or other signs of excessive coagulation. Increased 
concentrations of thrombin–anti-thrombin (TAT) and D-dimer were seen, which tended to be additive when both concizumab and eptacog alfa (rFVIIa) were present in circulation.
For an assessment of benefits and risks of the trial, see Section 18.1.
For further information, please refer to the Investigator’s Brochure.
3.[ADDRESS_932013] been finalised. Key safety and preliminary 
efficacy results from these phase 1 studies support further development of concizumab in 
haemophilia patients. Therefore, the main objective in the phase 2 of concizumab development is to 
assess efficacy and safety and provide data that will guide for the confirmatory phase 3 concizumab trials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 28 of 136
4 Objective(s) and endpoint(s)
4.1 Objective(s)
4.1.1 Primary objective
To assess the efficacy of concizumab administered s.c. once daily in preventing bleeding epi[INVESTIGATOR_687514] A and B patients with inhibitors
4.1.2 Secondary objectives
∀To assess the longer-term efficacy of concizum ab in haemophilia patients with inhibitors
∀To assess the safety of concizumab in haemophilia patients with inhibitors
∀To assess the safety of administering recombinant factor VIIa (rFVIIa) to haemophilia 
patients with inhibitors that are exposed to concizumab
∀To assess the immunogenicity of concizumab in haemophilia patients with inhibitors
4.2 Endpoint(s)
4.2.1 Primary endpoint
∀The number of bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
4.2.2 Secondary endpoints
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
∀The number of bleeding epi[INVESTIGATOR_51953] 76 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from tr eatment onset
∀The number of spontaneous bleeding ep isodes during 76 weeks from treatment onset
Supportive secondary safety endpoints
∀Number of treatment-emergent adverse events (TEAEs) during at least 24 weeks from
treatment onset
∀Number of TEAEs during 76 weeks from tr eatment onset
∀Number of TEAEs within 24 hours of rFVIIa administration
∀Occurrence of anti-concizumab antibodies during at least 24 weeks from tr eatment onset
∀Occurrence of anti-concizumab antibod ies during 76 weeks from treatment onset
∀Change from baseline of fibrinogen during 24 weeks from treatment onset
∀Change from baseline of fibrinogen during 76 weeks from treatment onset
∀Change from baseline of D-dimer during 24 weeks from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 29 of 136
∀Change from baseline of D-dimer during 76 weeks from treatment onset
∀Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
∀Change from baseline of F1 + 2 during 76 weeks from treatment onset
∀Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
∀Change from baseline of PT during 76 weeks from treatment onset
∀Change from baseline of activated partial thromboplastin time (APTT) during 24 weeks 
from treatment onset
∀Change from baseline of APTT during 76 weeks from treatment onset
∀Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
∀Change from baseline of AT 76 weeks from treatment onset
Supportive secondary pharmacokinetic endpoints
∀Concentration of concizumab prior to the last dose administration at 24 weeks
∀Concentration of concizumab prior to the last dose administration at 76 weeks
Supportive secondary pharmacodynamic endpoints
∀Free TFPI [INVESTIGATOR_687515] [ADDRESS_932014] dose administration at 76 weeks
∀Thrombin generation
oPeak thrombin generation (nM) prior to the last dose administration at 24 weeks 
oPeak thrombin generation (nM) prior to the last dose administration at 76 weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 24 
weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 76 
weeks
oVelocity index (nM/min) prior to the last dose administration at 24 weeks
oVelocity index (nM/min) prior to the last dose administration at 76 weeks
4.2.3 Exploratory endpoints
[IP_ADDRESS] Exploratory safety endpoints
∀Number of adverse events related to technical complaints during at least 24 weeks from 
treatment onset 
∀Number of adverse events related to technical complaints during at least 76 weeks from 
treatment onset 
[IP_ADDRESS] Exploratory patient reported outcome endpoints
∀Change in Hemo-TEM after 24 weeks from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 30 of 136
∀Change in Hemo-TEM after 76 weeks from treatment onset
∀Change in VERITAS-PRN®after 24 weeks from treatment onset
∀Change in VERITAS-PRN®after 76 weeks from treatment onset
∀Change in SF-36v2 after 24 weeks from treatment onset
∀Change in SF-36v2 after 76 weeks from treatment onset
∀Change in SDS after 24 weeks from treatment onset
∀Change in SDS after 76 weeks from treatment onset
∀Change in TSQM after 24 weeks from treatment onset
∀Change in TSQM after 76 weeks from treatment onset
∀Change in SIAQ-ISRQ after 24 weeks from treatment onset
∀Change in SIAQ-ISRQ after 76 weeks from treatment onset
∀Change in PGI-C after 24 weeks from treatment onset
∀Change in PGI-C after [ADDRESS_932015] w ill be evalu ated in the main 
part of the trial. All endpoints referring to a time frame of 76 weeks will be evaluated in the 
extension part of the trial.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 31 of 136
5 Trial design
5.1 Type of trial
The trial is a multi-centre, randomised (2:1),  open-label, controlled trial, aiming to evaluate the 
efficacy and safety of concizumab 0.15 mg/kg (with potential dose escalation) administered daily 
s.c. in haemophilia patients with inhibitors. The selected dose regimen is based on relevant PK and 
TFPI [INVESTIGATOR_535039]/PD modelling of the results from the preceding explorer™ trials. Only   
on-demand patients will be eligible for the trial.
Figure 5–1 Schematic diagram of the trial design
The total trial duration for the individual patient will be approximately 86-88 weeks, including a 2-4 
week screening period, a 76 week treatment period, and a follow-up period of 8 weeks, see Figure 
5–[ADDRESS_932016] completed a minimum of 24 weeks of eptacog alfa (rFVIIa) on-demand or have 
withdrawn.
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 32 of 136
In the concizumab arm bleeding epi[INVESTIGATOR_687516] 
(rFVIIa). In all patients treated with concizumab a single 90 μg/kg dose of eptacog alfa (rFVIIa)
will be administered in a non-bleeding state one week after dosing with concizumab has been initiated. The investigator will evaluate if there are any safety concerns [ADDRESS_932017] eptacog alfa 
(rFVIIa) administration. Furthermore, the scheduled administration of eptacog alfa (rFVIIa) for the 
first 4 patients entering the trial with concizumab will be staggered.
In the comparator arm, in the main part, patie nts will receive eptacog alfa (rFVIIa) on-demand 
treatment. After completion of the main part, the patien ts will continue the trial in the extension part 
being treated with prophylactic concizumab 0.15 mg/kg (with potential dose escalation) s.c. d aily 
administration.
Human biosamples (plasma, serum, and/or DNA for genot ypi[INVESTIGATOR_007]) will be collected in this trial for 
future exploratory analysis to pursue a deeper insight into the biology of TFPI, coagulation, and effect of concizumab on joint health.  That may include coagulation parameters and markers of joint status and damage. Acceptance of storage of human biosamples is voluntary and will not affect the 
patients’ participation in the trial. Therefore, p atients will have the possibility to sign the informed 
consent for the trial and participate, while refusing permission for human biosamples to be stored for future exploratory analysis, see Section 8.1.1 .
An independent data monitoring committee (DMC) w ill be established for this trial. The DMC will 
review all safety data from the ongoing tria l with concizumab exposure, see Section 12.8.2 .
5.1.1 Surgery
Minor surgery is allowed in this trial. Major surgery conducted earlier than one month (30 days) 
prior to trial start is allowed, see exclusion criteria no 6.
Minor surgery is defined as an invasive oper ative procedure where only the skin, the mucous 
membranes or superficial connective tissue is manipulated. Examples of minor surgery include 
implanting of central venous access devices (ports, CVC, pumps and other CVADs) in subcutaneous tissue, skin biopsies or simple dental procedures.
5.2 Rationale for trial design
Explorer™4 is a phase 2, clinical proof of concept (CPoC), and safety trial. The trial aims to 
substantiate CPoC that concizumab has the potential to prevent bleeding epi[INVESTIGATOR_687581]. A dose escalation design will allow cautious dose escalation in order to identify an efficacious and safe concizumab dose for the individual patient. A comparator arm is 
included to assess if concizumab is superior to on -demand treatment. Furthermore, the trial will 
give a possibility to assess safety of co-a dministration of eptacog alfa (rFVIIa) to the patients 
exposed to the concizumab treatment.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 33 of 136
The duration of 24 weeks for the main part of th e trial is deemed necessary in order to obtain 
information on the annualised bleeding rate on concizumab prophylaxis. The duration of the extension part of the trial will be 52 weeks and provide further information on efficacy, i.e.annualised bleeding rate, and also provide additional safety data upon 76 weeks treatment with 
concizumab.
A total of 26 patients previously on-demand (OD)  treatment will be randomised into one of the two 
arms, with 16 patients in the concizumab arm and 8 patients in the comparator arm see Figure 5–1 . 
Concizumab will be administered s.c. d aily for p atients randomised to the concizumab arm in the 
main and the extension part of the trial. For patien ts in the comparator arm in the extension part
treatment will be changed from on-demand with rFVIIa to prophylaxis with concizumab.
The concizumab dose regimens will be starting wi th 0.15 mg/kg with the possibility to escalate to
0.20 mg/kg and 0.25 mg/kg based on bleeding frequency, see Section 5.3.3 .
Daily dosing with concizu mab 0.15 mg/kg aims to ensure steady-state levels of concizumab plasma 
concentrations above 100 ng/mL for the majority of the patients starting on this dose. The PK results from explorer™3 showed exposure response in terms of fewer bleeding epi[INVESTIGATOR_535165] 100 ng/mL, see Figure 3–[ADDRESS_932018] the opportunity to be dose escalated to the dose of 0.2 mg/kg. A further dose escalation to 0.25 mg/kg per day is permitted, again based on the bleeding rate, see Section 5.3.3 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 34 of 136
Figure 5–2 Individual predicted concizumab concentration profiles for all concizumab-treated 
patients in explorer™2 (n=4 patients) and explorer™3 (n=18 patients). The 
horizontal lines indicate 100 ng/mL, and the shaded areas represent the full range (min-max) of the individual predicted profiles.
1
Due to the high between patient variability in concizumab concentration observed in explorer™3, a 
significant overlap in plasma concentrations of concizumab in patients who received 0.25, 0.5 and 
0.8 mg/kg doses was seen, see Figure 5–[ADDRESS_932019] mean plasma concentrations of concizumab, and thus different efficacy at each 
                                               
1Plasma concentrations in the same range as those in explorer™3 are expected to be reached in this trial with daily dose adminis tration. The starting 
dose for all patients will be 0.15 mg/kg daily. The plasma steady-state exposure for a typi[INVESTIGATOR_687518] a typi[INVESTIGATOR_535044] 0.8 mg/kg Q4D (cohort 3 of explorer3) in terms of both Cmax and AUC 0-24h. For 0.20 mg/kg dail y and 0.25 
mg/kg, the plasma steady-state exposure levels for a typi[INVESTIGATOR_687519] 40% and 70% respectively, comp ared to the typi[INVESTIGATOR_687520] 3rd cohort of explorer™3 (AUC and Cmax). The maximum predicted plasma exposure levels (Cmax and AUC 0-24 h) for the 
0.15 mg/kg daily dose level is predicted to be more than 8 fold lower than for 0.80 mg/kg Q4D. For 0.20 mg/kg daily both Cmax an d AUC 0-24h are 
predicted to be more than 3 times lower than for 0.80 mg/kg Q4D. For 0.25 mg/kg daily, the maximum Cmax and AUC 0-24h are predic ted to be 
35% lower than for 0.80 mg/kg Q4D .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932020], the titration trial design allows patients to start on a low dose, which is expected to ensure prophylaxis but not marked changes in coagulation parameters, for the majority of patients. Escalation to the next dose level will only occur in the case of lack of 
efficacy ( ≥ 3 spontaneous bleeding epi[INVESTIGATOR_535047] 12 weeks). In addition, the PK of 
concizumab is heavily influenced by [CONTACT_535297], which means that small 
differences in concizumab dose ultimately leads to large differences in plasma concentrations. Therefore, daily dosing is proposed for the phase 2 trial, explorer™4. Daily dosing will allow for 
the increase in trough levels and thus better efficacy may be expected with a lower dose.
A loading dose of 0.5 mg/kg concizumab will be given as the first dose, followed by [CONTACT_687617] 0.15 mg/kg in order to ensure steady-state lev els at the time of eptacog alfa 
(rFVIIa) administration. eptacog alfa (rFVIIa) will be administered one week after initiation of 
dosing with concizumab in a non-bleeding state to assess safety of tr eatment with eptacog alfa 
(rFVIIa) in patients exposed to concizumab treatment.
Embryonic exposure in pregnant female partners of men treated with concizumab is highly unlikely 
and there is no need for protocol requirements for use of contraception in phase 2 and 3 trials.
5.3 Treatment of patients
The following products will be administered in the trial.
Table 5–[ADDRESS_932021] of products provided by [CONTACT_687624] B a100 mg/mL solution for s.c. 
injection in a 3 mL cartridge
bSubcutaneous administration usingNovoPen
®4For prophylactic 
treatment in 76 weeks (for concizumab arm in 
the main part and 
extension part).
For prophylactic 
treatment in 52 weeks (for comparator arm in 
the extension part).
eptacog alfa (rFVIIa)a, c5 mg/vial Powder for solution 
for i.v. injectionIntravenous 
administrationFor treatment of 
breakthrough bleeding 
epi[INVESTIGATOR_687582] (screening, main, extension and follow up part). 
c
Administration of 
doses higher than histidine solvent (5 mL) Prefilled syringes for 
solution for i.v. 
injection 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 36 of 136
90μg/kg to patients 
exposed to concizumab is not allowed.
For on-demand 
treatment at the discretion of the 
investigator in 24 
weeks for comparator arm in the main part. 
In the concizumab arm 
and comparator arm after switching to 
concizumab in the 
extension part of the 
study a single 90 μg/kg 
dose for initial safety 
assessments in a non-
bleeding state.
a
Will be provided for as long as patients participate in the trial (screening, main, 
extension and follow 
up part)
aInvestigational medicinal product (IMP)
b Not to be confused with the daily injected volume (~150 μL, depending on dose strength and body weight)
cNon-investigational medicinal product (NIMP)
The NovoPen®4 injector will be supplied by [CONTACT_535242] s.c. administration of 
concizumab. It will be labelled in accordance with national legislation and a copy of the label can be found in the Trial Materials Manual, see Section 9.
5.3.1 Concizumab arm
[IP_ADDRESS] Concizumab prophylactic treatment (main and extension part)
Concizumab will be given s.c. once daily 0.15 mg/kg (with poten tial dose escalation to 0.20 and 
0.25 mg/kg). The dose escalation criteria are described, see Section 5.3.[ADDRESS_932022] dose of 
concizumab will be given at the trial site under medical supervision.
A loading dose of 0.5 mg/kg will be given as the first concizumab dose at visit 2 in order to ensure 
steady state levels at the time of the administrati on of eptacog alfa (rFVIIa) in a non-bleeding state 
at visit 3, see Section 5.3.4 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 37 of 136
The patients will be trained in s.c. administration of concizumab with NovoPen®[ADDRESS_932023] scheduled treatment visit. 
5.3.2 Comparator arm (eptacog alfa (rFVIIa))
[IP_ADDRESS] On-demand treatment (main part)
During the main part of the trial, patients will receive eptacog alfa (rFVIIa) for treatment of 
bleeding epi[INVESTIGATOR_1841], with a dose regimen at the discretion of the investigator.
[IP_ADDRESS] Concizumab prophylactic treatment (extension part)
After completion of the main part, the patients w ill continue the trial in the extension  part and will 
switch to prophylactic treatment with s.c. daily administration of concizumab 0.15 mg/kg (with potential dose escalation to 0.20 and 0.25 mg/kg) s.c. daily administration.
The same dose escalation criteria as described b elow (for the initial concizumab arm) will apply.
A loading dose of 0.5 mg/kg will be given as the first concizumab dose at visit [ADDRESS_932024] 2 weeks of the treatment with concizumab 0.15 mg/kg is considered as a run-in period. Hence, bleeding epi[INVESTIGATOR_687522] 2 weeks should not influence a dose escalation 
decision.
All spontaneous bleeding epi[INVESTIGATOR_1841] (sBEs) are co unted from 2 weeks after visit 2 (or visit 9 when
switching from eptacog alfa (rFVIIa) to concizumab) (first treatment visit) until visit 16 (end of
treatment visit), i.e. a total of [ADDRESS_932025] take into account the 
full clinical pi[INVESTIGATOR_535049], including coagulation parameters.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 38 of 136
Dose 0.15 mg/kg: 
When sBE occurs, the investigator will determine if ≥[ADDRESS_932026] occurred within the preceding 12
weeks (including the current sBE). If yes, and if investigator deems it safe, the patient will be dose escalated from 0.15 to 0.20 mg/kg at the next scheduled  visit. If the investigator judges that this 
visit is scheduled too late, he/she should contact [CONTACT_687625].
Dose 0.20 mg/kg: 
When sBE occurs, the investigator will determine if ≥[ADDRESS_932027] occurred within the preceding 12
weeks (including the current sBE), counting only new sBEs from the beginning of the 0.20 mg/kg 
treatment period. If yes, and if investigator deems it safe, the patient w ill be dose escalated from 
0.20 to 0.25 mg/kg at the next scheduled visit. If the investigator judges that this visit is scheduled too late, he/she should contact [CONTACT_941] p atient for an unscheduled visit sooner.
Dose 0.25 mg/kg: 
Patients are not dose escalated further regardless of the number of sBEs. When an sBE occurs, the 
investigator will determine if ≥ [ADDRESS_932028] occurred within the preceding 12 weeks (including the 
current sBE), counting only new sBEs from the beginning of the 0.25 mg/kg treatment period. If yes, then the patient must be discontinued due to lack of efficacy, see Section 6.4.
The possibility of dose escalation at unscheduled vi sits is necessary in order to avoid  bleeding
epi[INVESTIGATOR_687523]: e.g. if the dose escalation eliciti ng bleeding epi[INVESTIGATOR_687524] a scheduled visit, the patient will avoid to wait8 weeks for the next scheduled visit (in the extension part).
Figure 5–3 Dose escalation for one individual patient in the concizumab arm
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 39 of 136
Figure 5–4 Dose escalation for one individual patient in the comparator arm
5.3.4 Co-administr ation of eptacog alfa (rFVIIa)
eptacog alfa (rFVIIa) will be used for tr eating breakthrough bleeding epi[INVESTIGATOR_687525]; one 
week after initiation of dosing with concizumab, a single 90 μg/kg dose of eptacog alfa (rFVIIa)
will be administered in a non-bleeding state at th e trial site under medical supervision to assess 
safety of treatment with eptacog alfa (rFVIIa) in patients exposed to concizumab treatment. 
Hereafter, patients will be closely clinically obs erved at the site for potential safety issues for at 
least 12h and evaluated again at site after 24h. Between 12h and 24h, the patient must either stay at the site or at a hotel or at home if he lives nearby [CONTACT_687626] 3 or 9.1 the day after.
Dosing of eptacog alfa (rFVIIa) in the first 4 patients randomised to concizumab arm will be 
staggered so that the period between eptacog alfa (rFVIIa) administrations from one patient to 
another is at least 48 hours. If no safety concerns are observed (for example signs and symptoms of thromboembolism, such as swelling, pain and redness of the leg, shortness of breath, and chest pain) by [CONTACT_687627] (rFVIIa) and when 
the next daily concizumab dose is to be given, the investigator allows the individual patient to 
administer concizumab prophylactically at home and if needed, treat breakthrough bleeding epi[INVESTIGATOR_687526] (rFVIIa). The patients will receive prophylactic doses of concizumab 0.15 mg/kg daily throughout the main pa rt (24 weeks) and the extension part (52 
weeks), unless dose escalation criteria are fulfilled, see Section 5.3.3 .
In case safety concerns are raised by [CONTACT_687628] (rFVIIa) administration and 
these concerns meet the described criteria for putting enrolment of additional patients on hold, dosing in the individual patients will be halted and further recruitment in the trial will be halted, see 
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 40 of 136
Section 12.7. In case safety concerns that do not meet the criteria for putting enrolment of additional 
patients on hold are observed by [CONTACT_093], dosing in that individual patient will be halted 
until further evaluation. In such cases, all available data will be assessed by [CONTACT_1578] (DMC), see Section 12.8.2 .
5.3.5 Treatment of b leeding epi[INVESTIGATOR_687527] 1 and visit 2 can be treated with any by[CONTACT_71360] 
(e.g., eptacog alfa (rFVIIa), FEIBA®) up to a period of 24 hours (for eptacog alfa (rFVIIa)) or 48 
hours (for FEIBA®) prior to first concizumab administration at visit 2. N ovo Nordisk  will provide 
eptacog alfa (rFVIIa) throughout the trial. The patient can treat himself and then he must call the 
site. The bleeding epi[INVESTIGATOR_687528].
Breakthrough bleeding epi[INVESTIGATOR_687529] 2-[ADDRESS_932029] be treated with eptacog alf a (rFVIIa). Upon breakthrough bleeding epi[INVESTIGATOR_687530]. The investigator should instruct the patient about 
whether he should go to the site to  receive treatment or if he can administer a single dose of eptacog 
alfa (rFVIIa) which is not higher than 90 μg/kg without delay to treat the breakthrough bleeding
epi[INVESTIGATOR_1865]. If the patient is instructed to administer the eptacog alfa (rFVIIa) dose at home, following 
the administration, the patient should immediately go to the site for furthe r clinical evaluation. The 
bleeding epi[INVESTIGATOR_687531] (eDiary).
Breakthrough bleeding epi[INVESTIGATOR_687529] [ADDRESS_932030] be treated 
with eptacog alfa (rFVIIa). The patient can treat himself without delay but must inform the site that a bleeding epi[INVESTIGATOR_71274]. Doses of eptacog alfa (rFVIIa) those are lower than 90 μg/kg may 
be used to treat breakthrough bleeding epi[INVESTIGATOR_687532]. Administration 
of doses higher than 90 μg/kg to patients exposed to concizumab is not allowed. If a single dose of 
eptacog alfa (rFVIIa) is not sufficient to stop a bleeding epi[INVESTIGATOR_1865], the patient should inform the site and in agreement with the investigator may administer a second dose of eptacog alfa (rFVIIa) not 
higher than 90 μg/kg 2-3h after the first dose has been administered. The same procedure should be 
repeated in case the second dose of eptacog alfa (rFVIIa) is not sufficient to stop the bleeding epi[INVESTIGATOR_1865]. If more than three 90 μg/kg doses of eptacog alfa (rFVIIa) are needed to stop a bleeding 
epi[INVESTIGATOR_1865], the patient should go to the site without delay. The definition and diagnostic criteria of 
DIC, acute myocardial infraction, stroke, deep vein thrombosis, pulmonary embolism and 
peripheral artery occlusion is provided in section 12.1.[ADDRESS_932031] be recorded in 
the eDiary.
Breakthrough bleeding epi[INVESTIGATOR_687529] 16 and visit 17 (follow-up part) may be treated with 
eptacog alfa (rFVIIa) or other products at the discretion of the investigator. The patient can treat 
himself with eptacog alfa (rFVIIa) at home with out delay. Only eptacog alfa (rFVIIa) will be 
provided by [CONTACT_3454]. The bleeding epi[INVESTIGATOR_535167].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 41 of 136
See Table 5–1 and Table 8–3 .
5.3.6 Prohibited medication 
∀Treatment with anti-fibrinolytics (e.g. tranexamic acid, aminocaproic acid)
∀Heparin, except for sealing of central venous access ports according to local practice
∀Vitamin-K antagonists
∀Direct oral anticoagulants (DOACs)
∀Home treatment (between visit 2 and visit 16) with activated prothrombin complex 
concentrates (FEIBA®)
5.[ADDRESS_932032]
When discontinuing trial products (visit 16 or earlier), the patient should be switched to a suitable 
marketed product at the discretion of the inves tigator. Only eptacog alfa (rFVIIa) will be provided 
by [CONTACT_3454]. The patient will not be provided with concizumab or eptacog alfa (rFVIIa) after end of trial (EOT) (visit 17) by [CONTACT_3454].
5.[ADDRESS_932033] 24 weeks (the main pa rt of the trial) is considered necessary for 
providing r obust data that allow demonstration of clinical proof of concept and to support decision 
making regarding a phase 3 confirmatory trial. Dosing for additional 52 weeks will provide valuable long term efficacy and safety data.
Breakthrough bleeding epi[INVESTIGATOR_687533]. Therefore, it is expected that breakthrough bleeding epi[INVESTIGATOR_687583]. Consequently, eptacog alfa (rFVIIa) w ill be provided by [CONTACT_687629][INVESTIGATOR_1841]. In order to minimize the likelihood of any unforeseen adverse 
events associated with administration of eptacog alfa (rFVIIa) in these circumstances,administration of eptacog alfa (rFVIIa) in a controlled setting will be performed at visit 3 or 9.1.
Please refer to the Investigator’s Brochure for further information.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 42 of 136
6 Trial population
6.1 Number of patients
Number of patients planned to be screened: [ADDRESS_932034]: 26
Number of patients expected to complete the trial: 24
∀Preferably 21 haemophilia A patients
∀Preferably [ADDRESS_932035] be answered “yes”.
1. Informed consent obtained before any trial-r elated activities. Trial-related activities are any 
procedures that are carried out as part of the tr ial, including activities to determine the suitability 
for the trial
2. Male haemophilia A or B patients with inhibitors aged ≥ 18 years at the time of signing 
informed consent
3. Patients currently treated on-demand with a minimum of six bleeding epi[INVESTIGATOR_8728] 24 
weeks (or twelve bleeds during 52 weeks) prior to screening
4. Documented history of high-titer inhi bitors towards FVIII or FIX, defined as ≥[ADDRESS_932036] be answered “no”.
1. Known or suspected hypersensitivity  to trial product(s) or related products
2. Previous participation in this trial. Participation is defined as signed informed consent3. Participation in any clinical trial of an approved or non-approved investigational medicinal 
product within the last 30 days or 5 half-lives (whichever is longer) from the last drug 
administration before screening
4. Any disorder which in the investigator’s opi[INVESTIGATOR_1649], might jeopardise patient’s safety or
compliance with the protocol
5. Known inherited or acquired bleeding disorder other than haemophilia
6. Major surgery conducted within one month pri or to the initiation of trial activities or major 
surgery planned to occur during the trial3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932037] a significant infection or known systemic inflammatory 
condition which requires systemic treatment acc ording to the investigator’s judgement
10. Hepatic dysfunction defined as elevated liver transaminases (ALT) >3 times the upper limit of 
normal laboratory reference ranges at screening
11. Renal impairment measured as  estimated Glomerular Filtration Rate (eGFR) ≤ 60 ml/min/1.73 
m2for serum creatinine measured at screening for patients without evidence of renal damage
12. Platelet count ≤ 100x109/L at screening
13. Fibrinogen level < the lower limit of normal
14. Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX15. Antithrombin levels below the normal reference range at screening
6.[ADDRESS_932038] if the following applies:1. Included in the trial in violation of the inclus ion and/or exclusion criteria and/or randomised in 
violation of the randomisation criteria
2. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
3. Incapacity or unwillingness to follow the trial procedures4. Anaphylactic reaction
5. Thromboembolic event
6. Event of Disseminated Intravascular Coagulation7. Lack of efficacy due to neutralizing antibodies8. Lack of efficacy defined as ≥ [ADDRESS_932039] dose level (0.25 mg/kg) of concizumab.
See Section 8.1.[ADDRESS_932040] 
prematurely.
6.5 Withdrawal from trial
The patient may withdraw consent at will at any time.
See section 8.1.5 for procedures to be performed for patients withdrawing consent.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932041] been treated and therefore familiar 
with eptacog alfa (rFVIIa) on-demand treatment, this trial population is  considered the most suitable 
for assessing the safety of administering eptacog alfa (rFVIIa) to patients in whom plasma TFPI [INVESTIGATOR_687535]. Finally, the trial population reflects the patient population that will be selected in a potential subsequent phase 3 trial in which the efficacy and safety of concizumab are to be 
confirmed.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 45 of 136
7 Milestones
Planned duration of recruitment period (FPFV-LPFV): 28 weeks
Planned FPFV: 16-Aug-2017
Planned FPFT: 30-Aug-2017
Planned LPFV: 28-Feb-2018
Planned LPLV: 23-Oct-2019
The total duration of concizumab treatment in this trial is 76 weeks for an individual patient
randomised to concizumab prophylaxis treatment at visit 2.
The total duration of concizumab treatment in the trial is 52 weeks for an individual patient 
randomised to eptacog alfa (rFVIIa) on-demand treatment at visit 2.
EOT is defined as last patient last visit (LPLV).
Recruitment
The screening and randomisation rate will be followed closely via the interactive web response 
system (IWRS) in order to estimate when to stop screening. All investigators will be notified immediately when the recruitment period ends, after which no further patients may be screened and 
the IWRS will be closed for further screening. All patients screened during the recruitment period 
and found eligible for randomisation can be randomis ed in a 2:1 allocation to either the concizumab 
or the comparator arm within the timelines specified in the flow chart (see Section 2).
Trial registration:
Information of the trial will be disclo sed at clinicaltrials.gov, novonordisk-t rials.com and 
clinicaltrials.jp. According to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure,
how-we-disclose-trial-information, it will also be disclosed according to other applicable requirements such as those of the International Committee of Medical Journal Editors (ICMJE),
[ADDRESS_932042] (FDAAA),13European Commission 
Requirements,[ADDRESS_932043] at these web sites, Novo Nordisk may disclose the investigator’s contact [CONTACT_687646] e patient. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.
Primary Completion Date (PCD) is the last assessment of the primary endpoint, and is for this 
protocol LPFT (visit 2) + [ADDRESS_932044] completed visit 9. The PCD determines the deadline for results disclosure at ClinicalTrials.gov according to FDAAA.
133URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 46 of 136
8 Methods and assessments
Assessments to be performed at the scheduled and at the unscheduled visits in the trial are described 
in this section, Figure 8–1 , Figure 8–2 and in Section 2.
Figure 8–1 Visit schedule – concizumab arm.
Figure 8–2 Visit schedule – eptacog alfa (rFVIIa) arm later switching to concizumab.
8.[ADDRESS_932045] of the fo llowing scheduled parts and visits depending upon
which arm the patient is randomised to:
Screening Part:
∀Visit 1 (screening visit)
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 47 of 136
Main Part:
∀Visit 2 (Randomisation and 1sttreatment visit with concizumab at site for patients 
randomised to the concizumab-arm)
∀Home treatment with concizumab daily
∀Visit 3 (treatment and PK-visit with concizu mab and eptacog alfa (rFVIIa) at site only for 
patients randomised to the concizumab-arm  - phone visit for patients randomised to the 
eptacog alfa (rFVIIa) on-demand arm)
∀Visit 4 (Assessment visit, patients treat themselves at home)
∀Visit 5 (Assessment visit, patients treat themselves at home)
∀Visit 6 (Assessment visit, patien ts treat themselves at home)
∀Visit 7 (Assessment visit, patients treat themselves at home)
∀Visit 8 (Assessment visit, patients treat themselves at home)
∀Visit 9 (Assessment visit, after the visit patients treat themselves at home – 1sttreatment 
visit with concizumab at site for patients randomised to the eptacog alfa (rFVIIa) arm)
Extension Part:
∀Visit 9.1 (treatment and PK-visit with concizumab and eptacog alfa (rFVIIa) at site ONLY
for patients randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 9.2 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 10 (Assessment visit, patients treat themselves at home)
∀Visit 10.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 11 (Assessment visit, patients treat themselves at home)
∀Visit 11.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on demand-arm)
∀Visit 12 (Assessment visit, patients treat themselves at home)
∀Visit 13 (Assessment visit, patients treat themselves at home)
∀Visit 14 (Assessment visit, patients treat themselves at home)
∀Visit 15 (Assessment visit, patients treat themselves at home)
∀Visit 16 (Assessment visit, no treatment at home before the visit a nd End of Treatment)
Follow-up Part:
∀Visit 17 (Assessment visit and End of Trial)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 48 of 136
Unscheduled Part:
∀Unscheduled visits can occur e.g. for dispen sing of trial product, dose es calation or when an 
assessment of bleeding epi[INVESTIGATOR_535056].
The duration of the visits (V1-V17) will depend on the assessments and the p atient’s individual 
training and/or discussion need on concizumab and eptacog alfa (rFVIIa) administration, NovoPen
®4, usage of eDiary, completion of the PRO etc.
8.1.[ADDRESS_932046] be obtained before any trial related activity at visit 1, see Section 18.2.
The trial includes a separate informed consent for long-term storage of human biosamples, see 
Section 24.2.
Storage of human biosamples and/or genotypi[INVESTIGATOR_687536]’ 
participation in the trial. Therefore, patients will  have the possibility to sign the informed consent 
for the trial and participate, while refusing per mission for biological specimens and/or genotypi[INVESTIGATOR_535057].
8.1.[ADDRESS_932047] address(es) and telephone number(s) of relevant trial clinic staff. Patients should be 
instructed to return the card to the investigator at th e last trial visit or to destroy the card after the 
last visit.
Each patient will be assigned a unique 6-digit patient number which will remain the same 
throughout the trial.
8.1.3 Screening failures and re-screening
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reason for not continuing in the trial.
Serious and non-serious adverse events from screening failures must be transcribed by [CONTACT_687630]. Follow-up on serious adverse events (SAEs) must be carried out 
according to Section 12. A screening failure session must be made in the IWRS. The case book 
must be signed in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 49 of 136
Re-screening is NOT allowed if the patient has failed one of the inclusion or exclusion criteria; this 
includes re-sampling if the patient has failed one of the inclusion or exclusion criteria related to 
laboratory parameters.
8.1.[ADDRESS_932048] undertake procedures 
similar to those for visit 9 (the last treatment in the main part) or visit 16 (the last treatment visit in the extension part) as soon as possible. The fo llow up visit (visit 17) must be performed 8 weeks 
(window minus 7 days) after last dose of trial drug.
The primary reason for premature discontinuation of  trial product must be specified in the end of 
treatment form in the eCRF, and final drug accountability must be performed. A treatment discontinuation session must be made in the IWRS.
Permanent premature discontinuation of treatment with trial product will lead to patient withdrawal 
from the trial.
8.1.[ADDRESS_932049] aim to undertake procedures similar to those 
for visit 9 (the last visit in the main part) or visit 16 (the last visit in the extension part) as soon as 
possible depending on where the patient is in the trial schedule.
The end-of-trial form must be completed, and final drug accountability must be performed even if 
the patient is not able to come to the trial site. A treatment discontinuation session must be made in the IWRS and the case book must be signed in the eCRF.
Although a patient is not obliged to give his reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the patient’s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in the end-of-trial form in the eCRF.
8.1.6 Review/ evaluation of clinical outcome
Novo Nordisk has constituted an internal concizu mab safety committee and established an external 
DMC to perform ongoing safety surveillance of safety data relevant to concizumab, see Section 12.8.
Review of eDiary data and laborat ory reports etc. must be documented either on the documents or 
in the patient’s medical record.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932050] be asked for clarification and a conclusion made in the patient’s medical record. 
Care must be taken not to bias the patient.
8.1.7 Visit 1 (S creening part)
Informed consent must be obtained be fore any trial related activity, see Section 18.2
All assessments to be performed at screening are listed in Section 2.
After informed consent is given, patients will be as ked to complete the ePRO questionnaires before 
any other trial related activit ies are performed acc ording to Section 8.6.1 :
∀Hemo-TEM,
∀VERITAS-PRN®
Assessment results from physical examination and body measurements, as well as measurements of 
vital signs, urinalysis and ECG and details of any contemporary adverse events, must be entered 
into the eCRF.
A screening confirmation call must be performed in the IWRS, at the day of the visit.The investigator must review all information obtained from the screening procedures. If a patient 
does not meet all inclusion criteria or meets one or more of the exclusion criteria for the trial the 
patient does not qualify to be enrolled.
For bleeding epi[INVESTIGATOR_535058] (Visit1) to randomisation visit 
(Visit 2), information a bout the bleeding epi[INVESTIGATOR_535059] 2.
Patients will be provided with ep tacog alfa (rFVIIa), trial injection kits and direction for use (DFU) 
to cover the potential eptacog alfa (rFVIIa) treatment after the screening part of the trial and 
investigator will ensure that the patients are capable of treating themselves with eptacog alfa (rFVIIa).
Dispensing of eptacog alfa (rFVIIa ) should be performed in IWRS.
The patient must be instructed to call the site if any bleeding epi[INVESTIGATOR_1841], questions or issues arise after 
he has left the site.
8.1.8 Training of patients at visit 1, visit 2 and visit 9
During visit 1 and visit 2 and visit 9 (comparator arm) patients must be trained in self-
administration of concizumab in the home setting using NovoPen
®4. The dose of concizumab to be 
administered must be communicated to the patient a t visit 2 (if they are randomised to concizumab) 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 51 of 136
or at visit 9 (if they are randomised to eptacog alf a (rFVIIa) and switching to concizumab at visit 9). 
Furthermore, patients must be instructed and trained in the importance of reporting all the home treatments with concizumab, details of the bleeding epi[INVESTIGATOR_687537] (rFVIIa) treatments associated with these b leeding epi[INVESTIGATOR_254769]. The patient should call the site if 
bleeding epi[INVESTIGATOR_687584] [ADDRESS_932051], performed independently by [CONTACT_4677], preferably in the morning. Home treatment starts after visit 2 (concizumab arm) or when the 
patient is comfortable self-administrating trial product subcutaneously (concizumab) and 
intravenously (eptacog alfa (rFVIIa)).
8.1.10 Staggered recruitment
Dosing of eptacog alfa (rFVIIa) in the first 4 patien ts randomised to the concizumab arm will be 
staggered until the 4
thpatient randomised to the concizumab arm has completed visit 3 without any 
safety concerns raised by [CONTACT_093]. Until this time point, enrolled patients will not be 
randomised until the previous patient randomised to  concizumab has completed visit 3 without any 
safety concerns raised by [CONTACT_093]. No vo Nordisk will as sponsor control and communicate 
the staggered recruitment process.
8.1.11 Treatment  period – Main part
[IP_ADDRESS] Visit 2 (Randomisation)
Visit 2 should be scheduled  14 to 28 days after visit 1. The date of visit 2 will be considered as trial 
day 1.
It is important to verify the in/exclusion criter ia again and review central laboratory tests from 
screening.
The patients must be in a non-bleeding state and should not have received any by[CONTACT_71360] 
(e.g., eptacog alfa (rFVIIa), FEIBA®) for treatment of bleeding epi[INVESTIGATOR_42988] a period of 24 hours 
(for eptacog alfa (rFVIIa)) or 48 hours (for FEIBA®) prior to the potential first concizumab 
administration (depending on the treatment arm) . After visit 2 only treatment with ep tacog alfa 
(rFVIIa) for bleeding epi[INVESTIGATOR_71249].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 52 of 136
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments listed in 2, must be performed before poten tial admin istration of concizumab
(depending on the treatment arm). Vital signs must be assessed both before (within 1 hour) and after 
concizumab administration. Pre-dose blood sampli ng must take place no more than 1 hour before 
concizumab administration.
Assessment results from concomitant medication, vital signs, body measur ement (weight only) and 
details of adverse events must be entered into the eCRF.
A randomisation and dispensing call must be performed in the IWRS.
In order to determine the correct amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dos ing table in the Trial Materials Manual (TMM) on 
basis of the patient’s current body weight. Investigator will communicate the daily dose of 
concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
For patients randomised to the concizumab arm, the first treatment with the loading dose of 
concizumab will be given.
The time point at which the completion of the first dose takes place corresponds to ‘Time on 
treatment’ = [ADDRESS_932052] concizumab and/or eptacog alfa (rFVIIa)
and trial injection kits and an eDiary device to be able to conduct and report home treatment and 
bleeding epi[INVESTIGATOR_687538].
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa) during the 
trial as instructed by [CONTACT_093]. D rug accountability must be performed for eptacog alfa 
(rFVIIa), if applicable according to section 9.4.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932053] be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site. If the patient on concizumab needs to treat a bleeding epi[INVESTIGATOR_687540] (rFVIIa) at home, then he must visit the site immediately after.
[IP_ADDRESS] Visit 3 (Phone call for eptacog alfa  (rFVIIa) on-demand arm and PK visit for 
concizumab arm)
eptacog alfa (rFVIIa) on-demand arm:
Visit 3 for eptacog alfa (rFVIIa) on-demand arm is a phone call scheduled 7 days after visit 2 (with 
a visit window of +1 day).
All relevant assessments listed in Section 2, must be discussed.
Assessment results from concomitant medication and details of adverse events must be entered into 
the eCRF.
concizumab arm:
Visit 3 is to be scheduled 7 days after visit 2 (with a visit window of +1 day) and the visit takes two 
days.
All assessments are listed in Section 2, and must be performed accordingly and recorded in the 
eCRF.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed accordi ng to Section 8.6.1 :
∀PGI-C
∀Hemo-TEM
Pre-dose blood sampling must take place no more than 1 hour before eptacog alfa (rFVIIa)
administration. Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa) dosing.
eptacog alfa (rFVIIa) should be administered to the trial patients at the site under the surveillance of 
medically trained trial site staff. Patient should continue his daily concizumab injections regardless of eptacog alfa (rFVIIa) administration.
Samples for thrombin generation, haematology, coagulation parameters and FVII ELISA are taken 
pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h 
(± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (±20 min) and 24h (±20 min).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932054] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visits the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to c onduct home treatment until the next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 4, 5, 6, 7 and 8
Patients should treat themselves at home according to their individual dosing schedule regardless of 
when visits 4, 5, 6, 7 and 8 are scheduled.
Visits 4, 5, 6, 7 and 8 are to be scheduled on trial day 29 (4 weeks), day 57 (8 weeks), day 85 (12 
weeks), day 113 (16 weeks) and day 141 (20 weeks)  respectively with a visit window of ±7days.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀PGI-C
∀Hemo-TEM
All assessments are to be performed according to Section 2, and the assessment results from 
concomitant medication, vital signs, body measur ement (weight only) and details of adverse events 
must be entered into the eCRF.
Investigator must perform compliance check of tr eatment and reporting of bleeding epi[INVESTIGATOR_687541] e-Diary.  Based on the assessment of any spontaneous 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932055] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visits the patient will be provided w ith concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until the next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
At visit 8 patients should be reminded that treatment with concizumab (concizumab arm) must take 
place after the blood sampling at visit 9.
[IP_ADDRESS] Visit 9
Visit 9 is to be scheduled on trial day 169 (24 weeks) with a visit window of ±7days.
Patients randomised to eptacog alfa (rFVIIa) on-demand treatment at visit 2 will now be switched to 
concizumab treatment. At this visit the firs t treatment (loading dose) with concizumab will take 
place.
Treatment with concizumab must take place after the blood sampling for both the patients on the 
concizumab arm as well as patients on the eptacog alfa (rFVIIa on-demand) arm.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀PGI-C
∀Hemo-TEM
∀SF-36v2
∀SDS3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 56 of 136
∀TSQM
∀SIAQ-ISRQ
All assessments are to be performed according to Section 2, and the assessment results from 
physical examination, concomitant medication, vita l signs, body measurement (weight only) and 
details of adverse events must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687585] e-Diary. Based on the assessment of any spontaneous bleeding epi[INVESTIGATOR_687542], for patients randomised to concizumab arm at 
visit 2, evaluate if an escalation of the concizumab doses is needed according to the escalation rules 
described in Section 5.3.[ADDRESS_932056] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab and eptacog alfa 
(rFVIIa) during the trial as instructed by [CONTACT_941] i nvestigator. Drug accountability must be performed 
for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
8.1.12 Treatment period – Extension part
[IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog alfa (rFVIIa)
on-demand arm)
Visit 9.1 is to be scheduled on trial day 176 (25 weeks) with a visit window of +[ADDRESS_932057] be performed acc ordingly and recorded in the 
eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932058] no more than 1 hour before eptacog alfa (rFVIIa)
administration. Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa) dosing.
eptacog alfa (rFVIIa) should be administered at the site under the surveillance of medically trained 
trial site staff. Patient should continue his daily  concizumab injections regardless of eptacog alfa 
(rFVIIa) administration.
A dispensing call must be performed in the IWRS.In order to determine the correct amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
Samples for thrombin generation, haematology, coagulation parameters and FVII ELISA are taken 
pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9 h (± 10 min) and 12h (±20 min) and 24h (±20 min).
Investigator is requested to conclude after [ADDRESS_932059] the conclusion in the eCRF before the next dose of concizumab is given the day after.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 9.2 (ONLY patients  previously on the eptacog alfa (rFVIIa) on-demand 
arm)
Visit 9.2 is to be scheduled on trial day 197 (28 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight  only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932060] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab an d/or eptacog alfa (rFVIIa) and tr ial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 10
Visits 10 is to be scheduled on trial day 225 (32 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 .
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687586] 5.3.[ADDRESS_932061] be recorded in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932062] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed  by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if an y questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 10.1 (ONLY patients  previously on the eptacog alfa (rFVIIa) on-demand 
arm)
Visit 10.1 is to be scheduled on trial day 253 (36 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, evaluate if an escalation of the concizumab doses is needed according to the escalation rules described in section 5.3.[ADDRESS_932063] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 60 of 136
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 11
Visit 11 is to be scheduled on trial day 281 (40 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of tr eatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687586] 5.3.[ADDRESS_932064] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and tr ial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed  by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 11.1 (ONLY patients previously on the rFVIIa on-demand arm) 
Visit 11.1 is to be scheduled on trial day 309 (44 weeks) with a visit window of ±7days.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 61 of 136
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of tr eatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, evaluate if an escalation of the concizumab doses is needed according to the escalation rules described in section 5.3.[ADDRESS_932065] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided wi th concizumab and/or eptacog alfa (rFVIIa) and tr ial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 12, 13, 14 and 15
Visits 12, 13, 14 and 15 are to be scheduled on trial day 337 (48 weeks), 393(56 weeks), day 449 
(64 weeks) and day 505 (72 weeks) respectively with a visit window of ±7 days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687586] 5.3.[ADDRESS_932066] be recorded in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932067] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
At visit [ADDRESS_932068] after the
blood sampling at visit 16.
[IP_ADDRESS] Visit 16
Visit 16 is to be scheduled on trial day 533 (76 w eeks) with a visit window of ±7days. Further visit 
[ADDRESS_932069] day of  treatment with  concizumab.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs and details of adverse events must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066].
In the period from visit 16 to visit 17 patients can be treated with eptacog alfa (rFVIIa) or other 
products at the discretion of the investigator to treat eventual bleeding epi[INVESTIGATOR_1841]. Only eptacog alfa (rFVIIa) will be provided by [CONTACT_687631].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932070] be performed in the IWRS. At the visit the patient will be 
provided with eptacog alfa (rFVIIa) and trial injection ki ts to be able to conduct home treatment 
until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as in structed by [CONTACT_093]. NovoPen®[ADDRESS_932071] be performed for concizumab and eptacog alfa (rFVIIa).
The patient must be instructed to call the site if a ny questions or issues (e.g. bleeding epi[INVESTIGATOR_1841]) arise 
after he has left the site. 
8.1.13 Visit 17 (End of trial) - Follow-up part
Visit 17 is to be scheduled on trial day 589 (84 weeks) with a visit window of minus 7 days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
physical examination, body measurements (weight only), vital signs and details of adverse events 
must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687544]. Patients should be asked if their female partner has become pregnant, see Section 12.5.1 .
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa), eDiary 
device and Trial ca rd. D rug accountability must be performed for eptacog alfa (rFVIIa).
End-of-Trial information must be entered in the End-of-Trial form in the eCRF.
Completion or treatment discontinuati on (if the trial is not completed) session should be performed 
in IWRS, see Section 10.
8.1.[ADDRESS_932072] be 
performed via IWRS.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 64 of 136
The following forms can be found in the unscheduled visit in the eCRF:
∀Bleeding epi[INVESTIGATOR_1841]
∀Dosing with eptacog alfa (rFVIIa), concizumab including dose escalation, see Section 5.3.3 .
∀Surgery
∀Local, special and central laboratory (re-)sampling/results
∀Body measurements
8.2 Patient related information/assessments 
8.2.1 Demogr aphy
Demography will be recorded at screening and consists of:
∀Date of birth (according to local regulation)
∀Sex
∀Ethnicity (according to local regulation)
∀Race (according to local regulation)
8.2.2 Concomitan t illness and medical history other than haemophilia
A concomitant illness is any illness, other than haemophilia, that is present at the start of the trial 
(i.e. at the first visit) or found as a result of a screening procedure or other trial procedures 
performed before first exposure to trial product. A ll concomitant illnesses should be reported in the 
concomitant illness forms in the eCRF except information on haemophilia with inhibitors which is to be reported in the haemophilia medical history section of the eCRF.
Medical history is a medical event, other than haemophilia, which the patient has experienced in 
the past. Only relevant medical history should be reported.
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE.
It must be possible to verify the patient’s medical  history in source documen ts such as patient’s 
medical record, see Section 6.2and 6.3.
If a patient is not from the investigators own practice; the investigator must make a reasonable 
effort to obtain a copy of the patient’s medical record from relevant party e.g. primary physician. The investigator must document an y attempt to obtain external medical i nformation by [CONTACT_135540](s) when information was requested and who has been contact[INVESTIGATOR_530].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 65 of 136
8.2.3 Concomitant medication
A concomitant medication is any medication, other than the concizumab and eptacog alfa 
(rFVIIa), which is taken during the trial, including the screening and follow-up period .
Details of any concomitant medication must be recorded at the first visit. Changes in concomitant 
medication must be recorded at each visit as they occur.
The information collected for each concomitant medication includes trade name [CONTACT_18058], 
indication, start date and stop date or continuation.
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the patient’s eligibility to continue in the trial, the monitor must be informed.
8.2.4 Details of Haemophilia, Haemoph ilia treatment and bleed history
All available information on haemophilia, prior to screening should be recorded in the eCRF.
∀Diagnosis of haemophilia (date)
oClassification of haemophilia type (haemophilia A/B)
oSeverity of haemophilia (severe, moderate or mild)
oAetiology of haemophilia (congenital or acquired)
∀Family history of
oHaemophilia (Y/N)
oInhibitors (Y/N)
oProthrombotic disorders (Y/N)
oThromboembolism (Y/N)
∀Inhibitor tests taken (Y/N)
oDate (dd- mmm-yyyy) 
oResult (BU)
∀Cut-off for positive inhibitor result
∀Deficiency factor level
The following information on bleeding epi[INVESTIGATOR_535068]:
∀Type of treatment
oProphylaxis or on-demand
oStart date
oStop date
∀Number of bleeding epi[INVESTIGATOR_535141]
∀Coagulation factor product(s)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932073], (plasma derived or 
recombinant)
∀Dosage used for prophylaxis
∀Dosing frequency during prophylaxis 
∀Approximate dose to treat a bleeding epi[INVESTIGATOR_1865]
∀Approximate number of doses to treat a bleeding epi[INVESTIGATOR_1865]
∀Target joint listing (definition: a target joint is a joint in which [ADDRESS_932074] occurred within a consecutive 6-month period)
oLocation
oPosition (left/right)
oNumber of bleeding epi[INVESTIGATOR_1841]
8.3 Efficacy assessments
8.3.1 Bleeding epi[INVESTIGATOR_687545] (rFVIIa) and symptoms related to the underlying 
disease must be captured in the eDiary by [CONTACT_687647]. The trial 
site should be informed of the details of all bleeding epi[INVESTIGATOR_1841], including those that are treated outside of the trial site.
All information captured during visits to the trial site will be collected in the eCRF.
When home treatment is initiated at visit 2 all bl eeding epi[INVESTIGATOR_687587] a (rFVIIa) in jection occ urring outside the trial site should be entered in the eDiary by 
[CONTACT_102], Section 13.3.
The completed eDiary is considered source data.
For reporting of bleeding epi[INVESTIGATOR_687547]/SAEs, please refer to Section 12. In case of life-
threatening bleeding epi[INVESTIGATOR_1865], it should always be reported as an SAE, see Section 12.1.[ADDRESS_932075] be recorded for any bleeding epi[INVESTIGATOR_1865], including bleeding epi[INVESTIGATOR_687548] (rFVIIa):
∀Start date and time
∀Stop date and time (see Table 8–1 )
∀Anatomical location
oPosition (left/right)
∀Cause (see Table 8–2 )
ospontaneous
otraumatic
opost-surgical3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 67 of 136
∀Severity (see Table 8–3 )
omild/moderate, severe
oclassification and recording of severe bleeding epi[INVESTIGATOR_687549]
∀Treatment, if any 
oeptacog alfa (rFVIIa) administration or other product administration
odose, date, stop time
oother medicinal treatments related to the bleeding epi[INVESTIGATOR_1865] (pain relieving 
medication, non-medical therapy etc.)
orecord as concomitant medication (section 8.2.3 )
∀Symptoms during bleeding epi[INVESTIGATOR_1865](s)
oPain
oBlood in urine
oTingling sensation
oSwelling
oMouth/Gum bleed
oWarmth
oLoss of movement
oBruises
oNose bleed
Only report the bleeding epi[INVESTIGATOR_535074]/SAE if fatal, life threatening or evaluated as related to 
trial product, see Section 12.1.1 and12.1.2 .
Table 8–1 Definition of stop of bleeding epi[INVESTIGATOR_535075]: When the patient experiences/observes signs of cessation of the active bleeding 
epi[INVESTIGATOR_535076]; pain relief, no increase in swelling/limitation of motion and 
improvement in other objective signs of the bleeding epi[INVESTIGATOR_535077]: When pain and objective signs of the bleeding epi[INVESTIGATOR_687550] 8–2 Definitions of bleeding epi[INVESTIGATOR_1841] (cause of bleed)
Category Definition
Spontaneous Not linked to a specific, known action or event
Traumatic Caused by a specific, known action or event (e.g. injury or exercise)
Post-surgical Bleeding epi[INVESTIGATOR_535079]. Bleeding epi[INVESTIGATOR_1841] 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 68 of 136
Category Definition
during surgery do not fall under this category
Table 8–3 Definition of bleeding epi[INVESTIGATOR_535081]/Moderate Examples: uncomplicated musculoskeletal 
bleeding epi[INVESTIGATOR_1841] (joint, muscular bleeding 
epi[INVESTIGATOR_434840]), 
mucosal- or subcutaneous bleeding epi[INVESTIGATOR_434838]/moderate bleeding epi[INVESTIGATOR_687552]/moderate bleeding epi[INVESTIGATOR_1841]: 
∀patient must call the site between 
visit 1-2 and visit 3-16 (see 2-3 
and 9-9.1 below)
∀patient must call the site between 
visit 2-3 or visit 9-9.1 (eptacog 
alfa arm) and if treated at home, go to the site immediately after
∀patient can treat themselves at 
home between visit 16 and visit 
17
Severe Examples: intracranial, retroperitoneal, 
iliopsoas and internal neck bleeding epi[INVESTIGATOR_1841]; 
muscle bleeding epi[INVESTIGATOR_535084]; bleeding epi[INVESTIGATOR_80799] a significant decrease in the haemoglobin level (>3g/dl)
Severe bleeding epi[INVESTIGATOR_535085]-threatening bleeding epi[INVESTIGATOR_687553] a bleeding epi[INVESTIGATOR_687588]3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 69 of 136
Prophylactic treatment with concizumab should continue independent of bleeding epi[INVESTIGATOR_535089], i.e. the original dosing schedu le should be maintained unless investigator judges 
otherwise.
Dosing for bleeding epi[INVESTIGATOR_687555] (rFVIIa) should be documented in the eCRF (visit 1 
to visit 2) and eDiary (visit 2 to visit 17). After vi sit [ADDRESS_932076] be recorded either in 
the eDiary (if treated at home) or in the eCRF  (if treated at the trial site), see section 13.3.
Investigator must instruct the patient not to perform preventive treatment with eptacog alfa (rFVIIa)
after bleeding stop as defined in Table 8–[ADDRESS_932077] the patient to use eptacog alfa (rFVIIa) as rescue medication to treat 
bleeding epi[INVESTIGATOR_488840] [ADDRESS_932078] review the bleeding and treatment data collected by [CONTACT_687632] 13.3.
For in-between visit administrations of trial drug, patients will self-administer concizumab (and 
eptacog alfa (rFVIIa) as rescue medication) and will record treatment in the eDiary, which will be 
reviewed during periodic calls to/contact [CONTACT_687648].
8.[ADDRESS_932079] physical examination and include the following.
∀General appearance
∀Head, ears, eyes, nose, throat, neck
∀Respi[INVESTIGATOR_2133]
∀Cardiovascular system
∀Gastrointestinal system including mouth
∀Genito-urinary system, breast(s)
∀Musculoskeletal system
∀Central and peripheral nervous system
∀Skin
∀Lymph node palpation3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932080] evaluate the results of the examination and classify them as either:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as Medical History (Section 8.2.2 )
oIf observed after screening: report an AE/SAE (Section 12)
Measurements will be reported in the eCRF.
8.4.2 Body measurements
∀Height (cm), at screening
∀Body weight (kg), (with one decimal)
The body weight assessed at each visit will be us ed for calculation of the concizumab dose to be 
administered until next visit.
Measurements will be reported in the eCRF.
8.4.[ADDRESS_932081] administration unless otherwise 
specified.
∀Body temperature (°C)
∀Systolic and diastolic blood pressure, sitting (BP) (mmHg)
∀Pulse, sitting (beats/min)
∀Respi[INVESTIGATOR_535095]: At visits 2 and visit 3 (for patients randomised to concizumab) and at visit 9 and visit 9.1
(for patients initiating concizumab treatment at  visit 9), the measurements are also performed after 
concizumab administration.
The investigator must evaluate the vital signs and classify the outcome as either:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932082] if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness, section 8.2.2
oIf observed after screening:  report an AE/SAE, section [ADDRESS_932083] evaluate the ECG [standard 12 lead] at screening and classify the outcome as
either:
∀Normal or abnormal.
∀If abnormal the investigator must:
oSpecify the abnormality
oRecord if the result is clinically significant? (Yes/No)
oIf observed before or at Screening: record as Medical History, section 8.2.2
oIf observed after screening: report an AE/SAE, section [ADDRESS_932084] been 
reviewed. Outcome will be reported in the eCRF.
8.4.5 Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12.
[IP_ADDRESS] Medication error
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form:
∀Trial product involved 
∀Classification of medication error
∀Whether the patient experienced any adverse event(s) as a resu lt of the medication error 
∀Suspected primary reason for the medication error 
For definition of med ication errors, see Section 12.1.4 .
[IP_ADDRESS] Adverse events requiring additional data collection
For some AEs additional data collection is required and specific event forms must be completed in 
the eCRF in additi on to the AE form . 
In case any of these events fulfil the criteria for a serious adverse event, please report accordingly, 
see Section 12.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932085] be 
completed in the eCRF in addition to the AE form:
Injection site reaction 
Investigation of injection site reactions will be performed locally at all visits after visit 2 until visit 
16 based on patient feedback and by [CONTACT_687634]:
Symptoms e.g.
∀Pain
∀Numbness
∀Itching
∀Burning
Signs e.g.
∀Redness (mm x mm)
∀Induration (mm x mm)
∀Swelling
∀Dimpling
∀Macula
∀Haematoma
∀Bleeding
∀Other (visual reactions)
Any injection site reaction symptom (evaluated at visit 2-16) should be recorded in the AE form and 
the injection site reaction form, see Section 12.1.5 .
A separate AE should be recorded for each injection site reaction symptom. The affected area 
should also be evaluated for redness and induration in mm using a ruler. To ensure all local 
injection site assessments are performed at the in jection site, the area around the site will be marked 
with a pen prior to injection.
In the event of a local reaction, additional visual assessments (as described above) will be 
performed until resolution as judged necessary by [CONTACT_093].
Assessment of injection si te reactions can be performed at any time, if deemed necessary by [CONTACT_1275].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932086] be 
obtained if available on the hypersensitivity reaction form:
∀Signs and symptoms associated with the event
∀Time of appearance after administration of trial drug
∀Relevant immunological tests performed, see Section [IP_ADDRESS]
∀Treatment given for the reaction
∀Previous history of similar reactions
∀Association with the trial product(s)
∀Relevant risk factors associated with the event
∀Storage condition of the trial product
∀Total number of doses, from first day on trial product, up to the time of this event
8.5 Laboratory assessments
An approximate total blood volume of 725 mL will be taken from each patient on the concizumab 
arm and 625 mL from each patient on the eptacog alfa (rFVIIa) arm.
A laboratory manual will be provided for detailed description of obtaining and processing blood 
samples.
All laboratory blood samp les collected for this trial except for haematology samples at all visits and 
coagulation parameters at visits 3 and 9.1 are to be shipped for analysis at central laboratories or further distribution to special laboratories. Haematology samples (all visits) and coagulation 
parameters (visit 3 and 9.1) are to be analy sed locally. Ports cannot be used for blood sampling.
The laboratory provides resu lts to the trial sites in the units preferred by [CONTACT_135545].
Laboratory reports listing results from centrally analysed samples will be made available for the 
investigator. Investigator must review and evaluate the results and report AEs for results which are 
clinically significant. Laboratory reports will where possible indicate normal ranges.
Categorisation of clinical significance for out of range results may not be required for the following 
laboratory parameters and the investigator is there fore not required to perform a categorisation even 
though these parameters are listed in the laboratory report: FVIII/FIX activity, FVIII/FIX inhibitor 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932087], Thrombin generation, Free TFPI (TFPI [INVESTIGATOR_535096]), conc izumab concentration 
in plasma, anti-concizumab antibodies, Total TFPI [INVESTIGATOR_687556].
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested an alyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. The investigator must review all laboratory results for concomitant illnesses and AEs and report these according to Section 8.2.[ADDRESS_932088] be sent to the central laboratory for analysis; 
if additional laboratory sampling is needed, e.g. to follow up on AEs, this must be done at a local 
laboratory except for biomarkers and anti-drug antibodies (anti-concizumab IgE antibodies and 
anti-concizumab antibodies).
Laboratory samples will be destroyed no later than  at finalisation of the clinical trial report (CTR).
Antibody samples and human biosamples, if applicable, will be stored as described in Section 24.2.
The investigator may not be able to review the re sults of antibody measurements in relation to AEs 
as these are often analysed after LPLV.
8.5.1 Laboratory a ssessments for efficacy
[IP_ADDRESS] Thrombin generation
The Thrombin Generation Assay (TGA) will be collected at all visits.
Further at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9 h (± 
10 min), 12h (± 20 min) and 24h (± 20 min).
The TGA is included as an exploratory PD assessment.The generation of thrombin is a fundamental part of the haemostatic system, and is a key 
measurable parameter of the formation of a clot under bleeding or thrombotic conditions. The 
thrombin burst is crucial for the formation of a stable fibrin clot.
The Calibrated Automated Thrombogram (CAT) method (used by [CONTACT_535235]) will be 
used to measure thrombin generation (TG). This method uses a slow acting fluorogenic substrate that allows continuous measurement of thrombin generation in double centrifuged citrated plasma.
In this assay set-up thrombin generation is initiated by [CONTACT_687635]. The result is obtained by [CONTACT_49719] a constant known thrombin activity in a parallel non tissue factor initiated sample. The assay has been validated fit-for-purpose.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 75 of 136
The thrombin generation endpoints are defined but not limited to:
∀The Endogenous Thrombin Potential (ETP) – the area under the curve 
∀Peak thrombin generation
∀Velocity Index 
[IP_ADDRESS] Free TFPI
[INVESTIGATOR_687557] (TFPI [INVESTIGATOR_535096]) will be collected at all visits, pre-dose at visit 2 and 3 
(concizumab arm) and visit 9 and 9.1 (eptacog alfa (rFVIIa) arm).
The free TFPI [INVESTIGATOR_687558]  
 (named and referred to  TOTAL TFPI) and will be used for PD assessments.
8.5.2 Laboratory a ssessments for safety
[IP_ADDRESS] Urinalysis
∀pH
∀Protein
∀Glucose
∀Bilirubin
This is a semi qu alitative measurement which will be performed (locally) at the screening visit by 
[CONTACT_535236]. The results will be recorded in the 
eCRF.
The investigator must evaluate the results and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must:
oRecord if the result is clinically significant? (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
[IP_ADDRESS] Haematology
Haematology samples are to be sampled and analysed locally at all visits.
Further at visit 3 (concizumab arm) and 9.1 (ep tacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa), 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9 h (± 10 min), 12h (± 20 min) and 24h (± 20 min).
∀Haemoglobin
∀Erythrocytes (cell count)
∀Thrombocytes (platelet count)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 76 of 136
∀Leucocytes (cell c ount)
∀Differential leucocytes cell count
oLymphocytes
oMonocytes
oNeutrophils
oEosinophils
oBasophils
The investigator must evaluate the results and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must: 
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
Haematology results are to be entered into the eCRF.
[IP_ADDRESS] Biochemistry
Biochemistry samples are to be sampled and analysed centrally at all visits.
∀Creatinine
∀Albumin
∀Bilirubin; total, dir ect, indirect
∀Aspartate aminotransferase (AST)
∀Alanine aminotransferase (ALT)
∀Gamma glutamyltransferase (GGT) 
∀Alkaline phosphatase
∀C-reactive protein (CRP)
The investigator must evaluate the results of the examination and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
[IP_ADDRESS] FVIII/FIX activity
FVIII/FIX activity is to be sampled and analysed centrally at visit 1, visit 9 and visit 16.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 77 of 136
∀FVIII activity level (IU/mL) or
∀FIX activity level (IU/mL)
[IP_ADDRESS] Coagulation parameters
Coagulation parameters will be performed centrally at all visits with the exception of visit 3 and 
visit 9.1 where the PT, APTT, and Fibrinogen will be performed locally.
Further at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa) at 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9h 
(±10 min) and 12h (±20 min) and 24h (± 20 min) locally.
∀Fibrinogen – centrally and locally
∀Prothrombin time (incl. INR) (PT) centrally and locally
∀D-dimer – only centrally
∀Prothrombin fragment 1+2 – only centrally
∀Activated partial thromboplastin time (APTT) – centrally and locally
∀Antithrombin (AT) activity – only centrally
The investigator must evaluate the results of the examination and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
Coagulation parameters analysed locally are to be entered into the eCRF.
[IP_ADDRESS] FVIII/FIX inhibitors
FVIII/FIX inhibitor level will be measured by [CONTACT_535237] 1, visit 9 and visit 16. 
∀FVIII inhibitors (BU) or
∀FIX inhibitors (BU)
[IP_ADDRESS] Anti-concizumab antibodies
Samples for the determination of anti-drug antibodies collected during the treatment period must be 
drawn at all visits and prior to administering con cizumab at visit 2 and 3 (concizumab arm) and 
visit 9 and 9.1 (eptacog alfa (rFVIIa) arm) and visit 16 for both arms.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932089] conc izumab (anti-drug antibodies [ADA]) will be 
performed at specialised laboratories whereas a ssessment of neutralising antibodies will be 
performed at Novo Nordisk.
Analysis for ADA will be done with a bridging ECL assay (binding ADA assay), using labelled 
concizumab for antibody capture and detection. Confirmed positive samples will be characterised 
for binding to IgG backbone, CDR region or the S241P mutation. Furthermore, positive samples will be characterised for neutralising activity using a modified TFPI  [INVESTIGATOR_687589] 
(neutralising ADA assay). All antibody assays are validated according to international guidelines 
and recommendations.
The following analyses will be available:
∀Anti-concizumab antibodies assay
∀Specificity assay (Anti-concizumab antibodies cross reacting with IgG4 backbone, CDR 
region or S241P mutation)
∀Anti-concizumab neutralising antibodies assay
The samples will be analysed in batches during the trial and results will be available to the data 
monitoring committee approximately every third month after the first patient has been dosed. Neutralising antibodies will be analysed and reported at the EOT. A detailed description of the 
assay methods will be included in the antibody analysis report at the end of the trial.
In the event that a trial patient develops binding ADAs towards concizumab during the course of the 
trial and has measurable binding ADAs at his End-of-Trial visit, the patient may attend an ADA follow-up visit. The ADA positive patients will be called for additional visits, e.g. every 4 to 6 
weeks, for safety assessment and blood sampling for ADA and PD markers (free TFPI [INVESTIGATOR_535203]). The ADA positive patients will be followed no longer than one year after 
End-of-Trial.
Hypersensitivity
If suspi[INVESTIGATOR_1884] a hypersensitivity reaction occurs, patients should be instructed to contact [CONTACT_535238], see Section 12.1.5 .
In the event of a severe local and/or systemic hypersensitivity reaction possibly or probably related 
to trial product, blood sampling for assessment of anti -concizumab IgE antibodies as well as anti-
concizumab antibodies should be conducted in relation to the reaction and no later than 1-2 weeks 
after the event. Additional testing may be performed if deemed relevant (e.g. anti-Host Cell Proteins 
(HCP) antibodies).
In the event of a severe systemic hypersensitivity reaction to trial product it is recommended also to 
test for tryptase (total and/or mature tryptase) within 3 hours of the reaction. Moreover, a baseline 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932090] the hypersensitivity reaction for assessing the 
persistence of the IgE response. Tryptase measurements are not required at the follow up visits.
Additionally, basophil activation testing may be performed if deemed relevant. This can be 
performed using existing samples and/or by [CONTACT_535239]’s basophil cells from an additional 
blood sample taken 3-4 weeks and no later than 2 months after the event. Similarly, prick tests 
and/or intra-dermal tests may be performed if relevant using trial product or components of trial product. Complement may be measured in case of suspi[INVESTIGATOR_535150].
Results from the following additional tests will be reported to Novo Nordisk Safety Operations for 
inclusion in the ARGUS database and included in the narratives, if measured.
Test to be performed in case of severe hypersensitivity
∀Anti-concizumab IgE antibodies
∀Anti-concizumab antibodies (additional to scheduled time points)
Additional testing may be performed if deemed relevant e.g.
∀Anti-Host Cell Proteins (HCP) antibodies
∀Anti-HCP IgE antibodies
∀Basophil activation results
∀Prick test/intra-dermal test
∀Complement test results
Furthermore, it is recommended locally to test for
∀Tryptase (total and/or mature tryptase)
[IP_ADDRESS] Concizumab ELISA
Concizumab ELISA will be collected at all visits except at screening only for the concizumab arm.
Samples will be collected pre-dose at visit 2 an d 3 for concizumab arm and visit 9 and 9.1 for 
eptacog alfa (rFVIIa) arm) and visit 16 for both arms.
Concizumab will be quantified using a validated ELISA assay. 
Recombinant human TFPI [INVESTIGATOR_687559]. A colorimetric detection signal is 
obtained by [CONTACT_687636]-human IgG4 specific 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 80 of 136
antibodies with the chromogenic substrate TM B (3,3´, 5,5´-tetram ethylbenzidine). The amount of 
anti-TFPI [INVESTIGATOR_535103], quality control and test samples correlates with the obtained signal strength.
Validation of the assay follows current guidelines for bioanalytical method validation. Bioanalytical 
data will be reported in a bioanalytical report.
[IP_ADDRESS] FVII ELISA
FVII ELISA will be collected at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) pre-
dose eptacog alfa (rFVIIa) and post-dose at 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 
min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points, except pre-dose, occur after eptacog alfa (rFVIIa) administration.
FVII in plasma will be quantified using a validated enzyme-linked immunosorbent assay (ELISA).
The FVII ELISA will detect the total sum of FVII in a sample, including endogenous FVII, eptacog 
alfa (rFVIIa) and FVII in complex with other mo lecules e.g. antithrombi n. The ELISA has been 
validated for measuring FVII in human citrated plasma samples. Validation follows current guidelines for bioanalytical method validation. Bioanalytical data will be reported in a bioanalytical 
report.
[IP_ADDRESS] Total TFPI
[INVESTIGATOR_687560]. Samples w ill be collected pre-dose at visit 2 and 3 
(concizumab arm) and visit 9 and 9.1 (eptac og alfa (rFVIIa) arm) and visit 16 for both arms.
The total TFPI [INVESTIGATOR_67147] (free and concizumab bound) will be included as an exploratory biomarker 
assessment.
The assay is an ELISA, where TFPI [INVESTIGATOR_687561] a polyclonal anti-TFPI [CONTACT_30936], distanced from 
the binding site of concizumab; meaning that both free TFPI [INVESTIGATOR_687562]. Detection will be obtained with a monoclo nal antibody against TFPI, which does not bind 
to the concizumab epi[INVESTIGATOR_9230].
Data will be reported in ng/mL TFPI.
8.5.3 Human Biosamples
If patient permission is obtained plasma, serum and/or DNA for genotypi[INVESTIGATOR_535109], see Section 2. The blood samples can be stored up to 15 years, for future 
potential exploratory purposes please refer to section 24.2.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 81 of 136
Antibody samples storage and retention, see Section 24.2.1 . The investigator is not able to review 
the results of antibody measurements in relation to  AEs as these are analysed after LPLV. Plasma 
and serum is taken at visit 1 and 17. DNA for genotypi[INVESTIGATOR_687563] 1.
8.6 Other assessments8.6.1 Patient reported outcomes
A newly developed disease- specific electronic PRO (ePRO) the He mophilia Treatment Experience 
Measure (Hemo-TEM) - is being validated in this trial. In order to assess the psychometric properties of Hemo-TEM, other questionnaires  will be provided; s ee further appendix 1.
The following ePRO questionnaires will be used in the trial:
∀Hemophilia Treatment Experience Measure (Hemo-TEM)
∀Validated Hemophilia Regimen Treatment Adherence Scale (VERITAS-PRN
®) 16
∀36-Item Short Form Health S urvey (SF-36v2) (4 week recall)17
∀Patient’s Global Impression of Change (PGI-C)
∀Sheehan Disability Scale (SDS)18
∀Treatment Satisfaction Questionnaire for Medication (TSQM, version II)19 20 21
∀Injection Site Reaction Questionnaire (ISRQ) domain of SIAQ (SIAQ-ISRQ)22
The ePROs should be assessed at the scheduled visits following the order listed below:
∀visit 1 (Hemo-TEM, VERITAS-PRN®)
∀visit 2 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 3 (PGI-C, Hemo-TEM)
∀visit 4 (PGI-C, Hemo-TEM)
∀visit 5 (PGI-C, Hemo-TEM)
∀visit 6 (PGI-C, Hemo-TEM)
∀visit 7 (PGI-C, Hemo-TEM)
∀visit 8 (PGI-C, Hemo-TEM) 
∀visit 9 (PGI-C, Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 10 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 16 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
At visit 1: before any visit-related activities  all patients should complete Hemo-TEM and 
VERITAS-PRN®.
At visit 2: before any visit-related activities all patients should complete Hemo-TEM, SF-36v2, 
SDS, TSQM and SIAQ-ISRQ.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 82 of 136
At visit 3-8: before any visit-related activit ies the patient should complete the PGI-C before the 
Hemo-Tem. These are the rules that apply:
∀If the patient responds “1” to question 1 in the PGI-C, the patient should also complete the 
Hemo-TEM. In this case the patient should not fill in the PGI-C any more in the trial and the 
Hemo-TEM only again at visits 9, 10 and 16. 
∀If the patient responds “0” or “2” to question 1 in the PGI-C, the patient should not complete 
any other questionnaires at this visit, but should repeat the procedure at next visit. 
Exception: Patients randomised to eptacog alfa (rFVIIa) on-demand should not complete the 
ePRO at visit 3 as this is a phone visit.
At visit 9 if the patient has responded “0” or “2” in the PGI-C at all previous visits, the patient 
should complete PGI-C. All patients shoul d complete Hemo-TEM, SF-36v2, SDS, TSQM and 
SIAQ-ISRQ.
At visit [ADDRESS_932091].
[IP_ADDRESS] Concizumab and NovoPen®4
Direction for use (DFUs) will be available as a hand out for patients at visit 2. Training in 
NovoPen®4 can start at screening (visit 1) and s.c administration of concizumab using the 
NovoPen®[ADDRESS_932092] dose at the trial site (visit 2). Patients must be instructed that 
injections are to be performed subcutaneously, not intravenously. Concizumab and NovoPen®[ADDRESS_932093] be documented in the medical records.
Detailed instructions can be found in the DFUs.[IP_ADDRESS] eptacog alfa (rFVIIa)
A direction for use ( DFU) will be available as hand out for patients at visit 1. Training must be 
performed at site until patients feel comfortable performing the treatment. The training must be 
documented in the medical records.
The following should be emphasised for eptacog alfa (rFVIIa):3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 83 of 136
∀eptacog alfa (rFVIIa) should be slowly injected intravenously over 2 to 5 minutes
Detailed instructions can be found in the DFU
[IP_ADDRESS] eDiary
Training on the use of the eDiary can start at vis it 1. The eDiary will be provided to the patients at 
visit 2.
Training must be repeated at the site until patients feel comfortable using the device. The training 
must be documented in the medical records.
During the home treatment period the patient must ensure that all home treatments of concizumab, 
details of bleeding epi[INVESTIGATOR_687537] (rFVIIa) treatments associated with these bleeding 
epi[INVESTIGATOR_535111].
It will be the responsibility of the investig ator or delegated staff to  assess the eDiary data 
throughout the conduct of the trial and to ensure data entry compliance (timely entry, no duplicate data, no missing data etc.) and retraining if necessary.
For patients completing the trial or in case of withdrawal, the eD iary will be collected at the EOT.
8.6.3 Surgery
Minor surgery can be performed within this trial at the investigator’s discretion according to local 
guidelines. Definition of minor surgery, see Section 5.1.1. Major surgery is not allowed, see 
exclusion criteria no 6.
For minor surgery the following should be recorded in the eCRF:
∀Date, stop time and dose of preventive tr eatment with eptac og alfa (rFVIIa) before surgery, 
if this was deemed necessary by [CONTACT_093]
∀Indication for surgery
∀Location of surgery
∀Date of surgery
∀Start and stop time of surgery
8.7 Patient compliance
Throughout the trial, the investigator will remind the patients to follow the trial procedures and 
requirements to ensure patient compliance. If a patient is found to be non-compliant, the investigator will remind the patient of the importance of following the instructions given including taking the trial products as prescribed.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 84 of 136
8.8 Treatment compliance 
Treatment compliance will be monitored and documented through timely review of eDiary data and 
drug accountability. 
Concizumab will be administered at the trial site at visit 2 for the concizumab arm supervised by 
[CONTACT_687637] 2 if the patient 
feels comfortable with the s.c. administration. Administration of eptacog alfa (rFVIIa) for bleeding epi[INVESTIGATOR_535179] a medically trained trial staff or at home by [CONTACT_102], see Section 8.3.1 . 
Drug accountability will be performed and will be us ed to assess patient compliance together with 
the patients’ adherence to trial procedures.
Compliance check includes a cross check between records in EDC/eDiary (number of 
administrations and bleeding epi[INVESTIGATOR_1841]) and the used/returned cartridges/vials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932094] not be used if it contains visible particles or discoloration.
The reconstituted eptacog alfa (rFVIIa) solution appears clear and colourless. Do not use the 
reconstituted solution if it contains visible particles or if it is discoloured.
Trial products must not be dispensed to  any person not included in the trial.
9.1 Trial products
The following trial products will be provided by [CONTACT_3454], Denmark:
Table 9–[ADDRESS_932095] Strength Dosage form Route of 
administrationContainer/
delivery device
concizumab B 
(IMP)100 mg/mL Solution for injection s.c. injection 3 mL cartridge
eptacog alfa
(IMPaand NIMPb)5 mg/vial Powder for solution
for injectioni.v. injection Vial
histidine 5 mL N/A Solvent for solution 
for injectioni.v. injection prefilled syringe
aInvestigational Medicinal Product (IMP) given as IMP for a single dose at visit [ADDRESS_932096] (NIMP) given as NIMP for bleeding epi[INVESTIGATOR_535113]®[ADDRESS_932097] w ill be distributed to the tr ial sites according to enrolment 
and randomisation.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932098] 
dispensing visit (see Section 2).
9.3 Storage 
Table 9–[ADDRESS_932099] Storage conditions
(not-in-use)In-use conditions In-use timea
concizumab B 100 mg/mL Store in refrigerator (2oC-8oC)
Do not freeze
Protect from lightStore at room temperature 
(below 30°C)
Do not refrigerateProtect from lightUse within 4 weeks 
(28 days)
eptacog alfa
5mgStore between 2oC-25oC
Do not freezeProtect from lightFor single use
Do not freezeProtect from light
To be used immediately 
after reconstitutionIf not used 
immediately, store in refrigerator (2
oC-8oC)
for up to [ADDRESS_932100] from lightFor single use
N/A
aIn-use time for concizumab starts when first dose is administered from an individual cartridge and for eptacog alfa
(rFVIIa) when the product is reconstituted
The investigator must ensure that trial product is kept under proper storage conditions and record 
and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any patient before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take appropriate action to ensure correct storage.
Investigator must instruct the patient to use and store trial product according to the label.9.4 Drug accountability and destruction
Drug accountability of all trial products (concizumab  and eptacog alfa (rFVIIa) received at site is 
the responsibility of the investig ator. The patient will be as ked to return all used, partly used and 
unused trial product during the trial as instructed by  [CONTACT_093], ex cept for histidine which 
should be discarded at home and not accounted for.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 87 of 136
All cartridges (concizumab) and vials (eptacog alfa (rFVIIa)) must be accounted for as used, partly 
used or unused.
The investigator will perform drug accountability using the IWRS Drug Accountability module.Returned trial product (used/partly used and/or unused), expi[INVESTIGATOR_687590]-allocated trial product.
Non-allocated trial product includi ng expi[INVESTIGATOR_215519].
Destruction of concizumab and eptacog alfa (rFVIIa) can be performed on an on-going basis and 
will be done according to local procedures after accountability is finalised and reconciled by [CONTACT_36102]. Destruction of products must  be documented in the IWRS.
For Japan only : Responsibility for storage and drug accountability of the trial drug product at the 
trial site rests with the head of the trial site. The h ead of the trial site could assign some or all of the 
responsibilities for accountability of the trial drug product at the trial sites to a trial product storage 
manager (a pharmacist in principle). The trial product storage manager should control and take accountab ility of the tr ial drug product in accordance with proce dures specified by [CONTACT_3454]. 
The head of the trial site or the trial product storage manager must ensure the availability of proper 
storage conditions, and record and evaluate the temperature.
9.5 Auxiliary supplies
Novo Nordisk will provide the auxiliaries for this trial:
∀For concizumab administration: NovoPen
®4, needles and DFUs
∀For eptacog alfa (rFVIIa) reconstitution and administration: Trial Injection Kit and DFU
Only needles and trial injection kit provided by [CONTACT_535244].
For further guidance please see the TMM.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 88 of 136
10 Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone.  
Access to the IWRS must be restricted to and controlled by [CONTACT_36301].
IWRS is used for: 
∀Screening
∀Screening failure
∀Randomisation
∀Medication arrival
∀Dispensing
∀Dispensing verification
∀Treatment discontinuation 
∀Completion
∀Drug accountability
∀Data change
IWRS user manuals will be provided to each trial site.
11 Randomisation procedure and breaking of blinded codes
11.1 Randomisation 
Randomisation will be handed by [CONTACT_8784].
All patients included in the screening period and eligible for the trial will enter the trial and be 
randomised at visit 2 in a 2:1 allocation to either concizumab prophylaxis arm or eptacog alfa 
(rFVIIa) on-demand arm.
11.2 Breaking of blinded codes
Not applicable for this trial.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 89 of 136
12 Adverse events, and technical complaints
12.1 Definitions
12.1.1 Adverse event 
An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal 
product, and which does not necessarily have  a causal relati onship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product.
An AE includes:
∀A clinically significant worsening of a concomitant illness
∀A clinical laboratory adverse event (CLAE): a clinical laboratory abnormality which is 
clinically significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is 
of a severity that requires active management. Active management includes active treatment or further investigations, for example change of medicine dose or more frequent follow-up due to the abnormality.
The following should not be reported as AEs:
∀Pre-existing conditions, in cluding those found as a result of screening or other trial 
procedures performed before exposure to trial product (pre-existing c onditions s hould be 
reported as medical history or concomitant illness)
∀Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial related activity after  the patient has signed the informed consent
∀Bleeding epi[INVESTIGATOR_56238] (e.g. pain, swelling, synovitis, arthralgia, injection 
site haematoma) in connection with bleedi ng epi[INVESTIGATOR_49622]/SAEs 
unless the event is fatal, life-threatening or evalu ated by [CONTACT_535245]. All bleeding epi[INVESTIGATOR_535114]/eDiary.
The following three definitions are used when assessing an AE:
∀Severity 
∀Mild – no or transient symptoms, no interference with the patient’s daily activities
∀Moderate – marked symptoms, moderate interference with the patient’s daily activities
∀Severe – considerable interference with the patient’s daily activities; unacceptable
∀Causality 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932101](s): 
∀Probable - Good reason and sufficient documentation to assume a causal relationship
∀Possible - A causal relationship is conceivable and cannot be dismissed
∀Unlikely - The event is most likely related to aetiology other than the trial product
∀Final outcome 
∀Recovered/resolved - The patient has ful ly recovered or by [CONTACT_135548]-related activity 
after the patient signed the informed consent
∀Recovering/resolving - The condition is improving and the patient is expected to 
recover from the event. This term is only applicable if the patient has completed the trial 
or has died from another AE
∀Recovered/resolved with sequelae - The patient has recovered from the c ondition, but 
with lasting effect due to a disease, inj ury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE
∀Not recovered/not resolved - The condition of the patient has not improved and the 
symptoms are unchanged or the outcome is not known
∀Fatal - This term is only applicable if the pa tient died from a condition related to the 
reported AE. Outcomes of other reported AEs in a patient before he died should be 
assessed as “recovered/resolved”, “recovering/resolving”, “recovered/resolved with 
sequelae” or “not recovered/not resolved”. An AE with fatal outcome must be reported 
as an SAE
∀Unknown - This term is only applicable if the patient is lost to follow-up
12.1.2 Serious adverse event
A serious adverse event (SAE) is an experience that at any dose results in any of the following:
∀Death
∀A life-threateningaexperience
∀In-patient hospi[INVESTIGATOR_36220]
∀A persistent or significant disability or incapacityc
∀A congenital anomaly or birth defect
∀Important medical events that may not result in death, be life threateningaor require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement 
- they may jeopardise the patient and may require medical or surgical intervention to prevent 
one of the outcomes listed in the definition of SAEd
a.The term “life threatening” in the definition of SAE refers to an event in which the patient was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 91 of 136
b.The term “hospi[INVESTIGATOR_11956]” is used when a patient:
∀Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay or
∀Stays at the hospi[INVESTIGATOR_36223] [ADDRESS_932102] should be 
regarded as a hospi[INVESTIGATOR_11956]. Hospi[INVESTIGATOR_17957], trial related and social purposes do not constitute AEs and should therefore not be reported as AEs or SAEs. Hospi[INVESTIGATOR_41094], planned before trial inclusion, are not considered AEs or SAEs.
c.A substantial disruption of a patient’s ability to  conduct normal life functions (e.g. following the 
event or clinical investigation the patient has significant, persistent or permanent change, 
impairment, damage or disruption in his body function or structure, physical activity and/or quality of life).
d.For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not resu lt in hospi[INVESTIGATOR_36224].
The following adverse events must always be reported as an SAE using the important medical event 
criterion if no other seriousness criteria are applicable:
∀Suspi[INVESTIGATOR_36225]
∀Risk of liver injury defined as ALT or aspartate aminotransferase (AST) >3 x UNL and total 
bilirubin >2 x UNL, where no alternative aetiology exists (Hy's law).
12.1.3 Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.
12.1.4 Medicati on errors
A medication error concerning trial products is defined as:
∀Administration of wrong drug
Note: Use of wrong DUN is not considered a medication error unless it results in administration 
of wrong drug.
∀Wrong route of administration
∀Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product
∀Accidental administration of a lower or higher dose than intended. However, the 
administered dose must deviate from the intended dose to an extent where clinical 
consequences for the trial patient were likely to happen as judged by [CONTACT_093], although they did not necessarily occur3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932103] be reported on an AE form and a specific event form, see Section [IP_ADDRESS]
12.1.[ADDRESS_932104].
In this trial the following AEs require the co mpletion of specific event forms in the eCRF:
∀Injection site reaction, see Section [IP_ADDRESS]
∀Hypersensitivity type reactions, incl. anaphylactic reactions, see Section [IP_ADDRESS]
Injection site reactions: 
Any injection site reaction symptom must be recorded on the AE form and the injection site reaction form.
Hypersensitivity type reactions:
In cases where clinical signs of a severe and immediate hypersensitivity reaction resembling a type
I hypersensitivity reaction are present, blood should be sampled for central laboratory assessment of 
anti-drug IgE antibodies and anti-drug binding antibodies. In the event of an immediate systemic hypersensitivity reaction to the trial product, it is recommended to also test for tryptase (total and/or mature tryptase) within 3 hours of the reaction. Moreover, a baseline tryptase measurement is 
necessary ~1 week after the immediate severe hypersensitivity reaction due to individual to 
individual variation in tryptase baseline concentration. Tryptase concentrations (if measured) must be interpreted and considered in the context of a complete workup of each patient.
Special attention should be given to clinical signs and symptoms of hypersensitivity reactions of 
type II and III. Common clinical signs and symptoms characteristic for these type of reactions may 
include, but are not limited to: fever/malaise, cutaneous eruptions, arthralgia, lymphadenopat hy, 
itching, headaches and myalgia. Related laboratory findings may include, but are not limited to: mild proteinuria or haematuria, leukopenia or leucocytosis, decreased complement levels or 
increased complement split products and transient elevations of serum creatinine levels. In cases 
where there is a suspi[INVESTIGATOR_687591], additional 
sampling for the purpose of measuring ADA will be performed. 
Definition of anaphylaxis 
(25)
Anaphylaxis is highly likely when any one of the following 3 criteria is fulfilled:
∀Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal
tissue or both (e.g. generalised hives, pruritus or flushing, swollen lips-tongue-uvula) and at
least one of the following:
a) Respi[INVESTIGATOR_7798] (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced peak
expi[INVESTIGATOR_10229] [PEF], hypoxemia)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 93 of 136
b) Reduced blood pressure (BP) or associated symptoms of end-organ dysfunction (e.g.
hypotonia [collapse], syncope, incontinence)
∀Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for that
patient (minutes to several hours):
a) Involvement of the skin-mucosal tissue (e.g. generalised hives, itch-flush, swo llen 
lips-tongue-uvula)
b) Respi[INVESTIGATOR_7798] (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced PEF,
hypoxemia)
c) Reduced BP or associated symptoms (e.g. hypotonia [collapse], syncope, 
incontinence)
d) Persistent gastrointestinal symptoms (e.g. crampy abdominal pain, vomiting)
∀Reduced BP after exposure to known allergen for that patient (minutes to several hours):
Systolic BP of less than 90 mm Hg or greater than 30% decrease from that person’s baseline
BP.
If a patient fulfils any of the three criteria of anaphylaxis outlined above, the patient should receive 
epi[INVESTIGATOR_238]/adrenalin immediately. Dose regimen should be according to hospi[INVESTIGATOR_535116], and the patient should be transferred to an emergency department or intensive care unit, 
if clinically warranted.
Events not fulfilling the criteria for an anaphylactic reaction and other allergic reactions must be 
treated at the discretion of the treating physician. If according to the investigators judgement, 
hypersensitivity type reactions that require systemic treatment are suspected, dosing with 
concizumab should be stopped immediately and treatment at the discretion of the treating physician initiated.
12.1.[ADDRESS_932105] (AESI) is an event, which in the evaluation of safety, has a 
special focus. In this trial, the following AEs fulfil the AESI criteria:
∀Thromboembolic events including but not limited to,
odisseminated intravascular coagulation (DIC) (A),
oclinical signs or laboratory indications of arterial and venous thrombosis including 
myocardial infarction (B),
opulmonary embolism (C),
ostroke (D), 
odeep vein thrombosis (E),
oother clinically significant thromboembolic events (F) and peripheral artery 
occlusion (see below G), see definitions below
The AESIs must be reported on an AE form and a safety information form.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 94 of 136
A) Definition of disseminated intravascular coagulation (DIC), as defined below:
The definition of DIC in this trial should be  made according to the International Society on
Thrombosis and Haemostasis (ISTH) criteria. Thus, a DIC diagnosis may be based on clinical signs 
and symptoms of a bleeding tendency or thrombotic tendency, organ dysfunction and the laboratory 
parameters criteria as listed below:
∀Platelet coun t (>100 × 109/L = 0, <100 × 109/L = 1, <50 × 109/L = 2)
∀Elevated D-dimer (no increase = 0, moderate increase = 2, strong increase = 3)
∀Prolonged PT (<3 s = 0, >3 but <6 s = 1, >6 s = 2)
∀Fibrinogen level (>1 g/L = 0, <1 g/L = 1)
∀Calculate score: ≥5 compatible with overt DIC
B) Myocardial infarction is defined according to the “Third Universal Definition of
Myocardical Infarction” (26)
Criteria for acute myocardial infarction - The term acute myocardial infarction (MI) should be used 
when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial 
ischemia. Under these conditions any one of the following criteria meets the diagnosis for MI:
∀Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin
(cTn)] with at least one value above the 99th percentile upper reference limit (URL) and
with at least one of the following:
∀Symptoms of ischemia
∀New or presumed new significant ST-segment–T wave (ST–T) changes or new left
bundle branch block (LBBB)
∀Development of pathological Q waves in the ECG
∀Imaging evidence of new loss of viable my ocardium or new regional wall motion
abnormality
∀Identification of an intracoronary th rombus by [CONTACT_687638] - Any one of the following criteria meets the diagnosis for
prior MI:
∀Pathological Q waves with or without symptoms in the absence of non-ischemic causes.
Imaging evidence of a region of loss of viable myocardium that is thinned and fails to
contract, in the absence of a non-ischemic cause.
∀Pathological findings of a prior MI.
Recurrent myocardial infarction -Incident MI is defined as the individual’s first MI. When features 
of MI occur in the first 28 days after an incident event, this is not counted as a new event for 
epi[INVESTIGATOR_535117]. If characteristics of MI occur after 28 days following an incident MI, it is
considered to be a recurrent MI.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 95 of 136
C) Definition of pulmonary embolism:
The “Clinical Practice Guideline from the American Academy of Family Physicians and the
American College of Physicians” on diagnosis of venous thromboembolism recommends diagnostic
imaging studies for patients with intermediate or high pre-test probability of pulmonary embolism
(27).
Accordingly, the definition of pulmonary embolis m is the following: obstruction of a pulmonary 
artery or one of its branches, most frequently by [CONTACT_535246] a leg or pelvic vein, diagnosed by [CONTACT_37408]:
∀Positive findings in ventilation/perfusion scan
∀Positive findings in a spi[INVESTIGATOR_23585] (helical) computerised tomography (CT) or angiography
∀Positive findings in a magnetic resonance imaging (MRI)
∀Positive findings in a pulmonary angiography
D) Definition of stroke:
The definition of central nervous infarction is according to the American Heart
Association/American Stroke Association Expert Consensus Document:  “An Updated Definition of 
Stroke for the 21st Century” 
(28).
Accordingly, the term “stroke” should be broadly used to include all of the following:
Definition of central nervous system (CNS) infarction: CNS infarction is brain, spi[INVESTIGATOR_687592], based on:
o1. pathological, imaging or other objective evidence of cerebral, spi[INVESTIGATOR_687566] a defined vascular distribution or
o2. clinical evidence of cerebral, spi[INVESTIGATOR_1304] c ord or retinal focal ischemic injury based on
symptoms persisting 24 hours or until death, and other etiologies excluded
Note: CNS infarction includes haemorrhagic i nfarctions, types I and II; see “Haemorrhagic 
Infarction”.
Definition of ischemic stroke: An epi[INVESTIGATOR_535119],
spi[INVESTIGATOR_687568]. Note: Evidence of CNS infarction is defined above.
Definition of silent CNS infarction: Imagi ng or neuropathological evidence of CNS infarction,
without a history of acute neurological dysfunction attributable to the lesion.
Definition of intracerebral haemorrhage: A focal collection of blood within the brain parenchyma or
ventricular system that is not caused by [CONTACT_278066]. Note: Intracerebral haemorrhage includes
parenchymal haemorrhages after CNS infarction, types I and II - see “Haemorrhagic Infarction”).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 96 of 136
Definition of stroke caused by [CONTACT_535247]: Rapi[INVESTIGATOR_535157] a focal co llection of bl ood within the brain parenchyma or
ventricular system that is not caused by [CONTACT_278066].
Definition of silent cerebral haemorrhage: A focal collection of chronic blood products within the
brain parenchyma, subarachnoid space or ventricular system on neuroimaging or neuropathological
examination that is not caused by [CONTACT_535248] a history of acute neurological dysfunctionattributable to the lesion.
Definition of subarachnoid haemorrhage: Bleeding into the subarachnoid space (the space between
the arachnoid membrane and the pia mater of the brain or spi[INVESTIGATOR_1831]).
Definition of stroke caused by [CONTACT_535249]: Rapi[INVESTIGATOR_535121]/or headache because of bleeding into the subarachnoid space (thespace between the arachnoid membrane and the pia mater of the brain or spi[INVESTIGATOR_1831]), which is not
caused by [CONTACT_278066].
Definition of stroke caused by [CONTACT_535250]: Infarction or haemorrhage in the brain,
spi[INVESTIGATOR_687569] a cerebral venous structure. Symptoms or signscaused by [CONTACT_535276].
Definition of stroke, not otherwise specified: An epi[INVESTIGATOR_535122], persisting ≥24 hours or until death, but 
without sufficient evidence to be classified as one of the above.
Definition of a Transient Ischemic Attack: The definition of Transient Ischemic Attack is according
to the American Heart Association/American  Stroke Association. A Transient ischemic attack 
(TIA) is a transient epi[INVESTIGATOR_535123], spi[INVESTIGATOR_1304] c ord or r etinal 
ischemia, without acute infarction 
(29).
E) Definition of deep vein thrombosis:
The “Clinical Practice Guideline from the American Academy of Family Physicians and the
American College of Physicians” on diagnosis of venous thromboembolism recommends
ultrasound scanning for patients with intermediate or high pre-test probability of DVT in the lowerextremities
27. Accordingly, venous thrombosis should be demonstrated by [CONTACT_49734],
duplex ultrasound, colour Doppler imag ing or venography (phlebography).
F) Definition of other clinically significant thromboembolic events:
Signs or suspi[INVESTIGATOR_1884] a clinically significant thromboembolic event (e.g. visceral arterial 
embolus/thrombus, extremity arterial embolus/t hrombus or portal venous thrombosis). Superficial 
thrombophlebitis is not consider ed a clinically significant thromboembolic event unless evaluated 
as such by [CONTACT_093].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 97 of 136
G) Definition of peripheral artery occlusion:
Clinical signs of acute arterial occlusion verified by [CONTACT_535252]-brachial index (ABI) test, Doppler and
ultrasound (Duplex) imaging, computerised tomographic angiography, MRA or conventionalangiography. The 2011 American College of Ca rdiology Foundation/American Heart Association
Focused Update of the Guideline for the Management of Patients with Peripheral Artery Disease
could serve as a reference for the diagnosis of lower extremity peripheral artery disease 
(30).
12.1.[ADDRESS_932106] 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of techni cal complaints:
∀The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
∀All packaging material including labelling
∀Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)
12.[ADDRESS_932107]-treatment follow-up period (visit 17). The even ts must be recorded in the applicable eCRF 
forms in a timely manner, see timelines below and Figure 12–[ADDRESS_932108] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: “Have you e xperienced any problems since the last contact?”
All AEs, either observed by [CONTACT_687649], must be reported by [CONTACT_36306]. All AEs must be recorded by [CONTACT_687650]. The investigator should 
report the diagnosis, if available. If no diagnosis is available, the investigator should record each 
sign and symptom as individual AEs using separate AE forms.  
For SAEs, a safety information form must be completed in addition to the AE form. If several 
symptoms or diagnoses occur as part of the same clinical pi[INVESTIGATOR_1103], one safety information form can be used to describe all the SAEs.
AESIs regardless of the seriousness must be reported using the AE form and safety information 
form.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932109].
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the CRF/eCRF within the specified 
timelines:
∀SAEs: The AE form within 24 hours and the safety information form within 5 calendar
days of the investigator’s first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered in the 
eCRF.
For SAEs requiring reporting on a specific event form : In addition to the above the specific 
event form within 14 calendar days from the investigator’s first knowledge of the AE.
∀Non-serious AEs fulfilling the AESI criteria: The AE form and safety information form
within 14 calendar days of the investigator’s first knowledge of the event.
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by [CONTACT_6791], e-mail or courier within the same timelines as stated above. When the eCRF becomes available again, the investigator must enter the information on the form into the 
eCRF.
Contact [CONTACT_8972] (fax, telephone, e-mail and address) ar e provided in the investigator trial master file.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 99 of 136
Figure 12–1 Reporting of AEs
Novo Nordisk assessment of AE expectedness:
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents: Investigator’s Brochure; current version and any updates thereto.
When eptacog alfa (rFVIIa), NovoSeven®is used as IMP, expectedness should be performed 
according to the Company Core Data Sheet (CCDS).
Reporting of trial product-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and ICH GCP1. In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial procedure.
In accordance with regulatory requirements, Novo N ordisk will inform the re gulatory authorities, 
including EMA, of trial product-related S[LOCATION_003]Rs. In addition, Novo Nordisk will inform the
IRBs/IECs of trial product-related S[LOCATION_003]Rs in accorda nce with local requirement and ICH GCP1, 
unless locally this is an obligation of the investigator.
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932110]:
If an AE is considered to have a causal relationship with a Novo Nordisk marketed product used as 
non-investigational medicinal product (eptacog alfa (rFVIIa)) or concomitant medication in the 
trial, it is important that the suspected relationship is reported to Novo Nordisk, e.g. in the 
alternative aetiology section on the safety infor mation form. N ovo Nordisk may need to report this 
adverse event to relevant regulatory authorities.
12.[ADDRESS_932111] be reported to Novo Nordisk according to the following:
∀SAEs: All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. 
Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the outcome “recovering/resolving” or “not recovered/not 
resolved”. Cases can be closed with the outcome of “recovering/resolving” when the patient
has completed the follow-up period and is expected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator’s first knowledge of the 
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs.
∀Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until 
the end of the follow-up period s tated in the protocol, whichever comes first, and until all 
queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs 
ongoing at time of death (where death is due to another AE) may be closed with the 
outcome “recovering/resolving” or “not recovered/not resolved”. Cases can be closed with the outcome of “recovering/resolving” when the patient has completed the follow-up period and is expected by [CONTACT_36308].
∀Non-serious AEs fulfilling the AESI criteria: Non-serious AE fulfilling the AESI criteria 
must be followed as specified for non-seri ous AEs. Follow-up information on AESIs should 
only include new (e.g. corrections or additi onal) information and must be reported within 14 
calendar days of the investigator’s first knowledge of the information. This is also the case 
for previously reported non-serious AEs which  subsequently fulfil the AESI criteria.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932112] be reported as follow up with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_932113].
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the investigational medicinal product occurring to a patient after the patient has 
ended the trial, the investigator should report this SAE within the same timelines as for SAEs 
during the trial.
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of tec hnical complaints
All technical co mplaints on any of the following products: 
∀Concizumab B 100 mg/mL, solution for injection in a 3 mL cartridge
∀NovoPen
®4
∀Novo Nordisk needles
∀Eptacog alfa (rFVIIa) 5 mg/vial, powder for solution for in jection in  a vial
∀Histidine 5 mL, solvent for solution for injection in a prefilled syringe
∀Novo Nordisk trial injection kit
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Centre, Novo Nordisk.
Contact [CONTACT_8972] (fax, e-mail and address) are provided in Attachment I to the protocol.The investigator must assess whether the technical complaint is related to any AEs, AESI and/or 
SAEs.
Technical complaints must be reported on a separate technical complaint form:
∀One technical complaint form must be completed for each affected DUN 
∀If DUN is not available, a technical complaint form for each batch, code or lot number must 
be completed
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
∀Technical complaint assessed as related to an SAE within 24 hours
∀All other technical complaints within 5 calendar days3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932114] coordinate the shipment to 
Customer Complaint Centre, Novo Nordisk (the addr ess is provided in Att achment I) and ensure 
that the sample is sent as soon as possible. A copy of the technical complaint form must be included in the shipment of the sample. If several samples are returned in one shipment, the individual sample and the corresponding technical complaint form must be clearly separated.
The investigator must ensure that the technical complaint sample contains the batch, code or lot 
number and, if available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical
complaint form why it is unobtainable.
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product.
12.[ADDRESS_932115] be instructed to notify the investigator if their female partner becomes pregnant 
during the trial, except in the screening period (from visit 1 to dosing with concizumab at visit 2 or 
visit 9 depending on the arm). At the last scheduled visit (visit 17), male patients must be asked if 
their female partner has become pregnant.
If a female partner has become pregnant during the trial, the investigator must follow-up on the 
pregnancy outcome and until the newborn infant is one month of age, irrespective of whether the 
trial is completed or not. The investigator must ask the male patient and assess if the pregnancy outcome is normal or abnormal.
When the pregnancy outcome is normal this information is recorded in the patient’s medical record 
only, no further information is collected and reported to Novo Nordisk. When the pregnancy 
outcome is abnormal (i.e. congenital anomalies, foetal death including spontaneous abortion and/or 
any anomalies of the foetus observed at gross examination or during autopsy), the following must be reported by [CONTACT_687651] N ordisk electronically (e.g. in PDF format) or by [CONTACT_6791].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 103 of 136
1. Reporting of pregnancy information
Information from the male patient has to be reported on the Paternal Form. Furthermore, 
information from the female partner (including information about the pregnancy outcome and health s tatus of the infant until the age of one month) has to be reported on the Maternal Forms 
1A, 1B and 2, after an informed consent has been obtained from the female partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator’s first knowledge of initial or follow-up information.
2. Reporting of AE information
The following AEs in the foetus and newborn infant have to be reported:
oNon-serious AEs evaluated as possible/probably related to the father’s treatment 
with the trial product(s)
oSAEs in the foetus and newborn infant - whether or not related to the father’s 
treatment with the trial product(s). This  includes an abnormal outcome - such as 
foetal death (including spontaneous abortion) and congenital anomalies (including those observed at gross examination or during autopsy of the foetus)
Forms and timelines for reporting AEs:
Non-serious AEs: 
∀Paper AE formawithin 14 calendar days of the investigator’s first knowledge of the init ial 
or follow-up information to the non-serious AE
SAEs: 
∀Paper AE formawithin 24 hours of the investigator’s first knowledge of the SAE
∀Paper safety information form within 5 calendar days of the investigator’s first knowledge 
of the SAE
∀SAE follow-up information to the AE form and/or sa fety information form within 24 
hours of the investigator’s first knowledge of the follow-up information
aIt must be clearly stated in the AE diagnosis f ield on the AE form if the event occurred in the 
patient, foetus or newborn infant.
Any queries or follow-up requests from Novo Nordisk  to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_932116].
12.6 Precautions and/or overdose
Dose limiting toxicities of concizumab have not been investigated in clinical trials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932117] be submitted to the 
regulatory authori ties to support restart of the trial.
∀Significant thromboembolic event
*
∀Event of DIC
∀Anaphylactic reaction related to trial drug administration
∀Death of trial patient which may be related to the trial product
∀Two or more other trial product related SAEs s imilar in nature have been reported and/or 
detected by [CONTACT_66969]
∀Trends in AEs, clinical observations or laborat ory parameters which raise concerns about 
the safety of continued treatment.
*Superficial thrombophlebitis or venous thrombosis associated with indwelling catheters is not considered a significant 
thromboembolic event unless evaluated as such by [CONTACT_535253]/or detected 
by [CONTACT_66969], or if trends in AE s, clinical observations or laboratory parameters 
raise concerns about the safety of conti nued treatment, the safety committee (see Section 12.8.1 )
will d ecide if further dosing of any patients in the clinical trial programme s hould be c ontinued, 
paused or discontinued.
12.8 Committees related to safety
12.8.1 Novo Nordisk safety committee
Novo Nordisk has constituted an internal con cizumab safety committee to perform ongoing safety 
surveillance of safety data relevant to concizumab. The safety commit tee is a cross functional group 
within Novo Nordisk.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932118] interaction with those in trial management. The DMC recommendations should be a ddressed directly to the Novo Nordisk Global 
Safety department and the internal Novo Nordisk safety committee for concizumab. It is the 
responsibility of the Novo Nordisk internal safety committee for concizumab to take action(s) forpatient safety based on the DMC recommendations.
Information regardi ng responsibilities, procedures and workflow to be used by [CONTACT_215575].
13 Case report forms
For this trial a combination of electronic case report forms (eCRFs) and paper CRFs will be used.
Novo Nordisk will provide a system for the electronic case report forms (eCRF). This system and 
support services to the system will be provided by [CONTACT_215576].
Ensure that all relevant questions are answered, and that no empty data field exists. If a test or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not applicable), indicate this according to the data entry instructions.
The following will be provided as paper CRFs:
∀Pregnancy forms
∀Technical complaint forms
∀AE forms
∀Safety information forms
The paper version of the technical complaint form, AE form, and safety information form must only 
be used to ensure timely reporting when/if the electronic CRF is unavailable.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932119]/assessment has not been done and will not be  available, indic ate this by [CONTACT_565] “ND” (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 
indicate this by [CONTACT_565] “NA” (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all information is consistent with the source documentation. By 
[CONTACT_535278] e case book in the eCRF, the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.[ADDRESS_932120] igator’s delegated staff. 
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identif ication of the pe rson entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]’s delegated  staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].
13.[ADDRESS_932121] ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for data verification and validation purposes.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
13.[ADDRESS_932122] ronic recordi ng of det ails of their 
home treatment, bleeding epi[INVESTIGATOR_535124] (i.e. use of eptacog alfa 
(rFVIIa)).The eDiary and related support services will be supplied by a vendor working under the direction 
and supervision of Novo Nordisk.
Patients will be instructed in the use of the eD iary by [CONTACT_535254]. The eDiary will be dispen sed to the patient at visit 2. After visit 2 and 
onwards, data will be entered by [CONTACT_535255].
The eDiary will be returned by [CONTACT_687639].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932123] the number of v ials/cartridge accounted for as used by [CONTACT_102]. 
Upon review the Investigator must document that the review has taken place and any actions required e.g. retraining of the patient or decision to amend or correct the data reported by [CONTACT_102].
If the Investigator finds it necessary to amend or correct eDiary data, the patient must be consulted 
prior to requesting the actual data change. A Data Request Correction (DRC) must be submitted to the eDiary vendor. An audit trail will be maintained.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932124] 6 patients 
recruited in the trial. The monitoring visit in tervals will depend on the outcome of the centralised 
monitoring of the eCRFs (remote assessment of data by [CONTACT_3454]), the trial site's recruitment 
rate and the compliance of the trial site to the protocol and GCP, but will not exceed 12 weeks until LPLV at the trial site. This only applies to sites with scheduled, ongoing and/or discontinued patients.
The monitor must be given direct access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are important to the evaluation of the trial. If the electronic medical record does not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site st aff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by [CONTACT_535258]).
All data must be verifiable in source documentation other than the eCRF. eDiary data is entered by 
[CONTACT_535259].
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must onl y be one source defined at any time for any data element.
For historical data such as medical history , details of haemophilia a nd haemophilia treatment 
history, a reasonable effort must be made by [CONTACT_093], considering local requirements, to 
obtain this information from external sources, if not  known by [CONTACT_102]. It is accepted that the 
earliest practically retainable record should be considered as the location of the source data and therefore the source document. This means th at for laboratory results (e.g. biochemistry and 
haematology) a signed printout of the electronic results must be available.
Source data generated by [CONTACT_535292] c orrected by [CONTACT_535293]; an y correction must be explained, signed and dated 
by [CONTACT_36324].
The monitor will ensure that the eCRFs are completed and paper CRFs (if any) collected, that 
ePROs and eDiaries are completed and reviewed by [CONTACT_687640], if any.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 109 of 136
The following data will be source data verified for screening failures:
∀Date for obtaining informed consent
∀Inclusion and exclusion criteria
∀Screen failure reason if possible
∀Date patient left the trial
∀Data relating to AEs if applicable
∀Demography, see section 8.2.1
∀Date of visit
Monitors will review the patient’s medical rec ords and other source data (e.g. the eDiaries and 
ePROs) to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are found, the investigator must be questioned about these.
A follow-up letter (paper or electronic) will be se nt to the investigator following each monitoring 
visit. This should address any action to be taken.
[ADDRESS_932125] the identity of patients in all presentations and publications as required by [CONTACT_5737], regional and national requirements.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932126] Operating Procedures and IT architecture documentation. The use and control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.
Novo Nordisk will use the Global Haemophilia Network Investigator Portal to distribute and share
trial-related documents and information with the pa rticipating sites. After trial completion, Novo 
Nordisk will supply each trial site with long-life CDs or other relevant archiving containing the 
electronic Investigat or Trial Master File (eITMF) for each tr ial site. These CDs or other relevant 
archiving will contain site-specific trial documen tation as  well as trial specific news and other 
relevant trial information, including audit trail on documents and site staff users. The GHN Portal software and hardware implementation are compliant with the requirements of FDA 21 CFR Part 11 
and ICH E6 (EU directive for personal data protection).
1, 31
Novo Nordisk will provide electronic tablets for reporting of all PROs questionnaires described in 
section 8.6.1 and in Appendix 1. In case the electronic tablet is revoked the questionnaires will be 
available in paper.
The eDiary and ePRO software and hardware implementation are compliant with the requirements 
of FDA 21 CFR Part 11 and ICH E6 (EU directive for personal data protection).1,31After trial 
completion, each trial site will be supplied with long-life CDs. These CDs will contain site-specific patient records including the patient ’s eDiaries and audit trail including any data additions and 
corrections made on each form. The eDiary vendor will furthermore retain and securely store copi[INVESTIGATOR_687593] 15 years or as required by [CONTACT_56325].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932127] patient has completed a minimum of 24 weeks of treatment or at LPFT (visit 2) + [ADDRESS_932128] patient has withdrawn before visit 9. Please refer to Figure 
17–1 for further information. 
Data from when the on-demand treated patients are transferred to concizumab s.c. prophylaxis will 
not be included in this evaluation. Observations from the extension part in the on-demand arm will be summarised separately as well as combined w ith observations from the main part when reporting 
the extension part data.
Endpoints comprising number of bleeding epi[INVESTIGATOR_535125]. Multiple bleeding locations occurring from the same event (e.g., due to a bicycle accident) or at the same time point will be counted as one bleeding epi[INVESTIGATOR_1865]. Further, the endpoints 
will not include re-bleed. A re-bleed is defined as a bleeding epi[INVESTIGATOR_1865] (worsening of bleeding site 
conditions e.g. swelling, pain) within 72 hours after stoppi[INVESTIGATOR_31081] a previous bleeding epi[INVESTIGATOR_535126] (or subset of the same) anatomical location. If a bleeding epi[INVESTIGATOR_535127] [ADDRESS_932129] of the 24 patients has completed 24 weeks of dosing (or has withdrawn 
before that).
Two criteria will be evaluated in a hierarchical fashion in support of CPoC comprising a 
comparison of the ABR of all patients in the concizumab group, irrespective of individual dose titration, with the ABR of the patients in the on -demand arm using different sets of observations. 
The primary CPoC criterion aims at evaluating the effect of concizumab when given at the last dose 
level reached for the patient. Hence, for this ev aluation, only observations from the period where 
patients are on their end dose at time of analysis will contribute to the analysis. Furthermore, observations from the [ADDRESS_932130] one succeeds.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 112 of 136
The referred comparisons will be made using a negative binomial model with log of exposure time 
in main part as offset and regimen as factor (concizumab vs. on-demand). For each criterion, evidence of effect will be concluded if the 95% confidence interval of the treatment ratio is below 1.
Clinical arguments for the hierarchical test approach
Concizumab exhibits non-linear PK due to target mediated drug disposition and it is expected that 
the dose response curve of the ABR is rather steep. This implies that patients that are on a dose which is not efficacious are likely to bleed as patients that are not treated at all. Subset of data collected from the last dose clinically deemed as efficacious would reflect the efficacy of 
concizumab in the given patient.
17.1 Sample size calculation
The estimand will be defined as the “if  all patients had adhered” estimand.
The treatment ratio between prophylactic s.c. concizumab and on-demand i.v. eptacog alfa (rFVIIa)
during at least 24 weeks for all randomised patients if all patients a dhered to trial drug and did not 
initiate alternative treatment options.
This estimand is a de jure estimand assessing the expected added benefit a patient can achieve if 
continuing treatment with prophylactic s.c. concizumab  as compared to on-demand i.v. eptacog alfa 
(rFVIIa) under similar conditions as observed in this trial.
The sample size calculation has been determined based on this estimand and the CPoC criteria 
taking the small patient population into account, while also aiming for an acceptably narrow 95% 
confidence interval for the rate ratio.
Sufficient inference on bleeding epi[INVESTIGATOR_687573] 16 patients in the concizumab ar m and 8 in the comparator arm. It is expected 
that the treatment duration of the main part allowing for escalation time for some patients is on average 6 months in the below calculations.
When evaluating the power of the negative bino mial analysis refe rred above, annual bleeding rates 
of 24 and 6 are assumed for the on-demand patients and the end dose concizumab regimen, 
respectively. Assuming further over-dispersion of 7, the power for concluding superiority of the concizumab regimen becomes approximately 80%. Th e power under varying values of true ABR 
and over-dispersion for the primary CPoC criterion are shown below in Table 17–1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 113 of 136
Table 17–1Power in superiority comparison between concizumab prophylaxis and on-demand 
treatment under different assumptions of ABR for concizumab and over-
dispersion (assuming on-demand ABR=24).
Power Over-dispersion (over 6 months)
ABR (concizumab) 6 7 8
6 89% 82% 75%
7 84% 75% 70%
8 77% 69% 66%
For the secondary CPoC criterion that includes data prior to potential dose escalation, it is expected 
that the treatment duration of the main part is on average 8 months with an average ABR of 7.6 for the concizumab regimen. This yields a marginal power of approximately 70% for the secondary CPoC criterion.
In prior Novo Nordisk trials conducted in haemophilia patients, the typi[INVESTIGATOR_2855] 1-year over-dispersion 
for non-inhibitor patients on prophylaxis with FVIII or FIX has been in the range 4-8, implying 24 weeks over-dispersion of 3-5 (e.g. in NN7008-3543, NN7088-3859 a nd NN7999-3747). In the 
NN7128-1907 trial in inhibitor patients, larger 1-year over-dispersion values of approximately 21 
and 18, respectively, were observed during an initial  3-month on-demand period and a subsequent 
3-month prophylaxis period. It is expected that the va riation in the current trial will be smaller, 
partly due to the longer duration of the trial and partly due to an expected more homogenous patient 
population. Another pub lished trial including inhibitor patients, comparing prophylaxis using 
FEIBA
®with on-demand treatment, showed 6-month over-dispersion of 4-532. On that background, 
an over-dispersion of 7 over the 24 weeks in main part of the current trial is deemed realistic.
17.2 Definition of analysis sets
All dosed patients will be included in the Full Analysis Set (FAS) as well as in Safety Analysis Set 
(SAS).
17.[ADDRESS_932131] 24 weeks from treatment 
onset.
The endpoint will be analysed when the main part of trial has been completed.
17.3.1 Estimand and primary statistical analysis
The estimand for the primary endpoint is the “if all patients had adhered” estimand.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 114 of 136
The treatment ratio between prophylaxis s.c. concizumab and on-demand i.v. eptacog alfa (rFVIIa)
during at least 24 weeks for all randomised patients if all patients a dhered to trial drug and did not 
initiate alternative treatment options.
This estimand is a de jure estimand assessing th e expected added benefit a patient can achieve if 
continuing treatment with prophylactic s.c. concizumab as compared to on-demand i.v. eptacog alfa 
(rFVIIa) under similar conditions as observed in this trial.
The estimand for the primary endpoint will be estimated using negative binomial regression with 
log of exposure time in main part as offset and regimen as factor, providing an estimate of the ABR 
ratio between regimens (concizumab prophylactic and on-demand eptacog alfa (rFVIIa)) with 
corresponding 95% confidence interval and also actual estimate of the ABR with corresponding 95% confidence interval for each regimen. This analysis has the underlying assumption that the missing data mechanism is “missing at random”, i.e. MAR. Under this assumption, the statist ical 
behaviour of the missing data (given the observed res ponses and the mean value structure) is 
assumed to be the same as for the observed d ata. The estimand will be estimated based on the FAS
and only data collected prior to discontinuation of tr ial product or initiation of alternative treatment 
options will be used to draw inference.
17.3.[ADDRESS_932132] a worse outcome compared to what was observed during the main part of the trial. This will be done by [CONTACT_1583] a value Δto the observed bleeding epi[INVESTIGATOR_687574]. The offset is maintained as being the exposure 
during the main part since it is not possible to identify the amount of missing observation t ime. The 
degree of worsening, Δ
i,will gradually be increased to evaluate at which point concizumab 
prophylaxis no longer is superior to on-demand eptacog alfa (rFVIIa). The results of the primary 
analysis will be considered robust if the tippi[INVESTIGATOR_687575].
17.3.3 Additional analysis
An additional evaluation of the primary endpoint will be made, including actual concizumab dose 
level as additional factor in the primary analy sis model specified above. Point estimates and 95% 
confidence interval will be provided for the ABR at the different dose levels of concizumab (0.15, 
0.20 and 0.25 mg/kg). Furthermore, an analysis with individual steady state PK/PD assessments included as covariates in the negative binomial regression model as specified for the primary 
analysis of number of bleeding epi[INVESTIGATOR_687576]/PD and ABR that potentially could guide dose-selection. The referred steady-state PK/PD assessments comprise the concizumab trough level, TFPI [INVESTIGATOR_535160] s.c. dose 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 115 of 136
administration, peak thrombin generation (nM), Endogenous thrombin potential (nMxmin) and 
velocity index (nM/min).
17.4 Supportive secondary endpoints
17.4.1 Supportive secondary efficacy endpoints
∀The number of bleeding epi[INVESTIGATOR_51953] 76 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_51953] [ADDRESS_932133] 24 weeks from treatment onset w ill be 
addressed in terms of the same estimand as for the primary endpoint. The estimand will be 
estimated using the same negative binomial regression model as for the primary endpoint.
Furthermore, an additional evaluation will be made,  where actual concizumab dose is included as 
factors in the model.
The remaining supportive secondary efficacy endpoints will be summarised descriptively by 
[CONTACT_71397]. In addition, number of bleeding epi[INVESTIGATOR_51953] 76 weeks of treatment with 
prophylactic concizumab will be analysed using a negative binomial model with log of trial duration as offset, providing estimates of the ABR with confidence interval for that particular regimen.
17.4.2 Supportive secondary safety endpoints
∀Number of TEAEs during at least 24 weeks from treatment onset
∀Number of TEAEs during 76 weeks from treatment onset
∀Number of TEAEs within 24 hours of rFVIIa administration
∀Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset
∀Occurrence rate of  anti-concizumab antibodies during 76 weeks from treatment onset
∀Change from baseline of fibrinogen during 24 weeks from treatment onset
∀Change from baseline of fibrinogen during 76 weeks from treatment onset
∀Change from baseline of D-dimer  during 24 weeks from treatment onset
∀Change from baseline of D-dimer during 76 weeks from treatment onset
∀Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
∀Change from baseline of F1 + 2 during 76 weeks from treatment onset
∀Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
∀Change from baseline of PT during 76 weeks from treatment onset
∀Change from baseline of activated partial thromboplastin time (APTT) during 24 weeks 
from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 116 of 136
∀Change from baseline of APTT during 76 weeks from treatment onset
∀Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
∀Change from baseline of AT [ADDRESS_932134] recent version of Medical Dictionary for Regulatory 
Activities (MedDRA) coding.
TEAE is defined as an event that has onset from the first exposure to treatment until the last visit in 
the trial. Treatment-emergent adve rse event endpoints will be summarised by [CONTACT_9313], 
preferred term, seriousness, severity and relation to trial product. All adverse events will further be listed.
Frequency of binding anti-concizumab antibodies will by [CONTACT_535280] t ime frame 
according to the two endpoint definitions.
All laboratory safety  endpoints will be plotted by [CONTACT_5586], both as absolute values and change from 
baseline. Laboratory safe ty endpoints will further be summarised and listed.
17.4.3 Supportive secondary pharmacokinetic endpoints
∀Concentration of concizumab prior to the last dose administration at 24 weeks
∀Concentration of concizumab prior to the last dose administration at 76 weeks
The pharmacokinetic endpoints will be summarised and listed.
17.4.4 Supportive secondary pha rmacodynamic endpoints
∀Free TFPI [INVESTIGATOR_687515] [ADDRESS_932135] dose administration at 76 weeks
∀Thrombin generation
oPeak thrombin generation (nM) prior to the last dose administration at 24 weeks
oPeak thrombin generation (nM) prior to the last dose administration at 76 weeks
oEndogenous thrombin potential (nM
xmin) prior to the last dose administration at 24 
weeks
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 76
oVelocity index (nM/min) prior to the last dose administration at 24 weeks
oVelocity index (nM/min) prior to the last dose administration at 76 weeks
The PD endpoints will be summarized and listed.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 117 of 136
17.4.5 Exploratory endpoints
[IP_ADDRESS] Exploratory safety endpoints
∀Number of adverse events related to technical complaints during at least 24 weeks from 
treatment onset
∀Number of adverse events related to technical complaints during at least 76 weeks from 
treatment onset
Adverse events related to technical complaints will be listed and summarised
[IP_ADDRESS] Exploratory patient reported-outcome endpoints
∀Change in Hemo-TEM after 24 weeks from treatment onset
∀Change in Hemo-TEM after 76 weeks from treatment onset
∀Change in VERITAS-PRN®after 24 weeks from treatment onset
∀Change in VERITAS-PRN®after 76 weeks from treatment onset
∀Change in SF-36v2 after 24 weeks from treatment onset
∀Change in SF-36v2 after 76 weeks from treatment onset
∀Change in SDS after 24 weeks from treatment onset
∀Change in SDS after 76 weeks from treatment onset
∀Change in TSQM after 24 weeks from treatment onset
∀Change in TSQM after 76 weeks from treatment onset
∀Change in SIAQ-ISRQ after 24 weeks from treatment onset
∀Change in SIAQ-ISRQ after 76 weeks from treatment onset
∀Change in PGI-C after 24 weeks from treatment onset
∀Change in PGI-C after 76 weeks from treatment onset
VERITAS-PRN®, SF-36v2, SDS and TSQM will be scored according to their respective scoring 
algorithms. Change from visit 2 to visit 9 will be analysed with an ANCOVA model including 
regimen as a factor and baseline score as covariate.
The PRO endpoints will be summarised using descriptive statistics and the remaining 
questionnaires (Hemo-TEM, PGI-C, SIAQ-ISRQ) will be summarised and listed using descriptive statistics.
17.[ADDRESS_932136] patient has completed a minimum of 24 weeks of treatment or at LPFT (visit 2) + [ADDRESS_932137] patient has withdrawn before visit 9. Other reporting of the trial
might be done during the extension part once the data collection and review of the main part data 
has been finalised and individual CTRs might in such case be issued. A CTR describing results 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932138] patient has either completed or 
withdrawn from the trial. All main conclusions regarding clinical proof of concept and dose guidance for phase 3 will be based on the reporting after the main part, see Figure 17–1 .
Figure 17–1 Definition of main and extension part
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 119 of 136
18 Ethics
18.1 Benefit-risk assessment of the trial
Benefits
Results from a multiple dose phase 1 trial where concizumab was dosed for approximately 6 weeks 
showed a trend towards efficacy in a limited number of patients who reached concizumab plasma concentrations above 100 ng/mL, see Section 3.1.2 . Based on these results, it is expected that the 
majority of the patients randomised to the co ncizumab treatment with 0.15 mg/kg daily dose will be 
protected from bleeding epi[INVESTIGATOR_1841].  Patients who experience excessive bleeding epi[INVESTIGATOR_535161] a possibility to be escalated to a higher dose where bleeding preventiveefficacy of concizumab treatment is expected to improve. For haemophilia patients with inhibitors 
and who are treated on-demand, expected improved efficacy is considered to be a major benefit in 
participating in this trial. Also, concizumab is administered s.c. and might reduce the burden of frequent i.v. injections associated with current treatment options in haemophilia patients with inhibitors.
Information gained from this trial will contribute to gaining regulatory approval for a product that is 
anticipated to offer clinical advan tages over currently available products.
Risks
No risks have been recognised as identified risks by [CONTACT_535263]. However, the nonclin ical toxicity studies have identified 
thromboembolic events as a potential risk when treating non-human primates with concizumab at high exposures.
As observed for other pro-coagulant compounds, there is a potential safety risk of thrombosis and 
vascular ischemia with reaching very high concizumab plasma concentrations. In non-clinical 
toxicity studies with concizumab, thrombi were observed at high doses. However, a no observed 
adverse effect level ( NOAEL) for concizumab has been identified in non-haemophilic animals at 
plasma concentrations several folds higher than the currently anticipated effective plasma 
concentration (mean area under curve [AUC] and C
max) based on PK modelling.
In a drug–drug interaction study in monkeys, three doses of up to 1 mg/kg of NovoSeven®were 
administered at 2-h intervals, alone or in th e presence of a steady state concentration of 
concizumab. Increased concentrations of thrombin–anti-thrombin (TAT) and D-dimer were seen, 
which tended to be additive when both concizumab and eptacog alfa (rFVIIa) were present in 
circulation. No notable clinical observations were made.
In clinical trials, except for one case of superficial thrombophlebitis in a healthy volunteer who 
received a single dose of 1mg/kg, no other thromboembo lic events were observed. A phase 13URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 120 of 136
multiple dose trial was finalised in haemophilia  A patients (0.8 mg/kg s.c. every 4 days for 6 
weeks). In this clinical trial, marked changes in coagulation parameters were observed including a decrease from baseline in fibrinogen and a pronounced increase in D-dimer and F1+2 outside of normal range in patients with high plasma concentrations of concizumab. These changes were not 
judged as clinically significant by [CONTACT_535281][INVESTIGATOR_535134]™[ADDRESS_932139] not been observed so far in clinical trials. Furthermore, even if antibodies towards concizumab occur, the risk for the rate of immune complex formation exceeding the clearance capacity is considered low. Please refer to the Investigator’s Brochure for further information.
If antibodies against concizumab develop, they might also inhibit the function of the administered 
drug. The consequence of this could be that the patient may not be able to benefit from the drug in 
the future. Antibody development against concizumab is not expected to reduce the effect of other treatment options.
Theoretical risks include bleeding due to consumption of coagulation factors and adverse reactions 
due to potentiation of inflammatory reactions or ti ssue damage due to impairment of tissue repair 
mechanisms
33 34. TFPI [INVESTIGATOR_687594] h, in addition to its role in haemostasis, 
is implicated in tissue repair processes and in a variety of physiological  and pathophysiological 
states where repair mechanisms are activated. These include sepsis, DIC, inflammation, 
atherosclerosis, cancer and crush injuries35 36, 37.
There may be a risk of allergic reactions, including severe (anaphylactic) reactions, in connection 
with concizumab administration. Severe allergic reactions may potentially be life-threatening and thus, the trial products will be administered to the trial patients at the site under the surveillance of 
medically trained trial site staff in the beginning of the trial.
Overall the anticipated benefits from participating in the trial outweigh the potential risks.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932140] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki2.
Before any trial-related activity, the investigat or must give the patient verbal and written 
information about the trial and the procedures involved in a form that the patient can read and understand.
The patients must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.
The investigator must ensure the patient ample time to come to a decision whether or not to 
participate in the trial.
A voluntary, signed and personally dated informed consent must be obtained from the patient 
before any trial-related activity.
The responsibility for seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically  qualified person, in accordance with local 
requirements. The written informed consent must be  signed and personally dated by [CONTACT_135562]-related activity.
If information becomes available that may be releva nt to the patient’s willingness to continue 
participating in the trial, the investigator must inform the patient in a timely manner, and a revised
written patient information must be provided a nd a new informed consent must be obtained.
Only applicable for Japan: As a minor is unable to provide legally binding consent, informed 
consent must be sought from the parent(s)/LAR(s) on the child’s behalf prior to enrolling a child in 
the trial, according to local requirements.
18.[ADDRESS_932141] to  follow up, then the patient’s data will be handled 
as follows:
∀Data already collected and any data collected at the end-of-trial visit will be retained by 
[CONTACT_3454], entered into the database and used for the CTR.
∀Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used it will always be in accordance with local regulations and IRBs/IECs.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932142] be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_687595].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely termin ated, the investigator must inform the patients 
promptly a nd ensure appropriate therapy and follow- up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation.
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of patients who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the patients
should be described.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932143] to a sign ificant degree the safety 
and rights of a patient or the reliability and robustness of the data generated (potential serious 
breach) and if it should be reported to the Regulatory Authorities as a serious breach of GCP and/or 
the protocol.
In addition, deviations must be documented and explained in a protocol deviation by [CONTACT_535282], date, and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database.
Documentation on protocol deviations must be kept  in the investigator trial master file and sponsor 
trial master file.
19.[ADDRESS_932144] or withdrawal of consent to secure early mitigations in collaboration with the trial sites.
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, see Section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by [CONTACT_36340] (e.g. re-training of site staff).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932145] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are relevant to the evaluation of the trial.
21 Critical documents
An Investigator Portal (Globa l Haemophilia N etwork [GHN]) w ill be used as pr imary media for 
exchange and handling of investigator trial master file documents between Novo Nordisk and the site and for electronic storage of these documents during trial conduct.
Before a trial site is allowed to start screen ing patients, written notification from Novo Nordisk 
must be received and the following documents must be available to Novo Nordisk:
∀Regulatory approval and/or acknowle dgement of notification as required
∀Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendmen ts, patient information/informed consent form, 
any other written information to be provided to the patient and patient recruitment m aterials
∀List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
∀Curricula v itae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
∀Signed receipt of Investigator’s Brochure
∀SmPC or similar labelling of eptacog alfa (rFVIIa)
∀Signed and dated Agreement on Protocol
∀Signed and dated Agreement on Protocol Amendment, if applicable
∀Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigator’s 
site and Novo Nordisk
∀Source document agreement
∀Central laboratory certification and normal ranges
∀Insurance statement, if applicable
∀Financial disclosure form from investigator and sub-investigator(s)
∀Description of research facility obtained  (applicable for sites outside the US)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 125 of 136
Only applicable for US trial sites:
∀For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
∀For US trial sites: FDA form [ADDRESS_932146] be comp leted and signed by [CONTACT_237205] 1572:
For US sites:
∀Intended for US sites
∀Conducted under the IND
∀All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
∀Intended for participating sites outside of the US
∀Not conducted under the IND
∀All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
For local laboratory parameters the following w ill be collected:
∀Laboratory normal ranges
∀Laboratory certification, QA scheme or similar documentation
∀Laboratory assay methods (only non-standard assays) and/or analytical methods
By [CONTACT_36343], each investig ator agrees to comply fully with ICH GCP1
applicable regulatory requirements and the Declaration of Helsinki2.
By [CONTACT_36343], each investigat or also agrees to allow Novo Nordisk to make 
investigator’s name [CONTACT_36374] [CONTACT_36344].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932147] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure th at there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the conduct of the trial and to protect the rights, safety, and well-being of the patients.
At least investigator must be trained in the current protocol version at a Novo Nordisk Investigator 
meeting or by [CONTACT_687641]. It is recommended that all site staff 
completes the web protocol training.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related  medical decisions.
The investigator will follow instructions  from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced) in the investigator trial master file. The documents including the patient identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data.
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
patients to a specific qualified physician who will be readily available to patients during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932148], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial toresearchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial.One investigator will be appointed by [CONTACT_18036] (signatory 
investigator) on behalf of all participating investigators. The signatory investigator will be 
appointed based upon the criteria defined by [CONTACT_36346]
38. 
23.[ADDRESS_932149] for 
Clinical Trial Disclosure how-we-disclose-trial-information.
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, 
for example when the CTR is available. This includes the right not to release the results of interim 
analyses, because the release of such information may influence the results of the entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to [ADDRESS_932150] intellectual property.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 128 of 136
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any disagreement on the content of any publication, both the investigators’ and Novo Nordisk opi[INVESTIGATOR_36255].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary m aterial, as specified by [CONTACT_18038].
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors
38(sometimes referred to as the Vancouver 
Criteria).
23.1.2 Site-specific publication (s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statist ical 
limitations and frequently do not provide meaningful information for healthcare professionals or patients, and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that such individual reports do not precede the primary manuscript and should al ways reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of individual site results until the primary manuscript is accepted for publication. As Novo Nordisk wants to live up to the industry publication po licy, submission of a primary publication will take 
place no later than [ADDRESS_932151] access 
to the database.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 129 of 136
24 Retention of clinical trial documentation and human biosamples
24.1 Retention of clinical trial documentation
Patients’ medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other patient data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These data must be retained by [CONTACT_21655]. If the 
provided d ata (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least [ADDRESS_932152].
Only applicable for Spain: 25 years retention according to the Spanish Royal Decree 1090/2015.
The files from the trial site/institution must be retained for 15 years after EOT as defined in Section 
7, or longer if required by [CONTACT_36348]. In any case trial files cannot be 
destroyed until the trial site/institution is no tified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.
24.2 Retention of human biosamples
This trial will involve collectio n of human biosamples at visit 1 (screening visit) and at visit 17
(EOT) and these samples are to be stored max imum [ADDRESS_932153] the patients’ participation in the trial. 
Therefore, patients will have the possibility to sign the informed consent for the trial and 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 130 of 136
participate, while refusing permission for biological specimens to be stored for future exploratory 
analysis.
∀Human biosamples will be stored at the central laboratory
∀1.0 mL citrated plasma, 1.2 mL serum and/or 2.0 mL whole blood ( DNA for genotypi[INVESTIGATOR_007])
will be obtained
∀The intended use of the stored human biosamples e.g.: As new biomarkers related to the 
disease and/or safety, efficacy or mechanism of action of concizumab may evolve during the 
conduct of the trial, the analyses of the stored human biosamples may also include 
biomarkers that are unknown at present or have not been included in the scientific 
hypotheses at initiation of the trial
∀Human biosamples may be transferred to third parties e.g. research consortia
∀The human biosamples will be transferred a nd stored after the EOT at a designated central 
laboratory
∀Confidentiality and personal data protection will be ensured during storage after the EOT
∀The human biosamples may be transferred to other countries (not applicable if local 
regulations prohibit export of human biosamples)
∀The human biosamples will be destroyed at the latest 15 years from EOT
∀The patient may request the stored human biosamples to be destroyed by [CONTACT_535265]. The results obtained from any already performed analyses of the samples will still 
be used
∀Novo Nordisk and laboratory will have access to the stored human biosamples
∀Potential consequences for the patient and their relatives: In the event that the collected
human biosamples (plasma, serum and/or DNA for genotypi[INVESTIGATOR_007]) will be used in the future, 
the investigator will become directly informed  by [CONTACT_535266]. In such case, 
a written summary of the findings, including lis tings of patient specific values, will be 
provided once a firm conclusion from the results has been drawn by [CONTACT_3454]. 
Potentially, observations of ne oplastic diseases, serious hereditary diseases, other un-
treatable diseases, or any other abnormal findings could be part of the observations. Patients
can contact [CONTACT_687652] m their own body, see Section 5.1.
24.2.1 Antibod y samples
Antibody samples will be retained until drug approval by U.S. Food and Drug Administration 
(FDA) and/or European Medicines Agency (EMA).
The retained antibody samples may be used for later analysis for further characterisation of 
antibody responses towards drug if required by [CONTACT_49769]. Remaining blood from the samples already collected may be used for further development of Anti-Drug 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932154] 
terminates, but no longer than 15 years from EOT after which they will be destroyed.
The patients’ identity will remain confidential and the antibody samples will be identified only by 
[CONTACT_56324], visit number and trial identificati on number. No direct identification of the patient
will be stored together with the samples.
Only Novo Nordisk staff and bio-repository personnel will have access to the stored antibody 
samples.
Patients can contact [CONTACT_215591].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 132 of 136
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo No rdisk, as applicable, mu st promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to Investigator’s Brochure, unexpected SAEs where a causal relationship cannot be ruled out, protocol amendments 
according to local requirements, deviations to the protocol implemented to eliminate immediate 
hazards to the patients, new information that may affect adversely the safety of the patients or the conduct of the trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of the patients), annually written summaries of the trial status, and other 
documents as required by [CONTACT_1036]/IEC.
The investigator must ensure submission of the CTR synopsis to the IRB/IEC (not applicable for 
Japan).
Protocol amendments must not  be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the patients.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_56255].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the CTR according to national requirements.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932155] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials  in any country, unle ss others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_535286].
Novo Nordisk accepts liability in accordance with:
Only applicable for Austria: Arzneimittelgesetz (BGBI. Nr. 185/1983) last amended with BGBl. 
II Nr. 105/2015
Only applicable for [LOCATION_009]: The French Public Health Code article L 1121-10 (law n
o 2004-[ADDRESS_932156] 2004. “The sponsor is responsible for 
identification of the harmful consequences of the biomedical research for the person lending 
himself thereto and for indemnification of his beneficiaries, except in case of proof, incumbent on it, that the prejudice is not attributable to his fau lt or the fault of any intervening party, without the 
sponsor’s being entitled to call on acts by a third party or the voluntary withdrawal of the person 
who had initially consented to cooperating in the research”.
Only applicable for Poland: Novo Nordisk carries liability for the Trial exclusively in the scope 
defined by [CONTACT_687653] 6 September 2001 (uniform version Journal pf Laws of 2008 No. 45 item 271 with 
amendments). In order to support potential claims for liability attributable to the Trial, Novo 
Nordisk and Investigators are covered by [CONTACT_136779].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 134 of 136
27 References
1. International Conference on Harmonisation. ICH Harmonised Tripatite Guideline. Guideline 
for Good Clinical Practise E6(R2), Step 4. [ADDRESS_932157] amended by [CONTACT_941] 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.
3. International Organization for Standardization. ISO [ZIP_CODE]:2011, Clinical investigation of 
medical devices for human subjects - Good clinical practice. [ADDRESS_932158] Investigators. Am J Hematol. 1998;59(4):288-94.
5. World Federation of Hemophilia. Report on Annual Global Survey 2014.
6. White GC, 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. 
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII 
and factor IX of the scientific and standardization committee of the International Society on 
Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
7. Hoffman M, Monroe III. A cell-based model of hemostasis. Thrombosis and haemostasis. 
2001;85(6):958-65.
8. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-9.
9. Wight J, Paisley S. The epi[INVESTIGATOR_687578] A: a systematic review. 
Haemophilia. 2003;9(4):418-35.
10. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino 
acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. 
Mol Immunol. 1993;30(1):105-8.
11. Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, et al. Safety and 
pharmacokinetics of anti-TFPI [CONTACT_30936] (concizumab) in healthy volunteers and patients 
with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743-
54.
12. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
13. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007.
14. The European Parliament and the Council of  the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_932159] of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 01 May 
2001.
15. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March laying down 
Community procedures for the authorisation  and supervision of medicinal products for 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 135 of 136
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. April 2001.
16. Duncan NA, Kronenberger WG, Roberson CP, Shapi[INVESTIGATOR_71324]. VERITAS-PRN: a new 
measure of adherence to epi[INVESTIGATOR_535136]. Haemophilia. 
2010;16(1):47-53.
17. Maruish ME. User's manual for the SF-36v2 Health Survey (3rd ed.). Lincoln, RI: 
QualityMetric Inc orporated2013.
18. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin 
Psychopharmacol. 1996;[ADDRESS_932160] 3:89-95.
19. Atkinson MJ, et al. Validation of a general measure of treatment satisfaction, the Treatment 
Satisfaction Questionnaire for Medication (TSQM ), using a national pa nel study of chronic 
disease. Health Qual Life Outcomes. 2004;2:12.
20. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the 
treatment satisfaction questionnaire for medication (TSQM version II) among outpatient 
pharmacy consumers. Value Health. 2005;[ADDRESS_932161] 1:S9-S24.
21. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of 
an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among 
patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.
22. Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid 
arthritis: psychometric validation of the S elf-Injection Assessment Questionnaire (SIAQ). 
Health Qual Life Outcomes. 2011;9:2.
23. Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. Official Journal 
L 1692 12/07/1993.
24. European Commission. The Rules Governing Medicinal Products in the European Union, 
Volume 4, Annex 13, Investigational Medicinal Products (ENTR/F/2/AM/an D[2010] 
3374). 03 Feb 2010.
25. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et 
al. Second symposium on the definition and management of anaphylaxis: summary report--
Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy  Clin Immunol. 2006;117(2):391-7.
26. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third 
universal definition of myocardial  infarction. Circulation. 2012;126(16):2020-35.
27. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. Current diagnosis 
of venous thromboembolism in primary care: a clinical practice guideline from the 
American Academy of Family Physicians and the American College of Physicians. Ann 
Fam Med. 2007;5(1):57-62.
28. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated 
definition of stroke for the 21st century: a statement for healthcare professionals from the 
American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064-89.
29. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition 
and evaluation of transient ischemic attack: a scientific statement for healthcare 
professionals from the American Heart Association/American Stroke Association Stroke 
Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular 
Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 2
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 136 of 136
Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the 
value of this statement as an educational tool for neurologists. Stroke. 2009;40(6):2276-93.
30. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 
ACCF/AHA Focused Update of the Guideline for the Management of Patients With 
Peripheral Artery Disease (updating the 2005 guideline): a report of the American College 
of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J 
Am Coll Cardiol. 2011;58(19):2020-45.
31. U.S. Food and Drug Administration. Code of Federal Regulations, 21 CFR Part 11, 
Electronic Records, Electronic Signatures. 2009 2009.
32. Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-
inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 
2011;365(18):1684-92.
33. Levi M, Keller TT, van GE, ten CH. Infection and inflammation and the coagulation system. 
Cardiovasc Res. 2003;60(1):26-39.
34. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, Hall CL. Tissue factor 
pathway inhibitor binds to platelet t hrombospondin-1. J Biol Chem. 2000;275(41):[ZIP_CODE]-
21.
35. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. 
Arterioscler Thromb Vasc Biol. 2004;24(6):1015-22.
36. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in 
angiogenesis and cancer. Arterioscler Thromb Vasc Biol. 2005;25(8):1545-50.
37. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol. 
2005;25(1):47-56.
38. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scho larly Work in Medical Journals. December 
update 2016.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 1 of 138
Protocol
NN7415-4310
A Multi-Centre, Randomised, Open-Label, Controlled Trial 
Evaluating the Efficacy and Safety of Prophylactic 
Administration of Concizumab in Haemophilia A and B 
Patients with Inhibitors
Trial phase: 2
Includes: Protocol Version 1 (15 March 2017); Protocol Amendment no 1 (05 May 2017) for all 
participating countries; Protocol Amendment no 2 (15 November 2017) for all participating countries.
Protocol originator
, Senior International Trial Manager 
Biopharm Trial Ops [ADDRESS_932162] be restricted to relevant 
parties.
3URWRFROY
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932163] of abbreviations .......................................................................................................... .........................9
1 Summary ............................................................................................................................... .............16
2 Flow chart .................................................................................................................... ......................19
2.1 Visits and assessments ...................................................................................................... ......19
2.2 Explanatory descriptions .........................................................................................................22
3 Background information and rationale for the trial .........................................................................24
3.1 Background information ..........................................................................................................24
3.1.1 Haemophilia ..........................................................................................................24
3.1.2 Con cizumab ...........................................................................................................25
3.2 Rationale for the trial ...............................................................................................................28
4 Objective(s) and endpoint(s) ..............................................................................................................29
4.1 Objective(s) ............................................................................................................................29
4.1.1 Primary objective ...................................................................................................29
4.1.2 Sec ondary objectives .............................................................................................29
4.2 Endpoint(s) .............................................................................................................................29
4.2.1 Prima ry endpoint ...................................................................................................29
4.2.2 Sec ondary endpoints ..............................................................................................29
[IP_ADDRESS] Supportive secondary endpoints .......................................................[ADDRESS_932164] oratory endpoints ............................................................................................30
[IP_ADDRESS] Exploratory sa fety endpoints ............................................................30
[IP_ADDRESS] Exploratory patient re ported outcome endpoints ...............................30
5 Trial design .................................................................................................................. ......................32
5.1 Type of trial ............................................................................................................... .............32
5.1.1 S urgery ..................................................................................................................33
5.2 Rationale for trial design .........................................................................................................33
5.3 Treatment of patients ...............................................................................................................36
5.3.1 Concizumab arm ....................................................................................................37
[IP_ADDRESS] Concizumab prophylactic treatment (main and extension part) ..........37
5.3.2 Comparator arm (eptacog alfa (rFVIIa)).................................................................38
[IP_ADDRESS] On-demand treatment (main part) .....................................................38
[IP_ADDRESS] Concizumab prophylactic treatment (extension part) .........................38
5.3.3 Dose escalation ......................................................................................................38
5.3.4 Co-administration of ep tacog alfa (rFVIIa).............................................................[ADDRESS_932165] .......................................................................42
5.5 Rationale for treatment ............................................................................................................42
6 Trial population .............................................................................................................. ...................43
6.1 Number of patients ..................................................................................................................433URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932166] ..............................................................50
8.1.5 Withdra wal from trial .............................................................................................50
8.1.6 Review / evaluation of clinical outcome ..................................................................50
8.1.7 Visit 1 (Screen ing part)..........................................................................................51
8.1.8 Traini ng of patients at visit 1, visit 2 and visit 9 ......................................................51
8.1.9 Treatment peri od at home ......................................................................................52
8.1.10 Sta ggered recruitment ............................................................................................52
8.1.11 Treatment period – Main part.................................................................................52
[IP_ADDRESS] Visit 2 (R andomisation) ...................................................................52
[IP_ADDRESS] Visit 3 (Phone call for eptacog alfa (rFVIIa) on-demand arm and 
PK visit for concizumab arm) ...........................................................54
[IP_ADDRESS] Visit 4, 5, 6, 7 and 8 .........................................................................55
[IP_ADDRESS] Visit 9 ..............................................................................................56
8.1.12 Treatment period – E xtension part..........................................................................58
[IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog 
alfa (rFVIIa) on-demand arm) ..........................................................58
[IP_ADDRESS] Visit 9.2 (ONLY patients previously on the eptacog alfa (rFVIIa) 
on-demand arm) ...............................................................................59
[IP_ADDRESS] Visit 10 ............................................................................................59
[IP_ADDRESS] Visit 10.1 (ONLY patients previously on the eptacog alfa 
(rFVIIa) on-demand arm) .................................................................60
[IP_ADDRESS] Visit 11 ............................................................................................61
[IP_ADDRESS] Visit 11.1 (ONL Y patients previously on the rFVIIa on-demand 
arm) .................................................................................................62
[IP_ADDRESS] Visit 12, 13, 14 and 15 .....................................................................63
[IP_ADDRESS] Visit 16 ............................................................................................63
8.1.13 Visit 17 (End of trial) - Follow-up part ...................................................................64
8.1.14 Unscheduled Visit..................................................................................................65
8.2 Patient related information/assessments ...................................................................................65
8.2.1 Dem ography ..........................................................................................................65
8.2.2 Concom itant illness and medical history other than haemophilia ............................65
8.2.3 Conco mitant medication ........................................................................................66
8.2.4 Details  of Haemophilia, Haemophilia treatment and bleed history ..........................66
8.3 Efficacy assessments ...............................................................................................................67
8.3.1 Bleeding epis odes ..................................................................................................67
8.4 Safety assessments .......................................................................................................... ........713URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 4 of 138
8.4.1 Phys ical examination .............................................................................................71
8.4.2 Body measurements ...............................................................................................71
8.4.3 V ital Signs .............................................................................................................72
8.4.4 Electrocardiogram ..................................................................................................72
8.4.5 Adverse ev ents.......................................................................................................73
[IP_ADDRESS] Medicati on error ...............................................................................73
[IP_ADDRESS] Adverse events requiri ng additional data collection ..........................73
8.5 Laboratory assessments ...........................................................................................................75
8.5.1 Labora tory assessments for efficacy .......................................................................76
[IP_ADDRESS] Thrombin generation ........................................................................76
[IP_ADDRESS] Free TFPI .........................................................................................77
8.5.2 Labor atory assessments for safety ..........................................................................77
[IP_ADDRESS] Urinalys is.........................................................................................77
[IP_ADDRESS] Haematology ....................................................................................77
[IP_ADDRESS] Biochemistry ....................................................................................78
[IP_ADDRESS] FVIII/FIX activity ............................................................................78
[IP_ADDRESS] Coagulati on parameters ....................................................................79
[IP_ADDRESS] FVIII/FIX inhibitors .........................................................................79
[IP_ADDRESS] Anti-concizumab antibodies .............................................................79
[IP_ADDRESS] Concizumab ELISA .........................................................................81
[IP_ADDRESS] FVII ELI SA .....................................................................................82
[IP_ADDRESS] Total TFPI ........................................................................................82
8.5.3 Human Bios amples ................................................................................................83
8.6 Other assessments ........................................................................................................... ........83
8.6.1 P atient reported outcomes ......................................................................................83
8.6.2 Training .................................................................................................................8 4
[IP_ADDRESS] Concizumab and NovoPen®4............................................................84
[IP_ADDRESS] eptacog alfa (rFVIIa) ........................................................................85
[IP_ADDRESS] eDiary ..............................................................................................85
8.6.3 S urgery ..................................................................................................................85
8.7 Patient compliance ..................................................................................................................86
8.8 Treatment compliance .............................................................................................................86
9 Trial supplies ............................................................................................................................... .......87
9.1 Trial products ..........................................................................................................................87
9.2 Labelling ............................................................................................................................... ..87
9.3 Storage..................................................................................................................... ...............88
9.4 Drug accountability and destruction ........................................................................................88
9.5 Auxiliary supplies ...................................................................................................................89
10 Interactive voice/web response system ..............................................................................................90
11 Randomisation procedure and breaking of blinded codes................................................................90
11.1 Randomisation ........................................................................................................................90
11.2 Breaking of bli nded codes .................................................................................................. .....90
12 Adverse events, and technical complaints ..................................................................................... ....91
12.1 Defi nitions ..............................................................................................................................9 1
12.1.1 Adverse ev ent ........................................................................................................91
12.1.2 Serious advers e event.............................................................................................92
12.1.3 Non-serious adve rse event......................................................................................933URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932167] ..........................................................................95
12.1.7 Technical complaints .............................................................................................99
12.2 Reporting of a dverse events .....................................................................................................99
12.3 Follow-up of adve rse events................................................................................................ ..102
12.4 Technical complaints a nd technical complaint samples ..........................................................103
12.4.1 Reporti ng of technical complaints ........................................................................103
12.4.2 Co llection, storage and shipment of technical complaint samples .........................104
12.5 Pre gnancies ...........................................................................................................................104
12.5.1 Pregnancies in female pa rtners of male patients....................................................104
12.6 Precautions and/or overdose ..................................................................................................105
12.7 Rules for putting enrolment on hold ......................................................................................106
12.8 Committees related to safety .................................................................................................106
12.8.1 Novo N ordisk safety committee ...........................................................................106
12.8.2 Data m onitoring committee ..................................................................................106
13 Case report forms ............................................................................................................ ................107
13.1 Corrections to case report forms ............................................................................................108
13.2 Case report form flow ...........................................................................................................108
13.3 Electronic diary .....................................................................................................................108
14 Monitoring procedures ........................................................................................................ ............110
15 Data management ............................................................................................................................111
16 Computerised systems ......................................................................................................... ............112
17 Statistical considerations .................................................................................................................113
17.1 Sample size calculation .........................................................................................................114
17.2 Definition of analysis sets ......................................................................................................115
17.3 Primary endpoint ...................................................................................................................115
17.3.1 Estima nd and primary statistical analysis .............................................................115
17.3.2 Sens itivity analysis ..............................................................................................116
17.3.3 Add itional analysis ..............................................................................................116
17.4 Supportive sec ondary endpoints ............................................................................................117
17.4.1 Suppor tive secondary efficacy endpoints ..............................................................117
17.4.2 Suppor tive secondary safety endpoints .................................................................117
17.4.3 Suppor tive secondary pharmacokinetic endpoints .................................................118
17.4.4 Suppor tive secondary pharmacodynamic endpoints ..............................................118
17.4.5 Explor atory endpoints ..........................................................................................119
[IP_ADDRESS] Exploratory sa fety endpoints ..........................................................119
[IP_ADDRESS] Exploratory patient re ported-outcome endpoints .............................119
17.5 Interim analy sis........................................................................................................... ..........119
18 Ethics....................................................................................................................... .........................121
18.1 Benefit-risk asse ssment of the trial ....................................................................................... .121
18.2 Informed consent ..................................................................................................................123
18.3 Data handling ........................................................................................................................123
18.4 Information to patients during trial ........................................................................................124
18.5 Premature termination of the trial and/or trial site ..................................................................1243URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 6 of 138
19 Protocol compliance .........................................................................................................................125
19.1 Protocol  deviations ................................................................................................................125
19.2 Prevention of missing data ................................................................................................. ...125
20 Audits and inspections ....................................................................................................... ..............126
21 Critical documents........................................................................................................... ................126
22 Responsibilities ............................................................................................................................... ..128
23 Reports and publications ..................................................................................................... ............129
23.1 Communicati on of results ......................................................................................................129
23.1.1 Aut horship ...........................................................................................................130
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) .......................................................130
23.2 Investigator access to data and review of results ....................................................................130
24 Retention of clinical trial documentation and human biosamples ..................................................131
24.1 Retention of clinical trial documentation ...............................................................................131
24.2 Retention of human  biosamples.............................................................................................1 31
24.2.1 Anti body samples ................................................................................................132
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities ...........[ADDRESS_932168] of key staff and relev ant departments, if applicable for the individual . 
Appendix 1 Patient Reported Outcomes3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 7 of 138
Table of Figures
Page
Figure 3–1 Individual predicted PK profiles based on data merged with recorded spontaneous (circles) 
and traumatic (triangles) bleeding epi[INVESTIGATOR_535038]-up period. All data originates from explorer™3 (N=24 patients). PK of concizumab is subdivided into 
three exposure levels of !20 ng/mL, 20-100 ng/mL, and > 100 ng/mL together with the 
number of contributing patients. LLOQ: lower limit of quantification. .....................................27
Figure 5–1 Schematic diagram of the trial design ................................................................................ ......32
Figure 5–2 Individual predicted concizumab concentration profiles for all concizumab-treated patients 
in explorer™2 (n=4 patients) and explorer™3 (n=18 patients). The horizontal lines 
indicate 100 ng/mL, and the shaded areas represent the full range (min-max) of the 
individual predicted profiles. ...................................................................................................35
Figure 5– 3 Dose escalation for one individual patient in the concizumab arm ............................................39
Figure 5–4 Dose escalation for one indivi dual patient in the comparator arm .............................................40
Figure 8–1 Visit schedule – concizumab arm. ...........................................................................................47
Figure 8–2 Visit schedule – eptacog alfa (rFVIIa) arm later switching to concizumab. ........................47
Figure 12–1 Reporting of AEs .................................................................................................... ..............101
Figure 17–1 Definition of main and extension part ....................................................................................1203URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 8 of 138
Table of Tables
Page
Table 5–[ADDRESS_932169] of products provided by [CONTACT_3454] .............................................................................36
Table 8–1 Definition of stop of bleeding epi[INVESTIGATOR_1865] .....................................................................................69
Table 8–2 Definitions of bleeding epi[INVESTIGATOR_1841] (cause of bleed) ....................................................................69
Table 8–3 Definition of bleeding epi[INVESTIGATOR_535138] ...................................69
Table 9–1 Trial products ..........................................................................................................................87
Table 9–2 Storage conditions.................................................................................................... ...............88
Table 17–1 Power in superiority comparison between concizumab prophylaxis and on-demand 
treatment under different assumptions of ABR for concizumab and over-dispersion 
(assuming on-demand ABR=24). ..........................................................................................1153URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932170] aspartate aminotransferaseAT antithrombinAUC area under curveBP blood pressureBU Bethesda UnitCCDS company core data sheet CLAE clinical laboratory adverse eventC
max maximum plasma concentration
CNS central nervous system
concizumab Bthe name [CONTACT_687671] B. B is the formulation 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932171] correction DUN dispensing unit numberDVT deep vein thrombosisECG electrocardiogrameCRF electronic case report formeDiary electronic diaryeITMF electronic investigator trial master fileELISA enzyme-linked immunosorbent assay3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 11 of 138
EMA european medicines agency
EOT end of trialePRO electronic patien t reported outcome
eptacog alfa the name ‘eptacog alfa (rFVIIa)’ will be used throughout 
the protocol and the product is identical to rFVIIa,‘NovoSeven
®, and ‘NiaStaseRT®’
ETP endogenous thrombin potential FAS full analysis setFDA U.S. Food and Drug AdministrationFDAAA U.S. Food and Drug Administration Amendment ActFIX coagulation factor IXFPFV first patient first visitFVIIa activated coagulation factor VIIFVIII coagulation factor VIIIFVIII:C plasma activity of factor VIIIFX coagulation factor XFX
a activated coagulation factor X
GCP Good Clin ical Practice
GGT gamma glutamyl transferaseGHN global haemophilia network3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932172] cell protein
Hemo-TEM Hemophilia Treatment Experience Measure
IB investigator’s brochure
IC informed consent ICH International Conference on Harmonisation ICMJE International Committee of Medical Journal EditorsID identificationIEC independent ethics committeeIgG4 immunoglobulin G4IMP investigational medicinal product
INNInternational Non-Proprietary Names for Pharmaceuti cal 
Substances 
IRB institutional review boardISRQ-SIAQ Injection Site Reaction Questionnaire – Self-Injection 
Assessment Questionnaire 
ISTH International Society on Thrombosis and HaemostasisIT information technologyi.v. intravenous(-ly)IWRS interactive web response system3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932173] level 
NIMP non investigational medicinal productPCD primary completion date PD pharmacodynamicsPEF peak expi[INVESTIGATOR_687596]-C Patient’s Global Impression of ChangePK pharmacokineticsPP per protocolPRO patient reported outcome3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 14 of 138
PT prothrombin time
Q Inter compartmental clearanceQA quality assuranceQ4D every 4
thday
eptacog alfa (rFVIIa)the name ‘eptacog alfa (rFVIIa)’ will be used throughout 
the protocol and the product is identical to ‘NovoSeven®’
sABR spontaneous annualised bleeding rate
SAE serious adverse eventSAS safety analysis setsBE spontaneous bleeding epi[INVESTIGATOR_687508].c. subcutaneous(-ly)SDS Sheehan Disability ScaleSF-36v2 36-Item Short Form Health Survey
SI international system of unitsSmPC summary of product characteristicsS[LOCATION_003]R suspected unexpected serious adverse reactionTAT thrombin-antithrombin complexTEAE treatment emergent adverse eventsTIA transient ischemic attack3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932174] inhibitorTG thrombin generationTMM trial materials manualTSQM Treatment Satisfaction Questionnaire for Medication TVP trial validation planUTN Universal Trial NumberVERITAS-PRN
® Validated Hemophilia Regimen Treatment Adherence 
Scale3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 16 of 138
1 Summary
The main objective for the phase 2 trial NN7415-4310, explorer™4, is to assess the efficacy of 
concizumab administered s.c. once daily to pre vent bleeding epi[INVESTIGATOR_56178] A and B 
patients with inhibitors. Furthermore , this trial aims to assess the l onger-term efficacy and safety of 
concizumab in haemophilia A and B patients with i nhibitors and to establish the safety of treating 
breakthrough bleeding epi[INVESTIGATOR_687510] (rFVIIa) in these patients.
Objective(s) and endpoint(s)
Primary objective
∀To assess the efficacy of concizumab administered s.c. once daily in preventing bleeding 
epi[INVESTIGATOR_56178] A and B patients with inhibitors.
Secondary objectives
∀To assess the longer-term efficacy of concizumab in haemophilia patients with inhibitors
∀To assess the safety of concizumab in haemophilia patients with inhibitors
∀To assess the safety of administering recombinant factor VIIa (rFVIIa) to haemophilia 
patients with inhibitors that are exposed to concizumab
∀To assess the immunogenicity of concizumab in haemophilia patients with inhibitors
Primary endpoint
∀The number of bleeding epi[INVESTIGATOR_687579] 24 weeks from treatment onset
Key secondary endpoints
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from tr eatment onset
∀Number of treatment emergent adverse events (TEAEs) during at least 24 weeks from
treatment onset
Time frames for evaluation of Objectives/Endpoints
All endpoints referring to the time frame of at least [ADDRESS_932175] (or has withdrawn). In addition, number of bleeding epi[INVESTIGATOR_51953] 76 
weeks of treatment with prophylactic concizumab will be analysed. The extension part of the trial will provide additional safety and long-term efficacy data.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 17 of 138
Trial design
The trial is a multi-centre, randomised (2:1), open-label, controlled trial, aiming to evaluate the 
efficacy and safety of concizumab 0.15 mg/kg (with potential dose escalation) administered daily s.c. in haemophilia patients with inhibitors. We expect 16 patients to complete treatment in 
concizumab arm (concizumab prophylaxis) and 8 p atients in comparator arm (rFVIIa on demand). 
The dose regimen is selected based on relevant PK and TFPI [INVESTIGATOR_535039]/PD modelling of the results from the preceding explorer™ trials. Only on-demand patients will be eligible for the trial.
For all patients treated with concizumab (concizumab arm and comparator arm extention part) a 
loading dose of 0,5 mg/kg concizumab will be gi ven as the first dose, followed by [CONTACT_687617] 0,15 mg/kg. All patients in treatment with concizumab will in a non-bleeding 
state receive a single dose of 90 μg/kg eptacog alfa (rFVIIa) one week after dosing with 
concizumab. Hereafter, patients will be closely clinically observed at the site for potential safety 
issues for at least 12h and evaluated again at the site after 24h.
The total trial duration for the individual patient w ill be approximately 86-88 weeks, consisting of a 
2-4 week screening period, a subsequent 76-week treatment period and an 8-week follow-up period.
eptacog alfa (rFVIIa) for treatment of bleeding ep isodes during the trial will be provided by [CONTACT_49753]. The patient will not be provided with trial product or ep tacog alfa (rFVIIa) after end of 
trial.
The trial is split into a main part which lasts [ADDRESS_932176] completed a minimum of 24 weeks of eptacog alfa (rFVIIa) on-demand or have withdrawn. The analysis of the main part of the trial aims to substantiate the clinical proof of 
concept (CPoC) that concizumab has the potential to prevent bleeding epi[INVESTIGATOR_687512]. The extension part of the trial will provide additional safety and long-term efficacy data.
Trial population
Number of patients planned to be screened: [ADDRESS_932177]: 26Number of patients expected to complete the trial: 243URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 18 of 138
Key inclusion criteria
∀Informed consent obtained before any trial r elated activities. Trial related activities are any 
procedures that are carried out as part of the trial, including activities to determine the 
suitability for the trial
∀Male haemophilia A or B patients with inhibitors aged ≥ 18 years at the time of signing 
informed consent
∀Patients currently in need of treatment with by[CONTACT_687618]
∀Known or suspected hypersensitivity to trial product(s) or related products
∀Known inherited or acquired bleeding disorder other than haemophilia
∀Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX
Key Efficacy assessment
∀Number of bleeding epi[INVESTIGATOR_535025] 24 weeks of treatment onset
Key Safety assessment
∀Number of treatment emergent adverse events during at least 24 weeks of treatment onset
Trial products
The following products will be used in the trial:
∀Investigational Medicinal Products:
oconcizumab B, 100mg/mL to be administered s.c. with NovoPen®4 and needles
oeptacog alfa (rFVIIa), 5mg /vial and histidine (solvent). Reconstituted eptacog alfa 
(rFVIIa) is for intravenous administration and used in the trial at visit 3 and 9.1 for all patients with the purpose of investigating the safety of administering eptacog alfa (rFVIIa) to haemophilia patients
∀Non Investigational Medicinal Product :
oeptacog alfa (rFVIIa) 5 mg /vial and histidine (solvent). Reconstituted eptacog alfa is for 
intravenous administration and used in this trial for treatment of bleeding epi[INVESTIGATOR_1841]3URWRFROY
CONFIDENTIAL
Protocol UTN: U1111 -1179-2925 Date: 15 November 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932178] no.: 2016-000510-30 Version: 3.0 Page: 19 of 138
2 Flow chart
2.1 Visits and assessments
explorerTM4 trial periods Screening Treatment main a, bTreatment extension b Follow-
up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16Un-
scheduled e 17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169176
7 days 
after V9197 225 253 281 309 337 393 449 505 533When 
applicable589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1w 4w 8w 12w 16w 20w 24w 25w 28w 32w 36w 40w 44w 48w 56w 64w 72w 76w - 84w
PATIENT RELATED INFO/ASSESSMENTS
Informed consent/ Genotypi[INVESTIGATOR_535029]-term 
storage consent●
In/exclusion criteria ● ●g
Demography ●
Concomitant illness/Medical history ●
Concomitant medication ● ●●●●●●●●●●●●●●●●●●● ● ●
Details of Haemophilia/Haemophilia treatment and 
bleed history●
Withdrawal criteria/ Criteria for premature 
discontinuation of trial product●●●●●●●●●●●●●●●●●●● ● ●
Randomisation (IWRS) ●
EFFICACY
Bleeding epi[INVESTIGATOR_1841] h, i●●●●●●●●●●●●●●●●●●● ● ●
Thrombin generation (central lab) ● ●l●j, k, l●●●●●●l●j●●●●●●●●●●l● ●
Free TFPI (central lab)  ● ●l●k, l●●●●●●l●●●●●●●●●●●l● ●
SAFETY
Physical examination ● ●●k●● ● ● ● ●
Body measurements ● ●m●k, m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m
Vital signs ● ●n●k, n●●●●●●n●n●●●●●●●●●● ● ●
ECG ●
Adverse events ● ●●●●●●●●●●●●●●●●●●● ● ●3URWRFROY
Protocol UTN: U1111 -1179-2925 Date: 15 November 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932179] no.: 2016-000510-30 Version: 3.0 Page: 20 of 138
explorerTM4 trial periods Screening Treatment main a, bTreatment extension b Follow-
up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16Un-
scheduled e 17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169176
7 days 
after V9197 225 253 281 309 337 393 449 505 533When 
applicable589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1w 4w 8w 12w 16w 20w 24w 25w 28w 32w 36w 40w 44w 48w 56w 64w 72w 76w - 84w
Injection site reaction  ●●k●●●●●●●●●●●●●●●●● ●
Urinalysis (local lab) ●
Haematology (local lab) ● ●l●j, k, l●●●●●●l●j●●●●●●●●●●l● ●
Biochemistry (central lab) ● ●l●k, l●●●●●●l●●●●●●●●●●●l● ●
FVIII/ FIX activity (central lab) ● ●l●l
Coagulation parameters (central lab) ● ●l●●●●●●l●●●●●●●●●●l● ●
Coagulation parameters (PT, APTT and Fibrinogen 
(local lab))●j, k, l●j
FVIII/FIX  inhibitors (central lab) ● ●l●l
Anti-concizumab antibodies (ADA) (special lab) o● ●l●k, l, p●p●p●p●p●p●l, p●●●●●●●●●●●l● ●
Concizumab  ELISA (special lab) ●l●j, k, l, p●p●p●p●p●p●l, p●j●●●●●●●●●●l● ●
FVII ELISA (special lab) ●j, k. l●j
Total TFPI (special lab) ● ●l●k. l●●●●●●l●●●●●●●●●●●l● ●
TRIAL MATERIAL
IWRS call ● ●●k●●●●●●●●●●●●●●●●● ● ●
Dispensing visit (concizumab)r●k●k●k●k●k●k●k●●●●●●●●●●● ●
Dispensing visit (eptacog alfa, histidine)q● ●w●k● ●● ● ● ●●●●● ●
Administration of trial product (concizumab)r●k, s●k●d, s ● ●s●
Administration of trial product (eptacog alfa) ●k, t●t
Drug accountability (concizumab) ●k●k●k●k●k●k●k●●●●●●●●●●● ●
Drug accountability (eptacog alfa) ●●k●●●●●●●●●●●●●●●●● ● ●
New dose of trial product e, u●●●●●● ●●●●●●●●● ●
PRO questionnaires ● ●●k●●●●●● ● ●
REMINDERS
Human biological specimen for storage (central lab) ● ●3URWRFROY
Protocol UTN: U1111 -1179-2925 Date: 15 November 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932180] no.: 2016-000510-30 Version: 3.0 Page: 21 of 138
explorerTM4 trial periods Screening Treatment main a, bTreatment extension b Follow-
up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16Un-
scheduled e 17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169176
7 days 
after V9197 225 253 281 309 337 393 449 505 533When 
applicable589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) [ADDRESS_932181] ●
Training v● ● ●● ●
Compliance: eDiary ●●●●●●●●●●●●●●●●●● ● ●
End of treatment ●
End of trial ●
The cells marked in ‘red’ are only for the patients randomised to eptacog alfa (rFVIIa) arm.3URWRFROY
Protocol UTN: U1111 -1179-2925 Date: 15 November 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932182] no.: 2016-000510-30 Version: 3.0 Page: [ADDRESS_932183] according to patient’s individual training need on concizumab administration, NovoPen®4, eDiary training etc. Visit [ADDRESS_932184] a PK session of 24 hours and a safety follow up visit the following day. 
dVisit and procedures only performed for patients randomised to eptacog alfa and switching to concizumab treatment.Visit 9.1 sho uld be performed 7 days (+ 1 
day) after visit 9.
e For patients being dose escalated on concizumab a phone call is recommended [ADDRESS_932185] be registered in the eCRF.
i Eptacog alfa will be given to treat breakthrough bleeding epi[INVESTIGATOR_1841]. 
jSampling time schedule for thrombin generation, haematology,  coa gulation parameters, concizumab ELISA and FVII ELISA: pre-dose ( -1 hour), post-dose: 
10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points,  except pre-dose, occur after 
eptacog alfa administration.
kONLY for patients randomised to concizumab arm. The concizumab dose should be administered first followed by [CONTACT_687654]. T he interval between the 
concizumab and eptacog alfa should not exceed more than [ADDRESS_932186] not treat themselves with concizum ab until sampling has been 
performed.
m Only body weight should be measured. 
nVital signs should be evaluated before and after trial drug administration at visit 2 and visit 3 for concizumab arm and at vis it 9 and visit 9.1 for patients in 
eptacog alfa arm switching to concizumab treatment.
oIn case clinical signs of e.g. hypersensitivity reactions or immune related events are seen, additional samples for ADAs may be  taken. All antibod ysamples 
from the affected patient will be analysed on an ongoing basis. If antibodies are detected, additional blood samples will be ta ken and stored for characterisation 
of the antibodies.
p Blood sampling for anti-concizumab antibodies and concizumab ELISA testing should only be collected for patients on concizumab.
q If needed dispensing of eptacog alfa, histidine, trial injection kits and Direction For Use (DFU). 
r First treatment dose of concizumab is a loading dose and will be administered at visit [ADDRESS_932187] received any  by[CONTACT_687619],(e.g., 3URWRFROY
Protocol UTN: U1111 -1179-2925 Date: 15 November 2017 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932188] no.: 2016-000510-30 Version: 3.0 Page: 23 of 138
eptacog alfa, FEIBA®) for treatment of a bleeding epi[INVESTIGATOR_5319] a period of 24h (for eptacog alfa) or 48h (for FEIBA®) prior to first concizumab. Only 
eptacog alfa is allowed after visit 2.
tEptacog alfa administered in a non-bleeding state at site at visit [ADDRESS_932189] followed by [CONTACT_687654]. The interval between the concizumab and eptacog alfa should not exce ed more than 30 min.
uPatient treated with concizumab should be dose escalated at next scheduled visit if he experiences ≥[ADDRESS_932190] and whenever needed afterwards. Patients randomised to eptacog  alfa will be re-trained in 
NovoPen®4 and s.c. administration at visit 9 and 9.1. If necessary training can be performed as needed at other visits. The eDiary will  be provided to the 
patients at visit 2 if the patient feels capable in s.c. administration and using the eDiary. Further the patients will be trai ned in recognition of signs/symptoms of 
thrombosis.
w Only for patients randomised to on-demand arm.3URWRFROY
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932191] of 
the clinical trial at a trial site.
The INN name [CONTACT_687673] i ngredient is concizumab (synonyms used during early 
development are NNC0172-2021, anti-TFPI, NN7415 or mab2021). Throughout this document “concizumab” is used as the name [CONTACT_535317].
3.1 Background information
3.1.1 Hae mophilia
Haemophilia is an inherited bleeding disorder characterised by [CONTACT_535209], 
typi[INVESTIGATOR_535031]. Haemophilia A is  caused by a partial or complete deficiency of 
blood coagulation factor VIII (FVIII). In haemophilia B, it is factor IX (FIX) that is deficient. 
Inheritance is chromosome X-linked; therefore the disease mainly affects males. The incidence of haemophilia A and B on average is estimated to be about 1 in 5000 live male births 
4. According to 
the World Federation of H aemophilia global survey of [ZIP_CODE], about 178,500 persons are diagnosed 
with haemophilia worldwide. Of th ese, about 80% have haemophilia A.
Haemophilia is classified as “severe”, “moderate” or “mild” according to the plasma activity level 
of the affected coagulation factor6. With a deficiency of FVIII or FIX, the degree of activation of 
coagulation FX becomes insufficient. Consequently, the thrombin burst is delayed and insufficient 
for normal haemostasis7. The haemos tatic plug, if formed, in these patients is fragile and easily 
dissolved by [CONTACT_56264]. This leads to impaired haemostasis and spontaneous prolonge d bleeding epi[INVESTIGATOR_1841]. In severe haemophilia, b leeding in joints occurs spontaneously and is
the most frequent symptoms of the disease. Recurrent bleeding epi[INVESTIGATOR_56175] - most 
commonly a weight bearing joint - lead to chronic arthropathy, muscular atrophy and deformities. 
Treatment of bleeding epi[INVESTIGATOR_535032] (on-demand treatment) may delay arthropathy, but does not prevent it. The majority of children with severe haemophilia experience their first bleedingepi[INVESTIGATOR_687513] a joint prior to age [ADDRESS_932192] developed inhibitors towards FVIII or FIX, replacement therapy is rendered 
ineffective. Though prevalence studies and registry data indicate that the prevalence of inhibitors in 
the haemophiliac population overall has been reported to be between 5% and 7%9, the prevalence 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932193] patients with severe haem ophilia (FVIII:C < 1%) is higher and has been reported to be up 
to 30%9, 10. These patients may be treated with by[CONTACT_71363], activated FVII (NovoSeven®) and 
activated prothrombin complex concentrate (FEIBA®) given as i.v. injections.
Current treatment options in haemophilia, replacement therapy or by[CONTACT_687620], are hampered 
by [CONTACT_535211] i.v. injections. Furthermore, by[CONTACT_687621]-lives, the refore prophylactic treatment is burdensome. It is
also generally acknowledged that the efficacy profile of by[CONTACT_687645]. Consequently, delayed or sub-optimal treatme nt occurs in a significant number of patients
with inhibitors. A new therapeutic agent that can be administered subcutaneously will represent a 
major improvement in the treatment of these patients in a prophylaxis setting.
3.1.[ADDRESS_932194], concizumab, is a humanised recombinant monoclonal antibody (mAb) of the 
immunoglobulin G4 (IgG4) isotype with a molecular  weight of 149 kilo Da lton’s.  Like other 
antibodies, concizumab is composed of two light chains and two heavy chains linked together by [CONTACT_95999]. To prevent formation of half-antibodies, the serine at position 241 in the heavy chain has been replaced with a proline (S241P (Kabat annotation))
10. The mechanism of action of 
concizumab is based on the concept of inhibiting the activity of a natural coagulation inhibitor, 
tissue factor pathway inhibitor (TFPI). TFPI [CONTACT_832] a potent inhibitor of the initiation phase of the coagulation process, i.e. the activation of (FX) to FXa by [CONTACT_535213] (TF)/factor VIIa (FVIIa) complex. TFPI [INVESTIGATOR_687580]/FVIIa complex, forming a TF/FVIIa/FXa/TFPI [INVESTIGATOR_535034]. Thus, concizumab prevents both 
inhibition of FXa and inhibition of FVIIa/TF by  [CONTACT_535214]. In this manner, sufficient amounts of FXa to 
ensure effective haemostasis in the absence of a functional activated factor IX/activated factor VIII (FIXa/ FVIIIa) complex may be generated. This is a new concept that remains to be documented safe and efficacious in patients with haemophilia. More information about the physiological role of TFPI [INVESTIGATOR_535035]’s Brochure.
Key differentiators of this new mode of action (MoA) and the key benefit of concizumab in patients 
with severe haemophilia A and B with inhibitors is reduced treatment burden due to subcutaneous administration potentially leading to better adheren ce, more patients on prophylactic treatment and 
ultimately better outcome. 
Four clinical trials with concizumab have been co mpleted thus far: the first human-dose trial 
(NN7415-3813, explorer
TM1)11, a single dose trial in Japanese healthy subjects (NN7415-3981), 
two multiple dose trials (NN7415-3986, explorerTM2) and (NN7415-4159, explorer™3). When the 
first cohort with  4 (four) healthy sub jects in explorer™2 was completed, pri or to the initiation of the 
2ndcohort, the trial was halted, due to findings related to thrombosis in an ongoing 26-week toxicity 
study in primates. In this trial animal had concizumab plasma concentrations several hundred fold 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 26 of 138
above clinically relevant concentrations. Follow up investigations confirmed that the animal’s 
condition was related to thrombosis in the lungs caused by [CONTACT_535268]. Before the initiation of th e fourth phase 1 trial (NN7415-4159), explorer™3,
a new 52 week non-clinical toxicology study was conducted in primates to investigate the findings 
in the previous study. The conclusion from this new non-clinical study was that the results from 
non-clinical studies support further clinical development of concizumab. Explorer™3 was a multiple dose clinical trial which aimed to inve stigate the safety, pharmacokinetics and 
pharmacodynamics of concizumab at five different dose levels in adult severe haemophilia A 
patients without inhibitors. In th is trial multiple doses of concizumab were administered s.c. over a 
period of six weeks.
The explorer™3 trial was finalised following th e completion of cohort 3 (0.8 mg/kg s.c. every 4 
days for 6 weeks). Blinded preliminary safety and PK/PD data from the cohort was reviewed by [CONTACT_535216]. Marked changes in coagulation parameters were observed including 
a decrease from baseline in fibrinogen and a pronounced increase in D-dimer and F1+[ADDRESS_932195] variation in pro-coagulant response to the drug 
was observed. Based on this, the N ovo Nordisk safety committee (see Section 12.8.1 ) decided not 
to proceed to cohort 4 (1.1 mg/kg s.c. every 4 days for 6 weeks). No clinical consequences or 
serious adverse events were seen in the completed cohorts in explorer™3.
The PK results from explorer™3 showed exposure-response in terms of fewer bleeding epi[INVESTIGATOR_535036] 100 ng/mL. Individual predicted PK profiles merged with recorded spontaneous and traumatic bleeding
epi[INVESTIGATOR_535037] 3–1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 27 of 138
Figure 3–1 Individual predicted PK profiles based on data merged with recorded spontaneous 
(circles) and traumatic (triangles) bleeding epi[INVESTIGATOR_535020]-up period. All data originates from explorer™3 (N=24 patients). PK of 
concizumab is subdivided into three exposure levels of !!20 ng/mL, 20-100 ng/mL, 
and > 100 ng/mL together with the number of contributing patients. LLOQ: lower 
limit of quantification.
a‘Time in trial’ refers to the time that the patients spent on each concizumab exposure level, and the !20 ng/mL level 
therefore also includes the screening period (not shown on this figure).
A large difference between the peak and trough plasma concentrations of concizumab were 
observed as well, especially in the highest dose group (0.80 mg/kg) of explorer™3. In patients who 
received 0.25, 0.5 and 0.8 mg/kg doses a significant overlap in plasma concentrations of 
concizumab was seen due to high betw een-patient variability in concizumab.
Single doses of concizumab up to 9 mg/kg have been administered to haemophilia patients in the 
first human dose trial with concizumab, explorer™1. These doses resulted in plasma concentrations 
of concizumab that were significantly higher than the ones that are modelled to be reached in the 
highest escalated daily dose (0.25 mg/kg) of explorer™4.
In a drug–drug interaction study in monkeys  (NN215431), three doses of up to 1 mg/kg of 
NovoSeven®were administered at 2h intervals, alone or in the presence of a steady state 
concentration of concizumab. No notable clinical obse rvations were made, no treatment-related 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 28 of 138
adverse findings were seen, i.e. no thrombi or other signs of excessive coagulation. Increased 
concentrations of thrombin–anti-thrombin (TAT) and D-dimer were seen, which tended to be additive when both concizumab and eptacog alfa (rFVIIa) were present in circulation.
For an assessment of benefits and risks of the trial, see Section 18.1.
For further information, please refer to the Investigator’s Brochure.
3.[ADDRESS_932196] been finalised. Key safety and preliminary 
efficacy results from these phase 1 studies support further development of concizumab in 
haemophilia patients. Therefore, the main objective in the phase 2 of concizumab development is to 
assess efficacy and safety and provide data that will guide for the confirmatory phase 3 concizumab trials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 29 of 138
4 Objective(s) and endpoint(s)
4.1 Objective(s)
4.1.1 Primary objective
To assess the efficacy of concizumab administered s.c. once daily in preventing bleeding epi[INVESTIGATOR_687514] A and B patients with inhibitors
4.1.2 Secondary objectives
∀To assess the longer-term efficacy of concizum ab in haemophilia patients with inhibitors
∀To assess the safety of concizumab in haemophilia patients with inhibitors
∀To assess the safety of administering recombinant factor VIIa (rFVIIa) to haemophilia 
patients with inhibitors that are exposed to concizumab
∀To assess the immunogenicity of concizumab in haemophilia patients with inhibitors
4.2 Endpoint(s)
4.2.1 Primary endpoint
∀The number of bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
4.2.2 Secondary endpoints
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
∀The number of bleeding epi[INVESTIGATOR_51953] 76 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from tr eatment onset
∀The number of spontaneous bleeding ep isodes during 76 weeks from treatment onset
Supportive secondary safety endpoints
∀Number of treatment-emergent adverse events (TEAEs) during at least 24 weeks from
treatment onset
∀Number of TEAEs during 76 weeks from tr eatment onset
∀Number of TEAEs within 24 hours of rFVIIa administration
∀Occurrence of anti-concizumab antibodies during at least 24 weeks from tr eatment onset
∀Occurrence of anti-concizumab antibod ies during 76 weeks from treatment onset
∀Change from baseline of fibrinogen during 24 weeks from treatment onset
∀Change from baseline of fibrinogen during 76 weeks from treatment onset
∀Change from baseline of D-dimer during 24 weeks from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 30 of 138
∀Change from baseline of D-dimer during 76 weeks from treatment onset
∀Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
∀Change from baseline of F1 + 2 during 76 weeks from treatment onset
∀Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
∀Change from baseline of PT during 76 weeks from treatment onset
∀Change from baseline of activated partial thromboplastin time (APTT) during 24 weeks 
from treatment onset
∀Change from baseline of APTT during 76 weeks from treatment onset
∀Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
∀Change from baseline of AT 76 weeks from treatment onset
Supportive secondary pharmacokinetic endpoints
∀Concentration of concizumab prior to the last dose administration at 24 weeks
∀Concentration of concizumab prior to the last dose administration at 76 weeks
Supportive secondary pharmacodynamic endpoints
∀Free TFPI [INVESTIGATOR_687515] [ADDRESS_932197] dose administration at 76 weeks
∀Thrombin generation
oPeak thrombin generation (nM) prior to the last dose administration at 24 weeks 
oPeak thrombin generation (nM) prior to the last dose administration at 76 weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 24 
weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 76 
weeks
oVelocity index (nM/min) prior to the last dose administration at 24 weeks
oVelocity index (nM/min) prior to the last dose administration at 76 weeks
4.2.3 Exploratory endpoints
[IP_ADDRESS] Exploratory safety endpoints
∀Number of adverse events related to technical complaints during at least 24 weeks from 
treatment onset 
∀Number of adverse events related to technical complaints during at least 76 weeks from 
treatment onset 
[IP_ADDRESS] Exploratory patient reported outcome endpoints
∀Change in Hemo-TEM after 24 weeks from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 31 of 138
∀Change in Hemo-TEM after 76 weeks from treatment onset
∀Change in SF-36v2 after 24 weeks from treatment onset
∀Change in SF-36v2 after 76 weeks from treatment onset
∀Change in SDS after 24 weeks from treatment onset
∀Change in SDS after 76 weeks from treatment onset
∀Change in TSQM after 24 weeks from treatment onset
∀Change in TSQM after 76 weeks from treatment onset
∀Change in SIAQ-ISRQ after 24 weeks from treatment onset
∀Change in SIAQ-ISRQ after 76 weeks from treatment onset
∀Status of PGI-C after [ADDRESS_932198] 24 weeks, w ill be evalu ated 
in the main part of the trial.
All endpoints referring to a time frame of 76 weeks will be evaluated in the extension part of the 
trial.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 32 of 138
5 Trial design
5.1 Type of trial
The trial is a multi-centre, randomised (2:1), open-label, controlled trial, aiming to evaluate the 
efficacy and safety of concizumab 0.15 mg/kg (with potential dose escalation) administered daily 
s.c. in haemophilia patients with inhibitors. The selected dose regimen is based on relevant PK and 
TFPI [INVESTIGATOR_535039]/PD modelling of the results from the preceding explorer™ trials. Only   
on-demand patients will be eligible for the trial.
Figure 5–1 Schematic diagram of the trial design
The total trial duration for the individual patient w ill be approximately 86-88 weeks, including a 2-4 
week screening period, a 76 week treatment period, and a follow-up period of 8 weeks, see Figure 
5–[ADDRESS_932199] completed a minimum of 24 weeks of eptacog alfa (rFVIIa) on-demand or have 
withdrawn.
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 33 of 138
In the concizumab arm bleeding epi[INVESTIGATOR_687516] 
(rFVIIa). In all patients treated with concizumab a single 90 μg/kg dose of eptacog alfa (rFVIIa)
will be administered in a non-bleeding state one week after dosing with concizumab has been initiated. The investigator will evaluate if there are any safety concerns [ADDRESS_932200] eptacog alfa 
(rFVIIa) administration. Furthermore, the scheduled administration of eptacog alfa (rFVIIa) for the 
first 4 patients entering the trial with concizumab will be staggered.
In the comparator arm, in the main part, patie nts will receive eptacog alfa (rFVIIa) on-demand 
treatment. After completion of the main part, the patien ts will continue the tr ial in the extension part 
being treated with prophylactic concizumab 0.15 mg/kg (with potential dose escalation) s.c. d aily 
administration.
Human biosamples (plasma, serum, and/or DNA for genot ypi[INVESTIGATOR_007]) will be collected in this trial for 
future exploratory analysis to pursue a deeper insight into the biology of TFPI, coagulation, and effect of concizumab on joint health.  That may include coagulation parameters and markers of joint status and damage. Acceptance of storage of human biosamples is voluntary and will not affect the 
patients’ participation in the trial. Therefore, p atients will have the possibility to sign the informed 
consent for the trial and participate, while refusing permission for human biosamples to be stored for future exploratory analysis, see Section 8.1.1 .
An independent data monitoring committee (DMC) will be established for this trial. The DMC will 
review all safety data from the ongoing tria l with concizumab exposure, see Section 12.8.2 .
5.1.1 Surgery
Minor surgery is allowed in this trial. Major surgery conducted earlier than one month (30 days) 
prior to trial start is allowed, see exclusion criteria no 6.
Minor surgery is defined as an invasive oper ative procedure where only the skin, the mucous 
membranes or superficial connective tissue is manipulated. Examples of minor surgery include 
implanting of central venous access devices (ports, CVC, pumps and other CVADs) in subcutaneous tissue, skin biopsies or simple dental procedures.
5.2 Rationale for trial design
Explorer™4 is a phase 2, clinical proof of concept (CPoC), and safety trial. The trial aims to 
substantiate CPoC that concizumab has the potential to prevent bleeding epi[INVESTIGATOR_687581]. A dose escalation design will allow cautious dose escalation in order to identify an efficacious and safe concizumab dose for the individual patient. A comparator arm is 
included to assess if concizumab is superior to on -demand treatment. Furthermore, the trial will 
give a possibility to assess safety of co-a dministration of eptacog alfa (rFVIIa) to the patients 
exposed to the concizumab treatment.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 34 of 138
The duration of 24 weeks for the main part of the trial is deemed necessary in order to obtain 
information on the annualised bleeding rate on concizumab prophylaxis. The duration of the extension part of the trial will be 52 weeks and provide further information on efficacy, i.e.annualised bleeding rate, and also provide additional safety data upon 76 weeks treatment with 
concizumab.
A total of 26 patients previously on-demand (OD)  treatment will be randomised into one of the two 
arms, with 16 patients in the concizumab arm and 8 patients in the comparator arm see Figure 5–1 . 
Concizumab will be administered s.c. d aily for p atients randomised to the concizumab arm in the 
main and the extension part of the trial. For patien ts in the comparator arm in the extension part
treatment will be changed from on-demand with rFVIIa to prophylaxis with concizumab.
The concizumab dose regimens will be starting with  0.15 mg/kg with the possibility to escalate to
0.20 mg/kg and 0.25 mg/kg based on bleeding frequency, see Section 5.3.3 .
Daily dosing with concizu mab 0.15 mg/kg aims to ensure steady-state levels of concizumab plasma 
concentrations above 100 ng/mL for the majority of the patients starting on this dose. The PK results from explorer™3 showed exposure response in terms of fewer bleeding epi[INVESTIGATOR_535165] 100 ng/mL, see Figure 3–[ADDRESS_932201] the opportunity to be dose escalated to the dose of 0.2 mg/kg. A further dose escalation to 0.25 mg/kg per day is permitted, again based on the bleeding rate, see Section 5.3.3 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 35 of 138
Figure 5–2 Individual predicted concizumab concentration profiles for all concizumab-treated 
patients in explorer™2 (n=4 patients) and explorer™3 (n=18 patients). The 
horizontal lines indicate 100 ng/mL, and the shaded areas represent the full range (min-max) of the individual predicted profiles.
1
Due to the high between patient variability in concizumab concentration observed in explorer™3, a 
significant overlap in plasma concentrations of concizumab in patients who received 0.25, 0.5 and 
0.8 mg/kg doses was seen, see Figure 5–[ADDRESS_932202] mean plasma concentrations of concizumab, and thus different efficacy at each 
                                               
1Plasma concentrations in the same range as those in explorer™3 are expected to be reached in this trial with daily dose adminis tration. The starting 
dose for all patients will be 0.15 mg/kg daily. The plasma steady-state exposure for a typi[INVESTIGATOR_687518] a typi[INVESTIGATOR_535044] 0.8 mg/kg Q4D (cohort 3 of explorer3) in terms of both Cmax and AUC 0-24h. For 0.20 mg/kg dail y and 0.25 
mg/kg, the plasma steady-state exposure levels for a typi[INVESTIGATOR_687519] 40% and 70% respectively, comp ared to the typi[INVESTIGATOR_687520] 3rd cohort of explorer™3 (AUC and Cmax). The maximum predicted plasma exposure levels (Cmax and AUC 0-24 h) for the 
0.15 mg/kg daily dose level is predicted to be more than 8 fold lower than for 0.80 mg/kg Q4D. For 0.20 mg/kg daily both Cmax an d AUC 0-24h are 
predicted to be more than 3 times lower than for 0.80 mg/kg Q4D. For 0.25 mg/kg daily, the maximum Cmax and AUC 0-24h are predi cted to be 
35% lower than for 0.80 mg/kg Q4D .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932203], the titr ation trial design allows patients to start on a low 
dose, which is expected to ensure prophylaxis but not marked changes in coagulation parameters, for the majority of patients. Escalation to the next dose level will only occur in the case of lack of 
efficacy ( ≥ 3 spontaneous bleeding epi[INVESTIGATOR_535047] 12 weeks). In addition, the PK of 
concizumab is heavily influenced by [CONTACT_535219], which means that small 
differences in concizumab dose ultimately leads to large differences in plasma concentrations. Therefore, daily dosing is proposed for the phase 2 trial, explorer™4. Daily dosing will allow for 
the increase in trough levels and thus better efficacy may be expected with a lower dose.
A loading dose of 0.5 mg/kg concizumab will be given as the first dose, followed by [CONTACT_687617] 0.15 mg/kg in order to ensure steady-state lev els at the time of eptacog alfa 
(rFVIIa) administration. eptacog alfa (rFVIIa) will be administered one week after initiation of 
dosing with concizumab in a non-bleeding state to assess safety of tr eatment with eptacog alfa 
(rFVIIa) in patients exposed to concizumab treatment.
Embryonic exposure in pregnant female partners of men treated with concizumab is highly unlikely 
and there is no need for protocol requirements for use of contraception in phase 2 and 3 trials.
5.3 Treatment of patients
The following products will be administered in the trial.
Table 5–[ADDRESS_932204] of products provided by [CONTACT_687624] B a100 mg/mL solution for s.c. 
injection in a 3 mL cartridge
bSubcutaneous administration usingNovoPen
®4For prophylactic 
treatment in 76 weeks (for concizumab arm in 
the main part and 
extension part).
For prophylactic 
treatment in 52 weeks (for comparator arm in 
the extension part).
eptacog alfa (rFVIIa)a, c5 mg/vial Powder for solution 
for i.v. injectionIntravenous 
administrationFor treatment of 
breakthrough bleeding 
epi[INVESTIGATOR_687582] (screening, main, extension and follow up part). 
c
Administration of 
doses higher than histidine solvent (5 mL) Prefilled syringes for 
solution for i.v. 
injection 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 37 of 138
90μg/kg to patients 
exposed to concizumab is not allowed.
For on-demand 
treatment at the discretion of the 
investigator in 24 
weeks for comparator arm in the main part. 
In the concizumab arm 
and comparator arm after switching to 
concizumab in the 
extension part of the 
study a single 90 μg/kg 
dose for initial safety 
assessments in a non-
bleeding state.
a
Will be provided for as long as patients participate in the trial (screening, main, 
extension and follow 
up part)
aInvestigational medicinal product (IMP)
b Not to be confused with the daily injected volume (~150 μL, depending on dose strength and body weight)
cNon-investigational medicinal product (NIMP)
The NovoPen®4 injector will be supplied by [CONTACT_535242] s.c. administration of 
concizumab. It will be labelled in accordance with national legislation and a copy of the label can be found in the Trial Materials Manual, see Section 9.
5.3.1 Concizumab arm
[IP_ADDRESS] Concizumab prophylactic treatment (main and extension part)
Concizumab will be given s.c. once daily 0.15 mg/kg (with poten tial dose escalation to 0.20 and 
0.25 mg/kg). The dose escalation criteria are described, see Section 5.3.[ADDRESS_932205] dose of 
concizumab will be given at the trial site under medical supervision.
A loading dose of 0.5 mg/kg will be given as the first concizumab dose at visit 2 in order to ensure 
steady state levels at the time of the administrati on of eptacog alfa (rFVIIa) in a non-bleeding state 
at visit 3, see Section 5.3.4 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 38 of 138
The patients will be trained in s.c. administration of concizumab with NovoPen®[ADDRESS_932206] scheduled treatment visit. 
5.3.2 Comparator arm (eptacog alfa (rFVIIa))
[IP_ADDRESS] On-demand treatment (main part)
During the main part of the trial, patients will receive eptacog alfa (rFVIIa) for treatment of 
bleeding epi[INVESTIGATOR_1841], with a dose regimen at the discretion of the investigator.
[IP_ADDRESS] Concizumab prophylactic treatment (extension part)
After completion of the main part, the patients will continue the trial in the extension  part and will 
switch to prophylactic treatment with s.c. daily administration of concizumab 0.15 mg/kg (with potential dose escalation to 0.20 and 0.25 mg/kg) s.c. daily administration.
The same dose escalation criteria as described b elow (for the initial concizumab arm) will apply.
A loading dose of 0.5 mg/kg will be given as the first concizumab dose at visit [ADDRESS_932207] 2 weeks of the treatment with concizumab 0.15 mg/kg is considered as a run-in period. Hence, bleeding epi[INVESTIGATOR_687522] 2 weeks should not influence a dose escalation 
decision.
All spontaneous bleeding epi[INVESTIGATOR_1841] (sBEs) are counted from 2 weeks after visit 2 (or visit 9 when
switching from eptacog alfa (rFVIIa) to concizumab) (first treatment visit) until visit 16 (end of
treatment visit), i.e. a total of [ADDRESS_932208] take into account the 
full clinical pi[INVESTIGATOR_535049], including coagulation parameters.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 39 of 138
Dose 0.15 mg/kg: 
When sBE occurs, the investigator will determine if ≥[ADDRESS_932209] occurred within the preceding 12
weeks (including the current sBE). If yes, and if investigator deems it safe, the patient will be dose escalated from 0.15 to 0.20 mg/kg at the next scheduled  visit. If the investigator judges that this 
visit is scheduled too late, he/she should contact [CONTACT_687625].
Dose 0.20 mg/kg: 
When sBE occurs, the investigator will determine if ≥[ADDRESS_932210] occurred within the preceding 12
weeks (including the current sBE), counting only new sBEs from the beginning of the 0.20 mg/kg 
treatment period. If yes, and if investigator deems it safe, the patient will be dose escalated from 
0.20 to 0.25 mg/kg at the next scheduled visit. If the investigator judges that this visit is scheduled too late, he/she should contact [CONTACT_941] p atient for an unscheduled visit sooner.
Dose 0.25 mg/kg: 
Patients are not dose escalated further regardless of the number of sBEs. When an sBE occurs, the 
investigator will determine if ≥ [ADDRESS_932211] occurred within the preceding 12 weeks (including the 
current sBE), counting only new sBEs from the beginning of the 0.25 mg/kg treatment period. If yes, then the patient must be discontinued due to lack of effi cacy, see Section 6.4.
The possibility of dose escalation at unscheduled vi sits is necessary in order to avoid  bleeding
epi[INVESTIGATOR_687523]: e.g. if the dose escalation eliciti ng bleeding epi[INVESTIGATOR_687524] a scheduled visit, the patient will avoid to wait 8 weeks for the next scheduled visit (in the extension part).
Figure 5–3 Dose escalation for one individual patient in the concizumab arm
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 40 of 138
Figure 5–4 Dose escalation for one individual patient in the comparator arm
5.3.4 Co-administr ation of eptacog alfa (rFVIIa)
eptacog alfa (rFVIIa) will be used for tr eating breakthrough bleeding epi[INVESTIGATOR_687525]; one 
week after initiation of dosing with concizumab, a single 90 μg/kg dose of eptacog alfa (rFVIIa)
will be administered in a non-bleeding state at the trial site under medical supervision to assess 
safety of treatment with eptacog alfa (rFVIIa) in patients exposed to concizumab treatment. 
Hereafter, patients will be closely clinically obs erved at the site for potential safety issues for at 
least 12h and evaluated again at site after 24h. Between 12h and 24h, the patient must either stay at the site or at a hotel or at home if he lives nearby [CONTACT_687626] 3 or 9.1 the day after.
Dosing of eptacog alfa (rFVIIa) in the first 4 patients randomised to concizumab arm will be 
staggered so that the period between eptacog alfa (rFVIIa) administrations from one patient to 
another is at least 48 hours. If no safety concerns are observed (for example signs and symptoms ofthromboembolism, such as swelling, pain and redness of the leg, shortness of breath, and chest pain) by [CONTACT_687627] (rFVIIa) and when 
the next daily concizumab dose is to be given, the investigator allows the individual patient to 
administer concizumab prophylactically at home and if needed, treat breakthrough bleeding epi[INVESTIGATOR_687526] (rFVIIa). The patients will receive prophylactic doses of concizumab 0.15 mg/kg daily th roughout the main part (24 weeks) and the extension part (52 
weeks), unless dose escalation criteria are fulfilled, see Section 5.3.3 .
In case safety concerns are raised by [CONTACT_687628] (rFVIIa) administration and 
these concerns meet the described criteria for putting enrolment of additional patients on hold, dosing in the individual patients will be halted and furt her recruitment in the trial will be halted, see 
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 41 of 138
Section 12.7. In case safety concerns that do not meet the criteria for putting enrolment of additional 
patients on hold are observed by [CONTACT_093], dosing in that individual patient will be halted 
until further evaluation. In such cases, all available data will be assessed by [CONTACT_1578] (DMC), see Section 12.8.2 .
5.3.5 Treatment of b leeding epi[INVESTIGATOR_687527] 1 and visit 2 can be treated with any by[CONTACT_71360] 
(e.g., eptacog alfa (rFVIIa), FEIBA®) up to a period of 24 hours (for eptacog alfa (rFVIIa)) or 48 
hours (for FEIBA®) prior to first concizumab administration at visit 2. N ovo Nordisk  will provide 
eptacog alfa (rFVIIa) throughout the trial. The patient can treat himself and then he must call the 
site. The bleeding epi[INVESTIGATOR_687528].
Breakthrough bleeding epi[INVESTIGATOR_687529] 2-[ADDRESS_932212] be treated with eptacog alfa (rFVIIa). Upon breakthrough bleeding epi[INVESTIGATOR_687530]. The investigator should instruct the patient about 
whether he should go to the site to  receive treatment or if he can administer a single dose of eptacog 
alfa (rFVIIa) which is not higher than 90 μg/kg without delay to treat the breakthrough bleeding
epi[INVESTIGATOR_1865]. If the patient is instructed to administer the eptacog alfa (rFVIIa) dose at home, following 
the administration, the patient should immediately go to the site for further clinical evaluation. The 
bleeding epi[INVESTIGATOR_687531] (eDiary).
Breakthrough bleeding epi[INVESTIGATOR_687529] [ADDRESS_932213] be treated 
with eptacog alfa (rFVIIa). The patient can treat himself without delay but must inform the site that a bleeding epi[INVESTIGATOR_71274]. Doses of eptacog alfa (rFVIIa) those are lower than 90 μg/kg may 
be used to treat breakthrough bleeding epi[INVESTIGATOR_687597] i nvestigator. Ad ministration 
of doses higher than 90 μg/kg to patients exposed to concizumab is not allowed. If a single dose of 
eptacog alfa (rFVIIa) is not sufficient to stop a bleeding epi[INVESTIGATOR_1865], the patient should inform the site and in agreement with the investigator may administer a second dose of eptacog alfa (rFVIIa) not 
higher than 90 μg/kg 2-3h after the first dose has been administered. The same procedure should be 
repeated in case the second dose of eptacog alfa (rFVIIa) is not sufficient to stop the bleedingepi[INVESTIGATOR_1865]. If more than three 90 μg/kg doses of eptacog alfa (rFVIIa) are needed to stop a bleeding 
epi[INVESTIGATOR_1865], the patient should go to the site without delay. The definition and diagnostic criteria of 
DIC, acute myocardial infraction, stroke, deep vein thrombosis, pulmonary embolism and 
peripheral artery occlusion is provided in section 12.1.[ADDRESS_932214] be recorded in 
the eDiary.
Breakthrough bleeding epi[INVESTIGATOR_687529] 16 and visit 17 (follow-up part) may be treated with 
eptacog alfa (rFVIIa) or other products at the discretion of the investigator. The patient can treat 
himself with eptacog alfa (rFVIIa) at home with out delay. Only eptacog alfa (rFVIIa) will be 
provided by [CONTACT_3454]. The bleeding epi[INVESTIGATOR_535167].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 42 of 138
See Table 5–1 and Table 8–3 .
5.3.6 Prohibited medication 
∀Treatment with anti-fibrinolytics (e.g. tranexamic acid, aminocaproic acid)*
∀Heparin, except for sealing of central venous access ports according to local practice
∀Vitamin-K antagonists
∀Direct oral anticoagulants (DOACs)
∀Home treatment (between visit 2 and visit 16) with activated prothrombin complex 
concentrates (FEIBA®)
* Local/topi[INVESTIGATOR_535169]. Use of single systemic doses in se vere bleeding epi[INVESTIGATOR_1841], after careful benefit risk 
evaluation, is allowed.
5.[ADDRESS_932215]
When discontinuing trial products (visit 16 or earlier), the patient should be switched to a suitable 
marketed product at the discretion of the investigator. Only eptacog alfa (rFVIIa) will be provided 
by [CONTACT_3454]. The patient will not be provided with concizumab or eptacog alfa (rFVIIa) after 
end of trial (EOT) (visit 17) by [CONTACT_3454].
5.[ADDRESS_932216] 24 weeks (the main pa rt of the trial) is considered necessary for 
providing r obust data that allow demonstration of clinical proof of concept and to support decision 
making regarding a phase 3 confirmatory trial. Dosing for additional 52 weeks will provide 
valuable long term efficacy and safety data.
Breakthrough bleeding epi[INVESTIGATOR_687533]. Therefore, it is expected that breakthrough bleeding epi[INVESTIGATOR_687534]. 
Consequently, eptacog alfa (rFVIIa) w ill be provided by [CONTACT_687629][INVESTIGATOR_1841]. In order to minimize the likelihood of any unforeseen adverse 
events associated with administration of eptacog alfa (rFVIIa) in these circumstances,
administration of eptacog alfa (rFVIIa) in a controlled setting will be performed at visit 3 or 9.1.
Please refer to the Investigator’s Brochure for further information.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 43 of 138
6 Trial population
6.1 Number of patients
Number of patients planned to be screened: [ADDRESS_932217]: 26
Number of patients expected to complete the trial: 24
∀Preferably 21 haemophilia A patients
∀Preferably [ADDRESS_932218] be answered “yes”.
1. Informed consent obtained before any trial- related activities. Trial-related activities are any 
procedures that are carried out as part of the tr ial, including activities to determine the suitability 
for the trial
2. Male haemophilia A or B patients with inhibitors aged ≥ 18 years at the time of signing 
informed consent
3. Patients currently treated on-demand with a minimum of six bleeding epi[INVESTIGATOR_8728] 24 
weeks (or twelve bleeds during 52 weeks) prior to screening
4. Documented history of high-titer inhi bitors towards FVIII or FIX, defined as ≥[ADDRESS_932219] be answered “no”.
1. Known or suspected hypersensitivity  to trial product(s) or related products
2. Previous participation in this trial. Participation is defined as signed informed consent3. Participation in any clinical trial of an a pproved or non-approved investigational medicinal 
product within the last 30 days or 5 half-lives (whichever is longer) from the last drug 
administration before screening
4. Any disorder which in the investigator’s opi[INVESTIGATOR_1649], might jeopardise patient’s safety or 
compliance with the protocol
5. Known inherited or acquired bleeding disorder other than haemophilia
6. Major surgery conducted within one month pri or to the initiation of trial activities or major 
surgery planned to occur during the trial3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932220] a significant infection or known systemic inflammatory 
condition which requires systemic treatment acc ording to the investigator’s judgement
10. Hepatic dysfunction defined as elevated liver transaminases (ALT) >3 times the upper limit of 
normal laboratory reference ranges at screening
11. Renal impairment measured as  estimated Glomerular Filtration Rate (eGFR) ≤ 60 ml/min/1.73 
m2for serum creatinine measured at screening for patients without evidence of renal damage
12. Platelet count ≤ 100x109/L at screening
13. Fibrinogen level < the lower limit of normal
14. Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX15. Antithrombin levels below the normal reference range at screening
6.[ADDRESS_932221] if the following applies:1. Included in the trial in violation of the inclusi on and/or exclusion criteria and/or randomised in 
violation of the randomisation criteria
2. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
3. Incapacity or unwillingness to follow the trial procedures
4. Anaphylactic reaction
5. Thromboembolic event
6. Event of Disseminated Intravascular Coagulation7. Lack of efficacy due to neutralizing antibodies8. Lack of efficacy defined as ≥ [ADDRESS_932222] dose level (0.25 mg/kg) of concizumab.
See Section 8.1.[ADDRESS_932223] 
prematurely.
6.5 Withdrawal from trial
The patient may withdraw consent at will at any time.
See section 8.1.5 for procedures to be performed for patients withdrawing consent.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932224] been treated and therefore familiar 
with eptacog alfa (rFVIIa) on-demand treatment, this trial population is  considered the most suitable 
for assessing the safety of administering eptacog alfa (rFVIIa) to patients in whom plasma TFPI [INVESTIGATOR_687535]. Finally, the trial population ref lects the patient population that will be selected 
in a potential subsequent phase 3 trial in which  the efficacy and safety of concizumab are to be 
confirmed.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 46 of 138
7 Milestones
Planned duration of recruitment period (FPFV-LPFV): 28 weeks
Planned FPFV: 16-Aug-2017
Planned FPFT: 30-Aug-2017
Planned LPFV: 28-Feb-2018
Planned LPLV: 23-Oct-2019
The total duration of concizumab treatment in this trial is 76 weeks for an individual patient
randomised to concizumab prophylaxis treatment at visit 2.
The total duration of concizumab treatment in the trial is 52 weeks for an individual patient 
randomised to eptacog alfa (rFVIIa) on-demand treatment at visit 2.
EOT is defined as last patient last visit (LPLV).
Recruitment
The screening and randomisation rate will be followed closely via the interactive web response 
system (IWRS) in order to estimate when to stop screening. All investigators will be notified immediately when the recruitment period ends, after  which no further patients may be screened and 
the IWRS will be closed for further screening. All patients screened during the recruitment period 
and found eligible for randomisation can be randomis ed in a 2:1 allocation to either the concizumab 
or the comparator arm within the timelines specified in the flow chart (see Section 2).
Trial registration:
Information of the trial will be disclo sed at clinicaltrials.gov, novonordisk-trials.com and 
clinicaltrials.jp. According to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure,
how-we-disclose-trial-information, it will also be disclosed according to other applicable requirements such as those of the International Committee of Medical Journal Editors (ICMJE),
[ADDRESS_932225] (FDAAA),13European Commission 
Requirements,[ADDRESS_932226] at these web sites, Novo Nordisk may disclose the investigator’s contact [CONTACT_687646] e patient. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.
Primary Completion Date (PCD) is the last assessment of the primary endpoint, and is for this 
protocol LPFT (visit 2) + [ADDRESS_932227] completed visit 9. The PCD determines the deadline for results disclosure at ClinicalTrials.gov according to FDAAA.
133URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 47 of 138
8 Methods and assessments
Assessments to be performed at the scheduled and at the unscheduled visits in the trial are described 
in this section, Figure 8–1 , Figure 8–2 and in Section 2.
Figure 8–1 Visit schedule – concizumab arm.
Figure 8–2 Visit schedule – eptacog alfa (rFVIIa) arm later switching to concizumab.
8.[ADDRESS_932228] of the fo llowing scheduled parts and visits depending upon
which arm the patient is randomised to:
Screening Part:
∀Visit 1 (screening visit)
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 48 of 138
Main Part:
∀Visit 2 (Randomisation and 1sttreatment visit with concizumab at site for patients 
randomised to the concizumab-arm)
∀Home treatment with concizumab daily
∀Visit 3 (treatment and PK-visit with concizu mab and eptacog alfa (rFVIIa) at site only for 
patients randomised to the concizumab-arm  - phone visit for patients randomised to the 
eptacog alfa (rFVIIa) on-demand arm)
∀Visit 4 (Assessment visit, patients treat themselves at home)
∀Visit 5 (Assessment visit, patients treat themselves at home)
∀Visit 6 (Assessment visit, patien ts treat themselves at home)
∀Visit 7 (Assessment visit, patients treat themselves at home)
∀Visit 8 (Assessment visit, patients treat themselves at home)
∀Visit 9 (Assessment visit, after the visit patients treat themselves at home – 1sttreatment 
visit with concizumab at site for patients randomised to the eptacog alfa (rFVIIa) arm)
Extension Part:
∀Visit 9.1 (treatment and PK-visit with concizumab and eptacog alfa (rFVIIa) at site ONLY
for patients randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 9.2 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 10 (Assessment visit, patients treat themselves at home)
∀Visit 10.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 11 (Assessment visit, patients treat themselves at home)
∀Visit 11.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on demand-arm)
∀Visit 12 (Assessment visit, patients treat themselves at home)
∀Visit 13 (Assessment visit, patients treat themselves at home)
∀Visit 14 (Assessment visit, patients treat themselves at home)
∀Visit 15 (Assessment visit, patients treat themselves at home)
∀Visit 16 (Assessment visit, no treatment at home before the visit a nd End of Treatment)
Follow-up Part:
∀Visit 17 (Assessment visit and End of Trial)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 49 of 138
Unscheduled Part:
∀Unscheduled visits can occur e.g. for dispen sing of trial product, dose es calation or when an 
assessment of bleeding epi[INVESTIGATOR_535056].
The duration of the visits (V1-V17) will depend on the assessments and the p atient’s individual 
training and/or discussion need on concizumab and eptacog alfa (rFVIIa) administration, NovoPen
®4, usage of eDiary, completion of the PRO etc.
8.1.[ADDRESS_932229] be obtained before any trial related activity at visit 1, see Section 18.2.
The trial includes a separate informed consent for long-term storage of human biosamples, see 
Section 24.2.
Storage of human biosamples and/or genotypi[INVESTIGATOR_687536]’ 
participation in the trial. Therefore, patients will  have the possibility to sign the informed consent 
for the trial and participate, while refusing per mission for biological specimens and/or genotypi[INVESTIGATOR_535057].
8.1.[ADDRESS_932230] address(es) and telephone number(s) of relevant trial clinic staff. Patients should be 
instructed to return the card to the investigator at th e last trial visit or to destroy the card after the 
last visit.
Each patient will be assigned a unique 6-digit patient number which will remain the same 
throughout the trial.
8.1.3 Screening failures and re-screening
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reason for not continuing in the trial.
Serious and non-serious adverse events from screening failures must be transcribed by [CONTACT_687630]. Follow-up on serious adverse events (SAEs) must be carried out 
according to Section 12. A screening failure session must be made in the IWRS. The case book 
must be signed in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 50 of 138
Re-screening is NOT allowed if the patient has failed one of the inclusion or exclusion criteria; this 
includes re-sampling if the patient has failed one of the inclusion or exclusion criteria related to 
laboratory parameters.
8.1.[ADDRESS_932231] undertake procedures 
similar to those for visit 9 (the last treatment in the main part) or visit 16 (the last treatment visit in the extension part) as soon as possible. The fo llow up visit (visit 17) must be performed 8 weeks 
(window minus 7 days) after last dose of trial drug.
The primary reason for premature discontinuation of  trial product must be specified in the end of 
treatment form in the eCRF, and final drug accountability must be performed. A treatment discontinuation session must be made in the IWRS.
Permanent premature discontinuation of treatment with trial product will lead to patient withdrawal 
from the trial.
8.1.[ADDRESS_932232] aim to undertake procedures similar to those 
for visit 9 (the last visit in the main part) or visit 16 (the last visit in the extension part) as soon as 
possible depending on where the patient is in the trial schedule.
The end-of-trial form must be completed, and final drug accountability must be performed even if 
the patient is not able to come to the trial site. A treatment discontinuation session must be made in the IWRS and the case book must be signed in the eCRF.
Although a patient is not obliged to give his reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the patient’s rights. 
Where the reasons are obtained, the primary reason  for withdrawing consent must be specified in 
the end-of-trial form in the eCRF.
8.1.6 Review/ evaluation of clinical outcome
Novo Nordisk has constituted an internal concizu mab safety committee and established an external 
DMC to perform ongoing safety surveillance of safety data relevant to concizumab, see Section 12.8.
Review of eDiary data and laborat ory reports etc. must be documented either on the documents or 
in the patient’s medical record.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932233] be asked for clarification and a conclusion made in the patient’s medical record. 
Care must be taken not to bias the patient.
8.1.7 Visit 1 (S creening part)
Informed consent must be obtained be fore any trial related activity, see Section 18.2
All assessments to be performed at screening are listed in Section 2.
After informed consent is given, patients will be as ked to complete the ePRO questionnaires before 
any other trial related activit ies are performed acc ording to Section 8.6.1 :
∀Hemo-TEM,
∀VERITAS-PRN®
Assessment results from physical examination and body measurements, as well as measurements of 
vital signs, urinalysis and ECG and details of any contemporary adverse events, must be entered 
into the eCRF.
A screening confirmation call must be performed in the IWRS, at the day of the visit.The investigator must review all information obtained from the screening procedures. If a patient 
does not meet all inclusion criteria or meets one or more of the exclusion criteria for the trial the 
patient does not qualify to be enrolled.
For bleeding epi[INVESTIGATOR_535058] (Visit1) to randomisation visit 
(Visit 2), information a bout the bleeding epi[INVESTIGATOR_535059] 2.
Patients will be provided with ep tacog alfa (rFVIIa), trial injection kits and direction for use (DFU) 
to cover the potential eptacog alfa (rFVIIa) treatment after the screening part of the trial and 
investigator will ensure that the patients are capable of treating themselves with eptacog alfa (rFVIIa).
Dispensing of eptacog alfa (rFVIIa ) should be performed in IWRS.
The patient must be instructed to call the site if any bleeding epi[INVESTIGATOR_1841], questions or issues arise after 
he has left the site.
8.1.8 Training of patients at visit 1, visit 2 and visit 9
During visit 1 and visit 2 and visit 9 (comparator arm) patients must be trained in self-
administration of concizumab in the home setting using NovoPen
®4. The dose of concizumab to be 
administered must be communicated to the patient a t visit 2 (if they are randomised to concizumab) 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 52 of 138
or at visit 9 (if they are randomised to eptacog alf a (rFVIIa) and switching to concizumab at visit 9). 
Furthermore, patients must be instructed and trained in the importance of reporting all the home treatments with concizumab, details of the bleeding epi[INVESTIGATOR_687537] (rFVIIa) treatments associated with these b leeding epi[INVESTIGATOR_254769]. The patient should call the site if 
bleeding epi[INVESTIGATOR_687584] [ADDRESS_932234], performed independently by [CONTACT_4677], preferably in the morning. Home treatment starts after visit 2 (concizumab arm) or when the 
patient is comfortable self-administrating trial product subcutaneously (concizumab) and 
intravenously (eptacog alfa (rFVIIa)).
8.1.10 Staggered recruitment
Dosing of eptacog alfa (rFVIIa) in the first 4 patien ts randomised to the concizumab arm will be 
staggered until the 4
thpatient randomised to the concizumab arm has completed visit 3 without any 
safety concerns raised by [CONTACT_093]. Until this time point, enrolled patients will not be 
randomised until the previous patient randomised to  concizumab has completed visit 3 without any 
safety concerns raised by [CONTACT_093]. Novo Nordisk will as sponsor control and communicate the staggered recruitment process.
8.1.11 Treatment  period – Main part
[IP_ADDRESS] Visit 2 (Randomisation)
Visit 2 should be sche duled 14 to 28 days after visit 1. The date of visit 2 will be considered as trial 
day 1.
It is important to verify the in/exclusion criter ia again and review central laboratory tests from 
screening.
The patients must be in a non-bleeding state and should not have received any by[CONTACT_71360] 
(e.g., eptacog alfa (rFVIIa), FEIBA
®) for treatment of bleeding epi[INVESTIGATOR_42988] a period of 24 hours 
(for eptacog alfa (rFVIIa)) or 48 hours (for FEIBA®) prior to the potential first concizumab 
administration (depending on the treatment arm) . After visit 2 only treatment with ep tacog alfa 
(rFVIIa) for bleeding epi[INVESTIGATOR_71249].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 53 of 138
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments listed in 2, must be performed before poten tial admin istration of concizumab
(depending on the treatment arm). Vital signs must be assessed both before (within 1 hour) and after 
concizumab administration. Pre-dose blood sampli ng must take place no more than 1 hour before 
concizumab administration.
Assessment results from concomitant medication, vital signs, body measur ement (weight only) and 
details of adverse events must be entered into the eCRF.
A randomisation and dispensing call must be performed in the IWRS.
In order to determine the correct amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dos ing table in the Trial Materials Manual (TMM) on 
basis of the patient’s current body weight. Investigator will communicate the daily dose of 
concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
For patients randomised to the concizumab arm, the first treatment with the loading dose of 
concizumab will be given.
The time point at which the completion of the first dose takes place corresponds to ‘Time on 
treatment’ = [ADDRESS_932235] concizumab and/or eptacog alfa (rFVIIa)
and trial injection kits and an eDiary device to be able to conduct and report home treatment and 
bleeding epi[INVESTIGATOR_687538].
The patient w ill be asked to ret urn all used, partly used and unused eptacog alfa (rFVIIa) during the 
trial as instructed by [CONTACT_093]. D rug accountability must be performed for eptacog alfa 
(rFVIIa), if applicable according to section 9.4. Unused histidine syringes should be returned at 
every visit and new histidine syringes should be dispensed to the patient.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932236] be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site. If the patient on concizumab needs to treat a bleeding epi[INVESTIGATOR_687540] (rFVIIa) at home, then he must visit the site immediately after.
[IP_ADDRESS] Visit 3 (Phone call for eptacog alfa  (rFVIIa) on-demand arm and PK visit for 
concizumab arm)
eptacog alfa (rFVIIa) on-demand arm:
Visit 3 for eptacog alfa (rFVIIa) on-demand arm is a phone call scheduled 7 days after visit 2 (with 
a visit window of +1 day).
All relevant assessments listed in Section 2, must be discussed.
Assessment results from concomitant medication and details of adverse events must be entered into 
the eCRF.
concizumab arm:
Visit 3 is to be scheduled 7 days after visit 2 (with a visit window of +1 day) and the visit takes two 
days.
All assessments are listed in Section 2, and must be performed accordingly and recorded in the 
eCRF.
Patients will be asked to complete the ePRO ques tionnaires before any ot her trial related  activities 
are performed accordi ng to Section 8.6.1 :
∀PGI-C
∀Hemo-TEM
Pre-dose blood sampling must take place no more than 1 hour before eptacog alfa (rFVIIa)
administration. Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa)
administration.
The concizumab dose should be administered fi rst followed by [CONTACT_687654]. eptacog alfa 
(rFVIIa) should be administered to the trial patients at the site under the surveillance of medically trained trial site staff. The interval between th e concizumab and eptacog alfa dose administration 
should not exceed more than 30 min.  
Samples for thrombin generation, haematology, coagulation parameters, concizumab ELISA and 
FVII ELISA are taken pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 55 of 138
10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (±20 min) and 
24h (±20 min).
The investigator must ensure that all assessments are performed as described in Section 2, The 
Investigator is requested to conclude after [ADDRESS_932237] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
At the visits the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until the next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and ep tacog alfa (rFVIIa). Unused histid ine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 4, 5, 6, 7 and 8
Patients should treat themselves at home according to their individual dosing schedule regardless of 
when visits 4, 5, 6, 7 and 8 are scheduled.
Visits 4, 5, 6, 7 and 8 are to be scheduled on trial day 29 (4 weeks), day 57 (8 weeks), day 85 (12 
weeks), day 113 (16 weeks) and day 141 (20 weeks)  respectively with a visit window of ±7days.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀PGI-C
∀Hemo-TEM3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 56 of 138
All assessments are to be performed according to Section 2, and the assessment results from 
concomitant medication, vital signs, body measur ement (weight only) and details of adverse events 
must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687541] e-Diary. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients randomised to concizumab arm at visit 2, evaluate if an escalation of the concizumab doses is needed according to the escalation rules described in section 5.3.[ADDRESS_932238] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visits the patient will be provided w ith concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until the next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and ep tacog alfa (rFVIIa). Unused histid ine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
At visit 8 patients should be reminded that treatment with concizumab (concizumab arm) must take 
place after the blood sampling at visit 9.
[IP_ADDRESS] Visit 9
Visit 9 is to be scheduled on trial day 169 (24 weeks) with a visit window of ±7days.
Patients randomised to eptacog alfa (rFVIIa) on-demand treatment at visit 2 will now be switched to 
concizumab treatment. At this visit the firs t treatment (loading dose) with concizumab will take 
place.
Treatment with concizumab must take place after the blood sampling for both the patients on the 
concizumab arm as well as patients on the eptacog alfa (rFVIIa on-demand) arm.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 57 of 138
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀PGI-C
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments are to be performed according to Section 2, and the assessment results from 
physical examination, concomitant medication, vita l signs, body measurement (weight only) and 
details of adverse events must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687585] e-Diary. Based on the assessment of any spontaneous bleeding epi[INVESTIGATOR_687542], for patients randomised to concizumab arm at 
visit 2, evaluate if an escalation of the concizumab doses is needed according to the escalation rules 
described in Section 5.3.[ADDRESS_932239] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab and eptacog alfa 
(rFVIIa) during the trial as instructed by [CONTACT_941] i nvestigator. Drug accountability must be performed 
for concizumab and eptacog alfa (rFVIIa). Unused  histidine syringes shoul d be returned at every 
visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 58 of 138
8.1.12 Treatment period – Extension part
[IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog alfa (rFVIIa)
on-demand arm)
Visit 9.1 is to be scheduled on trial day 176 (25 weeks) with a visit window of +[ADDRESS_932240] no more than 1 hour before eptacog alfa (rFVIIa)
administration. Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa)administration.
The concizumab dose should be taken first followed by [CONTACT_687654]. eptacog alfa (rFVIIa)
should be administered at the site under the surveillance of medically trained trial site staff. The interval between the concizumab and eptacog alfa dose administration should not exceed more than [ADDRESS_932241] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
Samples for thrombin generation, haematology, coagulation parameters, concizumab ELISA and 
FVII ELISA are taken pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9 h (± 10 min) and 12h (±20 min) 
and 24h (±20 min).
The Investigator is requested to conclude after [ADDRESS_932242] the conclusion in the eCRF prior to administration of the next dose of concizumab.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 59 of 138
[IP_ADDRESS] Visit 9.2 (ONLY patients previously on the eptacog alfa (rFVIIa) on-demand 
arm)
Visit 9.2 is to be scheduled on trial day 197 (28 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight  only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and re porting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, evaluate if an escalation of the concizumab doses is needed according to the escalation rules 
described in section 5.3.[ADDRESS_932243] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s
current body weight. Investigator will communicate the daily dose of concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/ or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 10
Visits 10 is to be scheduled on trial day 225 (32 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 60 of 138
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous bleeding epi[INVESTIGATOR_687543] 5.3.[ADDRESS_932244] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed  by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 10.1 (ONLY patients  previously on the eptacog alfa (rFVIIa) on-demand 
arm)
Visit 10.1 is to be scheduled on trial day 253 (36 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932245] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 11
Visit 11 is to be scheduled on trial day 281 (40 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous bleeding epi[INVESTIGATOR_687543] 5.3.[ADDRESS_932246] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and record the dose for the coming home treatment period in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 62 of 138
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and ep tacog alfa (rFVIIa). Unused histid ine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 11.1 (ONLY patients previously on the rFVIIa on-demand arm) 
Visit 11.1 is to be scheduled on trial day 309 (44 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, 
evaluate if an escalation of the concizumab doses is needed according to the escalation rules described in section 5.3.[ADDRESS_932247] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa ). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 63 of 138
[IP_ADDRESS] Visit 12, 13, 14 and 15
Visits 12, 13, 14 and 15 are to be scheduled on trial day 337 (48 weeks), 393(56 weeks), day 449 
(64 weeks) and day 505 (72 weeks) respectively with a visit window of ±7 days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687586] 5.3.[ADDRESS_932248] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa ). Unused histidine syringes should be returned 
at every visit and new histidine s hould be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
At visit [ADDRESS_932249] after the 
blood sampling at visit 16.
[IP_ADDRESS] Visit 16
Visit 16 is to be scheduled on trial day 533 (76 w eeks) with a visit window of ±7days. Further visit 
[ADDRESS_932250] day of treatment with concizumab.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 64 of 138
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs and details of adverse events must be entered into the eCRF. Treatment with concizumab 
must take place after the blood sampling at this visit.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066].
In the period from visit 16 to visit 17 patients can be treated with eptacog alfa (rFVIIa) or other 
products at the discretion of the investigator to treat eventual bleeding epi[INVESTIGATOR_1841]. Only eptacog alfa (rFVIIa) will be provided by [CONTACT_687631].
If necessary, a dispensing call must be performed in the IWRS. At the visit the patient will be 
provided with eptacog alfa (rFVIIa) and trial injection ki ts to be able to conduct home treatment 
until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. NovoPen
®[ADDRESS_932251] be performed for concizumab  and eptacog alfa (rFVIIa). Unused histidine
syringes should be returned at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if an y questions or issues (e.g. bleeding epi[INVESTIGATOR_1841]) arise 
after he has left the site. 
8.1.13 Visit 17 (End of trial) - Follow-up part
Visit 17 is to be scheduled on trial day 589 (84 weeks) with a visit window of minus 7 days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
physical examination, body measurements (weight only), vital signs and details of adverse events 
must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687544]. Patients should be asked if their female partner has become 
pregnant, see Section 12.5.1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 65 of 138
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa), unused 
histidine syringes, eDiary device and Trial card. Drug accountability must be performed for eptacog alfa (rFVIIa).
End-of-Trial information must be entered in the End-of-Trial form in the eCRF.
Completion or treatment discontinuation (if the trial is not completed) session should be performed 
in IWRS, see Section 10.
8.1.[ADDRESS_932252] be 
performed via IWRS.
The following forms can be found in the unscheduled visit in the eCRF:
∀Bleeding epi[INVESTIGATOR_1841]
∀Dosing with eptacog alfa (rFVIIa), concizumab including dose escalation, see Section 5.3.3 .
∀Surgery
∀Local, special and central laboratory (re-)sampling/results
∀Body measurements
8.2 Patient related information/assessments 8.2.1 Demogr aphy
Demography will be recorded at screening and consists of:
∀Date of birth (according to local regulation)
∀Sex
∀Ethnicity (according to local regulation)
∀Race (according to local regulation)
8.2.2 Concomitan t illness and medical history other than haemophilia
A concomitant illness is any illness, other than haemophilia, that is present at the start of the trial 
(i.e. at the first visit) or found as a result of a screening procedure or other trial procedures performed before first exposure to trial product. Al l concomitant illnesses shoul d be reported in the 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932253] be possible to verify the patient’s medical  history in source documents such as patient’s 
medical record, see Section 6.2and 6.3.
If a patient is not from the investigators own practice; the investigator must make a reasonable 
effort to obtain a copy of the patient’s medical record from relevant party e.g. primary physician. 
The investigator must document any attempt to obtain external medical information by [CONTACT_135540](s) when information was requested and who has been contact[INVESTIGATOR_530].
8.2.3 Concomitant medication
A concomitant medication is any medication, other than the concizumab and eptacog alfa 
(rFVIIa), which is taken during the trial, including the screening and follow-up period .
Details of any concomitant medication must be recorded at the first visit. Changes in concomitant 
medication must be recorded at each visit as they occur.
The information collected for each concomitant medicat ion includes trade name [CONTACT_18058], 
indication, start date and stop date or continuation.
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the patient’s eligibility to continue in the trial, the monitor must be informed.
8.2.4 Details of Haemophilia, Haemoph ilia treatment and bleed history
All available information on haemophilia, prior to screening should be recorded in the eCRF.
∀Diagnosis of haemophilia (date)
oClassification of haemophilia type (haemophilia A/B)
oSeverity of haemophilia (severe, moderate or mild)
oAetiology of haemophilia (congenital or acquired)
∀Family history of
oHaemophilia (Y/N)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 67 of 138
oInhibitors (Y/N)
oProthrombotic disorders (Y/N)
oThromboembolism (Y/N)
∀Inhibitor tests taken (Y/N)
oDate (dd- mmm-yyyy) 
oResult (BU)
∀Cut-off for positive inhibitor result
∀Deficiency factor level
The following information on bleedi ng epi[INVESTIGATOR_535068]:
∀Type of treatment
oProphylaxis or on-demand
oStart date
oStop date
∀Number of bleeding epi[INVESTIGATOR_535141]
∀Coagulation factor product(s)
oBrand name, or if the brand is not known, the type of product, (plasma derived or 
recombinant)
∀Dosage used for prophylaxis
∀Dosing frequency during prophylaxis 
∀Approximate dose to treat a bleeding epi[INVESTIGATOR_1865]
∀Approximate number of doses to treat a bleeding epi[INVESTIGATOR_1865]
∀Target joint listing (definition: a target joint is a joint in which [ADDRESS_932254] occurred within a consecutive 6-month period)
oLocation
oPosition (left/right)
oNumber of bleeding epi[INVESTIGATOR_1841]
8.3 Efficacy assessments
8.3.1 Bleeding epi[INVESTIGATOR_687545] (rFVIIa) and symptoms related to the underlying 
disease must be captured in the eDiary by [CONTACT_687647]. The trial 
site should be informed of the details of all bleeding epi[INVESTIGATOR_1841], including those that are treated outside of the trial site.
All information captured during visits to the trial site will be collected in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 68 of 138
When home treatment is initiated at visit 2 all bl eeding epi[INVESTIGATOR_687587] a (rFVIIa) in jection occ urring outside the trial site should be entered in the eDiary by 
[CONTACT_102], Section 13.3.
The completed eDiary is considered source data.
For reporting of bleeding epi[INVESTIGATOR_687547]/SAEs, please refer to Section 12. In case of life-
threatening bleeding epi[INVESTIGATOR_1865], it should always be reported as an SAE, see Section 12.1.[ADDRESS_932255] be recorded for any bleeding epi[INVESTIGATOR_1865], including bleeding epi[INVESTIGATOR_687548] (rFVIIa):
∀Start date and time
∀Stop date and time (see Table 8–1 )
∀Anatomical location
oPosition (left/right)
∀Cause (see Table 8–2 )
ospontaneous
otraumatic
opost-surgical
∀Severity (see Table 8–3 )
omild/moderate, severe
oclassification and recording of severe bleeding epi[INVESTIGATOR_687549]
∀Treatment, if any 
oeptacog alfa (rFVIIa) administration or other product administration
odose, date, stop time
oother medicinal treatments related to the bleeding epi[INVESTIGATOR_1865] (pain relieving 
medication, non-medical therapy etc.)
orecord as concomitant medication (section 8.2.3 )
∀Symptoms during bleeding epi[INVESTIGATOR_1865](s)
oPain
oBlood in urine
oTingling sensation
oSwelling
oMouth/Gum bleed
oWarmth
oLoss of movement
oBruises
oNose bleed3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 69 of 138
Only report the bleeding epi[INVESTIGATOR_535074]/SAE if fatal, life threatening or evaluated as related to 
trial product, see Section 12.1.1 and12.1.2 .
Table 8–1 Definition of stop of bleeding epi[INVESTIGATOR_535075]: When the patient experiences/observes signs of cessation of the active bleeding 
epi[INVESTIGATOR_535076]; pain relief, no increase in swelling/limitation of motion and 
improvement in other objective signs of the bleeding epi[INVESTIGATOR_535077]: When pain and objective signs of the bleeding epi[INVESTIGATOR_687550] 8–2 Definitions of bleeding epi[INVESTIGATOR_1841] (cause of bleed)
Category Definition
Spontaneous Not linked to a specific, known action or event
Traumatic Caused by a specific, known action or event (e.g. injury or exercise)
Post-surgical Bleeding epi[INVESTIGATOR_535079]. Bleeding epi[INVESTIGATOR_687598] 8–3 Definition of bleeding epi[INVESTIGATOR_535081]/Moderate Examples: uncomplicated musculoskeletal 
bleeding epi[INVESTIGATOR_1841] (joint, muscular bleeding epi[INVESTIGATOR_434840]), 
mucosal- or subcutaneous bleeding epi[INVESTIGATOR_434838]/moderate bleeding epi[INVESTIGATOR_687552]/moderate bleeding epi[INVESTIGATOR_1841]: 
∀patient must call the site between 
visit 1-2 and visit 3-16 (see 2-3 
and 9-9.1 below)
∀patient must call the site between 
visit 2-3 or visit 9-9.1 (eptacog 
alfa arm) and if treated at home, 
go to the site immediately after
∀patient can treat themselves at 
home between visit 16 and visit 
173URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 70 of 138
Category Definition Treatment recommendation
Severe Examples: intracranial, retroperitoneal, 
iliopsoas and internal neck bleeding epi[INVESTIGATOR_1841]; 
muscle bleeding epi[INVESTIGATOR_535084]; bleeding epi[INVESTIGATOR_80799] a significant decrease in the haemoglobin level (>3g/dl)
Severe bleeding epi[INVESTIGATOR_535085]-threatening bleeding epi[INVESTIGATOR_687553] a bleeding epi[INVESTIGATOR_687554], i.e. the original dosing schedu le should be maintained unless investigator judges 
otherwise.
Dosing for bleeding epi[INVESTIGATOR_687555] (rFVIIa) should be documented in the eCRF (visit 1 
to visit 2) and eDiary (visit 2 to visit 17). After vi sit [ADDRESS_932256] be recorded either in 
the eDiary (if treated at home) or in the eCRF  (if treated at the trial site), see section 13.3.
Investigator must instruct the patient not to perform preventive treatment with eptacog alfa (rFVIIa)
after bleeding stop as defined in Table 8–[ADDRESS_932257] the patient to use eptacog alfa (rFVIIa) as rescue medication to treat 
bleeding epi[INVESTIGATOR_488840] [ADDRESS_932258] review the bleeding and treatment data collected by [CONTACT_687632] 13.3.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 71 of 138
For in-between visit administrations of trial drug, patients will self-administer concizumab (and 
eptacog alfa (rFVIIa) as rescue medication) and will record treatment in the eDiary, which will be reviewed during periodic calls to/contact [CONTACT_687648].
8.[ADDRESS_932259] physical examination and include the following.
∀General appearance
∀Head, ears, eyes, nose, throat, neck
∀Respi[INVESTIGATOR_2133]
∀Cardiovascular system
∀Gastrointestinal system including mouth
∀Genito-urinary system, breast(s)
∀Musculoskeletal system
∀Central and peripheral nervous system
∀Skin
∀Lymph node palpation
The investigator must evaluate the results of the examination and classify them as either:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as Medical History (Section 8.2.2 )
oIf observed after screening: report an AE/SAE (Section 12)
Measurements will be reported in the eCRF.
8.4.2 Body measurements
∀Height (cm), at screening
∀Body weight (kg), (with one decimal)
The body weight assessed at each visit will be us ed for calculation of the concizumab dose to be 
administered until next visit.
Measurements will be reported in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932260] administration unless otherwise 
specified.
∀Body temperature (°C)
∀Systolic and diastolic blood pressure, sitting (BP) (mmHg)
∀Pulse, sitting (beats/min)
∀Respi[INVESTIGATOR_535095]: At visits 2 and visit 3 (for patients randomised to concizumab) and at visit 9 and visit 9.1
(for patients initiating concizumab treatment at  visit 9), the measurements are also performed after 
concizumab administration.
The investigator must evaluate the vital signs and classify the outcome as either:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness, section 8.2.2
oIf observed after screening:  report an AE/SAE, section [ADDRESS_932261] evaluate the ECG [standard 12 lead] at screening and classify the outcome as
either:
∀Normal or abnormal.
∀If abnormal the investigator must:
oSpecify the abnormality
oRecord if the result is clinically significant? (Yes/No)
oIf observed before or at Screening: record as Medical History, section 8.2.2
oIf observed after screening: report an AE/SAE, section [ADDRESS_932262] been 
reviewed. Outcome will be reported in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 73 of 138
8.4.5 Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12.
[IP_ADDRESS] Medication error
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form:
∀Trial product involved 
∀Classification of medication error
∀Whether the patient experienced any adverse event(s) as a resu lt of the medication error 
∀Suspected primary reason for the medication error 
For definition of med ication errors, see Section 12.1.4 .
[IP_ADDRESS] Adverse events requiring additional data collection
For some AEs additional data collection is required and specific event forms must be completed in 
the eCRF in additi on to the AE form . 
In case any of these events fulfil the criteria for a serious adverse event, please report accordingly, 
see Section 12.
For the following AEs additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
Injection site reaction 
Investigation of injection site reactions will be performed locally at all visits after visit 2 until visit 
16 based on patient feedback and by [CONTACT_687634]:
Symptoms e.g.
∀Pain
∀Numbness
∀Itching
∀Burning
Signs e.g.
∀Redness (mm x mm)
∀Induration (mm x mm)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 74 of 138
∀Swelling
∀Dimpling
∀Macula
∀Haematoma
∀Bleeding
∀Other (visual reactions)
Any injection site reaction symptom (evaluated at visit 2-16) should be recorded in the AE form and 
the injection site reaction form, see Section 12.1.5 .
A separate AE should be recorded for each injection site reaction symptom. The affected area 
should also be evaluated for redness and induration in mm using a ruler. To ensure all local 
injection site assessments are performed at the in jection site, the area around the site will be marked 
with a pen prior to injection.
In the event of a local reaction, additional visual assessments (as described above) will be 
performed until resolution as judged necessary by [CONTACT_093].
Assessment of injection si te reactions can be performed at any time, if deemed necessary by [CONTACT_1275].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932263] be 
obtained if available on the hypersensitivity reaction form:
∀Signs and symptoms associated with the event
∀Time of appearance after administration of trial drug
∀Relevant immunological tests performed, see Section [IP_ADDRESS]
∀Treatment given for the reaction
∀Previous history of similar reactions
∀Association with the trial product(s)
∀Relevant risk factors associated with the event
∀Storage condition of the trial product
∀Total number of doses, from first day on trial product, up to the time of this event
8.5 Laboratory assessments
An approximate total blood volume of 625 mL will be taken from each patient on the concizumab 
arm and 725 mL from each patient on the eptacog alfa (rFVIIa) arm.
A laboratory manual will be provided for detailed description of obtaining and processing blood 
samples.
All laboratory blood samp les collected for this trial except for haematology samples at all visits and 
coagulation parameters at visits 3 and 9.1 are to be shipped for analysis at central laboratories or further distribution to special laboratories. Haematology samples (all visits) and coagulation 
parameters (visit 3 and 9.1) are to be analy sed locally. Ports cannot be used for blood sampling.
The laboratory provides resu lts to the trial sites in the units preferred by [CONTACT_135545].
Laboratory reports listing results from centrally analysed samples will be made available for the 
investigator. Investigator must review and evaluate the results and report AEs for results which are 
clinically significant. Laboratory reports will where possible indicate normal ranges.
Categorisation of clinical significance for out of range results may not be required for the following 
laboratory parameters and the investigator is there fore not required to perform a categorisation even 
though these parameters are listed in the laboratory report: FVIII/FIX activity, FVIII/FIX inhibitor 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932264], Thrombin generation, Free TFPI (TFPI [INVESTIGATOR_535096]), conc izumab concentration 
in plasma, anti-concizumab antibodies, Total TFPI [INVESTIGATOR_687556].
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested an alyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. The investigator must review all laboratory results for concomitant illnesses and AEs and report these according to Section 8.2.[ADDRESS_932265] be sent to the central laboratory for analysis; 
if additional laboratory sampling is needed, e.g. to follow up on AEs, this must be done at a local 
laboratory except for biomarkers and anti-drug antibodies (anti-concizumab IgE antibodies and 
anti-concizumab antibodies).
Laboratory samples will be destroyed no later than  at finalisation of the clinical trial report (CTR).
Antibody samples and human biosamples, if applicable, will be stored as described in Section 24.2.
The investigator may not be able to review the re sults of antibody measurements in relation to AEs 
as these are often analysed after LPLV.
8.5.1 Laboratory a ssessments for efficacy
[IP_ADDRESS] Thrombin generation
The Thrombin Generation Assay (TGA) will be collected at all visits.
Further at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9 h (± 
10 min), 12h (± 20 min) and 24h (± 20 min).
The TGA is included as an exploratory PD assessment.The generation of thrombin is a fundamental part of the haemostatic system, and is a key 
measurable parameter of the formation of a clot under bleeding or thrombotic conditions. The 
thrombin burst is crucial for the formation of a stable fibrin clot.
The Calibrated Automated Thrombogram (CAT) method (used by [CONTACT_535235]) will be 
used to measure thrombin generation (TG). This method uses a slow acting fluorogenic substrate that allows continuous measurement of thrombin generation in double centrifuged citrated plasma.
In this assay set-up thrombin generation is initiated by [CONTACT_687635]. The result is obtained by [CONTACT_49719] a constant known thrombin activity in a parallel non tissue factor initiated sample. The assay has been validated fit-for-purpose.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 77 of 138
The thrombin generation endpoints are defined but not limited to:
∀The Endogenous Thrombin Potential (ETP) – the area under the curve 
∀Peak thrombin generation
∀Velocity Index 
[IP_ADDRESS] Free TFPI
[INVESTIGATOR_687557] (TFPI [INVESTIGATOR_535096]) will be collected at all visits, pre-dose at visit 2 and 3 
(concizumab arm), visit 9 and 9.1 (eptacog alfa (rFVIIa) arm) and visit 16.
The free TFPI [INVESTIGATOR_687558]  
 (named and referred to  TOTAL TFPI) and will be used for PD assessments.
8.5.2 Laboratory a ssessments for safety
[IP_ADDRESS] Urinalysis
∀pH
∀Protein
∀Glucose
∀Bilirubin
This is a semi qu alitative measurement which will be performed (locally) at the screening visit by 
[CONTACT_687655]. The results will be recorded in the 
eCRF.
The investigator must evaluate the results and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must:
oRecord if the result is clinically significant? (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
[IP_ADDRESS] Haematology
Haematology samples are to be sampled and analysed locally at all visits.
Further at visit 3 (concizumab arm) and 9.1 (ep tacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa), 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9 h (± 10 min), 12h (± 20 min) and 24h (± 20 min).
∀Haemoglobin
∀Erythrocytes (cell count)
∀Thrombocytes (platelet count)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 78 of 138
∀Leucocytes (cell c ount)
∀Differential leucocytes cell count
oLymphocytes
oMonocytes
oNeutrophils
oEosinophils
oBasophils
The investigator must evaluate the results and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must: 
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
Haematology results are to be entered into the eCRF.
[IP_ADDRESS] Biochemistry
Biochemistry samples are to be sampled and analysed centrally at all visits.
∀Creatinine
∀Albumin
∀Bilirubin; total, dir ect, indirect
∀Aspartate aminotransferase (AST)
∀Alanine aminotransferase (ALT)
∀Gamma glutamyltransferase (GGT) 
∀Alkaline phosphatase
∀C-reactive protein (CRP)
The investigator must evaluate the results of the examination and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
[IP_ADDRESS] FVIII/FIX activity
FVIII/FIX activity is to be sampled and analysed centrally at visit 1, visit 9 and visit 16.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 79 of 138
∀FVIII activity level (IU/mL) or
∀FIX activity level (IU/mL)
[IP_ADDRESS] Coagulation parameters
Coagulation parameters will be performed centrally at all visits with the exception of visit 3 and 
visit 9.1 where the PT, APTT, and Fibrinogen will be performed locally.
Further at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa) at 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9h 
(±10 min) and 12h (±20 min) and 24h (± 20 min) locally.
∀Fibrinogen – centrally and locally
∀Prothrombin time (incl. INR) (PT) centrally and locally
∀D-dimer – only centrally
∀Prothrombin fragment 1+2 – only centrally
∀Activated partial thromboplastin time (APTT) – centrally and locally
∀Antithrombin (AT) activity – only centrally
The investigator must evaluate the results of the examination and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
Coagulation parameters analysed locally are to be entered into the eCRF.
[IP_ADDRESS] FVIII/FIX inhibitors
FVIII/FIX inhibitor level will be measured by [CONTACT_687656] 1, visit 9 and visit 16. 
∀FVIII inhibitors (BU) or
∀FIX inhibitors (BU)
[IP_ADDRESS] Anti-concizumab antibodies
Samples for the determination of anti-drug antibodies collected during the treatment period must be 
drawn at all visits and prior to administering c oncizumab at visit 2 and 3 (concizumab arm) and 
visit 9 and 9.1 (eptacog alfa (rFVIIa) arm) and visit 16 for both arms.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932266] conc izumab (anti-drug antibodies [ADA]) will be 
performed at specialised laboratories whereas a ssessment of neutralising antibodies will be 
performed at Novo Nordisk.
Analysis for ADA will be done with a bridging ECL assay (binding ADA assay), using labelled 
concizumab for antibody capture and detection. If a sample is confirmed positive in the 
confirmatory assay, the sample is considered  positive for bindi ng antibodies. Confirmed positive 
samples will be characterised in a specificity assa y for binding to IgG backbone, CDR region or the 
S241P mutation. Furthermore, positive samples will  be characterised for neutralising activity using 
a modified TFPI [INVESTIGATOR_687599] y (neutralising ADA assay). All anti body assays are validated 
according to international guidelines and recommendations.
The following analyses will be available:
∀Anti-concizumab antibodies assay
∀Specificity assay (Anti-concizumab antibodies cross reacting with IgG4 backbone, CDR 
region or S241P mutation)
∀Anti-concizumab neutralising antibodies assay
The samples will be analysed in batches during the trial and results will be available to the data 
monitoring committee approximately every third month after the first patient has been dosed. 
Neutralising antibodies will be analysed and reported at the EOT. A detailed description of the 
assay methods will be included in the antibody analysis report at the end of the trial.
Investigators will be notified in case their patient is shown to have developed neutralising 
antibodies against concizumab.
In the event that a trial patient develops binding ADAs towards concizumab during the course of the 
trial and has measurable binding ADAs at his End-of-Trial visit, the patient may attend an ADA follow-up visit. The ADA positive patients will be called for additional visits, e.g. every 4 to 6 weeks, for safety assessment and blood sampling for ADA and PD markers (free TFPI [INVESTIGATOR_535177]). The ADA positive patients will be followed no longer than one year after 
End-of-Trial.
Hypersensitivity
If suspi[INVESTIGATOR_1884] a hypersensitivity reaction occurs, patients should be instructed to contact [CONTACT_535238], see Section 12.1.5 .
In the event of a severe local and/or systemic hypersensitivity reaction possibly or probably related 
to trial product, blood sampling for assessment of anti -concizumab IgE antibodies as well as anti-
concizumab antibodies should be conducted in relation to the reaction and no later than 1-2 weeks 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 81 of 138
after the event. Additional testing may be performed if deemed relevant (e.g. anti-Host Cell Proteins 
(HCP) antibodies).
In the event of a severe systemic hypersensitivity  reaction to trial product it is recommended also to 
test for tryptase (total and/or mature tryptase) within [ADDRESS_932267] the hypersensitivity reaction for assessing the 
persistence of the IgE response. Tryptase measurements are not required at the follow up visits.
Additionally, basophil activation testing may be performed if deemed relevant. This can be 
performed using existing samples and/or by [CONTACT_535239]’s basophil cells from an additional 
blood sample taken 3-4 weeks and no later than 2 months after the event. Similarly, prick tests 
and/or intra-dermal tests may be performed if relevant using trial product or components of trial product. Complement may be measured in case of suspi[INVESTIGATOR_535150].
Results from the following additional tests will be reported to Novo Nordisk Safety Operations for 
inclusion in the ARGUS database and included in the narratives, if measured.
Test to be performed in case of severe hypersensitivity
∀Anti-concizumab IgE antibodies
∀Anti-concizumab antibodies (additional to scheduled time points)
Additional testing may be performed if deemed relevant e.g.
∀Anti-Host Cell Proteins (HCP) antibodies
∀Anti-HCP IgE antibodies
∀Basophil activation results
∀Prick test/intra-dermal test
∀Complement test results
Furthermore, it is recommended locally to test for
∀Tryptase (total and/or mature tryptase)
[IP_ADDRESS] Concizumab ELISA
Concizumab ELISA will be collected at all visits where patients are in tr eatment with concizumab.
Samples will be collected pre-dose at visit 2 for concizumab arm and visit 9 for eptacog alfa 
(rFVIIa) arm) and visit 16 for both arms.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 82 of 138
At visit 3 for concizumab arm and visi t 9.1 for ep tacog alfa arm samples for con cizumab ELISA are 
taken pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (±20 min) and 24h (±20 min).
Concizumab will be quantified using a validated ELISA assay. 
Recombinant human TFPI [INVESTIGATOR_687559]. A colorimetric detection signal is 
obtained by [CONTACT_687657]-human IgG4 specific 
antibodies with the chromogenic substrate TMB (3,3´, 5,5´- tetramethyl benzidine). The amount of 
anti-TFPI [INVESTIGATOR_535103], quality control and test samples correlates with the obtained 
signal strength.
Validation of the assay follows current guidelines for bioanalytical method validation. Bioanalytical 
data will be reported in a bioanalytical report.
[IP_ADDRESS] FVII ELISA
FVII ELISA will be collected at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) pre-
dose eptacog alfa (rFVIIa) and post-dose at 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 
min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points, except pre-dose, occur 
after eptacog alfa (rFVIIa) administration.
FVII in plasma will be quantified using a validated enzyme-linked immunosorbent assay (ELISA).
The FVII ELISA will detect the total sum of FVII in a sample, including endogenous FVII, eptacog 
alfa (rFVIIa) and FVII in complex with other mo lecules e.g. antithrombi n. The ELISA has been 
validated for measuring FVII in human citrated plasma samples. Validation follows current guidelines for bioanalytical method validation. Bioanalytical data will be reported in a bioanalytical report.
[IP_ADDRESS] Total TFPI
[INVESTIGATOR_687560]. Samples w ill be collected pre-dose at visit 2 and 3 
(concizumab arm) and visit 9 and 9.1 (eptac og alfa (rFVIIa) arm) and visit 16 for both arms.
The total TFPI [INVESTIGATOR_67147] (free and concizumab bound) will be included as an exploratory biomarker 
assessment.
The assay is an ELISA, where TFPI [INVESTIGATOR_687561] a polyclonal anti-TFPI [CONTACT_30936], distanced from 
the binding site of concizumab; meaning that both free TFPI [INVESTIGATOR_535151]. Detection will be obtained with a monoclo nal antibody against TFPI, which does not bind 
to the concizumab epi[INVESTIGATOR_9230].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 83 of 138
Data will be reported in ng/mL TFPI.
8.5.3 Human Biosamples
If patient permission is obtained plasma, serum and/or DNA for genotypi[INVESTIGATOR_535109], see Section 2. The blood samples can be stored up to 15 years, for future 
potential exploratory purposes please refer to section 24.2.
Antibody samples storage and retention, see Section 24.2.1 . The investigator is not able to review 
the results of antibody measurements in relation to AEs as these are analysed after LPLV. Plasma 
and serum is taken at visit 1 and 17. DNA for genotypi[INVESTIGATOR_687563] 1.
8.6 Other assessments
8.6.1 Patient reported outcomes
A newly developed disease- specific electronic PRO (ePRO) the He mophilia Treatment Experience 
Measure (Hemo-TEM) - is being validated in this trial. In order to assess the psychometric 
properties of Hemo-TEM, other questionnaires will be provi ded; see further appendix 1.
The following ePRO questionnaires will be used in the trial:
∀Hemophilia Treatment Experience Measure (Hemo-TEM)
∀Validated Hemophilia Regimen Treatment Adherence Scale (VERITAS-PRN®) 16
∀36-Item Short Form Health S urvey (SF-36v2) (4 week recall)17
∀Patient’s Global Impression of Change (PGI-C)
∀Sheehan Disability Scale (SDS)18
∀Treatment Satisfaction Questionnaire for Medication (TSQM, version II)19 20 21
∀Injection Site Reaction Questionnaire (ISRQ) domain of SIAQ (SIAQ-ISRQ)22
The ePROs should be assessed at the scheduled visits following the order listed below:
∀visit 1 (Hemo-TEM, VERITAS-PRN®)
∀visit 2 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 3 (PGI-C, Hemo-TEM)
∀visit 4 (PGI-C, Hemo-TEM)
∀visit 5 (PGI-C, Hemo-TEM)
∀visit 6 (PGI-C, Hemo-TEM)
∀visit 7 (PGI-C, Hemo-TEM)
∀visit 8 (PGI-C, Hemo-TEM) 
∀visit 9 (PGI-C, Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 10 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 16 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 84 of 138
At visit 1: before any visit-related activities  all patients should complete Hemo-TEM and 
VERITAS-PRN®.
At visit 2: before any visit-related activities all patients should complete Hemo-TEM, SF-36v2, 
SDS, TSQM and SIAQ-ISRQ.
At visit 3-8: before any visit-related activities the patient should complete the PGI-C before the 
Hemo-Tem. These are the rules that apply:
∀If the patient responds “1” to question 1 in the PGI-C, the patient should also complete the 
Hemo-TEM. In this case the patient should not fill in the PGI-C any more in the trial and the 
Hemo-TEM only again at visits 9, 10 and 16. 
∀If the patient responds “0” or “2” to question 1 in the PGI-C, the patient should not complete 
any other questionnaires at this visit, but should repeat the procedure at next visit. 
Exception: Patients randomised to eptacog alfa (rFVIIa) on-demand should not complete the 
ePRO at visit 3 as this is a phone visit.
At visit 9 if the patient has responded “0” or “2” in the PGI-C at all previous visits, the patient 
should complete PGI-C. All patients shoul d complete Hemo-TEM, SF-36v2, SDS, TSQM and 
SIAQ-ISRQ.
At visit [ADDRESS_932268].
[IP_ADDRESS] Concizumab and NovoPen®4
Direction for use (DFUs) will be available as a hand out for patients at visit 2. Training in 
NovoPen®4 can start at screening (visit 1) and s.c administration of concizumab using the 
NovoPen®[ADDRESS_932269] dose at the trial site (visit 2). Patients must be instructed that 
injections are to be performed subcutaneously, not intravenously. Concizumab and NovoPen®[ADDRESS_932270] be documented in the medical records.
Detailed instructions can be found in the DFUs.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 85 of 138
[IP_ADDRESS] eptacog alfa (rFVIIa)
A direction for use ( DFU) will be available as hand out for patients at visit 1. Training must be 
performed at site until patients feel comfortable performing the treatment. The training must be 
documented in the medical records.
The following should be emphasised for eptacog alfa (rFVIIa):
∀eptacog alfa (rFVIIa) should be slowly injected intravenously over 2 to 5 minutes
Detailed instructions can be found in the DFU
[IP_ADDRESS] eDiary
Training on the use of the eDiary can start at visit 1. The eDiary will be provided to the patients at 
visit 2.
Training must be repeated at the site until patients feel comfortable using the device. The training 
must be documented in the medical records.
During the home treatment period the patient must ensure that all home treatments of concizumab, 
details of bleeding epi[INVESTIGATOR_687537] (r FVIIa) treatments associated  with these bleeding 
epi[INVESTIGATOR_535111].
It will be the responsibility of the investig ator or delegated staff to assess the eDiary data 
throughout the conduct of the trial and to ensure data entry compliance (timely entry, no duplicate 
data, no missing data etc.) and retraining if necessary.
For patients completing the trial or in case of withdrawal, the eDiary will be collected at the EOT.
8.6.3 Surgery
Minor surgery can be performed within this trial at the investigator’s discretion according to local 
guidelines. Definition of minor surgery, see Section 5.1.1. Major surgery is not allowed, see 
exclusion criteria no 6.
For minor surgery the following should be recorded in the eCRF:
∀Date, stop time and dose of preventive tr eatment with eptac og alfa (rFVIIa) before surgery, 
if this was deemed necessary by [CONTACT_093]
∀Indication for surgery
∀Location of surgery
∀Date of surgery
∀Start and stop time of surgery3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 86 of 138
8.7 Patient compliance
Throughout the trial, the investigator will remind the patients to follow the trial procedures and 
requirements to ensure patient compliance. If a patient is found to be non-compliant, the investigator will remind the patient of the importance of following the instructions given including 
taking the trial products as prescribed.
8.8 Treatment compliance 
Treatment compliance will be monitored and documented through timely review of eDiary data and 
drug accountability. 
Concizumab will be administered at the trial site at visit 2 for the concizumab arm supervised by 
[CONTACT_687637] 2 if the patient feels comfortable with the s.c. administration. Administration of eptacog alfa (rFVIIa) for bleeding epi[INVESTIGATOR_535179] a medically trained trial staff or at home by [CONTACT_4677], see Section 8.3.1 . 
Drug accountability will be performed and will be us ed to assess patient compliance together with 
the patients’ adherence to trial procedures.
Compliance check includes a cross check between records in EDC/eDiary (number of 
administrations and bleeding epi[INVESTIGATOR_1841]) and the used/returned cartridges/vials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932271] not be used if it contains visible particles or discoloration.
The reconstituted eptacog alfa (rFVIIa ) solution appears clear and col ourless. Do not use the 
reconstituted solution if it contains visible particles or if it is discoloured.
Trial products must not be dispensed to  any person not included in the trial.
9.1 Trial products
The following trial products will be provided by [CONTACT_3454], Denmark:
Table 9–[ADDRESS_932272] Strength Dosage form Route of 
administrationContainer/
delivery device
concizumab B 
(IMP)100 mg/mL Solution for injection s.c. injection 3 mL cartridge
eptacog alfa
(IMPaand NIMPb)5 mg/vial Powder for solution
for injectioni.v. injection Vial
histidine 5 mL N/A Solvent for solution 
for injectioni.v. injection prefilled syringe
aInvestigational Medicinal Product (IMP) given as IMP for a single dose at visit [ADDRESS_932273] (NIMP) given as NIMP for bleeding epi[INVESTIGATOR_535113]®[ADDRESS_932274] w ill be distributed to the tr ial sites according to enrolment 
and randomisation.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932275] 
dispensing visit (see Section 2).
9.3 Storage 
Table 9–[ADDRESS_932276] Storage conditions
(not-in-use)In-use conditions In-use timea
concizumab B 100 mg/mL Store in refrigerator (2oC-8oC)
Do not freeze
Protect from lightStore at room temperature 
(below 30°C)
Do not refrigerateProtect from lightUse within 4 weeks 
(28 days)
eptacog alfa
5mgStore between 2oC-25oC
Do not freezeProtect from lightFor single use
Do not freezeProtect from light
To be used immediately 
after reconstitutionIf not used 
immediately, store in refrigerator (2
oC-8oC)
for up to [ADDRESS_932277] from lightFor single use
N/A
aIn-use time for concizumab starts when first dose is administered from an individual cartridge and for eptacog alfa
(rFVIIa) when the product is reconstituted
The investigator must ensure that trial product is kept under proper storage conditions and record 
and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any patient before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take appropriate action to ensure correct storage.
Investigator must instruct the patient to use and store trial product according to the label.
9.4 Drug accountability and destruction
Drug accountability of all trial products (concizumab and eptacog alfa (rFVIIa) received at site is 
the responsibility of the investig ator. The patient will be as ked to return all used, partly used and 
unused trial product during the trial as instructed by  [CONTACT_093], except for used histidine
syringes which should be discarded at home and not accounted for. Unused histidine syringes 
should be returned at every visit and new histid ine syringes should be dispensed to the patient.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 89 of 138
All cartridges (concizumab) and vials (eptacog alfa (rFVIIa)) must be accounted for as used, partly 
used or unused.
The investigator will perform drug accountability using the IWRS Drug Accountability module.Returned trial product (used/partly used and/or unused), expi[INVESTIGATOR_687590]-allocated trial product.
Non-allocated trial product including expi[INVESTIGATOR_215519].
Destruction of concizumab and eptacog alfa (rFVIIa) can be performed on an on-going basis and 
will be done according to local procedures after accountability is finalised and reconciled by [CONTACT_36102]. Destruction of products must  be documented in the IWRS.
For Japan only : Responsibility for storage and drug accountability of the trial drug product at the 
trial site rests with the head of the trial site. The head of the trial site could assign some or all of the 
responsibilities for accountability of the trial drug product at the trial sites to a trial product storage 
manager (a pharmacist in principle). The trial product storage manager should control and take accountability of the trial drug product in accordance with procedures specified by [CONTACT_3454]. The head of the trial site or the trial product storage manager must ensure the availability of proper 
storage conditions, and record and evaluate the temperature.
9.5 Auxiliary supplies
Novo Nordisk will provide the auxiliaries for this trial:
∀For concizumab administration: NovoPen
®4, needles and DFUs
∀For eptacog alfa (rFVIIa) reconstitution and administration: Trial Injection Kit and DFU
Only needles and trial injection kit provided by [CONTACT_535244].
For further guidance please see the TMM.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 90 of 138
10 Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone.  
Access to the IWRS must be restricted to and controlled by [CONTACT_36301].
IWRS is used for: 
∀Screening
∀Screening failure
∀Randomisation
∀Medication arrival
∀Dispensing
∀Dispensing verification
∀Treatment discontinuation 
∀Completion
∀Drug accountability
∀Data change
IWRS user manuals will be provided to each trial site.
11 Randomisation procedure and breaking of blinded codes
11.1 Randomisation 
Randomisation will be handed by [CONTACT_8784].
All patients included in the screening period and e ligible for the trial will enter the trial and be 
randomised at visit 2 in a 2:1 allocation to either concizumab prophylaxis arm or eptacog alfa 
(rFVIIa) on-demand arm.
11.2 Breaking of blinded codes
Not applicable for this trial.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 91 of 138
12 Adverse events, and technical complaints
12.1 Definitions
12.1.1 Adverse event 
An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal 
product, and which does not necessarily have  a causal relati onship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product.
An AE includes:
∀A clinically significant worsening of a concomitant illness
∀A clinical laboratory adverse event (CLAE): a clinical laboratory abnormality which is 
clinically significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is 
of a severity that requires active management. Active management includes active treatment or further investigations, for example change of medicine dose or more frequent follow-up due to the abnormality.
The following should not be reported as AEs:
∀Pre-existing conditions, in cluding those found as a result of screening or other trial 
procedures performed before exposure to tr ial product (pre-existing c onditions s hould be 
reported as medical history or concomitant illness)
∀Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the patient has signed the informed consent
∀Bleeding epi[INVESTIGATOR_56238] (e.g. pain, swelling, synovitis, arthralgia, injection 
site haematoma) in connection with bleedi ng epi[INVESTIGATOR_49622]/SAEs 
unless the event is fatal, life-thr eatening or evaluated by [CONTACT_687658]. All bleeding epi[INVESTIGATOR_535114]/eDiary.
The following three definitions are used when assessing an AE:
∀Severity 
∀Mild – no or transient symptoms, no interference with the patient’s daily activities
∀Moderate – marked symptoms, moderate interference with the patient’s daily activities
∀Severe – considerable interference with the patient’s daily activities; unacceptable
∀Causality 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932278](s): 
∀Probable - Good reason and sufficient documentation to assume a causal relationship
∀Possible - A causal relationship is conc eivable and cannot be dismissed
∀Unlikely - The event is most likely related to aetiology other than the trial product
∀Final outcome 
∀Recovered/resolved - The patient has ful ly recovered or by [CONTACT_687659]-related activity 
after the patient signed the informed consent
∀Recovering/resolving - The condition is improving and the patient is expected to 
recover from the event. This term is only applicable if the patient has completed the trial 
or has died from another AE
∀Recovered/resolved with sequelae - The patient has recovered from the c ondition, but 
with lasting effect due to a disease, inj ury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE
∀Not recovered/not resolved - The condition of the patient has not improved and the 
symptoms are unchanged or the outcome is not known
∀Fatal - This term is only applicable if the pa tient died from a condition related to the 
reported AE. Outcomes of other reported AEs in a patient before he died should be 
assessed as “recovered/resolved”, “recovering/resolving”, “recovered/resolved with 
sequelae” or “not recovered/not resolved”. An AE with fatal outcome must be reported 
as an SAE
∀Unknown - This term is only applicable if the patient is lost to follow-up
12.1.2 Serious adverse event
A serious adverse event (SAE) is an experience that at any dose results in any of the following:
∀Death
∀A life-threateningaexperience
∀In-patient hospi[INVESTIGATOR_36220]
∀A persistent or significant disability or incapacityc
∀A congenital anomaly or birth defect
∀Important medical events that may not result in death, be life threateningaor require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement 
- they may jeopardise the patient and may require medical or surgical intervention to prevent 
one of the outcomes listed in the definition of SAEd
a.The term “life threatening” in the definition of SAE refers to an event in which the patient was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 93 of 138
b.The term “hospi[INVESTIGATOR_11956]” is used when a patient:
∀Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay or
∀Stays at the hospi[INVESTIGATOR_36223] [ADDRESS_932279] should be 
regarded as a hospi[INVESTIGATOR_11956]. Hospi[INVESTIGATOR_17957], trial related and social purposes do not constitute AEs and should therefore not be reported as AEs or SAEs. Hospi[INVESTIGATOR_41094], planned before trial inclusion, are not considered AEs or SAEs.
c.A substantial disruption of a patient’s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the patient has significant, persistent or permanent change, 
impairment, damage or disruption in his body function or structure, physical activity and/or quality of life).
d.For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not resu lt in hospi[INVESTIGATOR_36224].
The following adverse events must always be reported as an SAE using the important medical event 
criterion if no other seriousness criteria are applicable:
∀Suspi[INVESTIGATOR_36225]
∀Risk of liver injury defined as ALT or aspartate aminotransferase (AST) >3 x UNL and total 
bilirubin >2 x UNL, where no alternative aetiology exists (Hy's law).
12.1.3 Non-serious adverse event
A non-serious AE is any AE which doe s not fulfil the definition of an SAE.
12.1.4 Medicati on errors
A medication error concerning trial products is defined as:
∀Administration of wrong drug
Note: Use of wrong DUN is not considered a medication error unless it results in administration 
of wrong drug.
∀Wrong route of administration
∀Administration of an overdose with the inte ntion to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product
∀Accidental administration of a lower or higher dose than intended. However, the 
administered dose must deviate from the intended dose to an extent where clinical 
consequences for the trial patient were likely to happen as judged by [CONTACT_093], although they did not necessarily occur3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932280] be reported on an AE form and a specific event form, see Section [IP_ADDRESS]
12.1.[ADDRESS_932281].
In this trial the following AEs require the co mpletion of specific event forms in the eCRF:
∀Injection site reaction, see Section [IP_ADDRESS]
∀Hypersensitivity type reactions, incl. anaphylactic reactions, see Section [IP_ADDRESS]
Injection site reactions: 
Any injection site reaction symptom must be recorded on the AE form and the injection site reaction form.
Hypersensitivity type reactions:
In cases where clinical signs of a severe and immediate hypersensitivity reaction resembling a type
I hypersensitivity reaction are present, blood should be sampled for central laboratory assessment of 
anti-drug IgE antibodies and anti-drug binding antibodies. In the event of an immediate systemic hypersensitivity reaction to the trial product, it is recommended to also test for tryptase (total and/or mature tryptase) within 3 hours of the reaction. Moreover, a baseline tryptase measurement is 
necessary ~1 week after the immediate severe hypers ensitivity reaction due to individual to 
individual variation in tryptase baseline concentration. Tryptase concentrations (if measured) must be interpreted and considered in the context of a complete workup of each patient.
Special attention should be given to clinical signs and symptoms of hypersensitivity reactions of 
type II and III. Common clinical signs and symptoms characteristic for these type of reactions may 
include, but are not limited to: fever/malaise, cutaneous eruptions, arthralgia, lymphadenopathy, itching, headaches and myalgia. Related laboratory findings may include, but are not limited to: mild proteinuria or haematuria, leukopenia or leucocytosis, decreased complement levels or 
increased complement split products and transient elevations of serum creatinine levels. In cases 
where there is a suspi[INVESTIGATOR_687591], additional 
sampling for the purpose of measuring ADA will be performed. 
Definition of anaphylaxis 
(25)
Anaphylaxis is highly likely when any one of the following 3 criteria is fulfilled:
∀Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal
tissue or both (e.g. generalised hives, pruritus or flushing, swollen lips-tongue-uvula) and at
least one of the following:
a) Respi[INVESTIGATOR_7798] (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced peak
expi[INVESTIGATOR_10229] [PEF], hypoxemia)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 95 of 138
b) Reduced blood pressure (BP) or associated symptoms of end-organ dysfunction (e.g.
hypotonia [collapse], syncope, incontinence)
∀Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for that
patient (minutes to several hours):
a) Involvement of the skin-mucosal tissue (e.g. generalised hives, itch-flush, swo llen 
lips-tongue-uvula)
b) Respi[INVESTIGATOR_7798] (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced PEF,
hypoxemia)
c) Reduced BP or associated symptoms (e.g. hypotonia [collapse], syncope, 
incontinence)
d) Persistent gastrointestinal symptoms (e.g. crampy abdominal pain, vomiting)
∀Reduced BP after exposure to known allergen for that patient (minutes to several hours):
Systolic BP of less than 90 mm Hg or greater than 30% decrease from that person’s baseline
BP.
If a patient fulfils any of the three criteria of anaphylaxis outlined above, the patient should receive 
epi[INVESTIGATOR_238]/adrenalin immediately. Dose regimen should be according to hospi[INVESTIGATOR_535116], and the patient should be transferred to an emergency department or intensive care unit, 
if clinically warranted.
Events not fulfilling the criteria for an anaphylactic reaction and other allergic reactions must be 
treated at the discretion of the treating physician. If according to the investigators judgement, 
hypersensitivity type reactions that require systemic treatment are suspected, dosing with 
concizumab should be stopped immediately and treatment at the discretion of the treating physician initiated.
12.1.[ADDRESS_932282] (AESI) is an event, which in the evaluation of safety, has a 
special focus. In this trial, the following AEs fulfil the AESI criteria:
∀Thromboembolic events including but not limited to,
odisseminated intravascular coagulation (DIC) (A),
oclinical signs or laboratory indications of arterial and venous thrombosis including 
myocardial infarction (B),
opulmonary embolism (C),
ostroke (D), 
odeep vein thrombosis (E),
oother clinically significant thromboembolic events (F) and peripheral artery 
occlusion (see below G), see definitions below
The AESIs must be reported on an AE form and a safety information form.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 96 of 138
A) Definition of disseminated intravascular coagulation (DIC), as defined below:
The definition of DIC in this trial should be made according to the International Society on
Thrombosis and Haemostasis (ISTH) criteria. Thus, a DIC diagnosis may be based on clinical signs 
and symptoms of a bleeding tendency or thrombo tic tendency, organ dysfunction and the laboratory 
parameters criteria as listed below:
∀Platelet coun t (>100 × 109/L = 0, <100 × 109/L = 1, <50 × 109/L = 2)
∀Elevated D-dimer (no increase = 0, moderate increase = 2, strong increase = 3)
∀Prolonged PT (<3 s = 0, >3 but <6 s = 1, >6 s = 2)
∀Fibrinogen level (>1 g/L = 0, <1 g/L = 1)
∀Calculate score: ≥5 compatible with overt DIC
B) Myocardial infarction is defined according to the “Third Universal Definition of
Myocardical Infarction” (26)
Criteria for acute myocardial infarction - The term acute myocardial infarction (MI) should be used 
when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Under these conditions any one of the following criteria meets the diagnosis for MI:
∀Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin
(cTn)] with at least one value above the 99th percentile upper reference limit (URL) and
with at least one of the following:
∀Symptoms of ischemia
∀New or presumed new significant ST-segment–T wave (ST–T) changes or new left
bundle branch block (LBBB)
∀Development of pathological Q waves in the ECG
∀Imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality
∀Identification of an intracoronary th rombus by [CONTACT_687638] - Any one of the following criteria meets the diagnosis for
prior MI:
∀Pathological Q waves with or without symptoms in the absence of non-ischemic causes.
Imaging evidence of a region of loss of viable myocardium that is thinned and fails to
contract, in the absence of a non-ischemic cause.
∀Pathological findings of a prior MI.
Recurrent myocardial infarction -Incident MI is defined as the individual’s first MI. When features 
of MI occur in the first 28 days after an incident event, this is not counted as a new event for 
epi[INVESTIGATOR_535117]. If characteristics of MI occur after 28 days following an incident MI, it is
considered to be a recurrent MI.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 97 of 138
C) Definition of pulmonary embolism:
The “Clinical Practice Guideline from the American Academy of Family Physicians and the
American College of Physicians” on diagnosis of venous thromboembolism recommends diagnosticimaging studies for patients with intermediate or high pre-test probability of pulmonary embolism
(27).
Accordingly, the definition of pulmonary embolis m is the following: obstruction of a pulmonary 
artery or one of its branches, most frequently by [CONTACT_535246] a leg or pelvic vein, diagnosed by [CONTACT_37408]:
∀Positive findings in ventilation/perfusion scan
∀Positive findings in a spi[INVESTIGATOR_23585] (helical) computerised tomography (CT) or angiography
∀Positive findings in a magnetic resonance imaging (MRI)
∀Positive findings in a pulmonary angiography
D) Definition of stroke:
The definition of central nervous infarction is according to the American Heart
Association/American Stroke Association Expert Consensus Document:  “An Updated Definition of 
Stroke for the 21st Century” 
(28).
Accordingly, the term “stroke” should be broadly used to include all of the following:
Definition of central nervous system (CNS) infarction: CNS infarction is brain, spi[INVESTIGATOR_687592], based on:
o1. pathological, imaging or other objective evidence of cerebral, spi[INVESTIGATOR_687566] a defined vascular distribution or
o2. clinical evidence of cerebral, spi[INVESTIGATOR_1304] c ord or retinal focal ischemic injury based on
symptoms persisting 24 hours or until death, and other etiologies excluded
Note: CNS infarction includes haemorrhagic i nfarctions, types I and II; see “Haemorrhagic 
Infarction”.
Definition of ischemic stroke: An epi[INVESTIGATOR_535119],
spi[INVESTIGATOR_687568]. Note: Evidence of CNS infarction is defined above.
Definition of silent CNS infarction: Imagi ng or neuropathological evidence of CNS infarction,
without a history of acute neurological dysfunction attributable to the lesion.
Definition of intracerebral haemorrhage: A focal collection of blood within the brain parenchyma or
ventricular system that is not caused by [CONTACT_278066]. Note: Intracerebral haemorrhage includes
parenchymal haemorrhages after CNS infarction, types I and II - see “Haemorrhagic Infarction”).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 98 of 138
Definition of stroke caused by [CONTACT_535247]: Rapi[INVESTIGATOR_535157] a focal co llection of bl ood within the brain parenchyma or
ventricular system that is not caused by [CONTACT_278066].
Definition of silent cerebral haemorrhage: A focal collection of chronic blood products within the
brain parenchyma, subarachnoid space or ventricular system on neuroimaging or neuropathological
examination that is not caused by [CONTACT_535248] a history of acute neurological dysfunction
attributable to the lesion.
Definition of subarachnoid haemorrhage: Bleeding into the subarachnoid space (the space between
the arachnoid membrane and the pia mater of the brain or spi[INVESTIGATOR_1831]).
Definition of stroke caused by [CONTACT_535249]: Rapi[INVESTIGATOR_535121]/or headache because of bleeding into the subarachnoid space (thespace between the arachnoid membrane and the pia mater of the brain or spi[INVESTIGATOR_1831]), which is not
caused by [CONTACT_278066].
Definition of stroke caused by [CONTACT_535250]: Infarction or haemorrhage in the brain,
spi[INVESTIGATOR_687569] a cerebral venous structure. Symptoms or signscaused by [CONTACT_535276].
Definition of stroke, not otherwise specified: An epi[INVESTIGATOR_535122], persisting ≥24 hours or until death, but 
without sufficient evidence to be classified as one of the above.
Definition of a Transient Ischemic Attack: The definition of Transient Ischemic Attack is according
to the American Heart Association/Amer ican Stroke Association. A Transient ischemic attack 
(TIA) is a transient epi[INVESTIGATOR_535123], spi[INVESTIGATOR_1304] c ord or r etinal 
ischemia, without acute infarction 
(29).
E) Definition of deep vein thrombosis:
The “Clinical Practice Guideline from the American Academy of Family Physicians and the
American College of Physicians” on diagnosis of venous thromboembolism recommends
ultrasound scanning for patients with intermediate or high pre-test probability of DVT in the lowerextremities
27. Accordingly, venous thrombosis should be demonstrated by [CONTACT_49734],
duplex ultrasound, colour Doppler imag ing or venography (phlebography).
F) Definition of other clinically significant thromboembolic events:
Signs or suspi[INVESTIGATOR_1884] a clinically significant  thromboembolic event (e.g. visceral arterial 
embolus/thrombus, extremity arterial embolus/t hrombus or portal venous thrombosis). Superficial 
thrombophlebitis is not consid ered a clinically significant thromboembolic event unless evaluated 
as such by [CONTACT_093].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 99 of 138
G) Definition of peripheral artery occlusion:
Clinical signs of acute arterial occlusion verified by [CONTACT_535252]-brachial index (ABI) test, Doppler and
ultrasound (Duplex) imaging, computerised tomographic angiography, MRA or conventionalangiography. The 2011 American College of Ca rdiology Foundation/American Heart Association
Focused Update of the Guideline for the Management of Patients with Peripheral Artery Disease
could serve as a reference for the diagnosis of lower extremity peripheral artery disease 
(30).
12.1.[ADDRESS_932283] 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of techni cal complaints:
∀The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
∀All packaging material including labelling
∀Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)
12.[ADDRESS_932284]-treatment follow-up period (visit 17). The events must be recorded in the applicable eCRF forms in a timely manner, see timelines below and Figure 12–[ADDRESS_932285] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: “Have you experienced any problems since the last contact?”
All AEs, either observed by [CONTACT_687649], must be reported by [CONTACT_36306]. All AEs must be recorded by [CONTACT_535277]. The investigator should 
report the diagnosis, if available. If no diagnosis is available, the investigator should record each 
sign and symptom as individual AEs using separate AE forms.  
For SAEs, a safety information form must be completed in addition to the AE form. If several 
symptoms or diagnoses occur as part of the same clinical pi[INVESTIGATOR_1103], one safety information form can be used to describe all the SAEs.
AESIs regardless of the seriousness must be reported using the AE form and safety information 
form.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932286].
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the CRF/eCRF within the specified 
timelines:
∀SAEs: The AE form within 24 hours and the safety information form within 5 calendar
days of the investigator’s first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered in the 
eCRF.
For SAEs requiring reporting on a specific event form : In addition to the above the specific 
event form within 14 calendar days from the investigator’s first knowledge of the AE.
∀Non-serious AEs fulfilling the AESI criteria: The AE form and safety information form
within 14 calendar days of the investigator’s first knowledge of the event.
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by [CONTACT_6791], e-mail or courier within the same timelines as stated above. When the eCRF becomes available again, the investigator must enter the information on the form into the 
eCRF.
Contact [CONTACT_8972] (fax, telephone, e-mail and address) are provided in the investigator trial master file.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 101 of 138
Figure 12–1 Reporting of AEs
Novo Nordisk assessment of AE expectedness:
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents: Investigator’s Brochure; current version and any updates thereto.
When eptacog alfa (rFVIIa), NovoSeven®is used as IMP, expecte dness should be performed 
according to the Company Core Data Sheet (CCDS).
Reporting of trial product-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and ICH GCP1. In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial procedure.
In accordance with regulatory requirements, Novo N ordisk will inform the regulatory authorities, 
including EMA, of trial product-related S[LOCATION_003]Rs. In addition, Novo Nordisk will inform the
IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local requirement and ICH GCP1, 
unless locally this is an obligation of the investigator.
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932287]:
If an AE is considered to have a causal relationship with a Novo Nordisk marketed product used as 
non-investigational medicinal product (eptacog alfa (rFVIIa)) or concomitant medication in the 
trial, it is important that the suspected relationship is reported to Novo Nordisk, e.g. in the 
alternative aetiology section on the safety infor mation form. N ovo Nordisk may need to report this 
adverse event to relevant regulatory authorities.
12.[ADDRESS_932288] be reported to Novo Nordisk according to the following:
∀SAEs: All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. 
Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the outcome “r ecovering/resolving” or “not recovered/not 
resolved”. Cases can be closed with the outcome of “recovering/resolving” when the patient
has completed the follow-up period and is e xpected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator’s first knowledge of the 
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs.
∀Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until 
the end of the follow-up period stated in the protocol, whichever comes first, and until all queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs 
ongoing at time of death (where death is due to another AE) may be closed with the 
outcome “recovering/resolving” or “not recovered/not resolved”. Cases can be closed with the outcome of “recovering/resolving” when the patient has completed the follow-up period and is expected by [CONTACT_36308].
∀Non-serious AEs fulfilling the AESI criteria: Non-serious AE fulfilling the AESI criteria 
must be followed as specified for non-seri ous AEs. Follow-up information on AESIs should 
only include new (e.g. corrections or additi onal) information and must be reported within 14 
calendar days of the investigator’s first knowledge of the information. This is also the case 
for previously reported non-serious AEs which  subsequently fulfil the AESI criteria.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932289] be reported as follow up with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_932290].
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the investigational medicinal product occurring to a patient after the patient has 
ended the trial, the investigator should report this SAE within the same timelines as for SAEs 
during the trial.
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of tec hnical complaints
All technical co mplaints on any of the following products: 
∀Concizumab B 100 mg/mL, solution for injection in a 3 mL cartridge
∀NovoPen
®4
∀Novo Nordisk needles
∀Eptacog alfa (rFVIIa) 5 mg/vial, powder for solution for in jection in  a vial
∀Histidine 5 mL, solvent for solution for injection in a prefilled syringe
∀Novo Nordisk trial injection kit
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Centre, Novo Nordisk.
Contact [CONTACT_8972] (fax, e-mail and address) are provided in Attachment I to the protocol.The investigator must assess whether the technical complaint is related to any AEs, AESI and/or 
SAEs.
Technical complaints must be reported on a separate technical complaint form:
∀One technical complaint form must be completed for each affected DUN 
∀If DUN is not available, a technical complaint form for each batch, code or lot number must 
be completed
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
∀Technical complaint assessed as related to an SAE within 24 hours
∀All other technical complaints within 5 calendar days3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932291] coordinate the shipment to 
Customer Complaint Centre, Novo Nordisk (the addr ess is provided in Att achment I) and ensure 
that the sample is sent as soon as possible. A copy of the technical complaint form must be included in the shipment of the sample. If several samples are returned in one shipment, the individual sample and the corresponding technical complaint form must be clearly separated.
The investigator must ensure that the technical complaint sample contains the batch, code or lot 
number and, if available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical
complaint form why it is unobtainable.
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product.
12.[ADDRESS_932292] be instructed to notify the investigator if their female partner becomes pregnant 
during the trial, except in the screening period (from visit 1 to dosing with concizumab at visit 2 or 
visit 9 depending on the arm). At the last scheduled visit (visit 17), male patients must be asked if 
their female partner has become pregnant.
If a female partner has become pregnant during the trial, the investigator must follow-up on the 
pregnancy outcome and until the newborn infant is one month of age, irrespective of whether the 
trial is completed or not. The investigator must ask the male patient and assess if the pregnancy outcome is normal or abnormal.
When the pregnancy outcome is normal this information is recorded in the patient’s medical record 
only, no further information is collected and reported to Novo Nordisk. When the pregnancy 
outcome is abnormal (i.e. congenital anomalies, foetal death including spontaneous abortion and/or 
any anomalies of the foetus observed at gross examination or during autopsy), the following must be reported by [CONTACT_687651] N ordisk electronically (e.g. in PDF format) or by [CONTACT_6791].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 105 of 138
1. Reporting of pregnancy information
Information from the male patient has to be reported on the Paternal Form. Furthermore, 
information from the female partner (including information about the pregnancy outcome and health s tatus of the infant until the age of one month) has to be reported on the Maternal Forms 
1A, 1B and 2, after an informed consent has been obtained from the female partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator’s first knowledge of initial or follow-up information.
2. Reporting of AE information
The following AEs in the foetus and newborn infant have to be reported:
oNon-serious AEs evaluated as possible/probably related to the father’s treatment 
with the trial product(s)
oSAEs in the foetus and newborn infant - whether or not related to the father’s 
treatment with the trial product(s). This  includes an abnormal outcome - such as 
foetal death (including s pontaneous abortion) and congenital anomalies (including 
those observed at gross examination or during autopsy of the foetus)
Forms and timelines for reporting AEs:
Non-serious AEs: 
∀Paper AE formawithin 14 calendar days of the investigator’s firs t knowledge of the init ial 
or follow-up information to the non-serious AE
SAEs: 
∀Paper AE formawithin 24 hours of the investigator’s first knowledge of the SAE
∀Paper safety information form within 5 calendar days of the investigator’s first knowledge
of the SAE
∀SAE follow-up information to the AE form and/or safety information form within 24 
hours of the investigator’s first knowledge of the follow-up information
aIt must be clearly stated in the AE diagnosis field on the AE form if the event occurred in the 
patient, foetus or newborn infant.
Any queries or follow-up requests from Novo Nordisk  to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_932293].
12.6 Precautions and/or overdose
Dose limiting toxicities of concizumab have not been investigated in clinical trials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932294] be submitted to the 
regulatory authori ties to support restart of the trial.
∀Significant thromboembolic event
*
∀Event of DIC
∀Anaphylactic reaction related to trial drug administration
∀Death of trial patient which may be related to the trial product
∀Two or more other trial product related SAEs s imilar in nature have been reported and/or 
detected by [CONTACT_66969]
∀Trends in AEs, clinical observations or laboratory parameters which raise concerns about 
the safety of continued treatment.
*Superficial thrombophlebitis or venous thrombosis associated with indwelling catheters is not considered a significant 
thromboembolic event unless evaluated as such by [CONTACT_093]
12.[ADDRESS_932295] the safety 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932296] interaction with those in trial management. The DMC recommendations should be addressed directly to the Novo Nordisk Global 
Safety department and the internal Novo Nordisk safety committee for concizumab. It is the 
responsibility of the Novo Nordisk internal safety committee for concizumab to take action(s) forpatient safety based on the DMC recommendations.
Information regarding responsibilities, procedures and workflow to be used by [CONTACT_215575].
13 Case report forms
For this trial a combination of electronic case report forms (eCRFs) and paper CRFs will be used.
Novo Nordisk will provide a system for the electronic case report forms (eCRF). This system and 
support services to the system will be provided by [CONTACT_215576].
Ensure that all relevant questions are answered, and that no empty data field exists. If a test or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not applicable), indicate this according to the data entry instructions.
The following will be provided as paper CRFs:
∀Pregnancy forms
∀Technical complaint forms
∀AE forms
∀Safety information forms
The paper version of the technical complaint form, AE form, and safety information form must only 
be used to ensure timely reporting when/if the electronic CRF is unavailable.
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered, 
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. If a test/assessment has not been done and will not be available, indicate this by [CONTACT_565] “ND” (not done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 108 of 138
indicate this by [CONTACT_565] “NA” (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.
The investigator must ensure that all infor mation is consistent with the source documentation. By 
[CONTACT_535278] e case book in the eCRF, the investigator confirms that the information in 
the eCRF and related forms is complete and correct.
13.1 Corrections to case report forms
Corrections to the eCRF data may be made by [CONTACT_36322]’s delegated staff. 
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]’s delegated  staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].
13.[ADDRESS_932297] ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for data verification and validation purposes.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
13.3 Electronic diary
Novo Nordisk will provide the patient with an eDiary for electronic recording of det ails of their 
home treatment, bleeding epi[INVESTIGATOR_535124] (i.e. use of eptacog alfa (rFVIIa)).The eDiary and related support services will be supplied by a vendor working under the direction 
and supervision of Novo Nordisk.
Patients will be instructed in the use of the eD iary by [CONTACT_535254]. The eDiary will be dispen sed to the patient at visit 2. After visit 2 and 
onwards, data will be entered by [CONTACT_687660].
The eDiary will be returned by [CONTACT_687639].
All data entered will be transferred from the device to an electronic database, where it is kept as a 
certified copy of the source data. Data entered in the device will upon confirmation of a successful back-up be deleted  from the device.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932298] the number of vials /cartridge accounted for as used by [CONTACT_102]. 
Upon review the Investigator must document that the review has taken place and any actions required e.g. retraining of the patient or decision to amend or correct the data reported by [CONTACT_4677].
If the Investigator finds it necessary to amend or correct eDiary data, the patient must be consulted 
prior to requesting the actual data change. A Data Request Correction (DRC) must be submitted to 
the eDiary vendor. An audit trail will be maintained.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932299] 6 patients 
recruited in the trial. The monitoring visit in tervals will depend on the outcome of the centralised 
monitoring of the eCRFs (remote assessment of data by [CONTACT_3454]), the trial site's recruitment 
rate and the compliance of the trial site to the protocol and GCP, but will not exceed 12 weeks until LPLV at the trial site. This only applies to sites with scheduled, ongoing and/or discontinued patients.
The monitor must be given direct access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are important to the evaluation of the trial. If the electronic medical record does not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site st aff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by [CONTACT_535258]).
All data must be verifiable in source documentation other than the eCRF. eDiary data is entered by 
[CONTACT_535259].
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must onl y be one source defined at any time for any data element.
For historical data such as medical history , details of haemophilia a nd haemophilia treatment 
history, a reasonable effort must be made by [CONTACT_093], considering local requirements, to 
obtain this information from external sources, if not  known by [CONTACT_102]. It is accepted that the 
earliest practically retainable record should be considered as the location of the source data and therefore the source document. This means th at for laboratory results (e.g. biochemistry and 
haematology) a signed printout of the electronic results must be available.
Source data generated by [CONTACT_535292] c orrected by [CONTACT_535293]; an y correction must be explained, signed and dated 
by [CONTACT_36324].
The monitor will ensure that the eCRFs are completed and paper CRFs (if any) collected, that 
ePROs and eDiaries are completed and reviewed by [CONTACT_687640], if any.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 111 of 138
The following data will be source data verified for screening failures:
∀Date for obtaining informed consent
∀Inclusion and exclusion criteria
∀Screen failure reason if possible
∀Date patient left the trial
∀Data relating to AEs if applicable
∀Demography, see section 8.2.1
∀Date of visit
Monitors will review the patient’s medical rec ords and other source data (e.g. the eDiaries and 
ePROs) to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are found, the investigator must be questioned about these.
A follow-up letter (paper or electronic) will be se nt to the investigator following each monitoring 
visit. This should address any action to be taken.
[ADDRESS_932300] the identity of patients in all presentations and publications as required by [CONTACT_5737], regional and national requirements.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932301] Operating Procedures and IT architecture documentation. The use and control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.
Novo Nordisk will use the Global Haemophilia Network Investigator Portal to distribute and share
trial-related documents and information with the pa rticipating sites. After trial completion, Novo 
Nordisk will supply each trial site with long-life CDs or other relevant archiving containing the 
electronic Investigator Trial Master File (eITMF) for each tri al site. These CDs or other relevant 
archiving will contain site-specific trial documen tation as  well as trial specific news and other 
relevant trial information, including audit trail on documents and site staff users. The GHN Portal software and hardware implementation are compliant with the requirements of FDA 21 CFR Part 11
and ICH E6 (EU directive for personal data protection).
1, 31
Novo Nordisk will provide electronic tablets for reporting of all PROs questionnaires described in 
section 8.6.1 and in Appendix 1. In case the electronic tablet is revoked the questionnaires will be 
available in paper.
The eDiary and ePRO software and hardware implementation are compliant with the requirements 
of FDA 21 CFR Part 11 and ICH E6 (EU directive for personal data protection).1,31After trial 
completion, each trial site will be supplied with long-life CDs. These CDs will contain site-specific patient records including the patient ’s eDiaries and audit trail including any data additions and 
corrections made on each form. The eDiary vendor will furthermore retain and securely store copi[INVESTIGATOR_687593] 15 years or as required by [CONTACT_56325].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932302] patien t has completed a minimum of 24 weeks of treatment or 
at LPFT (visit 2) + [ADDRESS_932303] patient has withdrawn before visit 9. Please refer to Figure 
17–1 for further information. 
Data from when the on-demand treated patients are transferred to concizumab s.c. prophylaxis will 
not be included in this evaluation. Observations from the extension part in the on-demand arm will be summarised separately as well as combined w ith observations from the main part when reporting 
the extension part data.
Endpoints comprising number of bleeding epi[INVESTIGATOR_535125]. Multiple bleeding locations occurring from the same event (e.g., due to a bicycle accident) or at the same time point will be counted as one bleeding epi[INVESTIGATOR_1865]. Further, the endpoints 
will not include re-bleed. A re-bleed is defined as a bleeding epi[INVESTIGATOR_1865] (worsening of bleeding site 
conditions e.g. swelling, pain) within 72 hours after stoppi[INVESTIGATOR_31081] a previous bleeding epi[INVESTIGATOR_535126] (or subset of the same) anatomical location. If a bleeding epi[INVESTIGATOR_535127] [ADDRESS_932304] of the 24 patients has completed 24 weeks of dosing (or has withdrawn 
before that).
Two criteria will be evaluated in a hierarchical fashion in support of CPoC comprising a 
comparison of the ABR of all patients in the concizumab group, irrespective of individual dose titration, with the ABR of the patients in the on -demand arm using different sets of observations. 
The primary CPoC criterion aims at evaluating the effect of concizumab when given at the last dose 
level reached for the patient. Hence, for this eval uation, only observations from the period where 
patients are on their end dose at time of analysis will contribute to the analysis. Furthermore, observations from the [ADDRESS_932305] one succeeds.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 114 of 138
The referred comparisons will be made using a negative binomial model with log of exposure time 
in main part as offset and regimen as factor (concizumab vs. on-demand). For each criterion, evidence of effect will be concluded if the 95% confidence interval of the treatment ratio is below 1.
Clinical arguments for the hierarchical test approach
Concizumab exhibits non-linear PK due to target mediated drug disposition and it is expected that 
the dose response curve of the ABR is rather steep. This implies that patients that are on a dose which is not efficacious are likely to bleed as  patients that are not treated at all. Subset of data 
collected from the last dose clinically deemed as efficacious would reflect the efficacy of 
concizumab in the given patient.
17.1 Sample size calculation
The estimand will be defined as the “i f all patients had adhered” estimand.
The treatment ratio between prophylactic s.c. concizumab and on-demand i.v. eptacog alfa (rFVIIa)
during at least 24 weeks for all randomised patients if all patients a dhered to trial drug and did not 
initiate alternative treatment options.
This estimand is a de jure estimand assessing the expected added benefit a patient can achieve if 
continuing treatment with prophylactic s.c. concizumab as compared to on-demand i.v. eptacog alfa 
(rFVIIa) under similar conditions as observed in this trial.
The sample size calculation has been determined based on this estimand and the CPoC criteria 
taking the small patient population into account, while also aiming for an acceptably narrow 95% 
confidence interval for the rate ratio.
Sufficient inference on bleeding epi[INVESTIGATOR_687573] 16 patients in the concizumab arm and 8 in the comparator arm. It is expected 
that the treatment duration of the main part allowing for escalation time for some patients is on average 6 months in the below calculations.
When evaluating the power of th e negative bi nomial analysi s referred above, annual bleeding rates 
of 24 and 6 are assumed for the on-demand patients and the end dose concizumab regimen, 
respectively. Assuming further over-dispersion of 7, the power for concluding superiority of the concizumab regimen becomes approximately 80%. Th e power under varying values of true ABR 
and over-dispersion for the primary CPoC criterion are shown below in Table 17–1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 115 of 138
Table 17–1Power in superiority comparison between concizumab prophylaxis and on-demand 
treatment under different assumptions of ABR for concizumab and over-
dispersion (assuming on-demand ABR=24).
Power Over-dispersion (over 6 months)
ABR (concizumab) 6 7 8
6 89% 82% 75%
7 84% 75% 70%
8 77% 69% 66%
For the secondary CPoC criterion that includes data prior to potential dose escalation, it is expected 
that the treatment duration of the main part is on average 8 months with an average ABR of 7.6 for the concizumab regimen. This yields a marginal power of approximately 70% for the secondary CPoC criterion.
In prior Novo Nordisk trials conducted in haemophilia patients, the typi[INVESTIGATOR_2855] 1-year over-dispersion 
for non-inhibitor patients on prophylaxis with FVIII or FIX has been in the range 4-8, implying 24 weeks over-dispersion of 3-5 (e.g. in NN7008-3543, NN7088-3859 a nd NN7999-3747). In the 
NN7128-1907 trial in inhibitor patients, larger 1-year over-dispersion values of approximately 21 
and 18, respectively, were observed during an initial  3-month on-demand period and a subsequent 
3-month prophylaxis period. It is expected that the va riation in the current trial will be smaller, 
partly due to the longer duration of the trial and partly due to an expected more homogenous patient 
population. Another pub lished trial including inhibitor patients, comparing prophylaxis using 
FEIBA
®with on-demand treatment, showed 6-month over-dispersion of 4-532. On that background, 
an over-dispersion of 7 over the 24 weeks in main part of the current trial is deemed realistic.
17.2 Definition of analysis sets
All dosed patients will be included in the Full Analysis Set (FAS) as well as in Safety Analysis Set 
(SAS).
17.[ADDRESS_932306] 24 weeks from treatment 
onset.
The endpoint will be analysed when the main part of trial has been completed.
17.3.1 Estimand and primary statistical analysis
The estimand for the primary endpoint is the “if all patients had adhered” estimand.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 116 of 138
The treatment ratio between prophylaxis s.c. concizumab and on-demand i.v. eptacog alfa (rFVIIa)
during at least 24 weeks for all randomised patients if all patients a dhered to trial drug and did not 
initiate alternative treatment options.
This estimand is a de jure estimand assessing th e expected added benefit a patient can achieve if 
continuing treatment with prophylactic s.c. concizumab as compared to on-demand i.v. eptacog alfa 
(rFVIIa) under similar conditions as observed in this trial.
The estimand for the primary endpoint will be estimated using negative binomial regression with 
log of exposure time in main part as offset and regimen as factor, providing an estimate of the ABR 
ratio between regimens (concizumab prophylactic and on-demand eptacog alfa (rFVIIa)) with 
corresponding 95% confidence interval and also actual estimate of the ABR with corresponding 95% confidence interval for each regimen. This analysis has the underlying assumption that the missing data mechanism is “missing at random”, i.e. MAR. Under this assumption, the statist ical 
behaviour of the missing data (given the observed res ponses and the mean value structure) is 
assumed to be the same as for the observed d ata. The estimand will be estimated based on the FAS
and only data collected prior to discontinuation of tr ial product or initiation of alternative treatment 
options will be used to draw inference.
17.3.[ADDRESS_932307] a worse outcome compared to what was observed during the main part of the trial. This will be done by [CONTACT_1583] a value Δto the observed bleeding epi[INVESTIGATOR_687574]. The offset is maintained as being the exposure 
during the main part since it is not possible to identify the amount of missing observation t ime. The 
degree of worsening, Δ
i,will gradually be increased to evaluate at which point concizumab 
prophylaxis no longer is superior to on-demand eptacog alfa (rFVIIa). The results of the primary 
analysis will be considered robust if the tippi[INVESTIGATOR_687575].
17.3.3 Additional analysis
An additional evaluation of the primary endpoint will be made, including actual concizumab dose 
level as additional factor in the primary analy sis model specified above. Point estimates and 95% 
confidence interval will be provided for the ABR at the different dose levels of concizumab (0.15, 
0.20 and 0.25 mg/kg). Furthermore, an analysis with individual steady state PK/PD assessments included as covariates in the negative binomial regression model as specified for the primary 
analysis of number of bleeding epi[INVESTIGATOR_687576]/PD and ABR that potentially could guide dose-selection. The referred steady-state PK/PD assessments comprise the concizumab trough level, TFPI [INVESTIGATOR_535160] s.c. dose 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 117 of 138
administration, peak thrombin generation (nM), Endogenous thrombin potential (nMxmin) and 
velocity index (nM/min).
17.4 Supportive secondary endpoints
17.4.1 Supportive secondary efficacy endpoints
∀The number of bleeding epi[INVESTIGATOR_51953] 76 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_51953] [ADDRESS_932308] 24 weeks from treatment onset w ill be 
addressed in terms of the same estimand as for the primary endpoint. The estimand will be 
estimated using the same negative binomial regression model as for the primary endpoint.
Furthermore, an additional evaluation will be mad e, where actual concizumab dose is included as 
factors in the model.
The remaining supportive secondary efficacy endpoints will be summarised descriptively by 
[CONTACT_71397]. In addition, number of bleeding epi[INVESTIGATOR_51953] 76 weeks of treatment with 
prophylactic concizumab will be analysed using a negative binomial model with log of trial duration as offset, providing estimates of the ABR with confidence interval for that particular regimen.
17.4.2 Supportive secondary safety endpoints
∀Number of TEAEs during at least 24 weeks from treatment onset
∀Number of TEAEs during 76 weeks from treatment onset
∀Number of TEAEs within 24 hours of rFVIIa administration
∀Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset
∀Occurrence rate of  anti-concizumab antibodies during 76 weeks from treatment onset
∀Change from baseline of fibrinogen during 24 weeks from treatment onset
∀Change from baseline of fibrinogen during 76 weeks from treatment onset
∀Change from baseline of D-dimer during 24 weeks from treatment onset
∀Change from baseline of D-dimer during 76 weeks from treatment onset
∀Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
∀Change from baseline of F1 + 2 during 76 weeks from treatment onset
∀Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
∀Change from baseline of PT during 76 weeks from treatment onset
∀Change from baseline of activated partial thromboplastin time (APTT) during 24 weeks 
from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 118 of 138
∀Change from baseline of APTT during 76 weeks from treatment onset
∀Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
∀Change from baseline of AT [ADDRESS_932309] recent version of Medical Dictionary for Regulatory 
Activities (MedDRA) coding.
TEAE is defined as an event that has onset from the first exposure to treatment until the last visit in 
the trial. Treatment-emergent adve rse event endpoints will be summarised by [CONTACT_9313], 
preferred term, seriousness, severity and relation to trial product. All adverse events will further be listed.
Frequency of binding anti-concizumab antibodies will by [CONTACT_535280] t ime frame 
according to the two endpoint definitions.
All laboratory safety  endpoints will be plotted by [CONTACT_5586], both as absolute values and change from 
baseline. Laboratory safe ty endpoints will further be summarised and listed.
17.4.3 Supportive secondary pharmacokinetic endpoints
∀Concentration of concizumab prior to the last dose administration at 24 weeks
∀Concentration of concizumab prior to the last dose administration at 76 weeks
The pharmacokinetic endpoints will be summarised and listed.
17.4.4 Supportive secondary pha rmacodynamic endpoints
∀Free TFPI [INVESTIGATOR_687515] [ADDRESS_932310] dose administration at 76 weeks
∀Thrombin generation
oPeak thrombin generation (nM) prior to the last dose administration at 24 weeks
oPeak thrombin generation (nM) prior to the last dose administration at 76 weeks
oEndogenous thrombin potential (nM
xmin) prior to the last dose administration at 24 
weeks
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 76
oVelocity index (nM/min) prior to the last dose administration at 24 weeks
oVelocity index (nM/min) prior to the last dose administration at 76 weeks
The PD endpoints will be summarized and listed.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 119 of 138
17.4.5 Exploratory endpoints
[IP_ADDRESS] Exploratory safety endpoints
∀Number of adverse events related to technical complaints during at least 24 weeks from 
treatment onset
∀Number of adverse events related to technical complaints during at least 76 weeks from 
treatment onset
Adverse events related to technical complaints will be listed and summarised
[IP_ADDRESS] Exploratory patient reported-outcome endpoints
∀Change in Hemo-TEM after 24 weeks from treatment onset
∀Change in Hemo-TEM after 76 weeks from treatment onset
∀Change in SF-36v2 after 24 weeks from treatment onset
∀Change in SF-36v2 after 76 weeks from treatment onset
∀Change in SDS after 24 weeks from treatment onset
∀Change in SDS after 76 weeks from treatment onset
∀Change in TSQM after 24 weeks from treatment onset
∀Change in TSQM after 76 weeks from treatment onset
∀Change in SIAQ-ISRQ after 24 weeks from treatment onset
∀Change in SIAQ-ISRQ after 76 weeks from treatment onset
∀Status of PGI-C after 24 weeks from treatment onset
VERITAS-PRN®, SF-36v2, SDS and TSQM will be scored according to their respective scoring 
algorithms. Change from visit 2 to visit 9 will be analysed with an ANCOVA model including 
regimen as a factor and baseline score as covariate.
The PRO endpoints will be summarised using descriptive statistics and the remaining 
questionnaires (Hemo-TEM, PGI-C, SIAQ-ISRQ) will be summarised and listed using descriptive 
statistics.
17.[ADDRESS_932311] patient has completed a minimum of 24 weeks of treatment or at LPFT (visit 2) + [ADDRESS_932312] patien t has either completed or 
withdrawn from the trial. All main conclusions regarding clinical proof of concept and dose guidance for phase 3 will be based on the reporting after the main part, see Figure 17–1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 120 of 138
Figure 17–1 Definition of main and extension part
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 121 of 138
18 Ethics
18.1 Benefit-risk assessment of the trial
Benefits
Results from a multiple dose phase 1 trial wh ere concizumab was dosed for approximately 6 weeks 
showed a trend towards efficacy in a limited number of patients who reached concizumab plasma concentrations above 100 ng/mL, see Section 3.1.2 . Based on these results, it is expected that the 
majority of the patients randomised to the co ncizumab treatment with 0.15 mg/kg daily dose will be 
protected from bleeding epi[INVESTIGATOR_1841].  Patients who experience excessive bleeding epi[INVESTIGATOR_535161] a possibility to be escalated to a higher dose where bleeding preventiveefficacy of concizumab treatment is expected to improve. For haemophilia patients with inhibitors 
and who are treated on-demand, expected improved efficacy is considered to be a major benefit in 
participating in this trial. Also, concizumab is administered s.c. and might reduce the burden of frequent i.v. injections associated with current treatment options in haemophilia patients with inhibitors.
Information gained from this trial will contribute to gaining regulatory approval for a product that is 
anticipated to offer clinical advan tages over currently available products.
Risks
No risks have been recognised as identified risks by [CONTACT_535263]. However, the nonclin ical toxicity studies have identified 
thromboembolic events as a potential risk when treating non-human primates with concizumab at high exposures.
As observed for other pro-coagulant compounds, there is a potential safety risk of thrombosis and 
vascular ischemia with reaching very high concizumab plasma concentrations. In non-clinical 
toxicity studies with concizumab, thrombi were observed at high doses. However, a no observed 
adverse effect level ( NOAEL) for concizumab has been identified in non-haemophilic animals at 
plasma concentrations at least 24 fold higher than the currently anticipated effective plasma 
concentration (mean area under curve [AUC] and C
max) based on PK modelling.
In a drug–drug interaction study in monkeys, three doses of up to 1 mg/kg of NovoSeven®were 
administered at 2-h intervals, alone or in th e presence of a steady state concentration of 
concizumab. Increased concentrations of thrombin– anti-thrombin (TAT) and D-dimer were seen, 
which tended to be additive when both concizumab and eptacog alfa (rFVIIa) were present in 
circulation. No notable clinical observations were made.
In clinical trials, except for one case of superficial thrombophlebitis in a healthy volunteer who 
received a single dose of 1mg/kg, no other thromboembo lic events were observed. A phase 13URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 122 of 138
multiple dose trial was finalised in haemophilia  A patients (0.8 mg/kg s.c. every 4 days for 6 
weeks). In this clinical trial, marked changes in coagulation parameters were observed including a decrease from baseline in fibrinogen and a pronounced increase in D-dimer and F1+2 outside of normal range in patients with high plasma concentrations of concizumab. These changes were not 
judged as clinically significant by [CONTACT_535281][INVESTIGATOR_535134]™[ADDRESS_932313] not been observed so far in clinical trials. Furthermore, even if antibodies towards concizumab occur, the risk for the rate of immune complex formation exceeding the clearance capacity is considered low. Please refer to the Investigator’s Brochure for further information.
If antibodies against concizumab develop, they might also inhibit the function of the administered 
drug. The consequence of this could be that the patient may not be able to benefit from the drug in 
the future. Antibody development against concizumab is not expected to reduce the effect of other treatment options.
Theoretical risks include bleeding due to consumption of coagulation factors and adverse reactions 
due to potentiation of inflammatory reactions or ti ssue damage due to impairment of tissue repair 
mechanisms
33 34. TFPI [INVESTIGATOR_535135], in addition to its role in haemostasis, 
is implicated in tissue repair processes and in a variety of physiological  and pathophysiological 
states where repair mechanisms are activated. These include sepsis, DIC, inflammation, 
atherosclerosis, cancer and crush injuries35 36, 37.
There may be a risk of allergic reactions, including severe (anaphylactic) reactions, in connection 
with concizumab administration. Severe allergic reactions may potentially be life-threatening and thus, the trial products will be administered to the trial patients at the site under the surveillance of 
medically trained trial site staff in the beginning of the trial.
Overall the anticipated benefits from participating in the trial outweigh the potential risks.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932314] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki2.
Before any trial-related activity, the investigat or must give the patient verbal and written 
information about the trial and the procedures involved in a form that the patient can read and understand.
The patients must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.
The investigator must ensure the patient ample time to come to a decision whether or not to 
participate in the trial.
A voluntary, signed and personally dated informed consent must be obtained from the patient
before any trial-related activity.
The responsibility for seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically  qualified person, in accordance with local 
requirements. The written informed consent must be  signed and personally dated by [CONTACT_135562]-related activity.
If information becomes available that may be releva nt to the patient’s willingness to continue 
participating in the trial, the investigator must inform the patient in a timely manner, and a revised
written patient information must be provided a nd a new informed consent must be obtained.
Only applicable for Japan: As a minor is unable to provide legally binding consent, informed 
consent must be sought from the parent(s)/LAR(s) on the child’s behalf prior to enrolling a child in 
the trial, according to local requirements.
18.[ADDRESS_932315] to follow up, then the patient ’s data will be handled 
as follows:
∀Data already collected and any data collected at the end-of-trial visit will be retained by 
[CONTACT_3454], entered into the database and used for the CTR.
∀Safety events will be reported to Novo Nordi sk and regulatory authorities according to 
local/national requirements.
If data is used it will always be in accordance with local regulations and IRBs/IECs.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932316] be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely termin ated, the investigator must inform the patients 
promptly a nd ensure appropriate therapy and follow- up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation.
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of patients who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the patients
should be described.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932317] to a sign ificant degree the safety 
and rights of a patient or the reliability and robustness of the data generated (potential serious 
breach) and if it should be reported to the Regulatory Authorities as a serious breach of GCP and/or 
the protocol.
In addition, deviations must be documented and explained in a protocol deviation by [CONTACT_535282], date, and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database.
Documentation on protocol deviations must be kept  in the investigator trial master file and sponsor 
trial master file.
19.[ADDRESS_932318] or withdrawal of consent to secure early mitigations in collaboration with the trial sites.
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, see Section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by [CONTACT_687661] (e.g. re-training of site staff).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932319] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are relevant to the evaluation of the trial.
21 Critical documents
An Investigator Portal (Gl obal Haemophilia N etwork [GHN]) w ill be used as pr imary media for 
exchange and handling of investigator trial master file documents between Novo Nordisk and the site and for electronic storage of these documents during trial conduct.
Before a trial site is allowed to start screening patients, written notification from Novo Nordisk 
must be received and the following documents must be available to Novo Nordisk:
∀Regulatory approval and/or acknowle dgement of notification as required
∀Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendmen ts, patient information/informed consent form, 
any other written information to be provided to the patient and patient recruitment m aterials
∀List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
∀Curricula v itae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
∀Signed receipt of Investigator’s Brochure
∀SmPC or similar labelling of eptacog alfa (rFVIIa)
∀Signed and dated Agreement on Protocol
∀Signed and dated Agreement on Protocol Amendment, if applicable
∀Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigator’s 
site and Novo Nordisk
∀Source document agreement
∀Central laboratory certification and normal ranges
∀Insurance statement, if applicable
∀Financial disclosure form from investigator and sub-investigator(s)
∀Description of research facility obtained  (applicable for sites outside the US)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 127 of 138
Only applicable for US trial sites:
∀For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
∀For US trial sites: FDA form [ADDRESS_932320] be comp leted and signed by [CONTACT_237205] 1572:
For US sites:
∀Intended for US sites
∀Conducted under the IND
∀All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
∀Intended for participating sites outside of the US
∀Not conducted under the IND
∀All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
For local laboratory parameters the following w ill be collected:
∀Laboratory normal ranges
∀Laboratory certification, QA scheme or similar documentation
∀Laboratory assay methods (only non-standard assays) and/or analytical methods
By [CONTACT_36343], each investig ator agrees to comply fully with ICH GCP1
applicable regulatory requirements and the Declaration of Helsinki2.
By [CONTACT_36343], each investigator also agrees to allow Novo Nordisk to make 
investigator’s name [CONTACT_36374] [CONTACT_36344].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932321] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure th at there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the conduct of the trial and to protect the rights, safety, and well-being of the patients.
At least investigator must be trained in the current protocol version at a Novo Nordisk Investigator 
meeting or by [CONTACT_687641]. It is recommended that all site staff 
completes the web protocol training.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related  medical decisions.
The investigator will follow instructions  from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced) in the investigator trial master file. The documents including the patient identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data.
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary informat ion or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
patients to a specific qualified physician who will be readily available to patients during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932322], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial.One investigator will be appointed by [CONTACT_687662] (signatory 
investigator) on behalf of all participating investigators. The signatory investigator will be 
appointed based upon the criteria defined by [CONTACT_36346]
38. 
23.[ADDRESS_932323] for 
Clinical Trial Disclosure how- we-disclose-trial-information.
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, 
for example when the CTR is available. This includes the right not to release the results of interim 
analyses, because the release of such information may influence the results of the entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to [ADDRESS_932324] intellectual property.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 130 of 138
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any disagreement on the content of any publication, both the investigators’ and Novo Nordisk opi[INVESTIGATOR_36255].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary m aterial, as specified by [CONTACT_18038].
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors
38(sometimes referred to as the Vancouver 
Criteria).
23.1.2 Site-specific publication (s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statist ical 
limitations and frequently do not provide meaningful  information for healthcare professionals or 
patients, and therefore may not be supported by  [CONTACT_3454]. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should al ways reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of individual site results until the primary manuscript is accepted for publication. As Novo Nordisk wants to live up to the industry publication po licy, submission of a primary publication will take 
place no later than [ADDRESS_932325] access 
to the database.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 131 of 138
24 Retention of clinical trial documentation and human biosamples
24.1 Retention of clinical trial documentation
Patients’ medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other patient data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These d ata must be retained by [CONTACT_21655]. If the 
provided d ata (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least [ADDRESS_932326].
Only applicable for Spain: 25 years retention according to the Spanish Royal Decree 1090/2015.
The files from the trial si te/institution must be  retained for 15 years after EOT as defined in Section 
7, or longer if required by [CONTACT_687663] N ovo Nordisk. In any case trial files cannot be 
destroyed until the trial site/institution is no tified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done  in accordance with local regulatory requirements.
24.2 Retention of human biosamples
This trial will involve collectio n of human biosamples at visit 1 (screening visit) and at visit 17
(EOT) and these samples are to be stored max imum [ADDRESS_932327] the patients’ participation in the trial. 
Therefore, patients will have the possibility to sign the informed consent for the trial and 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 132 of 138
participate, while refusing permission for biological specimens to be stored for future exploratory 
analysis.
∀Human biosamples will be stored at the central laboratory
∀1.0 mL citrated plasma, 1.2 mL serum and/or 2.0 mL whole blood ( DNA for genotypi[INVESTIGATOR_007])
will be obtained
∀The intended use of the stored human biosamples e.g.: As new biomarkers related to the 
disease and/or safety, efficacy or mechanism of action of concizumab may evolve during the 
conduct of the trial, the analyses of the stored human biosamples may also include 
biomarkers that are unknown at present or have not been included in the scientific 
hypotheses at initiation of the trial
∀Human biosamples may be transferred to third parties e.g. research consortia
∀The human biosamples will be transferred and stored after the EOT at a designated central 
laboratory
∀Confidentiality and personal data protection will be ensured during storage after the EOT
∀The human biosamples may be transferred to other countries (not applicable if local 
regulations prohibit export of human biosamples)
∀The human biosamples will be destroyed at the latest 15 years from EOT
∀The patient may request the stored human biosamples to be destroyed by [CONTACT_535265]. The results obtained from any already performed analyses of the samples will still 
be used
∀Novo Nordisk and laboratory will have access to the stored human biosamples
∀Potential consequences for the patient and their relatives: In the event that the collected
human biosamples (plasma, serum and/or DNA fo r genotypi[INVESTIGATOR_007]) will be used in the future, 
the investigator will become directly informed  by [CONTACT_535266]. In such case, 
a written summary of the findings, including lis tings of patient specific values, will be 
provided once a firm conclusion from the results has been drawn by [CONTACT_3454]. 
Potentially, observations of ne oplastic diseases, serious hereditary diseases, other un-
treatable diseases, or any other abnormal findings could be part of the observations. Patients
can contact [CONTACT_687652] m their own body, see Section 5.1.
24.2.1 Antibod y samples
Antibody samples will be retained until drug approval by U.S. Food and Drug Administration 
(FDA) and/or European Medicines Agency (EMA).
The retained antibody samples may be used for later analysis for further characterisation of 
antibody responses towards drug if required by [CONTACT_49769]. Remaining blood from the samples already collected may be used for further development of Anti-Drug 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932328] 
terminates, but no longer than 15 years from EOT after which they will be destroyed.
The patients’ identity will remain confidential and the antibody samples will be identified only by 
[CONTACT_56324], visit number and trial identificati on number. No direct identification of the patient
will be stored together with the samples.
Only Novo Nordisk staff and bio-repository personnel will have access to the stored antibody 
samples.
Patients can contact [CONTACT_215591].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 134 of 138
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordi sk, as applicable, must  promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to Investigator’s Brochure, unexpected SAEs where a causal relationship cannot be ruled out, protocol amendments 
according to local requirements, deviations to the protocol implemented to eliminate immediate 
hazards to the patients, new information that may affect adversely the safety of the patients or the conduct of the trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of the patients), annually written summaries of the trial status, and other 
documents as required by [CONTACT_1036]/IEC.
The investigator must ensure submission of the CTR synopsis to the IRB/IEC (not applicable for 
Japan).
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the patients.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_56255].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the CTR according to national requirements.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932329] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials  in any country, unle ss others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_535286].
Novo Nordisk accepts liability in accordance with:
Only applicable for Austria: Arzneimittelgesetz (BGBI. Nr. 185/1983) last amended with BGBl. 
II Nr. 105/2015
Only applicable for [LOCATION_009]: The French Public Health Code article L 1121-10 (law n
o 2004-[ADDRESS_932330] 2004. “The sponsor is responsible for 
identification of the harmful consequences of the biomedical research for the person lending 
himself thereto and for indemnification of his beneficiaries, except in case of proof, incumbent on it, that the prejudice is not attributable to his fau lt or the fault of any intervening party, without the 
sponsor’s being entitled to call on acts by a third party or the voluntary withdrawal of the person 
who had initially consented to cooperating in the research”.
Only applicable for Poland: Novo Nordisk carries liability for the Trial exclusively in the scope 
defined by [CONTACT_687653] 6 September 2001 (uniform version Journal pf Laws of 2008 No. 45 item 271 with 
amendments). In order to support potential claims for liability attributable to the Trial, Novo 
Nordisk and Investigators are covered by [CONTACT_136779].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 136 of 138
27 References
1. International Conference on Harmonisation. ICH Harmonised Tripatite Guideline. Guideline 
for Good Clinical Practise E6(R2), Step 4. [ADDRESS_932331] amended by [CONTACT_941] 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.
3. International Organization for Standardization. ISO [ZIP_CODE]:2011, Clinical investigation of 
medical devices for human subjects - Good clinical practice. [ADDRESS_932332] Investigators. Am J Hematol. 1998;59(4):288-94.
5. World Federation of Hemophilia. Report on Annual Global Survey 2014.
6. White GC, 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. 
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII 
and factor IX of the scientific and standardization committee of the International Society on 
Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
7. Hoffman M, Monroe III. A cell-based model of hemostasis. Thrombosis and haemostasis. 
2001;85(6):958-65.
8. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-9.
9. Wight J, Paisley S. The epi[INVESTIGATOR_687578] A: a systematic review. 
Haemophilia. 2003;9(4):418-35.
10. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino 
acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. 
Mol Immunol. 1993;30(1):105-8.
11. Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, et al. Safety and 
pharmacokinetics of anti-TFPI [CONTACT_30936] (concizumab) in healthy volunteers and patients 
with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743-
54.
12. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
13. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007.
14. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_932333] of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 01 May 
2001.
15. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Coun cil of 31 March laying down 
Community procedures for the authorisation  and supervision of medicinal products for 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 137 of 138
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. April 2001.
16. Duncan NA, Kronenberger WG, Roberson CP, Shapi[INVESTIGATOR_71324]. VERITAS-PRN: a new 
measure of adherence to epi[INVESTIGATOR_535136]. Haemophilia. 
2010;16(1):47-53.
17. Maruish ME. User's manual for the SF-36v2 Health Survey (3rd ed.). Lincoln, RI: 
QualityMetric Inc orporated2013.
18. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin 
Psychopharmacol. 1996;[ADDRESS_932334] 3:89-95.
19. Atkinson MJ, et al. Validation of a general measure of treatment satisfaction, the Treatment 
Satisfaction Questionnaire for Medication (TSQM ), using a national pa nel study of chronic 
disease. Health Qual Life Outcomes. 2004;2:12.
20. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the 
treatment satisfaction questionnaire for me dication (TSQM version II) among outpatient 
pharmacy consumers. Value Health. 2005;[ADDRESS_932335] 1:S9-S24.
21. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of 
an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among 
patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.
22. Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid 
arthritis: psychometric validation of the S elf-Injection Assessment Questionnaire (SIAQ). 
Health Qual Life Outcomes. 2011;9:2.
23. Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. Official Journal 
L 1692 12/07/1993.
24. European Commission. The Rules Governing Medicinal Products in the European Union, 
Volume 4, Annex 13, Investigational Medicinal Products (ENTR/F/2/AM/an D[2010] 
3374). 03 Feb 2010.
25. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et 
al. Second symposium on the definition and management of anaphylaxis: summary report--
Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy  Clin Immunol. 2006;117(2):391-7.
26. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third 
universal definition of myocardial  infarction. Circulation. 2012;126(16):2020-35.
27. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. Current diagnosis 
of venous thromboembolism in primary care: a clinical practice guideline from the 
American Academy of Family Physicians and the American College of Physicians. Ann 
Fam Med. 2007;5(1):57-62.
28. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated 
definition of stroke for the 21st century: a statement for healthcare professionals from the 
American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064-89.
29. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition 
and evaluation of transient ischemic attack: a scientific statement for healthcare 
professionals from the American Heart Association/American Stroke Association Stroke 
Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular 
Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 3.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 138 of 138
Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the 
value of this statement as an educational tool for neurologists. Stroke. 2009;40(6):2276-93.
30. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 
ACCF/AHA Focused Update of the Guideline for the Management of Patients With 
Peripheral Artery Disease (updating the 2005 guideline): a report of the American College 
of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J 
Am Coll Cardiol. 2011;58(19):2020-45.
31. U.S. Food and Drug Administration. Code of Federal Regulations, 21 CFR Part 11, 
Electronic Records, Electronic Signatures. 2009 2009.
32. Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-
inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 
2011;365(18):1684-92.
33. Levi M, Keller TT, van GE, ten CH. Infection and inflammation and the coagulation system. 
Cardiovasc Res. 2003;60(1):26-39.
34. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, Hall CL. Tissue factor 
pathway inhibitor binds to platelet t hrombospondin-1. J Biol Chem. 2000;275(41):[ZIP_CODE]-
21.
35. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. 
Arterioscler Thromb Vasc Biol. 2004;24(6):1015-22.
36. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in 
angiogenesis and cancer. Arterioscler Thromb Vasc Biol. 2005;25(8):1545-50.
37. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol. 
2005;25(1):47-56.
38. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholar ly Work in Medical Journals. December 
update 2016.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932336] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 1 of 143
Protocol
NN7415-4310
A Multi-Centre, Randomised, Open-Label, Controlled Trial 
Evaluating the Efficacy and Safety of Prophylactic 
Administration of Concizumab in Haemophilia A and B 
Patients with Inhibitors
Trial phase: 2
Includes: Protocol Version 1 (15 March 2017); Protocol Amendment no 1 (05 May 2017) for all 
participating countries; Protocol Amendment no 2 (15 November 2017) and Protocol Amendment no 3 ([ADDRESS_932337] 2018) for all participating countries.
Protocol originator
, International Trial Manager 
Biopharm Trial Ops [ADDRESS_932338] be restricted to relevant 
parties.
3URWRFROY
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: [ADDRESS_932339] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932340] of abbreviations .......................................................................................................... .......................13
1 Summary ............................................................................................................................... .............20
2 Flow chart .................................................................................................................... ......................23
2.1 Visits and assessments ...................................................................................................... ......23
2.2 Explanatory descriptions .........................................................................................................26
3 Background information and rationale for the trial .........................................................................28
3.1 Background information ..........................................................................................................28
3.1.1 Haem ophilia ..........................................................................................................28
3.1.2 Con cizumab ...........................................................................................................29
3.2 Rationale for the trial ...............................................................................................................32
4 Objective(s) and endpoint(s) ..............................................................................................................33
4.1 Objective(s) ............................................................................................................................33
4.1.1 Primary objective ...................................................................................................33
4.1.2 Sec ondary objectives .............................................................................................33
4.2 Endpoint(s) .............................................................................................................................33
4.2.1 Prima ry endpoint ...................................................................................................33
4.2.2 Sec ondary endpoints ..............................................................................................33
[IP_ADDRESS] Supportive secondary endpoints .......................................................[ADDRESS_932341] oratory endpoints ............................................................................................34
[IP_ADDRESS] Exploratory sa fety endpoints ............................................................34
[IP_ADDRESS] Exploratory patient re ported outcome endpoints ...............................35
5 Trial design .................................................................................................................. ......................36
5.1 Type of trial ............................................................................................................... .............36
5.1.1 S urgery ..................................................................................................................37
5.2 Rationale for trial design .........................................................................................................37
5.3 Treatment of patients ...............................................................................................................40
5.3.1 Concizumab arm ....................................................................................................41
[IP_ADDRESS] Concizumab prophylactic treatment (main and extension part) ..........41
5.3.2 Comparator arm (eptacog alfa (rFVIIa)).................................................................42
[IP_ADDRESS] On-demand treatment (main part) .....................................................42
[IP_ADDRESS] Concizumab prophylactic treatment (extension part) .........................42
5.3.3 Dose escalation ......................................................................................................42
5.3.4 Co-administration of ep tacog alfa (rFVIIa).............................................................[ADDRESS_932342] .......................................................................46
5.5 Rationale for treatment ............................................................................................................46
6 Trial population .............................................................................................................. ...................47
6.1 Number of patients ..................................................................................................................473URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932343] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932344] ..............................................................54
8.1.5 Withdra wal from trial .............................................................................................54
8.1.6 Review / evaluation of clinical outcome ..................................................................55
8.1.7 Visit 1 (Screen ing part)..........................................................................................55
8.1.8 Traini ng of patients at visit 1, visit 2 and visit 9 ......................................................56
8.1.9 Treatment peri od at home ......................................................................................56
8.1.10 Sta ggered recruitment ............................................................................................56
8.1.11 Treatment period – Main part.................................................................................56
[IP_ADDRESS] Visit 2 (R andomisation) ...................................................................56
[IP_ADDRESS] Visit 3 (Phone call for eptacog alfa (rFVIIa) on-demand arm and 
PK visit for concizumab arm) ...........................................................58
[IP_ADDRESS] Visit 4, 5, 6, 7 and 8 .........................................................................59
[IP_ADDRESS] Visit 9 ..............................................................................................60
8.1.12 Treatment period – E xtension part..........................................................................62
[IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog 
alfa (rFVIIa) on-demand arm) ..........................................................62
[IP_ADDRESS] Visit 9.2 (ONLY patients previously on the eptacog alfa (rFVIIa) 
on-demand arm) ...............................................................................63
[IP_ADDRESS] Visit 10 ............................................................................................63
[IP_ADDRESS] Visit 10.1 (ONLY patients previously on the eptacog alfa 
(rFVIIa) on-demand arm) .................................................................64
[IP_ADDRESS] Visit 11 ............................................................................................65
[IP_ADDRESS] Visit 11.1 (ONL Y patients previously on the rFVIIa on-demand 
arm) .................................................................................................66
[IP_ADDRESS] Visit 12, 13, 14 and 15, 15.1, 15.2, 15.n ............................................67
[IP_ADDRESS] Visit 16 ............................................................................................68
8.1.13 Visit 17 (End of trial) - Follow-up part ...................................................................69
8.1.14 Unscheduled Visit..................................................................................................70
8.2 Patient related information/assessments ...................................................................................70
8.2.1 Dem ography ..........................................................................................................70
8.2.2 Conco mitant illness and medical history other than haemophilia ............................70
8.2.3 Conco mitant medication ........................................................................................71
8.2.4 Details  of Haemophilia, Haemophilia treatment and bleed history ..........................71
8.3 Efficacy assessments ...............................................................................................................72
8.3.1 Bleeding epis odes ..................................................................................................72
8.4 Safety assessments .......................................................................................................... ........763URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932345] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 4 of 143
8.4.1 Phys ical examination .............................................................................................76
8.4.2 Body measurements ...............................................................................................76
8.4.3 V ital Signs .............................................................................................................77
8.4.4 Electrocardiogram ..................................................................................................77
8.4.5 Adverse ev ents.......................................................................................................78
[IP_ADDRESS] Medicati on error ...............................................................................78
[IP_ADDRESS] Adverse events requiri ng additional data collection ..........................78
8.5 Laboratory assessments ...........................................................................................................80
8.5.1 Labora tory assessments for efficacy .......................................................................81
[IP_ADDRESS] Thrombin generation ........................................................................81
[IP_ADDRESS] Free TFPI .........................................................................................82
8.5.2 Labor atory assessments for safety ..........................................................................82
[IP_ADDRESS] Urinalys is.........................................................................................82
[IP_ADDRESS] Haematology ....................................................................................82
[IP_ADDRESS] Biochemistry ....................................................................................83
[IP_ADDRESS] FVIII/FIX activity ............................................................................83
[IP_ADDRESS] Coagulati on parameters ....................................................................84
[IP_ADDRESS] FVIII/FIX inhibitors .........................................................................84
[IP_ADDRESS] Anti-concizumab antibodies .............................................................84
[IP_ADDRESS] Concizumab ELISA .........................................................................86
[IP_ADDRESS] FVII ELI SA .....................................................................................87
[IP_ADDRESS] Total TFPI ........................................................................................87
8.5.3 Human Bios amples ................................................................................................88
8.6 Other assessments ........................................................................................................... ........88
8.6.1 P atient reported outcomes ......................................................................................88
8.6.2 Training .................................................................................................................8 9
[IP_ADDRESS] Concizumab and NovoPen®4............................................................89
[IP_ADDRESS] eptacog alfa (rFVIIa) ........................................................................90
[IP_ADDRESS] eDiary ..............................................................................................90
8.6.3 S urgery ..................................................................................................................90
8.7 Patient compliance ..................................................................................................................91
8.8 Treatment compliance .............................................................................................................91
9 Trial supplies ............................................................................................................................... .......92
9.1 Trial products ..........................................................................................................................92
9.2 Labelling ............................................................................................................................... ..92
9.3 Storage..................................................................................................................... ...............93
9.4 Drug accountability and destruction ........................................................................................93
9.5 Auxiliary supplies ...................................................................................................................94
10 Interactive voice/web response system ..............................................................................................95
11 Randomisation procedure and breaking of blinded codes................................................................95
11.1 Randomisation ........................................................................................................................95
11.2 Breaking of bli nded codes .................................................................................................. .....95
12 Adverse events, and technical complaints ..................................................................................... ....96
12.1 Defi nitions ..............................................................................................................................9 6
12.1.1 Adverse ev ent ........................................................................................................96
12.1.2 Serious advers e event.............................................................................................97
12.1.3 Non-serious adve rse event......................................................................................983URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932346] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932347] ........................................................................100
12.1.7 Technical complaints ...........................................................................................104
12.2 Reporting of a dverse events ...................................................................................................104
12.3 Follow-up of adve rse events................................................................................................ ..107
12.4 Technical complaints a nd technical complaint samples ..........................................................108
12.4.1 Reporti ng of technical complaints ........................................................................108
12.4.2 Co llection, storage and shipment of technical complaint samples .........................109
12.5 Pre gnancies ...........................................................................................................................109
12.5.1 Pregnancies in female pa rtners of male patients....................................................109
12.6 Precautions and/or overdose ..................................................................................................110
12.7 Rules for putting enrolment on hold ......................................................................................111
12.8 Committees related to safety .................................................................................................111
12.8.1 Novo N ordisk safety committee ...........................................................................111
12.8.2 Data m onitoring committee ..................................................................................111
13 Case report forms ............................................................................................................ ................112
13.1 Corrections to case report forms ............................................................................................113
13.2 Case report form flow ...........................................................................................................113
13.3 Electronic diary .....................................................................................................................113
14 Monitoring procedures ........................................................................................................ ............115
15 Data management ............................................................................................................................116
16 Computerised systems ......................................................................................................... ............117
17 Statistical considerations .................................................................................................................118
17.1 Sample size calculation .........................................................................................................119
17.2 Definition of analysis sets ......................................................................................................120
17.3 Primary endpoint ...................................................................................................................120
17.3.1 Estima nd and primary statistical analysis .............................................................120
17.3.2 Sens itivity analysis ..............................................................................................121
17.3.3 Add itional analysis ..............................................................................................121
17.4 Supportive sec ondary endpoints ............................................................................................122
17.4.1 Suppor tive secondary efficacy endpoints ..............................................................122
17.4.2 Suppor tive secondary safety endpoints .................................................................122
17.4.3 Suppor tive secondary pharmacokinetic endpoints .................................................123
17.4.4 Suppor tive secondary pharmacodynamic endpoints ..............................................123
17.4.5 Explor atory endpoints ..........................................................................................124
[IP_ADDRESS] Exploratory sa fety endpoints ..........................................................124
[IP_ADDRESS] Exploratory patient re ported-outcome endpoints .............................124
17.5 Interim analy sis........................................................................................................... ..........125
18 Ethics....................................................................................................................... .........................126
18.1 Benefit-risk asse ssment of the trial ....................................................................................... .126
18.2 Informed consent ..................................................................................................................128
18.3 Data handling ........................................................................................................................128
18.4 Information to patients during trial ........................................................................................129
18.5 Premature termination of the trial and/or trial site ..................................................................1293URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932348] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 6 of 143
19 Protocol compliance .........................................................................................................................130
19.1 Protocol  deviations ................................................................................................................130
19.2 Prevention of missing data ................................................................................................. ...130
20 Audits and inspections ....................................................................................................... ..............131
21 Critical documents........................................................................................................... ................131
22 Responsibilities ............................................................................................................................... ..133
23 Reports and publications ..................................................................................................... ............134
23.1 Communicati on of results ......................................................................................................134
23.1.1 Aut horship ...........................................................................................................135
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) .......................................................135
23.2 Investigator access to data and review of results ....................................................................135
24 Retention of clinical trial documentation and human biosamples ..................................................136
24.1 Retention of clinical trial documentation ...............................................................................136
24.2 Retention of human  biosamples.............................................................................................1 36
24.2.1 Anti body samples ................................................................................................137
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities ...........[ADDRESS_932349] of abbreviations .......................................................................................................... .......................13
1 Summary ............................................................................................................................... .............20
2 Flow chart .................................................................................................................... ......................23
2.1 Visits and assessments ...................................................................................................... ......23
2.2 Explanatory descriptions .........................................................................................................26
3 Background information and rationale for the trial .........................................................................28
3.1 Background information ..........................................................................................................28
3.1.1 Haem ophilia ..........................................................................................................28
3.1.2 Con cizumab ...........................................................................................................29
3.2 Rationale for the trial ...............................................................................................................32
4 Objective(s) and endpoint(s) ..............................................................................................................33
4.1 Objective(s) ............................................................................................................................33
4.1.1 Primary objective ...................................................................................................33
4.1.2 Sec ondary objectives .............................................................................................33
4.2 Endpoint(s) .............................................................................................................................33
4.2.1 Prima ry endpoint ...................................................................................................33
4.2.2 Sec ondary endpoints ..............................................................................................33
[IP_ADDRESS] Supportive secondary endpoints .......................................................[ADDRESS_932350] oratory endpoints ............................................................................................34
[IP_ADDRESS] Exploratory sa fety endpoints ............................................................343URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932351] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 7 of 143
[IP_ADDRESS] Exploratory patient re ported outcome endpoints ...............................35
5 Trial design .................................................................................................................. ......................36
5.1 Type of trial ............................................................................................................... .............36
5.1.1 Surgery ..................................................................................................................3 7
5.2 Rationale for trial design .........................................................................................................37
5.3 Treatment of patients ...............................................................................................................40
5.3.1 Concizumab arm ....................................................................................................41
[IP_ADDRESS] Concizumab prophylactic treatment (main and extension part) ..........41
5.3.2 Comparator arm (eptacog alfa (rFVIIa)).................................................................42
[IP_ADDRESS] On-demand treatment (main part) .....................................................42
[IP_ADDRESS] Concizumab prophylactic treatment (extension part) .........................42
5.3.3 Dose escalation ......................................................................................................42
5.3.4 Co-administration of ep tacog alfa (rFVIIa).............................................................[ADDRESS_932352] ..............................................................54
8.1.5 Withdra wal from trial .............................................................................................54
8.1.6 Review / evaluation of clinical outcome ..................................................................55
8.1.7 Visit 1 (Screen ing part)..........................................................................................55
8.1.8 Traini ng of patients at visit 1, visit 2 and visit 9 ......................................................56
8.1.9 Treatment period at home ......................................................................................56
8.1.10 Sta ggered recruitment ............................................................................................56
8.1.11 Treatment period – Main part.................................................................................56
[IP_ADDRESS] Visit 2 (R andomisation) ...................................................................56
[IP_ADDRESS] Visit 3 (Phone call for eptacog alfa (rFVIIa) on-demand arm and 
PK visit for concizumab arm) ...........................................................58
[IP_ADDRESS] Visit 4, 5, 6, 7 and 8 .........................................................................59
[IP_ADDRESS] Visit 9 ..............................................................................................60
8.1.12 Treatment period – E xtension part..........................................................................62
[IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog 
alfa (rFVIIa) on-demand arm) ..........................................................623URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932353] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 8 of 143
[IP_ADDRESS] Visit 9.2 (ONLY patients previ ously on the eptacog alfa (rFVIIa) 
on-demand arm) ...............................................................................63
[IP_ADDRESS] Visit 10 ............................................................................................63
[IP_ADDRESS] Visit 10.1 (ONLY patients previously on the eptacog alfa 
(rFVIIa) on-demand arm) .................................................................64
[IP_ADDRESS] Visit 11 ............................................................................................65
[IP_ADDRESS] Visit 11.1 (ONLY patients previo usly on the rFVIIa on-demand 
arm) .................................................................................................66
[IP_ADDRESS] Visit 12, 13, 14 and 15 .....................................................................67
[IP_ADDRESS] Visit 16 ............................................................................................68
8.1.13 Visit 17 (End of trial) - Follow-up part ...................................................................69
8.1.14 Unscheduled Visit..................................................................................................70
8.2 Patient related information/assessments ...................................................................................70
8.2.1 Dem ography ..........................................................................................................70
8.2.2 Concom itant illness and medical history other than haemophilia ............................70
8.2.3 Conco mitant medication ........................................................................................71
8.2.4 Details  of Haemophilia, Haemophilia treatment and bleed history ..........................71
8.3 Efficacy assessments ...............................................................................................................72
8.3.1 Bleeding ep isodes ..................................................................................................72
8.4 Safety assessments .......................................................................................................... ........76
8.4.1 Phys ical examination .............................................................................................76
8.4.2 Body measurements ...............................................................................................76
8.4.3 V ital Signs .............................................................................................................77
8.4.4 Electrocar diogram ..................................................................................................77
8.4.5 Adverse even ts.......................................................................................................78
[IP_ADDRESS] Medicati on error ...............................................................................78
[IP_ADDRESS] Adverse events requiri ng additional data collection ..........................78
8.5 Laboratory assessments ...........................................................................................................80
8.5.1 Laboratory assessments for efficacy .......................................................................81
[IP_ADDRESS] Thrombin generation ........................................................................81
[IP_ADDRESS] Free TFPI .........................................................................................82
8.5.2 Laboratory assessments for safety ..........................................................................82
[IP_ADDRESS] Urinalysi s.........................................................................................82
[IP_ADDRESS] Haematology ....................................................................................82
[IP_ADDRESS] Biochemistry ....................................................................................83
[IP_ADDRESS] FVIII/FIX activity ............................................................................83
[IP_ADDRESS] Coagulati on parameters ....................................................................84
[IP_ADDRESS] FVIII/FIX inhibitors .........................................................................84
[IP_ADDRESS] Anti-concizumab antibodies .............................................................84
[IP_ADDRESS] Concizumab ELISA .........................................................................86
[IP_ADDRESS] FVII ELI SA .....................................................................................87
[IP_ADDRESS] Total TFPI ........................................................................................87
8.5.3 Human Bios amples ................................................................................................88
8.6 Other assessments ........................................................................................................... ........88
8.6.1 P atient reported outcomes ......................................................................................88
8.6.2 Training .................................................................................................................8 9
[IP_ADDRESS] Concizumab and NovoPen®4............................................................89
[IP_ADDRESS] eptacog alfa (rFVIIa) ........................................................................90
[IP_ADDRESS] eDiary ..............................................................................................903URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932354] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 9 of 143
8.6.3 S urgery ..................................................................................................................90
8.7 Patient compliance ..................................................................................................................91
8.8 Treatment compliance .............................................................................................................91
9 Trial supplies ............................................................................................................................... .......92
9.1 Trial products ..........................................................................................................................92
9.2 Labelling ............................................................................................................................... ..92
9.3 Storage..................................................................................................................... ...............93
9.4 Drug accountability and destruction ........................................................................................93
9.5 Auxiliary supplies ...................................................................................................................94
10 Interactive voice/web response system ..............................................................................................[ADDRESS_932355] ........................................................................100
12.1.7 Technical complaints ...........................................................................................104
12.2 Reporting of a dverse events ...................................................................................................104
12.3 Follow-up of adve rse events................................................................................................ ..107
12.4 Technical complaints a nd technical complaint samples ..........................................................108
12.4.1 Reporti ng of technical complaints ........................................................................108
12.4.2 Co llection, storage and shipment of technical complaint samples .........................109
12.5 Pre gnancies ...........................................................................................................................109
12.5.1 Pregna ncies in female partners of male patients ....................................................109
12.6 Precautions and/or overdose ..................................................................................................110
12.7 Rules for putting enrolment on hold ......................................................................................111
12.8 Committees related to safety .................................................................................................111
12.8.1 Novo N ordisk safety committee ...........................................................................111
12.8.2 Data m onitoring committee ..................................................................................111
13 Case report forms ............................................................................................................ ................112
13.1 Corrections to case report forms ............................................................................................113
13.2 Case report form flow ...........................................................................................................113
13.3 Electronic diary .....................................................................................................................113
14 Monitoring procedures ........................................................................................................ ............115
15 Data management ............................................................................................................................116
16 Computerised systems ......................................................................................................... ............117
17 Statistical considerations .................................................................................................................118
17.1 Sample size calculation .........................................................................................................119
17.2 Definition of analysis sets ......................................................................................................1203URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932356] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 10 of 143
17.3 Primary endpoint ...................................................................................................................120
17.3.1 Estima nd and primary statistical analysis .............................................................120
17.3.2 Sens itivity analysis ..............................................................................................121
17.3.3 Add itional analysis ..............................................................................................121
17.4 Supportive sec ondary endpoints ............................................................................................122
17.4.1 Suppor tive secondary efficacy endpoints ..............................................................122
17.4.2 Suppor tive secondary safety endpoints .................................................................122
17.4.3 Suppor tive secondary pharmacokinetic endpoints .................................................123
17.4.4 Suppor tive secondary pharmacodynamic endpoints ..............................................123
17.4.5 Explor atory endpoints ..........................................................................................124
[IP_ADDRESS] Exploratory sa fety endpoints ..........................................................124
[IP_ADDRESS] Exploratory patient re ported-outcome endpoints .............................124
17.5 Interim analy sis........................................................................................................... ..........125
18 Ethics....................................................................................................................... .........................126
18.1 Benefit-risk asse ssment of the trial ....................................................................................... .126
18.2 Informed consent ..................................................................................................................128
18.3 Data handling ........................................................................................................................128
18.4 Informati on to patients during trial ........................................................................................129
18.5 Premature termination of the trial and/or trial site ..................................................................129
19 Protocol compliance .........................................................................................................................130
19.1 Protocol  deviations ................................................................................................................130
19.2 Prevention of mi ssing data ................................................................................................. ...130
20 Audits and inspections ....................................................................................................... ..............131
21 Critical documents........................................................................................................... ................131
22 Responsibilities ............................................................................................................................... ..133
23 Reports and publications ..................................................................................................... ............134
23.1 Communicati on of results ......................................................................................................134
23.1.1 Aut horship ...........................................................................................................135
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) .......................................................135
23.2 Investigator access to data and review of results ....................................................................135
24 Retention of clinical trial documentation and human biosamples ..................................................136
24.1 Retention of clinical trial documentation ...............................................................................136
24.2 Retention of hu man biosamples .............................................................................................136
24.2.1 Anti body samples ................................................................................................137
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities ...........[ADDRESS_932357] of key staff and relevant departments, if applicable for the individual . 
Appendix 1 Patient Reported Outcomes3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932358] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 11 of 143
Table of Figures
Page
Figure 3–1 Individual predicted PK profiles based on data merged with recorded spontaneous (circles) 
and traumatic (triangles) bleeding epi[INVESTIGATOR_535038]-up period. All data originates from explorer™3 (N=24 patients). PK of concizumab is subdivided into 
three exposure levels of !20 ng/mL, 20-100 ng/mL, and > 100 ng/mL together with the 
number of contributing patients. LLOQ: lower limit of quantification. .....................................31
Figure 5–1 Schematic diagram of the trial design ................................................................................ ......36
Figure 5–2 Individual predicted concizumab concentration profiles for all concizumab-treated patients 
in explorer™2 (n=4 patients) and explorer™3 (n=18 patients). The horizontal lines 
indicate 100 ng/mL, and the shaded areas represent the full range (min-max) of the 
individual predicted profiles. ...................................................................................................39
Figure 5– 3 Dose escalation for one individual patient in the concizumab arm ............................................43
Figure 5–4 Dose escalation for one individual patient in the comparator arm .............................................44
Figure 8–1 Visit schedule – concizumab arm. ...........................................................................................51
Figure 8–2 Visit schedule – eptacog alfa (rFVIIa) arm later switching to concizumab. ........................51
Figure 12–1 Reporting of AEs .................................................................................................... ..............106
Figure 17–1 Definition of main and extension part ....................................................................................1253URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932359] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 12 of 143
Table of Tables
Page
Table 5–[ADDRESS_932360] of products provided by [CONTACT_3454] .............................................................................40
Table 8–1 Definition of stop of bleeding epi[INVESTIGATOR_1865] .....................................................................................74
Table 8–2 Definitions of bleeding epi[INVESTIGATOR_1841] (cause of bleed) ....................................................................74
Table 8–3 Definition of bleeding epi[INVESTIGATOR_535138] ...................................74
Table 9–1 Trial products ..........................................................................................................................92
Table 9–2 Storage conditions.................................................................................................... ...............93
Table 17–1 Power in superiority comparison between concizumab prophylaxis and on-demand 
treatment under different assumptions of ABR for concizumab and over-dispersion 
(assuming on-demand ABR=24). ..........................................................................................1203URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932361] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932362] aspartate aminotransferaseAT antithrombinAUC area under curveBP blood pressureBU Bethesda UnitCCDS company core data sheet CLAE clinical laboratory adverse eventC
max maximum plasma concentration
CNS central nervous system
concizumab Bthe name [CONTACT_687671] B. B is the formulation 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932363] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932364] correction DUN dispensing unit numberDVT deep vein thrombosisECG electrocardiogrameCRF electronic case report formeDiary electronic diaryeITMF electronic investigator trial master fileELISA enzyme-linked immunosorbent assay3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932365] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 15 of 143
EMA european medicines agency
EOT end of trialePRO electronic patien t reported outcome
eptacog alfa the name ‘eptacog alfa (rFVIIa)’ will be used throughout 
the protocol and the product is identical to rFVIIa,‘NovoSeven
®, and ‘NiaStaseRT®’
ETP endogenous thrombin potential FAS full analysis setFDA U.S. Food and Drug AdministrationFDAAA U.S. Food and Drug Administration Amendment ActFIX coagulation factor IXFPFV first patient first visitFVIIa activated coagulation factor VIIFVIII coagulation factor VIIIFVIII:C plasma activity of factor VIIIFX coagulation factor XFX
a activated coagulation factor X
GCP Good Clin ical Practice
GGT gamma glutamyl transferaseGHN global haemophilia network3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932366] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932367] cell protein
Hemo-TEM Hemophilia Treatment Experience Measure
IB investigator’s brochure
IC informed consent ICH International Conference on Harmonisation ICMJE International Committee of Medical Journal EditorsID identificationIEC independent ethics committeeIgG4 immunoglobulin G4IMP investigational medicinal product
INNInternational Non-Proprietary Names for Pharmaceuti cal 
Substances 
IRB institutional review boardISRQ-SIAQ Injection Site Reaction Questionnaire – Self-Injection 
Assessment Questionnaire 
ISTH International Society on Thrombosis and HaemostasisIT information technologyi.v. intravenous(-ly)IWRS interactive web response system3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932368] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932369] level 
NIMP non investigational medicinal productPCD primary completion date PD pharmacodynamicsPEF peak expi[INVESTIGATOR_687596]-C Patient’s Global Impression of ChangePK pharmacokineticsPP per protocolPRO patient reported outcome3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932370] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 18 of 143
PT prothrombin time
Q Inter compartmental clearanceQA quality assuranceQ4D every 4
thday
eptacog alfa (rFVIIa)the name ‘eptacog alfa (rFVIIa)’ will be used throughout 
the protocol and the product is identical to ‘NovoSeven®’
sABR spontaneous annualised bleeding rate
SAE serious adverse eventSAS safety analysis setsBE spontaneous bleeding epi[INVESTIGATOR_687508].c. subcutaneous(-ly)SDS Sheehan Disability ScaleSF-36v2 36-Item Short Form Health Survey
SI international system of unitsSmPC summary of product characteristicsS[LOCATION_003]R suspected unexpected serious adverse reactionTAT thrombin-antithrombin complexTEAE treatment emergent adverse eventsTIA transient ischemic attack3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932371] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932372] inhibitorTG thrombin generationTMM trial materials manualTSQM Treatment Satisfaction Questionnaire for Medication TVP trial validation planUTN Universal Trial NumberVERITAS-PRN
® Validated Hemophilia Regimen Treatment Adherence 
Scale3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932373] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 20 of 143
1 Summary
The main objective for the phase 2 trial NN7415-4310, explorer™4, is to assess the efficacy of 
concizumab administered s.c. once daily to pre vent bleeding epi[INVESTIGATOR_56178] A and B 
patients with inhibitors. Furthermore , this trial aims to assess the l onger-term efficacy and safety of 
concizumab in haemophilia A and B patients with inhibitors and to establish the safety of treating breakthrough bleeding epi[INVESTIGATOR_687510] (rFVIIa) in these patients.
Objective(s) and endpoint(s)
Primary objective
∀To assess the efficacy of concizumab administered s.c. once daily in preventing bleeding 
epi[INVESTIGATOR_56178] A and B patients with inhibitors.
Secondary objectives
∀To assess the longer-term efficacy of concizumab in haemophilia patients with inhibitors
∀To assess the safety of concizumab in haemophilia patients with inhibitors
∀To assess the safety of administering recombinant factor VIIa (rFVIIa) to haemophilia 
patients with inhibitors that are exposed to concizumab
∀To assess the immunogenicity of concizumab in haemophilia patients with inhibitors
Primary endpoint
∀The number of bleeding epi[INVESTIGATOR_687579] 24 weeks from treatment onset
Key secondary endpoints
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from tr eatment onset
∀Number of treatment emergent adverse events (TEAEs) during at least 24 weeks from
treatment onset
Time frames for evaluation of Objectives/Endpoints
All endpoints referring to the time frame of at least [ADDRESS_932374] (or has withdrawn). Th e extension part of the trial will provide 
additional safety and long-term efficacy data.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932375] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 21 of 143
Trial design
The trial is a multi-centre, randomised (2:1),  open-label, controlled trial, aiming to evaluate the 
efficacy and safety of concizumab 0.15 mg/kg (with potential dose escalation) administered daily s.c. in haemophilia patients with inhibitors. We expect 16 patients to complete treatment in 
concizumab arm (concizumab prophylaxis) and 8 p atients in comparator arm (rFVIIa on demand). 
The dose regimen is selected based on relevant PK and TFPI [INVESTIGATOR_535039]/PD modelling of the results from the preceding explorer™ trials. Only on-demand patients will be eligible for the trial.
For all patients treated with concizumab (concizumab arm and comparator arm extention part) a 
loading dose of 0,5 mg/kg concizumab will be gi ven as the first dose, followed by [CONTACT_687617] 0,15 mg/kg. All patients in treatment with concizumab will in a non-bleeding 
state receive a single dose of 90 μg/kg eptacog alfa (rFVIIa) one week after dosing with 
concizumab. Hereafter, patients will be closely clinically observed at the site for potential safety 
issues for at least 12h and evaluated again at the site after 24h.
The total trial duration for the individual patient will be approximately 86-130 weeks, consisting of
a 2-4 week screening period, a subsequent 76- 118 week treatment period and an 8-week follow-up 
period. eptacog alfa (rFVIIa) for treatment of bleeding epi[INVESTIGATOR_687600]. The patient will not be provided with  trial product or eptacog alf a (rFVIIa) after end 
of trial.
The trial is split into a main part which lasts at least [ADDRESS_932376] completed 24 weeks of treatment with eptacog alfa (rFVIIa) on-demand or have withdrawn. The analysis of the main part of the trial aims to substantiate the 
clinical proof of concept (CPoC) that concizumab has the potential to prevent bleeding epi[INVESTIGATOR_687601]. The extension part of the trial will provide additional 
safety and long-term efficacy data.
Trial population
Number of patients planned to be screened: [ADDRESS_932377]: 26Number of patients expected to complete the trial: 243URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932378] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 22 of 143
Key inclusion criteria
∀Informed consent obtained before any trial r elated activities. Trial related activities are any 
procedures that are carried out as part of the trial, including activities to determine the 
suitability for the trial
∀Male haemophilia A or B patients with inhibitors aged ≥ 18 years at the time of signing 
informed consent
∀Patients currently in need of treatment with by[CONTACT_687618]
∀Known or suspected hypersensitivity to trial product(s) or related products
∀Known inherited or acquired bleeding disorder other than haemophilia
∀Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX
Key Efficacy assessment
∀Number of bleeding epi[INVESTIGATOR_535025] 24 weeks of treatment onset
Key Safety assessment
∀Number of treatment emergent adverse events during at least 24 weeks of treatment onset
Trial products
The following products will be used in the trial:
∀Investigational Medicinal Products:
oconcizumab B, 100mg/mL to be administered s.c. with NovoPen®4 and needles
oeptacog alfa (rFVIIa), 5mg /vial and histidine (solvent). Reconstituted eptacog alfa 
(rFVIIa) is for intravenous administration and used in the trial at visit 3 and 9.1 for all patients with the purpose of investigating the safety of administering eptacog alfa (rFVIIa) to haemophilia patients
∀Non Investigational Medicinal Product :
oeptacog alfa (rFVIIa) 5 mg /vial and histidine (solvent). Reconstituted eptacog alfa is for 
intravenous administration and used in this trial for treatment of bleeding epi[INVESTIGATOR_1841]3URWRFROY
CONFIDENTIAL
Protocol UTN: U1111-1179-2925 D ate: [ADDRESS_932379] 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932380] no.: 2016-000510-30 Version: 4.0 Page: 23 of 143
2 Flow chart
2.1 Visits and assessments
explorerTM4 trial periods Screening Treatment main a, bTreatment extension bFollow-up
Visit number c1 2 3 4-5 6 7-8 9 9.1d9.2d10 10.1d11 11.1d12 13-1415, 15.1, 
15.2, 15.nw 16 Unscheduled e17x
Timing of visits (d) f14 - 28 d before
visit 2 1 8 29-57 85 113-141 169 176 197 225 253 281 309 337 393-449 505-785Up to
827When 
applicableUp to
883
Visit window (d)14 - 28 d before
visit 20 +1 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1wEvery 
4w12wEvery 
4w24w 25w 28w 32w 36w 40w 44w 48 w Every 8w Every 8wUp to  
118w- Up to 126w
PATIENT RELATED INFO/ASSESSMENTS
Informed consent/ Long-term storage consent ●
In/exclusion criteria ● ●g
Demography ●
Concomitant illness/Medical history ●
Concomitant medication ● ●●●●●●●●●●●●● ● ● ● ● ●
Details of Haemophilia/Haemophilia treatment and bleed 
history●
Withdrawal criteria/ Criteria for premature discontinuation 
of trial product●●●●●●●●●●●●● ● ● ● ● ●
Randomisation (IWRS) ●
EFFICACY
Bleeding epi[INVESTIGATOR_1841] h, i●●●●●●●●●●●●● ● ● ● ● ●
Thrombin generation (central lab) ● ●l●j, k, l●●●●l●j●●●●●● ● ● ●l● ●
Free TFPI (central lab)  ● ●l●k, l●●●●l●●●●●●● ● ● ●l● ●
SAFETY
Physical examination ● ●●k●● ● ● ● ●
Body measurements ● ●m●k, m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m
Vital signs ● ●n●k, n●●●●n●n●●●●●● ● ● ● ● ●
ECG ●
Adverse events ● ●●●●●●●●●●●●● ● ● ● ● ●3URWRFROY
Protocol UTN: U1111-1179-2925 D ate: [ADDRESS_932381] 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932382] no.: 2016-000510-30 Version: 4.0 Page: 24 of 143
explorerTM4 trial periods Screening Treatment main a, bTreatment extension bFollow-up
Visit number c1 2 3 4-5 6 7-8 9 9.1d9.2d10 10.1d11 11.1d12 13-1415, 15.1, 
15.2, 15.nw 16 Unscheduled e17x
Timing of visits (d) f14 - 28 d before
visit 2 1 8 29-57 85 113-141 169 176 197 225 253 281 309 337 393-449 505-785Up to
827When 
applicableUp to
883
Visit window (d)14 - 28 d before
visit 20 +1 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1wEvery 
4w12wEvery 
4w24w 25w 28w 32w 36w 40w 44w 48 w Every 8w Every 8wUp to  
118w- Up to 126w
Injection site reaction  ●●k●●●●●●●●●●● ● ● ● ●
Urinalysis (local lab) ●
Haematology (local lab) ● ●l●j, k, l●●●●l●j●●●●●● ● ● ●l● ●
Biochemistry (central lab) ● ●l●k, l●●●●l●●●●●●● ● ● ●l● ●
FVIII/ FIX activity (central lab) ● ●l●l
Coagulation parameters (central lab) ● ●l●●●●l●●●●●● ● ● ●l● ●
Coagulation parameters (PT, APTT and Fibrinogen (local 
lab))●j, k, l●j
FVIII/FIX  inhibitors (central lab) ● ●l●l
Anti-concizumab antibodies (ADA) (special lab) o● ●l●k, l, p●p●p●p●l, p●●●●●●● ● ● ●l● ●
Concizumab  ELISA (special lab) ●l●j, k, l, p●p●p●p●l, p●j●●●●●● ● ● ●l● ●
FVII ELISA (special lab) ●j,k, l●j
Total TFPI (special lab) ● ●l●k, l●●●●l●●●●●●● ● ● ●l● ●
TRIAL MATERIAL
IWRS call ● ●●k●●●●●●●●●●● ● ● ● ● ●
Dispensing visit (concizumab)r●k●k●k●k●k●●●●●●●● ● ● ●
Dispensing visit (eptacog alfa, histidine)q● ●k● ●● ● ● ● ● ● ● ●
Administration of trial product (concizumab)r●k, s●k●d, s ● ● s●
Administration of trial product (eptacog alfa) ●k, t●t
Drug accountability (concizumab) ●k●k●k●k●k●●●●●●● ● ● ● ●
Drug accountability (eptacog alfa) ●●k●●●●●●●●●●● ● ● ● ● ●
New dose of trial product e, u●●●● ●●●●●● ● ● ●
PRO questionnaires ● ●●k●●●● ● ●z● aa
REMINDERS
Human biological specimen for storage (central lab) ● ●3URWRFROY
Protocol UTN: U1111-1179-2925 D ate: [ADDRESS_932383] 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932384] no.: 2016-000510-30 Version: 4.0 Page: 25 of 143
explorerTM4 trial periods Screening Treatment main a, bTreatment extension bFollow-up
Visit number c1 2 3 4-5 6 7-8 9 9.1d9.2d10 10.1d11 11.1d12 13-1415, 15.1, 
15.2, 15.nw 16 Unscheduled e17x
Timing of visits (d) f14 - 28 d before
visit 2 1 8 29-57 85 113-141 169 176 197 225 253 281 309 337 393-449 505-785Up to
827When 
applicableUp to
883
Visit window (d)14 - 28 d before
visit 20 +1 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) [ADDRESS_932385] ●
Training v● ● ●● ●
Compliance: eDiary ●●●●●●●●●●●● ● ● ● ● ●
End of treatment ●
End of trial ●y●y
The cells marked in ‘red’ are only for the patients randomised to eptacog alfa (rFVIIa) arm.3URWRFROY
Protocol UTN: U1111-1179-2925 D ate: [ADDRESS_932386] 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932387] no.: 2016-000510-30 Version: 4.0 Page: [ADDRESS_932388] according to patient’s individual training need on concizumab administration, NovoPen®4, eDiary training etc. Visit [ADDRESS_932389] a PK session of 24 hours and a safety follow up visit the following day. 
dVisit and procedures only performed for patients randomised to eptacog alfa and switching to concizumab treatment.Visit 9.1 sho uld be performed 7 days (+ 1 
day) after visit 9.
e For patients being dose escalated on concizumab a phone call is recommended [ADDRESS_932390] be registered in the eCRF.
i Eptacog alfa will be given to treat breakthrough bleeding epi[INVESTIGATOR_1841]. 
jSampling time schedule for thrombin generation, haematology,  coagulation parameters, concizumab ELISA and FVII ELISA: pre-dose  (-1 hour), post-dose: 
10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points,  except pre-dose, occur after 
eptacog alfa administration.
kONLY for patients randomised to concizumab arm. The concizumab dose should be administered first followed by [CONTACT_687654]. The  interval between the 
concizumab and eptacog alfa should not exceed more than [ADDRESS_932391] not treat themselves with concizu mab until sampling has been 
performed.
m Only body weight should be measured. 
nVital signs should be evaluated before and after trial drug administration at visit 2 and visit 3 for concizumab arm and at vis it 9 and visit 9.1 for patients in 
eptacog alfa arm switching to concizumab treatment.
oIn case clinical signs of e.g. hypersensitivity reactions or immune related events are seen, additional samples for ADAs ma ybe taken. All antibody samples 
from the affected patient will be analysed on an ongoing basis. If antibodies are detected, additional blood samples will be ta ken and stored for characterisation 
of the antibodies.
p Blood sampling for anti-concizumab antibodies and concizumab ELISA testing should only be collected for patients on concizumab.
q If needed dispensing of eptacog alfa, histidine, trial injection kits and Direction For Use (DFU). 
r First treatment dose of concizumab is a loading dose and will be administered at visit [ADDRESS_932392] received any  by[CONTACT_687619],(e.g., 3URWRFROY
Protocol UTN: U1111-1179-2925 D ate: [ADDRESS_932393] 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932394] no.: 2016-000510-30 Version: 4.0 Page: 27 of 143
eptacog alfa, FEIBA®) for treatment of a bleeding epi[INVESTIGATOR_5319] a period of 24h (for eptacog alfa) or 48h (for FEIBA®) prior to first concizumab. Only 
eptacog alfa is allowed after visit 2.
tEptacog alfa administered in a non-bleeding state at site at visit [ADDRESS_932395] followed by [CONTACT_687654]. The interval between the concizumab and eptacog alfa should not exce ed more than 30 min.
uPatient treated with concizumab should be dose escalated at next scheduled visit if he experiences ≥[ADDRESS_932396] and whenever needed afterwards. Patients randomised to eptacog  alfa will be re-trained in 
NovoPen®4 and s.c. administration at visit 9 and 9.1. If necessary training can be performed as needed at other visits. The eDiary will  be provided to the 
patients at visit 2 if the patient feels capable in s.c. administration and using the eDiary. Further the patients will be trai ned in recognition of signs/symptoms of 
thrombosis.
w Only for patients randomised to on-demand arm.
x Visit repeated every [ADDRESS_932397] be completed at visit 17, 8 weeks after End of Treatment.
z PRO questionnaires should only be completed at 15.1 for patients continuing in the prolongation of the trial.
aa PRO questionnaires should only be completed at visit 16 for patients not continuing in the prolongation of the trial3URWRFROY_
Protocol
CONFIDENTIALDate: [ADDRESS_932398] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932399] of 
the clinical trial at a trial site.
The INN name [CONTACT_687673] i ngredient is concizumab (synonyms used during early 
development are NNC0172-2021, anti-TFPI, NN7415 or mab2021). Throughout this document “concizumab” is used as the name [CONTACT_535317].
3.1 Background information
3.1.1 Hae mophilia
Haemophilia is an inherited bleeding disorder characterised by [CONTACT_535209], 
typi[INVESTIGATOR_535031]. Haemophilia A is  caused by a partial or complete deficiency of 
blood coagulation factor VIII (FVIII). In haemophilia B, it is factor IX (FIX) that is deficient. 
Inheritance is chromosome X-linked; therefore the disease mainly affects males. The incidence of haemophilia A and B on average is estimated to be about 1 in 5000 live male births 
4. According to 
the World Federation of H aemophilia global survey of [ZIP_CODE], about 178,500 persons are diagnosed 
with haemophilia worldwide. Of th ese, about 80% have haemophilia A.
Haemophilia is classified as “severe”, “moderate” or “mild” according to the plasma activity level 
of the affected coagulation factor6. With a deficiency of FVIII or FIX, the degree of activation of 
coagulation FX becomes insufficient. Consequentl y, the thrombin burst is delayed and insufficient 
for normal haemostasis7. The haemos tatic plug, if formed, in these patients is fragile and easily 
dissolved by [CONTACT_56264]. This leads to impaired haemostasis and spontaneous prolonge d bleeding epi[INVESTIGATOR_1841]. In severe haemophilia, b leeding in joints occurs spontaneously and is
the most frequent symptoms of the disease. Recurrent bleeding epi[INVESTIGATOR_56175] - most 
commonly a weight bearing joint - lead to chronic arthropathy, muscular atrophy and deformities. 
Treatment of bleeding epi[INVESTIGATOR_535032] (on-demand treatment) may delay arthropathy, but does not prevent it. The majority of children with severe haemophilia experience their first bleedingepi[INVESTIGATOR_687513] a joint prior to age [ADDRESS_932400] developed inhibitors towards FVIII or FIX, replacement therapy is rendered 
ineffective. Though prevalence studies and registry data indicate that the prevalence of inhibitors in 
the haemophiliac population overall has been reported to be between 5% and 7%9, the prevalence 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932401] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932402] patients with severe haem ophilia (FVIII:C < 1%) is higher and has been reported to be up 
to 30%9, 10. These patients may be treated with by[CONTACT_71363], activated FVII (NovoSeven®) and 
activated prothrombin complex concentrate (FEIBA®) given as i.v. injections.
Current treatment options in haemophilia, replacement therapy or by[CONTACT_687620], are hampered 
by [CONTACT_535211] i.v. injections. Furthermore, by[CONTACT_687621]-lives, there fore prophylactic treatment is burdensome. It is 
also generally acknowledged that the efficacy profile of by[CONTACT_687645]. Consequently, delayed or sub-optimal treatme nt occurs in a significant number of patients
with inhibitors. A new therapeutic agent that can be administered subcutaneously will represent a 
major improvement in the treatment of these patients in a prophylaxis setting.
3.1.[ADDRESS_932403], concizumab, is a humanised recombinant monoclonal antibody (mAb) of the 
immunoglobulin G4 (IgG4) isotype with a molecu lar weight of 149 kilo Dalton’s.  Like other 
antibodies, concizumab is composed of two light chains and two heavy chains linked together by [CONTACT_95999]. To prevent formation of half-a ntibodies, the serine at position 241 in the heavy 
chain has been replaced with a proline (S241P (Kabat annotation))
10. The mechanism of action of 
concizumab is based on the concept of inhibiting the activity of a natural coagulation inhibitor, 
tissue factor pathway inhibitor (TFPI). TFPI [CONTACT_832] a potent inhibitor of th e initiation phase of the 
coagulation process, i.e. the activation of (FX) to FXa by [CONTACT_535213] (TF)/factor VIIa (FVIIa) 
complex. TFPI [INVESTIGATOR_687580]/FVIIa complex, forming a TF/FVIIa/FXa/TFPI [INVESTIGATOR_535034]. Thus, concizumab prevents both 
inhibition of FXa and inhibition of FVIIa/TF by  [CONTACT_535214]. In this manner, sufficient amounts of FXa to 
ensure effective haemostasis in the absence of a functional activated factor IX/activated factor VIII (FIXa/ FVIIIa) complex may be generated. This is  a new concept that remains to be documented 
safe and efficacious in patients with haemophilia. More information about the physiological role of TFPI [INVESTIGATOR_535035]’s Brochure.
Key differentiators of this new mode of action (MoA) and the key benefit of concizumab in patients 
with severe haemophilia A and B with inhibitors is reduced treatment burden due to subcutaneous administration potentially leading to better adhere nce, more patients on prophylactic treatment and 
ultimately better outcome. 
Four clinical trials with concizumab have been co mpleted thus far: the first human-dose trial 
(NN7415-3813, explorer
TM1)11, a single dose trial in Japanese healthy subjects (NN7415-3981), 
two multiple dose trials (NN7415-3986, explorerTM2) and (NN7415-4159, explorer™3). When the 
first cohort with  4 (four) healthy sub jects in explorer™2 was completed, pri or to the initiation of the 
2ndcohort, the trial was halted, due to findings re lated to thrombosis in an ongoing 26-week toxicity 
study in primates. In this trial animal had concizumab plasma concentrations several hundred fold 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932404] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 30 of 143
above clinically relevant concentrations. Follow up investigations confirmed that the animal’s 
condition was related to thrombosis in the lungs caused by [CONTACT_535268]. Before the initiation of th e fourth phase 1 trial (NN7415-4159), explorer™3,
a new 52 week non-clinical toxicology study was conducted in primates to investigate the findings 
in the previous study. The conclusion from this new non-clinical study was that the results from 
non-clinical studies support further clinical development of concizumab. Explorer™3 was a multiple dose clinical trial which aimed to investigate the safety, pharmacokinetics and pharmacodynamics of concizumab at five different dose levels in adult severe haemophilia A 
patients without inhibitors. In th is trial multiple doses of concizumab were administered s.c. over a 
period of six weeks.
The explorer™3 trial was finalised following th e completion of cohort 3 (0.8 mg/kg s.c. every 4 
days for 6 weeks). Blinded preliminary safety and PK/PD data from the cohort was reviewed by [CONTACT_535216]. Marked changes in coagulation parameters were observed including 
a decrease from baseline in fibrinogen and a pronounced increase in D-dimer and F1+[ADDRESS_932405] variation in pro-coagulant response to the drug
was observed. Based on this, the Novo Nordisk safety committee (see Section 12.8.1 ) decided not 
to proceed to cohort 4 (1.1 mg/kg s.c. every 4 days for 6 weeks). No clinical consequences or 
serious adverse events were seen in the completed cohorts in explorer™3.
The PK results from explorer™3 showed exposure-response in terms of fewer bleeding epi[INVESTIGATOR_535036] 100 ng/mL. Individual predicted PK profiles merged with recorded spontaneous and traumatic bleeding
epi[INVESTIGATOR_535037] 3–1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932406] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 31 of 143
Figure 3–1 Individual predicted PK profiles based on data merged with recorded spontaneous 
(circles) and traumatic (triangles) bleeding epi[INVESTIGATOR_535020]-up period. All data originates from explorer™3 (N=24 patients). PK of 
concizumab is subdivided into three exposure levels of !!20 ng/mL, 20-100 ng/mL, 
and > 100 ng/mL together with the number of contributing patients. LLOQ: lower 
limit of quantification.
a‘Time in trial’ refers to the time that the patients spent on each concizumab exposure level, and the !20 ng/mL level 
therefore also includes the screening period (not shown on this figure).
A large difference between the peak and trough plasma concentrations of concizumab were 
observed as well, especially in the highest dose group (0.80 mg/kg) of explorer™3. In patients who 
received 0.25, 0.5 and 0.8 mg/kg doses a significant overlap in plasma concentrations of 
concizumab was seen due to high betw een-patient variability in concizumab.
Single doses of concizumab up to 9 mg/kg have been administered to haemophilia patients in the 
first human dose trial with concizumab, explorer™1. These doses resulted in plasma concentrations 
of concizumab that were significantly higher than the ones that are modelled to be reached in the 
highest escalated daily dose (0.25 mg/kg) of explorer™4.
In a drug–drug interaction study in monkeys  (NN215431), three doses of up to 1 mg/kg of 
NovoSeven®were administered at 2h intervals, alone or in the presence of a steady state 
concentration of concizumab. No notable clinical obse rvations were made, no treatment-related 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932407] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 32 of 143
adverse findings were seen, i.e. no thrombi or other signs of excessive coagulation. Increased 
concentrations of thrombin–anti-thrombin (TAT) and D-dimer were seen, which tended to be additive when both concizumab and eptacog alfa (rFVIIa) were present in circulation.
For an assessment of benefits and risks of the trial, see Section 18.1.
For further information, please refer to the Investigator’s Brochure.
3.[ADDRESS_932408] been finalised. Key safety and preliminary 
efficacy results from these phase 1 studies support further development of concizumab in 
haemophilia patients. Therefore, the main objective in the phase 2 of concizumab development is to 
assess efficacy and safety and provide data that will guide for the confirmatory phase 3 concizumab trials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932409] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 33 of 143
4 Objective(s) and endpoint(s)
4.1 Objective(s)
4.1.1 Primary objective
To assess the efficacy of concizumab administered s.c. once daily in preventing bleeding epi[INVESTIGATOR_687514] A and B patients with inhibitors
4.1.2 Secondary objectives
∀To assess the longer-term efficacy of concizu mab in haemophilia patients with inhibitors
∀To assess the safety of concizumab in haemophilia patients with inhibitors
∀To assess the safety of administering recombinant factor VIIa (rFVIIa) to haemophilia 
patients with inhibitors that are exposed to concizumab
∀To assess the immunogenicity of concizumab in  haemophilia patients with inhibitors
4.2 Endpoint(s)
4.2.1 Primary endpoint
∀The number of bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
4.2.2 Secondary endpoints
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
∀The number of bleeding epi[INVESTIGATOR_535025] 76 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 76 weeks from treatment onset
Supportive secondary safety endpoints
∀Number of treatment-emergent adverse events (TEAEs) during at least 24 weeks from 
treatment onset
∀Number of TEAEs during at least 76 weeks from treatment onset
∀Number of TEAEs within 24 hours of rFVIIa administration
∀Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset
∀Occurrence of anti-concizumab antibodies during at least 76 weeks from treatment onset
∀Change from baseline of fibrinogen during 24 weeks from treatment onset
∀Change from baseline of fibrinogen during at least 76 weeks from treatment onset
∀Change from baseline of D-dimer during 24 weeks from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932410] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 34 of 143
∀Change from baseline of D-dimer during at least 76 weeks from treatment onset
∀Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
∀Change from baseline of F1 + [ADDRESS_932411] 76 weeks from treatment onset
∀Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
∀Change from baseline of PT during at least 76 weeks from treatment onset
∀Change from baseline of activated partial thromboplastin time (APTT) during 24 weeks 
from treatment onset
∀Change from baseline of APTT during at least 76 weeks from treatment onset
∀Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
∀Change from baseline of AT after at least 76 weeks from treatment onset
Supportive secondary pharmacokinetic endpoints
∀Concentration of concizumab prior to the last dose administration at 24 weeks
∀Concentration of concizumab prior to the last dose administration after at least 76 weeks
Supportive secondary pharmacodynamic endpoints
∀Free TFPI [INVESTIGATOR_687515] [ADDRESS_932412] 76 weeks
∀Thrombin generation
oPeak thrombin generation (nM) prior to the last dose administration at 24 weeks 
oPeak thrombin generation (nM) prior to the last dose administration after at least 76 
weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 24 
weeks 
oEndogenous thrombin potential (nMxmin) prior to the last dose administration after 
at least 76 weeks
oVelocity index (nM/min) prior to the last dose administration at 24 weeks
oVelocity index (nM/min) prior to the last dose administration after at least 76 weeks
4.2.3 Exploratory endpoints
[IP_ADDRESS] Exploratory safety endpoints
∀Number of adverse events related to technical complaints during at least 24 weeks from 
treatment onset 
∀Number of adverse events related to technical complaints during at least 76 weeks from 
treatment onset 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932413] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 35 of 143
[IP_ADDRESS] Exploratory patient reported outcome endpoints
∀Change in Hemo-TEM after 24 weeks from treatment onset
∀Change in Hemo-TEM after at least 76 weeks from treatment onset
∀Change in SF-36v2 after 24 weeks from treatment onset
∀Change in SF-36v2 after at least 76 weeks from treatment onset
∀Change in SDS after 24 weeks from treatment onset
∀Change in SDS after at least 76 weeks from treatment onset
∀Change in TSQM after 24 weeks from treatment onset
∀Change in TSQM after at least 76 weeks from treatment onset
∀Change in SIAQ-ISRQ after 24 weeks from treatment onset
∀Change in SIAQ-ISRQ after at least 76 weeks from treatment onset
∀Status of PGI-C after [ADDRESS_932414] 76 weeks will be evaluated in the extension part 
of the trial.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932415] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 36 of 143
5 Trial design
5.1 Type of trial
The trial is a multi-centre, randomised (2:1), ope n-label, controlled trial, aiming to evaluate the 
efficacy and safety of concizumab 0.15 mg/kg (with potential dose escalation) administered daily 
s.c. in haemophilia patients with inhibitors. The selected dose regimen is based on relevant PK and 
TFPI [INVESTIGATOR_535039]/PD modelling of the results from the preceding explorer™ trials. Only   
on-demand patients will be eligible for the trial.
Figure 5–1 Schematic diagram of the trial design
The total trial duration for the individual patient will be approximately 86-130 weeks, including a 2-
4 week screening period, a 76-118 week treatment period, and a follow-up period of 8 weeks, see 
Figure 5–[ADDRESS_932416] completed a minimum of 24 weeks of eptacog alfa 
(rFVIIa) on-demand or have withdrawn.
In the concizumab arm bleeding epi[INVESTIGATOR_687516] 
(rFVIIa). In all patients treated with concizumab a single 90 μg/kg dose of eptacog alfa (rFVIIa)
will be administered in a non-bleeding state one week after dosing with concizumab has been 
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932417] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932418] eptacog alfa 
(rFVIIa) administration. Furthermore, the scheduled administration of eptacog alfa (rFVIIa) for the 
first 4 patients entering the trial with concizumab will be staggered.
In the comparator arm, in the main part, patie nts will receive eptacog alfa (rFVIIa) on-demand 
treatment. After completion of the main part, the patien ts will continue the trial in the extension part 
being treated with prophylactic concizumab 0.15 mg/kg (with potential dose escalation) s.c. d aily 
administration.
Human biosamples (plasma, serum, and/or DNA for genotypi [INVESTIGATOR_007]) will be collected in this trial for 
future exploratory analysis to pursue a deeper insight into the biology of TFPI, coagulation, and effect of concizumab on joint health.  That may include coagulation parameters and markers of joint 
status and damage. Acceptance of storage of human biosamples is voluntary and will not affect the 
patients’ participation in the trial. Therefore, p atients will have the possibility to sign the informed 
consent for the trial and participate, while refusing permission for human biosamples to be stored for future exploratory analysis, see Section 8.1.1 .
An independent data monitoring committee (DMC) w ill be established for this trial. The DMC will 
review all safety data from the ongoing tria l with concizumab exposure, see Section 12.8.2 .
5.1.1 Surgery
Minor surgery is allowed in this trial. Major surgery conducted earlier than one month (30 days) 
prior to trial start is allowed, see exclusion criteria no 6.
Minor surgery is defined as an invasive oper ative procedure where only the skin, the mucous 
membranes or superficial connective tissue is manipulated. Examples of minor surgery include implanting of central venous access devices (ports, CVC, pumps and other CVADs) in subcutaneous tissue, skin biopsies or simple dental procedures.
5.2 Rationale for trial design
Explorer™4 is a phase 2, clinical proof of concept (CPoC), and safety trial. The trial aims to 
substantiate CPoC that concizumab has the potential to prevent bleeding epi[INVESTIGATOR_687581]. A dose escalation design will allow cautious dose escalation in order to 
identify an efficacious and safe concizumab dose for the individual patient. A comparator arm is 
included to assess if concizumab is superior to on -demand treatment. Furthermore, the trial will 
give a possibility to assess safety of co-a dministration of eptacog alfa (rFVIIa) to the patients 
exposed to the concizumab treatment.
The duration of at least 24 weeks for the main pa rt of the trial is deemed necessary in order to 
obtain information on the annualised bleeding rate on concizumab prophylaxis. The duration of the extension part of the trial will be up to 94 weeks and provide further information on efficacy, i.e. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932419] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 38 of 143
annualised bleeding rate, and also provide additional safety data upon 76-118 weeks treatment with 
concizumab.
Patients participating in NN7415- 4310 will be offered screening for eligibility to participate in the 
subsequent clinical trials for concizumab, following their participation in NN7415-4310 and 
provided that either the site particip ates in the subsequent trial with concizumab or if possible the 
patient can be transferred to a participating site. It is expected that the majority of the participating patients will join subsequent trial and t hus may continue prophylactic treatment with concizumab .
A total of 26 patients previously on-demand (OD)  treatment will be randomised into one of the two 
arms, with 16 patients in the concizumab arm and 8 patients in the comparator arm see Figure 5–1 . 
Concizumab will be administered s.c. d aily for p atients randomised to the concizumab arm in the 
main and the extension part of the trial. For patien ts in the comparator arm in the extension part
treatment will be changed from on-demand with rFVIIa to prophylaxis with concizumab.
The concizumab dose regimens will be starting with  0.15 mg/kg with the possibility to escalate to
0.20 mg/kg and 0.25 mg/kg based on bleeding frequency, see Section 5.3.3 .
Daily dosing with concizu mab 0.15 mg/kg aims to ensure steady-state levels of concizumab plasma 
concentrations above 100 ng/mL for the majority of the patients starting on this dose. The PK 
results from explorer™3 showed exposure response in terms of fewer bleeding epi[INVESTIGATOR_535042] 100 ng/mL, see Figure 3–[ADDRESS_932420] the opportunity to be dose escalated to the dose of 0.2 mg/kg. A further dose escalation to 0.25 mg/kg per day is 
permitted, again based on the bleeding rate, see Section 5.3.3 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932421] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 39 of 143
Figure 5–2 Individual predicted concizumab concentration profiles for all concizumab-treated 
patients in explorer™2 (n=4 patients) and explorer™3 (n=18 patients). The 
horizontal lines indicate 100 ng/mL, and the shaded areas represent the full range (min-max) of the individual predicted profiles.
1
Due to the high between patient variability in concizumab concentration observed in explorer™3, a 
significant overlap in plasma concentrations of concizumab in patients who received 0.25, 0.5 and 
0.8 mg/kg doses was seen, see Figure 5–[ADDRESS_932422] mean plasma concentrations of concizumab, and thus different efficacy at each 
                                               
1Plasma concentrations in the same range as those in explorer™3 are expected to be reached in this trial with daily dose adminis tration. The starting 
dose for all patients will be 0.15 mg/kg daily. The plasma steady-state exposure for a typi[INVESTIGATOR_687518] a typi[INVESTIGATOR_535044] 0.8 mg/kg Q4D (cohort 3 of explorer3) in terms of both Cmax and AUC 0-24h. For 0.20 mg/kg dail y and 0.25 
mg/kg, the plasma steady-state exposure levels for a typi[INVESTIGATOR_687519] 40% and 70% respectively, comp ared to the typi[INVESTIGATOR_687520] 3rd cohort of explorer™3 (AUC and Cmax). The maximum predicted plasma exposure levels (Cmax and AUC 0-24 h) for the 
0.15 mg/kg daily dose level is predicted to be more than 8 fold lower than for 0.80 mg/kg Q4D. For 0.20 mg/kg daily both Cmax an d AUC 0-24h are 
predicted to be more than 3 times lower than for 0.80 mg/kg Q4D. For 0.25 mg/kg daily, the maximum Cmax and AUC 0-24h are predi cted to be 
35% lower than for 0.80 mg/kg Q4D .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932423] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932424], the titration trial design allows patients to start on a low dose, which is expected to ensure prophylaxis but not marked changes in coagulation parameters, for the majority of patients. Escalation to the next dose level will only occur in the case of lack of 
efficacy ( ≥ 3 spontaneous bleeding epi[INVESTIGATOR_535047] 12 weeks). In addition, the PK of 
concizumab is heavily influenced by [CONTACT_535297], which means that small 
differences in concizumab dose ultimately leads to large differences in plasma concentrations. Therefore, daily dosing is proposed for the phase 2 trial, explorer™4. Daily dosing will allow for 
the increase in trough levels and thus better efficacy may be expected with a lower dose.
A loading dose of 0.5 mg/kg concizumab will be given as the first dose, followed by [CONTACT_687617] 0.15 mg/kg in order to ensure steady-state lev els at the time of eptacog alfa 
(rFVIIa) administration. eptacog alfa (rFVIIa) will be administered one week after initiation of 
dosing with concizumab in a non-bleeding state to assess safety of tr eatment with eptacog alfa 
(rFVIIa) in patients exposed to concizumab treatment.
Embryonic exposure in pregnant female partners of men treated with concizumab is highly unlikely 
and there is no need for protocol requirements for use of contraception in phase 2 and 3 trials.
5.3 Treatment of patients
The following products will be administered in the trial.
Table 5–[ADDRESS_932425] of products provided by [CONTACT_687624] B a100 mg/mL solution for s.c. 
injection in a 3 mL cartridge
bSubcutaneous administration usingNovoPen
®4For prophylactic 
treatment for at least 76 weeks (for concizumab 
arm in the main part 
and extension part).
For prophylactic 
treatment for at least 52 weeks (for comparator 
arm in the extension part).
eptacog alfa (rFVIIa)a, c5 mg/vial Powder for solution 
for i.v. injectionIntravenous 
administrationFor treatment of 
breakthrough bleeding 
epi[INVESTIGATOR_687597] 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932426] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 41 of 143
histidine solvent (5 mL) Prefilled syringes for 
solution for i.v. injection investigator (screening, 
main, extension and follow up part). 
c
Administration of doses higher than 
90μg/kg to patients 
exposed to concizumab is not allowed.
For on-demand 
treatment at the 
discretion of the investigator in 24 weeks for comparator arm in the main part. 
In the concizumab arm 
and comparator arm after switching to concizumab in the extension part of the study a single 90 μg/kg 
dose for initial safety assessments in a non-bleeding state.
a
Will be provided for as long as patients 
participate in the trial 
(screening, main, 
extension and follow up part)
aInvestigational medicinal product (IMP)
b Not to be confused with the daily injected volume (~150 μL, depending on dose strength and body weight)
cNon-investigational medicinal product (NIMP)
The NovoPen®4 injector will be supplied by [CONTACT_535242] s.c. administration of 
concizumab. It will be labelled in accordance with national legislation and a copy of the label can 
be found in the Trial M aterials Manual, see Section 9.
5.3.1 Concizumab arm
[IP_ADDRESS] Concizumab prophylactic treatment (main and extension part)
Concizumab will be given s.c. once daily 0.15 mg/kg (with poten tial dose escalation to 0.20 and 
0.25 mg/kg). The dose escalation criteria are described, see Section 5.3.[ADDRESS_932427] dose of 
concizumab will be given at the trial site under medical supervision.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932428] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 42 of 143
A loading dose of 0.5 mg/kg will be given as the first concizumab dose at visit 2 in order to ensure 
steady state levels at the time of the administrati on of eptacog alfa (rFVIIa) in a non-bleeding state 
at visit 3, see Section 5.3.4 .
The patients will be trained in s.c. administration of concizumab with NovoPen®[ADDRESS_932429] scheduled treatment visit. 
5.3.2 Comparator arm (eptacog alfa (rFVIIa))
[IP_ADDRESS] On-demand treatment (main part)
During the main part of the trial, patients will receive eptacog alfa (rFVIIa) for treatment of 
bleeding epi[INVESTIGATOR_1841], with a dose regimen at the discretion of the investigator.
[IP_ADDRESS] Concizumab prophylactic treatment (extension part)
After completion of the main part, the patients w ill continue the trial in the extension  part and will 
switch to prophylactic treatment with s.c. daily administration of concizumab 0.15 mg/kg (with potential dose escalation to 0.20 and 0.25 mg/kg) s.c. daily administration.
The same dose escalation criteria as described b elow (for the initial concizumab arm) will apply.
A loading dose of 0.5 mg/kg will be given as the first concizumab dose at visit [ADDRESS_932430] 2 weeks of the treatment with concizumab 0.15 mg/kg is considered as a run-in period. Hence, bleeding epi[INVESTIGATOR_687522] 2 weeks should not influence a dose escalation decision.
All spontaneous bleeding epi[INVESTIGATOR_1841] (sBEs) are co unted from 2 weeks after visit 2 (or visit 9 when
switching from eptacog alfa (rFVIIa) to concizumab) (first treatment visit) until visit 16 (end of
treatment visit), i.e. a total of up to [ADDRESS_932431] take into account the 
full clinical pi[INVESTIGATOR_535049], including 
coagulation parameters.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932432] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 43 of 143
Dose 0.15 mg/kg: 
When sBE occurs, the investigator will determine if ≥[ADDRESS_932433] occurred within the preceding 12
weeks (including the current sBE). If yes, and if investigator deems it safe, the patient will be dose escalated from 0.15 to 0.20 mg/kg at the next scheduled visit. If the investigator judges that this 
visit is scheduled too late, he/she should contact [CONTACT_687625].
Dose 0.20 mg/kg: 
When sBE occurs, the investigator will determine if ≥[ADDRESS_932434] occurred within the preceding 12
weeks (including the current sBE), counting only new sBEs from the beginning of the 0.20 mg/kg 
treatment period. If yes, and if investigator deems it safe, the patient w ill be dose escalated from 
0.20 to 0.25 mg/kg at the next scheduled visit. If the investigator judges that this visit is scheduled too late, he/she should contact [CONTACT_941] p atient for an unscheduled visit sooner.
Dose 0.25 mg/kg: 
Patients are not dose escalated further regardless of the number of sBEs. When an sBE occurs, the 
investigator will determine if ≥ [ADDRESS_932435] occurred within the preceding 12 weeks (including the 
current sBE), counting only new sBEs from the beginning of the 0.25 mg/kg treatment period. If yes, then the patient must be discontinued due to lack of efficacy, see Section 6.4.
The possibility of dose escalation at unscheduled vi sits is necessary in order to avoid  bleeding
epi[INVESTIGATOR_687523]: e.g. if the dos e escalation eliciting bleedi ng epi[INVESTIGATOR_687524] a scheduled visit, the patient will avoid to wait 8 weeks for the next scheduled visit (in the extension part).
Figure 5–3 Dose escalation for one individual patient in the concizumab arm
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932436] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 44 of 143
Figure 5–4 Dose escalation for one individual patient in the comparator arm
5.3.4 Co-administrati on of eptacog alfa (rFVIIa)
eptacog alfa (rFVIIa) will be used for treating breakthrough bleeding epi[INVESTIGATOR_687525]; one 
week after initiation of dosing with concizumab, a single 90 μg/kg dose of eptacog alfa (rFVIIa)
will be administered in a non-bleeding state at the trial site under medical supervision to assess 
safety of treatment with eptacog alfa (rFVIIa) in patients exposed to concizumab treatment. Hereafter, patients will be closely clinically obse rved at the site for potential safety issues for at 
least 12h and evaluated again at site after 24h. Between 12h and 24h, the patient must either stay at 
the site or at a hotel or at home if he lives nearby [CONTACT_687626] 3 or 9.1 the day after.
Dosing of eptacog alfa (rFVIIa) in the first 4 patients randomised to concizumab arm will be staggered so that the period between eptacog alfa (rFVIIa) administrations from one patient to another is at least 48 hours. If no safety concerns are observed (for example signs and symptoms of 
thromboembolism, such as swelling, pain and redness of the leg, shortness of breath, and chest 
pain) by [CONTACT_687627] (rFVIIa) and when the next daily concizumab dose is to be given, the investigator allows the individual patient to administer concizumab prophylactically at home and if needed, treat breakthrough bleeding 
epi[INVESTIGATOR_687526] (rFVIIa). The patients will receive prophylactic doses of 
concizumab 0.15 mg/kg daily throughout the main part  (at least 24 weeks) and the extension part 
(up to 94 weeks), unless dose escalation criteria are fulfilled, see Section 5.3.3 .
In case safety concerns are raised by [CONTACT_687628] (rFVIIa) administration and 
these concerns meet the described criteria for putting enrolment of additional patients on hold, 
dosing in the individual patients will be halted and further recruitment in the trial will be halted, see Section 12.7. In case safety concerns that do not meet the criteria for putting enrolment of additional 
patients on hold are observed by [CONTACT_093], dosing in that individual patient will be halted 
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932437] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 45 of 143
until further evaluation. In such cases, all available data will be assessed by [CONTACT_402052] (DMC), see Section 12.8.2 .
5.3.5 Treatment of b leeding epi[INVESTIGATOR_687527] 1 and visit 2 can be treated with any by[CONTACT_71360] 
(e.g., eptacog alfa (rFVIIa), FEIBA®) up to a period of 24 hours (for eptacog alfa (rFVIIa)) or 48 
hours (for FEIBA®) prior to first concizumab administration at visit 2. N ovo Nordisk  will provide 
eptacog alfa (rFVIIa) throughout the trial. The patient can treat himself and then he must call the site. The bleeding epi[INVESTIGATOR_687528].
Breakthrough bleeding epi[INVESTIGATOR_687529] 2-[ADDRESS_932438] be treated with eptacog alf a (rFVIIa). Upon breakthrough bleeding epi[INVESTIGATOR_687530]. The investigator should instruct the patient about whether he should go to the site to  receive treatment or if he can administer a single dose of eptacog 
alfa (rFVIIa) which is not higher than 90 μg/kg without delay to treat the breakthrough bleeding
epi[INVESTIGATOR_1865]. If the patient is instructed to administer the eptacog alfa (rFVIIa) dose at home, following the administration, the patient should immediately go to the site for furthe r clinical evaluation. The 
bleeding epi[INVESTIGATOR_687531] (eDiary).
Breakthrough bleeding epi[INVESTIGATOR_687529] [ADDRESS_932439] be treated 
with eptacog alfa (rFVIIa). The patient can treat himself without delay but must inform the site that a bleeding epi[INVESTIGATOR_71274]. Doses of eptacog alfa (rFVIIa) those are lower than 90 μg/kg may 
be used to treat breakthrough bleeding epi[INVESTIGATOR_687532]. Administration of doses higher than 90 μg/kg to patients exposed to concizumab is not allowed. If a single dose of 
eptacog alfa (rFVIIa) is not sufficient to stop a bleeding epi[INVESTIGATOR_1865], the patient should inform the site 
and in agreement with the investigator may administer a second dose of eptacog alfa (rFVIIa) not higher than 90 μg/kg 2-3h after the first dose has been administered. The same procedure should be 
repeated in case the second dose of eptacog alfa (rFVIIa) is not sufficient to stop the bleeding 
epi[INVESTIGATOR_1865]. If more than three 90 μg/kg doses of eptacog alfa (rFVIIa) are needed to stop a bleeding 
epi[INVESTIGATOR_1865], the patient should go to the site without  delay. The definition and diagnostic criteria of 
DIC, acute myocardial infraction, stroke, deep vein thrombosis, pulmonary embolism and peripheral artery occlusion is provided in section 12.1.[ADDRESS_932440] be recorded in 
the eDiary.
Breakthrough bleeding epi[INVESTIGATOR_687529] 16 and visit 17 (follow-up part) may be treated with 
eptacog alfa (rFVIIa) or other products at the discretion of the investigator. The patient can treat himself with eptacog alfa (rFVIIa) at home with out delay. Only eptacog alfa (rFVIIa) will be 
provided by [CONTACT_3454]. The bleeding epi[INVESTIGATOR_535167].
See Table 5–1 and Table 8–3 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932441] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 46 of 143
5.3.6 Prohibited medication 
∀Treatment with anti-fibrinolytics (e.g. tranexamic acid, aminocaproic acid)*
∀Heparin, except for sealing of central venous access ports according to local practice
∀Vitamin-K antagonists
∀Direct oral anticoagulants (DOACs)
∀Home treatment (between visit 2 and visit 16) with activated prothrombin complex 
concentrates (FEIBA®)
* Local/topi[INVESTIGATOR_535169]. Use of single systemic doses in se vere bleeding epi[INVESTIGATOR_1841], after careful benefit risk 
evaluation, is allowed.
5.[ADDRESS_932442]
When discontinuing trial products (visit 16 or earlier), the patient should be switched to a suitable 
marketed product at the discretion of the investigator. Only eptacog alfa (rFVIIa) will be provided by [CONTACT_3454]. The patient will not be provided with concizumab or eptacog alfa (rFVIIa) after 
end of trial (EOT) (visit 17) by [CONTACT_3454].
5.[ADDRESS_932443] 24 weeks (the main pa rt of the trial) is considered necessary for 
providing r obust data that allow demonstration of clinical proof of concept and to support decision 
making regarding a phase 3 confirmatory trial. Dosing for up to 94 additional weeks will provide 
valuable long term efficacy and safety data.
Breakthrough bleeding epi[INVESTIGATOR_687533]. Therefore, it is expected that breakthrough bleeding epi[INVESTIGATOR_687583]. 
Consequently, eptacog alfa (rFVIIa) w ill be provided by [CONTACT_687629][INVESTIGATOR_1841]. In order to minimize the likelihood of any unforeseen adverse 
events associated with administration of eptacog alfa (rFVIIa) in these circumstances,administration of eptacog alfa (rFVIIa) in a controlled setting will be performed at visit 3 or 9.1.
Please refer to the Investigator’s Brochure for further information.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932444] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 47 of 143
6 Trial population
6.1 Number of patients
Number of patients planned to be screened: [ADDRESS_932445]: 26
Number of patients expected to complete the trial: 24
∀Preferably 21 haemophilia A patients
∀Preferably [ADDRESS_932446] be answered “yes”.
1. Informed consent obtained before any trial-r elated activities. Trial-related activities are any 
procedures that are carried out as part of the tr ial, including activities to determine the suitability 
for the trial
2. Male haemophilia A or B patients with inhibitors aged ≥ 18 years at the time of signing 
informed consent
3. Patients currently treated on-demand with a minimum of six bleeding epi[INVESTIGATOR_8728] 24 
weeks (or twelve bleeds during 52 weeks) prior to screening
4. Documented history of high-titer i nhibitors towards FVIII or FIX, defined as ≥[ADDRESS_932447] be answered “no”.
1. Known or suspected hypersensitivity to trial product(s) or related products
2. Previous participation in this trial. Participation is defined as signed informed consent3. Participation in any clinical trial of an a pproved or non-approved investigational medicinal 
product within the last 30 days or 5 half-lives (whichever is longer) from the last drug 
administration before screening
4. Any disorder which in the investigator’s opi[INVESTIGATOR_1649], might jeopardise patient’s safety or 
compliance with the protocol
5. Known inherited or acquired bleeding disorder other than haemophilia
6. Major surgery conducted within one month prior to the initiation of trial activities or major 
surgery planned to occur during the trial3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932448] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932449] a significant infection or known systemic inflammatory 
condition which requires systemic treatment acc ording to the investigator’s judgement
10. Hepatic dysfunction defined as elevated liver transaminases (ALT) >3 times the upper limit of 
normal laboratory reference ranges at screening
11. Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) ≤ 60 ml/min/1.73 
m2for serum creatinine measured at screening for patients without evidence of renal damage
12. Platelet count ≤ 100x109/L at screening
13. Fibrinogen level < the lower limit of normal
14. Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX15. Antithrombin levels below the normal reference range at screening
6.[ADDRESS_932450] if the following applies:1. Included in the trial in violation of the inclusion and/or exclusion criteria and/or randomised in 
violation of the randomisation criteria
2. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
3. Incapacity or unwillingness to follow the trial procedures4. Anaphylactic reaction
5. Thromboembolic event
6. Event of Disseminated Intravascular Coagulation7. Lack of efficacy due to neutralizing antibodies8. Lack of efficacy defined as ≥ [ADDRESS_932451] dose level (0.25 mg/kg) of concizumab.
See Section 8.1.[ADDRESS_932452] 
prematurely.
6.5 Withdrawal from trial
The patient may withdraw consent at will at any time.
See section 8.1.5 for procedures to be performed for patients withdrawing consent.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932453] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932454] been treated and therefore familiar 
with eptacog alfa (rFVIIa) on-demand treatment, this trial population is  considered the most suitable 
for assessing the safety of administering eptacog alfa (rFVIIa) to patients in whom plasma TFPI [INVESTIGATOR_687535]. Finally, the trial population reflects the patient population that will be selected in a potential subsequent phase 3 trial in which the efficacy and safety of concizumab are to be 
confirmed.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932455] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 50 of 143
7 Milestones
Planned duration of recruitment period (FPFV-LPFV): 28 weeks
FPFV: 16-Aug-2017
FPFT: 30-Aug-2017
LPFV: 28-Feb-2018
Planned LPLV: 31-Jan-[ADDRESS_932456] 52 weeks for an individual patient 
randomised to eptacog alfa (rFVIIa) on-demand treatment at visit 2.
EOT is defined as last patient last visit (LPLV).
Recruitment
The screening and randomisation rate will be followed closely via the interactive web response 
system (IWRS) in order to estimate when to stop screening. All investigators will be notified immediately when the recruitment period ends, after which no further patients may be screened and 
the IWRS will be closed for further screening. All patients screened during the recruitment period 
and found eligible for randomisation can be randomis ed in a 2:1 allocation to either the concizumab 
or the comparator arm within the timelines specified in the flow chart (see Section 2).
Trial registration:
Information of the trial will be disclo sed at clinicaltrials.gov, novonordisk-t rials.com and 
clinicaltrials.jp. According to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure,
how-we-disclose-trial-information, it will also be disclosed according to other applicable requirements such as those of the International Committee of Medical Journal Editors (ICMJE),
[ADDRESS_932457] (FDAAA),13European Commission 
Requirements,[ADDRESS_932458] at these web sites, Novo Nordisk may disclose the investigator’s contact [CONTACT_687646] e patient. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.
Primary Completion Date (PCD) is the last assessment of the primary endpoint, and is for this 
protocol LPFT (visit 2) + [ADDRESS_932459] completed visit 9. The PCD determines the deadline for results disclosure at ClinicalTrials.gov according to FDAAA.
133URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932460] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 51 of 143
8 Methods and assessments
Assessments to be performed at the scheduled and at the unscheduled visits in the trial are described 
in this section, Figure 8–1 , Figure 8–2 and in Section 2.
Figure 8–1 Visit schedule – concizumab arm.
Figure 8–2 Visit schedule – eptacog alfa (rFVIIa) arm later switching to concizumab.
8.[ADDRESS_932461] of the follo wing scheduled parts a nd visits depending upon
which arm the patient is randomised to:
Screening Part:
∀Visit 1 (screening visit)
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932462] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 52 of 143
Main Part:
∀Visit 2 (Randomisation and 1sttreatment visit with concizumab at site for patients 
randomised to the concizumab-arm)
∀Home treatment with concizumab daily
∀Visit 3 (treatment and PK-visit with concizu mab and eptacog alfa (rFVIIa) at site only for 
patients randomised to the concizumab-arm - phone visit for patients randomised to the 
eptacog alfa (rFVIIa) on-demand arm)
∀Visit 4 (Assessment visit, patients treat themselves at home)
∀Visit 5 (Assessment visit, patients treat themselves at home)
∀Visit 6 (Assessment visit, patients treat themselves at home)
∀Visit 7 (Assessment visit, patients treat themselves at home)
∀Visit 8 (Assessment visit, patients treat themselves at home)
∀Visit 9 (Assessment visit, after the visit patients treat themselves at home – 1sttreatment 
visit with concizumab at site for patients randomised to the eptacog alfa (rFVIIa) arm)
Extension Part:
∀Visit 9.1 (treatment and PK-visit with concizumab and eptacog alfa (rFVIIa) at site ONLY
for patients randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 9.2 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 10 (Assessment visit, patients treat themselves at home)
∀Visit 10.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
∀Visit 11 (Assessment visit, patients treat themselves at home)
∀Visit 11.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on demand-arm)
∀Visit 12 (Assessment visit, patients treat themselves at home)
∀Visit 13 (Assessment visit, patients treat themselves at home)
∀Visit 14 (Assessment visit, patients treat themselves at home)
∀Visit 15 – 15.n (Assessment visit, patients treat themselves at home)
∀Visit 16 (Assessment visit, no treatment at home before the visit a nd End of Treatment)
Follow-up Part:
∀Visit 17 (Assessment visit and End of Trial)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932463] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 53 of 143
Unscheduled Part:
∀Unscheduled visits can occur e.g. for dispen sing of trial product, dose escalation or when an 
assessment of bleeding epi[INVESTIGATOR_535056].
The duration of the visits (V1-V17) will depend on the assessments and the p atient’s individual 
training and/or discussion need on concizumab and eptacog alfa (rFVIIa) administration, NovoPen
®4, usage of eDiary, completion of the PRO etc.
8.1.[ADDRESS_932464] be obtained before a ny trial related activity at visit 1, see Section 18.2.
The trial includes a separate informed consent for long-term storage of human biosamples, see 
Section 24.2.
Storage of human biosamples and/or genotypi[INVESTIGATOR_687536]’ 
participation in the trial. Therefore, patients wi ll have the possibility to sign the informed consent 
for the trial and participate, while refusing per mission for biological specimens and/or genotypi[INVESTIGATOR_535057].
8.1.[ADDRESS_932465] address(es) and telephone number(s) of relevant trial clinic staff. Patients should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
Each patient will be assigned a unique 6-digit patient number which will remain the same 
throughout the trial.
8.1.3 Screening failures and re-screening
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reason for not continuing in the trial.
Serious and non-serious adverse events from screening failures must be transcribed by [CONTACT_687630]. Follow-up on serious adverse events (SAEs) must be carried out according to Section 12. A screening failure session must be made in the IWRS. The case book 
must be signed in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932466] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 54 of 143
Re-screening is NOT allowed if the patient has failed one of the inclusion or exclusion criteria; this 
includes re-sampling if the patient has failed one of the inclusion or exclusion criteria related to 
laboratory parameters.
8.1.[ADDRESS_932467] undertake procedures 
similar to those for visit 9 (the last treatment in the main part) or visit 16 (the last treatment visit in the extension part) as soon as possible. The fo llow up visit (visit 17) must be performed 8 weeks 
(window minus 7 days) after last dose of trial drug.
The primary reason for premature discontinuation of  trial product must be specified in the end of 
treatment form in the eCRF, and final drug accountability must be performed. A treatment discontinuation session must be made in the IWRS.
The patients who permanently prematurely discontinue trial product at Investigator’s discretion due 
to a safety concern after completion of the main part of the trial may have visit [ADDRESS_932468] every 8 weeks for safety assessments (see Section 8.4and 8.5.2 ), PK and PD markers. The patients who 
permanently prematurely discontinue trial product due to safety concerns may have the safety 
follow up period extended at Investigator’s discretion  until the safety concern have been resolved, 
but no later than Last Patient Last Visit as defined in Milestones (Section 7of the protocol).
Permanent premature discontinuation of treatment with trial product will lead to patient withdrawal 
from the trial.
8.1.[ADDRESS_932469] aim to undertake procedures similar to those 
for visit 9 (the last visit in the main part) or visit 16 (the last visit in the extension part) as soon as possible depending on where the patient is in the trial schedule.
The end-of-trial form must be completed, and final drug accountability must be performed even if 
the patient is not able to come to the trial site. A treatment discontinuation session must be made in 
the IWRS and the case book must be signed in the eCRF.
Although a patient is not obliged to give his reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the patient’s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in 
the end-of-trial form in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932470] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 55 of 143
8.1.6 Review/ evaluation of clinical outcome
Novo Nordisk has constituted an internal concizu mab safety committee and established an external 
DMC to perform ongoing safety surveillance of safety data relevant to concizumab, see Section 12.8.
Review of eDiary data and laboratory  reports etc. must be documented either on the documents or 
in the patient’s medical record.
If unclear entries or discrepancies in the eDiary or ePRO are identified and a clarification is needed, 
the patient must be asked for clarification and a conclusion made in the patient’s medical record. 
Care must be taken not to bias the patient.
8.1.7 Visit 1 (S creening part)
Informed consent must be obtained be fore any trial related activity, see Section 18.2
All assessments to be performed at screening are listed in Section 2.
After informed consent is given, patients will be as ked to complete the ePRO questionnaires before 
any other trial related activit ies are performed acc ording to Section 8.6.1 :
∀Hemo-TEM,
∀VERITAS-PRN®
Assessment results from physical examination and body measurements, as well as measurements of 
vital signs, urinalysis and ECG and details of any contemporary adverse events, must be entered into the eCRF.
A screening confirmation call must be performed in the IWRS, at the day of the visit.
The investigator must review all information obtained from the screening procedures. If a patient 
does not meet all inclusion criteria or meets one or m ore of the exclusion criteria for the trial the 
patient does not qualify to be enrolled.
For bleeding epi[INVESTIGATOR_535058] (Visit1) to randomisation visit 
(Visit 2), information a bout the bleeding epi[INVESTIGATOR_535059] 2.
Patients will be provided with ep tacog alfa (rFVIIa), trial injection kits and direction for use (DFU) 
to cover the potential eptacog alfa (rFVIIa) treatment after the screening part of the trial and investigator will ensure that the patients are capable of treating themselves with eptacog alfa 
(rFVIIa).
Dispensing of eptacog alfa (rFVIIa ) should be performed in IWRS.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932471] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932472] be instructed to call the site if any bleeding epi[INVESTIGATOR_1841], questions or issues arise after 
he has left the site.
8.1.8 Training of patients at visit 1, visit 2 and visit 9
During visit 1 and visit 2 and visit 9 (comparator arm) patients must be trained in self-
administration of concizumab in the home setting using NovoPen®4. The dose of concizumab to be 
administered must be communicated to the patient at visit 2 (if they are randomised to concizumab) or at visit 9 (if they are randomised to eptacog alf a (rFVIIa) and switching to concizumab at visit 9). 
Furthermore, patients must be instructed and trained in the importance of reporting all the home 
treatments with concizumab, details of the bleeding epi[INVESTIGATOR_687537] (rFVIIa) 
treatments associated with these b leeding epi[INVESTIGATOR_254769]. The patient should call the site if 
bleeding epi[INVESTIGATOR_687584] [ADDRESS_932473], performed independently by [CONTACT_4677], preferably in the morning. Home treatment starts after visit 2 (concizumab arm) or when the patient is comfortable self-administrating trial product subcutaneously (concizumab) and intravenously (eptacog alfa (rFVIIa)).
8.1.10 Staggered recruitment
Dosing of eptacog alfa (rFVIIa) in the first 4 patien ts randomised to the concizumab arm will be 
staggered until the 4
thpatient randomised to the concizumab arm has completed visit 3 without any 
safety concerns raised by [CONTACT_093]. Until this time point, enrolled patients will not be 
randomised until the previous patient randomised to concizumab has completed visit 3 without any 
safety concerns raised by [CONTACT_093]. Novo Nordisk will as sponsor control and communicate 
the staggered recruitment process.
8.1.11 Treatment  period – Main part
[IP_ADDRESS] Visit 2 (Randomisation)
Visit 2 should be scheduled  14 to 28 days after visit 1. The date of visit 2 will be considered as trial 
day 1.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932474] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 57 of 143
It is important to verify the in/exclusion criter ia again and review central laboratory tests from 
screening.
The patients must be in a non-bleeding state and should not have received any by[CONTACT_71360] 
(e.g., eptacog alfa (rFVIIa), FEIBA®) for treatment of bleeding epi[INVESTIGATOR_42988] a period of 24 hours 
(for eptacog alfa (rFVIIa)) or 48 hours (for FEIBA®) prior to the potential first concizumab 
administration (depending on the treatment arm) . After visit 2 only treatment with ep tacog alfa 
(rFVIIa) for bleeding epi[INVESTIGATOR_71249].
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments listed in 2, must be performed before poten tial admin istration of concizumab
(depending on the treatment arm). Vital signs must be assessed both before (within 1 hour) and after 
concizumab administration. Pre-dose blood sampli ng must take place no more than 1 hour before 
concizumab administration.
Assessment results from concomitant medication, vital signs, body measur ement (weight only) and 
details of adverse events must be entered into the eCRF.
A randomisation and dispensing call must be performed in the IWRS.
In order to determine the correct amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dos ing table in the Trial Materials Manual (TMM) on 
basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
For patients randomised to the concizumab arm, the first treatment with the loading dose of 
concizumab will be given.
The time point at which the completion of the first dose takes place corresponds to ‘Time on 
treatment’ = [ADDRESS_932475] 
dose of concizumab.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932476] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932477] concizumab and/or eptacog alfa (rFVIIa)
and trial injection kits and an eDiary device to be able to conduct and report home treatment and bleeding epi[INVESTIGATOR_687538].
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa) during the 
trial as instructed by [CONTACT_093]. D rug accountability must be performed for eptacog alfa 
(rFVIIa), if applicable according to section 9.4. Unused histidine syringes should be returned at 
every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site. If the patient on concizumab needs to treat a 
bleeding epi[INVESTIGATOR_687540] (rFVIIa) at home, then he must visit the site immediately after.
[IP_ADDRESS] Visit 3 (Phone call for eptacog alfa  (rFVIIa) on-demand arm and PK visit for 
concizumab arm)
eptacog alfa (rFVIIa) on-demand arm:
Visit 3 for eptacog alfa (rFVIIa) on-demand arm is a phone call scheduled 7 days after visit 2 (with 
a visit window of +1 day).
All relevant assessments listed in Section 2, must be discussed.
Assessment results from concomitant medication and details of adverse events must be entered into 
the eCRF.
concizumab arm:
Visit 3 is to be scheduled 7 days after visit 2 (with a visit window of +1 day) and the visit takes two 
days.
All assessments are listed in Section 2, and must be performed accordingly and recorded in the 
eCRF.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed accordi ng to Section 8.6.1 :
∀PGI-C
∀Hemo-TEM
Pre-dose blood sampling must take place no more than 1 hour before eptacog alfa (rFVIIa)
administration. Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa)administration.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932478] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932479] followed by [CONTACT_687654]. eptacog alfa 
(rFVIIa) should be administered to the trial patients at the site under the surveillance of medically trained trial site staff. The interval between the concizumab and eptacog alfa dose administration should not exceed more than 30 min.  
Samples for thrombin generation, haematology, coagulation parameters, concizumab ELISA and 
FVII ELISA are taken pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (±20 min) and 24h (±20 min).
The investigator must ensure that all assessments are performed as described in Section 2, The 
Investigator is requested to conclude after [ADDRESS_932480] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate th e daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visits the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until the next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa ). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 4, 5, 6, 7 and 8
Patients should treat themselves at home according to their individual dosing schedule regardless of 
when visits 4, 5, 6, 7 and 8 are scheduled.
Visits 4, 5, 6, 7 and 8 are to be scheduled on trial day 29 (4 weeks), day 57 (8 weeks), day 85 (12 
weeks), day 113 (16 weeks) and day 141 (20 weeks)  respectively with a visit window of ±7days.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932481] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 60 of 143
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀PGI-C
∀Hemo-TEM
All assessments are to be performed according to Section 2, and the assessment results from 
concomitant medication, vital signs, body measur ement (weight only) and details of adverse events 
must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687541] e-Diary. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients randomised to concizumab arm at visit 2, evaluate if an escalation of the concizumab doses is needed according to the escalation rules described in section 5.3.[ADDRESS_932482] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visits the patient will be provided w ith concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until the next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and ep tacog alfa (rFVIIa). Unused histid ine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
At visit 8 patients should be reminded that treatment with concizumab (concizumab arm) must take 
place after the blood sampling at visit 9.
[IP_ADDRESS] Visit 9
Visit 9 is to be scheduled on trial day 169 (24 weeks) with a visit window of ±7days.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932483] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 61 of 143
Patients randomised to eptacog alfa (rFVIIa) on-demand treatment at visit 2 will now be switched to 
concizumab treatment. At this visit the firs t treatment (loading dose) with concizumab will take 
place.
Treatment with concizumab must take place after the blood sampling for both the patients on the 
concizumab arm as well as patients on the eptacog alfa (rFVIIa on-demand) arm.
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 :
∀PGI-C
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments are to be performed according to Section 2, and the assessment results from 
physical examination, concomitant medication, vita l signs, body measurement (weight only) and 
details of adverse events must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687585] e-Diary. Based on the assessment of any 
spontaneous bleeding epi[INVESTIGATOR_687542], for patients randomised to concizumab arm at 
visit 2, evaluate if an escalation of the concizumab doses is needed according to the escalation rules described in Section 5.3.[ADDRESS_932484] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab and eptacog alfa 
(rFVIIa) during the trial as instructed by [CONTACT_941] i nvestigator. Drug accountability must be performed 
for concizumab and eptacog alfa (rFVIIa). Unused  histidine syringes shoul d be returned at every 
visit and new histidine syringes should be dispensed to the patient.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932485] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932486] be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
8.1.12 Treatment period – Extension part
[IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog alfa (rFVIIa)
on-demand arm)
Visit 9.1 is to be scheduled on trial day 176 (25 weeks) with a visit window of +[ADDRESS_932487] no more than 1 hour before eptacog alfa (rFVIIa)
administration. Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa)
administration.
The concizumab dose should be taken first followed by [CONTACT_687654]. eptacog alfa (rFVIIa)
should be administered at the site under the surveillance of medically trained trial site staff. The 
interval between the concizumab and eptacog alfa dose administration should not exceed more than 
[ADDRESS_932488] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
Samples for thrombin generation, haematology, coagulation parameters, concizumab ELISA and 
FVII ELISA are taken pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 
10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9 h (± 10 min) and 12h (±20 min) and 24h (±20 min).
The Investigator is requested to conclude after [ADDRESS_932489] the conclusion in the eCRF prior to administration of the next dose of concizumab.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932490] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932491] be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 9.2 (ONLY patients previously on the eptacog alfa (rFVIIa) on-demand 
arm)
Visit 9.2 is to be scheduled on trial day 197 (28 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight  only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and re porting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, 
evaluate if an escalation of the concizumab doses is needed according to the escalation rules described in section 5.3.[ADDRESS_932492] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’scurrent body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/ or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 10
Visits 10 is to be scheduled on trial day 225 (32 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932493] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 64 of 143
Patients will be asked to complete the ePRO questionnaires before any other trial related activities 
are performed according to section 8.6.1 .
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687586] 5.3.[ADDRESS_932494] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed  by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 10.1 (ONLY patients  previously on the eptacog alfa (rFVIIa) on-demand 
arm)
Visit 10.1 is to be scheduled on trial day 253 (36 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932495] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932496] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 11
Visit 11 is to be scheduled on trial day 281 (40 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous bleeding epi[INVESTIGATOR_687586] 5.3.[ADDRESS_932497] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932498] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932499] the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and ep tacog alfa (rFVIIa). Unused histid ine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 11.1 (ONLY patients previously on the rFVIIa on-demand arm) 
Visit 11.1 is to be scheduled on trial day 309 (44 weeks) with a visit window of ±7days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body meas urement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous bleeding epi[INVESTIGATOR_687542], for patients initiating concizumab treatment at visit 9, evaluate if an escalation of the concizumab doses is needed according to the escalation rules 
described in section 5.3.[ADDRESS_932500] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s 
current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptac og alfa (rFVIIa) and trial 
injection kits, if necessary, to be able to conduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. D rug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa ). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932501] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932502] be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
[IP_ADDRESS] Visit 12, 13, 14 and 15, 15.1, 15.2, 15.n 
Visits 12, to15.n are to be scheduled with an interval of 8 weeks with a visit window of ±7 days 
until the patient either discontinues treatment or completes visit 16.
If patient declines participation in the prolongation of the extension, visit 16 should be conducted 4 
weeks after visit 15 (see Section [IP_ADDRESS] )
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight only) and details of adverse events must be entered into the 
eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066]. Based on the assessment of any spontaneous 
bleeding epi[INVESTIGATOR_687543] 5.3.[ADDRESS_932503] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with  concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to  be able to conduct home treatmen t until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine s hould be dispensed to the patient.
The patient must be instructed to call the site if  any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
At visit 15.1 only patients in the prolongation will be asked to complete the ePRO questionnaires 
before any other trial related activities are performed according to section 8.6.1 ;
∀Hemo-TEM3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932504] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 68 of 143
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
At the last visit (visit 15 or 15.n) before visit 16 (End of treatment) patients should be reminded that 
treatment with concizumab must take place after the blood sampling at visit 16.
[IP_ADDRESS] Visit 16
Visit 16 is to be scheduled:
∀on trial day 533 (for patients declining participation in the prolongation of the trial) 
∀or later (for patients continuing in the exten sion or enrolled in a subsequent trial) 
with a visit window of ± 7days. Further visit [ADDRESS_932505] day 
of treatment with concizumab.
Patients notcontinuing in the prolongation will be asked to complete the PRO questionnaires before 
any other trial related activities are performed according to section 8.6.1 ;
∀Hemo-TEM
∀SF-36v2
∀SDS
∀TSQM
∀SIAQ-ISRQ
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs and details of adverse events must be entered into the eCRF. Treatment with concizumab 
must take place after the blood sampling at this visit.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066].
For patients not continuing in the prolongation of the trial a completion session must be made at 
Visit 16 in the IWRS. In the period from visit 16 to  visit 17 patients can be treated with eptacog alfa 
(rFVIIa) or other products at the discretion of the investigator to treat any bleeding epi[INVESTIGATOR_1841]. 
Eptacog alfa (rFVIIa) may be requested via IWRS.  Only eptacog alfa (rFVIIa) will be provided by [CONTACT_687664]. If necessary, the patien t will be provided with ep tacog alfa 
(rFVIIa) and trial injection kits to be able to conduct home treatment until next scheduled visit.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932506] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932507] (eptacog 
alfa) will be provided to the patient
For patients continuing in the prolongation of the trial but not enrolled in a subsequent trial a 
completion session must be made at Visit 16 in the IWRS. In the period from visit 16 to visit 17 the 
patient can be treated with eptacog alfa (rFVIIa) or other products at the discretion of the investigator to treat any bleeding epi[INVESTIGATOR_1841]. Only eptacog alfa (rFVIIa) will be provided by [CONTACT_687631]. If necessary, the patient will be provided with eptacog alfa (rFVIIa) and 
trial injection kits to be able to c onduct home treatment until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed  by [CONTACT_093]. NovoPen®[ADDRESS_932508] be performed for concizumab and eptacog alfa (rFVIIa). Unused 
histidine syringes should be returned at every visi t and new histidine syringes should be dispensed 
to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_1841]) arise 
after he has left the site.
The End-of-Trial information must be entered in the End-of-Trial form in the eCRF at visit 16 for 
all patients continuing in a subsequent trial with concizumab. 
8.1.13 Visit 17 (End of trial) - Follow-up part
For patients not enrolled into a subsequent trial with concizumab visit 17 is to be scheduled 8 weeks 
after visit 16 with a visit window of minus 7 days. 
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
physical examination, body measurements (weight only), vital signs and details of adverse events 
must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687544]. Patients should be asked if their female partner has become 
pregnant, see Section 12.5.1 .
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa), unused 
histidine syringes, eDiary device and Trial card. Drug accountability must be performed for eptacog 
alfa (rFVIIa).
End-of-Trial information must be entered in the End-of-Trial form in the eCRF at visit 17 for all 
patients not continuing in a subsequent trial with concizumab.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932509] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 70 of 143
If eptacog alfa (rFVIIa) was requested at visit [ADDRESS_932510] due to a safety concern (see Section 8.1.4 ). The 
purpose of the unscheduled visit must be documented in the eCRF.
During unscheduled visits assessments and blood sampling must be performed according to Section 
2. Assessment results must be recorded in the eCRF. Assessments and blood sampling can be 
omitted if the only reason for the unscheduled visit is dispensing of trial product or replacement of 
eDiary or NovoPen®4.
If trial product administration or dispensing is required, dispensing of trial product must be 
performed via IWRS.
The following forms can be found in the unscheduled visit in the eCRF:
∀Bleeding epi[INVESTIGATOR_1841]
∀Dosing with eptacog alfa (rFVIIa), concizumab including dose escalation, see Section 5.3.3 .
∀Surgery
∀Local, special and central laboratory (re-)sampling/results
∀Body measurements
8.2 Patient related information/assessments 
8.2.1 Demogr aphy
Demography will be recorded at screening and consists of:
∀Date of birth (according to local regulation)
∀Sex
∀Ethnicity ( according to lo cal regulation)
∀Race (according to local regulation)
8.2.2 Concomitan t illness and medical history other than haemophilia
A concomitant illness is any illness, other than haemophilia, that is present at the start of the trial 
(i.e. at the first visit) or found as a result of a screening procedure or other trial procedures performed before first exposure to trial product. Al l concomitant illnesses shoul d be reported in the 
concomitant illness forms in the eCRF except information on haemophilia with inhibitors which is to be reported in the haemophilia medical history section of the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932511] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932512] be possible to verify the patient’s medical  history in source documents such as patient’s 
medical record, see Section 6.2and 6.3.
If a patient is not from the investigators own practice; the investigator must make a reasonable 
effort to obtain a copy of the patient’s medical record from relevant party e.g. primary physician. The investigator must document any attempt to obtain external medical information by [CONTACT_18031](s) when information was requested and who has been contact[INVESTIGATOR_530].
8.2.3 Concomitant medication
A concomitant medication is any medication, other than the concizumab and eptacog alfa 
(rFVIIa), which is taken during the trial, including the screening and follow-up period .
Details of any concomitant medication must be recorded at the first visit. Changes in concomitant 
medication must be recorded at each visit as they occur.
The information collected for each concomitant medi cation includes trade name [CONTACT_18058], 
indication, start date and stop date or continuation.
If a change is due to an AE, then this must be reported according to Section 12. If the change 
influences the patient’s eligibility to continue in the trial, the monitor must be informed.
8.2.4 Details of Haemophilia, Haemoph ilia treatment and bleed history
All available information on haemophilia, prior to screening should be recorded in the eCRF.
∀Diagnosis of haemophilia (date)
oClassification of haemophilia type (haemophilia A/B)
oSeverity of haemophilia (severe, moderate or mild)
oAetiology of haemophilia (congenital or acquired)
∀Family history of
oHaemophilia (Y/N)
oInhibitors (Y/N)
oProthrombotic disorders (Y/N)
oThromboembolism (Y/N)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932513] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 72 of 143
∀Inhibitor tests taken (Y/N)
oDate (dd- mmm-yyyy) 
oResult (BU)
∀Cut-off for positive inhibitor result
∀Deficiency factor level
The following information on bleeding epi[INVESTIGATOR_535068]:
∀Type of treatment
oProphylaxis or on-demand
oStart date
oStop date
∀Number of bleeding epi[INVESTIGATOR_535141]
∀Coagulation factor product(s)
oBrand name, or if the brand is not known, the type of product, (plasma derived or 
recombinant)
∀Dosage used for prophylaxis
∀Dosing frequency during prophylaxis 
∀Approximate dose to treat a bleeding epi[INVESTIGATOR_1865]
∀Approximate number of doses to treat a bleeding epi[INVESTIGATOR_1865]
∀Target joint listing (definition: a target joint is a joint in which [ADDRESS_932514] occurred within a consecutive 6-month period)
oLocation
oPosition (left/right)
oNumber of bleeding epi[INVESTIGATOR_1841]
8.3 Efficacy assessments
8.3.1 Bleeding epi[INVESTIGATOR_687545] (rFVIIa) and symptoms related to the underlying 
disease must be captured in the eDiary by [CONTACT_687647]. The trial 
site should be informed of the details of all bleeding epi[INVESTIGATOR_1841], including those that are treated 
outside of the trial site.
All information captured during visits to the trial site will be collected in the eCRF.
When home treatment is initiated at visit 2 all bl eeding epi[INVESTIGATOR_687587] a (rFVIIa) in jection occ urring outside the trial site should be entered in the eDiary by 
[CONTACT_102], Section 13.3.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932515] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 73 of 143
The completed eDiary is considered source data.
For reporting of bleeding epi[INVESTIGATOR_687547]/SAEs, please refer to Section 12. In case of life-
threatening bleeding epi[INVESTIGATOR_1865], it should always be reported as an SAE, see Section 12.1.[ADDRESS_932516] be recorded for any bleeding epi[INVESTIGATOR_1865], including bleeding epi[INVESTIGATOR_687548] (rFVIIa):
∀Start date and time
∀Stop date and time (see Table 8–1 )
∀Anatomical location
oPosition (left/right)
∀Cause (see Table 8–2 )
ospontaneous
otraumatic
opost-surgical
∀Severity (see Table 8–3 )
omild/moderate, severe
oclassification and recording of severe bleeding epi[INVESTIGATOR_687549]
∀Treatment, if any 
oeptacog alfa (rFVIIa) administration or other product administration
odose, date, stop time
oother medicinal treatments related to the bleeding epi[INVESTIGATOR_1865] (pain relieving 
medication, non-medical therapy etc.)
orecord as concomitant medication (section 8.2.3 )
∀Symptoms during bleeding epi[INVESTIGATOR_1865](s)
oPain
oBlood in urine
oTingling sensation
oSwelling
oMouth/Gum bleed
oWarmth
oLoss of movement
oBruises
oNose bleed
Only report the bleeding epi[INVESTIGATOR_535074]/SAE if fatal, life threatening or evaluated as related to 
trial product, see Section 12.1.1 and12.1.2 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932517] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 74 of 143
Table 8–1 Definition of stop of bleeding epi[INVESTIGATOR_535075]: When the patient experiences/observes signs of cessation of the active bleeding 
epi[INVESTIGATOR_535076]; pain relief, no increase in swelling/limitation of motion and 
improvement in other objective signs of the bleeding epi[INVESTIGATOR_535077]: When pain and objective signs of the bleeding epi[INVESTIGATOR_687550] 8–2 Definitions of bleeding epi[INVESTIGATOR_1841] (cause of bleed)
Category Definition
Spontaneous Not linked to a specific, known action or event
Traumatic Caused by a specific, known action or event (e.g. injury or exercise)
Post-surgical Bleeding epi[INVESTIGATOR_535079]. Bleeding epi[INVESTIGATOR_687598] 8–3 Definition of bleeding epi[INVESTIGATOR_535081]/Moderate Examples: uncomplicated musculoskeletal 
bleeding epi[INVESTIGATOR_1841] (joint, muscular bleeding 
epi[INVESTIGATOR_434840]), 
mucosal- or subcutaneous bleeding epi[INVESTIGATOR_434838]/moderate bleeding epi[INVESTIGATOR_687552]/moderate bleeding epi[INVESTIGATOR_1841]: 
∀patient must call the site between 
visit 1-2 and visit 3-16 (see 2-3 
and 9-9.1 below)
∀patient must call the site between 
visit 2-3 or visit 9-9.1 (eptacog 
alfa arm) and if treated at home, go to the site immediately after
∀patient can treat themselves at 
home between visit 16 and visit 
173URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932518] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 75 of 143
Category Definition Treatment recommendation
Severe Examples: intracranial, retroperitoneal, 
iliopsoas and internal neck bleeding epi[INVESTIGATOR_1841]; 
muscle bleeding epi[INVESTIGATOR_535084]; bleeding epi[INVESTIGATOR_80799] a significant decrease in the haemoglobin level (>3g/dl)
Severe bleeding epi[INVESTIGATOR_535085]-threatening bleeding epi[INVESTIGATOR_687553] a bleeding epi[INVESTIGATOR_687554], i.e. the original dosing schedu le should be maintained unless investigator judges 
otherwise.
Dosing for bleeding epi[INVESTIGATOR_687555] (rFVIIa) should be documented in the eCRF (visit 1 
to visit 2) and eDiary (visit 2 to visit 17). After vi sit [ADDRESS_932519] be recorded either in 
the eDiary (if treated at home) or in the eCRF  (if treated at the trial site), see section 13.3.
Investigator must instruct the patient not to perform preventive treatment with eptacog alfa (rFVIIa)
after bleeding stop as defined in Table 8–[ADDRESS_932520] the patient to use eptacog alfa (rFVIIa) as rescue medication to treat 
bleeding epi[INVESTIGATOR_488840] [ADDRESS_932521] review the bleeding and treatment data collected by [CONTACT_687632] 13.3.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932522] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 76 of 143
For in-between visit administrations of trial drug, patients will self-administer concizumab (and 
eptacog alfa (rFVIIa) as rescue medication) and will record treatment in the eDiary, which will be reviewed during periodic calls to/contact [CONTACT_687648].
8.[ADDRESS_932523] physical examination and include the following.
∀General appearance
∀Head, ears, eyes, nose, throat, neck
∀Respi[INVESTIGATOR_2133]
∀Cardiovascular system
∀Gastrointestinal system including mouth
∀Genito-urinary system, breast(s)
∀Musculoskeletal system
∀Central and peripheral nervous system
∀Skin
∀Lymph node palpation
The investigator must evaluate the results of the examination and classify them as either:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clin ically significant (Yes/No)
oIf observed before or at screening: record as Medical History (Section 8.2.2 )
oIf observed after screening: report an AE/SAE (Section 12)
Measurements will be reported in the eCRF.
8.4.2 Body measurements
∀Height (cm), at screening
∀Body weight (kg), (with one decimal)
The body weight assessed at each visit will be us ed for calculation of the concizumab dose to be 
administered until next visit.
Measurements will be reported in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932524] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932525] administration unless otherwise 
specified.
∀Body temperature (°C)
∀Systolic and diastolic blood pressure, sitting (BP) (mmHg)
∀Pulse, sitting (beats/min)
∀Respi[INVESTIGATOR_535095]: At visits 2 and visit 3 (for patients randomis ed to concizumab) and at visit 9 and visit 9.1
(for patients initiating concizumab treatment at  visit 9), the measurements are also performed after 
concizumab administration.
The investigator must evaluate the vital signs and classify the outcome as either:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness, section 8.2.2
oIf observed after screening:  report an AE/SAE, section [ADDRESS_932526] evaluate the ECG [standard 12 lead] at screening and classify the outcome as
either:
∀Normal or abnormal.
∀If abnormal the investigator must:
oSpecify the abnormality
oRecord if the result is clinically significant? (Yes/No)
oIf observed before or at Screening: record as Medical History, section 8.2.2
oIf observed after screening: report an AE/SAE, section [ADDRESS_932527] been 
reviewed. Outcome will be reported in the eCRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932528] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 78 of 143
8.4.5 Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12.
[IP_ADDRESS] Medication error
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form:
∀Trial product involved 
∀Classification of medication error
∀Whether the patient experienced any adverse event(s) as a result of the medication error 
∀Suspected primary reason for the medication error 
For definition of medication errors, see Section 12.1.4 .
[IP_ADDRESS] Adverse events requiring additional data collection
For some AEs additional data collection is required and specific event forms must be completed in 
the eCRF in additi on to the AE form . 
In case any of these events fulfil the criteria for a serious adverse event, please report accordingly, 
see Section 12.
For the following AEs additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form:
Injection site reaction 
Investigation of injection site reactions will be performed locally at all visits after visit 2 until visit 
16 based on patient feedback and by [CONTACT_687634]:
Symptoms e.g.
∀Pain
∀Numbness
∀Itching
∀Burning
Signs e.g.
∀Redness (mm x mm)
∀Induration (mm x mm)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932529] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 79 of 143
∀Swelling
∀Dimpling
∀Macula
∀Haematoma
∀Bleeding
∀Other (visual reactions)
Any injection site reaction symptom (evaluated at visit 2-16) should be recorded in the AE form and 
the injection site reaction form, see Section 12.1.5 .
A separate AE should be recorded for each injection site reaction symptom. The affected area 
should also be evaluated for redness and induration in mm using a ruler. To ensure all local 
injection site assessments are performed at the injection site, the area around the site will be marked 
with a pen prior to injection.
In the event of a local reaction, additional visual assessments (as described above) will be 
performed until resolution as judged necessary by [CONTACT_093].
Assessment of injection si te reactions can be performed at any time, if deemed necessary by [CONTACT_1275].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932530] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932531] be 
obtained if available on the hypersensitivity reaction form:
∀Signs and symptoms associated with the event
∀Time of appearance after administration of trial drug
∀Relevant immunological tests performed, see Section [IP_ADDRESS]
∀Treatment given for the reaction
∀Previous history of similar reactions
∀Association with the trial product(s)
∀Relevant risk factors associated with the event
∀Storage condition of the trial product
∀Total number of doses, from first day on trial product, up to the time of this event
8.5 Laboratory assessments
An approximate total blood volume of 768 mL will be taken from each patient on the concizumab 
arm and 868 mL from each patient on the eptacog alfa (rFVIIa) arm.
A laboratory manual will be provided for detailed description of obtaining and processing blood 
samples.
All laboratory blood samp les collected for this trial except for haematology samples at all visits and 
coagulation parameters at visits 3 and 9.1 are to be shipped for analysis at central laboratories or further distribution to special laboratories. Haemat ology samples (all visits) and coagulation 
parameters (visit 3 and 9.1) are to be analy sed locally. Ports cannot be used for blood sampling.
The laboratory provides results  to the trial sites in the units preferred by [CONTACT_135545].
Laboratory reports listing results from centrally analysed samples will be made available for the 
investigator. Investigator must review and evaluate the results and report AEs for results which are 
clinically significant. Laboratory reports will where possible indicate normal ranges.
Categorisation of clinical significance for out of range results may not be required for the following 
laboratory parameters and the investigator is therefore not required to perform a categorisation even though these parameters are listed in the laboratory report: FVIII/FIX activity, FVIII/FIX inhibitor 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932532] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932533], Thrombin generation, Free TFPI (TFPI [INVESTIGATOR_535096]), concizumab concentration 
in plasma, anti-concizumab antibodies, Total TFPI [INVESTIGATOR_687556].
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. The investigator must review all laboratory results for concomitant illnesses and AEs and report these according to Section 8.2.[ADDRESS_932534] be sent to the central laboratory for analysis; 
if additional laboratory sampling is needed, e.g. to follow up on AEs, this must be done at a local 
laboratory except for biomarkers and anti-drug antibodies (anti-concizumab IgE antibodies and 
anti-concizumab antibodies).
Laboratory samples will be destroyed no later than  at finalisation of the clinical trial report (CTR).
Antibody samples and human biosamples, if applicable, will be stored as described in Section 24.2.
The investigator may not be able to review the re sults of antibody measurements in relation to AEs 
as these are often analysed after LPLV.
8.5.1 Laboratory a ssessments for efficacy
[IP_ADDRESS] Thrombin generation
The Thrombin Generation Assay (TGA) will be collected at all visits.
Further at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9 h (± 
10 min), 12h (± 20 min) and 24h (± 20 min).
The TGA is included as an exploratory PD assessment.The generation of thrombin is a fundamental part of the haemostatic system, and is a key 
measurable parameter of the formation of a clot under bleeding or thrombotic conditions. The 
thrombin burst is crucial for the formation of a stable fibrin clot.
The Calibrated Automated Thrombogram (CAT) method (used by [CONTACT_535235]) will be 
used to measure thrombin generation (TG). This method uses a slow acting fluorogenic substrate that allows continuous measurement of thrombin generation in double centrifuged citrated plasma.
In this assay set-up thrombin generation is initiated by [CONTACT_687635]. The result is obtained by [CONTACT_49719] a constant known thrombin activity in a parallel non tissue factor initiated sample. The assay has been validated fit-for-purpose.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932535] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 82 of 143
The thrombin generation endpoints are defined but not limited to:
∀The Endogenous Thrombin Potential (ETP) – the area under the curve 
∀Peak thrombin generation
∀Velocity Index 
[IP_ADDRESS] Free TFPI
[INVESTIGATOR_687557] (TFPI [INVESTIGATOR_535096]) will be collected at all visits, pre-dose at visit 2 and 3 
(concizumab arm), visit 9 and 9.1 (eptacog alfa (rFVIIa) arm) and visit 16.
The free TFPI [INVESTIGATOR_687558]  
 (named and referred to  TOTAL TFPI) and will be used for PD assessments.
8.5.2 Laboratory a ssessments for safety
[IP_ADDRESS] Urinalysis
∀pH
∀Protein
∀Glucose
∀Bilirubin
This is a semi qu alitative measurement which will be performed (locally) at the screening visit by 
[CONTACT_535272]. The results will be recorded in the 
eCRF.
The investigator must evaluate the results and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must:
oRecord if the result is clinically significant? (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
[IP_ADDRESS] Haematology
Haematology samples are to be sampled and analysed locally at all visits.
Further at visit 3 (concizumab arm) and 9.1 (ep tacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa), 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9 h (± 10 min), 12h (± 20 min) and 24h (± 20 min).
∀Haemoglobin
∀Erythrocytes (cell count)
∀Thrombocytes (platelet count)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932536] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 83 of 143
∀Leucocytes (cell c ount)
∀Differential leucocytes cell count
oLymphocytes
oMonocytes
oNeutrophils
oEosinophils
oBasophils
The investigator must evaluate the results and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must: 
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
Haematology results are to be entered into the eCRF.
[IP_ADDRESS] Biochemistry
Biochemistry samples are to be sampled and analysed centrally at all visits.
∀Creatinine
∀Albumin
∀Bilirubin; total, dir ect, indirect
∀Aspartate aminotransferase (AST)
∀Alanine aminotransferase (ALT)
∀Gamma glutamyltransferase (GGT) 
∀Alkaline phosphatase
∀C-reactive protein (CRP)
The investigator must evaluate the results of the examination and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clin ically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening:  report an A E/SAE (section 12)
[IP_ADDRESS] FVIII/FIX activity
FVIII/FIX activity is to be sampled and analysed centrally at visit 1, visit 9 and visit 16.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932537] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 84 of 143
∀FVIII activity level (IU/mL) or
∀FIX activity level (IU/mL)
[IP_ADDRESS] Coagulation parameters
Coagulation parameters will be performed centrally at all visits with the exception of visit 3 and 
visit 9.1 where the PT, APTT, and Fibrinogen will be performed locally.
Further at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) samples are taken pre- and 
post-dose eptacog alfa (rFVIIa) at 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 min), 9h 
(±10 min) and 12h (±20 min) and 24h (± 20 min) locally.
∀Fibrinogen – centrally and locally
∀Prothrombin time (incl. INR) (PT) centrally and locally
∀D-dimer – only centrally
∀Prothrombin fragment 1+2 – only centrally
∀Activated partial thromboplastin time (APTT) – centrally and locally
∀Antithrombin (AT) activity – only centrally
The investigator must evaluate the results of the examination and record the outcome as:
∀Normal or abnormal
∀If abnormal the investigator must:
oSpecify the abnormality 
oRecord if the result is clinically significant (Yes/No)
oIf observed before or at screening: record as concomitant illness (section 8.2.2 )
oIf observed after screening: report an AE/SAE (section 12)
Coagulation parameters analysed locally are to be entered into the eCRF.
[IP_ADDRESS] FVIII/FIX inhibitors
FVIII/FIX inhibitor level will be measured by [CONTACT_535237] 1, visit 9 and visit 16. 
∀FVIII inhibitors (BU) or
∀FIX inhibitors (BU)
[IP_ADDRESS] Anti-concizumab antibodies
Samples for the determination of anti-drug antibodies collected during the treatment period must be 
drawn at all visits and prior to administering con cizumab at visit 2 and 3 (concizumab arm) and 
visit 9 and 9.1 (eptacog alfa (rFVIIa) arm) and visit 16 for both arms.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932538] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932539] conc izumab (anti-drug antibodies [ADA]) will be 
performed at specialised laboratories whereas a ssessment of neutralising antibodies will be 
performed at Novo Nordisk.
Analysis for ADA will be done with a bridging ECL assay (binding ADA assay), using labelled 
concizumab for antibody capture and detection. If a sample is confirmed positive in the 
confirmatory assay, the sample is considered  positive for bindi ng antibodies. Confirmed positive 
samples will be characterised in a specificity assa y for binding to IgG backbone, CDR region or the 
S241P mutation. Furthermore, positive samples will be characterised for neutralising activity using 
a modified TFPI [INVESTIGATOR_687599] y (neutralising ADA assay). All anti body assays are validated 
according to international guidelines and recommendations.
The following analyses will be available:
∀Anti-concizumab antibodies assay
∀Specificity assay (Anti-concizumab antibodies cross reacting with IgG4 backbone, CDR 
region or S241P mutation)
∀Anti-concizumab neutralising antibodies assay
The binding ADA samples will be analysed in batches during the trial and results will be available 
to the data monitoring committee approximately every thi rd month after the first patient has been 
dosed. Neutralising antibodies will be analysed a nd reported at the EOT. A detailed description of 
the assay methods will be included in the antibody analysis report at the end of the trial.
Investigators will be notified in case their patient is shown to have developed binding and/or
neutralising antibodies against concizumab.
In the event that a trial patient develops binding ADAs towards concizumab during the course of the 
trial and has measurable binding ADAs at his End-of-Trial visit, the patient may attend an ADA follow-up visit. The ADA positive patients will be called for additional visits, e.g. every 4 to 6 weeks, for safety assessment and blood sampling for binding ADA and PD markers (free TFPI [INVESTIGATOR_535177]). The ADA positive patients will be followed no longer than one year after 
End-of-Trial.
Hypersensitivity
If suspi[INVESTIGATOR_1884] a hypersensitivity reaction occurs, patients should be instructed to contact [CONTACT_535238], see Section 12.1.5 .
In the event of a severe local and/or systemic hypersensitivity reaction possibly or probably related 
to trial product, blood sampling for assessment of anti -concizumab IgE antibodies as well as anti-
concizumab antibodies should be conducted in relation to the reaction and no later than 1-2 weeks 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932540] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 86 of 143
after the event. Additional testing may be performed if deemed relevant (e.g. anti-Host Cell Proteins 
(HCP) antibodies).
In the event of a severe systemic hypersensitivity reaction to trial product it is recommended also to 
test for tryptase (total and/or mature tryptase) within [ADDRESS_932541] the hypersensitivity reaction for assessing the 
persistence of the IgE response. Tryptase measurements are not required at the follow up visits.
Additionally, basophil activation testing may be performed if deemed relevant. This can be 
performed using existing samples and/or by [CONTACT_535239]’s basophil cells from an additional 
blood sample taken 3-4 weeks and no later than 2 mo nths after the event. Similarly, prick tests 
and/or intra-dermal tests may be performed if relevant using trial product or components of trial product. Complement may be measured in case of suspi[INVESTIGATOR_535150].
Results from the following additional tests will be reported to Novo Nordisk Safety Operations for 
inclusion in the ARGUS database and included in the narratives, if measured.
Test to be performed in case of severe hypersensitivity
∀Anti-concizumab IgE antibodies
∀Anti-concizumab antibodies (additional to scheduled time points)
Additional testing may be performed if deemed relevant e.g.
∀Anti-Host Cell Proteins (HCP) antibodies
∀Anti-HCP IgE antibodies
∀Basophil activation results
∀Prick test/intra-dermal test
∀Complement test results
Furthermore, it is recommended locally to test for
∀Tryptase (total and/or mature tryptase)
[IP_ADDRESS] Concizumab ELISA
Concizumab ELISA will be collected at all visits where patients are in tr eatment with concizumab.
Samples will be collected pre-dose at visit 2 for concizumab arm and visit 9 for eptacog alfa 
(rFVIIa) arm) and visit 16 for both arms.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932542] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 87 of 143
At visit 3 for concizumab arm and visit 9.1 for eptacog alfa arm samples for concizumab ELISA are 
taken pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (±20 min) and 24h (±20 min).
Concizumab will be quantified using a validated ELISA assay. 
Recombinant human TFPI [INVESTIGATOR_687559]. A colorimetric detection signal is 
obtained by [CONTACT_687636]-human IgG4 specific antibodies with the chromogenic substrate TMB (3,3´, 5,5´- tetramethylbenzidine). The amount of 
anti-TFPI [INVESTIGATOR_535103], quality control and test samples correlates with the obtained 
signal strength.
Validation of the assay follows current guidelines for bioanalytical method validation. Bioanalytical 
data will be re ported in a bioanalytical report.
[IP_ADDRESS] FVII ELISA
FVII ELISA will be collected at visit 3 (concizumab arm) and 9.1 (eptacog alfa (rFVIIa) arm) pre-
dose eptacog alfa (rFVIIa) and post-dose at 10 min (±2 min), 1h (±10 min), 3h (±10 min), 6h (±10 
min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points, except pre-dose, occur 
after eptacog alfa (rFVIIa) administration.
FVII in plasma will be quantified using a validated enzyme-linked immunosorbent assay (ELISA).
The FVII ELISA will detect the total sum of FVII in a sample, including endogenous FVII, eptacog 
alfa (rFVIIa) and FVII in complex with other mo lecules e.g. antithrombi n. The ELISA has been 
validated for measuring FVII in human citrated plasma samples. Validation follows current guidelines for bioanalytical method validation. Bioanalytical data will be reported in a bioanalytical report.
[IP_ADDRESS] Total TFPI
[INVESTIGATOR_687560]. Samples w ill be collected pre-dose at visit 2 and 3 
(concizumab arm) and visit 9 and 9.1 (eptac og alfa (rFVIIa) arm) and visit 16 for both arms.
The total TFPI [INVESTIGATOR_67147] (free and concizumab bound) will be included as an exploratory biomarker 
assessment.
The assay is an ELISA, where TFPI [INVESTIGATOR_687561] a polyclonal anti-TFPI [CONTACT_30936], distanced from 
the binding site of concizumab; meaning that both free TFPI [INVESTIGATOR_535151]. Detection will be obtained with a monoclo nal antibody against TFPI, which does not bind 
to the concizumab epi[INVESTIGATOR_9230].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932543] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 88 of 143
Data will be reported in ng/mL TFPI.
8.5.3 Human Biosamples
If patient permission is obtained plasma, serum and/or DNA for genotypi[INVESTIGATOR_535109], see Section 2. The blood samples can be stored up to 15 years, for future 
potential exploratory purposes please refer to section 24.2.
Antibody samples storage and retention, see Section 24.2.1 . The investigator is not able to review 
the results of antibody measurements in relation to AEs as these are analysed after LPLV. Plasma 
and serum is taken at visit 1 and 17. DNA for genotypi[INVESTIGATOR_687563] 1.
8.6 Other assessments
8.6.1 Patient reported outcomes
A newly developed disease- specific electronic PRO (ePRO) the He mophilia Treatment Experience 
Measure (Hemo-TEM) - is being validated in this trial. In order to assess the psychometric 
properties of Hemo-TEM, other questionnaires  will be provided; s ee further appendix 1.
The following ePRO questionnaires will be used in the trial:
∀Hemophilia Treatment Experience Measure (Hemo-TEM)
∀Validated Hemophilia Regimen Treatment Adherence Scale (VERITAS-PRN®) 16
∀36-Item Short Form Health S urvey (SF-36v2) (4 week recall)17
∀Patient’s Global Impression of Change (PGI-C)
∀Sheehan Disability Scale (SDS)18
∀Treatment Satisfaction Questionnaire for Medication (TSQM, version II)19 20 21
∀Injection Site Reaction Questionnaire (ISRQ) domain of SIAQ (SIAQ-ISRQ)22
The ePROs should be assessed at the scheduled visits following the order listed below:
∀visit 1 (Hemo-TEM, VERITAS-PRN®)
∀visit 2 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 3 (PGI-C, Hemo-TEM)
∀visit 4 (PGI-C, Hemo-TEM)
∀visit 5 (PGI-C, Hemo-TEM)
∀visit 6 (PGI-C, Hemo-TEM)
∀visit 7 (PGI-C, Hemo-TEM)
∀visit 8 (PGI-C, Hemo-TEM) 
∀visit 9 (PGI-C, Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 10 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
∀visit 15.1 or 16 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932544] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 89 of 143
At visit 1: before any visit-related activities  all patients should complete Hemo-TEM and 
VERITAS-PRN®.
At visit 2: before any visit-related activities all patients should complete Hemo-TEM, SF-36v2, 
SDS, TSQM and SIAQ-ISRQ.
At visit 3-8: before any visit-related activities the patient should complete the PGI-C before the 
Hemo-Tem. These are the rules that apply:
∀If the patient responds “1” to question 1 in the PGI-C, the patient should also complete the 
Hemo-TEM. In this case the patient should not fill in the PGI-C any more in the trial and the 
Hemo-TEM only again at visits 9, 10 and 15.1 or 16. 
∀If the patient responds “0” or “2” to question 1 in the PGI-C, the patient should not complete 
any other questionnaires at this visit, but should repeat the procedure at next visit. 
Exception: Patients randomised to eptacog alfa (rFVIIa) on-demand should not complete the 
ePRO at visit 3 as this is a phone visit.
At visit 9 if the patient has responded “0” or “2” in the PGI-C at all previous visits, the patient 
should complete PGI-C. All patients shoul d complete Hemo-TEM, SF-36v2, SDS, TSQM and 
SIAQ-ISRQ.
At visit [ADDRESS_932545].
[IP_ADDRESS] Concizumab and NovoPen®4
Direction for use (DFUs) will be available as a hand out for patients at visit 2. Training in 
NovoPen®4 can start at screening (visit 1) and s.c administration of concizumab using the 
NovoPen®[ADDRESS_932546] dose at the trial site (visit 2). Patients must be instructed that 
injections are to be performed subcutaneously, not intravenously. Concizumab and NovoPen®[ADDRESS_932547] be documented in the medical records.
Detailed instructions can be found in the DFUs.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932548] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 90 of 143
[IP_ADDRESS] eptacog alfa (rFVIIa)
A direction for use ( DFU) will be available as hand out for patients at visit 1. Training must be 
performed at site until patients feel comfortable perf orming the treatment. Th e training must be 
documented in the medical records.
The following should be emphasised for eptacog alfa (rFVIIa):
∀eptacog alfa (rFVIIa) should be slowly injected intravenously over 2 to 5 minutes
Detailed instructions can be found in the DFU
[IP_ADDRESS] eDiary
Training on the use of the eDiary can start at visit 1. The eDiary will be provided to the patients at 
visit 2.
Training must be repeated at the site until patients feel comfortable using the device. The training 
must be documented in the medical records.
During the home treatment period the patient must ensure that all home treatments of concizumab, 
details of bleeding epi[INVESTIGATOR_687537] (r FVIIa) treatments associated  with these bleeding 
epi[INVESTIGATOR_535111].
It will be the responsibility of the investig ator or delegated staff to  assess the eDiary data 
throughout the conduct of the trial and to ensure data entry compliance (timely entry, no duplicate 
data, no missing data etc.) and retraining if necessary.
For patients completing the trial or in case of withdrawal, the eD iary will be collected at the EOT.
8.6.3 Surgery
Minor surgery can be performed within this trial at the investigator’s discretion according to local 
guidelines. Definition of minor surgery, see Section 5.1.1. Major surgery is not allowed, see 
exclusion criteria no 6.
For minor surgery the following should be recorded in the eCRF:
∀Date, stop time and dose of preventive tr eatment with eptac og alfa (rFVIIa) be fore surgery, 
if this was deemed necessary by [CONTACT_093]
∀Indication for surgery
∀Location of surgery
∀Date of surgery
∀Start and stop time of surgery3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932549] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 91 of 143
8.7 Patient compliance
Throughout the trial, the investigator will remind th e patients to follow the trial procedures and 
requirements to ensure patient compliance. If a patient is found to be non-compliant, the investigator will remind the patient of the importance of following the instructions given including 
taking the trial products as prescribed.
8.8 Treatment compliance 
Treatment compliance will be monitored and documented through timely review of eDiary data and 
drug accountability. 
Concizumab will be administered at the trial site at visit 2 for the concizumab arm supervised by 
[CONTACT_687665] 2 if the patient 
feels comfortable with the s.c. administration. Administration of eptacog alfa (rFVIIa) for bleeding epi[INVESTIGATOR_535179] a medically trained trial staff or at home by [CONTACT_4677], see Section 8.3.1 . 
Drug accountability will be performed and will be us ed to assess patient compliance together with 
the patients’ adherence to trial procedures.
Compliance check includes a cross check between records in EDC/eDiary (number of 
administrations and bleeding epi[INVESTIGATOR_1841]) and the used/returned cartridges/vials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932550] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932551] not be used if it contains visible particles or discoloration.
The reconstituted eptacog alfa (rFVIIa ) solution appears clear and col ourless. Do not use the 
reconstituted solution if it contains visible particles or if it is discoloured.
Trial products must not be dispensed to  any person not included in the trial.
9.1 Trial products
The following trial products will be provided by [CONTACT_3454], Denmark:
Table 9–[ADDRESS_932552] Strength Dosage form Route of 
administrationContainer/
delivery device
concizumab B 
(IMP)100 mg/mL Solution for injection s.c. injection 3 mL cartridge
eptacog alfa
(IMPaand NIMPb)5 mg/vial Powder for solution
for injectioni.v. injection Vial
histidine 5 mL N/A Solvent for solution 
for injectioni.v. injection prefilled syringe
aInvestigational Medicinal Product (IMP) given as IMP for a single dose at visit [ADDRESS_932553] (NIMP) given as NIMP for bleeding epi[INVESTIGATOR_535113]®[ADDRESS_932554] w ill be distributed to the tr ial sites according to enrolment 
and randomisation.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932555] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932556] 
dispensing visit (see Section 2).
9.3 Storage 
Table 9–[ADDRESS_932557] Storage conditions
(not-in-use)In-use conditions In-use timea
concizumab B 100 mg/mL Store in refrigerator (2oC-8oC)
Do not freeze
Protect from lightStore at room temperature 
(below 30°C)
Do not refrigerateProtect from lightUse within 4 weeks 
(28 days)
eptacog alfa
5mgStore between 2oC-25oC
Do not freezeProtect from lightFor single use
Do not freezeProtect from light
To be used immediately 
after reconstitutionIf not used 
immediately, store in refrigerator (2
oC-8oC)
for up to [ADDRESS_932558] from lightFor single use
N/A
aIn-use time for concizumab starts when first dose is administered from an individual cartridge and for eptacog alfa
(rFVIIa) when the product is reconstituted
The investigator must ensure that trial product is kept under proper storage conditions and record 
and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial 
product has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the TMM.
Trial product that has been stored improperly must not be dispensed to any patient before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take appropriate action to ensure correct storage.
Investigator must instruct the patient to use and store trial product according to the label.9.4 Drug accountability and destruction
Drug accountability of all trial products (concizumab  and eptacog alfa (rFVIIa) received at site is 
the responsibility of the investig ator. The patient will be as ked to return all used, partly used and 
unused trial product during the trial as instructed by  [CONTACT_093], except for used histidine
syringes which should be discarded at home and not accounted for. Unused histidine syringes 
should be returned at every visit and new histidine syringes should be dispensed to the patient.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932559] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 94 of 143
All cartridges (concizumab) and vials (eptacog alfa (rFVIIa)) must be accounted for as used, partly 
used or unused.
The investigator will perform drug accountability using the IWRS Drug Accountability module.Returned trial product (used/partly used and/or unused), expi[INVESTIGATOR_687602] d separately from non-allocated trial product.
Non-allocated trial product including expi[INVESTIGATOR_215519].
Destruction of concizumab and eptacog alfa (rFVIIa) can be performed on an on-going basis and 
will be done according to local procedures after accountability is finalised and reconciled by [CONTACT_36102]. Destruction of products must  be documented in the IWRS.
For Japan only : Responsib ility for storag e and drug accountability of the trial drug product at the 
trial site rests with the head of the trial site. The head of the trial site could assign some or all of the 
responsibilities for accountability of the trial drug product at the trial sites to a trial product storage 
manager (a pharmacist in principle). The trial product storage manager should control and take accountability of the trial drug product in accordance with procedures specified by [CONTACT_3454]. 
The head of the trial site or th e trial product storage manager must  ensure the availability of proper 
storage conditions, and record and evaluate the temperature.
9.5 Auxiliary supplies
Novo Nordisk will provide the auxiliaries for this trial:
∀For concizumab administration: NovoPen
®4, needles and DFUs
∀For eptacog alfa (rFVIIa) reconstitution and administration: Trial Injection Kit and DFU
Only needles and trial injection kit provided by [CONTACT_535244].
For further guidance please see the TMM.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932560] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 95 of 143
10 Interactive voice/web response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone.  
Access to the IWRS must be restricted to and controlled by [CONTACT_36301].
IWRS is used for: 
∀Screening
∀Screening failure
∀Randomisation
∀Medication arrival
∀Dispensing
∀Dispensing verification
∀Treatment discontinuation 
∀Completion
∀Drug accountability
∀Data change
IWRS user manuals will be provided to each trial site.
11 Randomisation procedure and breaking of blinded codes
11.1 Randomisation 
Randomisation will be handed by [CONTACT_8784].
All patients included in the screening period and eligible for the trial will enter the trial and be 
randomised at visit 2 in a 2:1 allocation to either concizumab prophylaxis arm or eptacog alfa 
(rFVIIa) on-demand arm.
11.2 Breaking of blinded codes
Not applicable for this trial.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932561] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 96 of 143
12 Adverse events, and technical complaints
12.1 Definitions
12.1.1 Adverse event 
An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal 
product, and which does not necessarily have  a causal relati onship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product.
An AE includes:
∀A clinically significant worsening of a concomitant illness
∀A clinical laboratory adverse event (CLAE): a clinical laboratory abnormality which is 
clinically significant, i.e. an abnormality that s uggests a disease and/or organ toxicity and is 
of a severity that requires active management. Active management includes active treatment or further investigations, for example change of medicine dose or more frequent follow-up due to the abnormality.
The following should not be reported as AEs:
∀Pre-existing conditions, in cluding those found as a result of screening or other trial 
procedures performed before exposure to trial product (pre-existing c onditions s hould be 
reported as medical history or concomitant illness)
∀Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the patient has signed the informed consent
∀Bleeding epi[INVESTIGATOR_56238] (e.g. pain, swelling, synovitis, arthralgia) in 
connection with bleeding epi[INVESTIGATOR_49622]/SAEs unless the event is 
fatal, life-threatening or evaluated by [CONTACT_941] i nvestigator as related to trial product or trial 
procedure. All bleeding epi[INVESTIGATOR_535189]/eDiary.
The following three definitions are used when assessing an AE:
∀Severity 
∀Mild – no or transient symptoms, no interference with the patient’s daily activities
∀Moderate – marked symptoms, moderate interference with the patient’s daily activities
∀Severe – considerable interference with the patient’s daily activities; unacceptable
∀Causality 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932562] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932563](s): 
∀Probable - Good reason and sufficient documentation to assume a causal relationship
∀Possible - A causal relationship is conceivable and cannot be dismissed
∀Unlikely - The event is most likely related to aetiology other than the trial product
∀Final outcome 
∀Recovered/resolved - The patient has ful ly recovered or by [CONTACT_135548]-related activity 
after the patient signed the informed consent
∀Recovering/resolving - The condition is improving and the patient is expected to 
recover from the event. This term is only applicable if the patient has completed the trial 
or has died from another AE
∀Recovered/resolved with sequelae - The patient has recovered from the c ondition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE
∀Not recovered/not resolved - The condition of the patient has not improved and the 
symptoms are unchanged or the outcome is not known
∀Fatal - This term is only applicable if the pa tient died from a condition related to the 
reported AE. Outcomes of other reported AEs in a patient before he died should be 
assessed as “recovered/resolved”, “recovering/resolving”, “recovered/resolved with 
sequelae” or “not recovered/not resolved”. An AE with fatal outcome must be reported 
as an SAE
∀Unknown - This term is only applicable if the patient is lost to follow-up
12.1.2 Serious adverse event
A serious adverse event (SAE) is an experience that at any dose results in any of the following:
∀Death
∀A life-threateningaexperience
∀In-patient hospi[INVESTIGATOR_36220]
∀A persistent or significant disability or incapacityc
∀A congenital anomaly or birth defect
∀Important medical events that may not result in death, be life threateningaor require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement 
- they may jeopardise the patient and may require medical or surgical intervention to prevent 
one of the outcomes listed in the definition of SAEd
a.The term “life threatening” in the definition of SAE refers to an event in which the patient was at 
risk of death at the time of the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932564] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 98 of 143
b.The term “hospi[INVESTIGATOR_11956]” is used when a patient:
∀Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay or
∀Stays at the hospi[INVESTIGATOR_36223] [ADDRESS_932565] should be 
regarded as a hospi[INVESTIGATOR_11956]. Hospi[INVESTIGATOR_17957], trial related and social purposes do not constitute AEs and should therefore not be reported as AEs or SAEs. Hospi[INVESTIGATOR_49627], planned before trial inclusion, are not considered AEs or SAEs.
c.A substantial disruption of a patient’s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the patient has significant, persistent or permanent change, 
impairment, damage or disruption in his body function or structure, physical activity and/or quality of life).
d.For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasia or convulsions that do not resu lt in hospi[INVESTIGATOR_36224].
The following adverse events must always be reported as an SAE using the important medical event 
criterion if no other seriousness criteria are applicable:
∀Suspi[INVESTIGATOR_36225]
∀Risk of liver injury defined as ALT or aspartate aminotransferase (AST) >3 x UNL and total 
bilirubin >2 x UNL, where no alternative aetiology exists (Hy's law).
12.1.3 Non-serious adverse event
A non-serious AE is any AE which doe s not fulfil the definition of an SAE.
12.1.4 Medicati on errors
A medication error concerning trial products is defined as:
∀Administration of wrong drug
Note: Use of wrong DUN is not considered a medication error unless it results in administration 
of wrong drug.
∀Wrong route of administration
∀Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product
∀Accidental administration of a lower or higher dose than intended. However, the 
administered dose must deviate from the intended dose to an extent where clinical 
consequences for the trial patient were likely to happen as judged by [CONTACT_093], although they did not necessarily occur3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932566] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932567] be reported on an AE form and a specific event form, see Section [IP_ADDRESS]
12.1.[ADDRESS_932568].
In this trial the following AEs require the co mpletion of specific event forms in the eCRF:
∀Injection site reaction, see Section [IP_ADDRESS]
∀Hypersensitivity type reactions, incl. anaphylactic reactions, see Section [IP_ADDRESS]
Injection site reactions: 
Any injection site reaction symptom must be recorded on the AE form and the injection site reaction form.
Hypersensitivity type reactions:
In cases where clinical signs of a severe and immediate hypersensitivity reaction resembling a type
I hypersensitivity reaction are present, blood should be sampled for central laboratory assessment of 
anti-drug IgE antibodies and anti-drug binding antibodies. In the event of an immediate systemic hypersensitivity reaction to the trial product, it is recommended to also test for tryptase (total and/or mature tryptase) within 3 hours of the reaction. Moreover, a baseline tryptase measurement is 
necessary ~1 week after the immediate severe hypers ensitivity reaction due to individual to 
individual variation in tryptase baseline concentration. Tryptase concentrations (if measured) must be interpreted and considered in the context of a complete workup of each patient.
Special attention should be given to clinical signs and symptoms of hypersensitivity reactions of 
type II and III. Common clinical signs and symptoms characteristic for these type of reactions may 
include, but are not limited to: fever/malaise, cutaneous eruptions, arthralgia, lymphadenopathy, itching, headaches and myalgia. Related laboratory findings may include, but are not limited to: mild proteinuria or haematuria, leukopenia or leucocytosis, decreased complement levels or 
increased complement split products and transient elevations of serum creatinine levels. In cases 
where there is a suspi[INVESTIGATOR_687591], additional 
sampling for the purpose of measuring ADA will be performed. 
Definition of anaphylaxis 
(25)
Anaphylaxis is highly likely when any one of the following 3 criteria is fulfilled:
∀Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal
tissue or both (e.g. generalised hives, pruritus or flushing, swollen lips-tongue-uvula) and at
least one of the following:
a) Respi[INVESTIGATOR_7798] (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced peak
expi[INVESTIGATOR_10229] [PEF], hypoxemia)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932569] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 100 of 143
b) Reduced blood pressure (BP) or associated symptoms of end-organ dysfunction (e.g.
hypotonia [collapse], syncope, incontinence)
∀Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for that
patient (minutes to several hours):
a) Involvement of the skin-mucosal tissue (e.g. generalised hives, itch-flush, swo llen 
lips-tongue-uvula)
b) Respi[INVESTIGATOR_7798] (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced PEF,
hypoxemia)
c) Reduced BP or associated symptoms (e.g. hypotonia [collapse], syncope, 
incontinence)
d) Persistent gastrointestinal symptoms (e.g. crampy abdominal pain, vomiting)
∀Reduced BP after exposure to known allergen for that patient (minutes to several hours):
Systolic BP of less than 90 mm Hg or greater than 30% decrease from that person’s baseline
BP.
If a patient fulfils any of the three criteria of anaphylaxis outlined above, the patient should receive 
epi[INVESTIGATOR_238]/adrenalin immediately. Dose regimen should be according to hospi[INVESTIGATOR_535116], and the patient should be transferred to an emergency department or intensive care unit, 
if clinically warranted.
Events not fulfilling the criteria for an anaphylactic reaction and other allergic reactions must be 
treated at the discretion of the treating physician. If according to the investigators judgement, 
hypersensitivity type reactions that require systemic treatment are suspected, dosing with 
concizumab should be stopped immediately and treatment at the discretion of the treating physician initiated.
12.1.[ADDRESS_932570] (AESI) is an event, which in the evaluation of safety, has a 
special focus. In this trial, the following AEs fulfil the AESI criteria:
∀Thromboembolic events including but not limited to,
odisseminated intravascular coagulation (DIC) (A),
oclinical signs or laboratory indications of arterial and venous thrombosis including 
myocardial infarction (B),
opulmonary embolism (C),
ostroke (D), 
odeep vein thrombosis (E),
oother clinically significant thromboembolic events (F) and peripheral artery 
occlusion (see below G), see definitions below
The AESIs must be reported on an AE form and a safety information form.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932571] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 101 of 143
A) Definition of disseminated intravascular coagulation (DIC), as defined below:
The definition of DIC in this trial should be made according to the International Society on
Thrombosis and Haemostasis (ISTH) criteria. Thus, a DIC diagnosis may be based on clinical signs 
and symptoms of a bleeding tendency or thrombo tic tendency, organ dysfunction and the laboratory 
parameters criteria as listed below:
∀Platelet coun t (>100 × 109/L = 0, <100 × 109/L = 1, <50 × 109/L = 2)
∀Elevated D-dimer (no increase = 0, moderate increase = 2, strong increase = 3)
∀Prolonged PT (<3 s = 0, >3 but <6 s = 1, >6 s = 2)
∀Fibrinogen level (>1 g/L = 0, <1 g/L = 1)
∀Calculate score: ≥5 compatible with overt DIC
B) Myocardial infarction is defined according to the “Third Universal Definition of
Myocardical Infarction” (26)
Criteria for acute myocardial infarction - The term acute myocardial infarction (MI) should be used 
when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Under these conditions any one of the following criteria meets the diagnosis for MI:
∀Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin
(cTn)] with at least one value above the 99th percentile upper reference limit (URL) and
with at least one of the following:
∀Symptoms of ischemia
∀New or presumed new significant ST-segment–T wave (ST–T) changes or new left
bundle branch block (LBBB)
∀Development of pathological Q waves in the ECG
∀Imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality
∀Identification of an intracoronary th rombus by [CONTACT_687638] - Any one of the following criteria meets the diagnosis for
prior MI:
∀Pathological Q waves with or without symptoms in the absence of non-ischemic causes.
Imaging evidence of a region of loss of viable myocardium that is thinned and fails to
contract, in the absence of a non-ischemic cause.
∀Pathological findings of a prior MI.
Recurrent myocardial infarction -Incident MI is defined as the individual’s first MI. When features 
of MI occur in the first 28 days after an incident event, this is not counted as a new event for 
epi[INVESTIGATOR_535117]. If characteristics of MI occur after 28 days following an incident MI, it is
considered to be a recurrent MI.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932572] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 102 of 143
C) Definition of pulmonary embolism:
The “Clinical Practice Guideline from the American Academy of Family Physicians and the
American College of Physicians” on diagnosis of venous thromboembolism recommends diagnosticimaging studies for patients with intermediate or high pre-test probability of pulmonary embolism
(27).
Accordingly, the definition of pulmonary embolis m is the following: obstruction of a pulmonary 
artery or one of its branches, most frequently by [CONTACT_535246] a leg or pelvic vein, diagnosed by [CONTACT_37408]:
∀Positive findings in ventilation/perfusion scan
∀Positive findings in a spi[INVESTIGATOR_23585] (helical) computerised tomography (CT) or angiography
∀Positive findings in a magnetic resonance imaging (MRI)
∀Positive findings in a pulmonary angiography
D) Definition of stroke:
The definition of central nervous infarction is according to the American Heart
Association/American Stroke Association Expert Consensus Document:  “An Updated Definition of 
Stroke for the 21st Century” 
(28).
Accordingly, the term “stroke” should be broadly used to include all of the following:
Definition of central nervous system (CNS) infarction: CNS infarction is brain, spi[INVESTIGATOR_687592], based on:
o1. pathological, imaging or other objective evidence of cerebral, spi[INVESTIGATOR_687566] a defined vascular distribution or
o2. clinical evidence of cerebral, spi[INVESTIGATOR_1304] c ord or retinal focal ischemic injury based on
symptoms persisting 24 hours or until death, and other etiologies excluded
Note: CNS infarction includes haemorrhagic i nfarctions, types I and II; see “Haemorrhagic 
Infarction”.
Definition of ischemic stroke: An epi[INVESTIGATOR_535119],
spi[INVESTIGATOR_687568]. Note: Evidence of CNS infarction is defined above.
Definition of silent CNS infarction: Imagi ng or neuropathological evidence of CNS infarction,
without a history of acute neurological dysfunction attributable to the lesion.
Definition of intracerebral haemorrhage: A focal collection of blood within the brain parenchyma or
ventricular system that is not caused by [CONTACT_278066]. Note: Intracerebral haemorrhage includes
parenchymal haemorrhages after CNS infarction, types I and II - see “Haemorrhagic Infarction”).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932573] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 103 of 143
Definition of stroke caused by [CONTACT_535247]: Rapi[INVESTIGATOR_535157] a focal co llection of bl ood within the brain parenchyma or
ventricular system that is not caused by [CONTACT_278066].
Definition of silent cerebral haemorrhage: A focal collection of chronic blood products within the
brain parenchyma, subarachnoid space or ventricular system on neuroimaging or neuropathological
examination that is not caused by [CONTACT_535248] a history of acute neurological dysfunction
attributable to the lesion.
Definition of subarachnoid haemorrhage: Bleeding into the subarachnoid space (the space between
the arachnoid membrane and the pia mater of the brain or spi[INVESTIGATOR_1831]).
Definition of stroke caused by [CONTACT_535249]: Rapi[INVESTIGATOR_535121]/or headache because of bleeding into the subarachnoid space (thespace between the arachnoid membrane and the pia mater of the brain or spi[INVESTIGATOR_1831]), which is not
caused by [CONTACT_278066].
Definition of stroke caused by [CONTACT_535250]: Infarction or haemorrhage in the brain,
spi[INVESTIGATOR_687569] a cerebral venous structure. Symptoms or signscaused by [CONTACT_535276].
Definition of stroke, not otherwise specified: An epi[INVESTIGATOR_535122], persisting ≥24 hours or until death, but 
without sufficient evidence to be classified as one of the above.
Definition of a Transient Ischemic Attack: The definition of Transient Ischemic Attack is according
to the American Heart Association/Amer ican Stroke Association. A Transient ischemic attack 
(TIA) is a transient epi[INVESTIGATOR_535123], spi[INVESTIGATOR_1304] c ord or r etinal 
ischemia, without acute infarction 
(29).
E) Definition of deep vein thrombosis:
The “Clinical Practice Guideline from the American Academy of Family Physicians and the
American College of Physicians” on diagnosis of venous thromboembolism recommends
ultrasound scanning for patients with intermediate or high pre-test probability of DVT in the lowerextremities
27. Accordingly, venous thrombosis should be demonstrated by [CONTACT_49734],
duplex ultrasound, colour Doppler imag ing or venography (phlebography).
F) Definition of other clinically significant thromboembolic events:
Signs or suspi[INVESTIGATOR_1884] a clinically significant  thromboembolic event (e.g. visceral arterial 
embolus/thrombus, extremity arterial embolus/t hrombus or portal venous thrombosis). Superficial 
thrombophlebitis is not consid ered a clinically significant thromboembolic event unless evaluated 
as such by [CONTACT_093].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932574] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 104 of 143
G) Definition of peripheral artery occlusion:
Clinical signs of acute arterial occlusion verified by [CONTACT_535252]-brachial index (ABI) test, Doppler and
ultrasound (Duplex) imaging, computerised tomographic angiography, MRA or conventionalangiography. The 2011 American College of Ca rdiology Foundation/American Heart Association
Focused Update of the Guideline for the Management of Patients with Peripheral Artery Disease
could serve as a reference for the diagnosis of lower extremity peripheral artery disease 
(30).
12.1.[ADDRESS_932575] 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of techni cal complaints:
∀The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
∀All packaging material including labelling
∀Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)
12.[ADDRESS_932576] trial-related activity after the pati ent has signed the informed consent until visit 16 
(end of treatment) for patients enrolling into a subsequent trial with concizumab and at the end of the post-treatment follow-up period (visit 17) for patient not enrolling into a new trial. The events 
must be recorded in the applicable eCRF forms in a timely manner, see timelines below and Figure 
12–[ADDRESS_932577] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: “Have you experienced any problems since the last contact?”
All AEs, either observed by [CONTACT_687649], must be reported by [CONTACT_36306]. All AEs must be recorded by [CONTACT_535277]. The investigator should 
report the diagnosis, if available. If no diagnosis is available, the investigator should record each sign and symptom as individual AEs using separate AE forms.  
For SAEs, a safety information form must be completed in addition to the AE form. If several 
symptoms or diagnoses occur as part of the same clinical pi[INVESTIGATOR_1103], one safety information form can 
be used to describe all the SAEs.
AESIs regardless of the seriousness must be reported using the AE form and safety information 
form.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932578] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932579].
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the CRF/eCRF within the specified 
timelines:
∀SAEs: The AE form within 24 hours and the safety information form within 5 calendar
days of the investigator’s first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered in the 
eCRF.
For SAEs requiring reporting on a specific event form : In addition to the above the specific 
event form within 14 calendar days from the investigator’s first knowledge of the AE.
∀Non-serious AEs fulfilling the AESI criteria: The AE form and safety information form
within 14 calendar days of the investigator’s first knowledge of the event.
If the eCRF is unavailable, the concerned AE information must be reported on a paper AE form and 
sent to Novo Nordisk by [CONTACT_6791], e-mail or courier within the same timelines as stated above. When the eCRF becomes available again, the investigator must enter the information on the form into the 
eCRF.
Contact [CONTACT_8972] (fax, telephone, e-mail and address) are provided in the investigator trial master file.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932580] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 106 of 143
Figure 12–1 Reporting of AEs
Novo Nordisk assessment of AE expectedness:
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents: Investigator’s Brochure; current version and any updates thereto.
When eptacog alfa (rFVIIa), NovoSeven®is used as IMP, expectedness is performed according to 
the following reference documents: Investigator’s Brochure; current version and any updates thereto.
Reporting of trial product-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and ICH GCP1. In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial 
procedure.
In accordance with regulatory requirements, Novo N ordisk will inform the re gulatory authorities, 
including EMA, of trial product-related S[LOCATION_003]Rs. In addition, Novo Nordisk will inform the
IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local requirement and ICH GCP1, 
unless locally this is an obligation of the investigator.
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932581] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932582]:
If an AE is considered to have a causal relationship with a Novo Nordisk marketed product used as 
non-investigational medicinal product (eptacog alfa (rFVIIa)) or concomitant medication in the 
trial, it is important that the suspected relationship is reported to Novo Nordisk, e.g. in the 
alternative aetiology section on the safety infor mation form. Novo N ordisk may need to report this 
adverse event to relevant regulatory authorities.
12.[ADDRESS_932583] be reported to Novo Nordisk according to the following:
∀SAEs: All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. 
Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the outcome “recovering/resolving” or “not recovered/not 
resolved”. Cases can be closed with the outcome of “recovering/resolving” when the patient
has completed the follow-up period and is e xpected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator’s first knowledge of the 
information. This is also the case for previously non-serious AEs which subsequently become 
SAEs.
∀Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until 
the end of the follow-up period stated in the protocol, whichever comes first, and until all queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs 
ongoing at time of death (where death is due to another AE) may be closed with the 
outcome “recovering/resolving” or “not recovered/not resolved”. Cases can be closed with the outcome of “recovering/resolving” when the patient has completed the follow-up period and is expected by [CONTACT_36308].
∀Non-serious AEs fulfilling the AESI criteria: Non-serious AE fulfilling the AESI criteria 
must be followed as specified for non-seri ous AEs. Follow-up information on AESIs should 
only include new (e.g. corrections or additi onal) information and must be reported within 14 
calendar days of the investigator’s first knowledge of the information. This is also the case 
for previously reported non-serious AEs which  subsequently fulfil the AESI criteria.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932584] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932585] be reported as follow up with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_932586].
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the investigational medicinal produ ct occurring to a patient after the patient has 
ended the trial, the investigator should report this SAE within the same timelines as for SAEs 
during the trial.
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of tec hnical complaints
All technical complaints on any of the following products: 
∀Concizumab B 100 mg/mL, solution for injection in a 3 mL cartridge
∀NovoPen
®4
∀Novo Nordisk needles
∀Eptacog alfa (rFVIIa) 5 mg/vial, powder for solution for in jection in  a vial
∀Histidine 5 mL, solvent for solution for injection in a prefilled syringe
∀Novo Nordisk trial injection kit
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Centre, Novo Nordisk.
Contact [CONTACT_8972] (fax, e-mail and address) are provided in Attachment I to the protocol.The investigator must assess whether the technical complaint is related to any AEs, AESI and/or 
SAEs.
Technical complaints must be reported on a separate technical complaint form:
∀One technical complaint form must be completed for each affected DUN 
∀If DUN is not available, a technical complaint form for each batch, code or lot number must 
be completed
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
∀Technical complaint assessed as related to an SAE within 24 hours
∀All other technical complaints within 5 calendar days3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932587] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932588] coordinate the shipment to 
Customer Complaint Centre, Novo Nordisk (the addr ess is provided in Att achment I) and ensure 
that the sample is sent as soon as possible. A copy of the technical complaint form must be included in the shipment of the sample. If several samples are returned in one shipment, the individual sample and the corresponding technical complaint form must be clearly separated.
The investigator must ensure that the technical complaint sample contains the batch, code or lot 
number and, if available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable.
Storage of the technical complaint sample must be done in accordance with the conditions 
prescribed for the product.
12.[ADDRESS_932589] be instructed to notify the investigator if their female partner becomes pregnant 
during the trial, except in the screening period (from visit 1 to dosing with concizumab at visit 2 or 
visit 9 depending on the arm). At the last scheduled visit (visit 17), male patients must be asked if 
their female partner has become pregnant.
If a female partner has become pregnant during the trial, the investigator must follow-up on the 
pregnancy outcome and until the newborn infant is one month of age, irrespective of whether the 
trial is completed or not. The investigator must ask the male patient and assess if the pregnancy outcome is normal or abnormal.
When the pregnancy outcome is normal this information is recorded in the patient’s medical record 
only, no further information is collected and reported to Novo Nordisk. When the pregnancy 
outcome is abnormal (i.e. congenital anomalies, foetal death including spontaneous abortion and/or 
any anomalies of the foetus observed at gross examination or during autopsy), the following must be reported by [CONTACT_687666] (e.g. in PDF format) or by [CONTACT_6791].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932590] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 110 of 143
1. Reporting of pregnancy information
Information from the male patient has to be reported on the Paternal Form. Furthermore, 
information from the female partner (including information about the pregnancy outcome and health s tatus of the infant until the age of one month) has to be reported on the Maternal Forms 
1A, 1B and 2, after an informed consent has been obtained from the female partner.
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator’s first knowledge of initial or follow-up information.
2. Reporting of AE information
The following AEs in the foetus and newborn infant have to be reported:
oNon-serious AEs evaluated as possible/probably related to the father’s treatment 
with the trial product(s)
oSAEs in the foetus and newborn infant - whether or not related to the father’s 
treatment with the trial product(s). This  includes an abnormal outcome - such as 
foetal d eath (including spontaneous abortion) and congenital anomalies (including 
those observed at gross examination or during autopsy of the foetus)
Forms and timelines for reporting AEs:
Non-serious AEs: 
∀Paper AE formawithin 14 calendar days of the investigator’s fi rst knowledge of the init ial 
or follow-up information to the non-serious AE
SAEs: 
∀Paper AE formawithin 24 hours of the investigator’s first knowledge of the SAE
∀Paper safety information form within 5 calendar days of the investigator’s first knowledge 
of the SAE
∀SAE follow-up information to the AE form and/or safety information form within 24 
hours of the investigator’s first knowledge of the follow-up information
aIt must be clearly stated in the AE diagnosis field on the AE form if the event occurred in the 
patient, foetus or newborn infant.
Any queries or follow-up requests from Novo Nordisk  to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_932591].
12.6 Precautions and/or overdose
Dose limiting toxicities of concizumab have not been investigated in clinical trials.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932592] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932593] be submitted to the 
regulatory authori ties to support restart of the trial.
∀Significant thromboembolic event
∀Event of DIC
∀Anaphylactic reaction related to trial drug administration
∀Death of trial patient which may be related to the trial product
∀Two or more other trial product related SAEs s imilar in nature have been reported and/or 
detected by [CONTACT_66969]
∀Trends in AEs, clinical observations or laborat ory parameters which raise concerns about 
the safety of continued treatment.
12.[ADDRESS_932594] access to the data, and 
will provide recommendations on trial continuation, modification or termination.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932595] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932596] interaction with those in trial 
management. The DMC recommendations should be addressed directly to the Novo Nordisk Global Safety department and the internal Novo Nordisk safety committee for concizumab. It is the responsibility of the Novo Nordisk internal safety committee for concizumab to take action(s) for
patient safety based on the DMC recommendations.
Information regarding responsibilities, procedures and workflow to be used by [CONTACT_215575].
13 Case report forms
For this trial a combination of electronic case report forms (eCRFs) and paper CRFs will be used.
Novo Nordisk will provide a system for the electronic case report forms (eCRF). This system and 
support services to the system will be provided by [CONTACT_215576].
Ensure that all relevant questions are answered, and that no empty data field exists. If a test or an 
assessment has not been done and will not be availab le, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper CRFs:
∀Pregnancy forms
∀Technical complaint forms
∀AE forms
∀Safety information forms
The paper version of the technical complaint form, AE form, and safety information form must only 
be used to ensure timely reporting when/if the electronic CRF is unavailable.
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered, 
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. 
If a test/assessment has not been done and will not be available, indicate this by [CONTACT_565] “ND” (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) indicate this by [CONTACT_565] “NA” (not applicable) in the appropriate answer field. Further guidance can be obtained from the instructions in the CRF.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932597] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932598] igator’s delegated staff. 
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the new data, identification of  the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]’s delegated  staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].
13.[ADDRESS_932599] ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
13.3 Electronic diary
Novo Nordisk will provide the patient with an eDiary for electronic recording of det ails of their 
home treatment, bleeding epi[INVESTIGATOR_1841] a nd treatment of bleeding epi[INVESTIGATOR_1865] s (i.e. use of eptacog alfa 
(rFVIIa)).
The eDiary and related support services will be supplied by a vendor working under the direction and supervision of Novo Nordisk.
Patients will be instructed in the use of the eDiary by [CONTACT_535254]. The eDiary will be dispen sed to the patient at visit 2. After visit [ADDRESS_932600] built in edit checks and reminders to ensure that all relevant questions are 
answered. 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932601] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932602] the number of v ials/cartridge accounted for as used by [CONTACT_102]. 
Upon review the Investigator must document that the review has taken place and any actions 
required e.g. retraining of the patient or decision to amend or correct the data reported by [CONTACT_102].
If the Investigator finds it necessary to amend or correct eDiary data, the patient must be consulted 
prior to requesting the actual data change. A Data Request Correction (DRC) must be submitted to 
the eDiary vendor. An audit trail will be maintained.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932603] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932604] 6 patients 
recruited in the trial. The monitoring visit in tervals will depend on the outcome of the centralised 
monitoring of the eCRFs (remote assessment of data by [CONTACT_3454]), the trial site's recruitment 
rate and the compliance of the trial site to the protocol and GCP, but will not exceed 12 weeks until LPLV at the trial site. This only applies to sites with scheduled, ongoing and/or discontinued patients.
The monitor must be given direct access to a ll source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are important to the evaluation of the trial. If the electronic medical record does not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. In addition the relevant trial site st aff should be available for discussions at monitoring 
visits and between monitoring vi sits (e.g. by [CONTACT_535258]).
All data must be verifiable in source documentation other than the eCRF. eDiary data is entered by 
[CONTACT_535259].
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must onl y be one source defined at any time for any data element.
For historical data such as medical history , details of haemophilia a nd haemophilia treatment 
history, a reasonable effort must be made by [CONTACT_093], considering local requirements, to 
obtain this information from external sources, if not  known by [CONTACT_102]. It is accepted that the 
earliest practically retainable record should be considered as the location of the source data and therefore the source document. This means that for laboratory results (e.g. biochemistry and haematology) a signed printout of the electronic results must be available.
Source data generated by [CONTACT_535292] c orrected by [CONTACT_535293]; any correction must be explained, signed and dated by [CONTACT_36324].
The monitor will ensure that the eCRFs are completed and paper CRFs (if any) collected, that 
ePROs and eDiaries are completed and reviewed by [CONTACT_687640], if any.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932605] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 116 of 143
The following data will be source data verified for screening failures:
∀Date for obtaining informed consent
∀Inclusion and exclusion criteria
∀Screen failure reason if possible
∀Date patient left the trial
∀Data relating to AEs if applicable
∀Demography, see section 8.2.1
∀Date of visit
Monitors will review the patient’s medical rec ords and other source data (e.g. the eDiaries and 
ePROs) to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are found, the investigator must be questioned about these.
A follow-up letter (paper or electronic) will be se nt to the investigator following each monitoring 
visit. This should address any action to be taken.
[ADDRESS_932606] the identity of patients in all presentations and publications as required by [CONTACT_5737], regional and national requirements.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932607] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932608] Operating Procedures and IT architecture documentation. The use and control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.
Novo Nordisk will use the Global Haemophilia Network Investigator Portal to distribute and share
trial-related documents and information with the pa rticipating sites. After trial completion, Novo 
Nordisk will supply each trial site with long-life CDs or other relevant archiving containing the 
electronic Investigat or Trial Master File (eITMF) for each tr ial site. These CDs or other relevant 
archiving will contain site-specific trial documen tation as  well as trial specific news and other 
relevant trial information, including audit trail on documents and site staff users. The GHN Portal software and hardware implementation are compliant with the requirements of FDA 21 CFR Part 11 
and ICH E6 (EU directive for personal data protection).
1, 31
Novo Nordisk will provide electronic tab lets for reporting of all PROs questionnaires described in 
section 8.6.1 and in Appendix 1. In case the electronic tablet is revoked the questionnaires will be 
available in paper.
The eDiary and ePRO software and hardware implementation are compliant with the requirements 
of FDA 21 CFR Part 11 and ICH E6 (EU directive for personal data protection).1,31After trial 
completion, each trial site will be supplied with long-life CDs. These CDs will contain site-specific patient records including the patient’s eDiaries a nd audit trail including any data additions and 
corrections made on each form. The eDiary vendor will furthermore retain and securely store copi[INVESTIGATOR_687593] 15 years or as required by [CONTACT_56325].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932609] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932610] patient has completed a minimum of 24 weeks of treatment or at LPFT (visit 2) + [ADDRESS_932611] patient has withdrawn before visit 9. Please refer to Figure 
17–1 for further information. 
Data from when the on-demand treated patients are transferred to concizumab s.c. prophylaxis will 
not be included in this evaluation. Observations from the extension part in the on-demand arm will be summarised separately as well as combined w ith observations from the main part when reporting 
the extension part data.
Endpoints comprising number of bleeding epi[INVESTIGATOR_535125]. Multiple bleeding locations occurring from the same event (e.g., due to a bicycle accident) or at the same time point will be counted as one bleeding epi[INVESTIGATOR_1865]. Further, the endpoints 
will not include re-bleed. A re-bleed is defined as a bleeding epi[INVESTIGATOR_1865] (worsening of bleeding site 
conditions e.g. swelling, pain) within 72 hours after stoppi[INVESTIGATOR_535180] a previous bleeding epi[INVESTIGATOR_535126] (or subset of the same) anatomical location. If a bleeding epi[INVESTIGATOR_535127] [ADDRESS_932612] due to a safety 
concern patients after visit 17, in the possible extended safety follow-up period (ref section 8.1.4 ) 
will be listed only . 
Clinical proof of concept
The statistical analysis of the collected data aims to establish CPoC that concizumab is efficacious 
in preventing bleeding epi[INVESTIGATOR_56178] p atients with inhibitors. The objective will be 
assessed when the last of the 24 patients has completed 24 weeks of dosing (or has withdrawn before that).
Two criteria will be evaluated in a hierarchical fashion in support of CPoC comprising a 
comparison of the ABR of all patients in the concizumab group, irrespective of individual dose titration, with the ABR of the patients in the on-d emand arm using different sets of observations. 
The primary CPoC criterion aims at evaluating the effect of concizumab when given at the last dose 
level reached for the patient. Hence, for this evaluation, only observations from the period where 
patients are on their end dose at time of analysis will contribute to the analysis. Furthermore, observations from the [ADDRESS_932613] of concizumab when given 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932614] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932615] one succeeds.
The referred comparisons will be made using a negative binomial model with log of exposure time 
in main part as offset and regimen as factor (concizumab vs. on-demand). For each criterion, 
evidence of effect will be concluded if the 95% confidence interval of the treatment ratio is below 1.
Clinical arguments for the hierarchical test approach
Concizumab exhibits non-linear PK due to target mediated drug disposition and it is expected that 
the dose response curve of the ABR is rather steep. This implies that patients that are on a dose 
which is not efficacious are likely to bleed as patients that are not treated at all. Subset of data collected from the last dose clinically deemed as efficacious would reflect the efficacy of concizumab in the given patient.
17.1 Sample size calculation
The estimand w ill be defined as the “if all pa tients had adhe red” es timand.
The treatment ratio between prophylactic s.c. concizumab and on-demand i.v. eptacog alfa (rFVIIa)
during at least 24 weeks for all randomised patients if all patients a dhered to trial drug and did not 
initiate alternative treatment options.
This estimand is a de jure estimand assessing the expected added benefit a patient can achieve if 
continuing treatment with prophylactic s.c. concizumab as compared to on-demand i.v. eptacog alfa (rFVIIa) under similar conditions as observed in this trial.
The sample size calculation has been determined based on this estimand and the CPoC criteria 
taking the small patient population into account, while also aiming for an acceptably narrow 95% 
confidence interval for the rate ratio.
Sufficient inference on bleeding epi[INVESTIGATOR_687573] 16 patients in the concizumab arm and 8 in the comparator arm. It is expected 
that the treatment duration of the main part allowing for escalation time for some patients is on 
average 6 months in the below calculations.
When evaluating the power of th e negative bi nomial analysi s referred above, annual bleeding rates 
of 24 and 6 are assumed for the on-demand patients and the end dose concizumab regimen, 
respectively. Assuming further over-dispersion of 7, the power for concluding superiority of the 
concizumab regimen becomes approximately 80%. Th e power under varying values of true ABR 
and over-dispersion for the primary CPoC criterion are shown below in Table 17–1 .3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932616] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 120 of 143
Table 17–1Power in superiority comparison between concizumab prophylaxis and on-demand 
treatment under different assumptions of ABR for concizumab and over-
dispersion (assuming on-demand ABR=24).
Power Over-dispersion (over 6 months)
ABR (concizumab) 6 7 8
6 89% 82% 75%
7 84% 75% 70%
8 77% 69% 66%
For the secondary CPoC criterion that includes data prior to potential dose escalation, it is expected 
that the treatment duration of the main part is on average 8 months with an average ABR of 7.6 for the concizumab regimen. This yields a marginal power of approximately 70% for the secondary CPoC criterion.
In prior Novo Nordisk trials conducted in haemophilia patients, the typi[INVESTIGATOR_2855] 1-year over-dispersion 
for non-inhibitor patients on prophylaxis with FVIII or FIX has been in the range 4-8, implying 24 weeks over-dispersion of 3-5 (e.g. in NN7008-3543, NN7088-3859 a nd NN7999-3747). In the 
NN7128-1907 trial in inhibitor patients, larger 1-year over-dispersion values of approximately 21 
and 18, respectively, were observed during an initial  3-month on-demand period and a subsequent 
3-month prophylaxis period. It is expected that the variation in the current trial will be smaller, partly due to the longer duration of the trial and partly due to an expected more homogenous patient 
population. Another pub lished trial including inhibitor patients, comparing prophylaxis using 
FEIBA
®with on-demand treatment, showed 6-month over-dispersion of 4-532. On that background, 
an over-dispersion of 7 over the 24 weeks in main part of the current trial is deemed realistic.
17.2 Definition of analysis sets
All dosed patients will be included in the Full Analysis Set (FAS) as well as in Safety Analysis Set 
(SAS).
17.[ADDRESS_932617] 24 weeks from treatment 
onset.
The endpoint will be analysed when the main part of trial has been completed.
17.3.1 Estimand and primary statistical analysis
The estimand for the primary endpoint is the “if all patients had adhered” estimand.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932618] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 121 of 143
The treatment ratio between prophylaxis s.c. concizumab and on-demand i.v. eptacog alfa (rFVIIa)
during at least 24 weeks for all randomised patients if all patients a dhered to trial drug and did not 
initiate alternative treatment options.
This estimand is a de jure estimand assessing th e expected added benefit a patient can achieve if 
continuing treatment with prophylactic s.c. concizumab as compared to on-demand i.v. eptacog alfa 
(rFVIIa) under similar conditions as observed in this trial.
The estimand for the primary endpoint will be estimated using negative binomial regression with 
log of exposure time (the included observational period of the main part) as offset and regimen as 
factor. The offset for first CPoC criterion of patients in concizumab arm is the log of the individual 
exposure time at the last dose level reached at the time of analysis excluding the 2 weeks run-in period for subjects on 0.15 mg/kg. The offset for the second criterion of patients in concizumab arm is the log of the individual exposure time in the main part. For both criteria and patients in the on-
demand arm, the offset is the log of the exposure  time in the main part. The analysis provides an 
estimate of the ABR ratio between regimens (concizumab prophylactic and on-demand eptacog alfa (rFVIIa)) with corresponding 95% confidence inte rval and also actual estimate of the ABR with 
corresponding 95% confidence interval for each regimen. This analysis has the underlying 
assumption that the missing data mechanism is “missing at random”, i.e. MAR. Under this 
assumption, the statist ical behavi our of the missing data (given the observed responses and the 
mean value structure) is assumed to be the same as for the observed data. The estimand will be estimated based on the FAS and only data collected prior to discontinuation of trial product or initiation of alternative treatment options will be used to draw inference.
17.3.[ADDRESS_932619] a worse outcome compared to what was observed during the 
main part of the trial. This will be done by [CONTACT_1583] a value Δto the observed bleeding epi[INVESTIGATOR_687574]. The offset is maintained as being the exposure during the main part since it is not possible to identify the amount of missing observation t ime. The 
degree of worsening, Δ
i,will gradually be increased to evaluate at which point concizumab 
prophylaxis no longer is superior to  on-demand eptacog alfa (rFVIIa). The results of the primary 
analysis will be considered robust if the tippi[INVESTIGATOR_687603].
17.3.3 Additional analysis
An additional evaluation of the primary endpoint will be made, including the actual concizumab 
dose level (interpreted as the patients last dose le vel) as additional factor in the primary analysis 
model specified above. Point estimates and 95% c onfidence interval will be provided for the ABR 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932620] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 122 of 143
at the different dose levels of concizumab (0.15, 0.20 and 0.25 mg/kg). Furthermore, series of 
analyses with individual steady state PK/PD assessments included as covariates in the negative binomial regression model as specified for the primary analysis of number of bleeding epi[INVESTIGATOR_687604]/PD and ABR that potentially 
could guide dose-selection. The referred steady-state PK/PD assessments comprise the concizumab 
trough level, TFPI [INVESTIGATOR_535160] s.c. dose administration, peak thrombin generation (nM), Endogenous thrombin potential (nMxmin) and velocity index (nM/min).
17.4 Supportive secondary endpoints17.4.1 Supportive secondary efficacy endpoints
∀The number of bleeding epi[INVESTIGATOR_535025] 76 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment onset
∀The number of spontaneous bleeding epi[INVESTIGATOR_535025] [ADDRESS_932621] 76 weeks of treatment with prophylactic concizumab will be analysed using a negative binomial model with log of trial duration as offset, providing estimates of the ABR with confidence interval for that particular 
regimen.
17.4.2 Supportive secondary safety endpoints
∀Number of treatment-emergent adverse events (TEAEs) during at least 24 weeks from 
treatment onset
∀Number of TEAEs during at least 76 weeks from treatment onset
∀Number of TEAEs within 24 hours of rFVIIa administration
∀Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset
∀Occurrence of anti-concizumab antibodies during at least 76 weeks from treatment onset
∀Change from baseline of fibrinogen during 24 weeks from treatment onset
∀Change from baseline of fibrinogen during at least 76 weeks from treatment onset
∀Change from baseline of D-dimer during 24 weeks from treatment onset
∀Change from baseline of D-dimer during at least 76 weeks from treatment onset3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932622] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 123 of 143
∀Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
∀Change from baseline of F1 + [ADDRESS_932623] 76 weeks from treatment onset
∀Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
∀Change from baseline of PT during at least 76 weeks from treatment onset
∀Change from baseline of activated partial thromboplastin time (A PTT) during 24 weeks 
from treatment onset
∀Change from baseline of APTT during at least 76 weeks from treatment onset
∀Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
∀Change from baseline of AT after at least [ADDRESS_932624] recent version of Medical Dictionary for Regulatory 
Activities (MedDRA) coding.
TEAE is defined as an event that has onset after randomisation until the last visit in the trial. 
Adverse events collected among permanently prematurely discontinued from trial product due to a 
safety concern patients after visit 17 in the possible extended safety follow-up period (ref section 
8.1.4 ) are not considered treatment emergent. Treatment-emergent adverse event endpoints will be 
summarised by [CONTACT_9313], preferred term,  seriousness, severity and relation to trial 
product. All adverse events will further be listed. Relations to Novo Nordisk marketed products 
used by [CONTACT_687667], such as eptacog alpha, is reported as described in section 12.2 of the 
protocol and not reported in the report of the trial.
Frequency of binding anti-concizumab antibodies will by [CONTACT_535280] t ime frame 
according to the two endpoint definitions.
All laboratory safety  endpoints will be plotted by [CONTACT_5586], both as absolute values and change from 
baseline. Laboratory safe ty endpoints will further be summarised and listed.
17.4.3 Supportive secondary pharmacokinetic endpoints
∀Concentration of concizumab prior to the last dose administration at 24 weeks
∀Concentration of concizumab prior to the last dose administration after at least 76 weeks
The pharmacokinetic endpoints will be summarised and listed.17.4.4 Supportive secondary pharmacodynamic endpoints
∀Free TFPI [INVESTIGATOR_687515] [ADDRESS_932625] 76 weeks
∀Thrombin generation3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932626] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 124 of 143
oPeak thrombin generation (nM) prior to the last dose administration at 24 weeks
oPeak thrombin generation (nM) prior to the last dose administration after at least 76 
weeks
oEndogenous thrombin potential (nMxmin) prior to the last dose administration at 24 
weeks
oEndogenous thrombin potential (nMxmin) prior to the last dose administration after 
at least 76 weeks
oVelocity index (nM/min) prior to the last dose administration at 24 weeks
oVelocity index (nM/min) prior to the last dose administration after at least 76 weeks
The PD endpoints will be summarized and listed.
17.4.5 Exploratory endpoints17.4.5.1 Exploratory safety endpoints
∀Number of adverse events related to technical complaints during at least 24 weeks from 
treatment onset
∀Number of adverse events related to technical complaints during at least 76 weeks from 
treatment onset
Adverse events related to technical complaints will be listed and summarised17.4.5.2 Exploratory patient reported-outcome endpoints
∀Change in Hemo-TEM after 24 weeks from treatment onset
∀Change in Hemo-TEM after at least 76 weeks from treatment onset
∀Change in SF-36v2 after 24 weeks from treatment onset
∀Change in SF-36v2 after at least 76 weeks from treatment onset
∀Change in SDS after 24 weeks from treatment onset
∀Change in SDS after at least 76 weeks from treatment onset
∀Change in TSQM after 24 weeks from treatment onset
∀Change in TSQM after at least 76 weeks from treatment onset
∀Change in SIAQ-ISRQ after 24 weeks from treatment onset
∀Change in SIAQ-ISRQ after at least 76 weeks from treatment onset
∀Status of PGI-C after 24 weeks from treatment onset
VERITAS-PRN
®, SF-36v2, SDS and TSQM will be scored according to their respective scoring 
algorithms. Change after 24 weeks of tr eatment onset for SF-36v2, SDS and TSQM from visit 2 to 
visit 9 will be analysed with an ANCOVA model including regimen as a factor and baseline score as covariate.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932627] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 125 of 143
The PRO endpoints will be summarised using descriptive statistics and the remaining 
questionnaires (Hemo-TEM, PGI-C, SIAQ-ISRQ) will be summarised and listed using descriptive 
statistics.
17.[ADDRESS_932628] patient has completed a minimum of 24 weeks of treatment or at LPFT (visit 2) + [ADDRESS_932629] patient has either completed or withdrawn from the trial. All main conclusions regarding clinical proof of concept and dose guidance for phase 
3 will be based on the reporting after the main part, see Figure 17–1 .
Figure 17–1 Definition of main and extension part
3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932630] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 126 of 143
18 Ethics
18.1 Benefit-risk assessment of the trial
Benefits
Results from a multiple dose phase 1 trial wher e concizumab was dosed for approximately 6 weeks 
showed a trend towards efficacy in a limited number of patients who reached concizumab plasma concentrations above 100 ng/mL, see Section 3.1.2 . Based on these results, it is expected that the 
majority of the patients randomised to the co ncizumab treatment with 0.15 mg/kg daily dose will be 
protected from bleeding epi[INVESTIGATOR_1841].  Patients who experience excessive bleeding epi[INVESTIGATOR_535161] a possibility to be escalated to a higher dose where bleeding preventiveefficacy of concizumab treatment is expected to improve. For haemophilia patients with inhibitors 
and who are treated on-demand, expected improved efficacy is considered to be a major benefit in 
participating in this trial. Also, concizumab is administered s.c. and might reduce the burden of frequent i.v. injections associated with current treatment options in haemophilia patients with inhibitors.
Information gained from this trial will contribute to gaining regulatory approval for a product that is 
anticipated to offer clinical advan tages over currently available products.
Risks
No risks have been recognised as identified risks by [CONTACT_535263]. However, the nonclini cal toxicity studies have identified 
thromboembolic events as a potential risk when treating non-human primates with concizumab at high exposures.
As observed for other pro-coagulant compounds, there is a potential safety risk of thrombosis and 
vascular ischemia with reaching very high concizumab plasma concentrations. In non-clinical 
toxicity studies with concizumab, thrombi were observed at high doses. However, a no observed 
adverse effect level ( NOAEL) for concizumab has been identified in non-haemophilic animals at 
plasma concentrations at least 24 fold higher than the currently anticipated effective plasma 
concentration (mean area under curve [AUC] and C
max) based on PK modelling.
In a drug–drug interaction study in monkeys, three doses of up to 1 mg/kg of NovoSeven®were 
administered at 2-h intervals, alone or in th e presence of a steady state concentration of 
concizumab. Increased concentrations of thrombin–anti-thrombin (TAT) and D-dimer were seen, 
which tended to be additive when both concizumab and eptacog alfa (rFVIIa) were present in 
circulation. No notable clinical observations were made.
In clinical trials, except for one case of superficial t hrombophlebitis in a h ealthy volunteer who 
received a single dose of 1mg/kg, no other thromboembo lic events were observed. A phase 13URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932631] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 127 of 143
multiple dose trial was finalised in haemophilia  A patients (0.8 mg/kg s.c. every 4 days for 6 
weeks). In this clinical trial, marked changes in coagulation parameters were observed including a decrease from baseline in fibrinogen and a pronounced increase in D-dimer and F1+2 outside of normal range in patients with high plasma concentrations of concizumab. These changes were not 
judged as clinically significant by [CONTACT_535281][INVESTIGATOR_535134]™[ADDRESS_932632] not been observed so far in clinical trials. Furthermore, even if antibodies towards concizumab occur, the risk for the rate of immune complex formation exceeding the clearance capacity is considered low. Please refer to the Investigator’s Brochure for further information.
If antibodies against concizumab develop, they might also inhibit the function of the administered 
drug. The consequence of this could be that the patient may not be able to benefit from the drug in 
the future. Antibody development against concizumab is not expected to reduce the effect of other treatment options.
Theoretical risks include bleeding due to consumption of coagulation factors and adverse reactions 
due to potentiation of inflammatory reactions or ti ssue damage due to impairment of tissue repair 
mechanisms
33 34. TFPI [INVESTIGATOR_687594] h, in addition to its role in haemostasis, 
is implicated in tissue repair processes and in a variety of physiological  and pathophysiological 
states where repair mechanisms are activated. These include sepsis, DIC, inflammation, 
atherosclerosis, cancer and crush injuries35 36, 37.
There may be a risk of allergic reactions, includi ng severe (anaphylactic) reactions, in connection 
with concizumab administration. Severe allergic reactions may potentially be life-threatening and thus, the trial products will be administered to the trial patients at the site under the surveillance of 
medically trained trial site staff in the beginning of the trial.
Overall the anticipated benefits from participating in the trial outweigh the potential risks.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932633] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932634] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki2.
Before any trial-related activity, the investigat or must give the patient verbal and written 
information about the trial and the procedures i nvolved in a form that the patient can read and 
understand.
The patients must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.
The investigator must ensure the patient ample time to come to a decision whether or not to 
participate in the trial.
A voluntary, signed and personally dated informed consent must be obtained from the patient 
before any trial-related activity.
The responsibility for seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically  qualified person, in accordance with local 
requirements. The written informed consent must be  signed and personally dated by [CONTACT_135562]-related activity.
If information becomes available that may be releva nt to the patient’s willingness to continue 
participating in the trial, the investigator must inform the patient in a timely manner, and a revised
written patient information must be provided a nd a new informed consent must be obtained.
Only applicable for Japan: As a minor is unable to provide legally binding consent, informed 
consent must be sought from the parent(s)/LAR(s) on the child’s behalf prior to enrolling a child in 
the trial, according to local requirements.
18.[ADDRESS_932635] to follow up, then the patient’s data will be handled 
as follows:
∀Data already collected and any data collected at the end-of-trial visit will be retained by 
[CONTACT_3454], entered into the database and used for the CTR.
∀Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used it will always be in accordance with local regulations and IRBs/IECs.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932636] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932637] be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_687595].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely termin ated, the investigator must inform the patients 
promptly a nd ensure appropriate therapy and follow- up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation.
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of patients who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the patients
should be described.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932638] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932639] to a sign ificant degree the safety 
and rights of a patient or the reliability and robustness of the data generated (potential serious 
breach) and if it should be reported to the Regu latory Authorities as a serious breach of GCP and/or 
the protocol.
In addition, deviations must be documented and explained in a protocol deviation by [CONTACT_535282], date, and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database.
Documentation on protocol deviations must be kept  in the investigator trial master file and sponsor 
trial master file.
19.[ADDRESS_932640] or withdrawal of consent to secure early mitigations in collaboration with the trial sites.
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, see Section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by [CONTACT_687661] (e.g. re-training of site staff).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932641] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932642] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are relevant to the evaluation of the trial.
21 Critical documents
An Investigator Portal (Gl obal Haemophilia N etwork [GHN]) w ill be used as pr imary media for 
exchange and handling of investigator trial master file documents between Novo Nordisk and the site and for electronic storage of these documents during trial conduct.
Before a trial site is allowed to start screen ing patients, written notification from Novo Nordisk 
must be received and the following documents must be available to Novo Nordisk:
∀Regulatory approval and/or acknowledg ement of notification as required
∀Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendmen ts, patient information/informed consent form, 
any other written information to be provided to the patient and patient recruitment m aterials
∀List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
∀Curricula v itae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
∀Signed receipt of Investigator’s Brochure
∀SmPC or similar labelling of eptacog alfa (rFVIIa)
∀Signed and dated Agreement on Protocol
∀Signed and dated Agreement on Protocol Amendment, if applicable
∀Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigator’s 
site and Novo Nordisk
∀Source document agreement
∀Central laboratory certification and normal ranges
∀Insurance statement, if applicable
∀Financial disclosure form from investigator and sub-investigator(s)
∀Description of research facility obtained  (applicable for sites outside the US)3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932643] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 132 of 143
Only applicable for US trial sites:
∀For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
∀For US trial sites: FDA form [ADDRESS_932644] be comp leted and signed by [CONTACT_237205] 1572:
For US sites:
∀Intended for US sites
∀Conducted under the IND
∀All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
∀Intended for participating sites outside of the US
∀Not conducted under the IND
∀All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
For local laboratory parameters the following w ill be collected:
∀Laboratory normal ranges
∀Laboratory certification, QA scheme or similar documentation
∀Laboratory assay methods (only non-standard assays) and/or analytical methods
By [CONTACT_36343], each investig ator agrees to comply fully with ICH GCP1
applicable regulatory requirements and the Declaration of Helsinki2.
By [CONTACT_36343], each investigat or also agrees to allow Novo Nordisk to make 
investigator’s name [CONTACT_36374] [CONTACT_36344].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932645] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932646] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the conduct of the trial and to protect the rights, safety, and well-being of the patients.
At least investigator must be trained in the current protocol version at a Novo Nordisk Investigator 
meeting or by [CONTACT_687641]. It is recommended that all site staff 
completes the web protocol training.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related  medical decisions.
The investigator will follow instructions  from Novo Nordisk when processing data.
The investigator is responsible for filing esse ntial documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced) in the investigator trial master file. The documents including the patient identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data.
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
patients to a specific qualified physician who will be readily available to patients during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932647] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932648], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial.One investigator will be appointed by [CONTACT_18036] (signatory 
investigator) on behalf of all participating i nvestigators. The signatory investigator will be 
appointed based upon the criteria defined by [CONTACT_36346]
38. 
23.[ADDRESS_932649] for 
Clinical Trial Disclosure how-we-disclose-trial-information.
Novo Nordisk reserves the right to defer the rel ease of data until specified milestones are reached, 
for example when the CTR is available. This includes the right not to release the results of interim 
analyses, because the release of such information may influence the results of the entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to [ADDRESS_932650] intellectual property.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932651] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 135 of 143
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any disagreement on the content of any publication, both the investigators’ and Novo Nordisk opi[INVESTIGATOR_36255].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary m aterial, as specified by [CONTACT_18038].
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors
38(sometimes referred to as the Vancouver 
Criteria).
23.1.2 Site-specific publication(s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statist ical 
limitations and frequently do not provide meaningful information for healthcare professionals or patients, and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that such individual reports do not precede the primary manuscript and should al ways reference the 
primary manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of individual site results until the primary manuscript is accepted for publication. As Novo Nordisk wants to live up to the industry publication polic y, submission of a primary publication will take 
place no later than [ADDRESS_932652] access 
to the database.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932653] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 136 of 143
24 Retention of clinical trial documentation and human biosamples
24.1 Retention of clinical trial documentation
Patients’ medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other patient data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These d ata must be retained by [CONTACT_21655]. If the 
provided d ata (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least [ADDRESS_932654].
Only applicable for Spain: 25 years retention according to the Spanish Royal Decree 1090/2015.
The files from the trial si te/institution must be  retained for 15 years after EOT as defined in Section 
7, or longer if required by [CONTACT_36348]. In any case trial files cannot be 
destroyed until the trial site/institution is no tified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.
24.2 Retention of human biosamples
This trial will involve collectio n of human biosamples at visit 1 (screening visit) and at visit 17
(EOT) and these samples are to be stored max imum [ADDRESS_932655] the patients’ participation in the trial. 
Therefore, patients will have the possibility to sign the informed consent for the trial and 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932656] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 137 of 143
participate, while refusing permission for biologi cal specimens to be stored for future exploratory 
analysis.
∀Human biosamples will be stored at the central laboratory
∀1.0 mL citrated plasma, 1.2 mL serum and/or 2.0 mL whole blood ( DNA for genotypi[INVESTIGATOR_007])
will be obtained
∀The intended use of the stored human biosamples e.g.: As new biomarkers related to the 
disease and/or safety, efficacy or mechanism of action of concizumab may evolve during the 
conduct of the trial, the analyses of the stored human biosamples may also include 
biomarkers that are unknown at present or have not been included in the scientific 
hypotheses at initiation of the trial
∀Human biosamples may be transferred to third parties e.g. research consortia
∀The human biosamples will be transferred a nd stored after the EOT at a designated central 
laboratory
∀Confidentiality and personal data protection will be ensured during storage after the EOT
∀The human biosamples may be transferred to other countries (not applicable if local 
regulations prohibit export of human biosamples)
∀The human biosamples will be destroyed at the latest 15 years from EOT
∀The patient may request the stored human biosamples to be destroyed by [CONTACT_535265]. The results obtained from any already performed analyses of the samples will still 
be used
∀Novo Nordisk and laboratory will have access to the stored human biosamples
∀Potential consequences for the patient and their relatives: In the event that the collected
human biosamples (plasma, serum and/or DNA for genotypi[INVESTIGATOR_007]) will be used in the future, 
the investigator will become directly informed by [CONTACT_535266]. In such case, 
a written summary of the findings, including lis tings of patient specific values, will be 
provided once a firm conclusion from the results has been drawn by [CONTACT_3454]. 
Potentially, observations of ne oplastic diseases, serious hereditary diseases, other un-
treatable diseases, or any other abnormal findings could be part of the observations. Patients
can contact [CONTACT_687652] m their own body, see Section 5.1.
24.2.1 Antibod y samples
Antibody samples will be retained until drug approval by U.S. Food and Drug Administration 
(FDA) and/or European Medicines Agency (EMA).
The retained antibody samples may be used for later analysis for further characterisation of 
antibody responses towards drug if required by [CONTACT_49769]. Remaining blood from the samples already collected may be used for further development of Anti-Drug 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932657] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932658] 
terminates, but no longer than 15 years from EOT after which they will be destroyed.
The patients’ identity will remain confidential and the antibody samples will be identified only by 
[CONTACT_56324], visit number and trial identificati on number. No direct identification of the patient
will be stored together with the samples.
Only Novo Nordisk staff and bio-repository personnel will have access to the stored antibody 
samples.
Patients can contact [CONTACT_215591].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932659] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 139 of 143
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordi sk, as applicable, mu st promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to Investigator’s Brochure, unexpected SAEs where a causal relationship cannot be ruled out, protocol amendments 
according to local requirements, deviations to the protocol implemented to eliminate immediate 
hazards to the patients, new information that may affect adversely the safety of the patients or the conduct of the trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of the patients), annually written summaries of the trial status, and other 
documents as required by [CONTACT_1036]/IEC.
The investigator must ensure submission of the CTR synopsis to the IRB/IEC (not applicable for 
Japan).
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the patients.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_56255].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the CTR according to national requirements.3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932660] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: [ADDRESS_932661] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials  in any country, unle ss others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_535286].
Novo Nordisk accepts liability in accordance with:
Only applicable for Austria: Arzneimittelgesetz (BGBI. Nr. 185/1983) last amended with BGBl. 
II Nr. 105/2015
Only applicable for [LOCATION_009]: The French Public Health Code article L 1121-10 (law n
o 2004-[ADDRESS_932662] 2004. “The sponsor is responsible for 
identification of the harmful consequences of the biomedical research for the person lending 
himself thereto and for indemnification of his beneficiaries, except in case of proof, incumbent on it, that the prejudice is not attributable to his fau lt or the fault of any intervening party, without the 
sponsor’s being entitled to call on acts by a third party or the voluntary withdrawal of the person 
who had initially consented to cooperating in the research”.
Only applicable for Poland: Novo Nordisk carries liability for the Trial exclusively in the scope 
defined by [CONTACT_687653] 6 September 2001 (uniform version Journal pf Laws of 2008 No. 45 item 271 with 
amendments). In order to support potential claims for liability attributable to the Trial, Novo 
Nordisk and Investigators are covered by [CONTACT_136779].3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932663] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 141 of 143
27 References
1. International Conference on Harmonisation. ICH Harmonised Tripatite Guideline. Guideline 
for Good Clinical Practise E6(R2), Step 4. [ADDRESS_932664] amended by [CONTACT_941] 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.
3. International Organization for Standardization. ISO [ZIP_CODE]:2011, Clinical investigation of 
medical devices for human subjects - Good clinical practice. [ADDRESS_932665] Investigators. Am J Hematol. 1998;59(4):288-94.
5. World Federation of Hemophilia. Report on Annual Global Survey 2014.
6. White GC, 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. 
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII 
and factor IX of the scientific and standardization committee of the International Society on 
Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
7. Hoffman M, Monroe III. A cell-based model of hemostasis. Thrombosis and haemostasis. 
2001;85(6):958-65.
8. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-9.
9. Wight J, Paisley S. The epi[INVESTIGATOR_687578] A: a systematic review. 
Haemophilia. 2003;9(4):418-35.
10. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino 
acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. 
Mol Immunol. 1993;30(1):105-8.
11. Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, et al. Safety and 
pharmacokinetics of anti-TFPI [CONTACT_30936] (concizumab) in healthy volunteers and patients 
with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743-
54.
12. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
13. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007.
14. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_932666] of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 01 May 
2001.
15. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March laying down 
Community procedures for the authorisation  and supervision of medicinal products for 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932667] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 142 of 143
human and veterinary use and establishing a European Medicines Agency, article 57. 
Official Journal of the European Communities. April 2001.
16. Duncan NA, Kronenberger WG, Roberson CP, Shapi[INVESTIGATOR_71324]. VERITAS-PRN: a new 
measure of adherence to epi[INVESTIGATOR_535136]. Haemophilia. 
2010;16(1):47-53.
17. Maruish ME. User's manual for the SF-36v2 Health Survey (3rd ed.). Lincoln, RI: 
QualityMetric Inc orporated2013.
18. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin 
Psychopharmacol. 1996;[ADDRESS_932668] 3:89-95.
19. Atkinson MJ, et al. Validation of a general measure of treatment satisfaction, the Treatment 
Satisfaction Questionnaire for Medication (TSQM ), using a national pa nel study of chronic 
disease. Health Qual Life Outcomes. 2004;2:12.
20. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the 
treatment satisfaction questionnaire for med ication (TSQM version II) among outpatient 
pharmacy consumers. Value Health. 2005;[ADDRESS_932669] 1:S9-S24.
21. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of 
an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among 
patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.
22. Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid 
arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). 
Health Qual Life Outcomes. 2011;9:2.
23. Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. Official Journal 
L 1692 12/07/1993.
24. European Commission. The Rules Governing Medicinal Products in the European Union, 
Volume 4, Annex 13, Investigational Medicinal Products (ENTR/F/2/AM/an D[2010] 
3374). 03 Feb 2010.
25. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et 
al. Second symposium on the definition and management of anaphylaxis: summary report--
Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy  Clin Immunol. 2006;117(2):391-7.
26. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third 
universal definition of myocardial  infarction. Circulation. 2012;126(16):2020-35.
27. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. Current diagnosis 
of venous thromboembolism in primary care: a clinical practice guideline from the 
American Academy of Family Physicians and the American College of Physicians. Ann 
Fam Med. 2007;5(1):57-62.
28. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated 
definition of stroke for the 21st century: a statement for healthcare professionals from the 
American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064-89.
29. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition 
and evaluation of transient ischemic attack: a scientific statement for healthcare 
professionals from the American Heart Association/American Stroke Association Stroke 
Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular 
Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary 3URWRFROY
CONFIDENTIAL
Protocol
CONFIDENTIALDate: [ADDRESS_932670] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 4.0
UTN: U1111-1179-2925 Status: Final
EudraCT no.: 2016-000510-30 Page: 143 of 143
Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the 
value of this statement as an educational tool for neurologists. Stroke. 2009;40(6):2276-93.
30. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 
ACCF/AHA Focused Update of the Guideline for the Management of Patients With 
Peripheral Artery Disease (updating the 2005 guideline): a report of the American College 
of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J 
Am Coll Cardiol. 2011;58(19):2020-45.
31. U.S. Food and Drug Administration. Code of Federal Regulations, 21 CFR Part 11, 
Electronic Records, Electronic Signatures. 2009 2009.
32. Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-
inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 
2011;365(18):1684-92.
33. Levi M, Keller TT, van GE, ten CH. Infection and inflammation and the coagulation system. 
Cardiovasc Res. 2003;60(1):26-39.
34. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, Hall CL. Tissue factor 
pathway inhibitor binds to platelet t hrombospondin-1. J Biol Chem. 2000;275(41):[ZIP_CODE]-
21.
35. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. 
Arterioscler Thromb Vasc Biol. 2004;24(6):1015-22.
36. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in 
angiogenesis and cancer. Arterioscler Thromb Vasc Biol. 2005;25(8):1545-50.
37. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol. 
2005;25(1):47-56.
38. International Committee of Medical Journal Editors. Reco mmendations for the Conduct, 
Reporting, Editing, and Publication of Scholar ly Work in Medical Journals. December 
update 2016.3URWRFROY
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 1 of 14
Appendix 1
NN7415-4310
A Multi-Centre, Randomised, Open-Label, Controlled Trial 
Evaluating the Efficacy and Safety of Prophylactic Administration 
of Concizumab in Haemophilia A and B Patients with Inhibitors
Trial phase: [ADDRESS_932671] be restricted to relevant 
parties
3URWRFRODSS[
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 2 of 14
Table of Contents
Page
Table of Contents.............................................................................................................. ..........................2
1 Hemophilia Treatment Experience Measure (Hemo-TEM) ...............................................................3
2 Validated Hemophilia Regimen Treatment Adherence Scale - PRN (VERITAS-PRN®)..................6
3 36-Item Short Form Health Survey (SF-36v2) (standard) ..................................................................8
4 Patient’s Global Impression of Change (PGI-C) ................................................................................9
5 Sheehan Disability Scale (SDS) ..........................................................................................................10
6 Treatment Satisfaction Questionnaire for Medication (TSQM, version II) .....................................11
7 Injection Site Reaction Questionnaire (ISRQ) domain of SIAQ (SIAQ-ISRQ) ...............................143URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 3 of 14
1 Hemophilia Treatment Experience Measure (Hemo-TEM)
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 4 of 14
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 5 of 14
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 6 of 14
2 Validated Hemophilia Regimen Treatment Adherence Scale - PRN 
(VERITAS-PRN®)
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 7 of 14
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 8 of 14
3 36-Item Short Form Health Survey (SF-36v2) (standard)
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 9 of 14
4 Patient’s Global Impression of Change (PGI-C)
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 10 of 14
5 Sheehan Disability Scale (SDS)
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 11 of 14
6 Treatment Satisfaction Questionnaire for Medication (TSQM, 
version II)
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 12 of 14
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 13 of 14
3URWRFRODSS[
CONFIDENTIAL
Concizumab
CONFIDENTIALDate: 05 May 2017 Novo Nordisk
Trial ID: NN7415-4310 Version: 2.0
Protocol - Appendix 1 Status: Final
EudraCT No.: 2016-000510-30 Page: 14 of 14
7 Injection Site Reaction Questionnaire (ISRQ) domain of SIAQ 
(SIAQ-ISRQ)
3URWRFRODSS[
CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staff&21),'(17,$/'DWH 1RYR1RUGLVN
9HUVLRQ
6WDWXV&RQFL]XPDE
7ULDO,'11&OLQLFDO7ULDO5HSRUW
$SSHQGL[-XQH

)LQDOCONFIDENTIAL
Protocol Amendment no. 1
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 1 of 6
Protocol Amendment
no 1
to Protocol, version 1
dated 15 March 2017
Trial ID: NN7415-4310
A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and 
Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with 
Inhibitors
Trial phase: 2
Applicable to all countries
Amendment originator:
 - Senior International Trial Manager
Biopharm Trial Ops [ADDRESS_932672] be restricted to relevant parties.
3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment no. 1
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 2 of 6
Table of Contents   
Page
Table of Contents.............................................................................................................. ..........................2
1 Introduction including rationale for the protocol amendment ...........................................................3
2 Changes ....................................................................................................................... .........................33URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 1
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 3 of 6
1 Introduction including rationale for the protocol amendment
This protocol amendment has been prepared to address VHP1081 requirements to clarify individual 
discontinuation criteria, holding rules for the tr ial, protocol deviations and patient eligibility in order 
to improve safety and rights of the patients.
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
2 Changes
Individual discontinuation criteria:
Section 5.3.3 Dose escalation
Dose 0.25 mg/kg:
Patients are not dose escalated further regardless of the number of sBEs. When an sBE occurs, the 
investigator will determine if ≥ [ADDRESS_932673] occurred within the preceding 12 weeks (including the 
current sBE), counting only new sBEs from the beginning of the 0.25 mg/kg treatment period. If yes,then the patient must be discontinued due to lack of efficacy, see Section 6.4.
Section 6.[ADDRESS_932674] if the following applies:
1. Included in the trial in violation of the incl usion and/or exclusion criteria and/or randomised 
in violation of the randomisation criteria
2. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product
3. Incapacity or unwillingness to follow the trial procedures
4. Anaphylactic reaction 5. Thromboembolic event6. Event of Disseminated Intravascular Coagulation
7.Lack Loss of efficacy due to neutralizing antibodies
8.Lack of efficacy defined as ≥ [ADDRESS_932675] dose level (0.25 mg/kg) of concizumab.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 1
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 4 of 6
Holding rules for the trial:
Section 12.[ADDRESS_932676] be submitted to the 
regulatory authorities to support restart of the trial.• Significant thromboembolic event*• Event of DIC
• Anaphylactic reaction related to trial drug administration
• Death of trial patient which may be related to the trial product
• Two or more other trial product related SAEs similar in nature have been reported and/or 
detected by [CONTACT_66969]
• Trends in AEs, clinical observations or laboratory parameters which raise concerns about the 
safety of continued treatment .
Protocol deviations:
Section 19.[ADDRESS_932677] to a significant degree the safety and rights of a patient or the reliability and robustness of the data generated (potential serious breach) and if it should be reported to the Regulatory Authorities as a serious breach of GCP 
and/or the protocol.
In addition, d Deviations must be documented …
Patient eligibility 6: 
Section 1 SummaryOnly Both on-demand and prophylaxis patients will be eligible for the trial. 
Section 2.1 Visits and assessments3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 1
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 5 of 6
Section 2.2 Explanatory descriptions
Section [IP_ADDRESS] Exploratory patient reported outcome endpoints
Change in VERITAS-Pro®or VERITAS-PRN®after 24 weeks from treatment onset
Change in VERITAS-Pro®or VERITAS-PRN®after 76 weeks from treatment onset
Section 5.1 Type of trial Only Both on-demand and prophylaxis patients will be eligible for the trial. 
Section 5.2 Rationale for trial design
A total of 26 patients previously on prophylaxis  (PPX) or on-demand (OD) treatment will be 
randomised into one of the two arms, with 16 patients in the concizumab arm and 8 patients in the 
comparator arm ..
Section 6.2 Inclusion criteria
3. For p Patients currently treated on-demand with, a minimum of six bleeding epi[INVESTIGATOR_8728] 
24 weeks (or twelve bleeds during 52 weeks) prior to screening
Section 8.1.7 Visit 1 (Screening part)
After informed consent is given, patients will be asked to complete the ePRO questionnaires before 
any other trial related activities are performed accordi ng to S ection 8.6.1:
!Hemo-TEM,
3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 1
CONFIDENTIALDate: 05 May 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 6 of 6
!VERITAS-Pro® or VERITAS-PRN®
Section 8.6.1 Patient reported outcomes 
The following ePRO questionnaires will be used in the trial:
!Hemophilia Treatment Experience Measure (Hemo-TEM) 
!Validated Hemophilia Regimen Treatment Adherence Scale - Prophylaxis (VERITAS-Pro®)
or Validated Hemophilia Regimen Treatment Adherence Scale (VERITAS-PRN®) 16
The ePROs should be assessed at the scheduled visits following the order listed below:
!visit 1 (Hemo-TEM, VERITAS-Pro®or VERITAS-PRN®)
At visit 1: before any visit-related activit ies all patients should complete Hemo-TEM and 
VERITAS-Pro® (if the patient at baseline receives prophylactic treatment) or VERITAS-PRN® (if 
the patient at baseline receives on-demand treatment).
Section [IP_ADDRESS] Exploratory patient reported-outcome endpoints
!Change in Hemo-TEM after 24 weeks from treatment onset
!Change in Hemo-TEM after 76 weeks from treatment onset
!Change in VERITAS-Pro®or VERITAS-PRN®after 24 weeks from treatment onset
!Change in VERITAS-Pro®or VERITAS-PRN®after 76 weeks from treatment onset
VERITAS-Pro®or VERITAS-PRN®, SF-36v2, SDS and TSQM will be scored according to their 
respective scoring algorithms. Change from visit 2 to visit 9 will be analysed with an ANCOVA 
model including regimen as a factor and baseline score as covariate.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 1 of 12
Protocol Amendment
no 2
to Protocol, version 2
dated 05 May 2017
Trial ID:NN7415-4310
A Multi-Centre, Randomised, Open-Label, Co ntrolled Trial Evaluating the Efficacy and
Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with
Inhibitors
Trial phase: [ADDRESS_932678] be restricted to relevant 
parties.
3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 2 of 12
Table of Contents
1 Introduction including rationale for the protocol amendment ...........................................................3
2 Changes ....................................................................................................................... .........................43URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 3 of 12
1 Introduction including rationale for the protocol amendment
This protocol amendment has been prepared to address: 
!Section 2.2, [IP_ADDRESS], [IP_ADDRESS] and [IP_ADDRESS] ‘Concizumab ELISA’ updated due to concizumab 
PK has been added to the trial in order to obtain PK-profile of daily dosing with concizumab 
after initiation of multiple dosing
!Section [IP_ADDRESS] and Section [IP_ADDRESS] ‘Exploratory patient reported-outcome endpoints’ 
updated as VERITAS-PRN is not assessed at visit 9 and visit 16 and PGI-C is not assessed 
at visit 1 and visit 16
!Section 5.3.6 ‘Prohibited medication’ is updated because the use of anti-fibrinolytics is 
commonly local/topi[INVESTIGATOR_687605]. 
A single systemic dose may be needed: Tranexamic acid has been used to reduce bleedings during orthopaedic surgery and trauma  bleed without causing additional major 
thrombotic risks. It is also used in haemophilia patients during severe bleeding epi[INVESTIGATOR_1841]. 
It is therefore considered adequate to allow a single dose after careful benefit risk 
evaluation by [CONTACT_093].
!Section [IP_ADDRESS] ‘Anti-concizumab antibodies’ updated to provide clarity on when a patient is 
considered to be positive for binding antibodies as this is difficult to interpret with current 
text in version 2.0 of the protocol if reader is not in possession of thorough knowledge on 
the different tests described
!Section 9.4 ‘Drug accountability and destruction’ updated to ensure solvent does not reach 
expi[INVESTIGATOR_687606]’s custody this includes clarification in relevant visits described in 
section 8 
o8.1.11.1; [IP_ADDRESS]; [IP_ADDRESS]; [IP_ADDRESS]; [IP_ADDRESS]; [IP_ADDRESS]; [IP_ADDRESS]; [IP_ADDRESS]; [IP_ADDRESS]; 
[IP_ADDRESS]; [IP_ADDRESS]; [IP_ADDRESS]; 8.1.13
!Section 18.1 ‘Benefit-risk assessment of the trial’ updated to specify the minimum 
difference in plasma concentration between the NOAEL in non-haemophilic animals and 
highest anticipated plasma concentration in phase 2
!Clarifications and corrections which are seen as being minor
oList of abbreviations; Figure 8-1 and Figure 8-2; Section 2.1; 2.2; 3.1.1; [IP_ADDRESS]; 
[IP_ADDRESS]; [IP_ADDRESS]; [IP_ADDRESS]; 8.5; [IP_ADDRESS]; 12.7
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nove mber 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: [ADDRESS_932679] of abbreviations
Hemo-TEM Hemophilia Treatment Experience Measure
ISRQ-SIAQ Injection Site Reaction Questionnaire - Self-Injection
Assessment Questionnaire
PGI-C Patient’s Global Impression of ChangeSDS Sheehan Disability ScaleSF-36v2 36-Item Short Form Health Survey
TSQM Treatment Satisfaction Questionnaire for Medication 
VERITAS-PRN
® Validated Hemophilia Regimen Treatment Adherence Scale
Section 2.1 Visits and assessments
explorerTM4 trial periodsScreeni
ngTreatment main a, bTreatment extension b Follo
w-up
Visit number c1 2 3 4 5 6 7 89
9.1d9.2d1010.1d1111.1d12 13 141516Un-
schedul
ed e17
Timing of visits (d) f14 to 28 
d 
before
visit 21 8 29 57 85 113 141 169176
7 days 
after 
V9197 225 253 281 309 337 393 449505533When 
applica
ble589
Visit window (d)14 to 28 
d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7±7±7Not 
applica
ble-7
Treatment week (w) 0 1w 4w 8w 12w 16w 20w 24w 25w 28w 32w 36w 40w 44w 48w 56w64
w72
w76w - 84w
PATIENT RELATED 
INFO/ASSESSMENTS
Informed consent/ Genotypi[INVESTIGATOR_687607]-term storage consent●
In/exclusion criteria ●●g
Demography ●
Concomitant illness/Medical history ●
Concomitant medication ●●●●●●●●●●●●●●●●●●●●●●
Details of Haemophilia/Haemophilia 
treatment and bleed history●
Withdrawal criteria/ Criteria for 
premature discontinuation of trial 
product●●●●●●●●●●●●●●●●●●●●●
Randomisation (IWRS) ●
EFFICACY
Bleeding epi[INVESTIGATOR_1841] h, i●●●●●●●●●●●●●●●●●●●●●
Thrombin generation (central lab) ●●l●j, k, l●●●●●●l●j●●●●●●●●●●l●●
Free TFPI (central lab)  ●●l●k, l●●●●●●l●●●●●●●●●●●l●●
SAFETY
Physical examination ●●●k●● ● ●●●
Body measurements ●●m●k, m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m
Vital signs ●●n●k, n●●●●●●n●n●●●●●●●●●●●●
ECG ●
Adverse events ●●●●●●●●●●●●●●●●●●●●●●
Injection site reaction  ●●k●●●●●●●●●●●●●●●●●●3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 5 of 12
explorerTM4 trial periodsScreeni
ngTreatment main a, bTreatment extension b Follo
w-up
Visit number c1 2 3 4 5 6 7 89
9.1d9.2d1010.1d1111.1d12 13 141516Un-
schedul
ed e17
Timing of visits (d) f14 to 28 
d 
before
visit 21 8 29 57 85 113 141 169176
7 days 
after 
V9197 225 253 281 309 337 393 449505533When 
applica
ble589
Visit window (d)14 to 28 
d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7±7±7Not 
applica
ble-7
Treatment week (w) 0 1w 4w 8w 12w 16w 20w 24w 25w 28w 32w 36w 40w 44w 48w 56w64
w72
w76w - 84w
Urinalysis (local lab) ●
Haematology (local lab) ●●l●j, k, l●●●●●●l●j●●●●●●●●●●l●●
Biochemistry (central lab) ●●l●k, l●●●●●●l●●●●●●●●●●●l●●
FVIII/ FIX activity (central lab)●●l●l
Coagulation parameters (central lab) ●●l●●●●●●l●●●●●●●●●●l●●
Coagulation parameters (PT, APTT 
and Fibrinogen (local lab))●j, k, l●j
FVIII/FIX  inhibitors (central lab)●●l●l
Anti-concizumab antibodies (ADA) 
(special lab) o ●●l●k, l, p●p●p●p●p●p●l, p●●●●●●●●●●●l●●
Concizumab  ELISA (special lab) ●l●j, k, l,
p●p●p●p●p●p●l, p●j●●●●●●●●●●l●●
FVII ELISA (special lab) ●j, k, l●j
Total TFPI (special lab) ●●l●k, l●●●●●●l●●●●●●●●●●●l●●
TRIAL MATERIAL
IWRS call ●●●k●●●●●●●●●●●●●●●●●●●
Dispensing visit (concizumab)r●k●k●k●k●k●k●k●●●●●●●●●●● ●
Dispensing visit (eptacog alfa, 
histidine)q ●●w●k● ●● ● ● ●●●●●●
Administration of trial product 
(concizumab)r ●k, s●k●d, s ● ●s●
Administration of trial product 
(eptacog alfa)●k, t●t
Drug accountability (concizumab) ●k●k●k●k●k●k●k●●●●●●●●●●●●
Drug accountability (eptacog alfa) ●●k●●●●●●●●●●●●●●●●●●●
New dose of trial product e, u●●●●●● ●●●●●●●●● ●
PRO questionnaires ●●●k●●●●●● ● ●
REMINDERS
Human biological specimen for 
storage (central lab)● ●
Handout ID card ●
Training v●● ●● ●
Compliance: eDiary ●●●●●●●●●●●●●●●●●●●●
End of treatment ●
End of trial ●3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 6 of 12
Section 2.2 Explanatory descriptions
Footer ‘d’: Visit and procedures only performed for patients randomised to eptacog alfa and 
switching to concizumab treatment. Visit 9.1 should be performed 7 days (+ 1 day) after visit 9.
Footer ‘j’: Sampling time schedule for thrombin generation, haematology,  coagulation parameters,  
concizumab ELISA and FVII ELISA: pre-dose (-1 hour), post-dose: 10 min (±2 min), 1h (± 10 min), 
3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points, 
except pre-dose, occur after eptacog alfa administration.Footer ‘k’: ONLY for patients randomised to concizumab arm. The concizumab dose should be 
administered first followed by [CONTACT_687654]. The interval between the concizumab and eptacog 
alfa should not exceed more than 30 min. 
Footer ‘l’: At visit 2, visit 3, visit [ADDRESS_932680] not treat themselves with concizumab until sampling has been performed.
Footer ‘t’: Eptacog alfa administered in a non-bleeding state at site at visit [ADDRESS_932681] (concizumab): Dot and ‘s’ footnote added to visit 16 
Section 3.1.1 Haemophilia
Haemophilia is classified as “severe”, “m oderate” or “mild” according to the plasma activity level
of the affected coagulation factor. 
Section [IP_ADDRESS] Exploratory patient reported outcome endpoints
!Change in Hemo-TEM after 24 weeks from treatment onset
!Change in Hemo-TEM after 76 weeks from treatment onset
!Change in VERITAS-PRN® after 24 weeks from treatment onset
!Change in VERITAS-PRN® after 76 weeks from treatment onset
!Change in SF-36v2 after 24 weeks from treatment onset
!Change in SF-36v2 after 76 weeks from treatment onset
!Change in SDS after 24 weeks from treatment onset
!Change in SDS after 76 weeks from treatment onset
!Change in TSQM after 24 weeks from treatment onset
!Change in TSQM after 76 weeks from treatment onset
!Change in SIAQ-ISRQ after 24 weeks from treatment onset
!Change in SIAQ-ISRQ after 76 weeks from treatment onset
!Status of Change in PGI-C after 24 weeks from treatment onset
!Change in PGI-C after [ADDRESS_932682] 24 weeks, will be evaluated 
in the main part of the trial. 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 7 of 12
Section 5.3.6 Prohibited medication 
!Treatment with anti-fibrinolytics (e.g. tranexamic acid, aminocaproic acid) *
!Heparin, except for sealing of central venous access ports according to local practice
!Vitamin-K antagonists
!Direct oral anticoagulants (DOACs)
!Home treatment (between visit 2 and visit 16) with activated prothrombin complex 
concentrates (FEIBA®)
* Local/topi[INVESTIGATOR_535169]. Use of single systemic doses in severe bleeding epi[INVESTIGATOR_1841], after careful benefit risk 
evaluation, is allowed.
Section 8; Figure 8-1 and Figure 8-2.
Figure 8.1
Figure 8.2
3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 8 of 12
Section [IP_ADDRESS] Visit 2 (Randomisation)
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa) during the 
trial as instructed by [CONTACT_093]. Drug accountability must be performed for eptacog alfa 
(rFVIIa), if applicable according to section 9.4. Unused histidine syringes should be returned at 
every visit and new histidine syringes should be dispensed to the patient.
Section [IP_ADDRESS] Visit 3 (Phone call for eptacog alfa (rFVIIa) on-demand arm and PK visit for 
concizumab arm)
Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa) administration dosing.
The concizumab dose should be administered first followed by [CONTACT_687654]. eptacog alfa 
(rFVIIa) should be administered to the trial patients at the site under the surveillance of medically trained trial site staff. The interval between the concizumab and eptacog alfa dose administration 
should not exceed more than 30 min. Patient should continue his daily concizumab injections 
regardless of eptacog alfa (rFVIIa) administration.
Samples for thrombin generation, haematology, coagulation parameters, concizumab ELISA and 
FVII ELISA are taken pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (±20 min) and 
24h (±20 min).
The investigator must ensure thatall assessments are performed as described in Section 2, The 
Investigator is requested to conclude after [ADDRESS_932683] the conclusion in the eCRF prior to administration of the before next dose ofwith  
concizumab is given the day after.
…
The patient will be asked to return all used, partly used and unused concizumab cartridges and eptacog alfa (rFVIIa) during the trial as instructed by  [CONTACT_093]. Dr ug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
Section [IP_ADDRESS] Visit 4, 5, 6, 7 and 8
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Dr ug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
Section [IP_ADDRESS] Visit 9
The patient will be asked to return all used, partly used and unused concizumab and eptacog alfa 
(rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be performed 
for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned at every 
visit and new histidine syringes should be dispensed to the patient.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 9 of 12
Section [IP_ADDRESS] Visit 9.1 (PK visit and ONLY patients previously on the eptacog alfa (rFVIIa) 
on-demand arm)
Vital signs are assessed within 1 hour before and after eptacog alfa (rFVIIa) administration dosing.
The concizumab dose should be taken first followed by [CONTACT_687654]. eptacog alfa (rFVIIa) 
should be administered at the site under the surveillance of medically trained trial site staff. The 
interval between the concizumab and eptacog alfa dose administration should not exceed more than 
30 min. Patient should continue his daily concizumab injections regardless of eptacog alfa (rFVIIa) 
administration.
…
Samples for thrombin generation, h aematology, coagulation parameters, concizumab ELISA and 
FVII ELISA are taken pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9 h (± 10 min) and 12h (±20 min) and 24h (±20 min).
TheInvestigator is requested to conclude after [ADDRESS_932684] the conclusion in the eCRF prior to administration of before the next dose of 
concizumab is given the day after.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by  [CONTACT_093]. Dr ug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
Section [IP_ADDRESS] Visit 9.2 (ONLY patients previously on the eptacog alfa (rFVIIa) on-demand 
arm)
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by  [CONTACT_093]. Dr ug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
Section [IP_ADDRESS] Visit 10
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
Section [IP_ADDRESS] Visit 10.1 (ONLY patients previously on the eptacog alfa (rFVIIa) on-demand 
arm)
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by  [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 10 of 12
Section [IP_ADDRESS] Visit 11
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by  [CONTACT_093]. Dr ug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
Section [IP_ADDRESS] Visit 11.1 (ONLY patients previously on the rFVIIa on-demand arm) 
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by  [CONTACT_093]. Dr ug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
Section [IP_ADDRESS] Visit 12, 13, 14 and 15
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by  [CONTACT_093]. Drug  accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned 
at every visit and new histidine syringes should be dispensed to the patient.
Section [IP_ADDRESS] Visit [ADDRESS_932685] after the blood sampling at this visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed  by [CONTACT_093]. NovoPen®[ADDRESS_932686] be performed for concizumab and eptacog alfa (rFVIIa). Unused 
histidine syringes should be returned at every vis it and new histidine syringes should be dispensed 
to the patient.
Section 8.1.13 Visit 17 (End of trial) - Follow-up part
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa), unused 
histidine syringes , eDiary device and Tria l card. Drug accountability must be performed for eptacog 
alfa (rFVIIa).
Section 8.5 Laboratory assessments
An approximate total blood volume of 625725 mL will be taken from each patient on the 
concizumab arm and 725625 mL from each patient on the eptacog alfa (rFVIIa) arm.
Section [IP_ADDRESS] Free TFPI
[INVESTIGATOR_687557] (TFPI [INVESTIGATOR_535096]) will be collected at all visits, pre-dose at visit 2 and 3 
(concizumab arm) ,and visit 9 and 9.1 (eptacog alfa (rFVIIa) arm) and visit 16 .3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 11 of 12
Section [IP_ADDRESS] Anti-concizumab antibodies
Analysis for ADA will be done with a bridging ECL assay (binding ADA assay), using labelled 
concizumab for antibody capture and detection. If a sample is confirmed positive in the 
confirmatory assay, the sample is considered positive for binding antibodies. Confirmed positive 
samples will be characterised in a specificity assay for binding to IgG backbone, CDR region or the 
S241P mutatio n. Furthermore, positive samples w ill be chara cterised for neutr alising activity using 
a modified TFPI [INVESTIGATOR_687599] y (neutralising ADA assay). All anti body assays are validated 
according to international guidelines and recommendations.
A detailed description of the assay methods will be included in the antibody analysis report at the 
end of the trial.Investigators will be notified in case their patient is shown to have developed neutralising antibodies against concizumab.
In the event that a trial patient develops binding ADAs towards concizumab during the course of the 
trial and has measurable binding ADAs at his End-of-Trial visit, the patient may attend an ADA follow-up visit.
Section [IP_ADDRESS] Concizumab ELISA
Concizumab ELISA will be collected at all visits where except at screening patients are in treatment 
with only for the concizumab arm.
Samples will be collected pre-dose at visit 2 and 3 for concizumab arm and visit 9 and 9.1 for 
eptacog alfa (rFVIIa) arm) and visit 16 for both arms.
At visit 3 for concizumab arm and visit 9.1 for eptacog alfa arm samples for concizumab ELISA are taken pre-dose eptacog alfa (rFVIIa) (-1 hour) and post-dose eptacog alfa (rFVIIa): 10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (±20 min) and 24h (±20 min).
Section 9.4 Drug accountability and destruction
Drug accountability of all trial products (concizumab and eptacog alfa (rFVIIa) received at site is 
the responsibility of the investigator. The patient will be asked to return all used, partly used and 
unused trial product during the trial as in structed by [CONTACT_093], except for used histidine
syringes which should be discarded at home and not accounted for. Unused histidine syringes 
should be returned at every visit and new histidine syringes should be dispensed to the patient.
Section 12.[ADDRESS_932687] be submitted to the 
regulatory authorities to support restart of the trial.
!Significant thromboembolic event*3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no. 2
CONFIDENTIALDate: 15 Nov ember 2017 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT no: 2016-000510-30 Page: 12 of 12
!Event of DIC
!Anaphylactic reaction related to trial drug administration
!Death of trial patient which may be related to the trial product
!Two or more other trial product related SAEs similar in nature have been reported and/or 
detected by [CONTACT_66969]
!Trends in AEs, clinical observations or laboratory parameters which raise concerns about 
the safety of continued treatment. 
*Superficial thrombophlebitis or venous thrombosis associated with indwelling catheters is not considered a significant 
thromboembolic event unless evaluated as such by [CONTACT_535253]/or detected 
by [CONTACT_66969], or if trends in AE s, clinical observations or laboratory parameters 
raise concerns about the safety of continued treatment, the safety co mmit tee (see Section 12.8.1) 
will decide if further dosing of any patients in the clinical trial programme should be continued, 
paused or discontinued.
Section [IP_ADDRESS] Exploratory patient reported-outcome endpoints
!Change in Hemo-TEM after 24 weeks from treatment onset
!Change in Hemo-TEM after 76 weeks from treatment onset
!Change in VERITAS-PRN® after 24 weeks from treatment onset
!Change in VERITAS-PRN® after 76 weeks from treatment onset
!Change in SF-36v2 after 24 weeks from treatment onset
!Change in SF-36v2 after 76 weeks from treatment onset
!Change in SDS after 24 weeks from treatment onset
!Change in SDS after 76 weeks from treatment onset
!Change in TSQM after 24 weeks from treatment onset
!Change in TSQM after 76 weeks from treatment onset
!Change in SIAQ-ISRQ after 24 weeks from treatment onset
!Change in SIAQ-ISRQ after 76 weeks from treatment onset
!Status of Change in PGI-C after 24 weeks from treatment onset
!Change in PGI-C after [ADDRESS_932688] level (NOAEL) for concizumab has been identified in non-haemophilic animals at plasma concentrations at least 24 several folds higher than the currently 
anticipated effective plasma concentration (mean area under curve [AUC] and Cmax) based on PK 
modelling.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932689] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 1 of 31
Protocol Amendment
no 3
to Protocol, final version 3
dated 15 November 2017
Trial ID: NN7415-4310
A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and
Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with 
Inhibitors
Trial phase: 2
Applicable to all countries
Amendment originator:
, International Trial Manager
Biopharm Trial Ops [ADDRESS_932690] be restricted to relevant parties.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932691] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 2 of 31
Table of Contents  
Page
Table of Contents.............................................................................................................. ..........................2
1 Introduction including rationale for the protocol amendment and informed consent ......................3
2 Changes ....................................................................................................................... .........................6
2.1 Protocol .................................................................................................................... ................6
2.2 Informed Consent ....................................................................................................................28
2.2.1 Master  Informed Consent .......................................................................................28
2.2.2 Genot ypi[INVESTIGATOR_535029]-term Storage of Human Samples Informed Consent 
(page [ADDRESS_932692] paragraph)...........................................................................................[ADDRESS_932693] in Case of an Abnormal Pregnancy Informed 
Consent (page [ADDRESS_932694] paragraph) .............................................................................303URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932695] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 3 of 31
1 Introduction including rationale for the protocol amendment and 
informed consent
The intention of this amendment is to provide patients current in an ongoing trial the option their 
participation in the trial being prolonged. During the prolongations the patients will be offered to be 
screened for eligibility for a subsequent clinical trial with concizumab. Further more additional 
clarification is made to the section of permanently premature discontinuation to ensure that patients 
with a safety concern are being followed until resolu tion or planned LPLV. Finally there is a change 
in the reporting to investigators about Anti-drug antibodies towards concizumab (ADA) to ensure 
that investigators are informed at an earlier time point than originally described.
Sections affected
Sections 1, 2, 5.1, 5.1 (Figure 5-1), 5.3 (Fi gures 5-3 and 5-4), 5.3.3, 5.3.4, 5.5, 7 and 17.5 (Fi gure 
17-1) are updated to reflect the prolongation of the extension part to offer patients the possibility of being screened for eligibility to participate in the subsequent clinical trials for concizumab provided 
that either the study site participates in the subsequent trial programme or the patient can be
transferred to a participating site.  
Sections [IP_ADDRESS], [IP_ADDRESS], 17.4.1, 17.4.2, 17.4.3, 17.4.4 and [IP_ADDRESS] are updated to include the 
additional treatment week s in the prolongation of the ex tension part. Currently the trial only 
accounts for [ADDRESS_932696] 76 week s in total. 
Section 5.2, ‘Rationale of the trial design’ has been updated with an option ofor patients being 
screened for eligibility for a subsequent clinical trial based on site availability or if transferred to a 
participating site in the new trial. 
Section 5.3 ‘Treatment of patients’, Table 5-[ADDRESS_932697] the extended use of 
concizumab based on the prolongation of the trial. 
Section 8 (Figures 8-1 and 8-2 ), 8.1, [IP_ADDRESS], [IP_ADDRESS], 8.1.[ADDRESS_932698] been added to the trial. Between visit 15 and visit 16
(End of Treatment) additional visits have been added with 8 week intervals. Visit numbering is as following: 15, 15.1, 15.2, 15.n up to a maximum of 5 additional visits or un til a s ubsequent clinical 
trial with concizumab is open for recruitment. When the patient can be enrolled in the trial the 
patient is scheduled for visit 16 and can from here be enro lled in the new trial. 
Section 8.1.4 and 8.1.14‘Premature discontinuation of trial product’ has been updated as well as 
‘Unscheduled Visit’ to provide the option of following patients who has permanently prematurely discontinue trial product due to a safety concern after visit 17 (End of trial). The purpose of the 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932699] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: [ADDRESS_932700] additional safety information, if applicable. The additional follow up period may 
not be continued after the planned LPLV in Section 7, Milestones as described in section 8.1.4.
Section [IP_ADDRESS] and 8.6.[ADDRESS_932701] ePRO 
questionnaires at visit 16. 
Section [IP_ADDRESS] ‘anti-concizumab antibodies’ is updated to ensure that investigators are informed 
about any positive results of binding antibodies against concizumab and not only of neutralising 
antibodies towards concizumab as binding ADAs can affect PK of concizumab and thus efficacy 
and safety as well.
Section 8.6.1 ‘Patient reported outcome’ the requiremen t of the investigator to review the ePROs 
for AEs and SAEs after completion has been removed as  it is not possible for the patient to add own 
text to the ePROs.
Section 12.1.1 ‘Adverse event’ has been updated due to a leftover in the standard text from former 
trials where i.v. administration was the treatment being investigated. As current trial is investigating a new route of administration, subcutaneous, in jection site reactions including haematomas are AEs 
requiring additional data collection.
12.2 ‘Reporting of adverse events’ has been updated to specify the AE reporting requirements if the 
patients will be enrolled in a subsequent trial with concizumab or not. Furthermore the section has 
been updated to accommodate the latest requirements in regards to Novo Nordisk assessment of AE expectedness. For patients enrolling into a new trial with concizumab any AEs reported after visit 
16 will be reported in the new trial.  
Section 12.7 ‘Rules for putting enrolment on hold’ has per request from the Safety Committee been 
updated by [CONTACT_535310]. The footnote was not clear enough in regards to if 
thromboembolic events are considered significant or not
Section 17, 17.3.1 and 17.3 ‘S tatistical consider ations’ has been updated due to technical details 
related to selection of bleeds and estimation of offset has been added
Section [IP_ADDRESS], Exploratory patient reported-outcome  endpoints, are updated as the questionnaire 
VERITAS-PRN is only assessed at visit 1 and th erefore no change in outcome can be analysed. 
Main Informed consent is updated for give the patient the option of continuing in the trial after 76 
weeks of treatment has passed. By [CONTACT_687668] p atient may stay in the trial for up to 118 weeks
of treatment and be given the possibility to parti cipate in a subsequent trial with concizumab if he is 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932702] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 5 of 31
eligible and site continues in the trial or he can be transferred to a participating site. Furthermore 
has the GDPR (patient confidentiality) standard text been added as required.
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932703] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 6 of 31
2 Changes
2.1 Protocol
Section 1 Summary 
Time frames for evaluation of Objectives/Endpoints
All endpoints referring to the time frame of at least [ADDRESS_932704] (or has withdrawn). In addition, number of bleeding epi[INVESTIGATOR_687608] 76 weeks of treatment with prophylactic concizumab will be analysed. The extension part of 
the trial will provide additional safety and long-term efficacy data.
Section 1 Summary
Trial design
The total trial duration for the individual patient will be approximately 86-88 -130 weeks, consisting 
of a 2-4 week screening period, a subsequent 76- 118week treatment period and an 8-week follow-
up period. eptacog alfa (rFVIIa) for treatment of bleed ing epi[INVESTIGATOR_687609]. The patient will not be provided with trial product or eptacog alfa (rFVIIa) after end of trial.
The trial is split into a main part which lasts at least [ADDRESS_932705] completed a minimum of 24 weeks of treatment with 
eptacog alfa (rFVIIa) on-demand or have withdrawn. The analysis of the main part of the trial aims 
to substantiate the clinical proof of concept (CPoC) that concizumab has the potential to prevent 
bleeding epi[INVESTIGATOR_687610]. The extension part of the trial will provide additional safety and long-term efficacy data.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3 UTN: U1111 -1179-2925 Date: [ADDRESS_932706] 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932707] No.: 2016-000510-30 Version: 1.0 Page: 7 of 31
Section 2 Flow chart with deletions (strike through)
explorerTM4 trial periods Screening Treatment main a,bTreatment extension bFollow-up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16 Un-scheduled e17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169 176 197 225 253 281 309 337 393 449 505 533 When applicable 589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1w 4w 8w 12w 16w 20w 24w 25w 28w 32w 36w 40w 44w 48w 56w 64w 72w 76w - 84w
PATIENT RELATED INFO/ASSESSMENTS
Informed consent/ Long-term storage consent ●
In/exclusion criteria ● ●g
Demography ●
Concomitant illness/Medical history ●
Concomitant medication ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Details of Haemophilia/Haemophilia treatment and bleed history ●
Withdrawal criteria/ Criteria for premature discontinuation of trial product ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Randomisation (IWRS) ●
EFFICACY
Bleeding epi[INVESTIGATOR_1841] h, i● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Thrombin generation (central lab) ● ●l●j, k, l● ● ● ● ● ●l●j● ● ● ● ● ● ● ● ● ●l● ●
Free TFPI (central lab)  ● ●l●k, l● ● ● ● ● ●l● ● ● ● ● ● ● ● ● ● ●l● ●
SAFETY
Physical examination ● ● ●k● ● ● ● ● ●
Body measurements ● ●m●k, m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m
Vital signs ● ●n●k, n ● ● ● ● ●●n●n● ● ● ● ● ● ● ● ● ● ● ●
ECG ●
Adverse events ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Injection site reaction  ● ●k ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●
Urinalysis (local lab) ●
Haematology (local lab) ● ●l●j, k, l● ● ● ● ● ●l●j● ● ● ● ● ● ● ● ● ●l● ●
Biochemistry (central lab) ● ●l●k, l● ● ● ● ● ●l● ● ● ● ● ● ● ● ● ● ●l● ●
FVIII/ FIX activity (central lab) ● ●l●l
Coagulation parameters (central lab) ● ●l● ● ● ● ● ●l● ● ● ● ● ● ● ● ● ●l● ●
Coagulation parameters (PT, APTT and Fibrinogen (local lab)) ●j, k, l●j
FVIII/FIX  inhibitors (central lab) ● ●l●l
Anti-concizumab antibodies (ADA) (special lab) o● ●l●k, l, p●p●p●p●p●p●l, p● ● ● ● ● ● ● ● ● ● ●l● ●
Concizumab  ELISA (special lab) ●l●j, k, l, p●p●p●p●p●p●l, p●j● ● ● ● ● ● ● ● ● ●l● ●
FVII ELISA (special lab) ●j, k, l●j
Total TFPI (special lab) ● ●l●k, l● ● ● ● ● ●l● ● ● ● ● ● ● ● ● ● ●l● ●
TRIAL MATERIAL
IWRS call ● ● ●k● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Dispensing visit (concizumab)r●k●k●k●k●k●k●k● ● ● ● ● ● ● ● ● ● ● ●
Dispensing visit (eptacog alfa, histidine)q● ●w●k● ● ● ● ● ● ● ● ● ● ●
Administration of trial product (concizumab)r●k, s●k●d, s ● ●s●
Administration of trial product (eptacog alfa) ●k, t●t
Drug accountability (concizumab) ●k●k●k●k●k●k●k● ● ● ● ● ● ● ● ● ● ● ●
Drug accountability (eptacog alfa) ● ●k● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
New dose of trial product e, u● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
PRO questionnaires ● ● ●k● ● ● ● ● ● ● ●
REMINDERS
Human biological specimen for storage (central lab) ● ●3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3 UTN: U1111 -1179-2925 Date: [ADDRESS_932708] 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932709] No.: 2016-000510-30 Version: 1.0 Page: 8 of 31
explorerTM4 trial periods Screening Treatment main a,bTreatment extension bFollow-up
Visit number c1 2 3 4 5 6 7 8 9 9.1d9.2d10 10.1d11 11.1d12 13 14 15 16 Un-scheduled e17
Timing of visits (d) f14 to 28 d 
before
visit 21 8 29 57 85 113 141 169 176 197 225 253 281 309 337 393 449 505 533 When applicable 589
Visit window (d)14 to 28 d 
before
visit 20 +1 ±7 ±7 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) [ADDRESS_932710] ●
Training v● ● ● ● ●
Compliance: eDiary ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
End of treatment ●
End of trial ●
Section 2 Flow chart with updates (italics)
4310 trial periods Screening Treatment main a, bTreatment extension bFollow-up
Visit number c1 2 3 4-5 6 7-8 9 9.1d9.2d10 10.1d11 11.1d12 13-1415, 15.1, 
15.2, 15.nw 16 Unscheduled e17x
Timing of visits (d) f14 - 28 d before
visit 2 1 8 29-57 85 113-141 169 176 197 225 253 281 309 337 393-449 505-785Up to
827When applicableUp to
883
Visit window (d)14 - 28 d before
visit 20 +1 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1w Every 4w 12w Every 4w 24w 25w 28w 32w 36w 40w 44w 48 w Every 8w Every 8w Up to  118w - Up to 126w
PATIENT RELATED INFO/ASSESSMENTS
Informed consent/ Long-term storage consent ●
In/exclusion criteria ● ●g
Demography ●
Concomitant illness/Medical history ●
Concomitant medication ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Details of Haemophilia/Haemophilia treatment and bleed history ●
Withdrawal criteria/ Criteria for premature discontinuation of trial product ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Randomisation (IWRS) ●
EFFICACY
Bleeding epi[INVESTIGATOR_1841] h, i● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Thrombin generation (central lab) ● ●l●j, k, l● ● ● ●l●j● ● ● ● ● ● ● ● ●l● ●
Free TFPI (central lab)  ● ●l●k, l● ● ● ●l● ● ● ● ● ● ● ● ● ●l● ●
SAFETY
Physical examination ● ● ●k● ● ● ● ● ●
Body measurements ● ●m●k, m●m●m●m●m●m●m●m●m●m●m●m●m●m●m●m
Vital signs ● ●n●k, n ● ● ●●n●n● ● ● ● ● ● ● ● ● ● ●
ECG ●
Adverse events ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Injection site reaction  ● ●k ● ● ●● ● ● ● ● ● ● ● ● ● ● ●
Urinalysis (local lab) ●
Haematology (local lab) ● ●l●j, k, l● ● ● ●l●j● ● ● ● ● ● ● ● ●l● ●
Biochemistry (central lab) ● ●l●k, l● ● ● ●l● ● ● ● ● ● ● ● ● ●l● ●
FVIII/ FIX activity (central lab) ● ●l●l
Coagulation parameters (central lab) ● ●l● ● ● ●l● ● ● ● ● ● ● ● ●l● ●
Coagulation parameters (PT, APTT and Fibrinogen (local lab)) ●j, k, l●j
FVIII/FIX  inhibitors (central lab) ● ●l●l
Anti-concizumab antibodies (ADA) (special lab) o● ●l●k, l, p●p●p●p●l, p● ● ● ● ● ● ● ● ● ●l● ●3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3 UTN: U1111- 1179-2925 Date: [ADDRESS_932711] 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932712] No.: 2016-000510-30 Version: 1.0 Page: 9 of 31
4310 trial periods Screening Treatment main a, bTreatment extension bFollow-up
Visit number c1 2 3 4-5 6 7-8 9 9.1d9.2d10 10.1d11 11.1d12 13-1415, 15.1, 
15.2, 15.nw 16 Unscheduled e17x
Timing of visits (d) f14 - 28 d before
visit 2 1 8 29-57 85 113-141 169 176 197 225 253 281 309 337 393-449 505-785Up to
827When applicableUp to
883
Visit window (d)14 - 28 d before
visit 20 +1 ±7 ±7 ±7 ±7 +1 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7Not 
applicable-7
Treatment week (w) 0 1w Every 4w 12w Every 4w 24w 25w 28w 32w 36w 40w 44w 48 w Every 8w Every 8w Up to  118w - Up to 126w
Concizumab  ELISA (special lab) ●l●j, k, l, p●p●p●p●l, p●j● ● ● ● ● ● ● ● ●l● ●
FVII ELISA (special lab) ●j,k, l●j
Total TFPI (special lab) ● ●l●k, l● ● ● ●l● ● ● ● ● ● ● ● ● ●l● ●
TRIAL MATERIAL
IWRS call ● ● ●k● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Dispensing visit (concizumab)r●k●k●k●k●k● ● ● ● ● ● ● ● ● ● ●
Dispensing visit (eptacog alfa, histidine)q● ●k● ● ● ● ● ● ● ● ● ●
Administration of trial product (concizumab)r●k, s●k●d, s ● ● s●
Administration of trial product (eptacog alfa) ●k, t●t
Drug accountability (concizumab) ●k●k●k●k●k● ● ● ● ● ● ● ● ● ● ●
Drug accountability (eptacog alfa) ● ●k● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
New dose of trial product e, u● ● ● ● ● ● ● ● ● ● ●●●
PRO questionnaires ● ● ●k● ● ● ● ● ●z● aa
REMINDERS
Human biological specimen for storage (central lab) ● ●
Handout ID card ●
Training v● ● ● ● ●
Compliance: eDiary ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
End of treatment●
End of trial ●y●y
Footer Description
a There is staggered recruitment for the [ADDRESS_932713] according to patient’s individual training need on concizumab administration, NovoPen®4, eDiary training etc. Visit [ADDRESS_932714] a PK session of 24 hours and a safety follow up visit the following day. 
dVisit and procedures only performed for patients randomised to eptacog alfa and switching to concizumab treatment.Visit 9.1 sho uld be performed 7 days (+ 1 
day) after visit 9.
e For patients being dose escalated on concizumab a phone call is recommended [ADDRESS_932715] be registered in the eCRF.
i Eptacog alfa will be given to treat breakthrough bleeding epi[INVESTIGATOR_1841]. 
jSampling time schedule for thrombin generation, haematology,  coagulation parameters, concizumab ELISA and FVII ELISA: pre-dose  (-1 hour), post-dose: 
10 min (±2 min), 1h (± 10 min), 3h (± 10 min), 6h (± 10 min), 9h (± 10 min), 12h (± 20 min) and 24h (± 20 min). All time points , except pre-dose, occur after 
eptacog alfa administration.
kONLY for patients randomised to concizumab arm. The concizumab dose should be administered first followed by [CONTACT_687654].  The interval between the 
concizumab and eptacog alfa should not exceed more than [ADDRESS_932716] not treat themselves with concizu mab until sampling has been 
performed.
m Only body weight should be measured. 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3 UTN: U1111- 1179-2925 Date: [ADDRESS_932717] 2018 Status: Final 1RYR1RUGLVN
Trial ID: NN7415-[ADDRESS_932718] No.: 2016-000510-30 Version: 1.0 Page: 10 of 31
nVital signs should be evaluated before and after trial drug administration at visit 2 and visit 3 for concizumab arm and at vis it 9 and visit 9.1 for patients in 
eptacog alfa arm switching to concizumab treatment.
oIn case clinical signs of e.g. hypersensitivity reactions or immune related events are seen, additional samples for ADAs may be  taken. All antibody samples 
from the affected patient will be analysed on an ongoing basis. If antibodies are detected, additional blood samples will be ta ken and stored for characterisation 
of the antibodies.
p Blood sampling for anti-concizumab antibodies and concizumab ELISA testing should only be collected for patients on concizumab.
q If needed dispensing of eptacog alfa, histidine, trial injection kits and Direction For Use (DFU). 
r First treatment dose of concizumab is a loading dose and will be administered at visit [ADDRESS_932719] received any  by[CONTACT_687619],(e.g., 
eptacog alfa, FEIBA®) for treatment of a bleeding epi[INVESTIGATOR_5319] a period of 24h (for eptacog alfa) or 48h (for FEIBA®) prior to first concizumab. Only 
eptacog alfa is allowed after visit 2.
tEptacog alfa administered in a non-bleeding state at site at visit [ADDRESS_932720] followed by [CONTACT_687654]. The interval between the concizumab and eptacog alfa should not exc eed more than 30 min.
uPatient treated with concizumab should be dose escalated at next scheduled visit if he experiences ≥[ADDRESS_932721] and whenever needed afterwards. Patients randomised to eptacog alfa will be re-trained in 
NovoPen®4 and s.c. administration at visit 9 and 9.1. If necessary training can be performed as needed at other visits. The eDiary will  be provided to the 
patients at visit 2 if the patient feels capable in s.c. administration and using the eDiary. Further the patients will be trai ned in recognition of signs/symptoms of 
thrombosis.
w Only for patients randomised to on-demand arm.
x Visit repeated every [ADDRESS_932722] be completed at visit 17, 8 weeks after End of Treatment.
z PRO questionnaires should only be completed at 15.1 for patients continuing in the prolongation of the trial.
aa PRO questionnaires should only be completed at visit 16 for patients not continuing in the prolongation of the trial3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932723] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 11 of 31
Section [IP_ADDRESS] Supportive secondary efficacy endpoints
!The number of bleeding epi[INVESTIGATOR_535025] 76 weeks from treatment onset
!The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment 
onset
!The number of spontaneous bleeding epi[INVESTIGATOR_535025] 76 weeks from treatment 
onset
Supportive secondary safety endpoints
!Number of treatment-emergent adverse events (TEAEs) during at least 24 weeks from 
treatment onset
!Number of TEAEs during at least 76 weeks from treatment onset
!Number of TEAEs within 24 hours of rFVIIa administration
!Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset
!Occurrence of anti-concizumab antibodies during at least 76 weeks from treatment onset
!Change from baseline of fibrinogen during 24 weeks from treatment onset
!Change from baseline of fibrinogen during at least 76 weeks from treatment onset
!Change from baseline of D-d imer during 24 weeks from treatment onset
!Change from baseline of D-dimer during at least 76 weeks from treatment onset
!Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
!Change from baseline of F1 + [ADDRESS_932724] 76 weeks from treatment onset
!Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
!Change from baseline of PT during at least 76 weeks from treatment onset
!Change from baseline of activated partial thromboplastin time (APTT) during 24 weeks 
from treatment onset
!Change from baseline of APTT during at least 76 weeks from treatment onset
!Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
!Change from baseline of AT after at least 76 weeks from treatment onset
Supportive secondary pharmacokinetic endpoints
!Concentration of concizumab prior to the last dose administration at 24 weeks
!Concentration of concizumab prior to the last dose administration after at least 76 weeks
Supportive secondary pharmacodynamic endpoints
!Free TFPI [CONTACT_376412]
!Value prior to the last dose administration at 24 weeks
!Value prior to the last dose administration after atleast 76 weeks
!Thrombin generation
!Peak thrombin generation (nM) prior to the last dose administration at 24 weeks 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932725] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 12 of 31
!Peak thrombin generation (nM) prior to the last dose administration after at least 76 weeks 
!Endogenous thrombin potential (nMxmin) prior to the last dose administration at 24 weeks 
!Endogenous thrombin potential (nMxmin) prior to the last dose administration after at least
76 weeks
!Velocity index (nM/min) prior to the last dose administration at 24 weeks
!Velocity index (nM/min) prior to the last dose administration after at least 76 weeks
Section [IP_ADDRESS] Exploratory patient reported outcome endpoints
!Change in Hemo-TEM after 24 weeks from treatment onset
!Change in Hemo-TEM after at least 76 weeks from treatment onset
!Change in SF-36v2 after 24 weeks from treatment onset
!Change in SF-36v2 after at least 76 weeks from treatment onset
!Change in SDS after 24 weeks from treatment onset
!Change in SDS after at least 76 weeks from treatment onset
!Change in TSQM after 24 weeks from treatment onset
!Change in TSQM after at least 76 weeks from treatment onset
!Change in SIAQ-ISRQ after 24 weeks from treatment onset
!Change in SIAQ-ISRQ after at least 76 weeks from treatment onset
!Status of PGI-C after [ADDRESS_932726] 76 weeks will be evaluated in the extension part 
of the trial.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932727] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 13 of 31
Section 5.1 Type of trial (Figure 5-1)
Section 5.[ADDRESS_932728] completed a minimum of 24 weeks of eptacog alfa 
(rFVIIa) on-demand or have withdrawn.
Section 5.[ADDRESS_932729] 24 weeks for the main part of the trial is deemed necessary in order to 
obtain information on the annualised bleeding rate on concizumab prophylaxis. The duration of the extension part of the trial will be up to 94 52 weeks and provide further information on efficacy, i.e. 
annualised bleeding rate, and also provide additional safety data upon 76 -118 weeks treatment with 
concizumab.
Patients participating in NN7415-4310 will be offered screening for eligibility to participate in the subsequent clinical trials for concizumab, following their participation in NN7415-4310 and provided that either the site participates in the subsequent trial with concizumab or if possible the 
patient can be transferred to a participating site. It is expected that the majority of the participating 
patients will join subsequent trial and thus ma y continue prophylactic treatment with concizumab.
3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932730] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 14 of 31
Section 5.3 Treatment of patients (Table 5-1)
Compound Name [CONTACT_687674] B a100 
mg/mLsolution for s.c. 
injection in a 3 mL cartridge 
bSubcutaneous administration using NovoPen
®4For prophylactic 
treatment in for at 
least 76 weeks (for 
concizumab arm in 
the main part and extension part).For prophylactic 
treatment in for at 
least 52 weeks (for 
comparator arm in the extension part).
eptacog alfa (rFVIIa) 
a, c5 mg/vial Powder for 
solution for i.v. injectionIntravenous 
administrationFor treatment of 
breakthrough bleeding epi[INVESTIGATOR_687611] 
(screening, main, extension and follow up part). 
c
Administration of doses higher than 90μg/kg to patients 
exposed to 
concizumab is not 
allowed.For on-demand treatment at the discretion of the 
investigator in 24 
weeks for comparator arm in the main part. 
In the concizumab 
arm and comparator arm after switching to 
concizumab in the 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932731] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 15 of 31
extension part of 
the study a single 
90μg/kg dose for 
initial safety assessments in a 
non-bleeding state. 
a
Will be provided 
for as long as 
patients participate 
in the trial (screening, main, extension and 
follow up part)
Section 5.3.3 Dose escalation 
All spontaneous bleeding epi[INVESTIGATOR_1841] (sBEs) are counted from 2 weeks after visit 2 (or visit 9 when 
switching from eptacog alfa (rFVIIa) to concizumab) (first treatment visit) until visit 16 (end of 
treatment visit), i.e. a total of [ADDRESS_932732] take into account the 
full clinical pi[INVESTIGATOR_535049], including 
coagulation parameters.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932733] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 16 of 31
Section 5.3.3 Dose escalation (Figure 5-3)
Section 5.3.3 Dose escalation (Figure 5-4)
Section 5.3.4 Co-administration of eptacog alfa (rFVIIa)
The patients will receive prophylactic doses of concizumab 0.15 mg/kg daily throughout the main 
part ( at least 24 weeks) and the extension part (52 up to 94 weeks), unless dose escalation criteria 
are fulfilled, see Section 5.3.3.
Section 5.[ADDRESS_932734] 24 weeks (the main part of the trial) is considered necessary for 
providing r obust data that allow demonstration of clinical proof of concept and to support decision 
3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932735] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 17 of 31
making regarding a phase 3 confirmatory trial. Dosing for up to 94 additional 52 weeks will provide 
valuable long term efficacy and safety data.
Section 7 Milestones
Planned FPFV: 10-Aug-2017
Planned FPFT: 30-Aug-2017
Planned LPFV: 09-Mar-2018
Planned LPLV: 23-Oct-[ADDRESS_932736] 52 weeks for an individual patient 
randomised to eptacog alfa (rFVIIa) on-demand treatment at visit 2.
Section 8 Methods and assessments (Figure 8-1) 
Section 8 Methods and assessments (Figure 8-2) 
3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932737] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 18 of 31
Section 8.1 Visit procedures 
Extension Part:
!Visit 9.1 (treatment and PK-visit with c oncizumab and eptacog alfa (rFVIIa) at site ONLY 
for patients randomised to the eptacog alfa (rFVIIa) on-demand arm)
!Visit 9.2 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
!Visit 10 (Assessment visit, patients treat themselves at home)
!Visit 10.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on-demand arm)
!Visit 11 (Assessment visit, patients treat themselves at home)
!Visit 11.1 (Assessment visit, patients treat themselves at home - ONLY for patients 
randomised to the eptacog alfa (rFVIIa) on demand-arm)
!Visit 12 (Assessment visit, patients treat themselves at home)
!Visit 13 (Assessment visit, patients treat themselves at home)
!Visit 14 (Assessment visit, patients treat themselves at home)
!Visit 15 -15.n (Assessment visit, patients treat themselves at home)
!Visit 16 (Assessment visit and End of treatment)
Follow-up part
!Visit 17 (Assessment visit and End of trial)
Section 8.1.[ADDRESS_932738] at Investigator’s discretion
due to a safety concern after completion of the main part of the trial may have visit [ADDRESS_932739] every 8 
weeks for safety assessments (see Section 8.4 and 8.5.2), PK  and PD markers. The patients who 
permanently prematurely discontinue trial product due to safety concerns may have the safety 
follow up period extended at Investigator’s discretion until the safety concern have been resolved,
but no later than Last Patient Last Visit as defined in Milestones (Section 7 of the protocol).
Section [IP_ADDRESS] Visit 12, 13, 14 and 15 , 15.1, 15.2, 15.n
Visits 12, to15.n 13, 14 and 15 are to be scheduled with an interval of 8 weeks on trial day 337 (48 
weeks), 393(56 weeks), day 449 (64 weeks) and day 505 (72 weeks) respectively with a visit 
window of ±7 days until the patient either discontinues treatment or completes visit 16.
If patient declines participation in the prolongation of the extension, visit 16 should be conducted 4 
weeks after visit 15 (see Section [IP_ADDRESS])
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs, body measurement (weight only) and details of adverse events must be entered into the eCRF.3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932740] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: [ADDRESS_932741] amount of the patient’s daily dose of concizumab, until next 
scheduled visit, investigator will consult the dosing table in the TMM on basis of the patient’s current body weight. Investigator will communicate the daily dose of concizumab to the patient and 
record the dose for the coming home treatment period in the eCRF.
At the visit the patient will be provided with concizumab and/or eptacog alfa (rFVIIa) and trial 
injection kits, if necessary, to  be able to conduct home treatmen t until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed by [CONTACT_093]. Drug accountability must be 
performed for concizumab and eptacog alfa (rFVIIa). Unused histidine syringes should be returned at every visit and new histidine should be dispensed to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_687539]) arise after he has left the site.
At visit 15.1 only patients in the prolongation will be asked to complete the ePRO questionnaires 
before any other trial related activities are performed according to section 8.6.1;
!Hemo-TEM
!SF-36v2
!SDS
!TSQM
!SIAQ-ISRQ
Atthe last visit (visit 15 or 15.n) before visit 16 (End of treatment) ( visit 15) patients should be 
reminded that treatment with concizumab must take place after the blood sampling at visit 16.
Section [IP_ADDRESS] Visit 16
Visit 16 is to be scheduled:
! on trial day 533 (for patients declining participation in the prolongation of the trial) 
!or later (for patients continuing in the extension or enrolled in a subsequent trial) (76 
weeks) 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932742] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 20 of 31
with a visit window of ± 7days. Further visit [ADDRESS_932743] day 
of treatment with concizumab.
Patients notcontinuing in the prolongation will be asked to comp lete the PRO questionnaires 
before any other trial related activities are performed according to section 8.6.1
!Hemo-TEM
!SF-36v2
!SDS
!TSQM
!SIAQ-ISRQ
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
vital signs and details of adverse events must be entered into the eCRF. Treatment with concizumab must take place after the blood sampling at this visit.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_535066].
For patients not continuing in the prolongation of the trial a completion session must be made at 
Visit 16 in the IWRS. In the period from visit 16 to visit 17 patients can be treated with eptacog alfa (rFVIIa) or other products at the discretion of the investigator to treat any bleeding epi[INVESTIGATOR_1841].Eptacog alfa (rFVIIa) may be requested via IWRS.  Only eptacog alfa (rFVIIa) will be provided by 
[CONTACT_687631]. If necessary, the  patient will be provided with eptacog alfa 
(rFVIIa) and trial injection kits to be able to conduct home treatment until next scheduled visit.
For patients continuing in the prolongation of the trial and are enrolled in a subsequent trial as 
completion session must be made at visit [ADDRESS_932744] (eptacog 
alfa) will be provided to the patient
For patients continuing in the prolongation of the trial but not enrolled in a subsequent trial a 
completion session must be made at Visit 16 in the IWRS. In the period from visit 16 to visit 17 the patient can be treated with eptacog alfa (rFVIIa) or other products at the discretion of the 
investigator to treat any bleeding epi[INVESTIGATOR_1841]. Only eptacog alfa (rFVIIa) will be provided by [CONTACT_687669]. If necessary, the patien t will be provided with eptacog alfa (rFVIIa) and 
trial injection kits to be able to conduct home treatment until next scheduled visit.
In the period from visit 16 to visit 17 patients can be treated with eptacog alfa (rFVIIa) or other 
products at the discretion of the investigator to treat eventual bleeding epi[INVESTIGATOR_1841]. Only eptacog alfa 
(rFVIIa) will be provided by [CONTACT_687631].3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932745] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: [ADDRESS_932746] be performed in the IWRS. At the visit the patient will be 
provided with eptacog alfa (rFVIIa) and trial injection kits to be able to conduct home treatment 
until next scheduled visit.
The patient will be asked to return all used, partly used and unused concizumab cartridges and 
eptacog alfa (rFVIIa) during the trial as instructed  by [CONTACT_093]. NovoPen®[ADDRESS_932747] be performed for concizumab and eptacog alfa (rFVIIa). Unused 
histidine syringes should be returned at every visi t and new histidine syringes should be dispensed 
to the patient.
The patient must be instructed to call the site if any questions or issues (e.g. bleeding epi[INVESTIGATOR_1841]) arise 
after he has left the site.
The End-of-Trial information must be entered in the End-of-Trial form in the eCRF at visit 16 for 
all patients continuing in a subsequent trial with concizumab.
Section 8.1.13 Visit 17 (End of trial) – Follow-up part 
Visit For patients not enrolled into a subsequent trial with concizumab visit 17 is to be scheduled 8 
weeks after visit 16 on trial day 589 (84 weeks) with a visit window of minus 7 days.
All assessments are listed in Section 2, and the assessment results from concomitant medication, 
physical examination, body measurements (weight only), vital signs and details of adverse events 
must be entered into the eCRF.
Investigator must perform compliance check of treatment and reporting of bleeding epi[INVESTIGATOR_687544]. Patients should be asked if their female partner has become pregnant, see Section 12.5.1.
The patient will be asked to return all used, partly used and unused eptacog alfa (rFVIIa), unused 
histidine syringes, eDiary device and Trial ca rd. Drug accountability must be performed for eptacog 
alfa (rFVIIa).
End-of-Trial information must be entered in the End-of-Trial form in the eCRF at visit 17 for all 
patients not continuing in a subsequent trial with concizumab. .
Completion or treatment discontinuati on (if the trial is not completed) session should be performed 
in IWRS If eptacog alfa (rFVIIa) was requested at visit 16 drug accountability should be performed 
in IWRS , see Section 10.
Section 8.1.14 Unscheduled Visit
Unscheduled visits can be performed at any time during the trial as listed in Section 2. Unscheduled 
visits may be performed after visit 17 at the discretion of the investigator for patients who has 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932748] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: [ADDRESS_932749] due to a safety concern (see Section 8.1.4). The 
purpose of the unscheduled visit must be documented in the eCRF.
During unscheduled visits assessments and blood sampling must be performed according to Section 
2. Assessment results must be recorded in the eCRF. Assessments and blood sampling can be omitted if the only reason for the unscheduled visit is dispensing of trial product or replacement of 
eDiary or NovoPen
®4 .
Section 8.5 Laboratory assessments
An approximate total blood volume of 768 625 mL will be taken from each patient on the 
concizumab arm and 868 725 mL from each patient on the eptacog alfa (rFVIIa) arm.
Section [IP_ADDRESS] Anti-concizumab antibodies 
The binding ADA samples will be analysed in batches during the trial and results will be available 
to the data monitoring committee approximately every third month after the first patient has been dosed. Neutralising antibodies will be analysed and reported at the EOT. A detailed description of 
the assay methods will be included in the antibody analysis report at the end of the trial.
Investigators will be notified in case their patient is shown to have developed binding and/or
neutralising antibodies against concizumab.
In the event that a trial patient develops binding ADAs towards concizumab during the course of the 
trial and has measurable binding ADAs at his End-of-Trial visit, the patient may attend an ADA 
follow-up visit. The ADA positive patients will be called for additional visits, e.g. every 4 to 6 weeks, for safety assessment and blood sampling for binding ADA sand PD markers (free TFPI [INVESTIGATOR_535203]). The ADA positive patients will be followed no longer than one year after 
End-of-Trial.
Section 8.6.1 Patient reported outcome
The PROs should be assessed at the scheduled visits following the order listed below:
!visit 1 (Hemo-TEM, VERITAS-Pro
®or VERITAS-PRN®)
!visit 2 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
!visit 3 (PGI-C, Hemo-TEM)
!visit 4 (PGI-C, Hemo-TEM)a
!visit 5 (PGI-C, Hemo-TEM)
!visit 6 (PGI-C, Hemo-TEM)
!visit 7 (PGI-C, Hemo-TEM)
!visit 8 (PGI-C, Hemo-TEM)
!visit 9 (PGI-C, Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
!visit 10 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)
!visit 16 15.1 or 16 (Hemo-TEM, SF-36v2, SDS, TSQM, SIAQ-ISRQ)3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932750] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 23 of 31
Section 8.6.1 Patient reported outcome
At visit 3-8: before any visit-related activities the patient should complete the PGI-C before the 
Hemo-Tem. These are the rules that apply:
!If the patient responds “1” to question 1 in the PGI-C, the patient should also complete the 
Hemo-TEM. In this case the patient should not fill in the PGI-C any more in the trial and the 
Hemo-TEM only again at visits 9, 10 and 15.1or 16.
!If the patient responds “0” or “2” to question [ADDRESS_932751] check the ePROs for completeness. potential AEs and SAEs. The completed 
ePROs should be transmitted at each visit to the PRO database by [CONTACT_737].
Section 12.1.1 Adverse event 
Bleeding epi[INVESTIGATOR_56238] (e.g. pain, swelling, synovitis, arthralgia, injection site 
haematoma) in connection with bleeding epi[INVESTIGATOR_49622]/SAEs unless the 
event is fatal, life-thr eatening or evaluated by [CONTACT_687670]. All bleeding epi[INVESTIGATOR_535204]/eDiary
Section 12.[ADDRESS_932752] trial-related activity after the patient has signed the informed consent until visit 16 
(end of treatment) for patients enrolling into a subsequent trial with concizumab and at the end of 
the post-treatment follow-up period (visit 17) for patient not enrolling into a new trial . The events 
must be recorded in the applicable eCRF forms in a timely manner, see timelines below and Figure 
12-1
Section 12.2 Reporting of adverse events 
When eptacog alfa (rFVIIa), NovoSeven®is used as IMP, exp ectedness s hould be performed 
according to the Company Core Data Sheet (CCDS) is performed according to the following 
reference documents: Investigator’s Brochure; current version and any updates thereto .
Section 12.7 Rules for putting enrolment on hold 
*Superficial thrombophlebitis or venous thrombosis associated with indwelling catheters is not 
considered a significant thromboembolic event unless evaluated as such by [CONTACT_093]3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932753] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 24 of 31
Section 17 Statistical considerations
Endpoints comprising number of bleeding epi[INVESTIGATOR_687612]. Multiple bleeding locations occurring from the same event (e.g., due to a bicycle accident) or at the same time point will be counted as one bleeding epi[INVESTIGATOR_1865]. Further, the endpoints will not include re-bleed. A re-bleed is defined as a bleeding epi[INVESTIGATOR_1865] (worsening of bleeding site 
conditions e.g. swelling, pain) within 72 hours after stoppi[INVESTIGATOR_535180] a previous bleeding 
epi[INVESTIGATOR_535126] (or s ubset of the same) anatomical lo cation. If a bleeding epi[INVESTIGATOR_687613] [ADDRESS_932754] due to a safety 
concern patients after visit 17, in the possible extended safety follow-up period (ref section 8.1.4) will be listed only. 
Section 17.3.[ADDRESS_932755] imated using negative binomial regression with 
log of exposure time in ( the included observational period of the main part )as offset and regimen 
as factor. The offset for first CPoC criterion of patients in concizumab arm is the log of the 
individual exposure time at the last dose level reached at the time of analysis excluding the 2 weeks 
run-in period for subjects on 0.15 mg/kg. The offset for the second criterion of patients in 
concizumab arm is the log of the individual exposure time in the main part. For both criteria and patients in the on-demand arm, the offset is the log of the exposure time in the main part. The analysis provides , providing an estimate of the ABR ratio between regimens (concizumab 
prophylactic and on-demand eptacog alfa (rFVIIa)) with corresponding 95% confidence interval 
and also actual estimate of the ABR with corresponding 95% confidence interval for each regimen. This analysis has the underlying assumption that the missing data mechanism is “missing at random”, i.e. MAR. Under this assumpti on, the statist ical be haviour of the missing d ata (given the 
observed responses and the mean value structure) is assumed to be the same as for the observed 
data. The estimand will be estimated based on the FAS and only data collected prior to discontinuation of trial product or initiation of alternative treatment options will be used to draw inference.
Section 17.3.3 Additional analysis 
An additional evaluation of the primary endpoint will be made, including theactual concizumab 
dose level (interpreted as the patients last dose level) as additional factor in the primary analysis 
model specified above. Point estimates and 95% conf idence interval will be provided for the ABR 
at the different dose levels of concizu mab (0.15, 0.20 and 0.25 mg/kg). Furthermore, an series of
analyseis analyses with individual steady state PK/PD assess ments included as covariates in the 
negative binomial regression model as specified for the primary analysis of number of bleeding 
epi[INVESTIGATOR_687614]/PD and ABR that potentially could guide dose-se lection. The referred steady-s tate PK/PD assessments comprise the 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932756] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: [ADDRESS_932757] s.c. dose administration, peak thrombin 
generation (nM), Endogenous thrombin potential (nMxmin) and velocity index (nM/min).
17.4.1 Supportive secondary efficacy endpoints 
!The number of bleeding epi[INVESTIGATOR_535025] 76 weeks from treatment onset
!The number of spontaneous bleeding epi[INVESTIGATOR_535025] 24 weeks from treatment 
onset
!The number of spontaneous bleeding epi[INVESTIGATOR_535025] [ADDRESS_932758] 76 weeks of treatment 
with prophylactic concizumab will be analysed using a negative binomial model with log of trial duration as offset, providing estimates of the ABR with confidence interval for that particular regimen.
Section 17.4.2 Supportive secondary safety endpoints
!Number of treatment-emergent adverse events (TEAEs) during at least 24 weeks from 
treatment onset
!Number of TEAEs during at least 76 weeks from treatment onset
!Number of TEAEs within 24 hours of rFVIIa administration
!Occurrence of anti-concizumab antibodies during at least 24 weeks from treatment onset
!Occurrence of anti-concizumab antibodies during at least 76 weeks from treatment onset
!Change from baseline of fibrinogen during 24 weeks from treatment onset
!Change from baseline of fibrinogen during at least 76 weeks from treatment onset
!Change from baseline of D-dimer during 24 weeks from treatment onset
!Change from baseline of D-dimer during at least 76 weeks from treatment onset
!Change from baseline of prothrombin fragment 1 + 2 (F1 + 2) during 24 weeks from 
treatment onset
!Change from baseline of F1 + [ADDRESS_932759] 76 weeks from treatment onset
!Change from baseline of prothrombin time (PT) during 24 weeks from treatment onset
!Change from baseline of PT during at least 76 weeks from treatment onset
!Change from baseline of activated partial thromboplastin time (APTT) during 24 weeks 
from treatment onset
!Change from baseline of APTT during at least 76 weeks from treatment onset
!Change from baseline of anti-thrombin (AT) during 24 weeks from treatment onset
!Change from baseline of AT after at least 76 weeks from treatment onset3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932760] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: [ADDRESS_932761] recent version of Medical Dictionary for Regulatory 
Activities (MedDRA) coding .
TEAE is defined as an event that has onset from the first exposure to treatment after randomisation   
until the last visit in the trial. Adverse events collected among permanently prematurely 
discontinued from trial product due to a safety concern patients after visit 17 in the possible 
extended safety follow-up period (ref section 8.1.4) are not considered treatment emergent.
Treatment-emergent adverse event endpoints will be summarised by [CONTACT_9313], preferred 
term, seriousness, severity and r elation to trial product. All adverse events will further be listed. 
Relations to Novo Nordisk marketed products used by [CONTACT_687667], such as eptacog alpha, is 
reported as described in section 12.2 of the protocol and not reported in the report of the trial
Section 17.4.3 Supportive secondary pharmacokinetic endpoints
!Concentration of concizumab prior to the last dose administration at 24 weeks
!Concentration of concizumab prior to the last dose administration after atleast 76 weeks
Section 17.4.4 Supportive secondary pharmacodynamic endpoints
!Free TFPI [CONTACT_376412]
!Value prior to the last dose administration at 24 weeks
!Value prior to the last dose administration after atleast 76 weeks
!Thrombin generation
!Peak thrombin generation (nM) prior to the last dose administration at 24 weeks 
!Peak thrombin generation (nM) prior to the last dose administration after atleast 76 weeks 
!Endogenous thrombin potential (nMxmin) prior to the last dose administration at 24 weeks 
!Endogenous thrombin potential (nMxmin) prior to the last dose administration after atleast
76 weeks
!Velocity index (nM/min) prior to the last dose administration at 24 weeks
!Velocity index (nM/min) prior to the last dose administration after atleast 76 weeks
Section [IP_ADDRESS] Exploratory patient reported outcome endpoints
!Change in Hemo-TEM after 24 weeks from treatment onset
!Change in Hemo-TEM after at least 76 weeks from treatment onset
!Change in SF-36v2 after 24 weeks from treatment onset
!Change in SF-36v2 after at least 76 weeks from treatment onset
!Change in SDS after 24 weeks from treatment onset
!Change in SDS after at least 76 weeks from treatment onset
!Change in TSQM after 24 weeks from treatment onset
!Change in TSQM after at least 76 weeks from treatment onset
!Change in SIAQ-ISRQ after 24 weeks from treatment onset
!Change in SIAQ-ISRQ after at least 76 weeks from treatment onset3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932762] 2018 1RYR1RUGLVN
Trial ID: NN7415-4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 27 of 31
!Status of PGI-C after 24 weeks from treatment onset
VERITAS-PRN®, SF-36v2, SDS and TSQM will be scored according to their respective scoring 
algorithms. Change after [ADDRESS_932763] patient has 
completed a minimum of 24 weeks of treatment or at LPFT (visit 2) + [ADDRESS_932764] patient has either completed or withdrawn 
from the trial. All main conclusions regarding clinical proof of concept and dose guidance for phase 3 will be based on the reporting after the main part, see Figure 17-1. 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932765] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 28 of 31
Section 17.5 Interim analysis (Figure 17-1)
2.2 Informed Consent
2.2.1 Master Informed Consent
What kind of trial products will you receive? 
If you agree to participate in the trial you will ei ther inject one dose of concizumab daily for up to 
76 118weeks (concizumab treatment), or receive on-demand treatment with eptacog alfa for 
bleeding epi[INVESTIGATOR_687615] 24 weeks of the tr ial (on-demand tr eatment), before switching to daily 
concizumab treatment for the remaining period (52 56 -94weeks). If you experience a bleeding 
epi[INVESTIGATOR_687616], you will tr eat this with eptacog alfa. If you experience [ADDRESS_932766] dose of concizumab, 0.15 mg/kg. It will be possible to increase your dose twice during the trial: from 0.15 
to 0.20 mg/kg and from 0.20 to 0.25 mg/kg if the bleeding epi[INVESTIGATOR_535205] a second [ADDRESS_932767] visit will be visit 16 and you will continue in the new trial. If you choose to say no you will discontinue treatment with concizumab at 
3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932768] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 29 of 31
visit 16 and be followed for an additional 8 weeks before completing the trial. During this period 
you will be provided with eptacog alfa for the treatment of bleeding epi[INVESTIGATOR_1841].
What will happen at the different visits in the trial? 
If you meet all criteria, your involvement in the trial will last from approximately [ADDRESS_932769] to spend on each specific visit.
Treatment at Home (Visits 4 to 16):
Concizumab Treatment 
Visit [ADDRESS_932770] 
occurred between visits. You will be asked to complete 2 questionnaires related to your quality of 
life, well-being and treatment at visits 4 to 8 and 5 questionnaires at visit 10 and 16 15.1. 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932771] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: 30 of 31
Follow-up visit (Visit 17):
This visit will only happen if you do not continue in a new trial.
Concizumab & On-demand Treatment
There will be a period of approximately 8 weeks between visit 16 and 17 (follow-up and end of trial 
visit). Blood will be drawn for analysis, vital signs measured, details of any other medications you 
may be taking recorded and a physical examination performed. You will return the electronic diary 
and any remaining eptacog alfa. At the final visit, you and your trial doctor will discuss the best alternatives for your fu ture treatment. Novo Nordisk will not offer any free medication, additional 
care or continued treatment with the trial products after the completion of the trial .
Between Visits:
During the trial blood samples will be taken for different tests. The total amount of blood drawn in 
the course of the trial is approximately [ADDRESS_932772] during and after the trial?
<EU countries only: If you have any questions, concerns or complaints as to how Novo Nordisk is 
using your personal information, you can contact [CONTACT_6814]. Your study doctor will then 
contact [CONTACT_3454]’s Data Protection Officer. The [Country] Data Protection Authority is responsible for making sure that laws about personal information are followed in [Country]. For more information about your rights, or if you wish to make a complaint, you can contact [Data 
Protection Authorities contact [CONTACT_3031]].>
2.2.2 Genotypi[INVESTIGATOR_535029]-term Storage of Human Samples Informed Consent
<EU countries only: If you have any questions, concerns or complaints as to how Novo Nordisk is 
using your personal information, you can contact [CONTACT_6814]. Your study doctor will then 
contact [CONTACT_3454]’s Data Protection Officer. The [Country] Data Protection Authority is 
responsible for making sure that laws about personal information are followed in [Country]. For more information about your rights, or if you wish to make a complaint, you can contact [Data Protection Authorities contact [CONTACT_3031]].>
2.2.[ADDRESS_932773] in Case of an Abnormal Pregnancy Informed 
Consent
<EU countries only: If you have any questions, concerns or complaints as to how Novo Nordisk is 
using your personal information, you can contact [CONTACT_6814]. Your study doctor will then contact [CONTACT_3454]’s Data Protection Officer. The [Country] Data Protection Authority is 
responsible for making sure that laws about personal information are followed in [Country]. For 3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL
Protocol Amendment no 3
CONFIDENTIALDate: [ADDRESS_932774] 2018 1RYR1RUGLVN
Trial ID: NN7415- 4310 Version: 1.0
UTN: U1111-1179-2925 Status: Final
EudraCT No.: 2016-000510-30 Page: [ADDRESS_932775] [Data 
Protection Authorities contact [CONTACT_3031]].>3URWRFRO$PHQGPHQWJORE
CONFIDENTIAL